assay_strain,bao_format,assay_type,assay_test_type,assay_cell_type,tid,relationship_type,assay_organism,curated_by,doc_id,assay_subcellular_fraction,assay_tax_id,chembl_id,src_id,assay_category,confidence_score,assay_tissue,src_assay_id,variant_id,tissue_id,cell_id,assay_id,description
,BAO_0000019,B,,,12052.0,H,,Autocuration,11087.0,,,CHEMBL615117,1.0,,8.0,,,,,,1.0,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM
,BAO_0000219,F,,,22226.0,U,,Autocuration,684.0,,,CHEMBL615118,1.0,,0.0,,,,,,2.0,Compound was evaluated for its ability to mobilize calcium in 1321NI cells
,BAO_0000019,B,,,22226.0,U,,Autocuration,15453.0,,,CHEMBL615119,1.0,,0.0,,,,,,3.0,
,BAO_0000249,B,,,104729.0,H,Bos taurus,Autocuration,17841.0,,9913.0,CHEMBL615120,1.0,,4.0,,,,,,4.0,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680
,BAO_0000219,F,,143B,80001.0,N,Homo sapiens,Intermediate,17430.0,,9606.0,CHEMBL615121,1.0,,1.0,,,,,163.0,5.0,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line)
,BAO_0000219,F,,143B,80001.0,N,Homo sapiens,Intermediate,17430.0,,9606.0,CHEMBL615122,1.0,,1.0,,,,,163.0,6.0,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line)
,BAO_0000219,F,,143B,80001.0,N,Mus musculus,Intermediate,13799.0,,10090.0,CHEMBL615123,1.0,,1.0,,,,,163.0,7.0,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells
,BAO_0000219,F,,143B,80001.0,N,Homo sapiens,Expert,17774.0,,9606.0,CHEMBL615124,1.0,,1.0,,,,,163.0,8.0,In vitro cell cytotoxicity was determined against 143B cell line
,BAO_0000219,F,,143B,80001.0,N,Homo sapiens,Intermediate,3801.0,,9606.0,CHEMBL615125,1.0,,1.0,,,,,163.0,9.0,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound
,BAO_0000219,F,,143B,80001.0,N,Homo sapiens,Intermediate,17430.0,,9606.0,CHEMBL615126,1.0,,1.0,,,,,163.0,10.0,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK
,BAO_0000219,F,,143B,80001.0,N,Homo sapiens,Intermediate,17430.0,,9606.0,CHEMBL615127,1.0,,1.0,,,,,163.0,11.0,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK
,BAO_0000219,F,,143B,80001.0,N,Homo sapiens,Expert,17774.0,,9606.0,CHEMBL615128,1.0,,1.0,,,,,163.0,12.0,In vitro cell cytotoxicity was determined against 143B-LTK cell line
,BAO_0000218,F,,,50185.0,N,Staphylococcus aureus,Intermediate,11324.0,,1280.0,CHEMBL857900,1.0,,1.0,,,,,,13.0,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus"
,BAO_0000218,F,,,50185.0,N,Staphylococcus aureus,Intermediate,11324.0,,1280.0,CHEMBL615129,1.0,,1.0,,,,,,14.0,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus"
,BAO_0000218,F,,,50185.0,N,Staphylococcus aureus,Intermediate,11324.0,,1280.0,CHEMBL615130,1.0,,1.0,,,,,,15.0,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus"
,BAO_0000218,F,,,50185.0,N,Staphylococcus aureus,Intermediate,11324.0,,1280.0,CHEMBL615131,1.0,,1.0,,,,,,16.0,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus"
,BAO_0000357,A,,,100122.0,D,Rattus norvegicus,Expert,11347.0,,10116.0,CHEMBL884521,1.0,,9.0,,,,,,17.0,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase
,BAO_0000357,B,,,12054.0,H,,Autocuration,16474.0,,,CHEMBL615132,1.0,,8.0,,,,,,18.0,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO)
,BAO_0000019,B,,,12054.0,H,,Autocuration,10091.0,,,CHEMBL615133,1.0,,8.0,,,,,,19.0,Inhibition of partially purified 15-lipoxygenase from human leukocytes
,BAO_0000357,B,,,12054.0,H,,Autocuration,16474.0,,,CHEMBL615134,1.0,,8.0,,,,,,20.0,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO)
,BAO_0000357,B,,,12054.0,H,,Autocuration,16474.0,,,CHEMBL615135,1.0,,8.0,,,,,,21.0,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO)
,BAO_0000357,B,,,12054.0,H,,Autocuration,16474.0,,,CHEMBL615136,1.0,,8.0,,,,,,22.0,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO)
,BAO_0000357,B,,,12054.0,H,,Autocuration,16474.0,,,CHEMBL615137,1.0,,8.0,,,,,,23.0,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition
,BAO_0000357,B,,,12054.0,H,,Autocuration,16474.0,,,CHEMBL615138,1.0,,8.0,,,,,,24.0,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition
,BAO_0000219,B,,,22226.0,U,,Autocuration,14352.0,,,CHEMBL836324,1.0,,0.0,,,,,,25.0,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M."
,BAO_0000357,B,,,12054.0,H,Oryctolagus cuniculus,Autocuration,5646.0,,9986.0,CHEMBL615139,1.0,,8.0,,,,,,26.0,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase
,BAO_0000357,B,,,12054.0,H,Oryctolagus cuniculus,Autocuration,5646.0,,9986.0,CHEMBL615140,1.0,,8.0,,,,,,27.0,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM)
,BAO_0000219,B,,,12426.0,H,,Autocuration,10997.0,,,CHEMBL615141,1.0,,8.0,,,,,,28.0,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes
,BAO_0000357,B,,,12054.0,H,soya bean,Autocuration,6309.0,,3847.0,CHEMBL615142,1.0,,8.0,,,,,,29.0,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean
,BAO_0000357,B,,,12054.0,H,Glycine max,Autocuration,167.0,,3847.0,CHEMBL615143,1.0,,8.0,,,,,,30.0,Inhibitory activity against soybean 15-lipoxygenase was evaluated
,BAO_0000357,B,,,12054.0,H,Glycine max,Autocuration,167.0,,3847.0,CHEMBL615144,1.0,,8.0,,,,,,31.0,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM
,BAO_0000357,B,,,12054.0,H,Glycine max,Autocuration,11087.0,,3847.0,CHEMBL872867,1.0,,8.0,,,,,,32.0,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM
,BAO_0000357,B,,,12054.0,H,Glycine max,Autocuration,11087.0,,3847.0,CHEMBL615145,1.0,,8.0,,,,,,33.0,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM
,BAO_0000357,B,,,12054.0,H,Glycine max,Autocuration,13622.0,,3847.0,CHEMBL615146,1.0,,8.0,,,,,,34.0,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean
,BAO_0000357,B,,,12054.0,H,Glycine max,Autocuration,13622.0,,3847.0,CHEMBL615147,1.0,,8.0,,,,,,35.0,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean
,BAO_0000019,A,,,22226.0,U,Rattus norvegicus,Autocuration,11347.0,,10116.0,CHEMBL615148,1.0,,0.0,,,,,,36.0,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase
,BAO_0000019,B,,,22226.0,U,Escherichia coli,Autocuration,5926.0,,562.0,CHEMBL615149,1.0,,0.0,,,,,,37.0,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay
,BAO_0000019,B,,,22226.0,U,,Autocuration,4567.0,,,CHEMBL615150,1.0,,0.0,,,,,,38.0,Dissociation constant with dimeric 16S rRNA RNA construct B
,BAO_0000225,B,,,22222.0,M,,Intermediate,3782.0,,,CHEMBL615151,1.0,,3.0,,,,,,39.0,Dissociation constant towards 16S rRNA construct A
,BAO_0000225,B,,,22222.0,M,,Intermediate,3782.0,,,CHEMBL615152,1.0,,3.0,,,,,,40.0,Dissociation constant towards 16S rRNA construct B
,BAO_0000225,B,,,100263.0,M,Escherichia coli,Expert,4466.0,,562.0,CHEMBL615153,1.0,,3.0,,,,,,41.0,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli
,BAO_0000225,B,,,100263.0,M,Escherichia coli,Expert,6592.0,,562.0,CHEMBL615154,1.0,,3.0,,,,,,42.0,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli
,BAO_0000019,B,,,13053.0,H,,Autocuration,898.0,,,CHEMBL615155,1.0,,8.0,,,,,,43.0,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2)
,BAO_0000019,B,,,13053.0,H,,Autocuration,898.0,,,CHEMBL615156,1.0,,8.0,,,,,,44.0,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2)
,BAO_0000019,B,,,20001.0,H,Homo sapiens,Autocuration,13163.0,,9606.0,CHEMBL615157,1.0,,8.0,,,,,,45.0,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes
,BAO_0000019,B,,,20001.0,H,Homo sapiens,Autocuration,13163.0,,9606.0,CHEMBL615158,1.0,,8.0,,,,,,46.0,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes
,BAO_0000019,B,,,12971.0,D,Rattus norvegicus,Expert,10691.0,,10116.0,CHEMBL615159,1.0,,9.0,,,,,,47.0,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation"
,BAO_0000019,B,,,12971.0,D,Rattus norvegicus,Expert,10691.0,,10116.0,CHEMBL615172,1.0,,9.0,,,,,,48.0,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation"
,BAO_0000019,B,,,12971.0,D,Rattus norvegicus,Expert,10691.0,,10116.0,CHEMBL615173,1.0,,9.0,,,,,,49.0,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM"
,BAO_0000019,B,,,12971.0,D,Rattus norvegicus,Expert,10691.0,,10116.0,CHEMBL615174,1.0,,9.0,,,,,,50.0,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM"
,BAO_0000019,B,,,13053.0,H,,Autocuration,898.0,,,CHEMBL884518,1.0,,8.0,,,,,,51.0,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2)
,BAO_0000357,B,,,11512.0,H,,Autocuration,912.0,,,CHEMBL615175,1.0,,8.0,,,,,,52.0,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1)
,BAO_0000357,B,,,11512.0,H,,Autocuration,912.0,,,CHEMBL615176,1.0,,8.0,,,,,,53.0,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration
,BAO_0000357,B,,,11512.0,H,,Autocuration,912.0,,,CHEMBL615177,1.0,,8.0,,,,,,54.0,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration
,BAO_0000249,B,,,104740.0,D,Rattus norvegicus,Autocuration,15103.0,Membranes,10116.0,CHEMBL615178,1.0,,5.0,,,,,,55.0,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes
,BAO_0000219,F,,1A9,80002.0,N,Homo sapiens,Intermediate,5116.0,,9606.0,CHEMBL615179,1.0,,1.0,,,,,506.0,56.0,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined
,BAO_0000219,F,,Oocytes,104835.0,D,Rattus norvegicus,Autocuration,14578.0,,10116.0,CHEMBL615180,1.0,,7.0,,,,,,57.0,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype
,BAO_0000219,F,,Oocytes,104821.0,D,Rattus norvegicus,Autocuration,14578.0,,10116.0,CHEMBL615181,1.0,,7.0,,,,,,58.0,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor
,BAO_0000219,F,,Oocytes,104848.0,D,Rattus norvegicus,Autocuration,14578.0,,10116.0,CHEMBL615182,1.0,,7.0,,,,,,59.0,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor
,BAO_0000219,F,,1A9,80002.0,N,Homo sapiens,Expert,4787.0,,9606.0,CHEMBL615183,1.0,,1.0,,,,,506.0,60.0,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation
,BAO_0000219,F,,1A9,80002.0,N,Homo sapiens,Intermediate,4787.0,,9606.0,CHEMBL615184,1.0,,1.0,,,,,506.0,61.0,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation
,BAO_0000219,F,,1A9,80002.0,N,Homo sapiens,Intermediate,3547.0,,9606.0,CHEMBL615185,1.0,,1.0,,,,,506.0,62.0,Cytotoxic activity against human ovarian cancer (1A9) cell line
,BAO_0000219,F,,1A9,80002.0,N,Homo sapiens,Intermediate,3547.0,,9606.0,CHEMBL615186,1.0,,1.0,,,,,506.0,63.0,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined
,BAO_0000219,F,,1A9,80002.0,N,Homo sapiens,Intermediate,6726.0,,9606.0,CHEMBL615187,1.0,,1.0,,,,,506.0,64.0,Effective dose of compound against replication of 1A9 cell line was evaluated
,BAO_0000219,F,,1A9,80002.0,N,Homo sapiens,Expert,3455.0,,9606.0,CHEMBL885343,1.0,,1.0,,,,,506.0,65.0,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line
,BAO_0000219,F,,1A9,80002.0,N,Homo sapiens,Intermediate,5726.0,,9606.0,CHEMBL615188,1.0,,1.0,,,,,506.0,66.0,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line)
,BAO_0000219,F,,1A9,80002.0,N,Homo sapiens,Intermediate,5726.0,,9606.0,CHEMBL615189,1.0,,1.0,,,,,506.0,67.0,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active
,BAO_0000219,F,,1A9,80002.0,N,Homo sapiens,Intermediate,5726.0,,9606.0,CHEMBL615190,1.0,,1.0,,,,,506.0,68.0,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL
,BAO_0000219,F,,1A9,80002.0,N,Homo sapiens,Intermediate,3395.0,,9606.0,CHEMBL615191,1.0,,1.0,,,,,506.0,69.0,Inhibitory activity against Taxol resistant 1A9 cell lines
,BAO_0000219,F,,1A9,80002.0,N,Homo sapiens,Expert,3415.0,,9606.0,CHEMBL615192,1.0,,1.0,,,,,506.0,70.0,Cytotoxicity against human ovarian cancer (1A9) cell lines.
,BAO_0000219,F,,1A9,80002.0,N,Homo sapiens,Expert,3415.0,,9606.0,CHEMBL827083,1.0,,1.0,,,,,506.0,71.0,Percentage inhibition of human ovarian cancer (1A9) cell lines.
,BAO_0000219,F,,1A9,80002.0,N,Homo sapiens,Expert,17099.0,,9606.0,CHEMBL615193,1.0,,1.0,,,,,506.0,72.0,Effective dose required for inhibitory activity against 1A9 human tumor cell line.
,BAO_0000219,F,,1A9,80002.0,N,Homo sapiens,Intermediate,17099.0,,9606.0,CHEMBL615194,1.0,,1.0,,,,,506.0,73.0,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL
,BAO_0000219,F,,1A9,80002.0,N,Homo sapiens,Intermediate,17099.0,,9606.0,CHEMBL615195,1.0,,1.0,,,,,506.0,74.0,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL
,BAO_0000219,F,,1A9,80002.0,N,Homo sapiens,Intermediate,17099.0,,9606.0,CHEMBL615196,1.0,,1.0,,,,,506.0,75.0,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL
,BAO_0000219,F,,Jurkat,81072.0,N,Homo sapiens,Intermediate,17721.0,,9606.0,CHEMBL615197,1.0,,1.0,,,,,503.0,76.0,Inhibitory concentration against Jurkat cells
,BAO_0000019,F,,,22226.0,U,,Intermediate,1229.0,,,CHEMBL615198,1.0,,0.0,,,,,,77.0,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive
,BAO_0000357,A,,,100121.0,D,Rattus norvegicus,Expert,11347.0,,10116.0,CHEMBL615199,1.0,,9.0,,,,,,78.0,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase
,BAO_0000357,B,,,11231.0,H,,Expert,17117.0,,,CHEMBL615200,1.0,,8.0,,,,,,79.0,"In vitro inhibition of human 2,3-oxidosqualene cyclase."
,BAO_0000357,B,,,11231.0,H,,Expert,17117.0,,,CHEMBL615201,1.0,,8.0,,,,,,80.0,"In vitro inhibition of human 2,3-oxidosqualene cyclase."
,BAO_0000357,B,,,11231.0,H,,Expert,17117.0,,,CHEMBL615202,1.0,,8.0,,,,,,81.0,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM."
,BAO_0000251,B,,,11231.0,H,Candida albicans,Autocuration,11375.0,Microsomes,5476.0,CHEMBL615203,1.0,,8.0,,,,,,82.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes"
,BAO_0000251,B,,,11231.0,H,Candida albicans,Autocuration,11375.0,Microsomes,5476.0,CHEMBL615204,1.0,,8.0,,,,,,83.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes"
,BAO_0000251,B,,,11231.0,H,Saccharomyces cerevisiae,Autocuration,11375.0,Microsomes,4932.0,CHEMBL615205,1.0,,8.0,,,,,,84.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes"
,BAO_0000251,B,,,11231.0,H,Saccharomyces cerevisiae,Autocuration,11375.0,Microsomes,4932.0,CHEMBL615206,1.0,,8.0,,,,,,85.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes"
,BAO_0000251,B,,,12083.0,H,Sus scrofa,Autocuration,11375.0,Microsomes,9823.0,CHEMBL615207,1.0,,8.0,Liver,,,2107.0,,86.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes"
,BAO_0000019,B,,,11231.0,H,Rattus norvegicus,Autocuration,791.0,,10116.0,CHEMBL827084,1.0,,8.0,,,,,,87.0,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase"
,BAO_0000019,B,,,11231.0,H,Rattus norvegicus,Autocuration,791.0,,10116.0,CHEMBL615208,1.0,,8.0,,,,,,88.0,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)"
,BAO_0000019,B,,,11231.0,H,Rattus norvegicus,Autocuration,791.0,,10116.0,CHEMBL615209,1.0,,8.0,,,,,,89.0,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki"
,BAO_0000251,B,,,12083.0,D,Rattus norvegicus,Autocuration,11375.0,Microsomes,10116.0,CHEMBL615210,1.0,,9.0,Liver,,,2107.0,,90.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes"
,BAO_0000251,B,,,12083.0,D,Rattus norvegicus,Autocuration,11375.0,Microsomes,10116.0,CHEMBL615211,1.0,,9.0,Liver,,,2107.0,,91.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes"
,BAO_0000251,B,,,12083.0,D,Rattus norvegicus,Autocuration,153.0,Microsomes,10116.0,CHEMBL615212,1.0,,9.0,Liver,,,2107.0,,92.0,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes"
,BAO_0000357,B,,,11377.0,H,,Expert,8269.0,,,CHEMBL615213,1.0,,8.0,,,,,,93.0,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease)
,BAO_0000357,B,,,11377.0,H,,Expert,8269.0,,,CHEMBL615273,1.0,,8.0,,,,,,94.0,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex
,BAO_0000219,F,,HepG2,81020.0,N,Homo sapiens,Expert,17653.0,,9606.0,CHEMBL615274,1.0,,1.0,,,,,726.0,95.0,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line
,BAO_0000219,F,,HepG2,81020.0,N,Homo sapiens,Intermediate,14277.0,,9606.0,CHEMBL615275,1.0,,1.0,,,,,726.0,96.0,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.
,BAO_0000219,F,,HepG2,81020.0,N,Homo sapiens,Intermediate,1717.0,,9606.0,CHEMBL615276,1.0,,1.0,,,,,726.0,97.0,Antiviral activity against Hepatitis B virus in 2.2.15 cell line
,BAO_0000219,F,,HepG2,81020.0,N,Homo sapiens,Intermediate,14091.0,,9606.0,CHEMBL615277,1.0,,1.0,,,,,726.0,98.0,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells
,BAO_0000219,F,,HepG2,81020.0,N,Homo sapiens,Intermediate,14091.0,,9606.0,CHEMBL615326,1.0,,1.0,,,,,726.0,99.0,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined
,BAO_0000218,F,,,50606.0,N,Hepatitis B virus,Expert,17653.0,,10407.0,CHEMBL883130,1.0,,1.0,,,,,,100.0,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line
,BAO_0000219,F,,HepG2,81020.0,N,Homo sapiens,Intermediate,13105.0,,9606.0,CHEMBL884519,1.0,,1.0,,,,,726.0,101.0,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.
,BAO_0000219,F,,HepG2,81020.0,N,Homo sapiens,Intermediate,1717.0,,9606.0,CHEMBL615327,1.0,,1.0,,,,,726.0,102.0,Concentration required to inhibit 50% of 2.2.15 cell line
,BAO_0000219,A,,HepG2,81020.0,N,Homo sapiens,Intermediate,13105.0,,9606.0,CHEMBL615328,1.0,,1.0,,,,,726.0,103.0,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).
,BAO_0000218,F,,2.2.15,50587.0,N,Homo sapiens,Intermediate,13600.0,,9606.0,CHEMBL615329,1.0,,1.0,,,,,,104.0,Cytotoxic activity of compound against uninfected 2.2.15 cells.
,BAO_0000218,F,,2.2.15,50587.0,N,Homo sapiens,Intermediate,13467.0,,9606.0,CHEMBL615330,1.0,,1.0,,,,,,105.0,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.
,BAO_0000218,F,,2.2.15,50606.0,N,Hepatitis B virus,Expert,17477.0,,10407.0,CHEMBL615331,1.0,,1.0,,,,,,106.0,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay"
,BAO_0000218,F,,2.2.15,50587.0,N,Homo sapiens,Intermediate,1593.0,,9606.0,CHEMBL615332,1.0,,1.0,,,,,,107.0,In vitro anti-HBV activity in 2.2.15 cells
,BAO_0000218,F,,2.2.15,50587.0,N,Homo sapiens,Intermediate,1593.0,,9606.0,CHEMBL615333,1.0,,1.0,,,,,,108.0,In vitro anti-HBV activity in 2.2.15 cells; Not determined
,BAO_0000218,F,,2.2.15,50587.0,N,Homo sapiens,Intermediate,15089.0,,9606.0,CHEMBL615334,1.0,,1.0,,,,,,109.0,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells
,BAO_0000218,F,,2.2.15,50587.0,N,Homo sapiens,Intermediate,15089.0,,9606.0,CHEMBL615335,1.0,,1.0,,,,,,110.0,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells
,BAO_0000218,F,,2.2.15,50587.0,N,Homo sapiens,Intermediate,1593.0,,9606.0,CHEMBL615336,1.0,,1.0,,,,,,111.0,Cytotoxicity in 2.2.15 cells
,BAO_0000218,F,,2.2.15,50587.0,N,Homo sapiens,Intermediate,1593.0,,9606.0,CHEMBL615337,1.0,,1.0,,,,,,112.0,Cytotoxicity in 2.2.15 cells; Not determined
,BAO_0000218,F,,2.2.15,50587.0,N,Homo sapiens,Intermediate,13600.0,,9606.0,CHEMBL615338,1.0,,1.0,,,,,,113.0,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells
,BAO_0000218,F,,2.2.15,50587.0,N,Homo sapiens,Intermediate,13467.0,,9606.0,CHEMBL615339,1.0,,1.0,,,,,,114.0,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.
,BAO_0000218,F,,2.2.15,50587.0,N,Homo sapiens,Intermediate,13467.0,,9606.0,CHEMBL615340,1.0,,1.0,,,,,,115.0,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.
,BAO_0000219,F,,HepG2,81020.0,N,Homo sapiens,Intermediate,14764.0,,9606.0,CHEMBL615341,1.0,,1.0,,,,,726.0,116.0,Antiviral activity against HBV was determined in 2.215 cell line
,BAO_0000251,B,,,22226.0,U,Homo sapiens,Autocuration,6531.0,Microsomes,9606.0,CHEMBL615342,1.0,,0.0,,,,,,117.0,Inhibition of 20-HETE synthesis in human renal microsomes
,BAO_0000019,B,,,22226.0,U,,Autocuration,17322.0,,,CHEMBL615343,1.0,,0.0,,,,,,118.0,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.
,BAO_0000219,F,,2008,80612.0,N,Homo sapiens,Intermediate,17072.0,,9606.0,CHEMBL615344,1.0,,1.0,,,,,388.0,119.0,Inhibitory concentration against 2008 (ovarian) cells
,BAO_0000219,F,,2008,80612.0,N,Homo sapiens,Intermediate,16936.0,,9606.0,CHEMBL615345,1.0,,1.0,,,,,388.0,120.0,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.
,BAO_0000219,F,,2008,80612.0,N,Homo sapiens,Intermediate,16936.0,,9606.0,CHEMBL615346,1.0,,1.0,,,,,388.0,121.0,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008)
,BAO_0000219,F,,2008,80612.0,N,Homo sapiens,Intermediate,17146.0,,9606.0,CHEMBL615347,1.0,,1.0,,,,,388.0,122.0,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells
,BAO_0000219,F,,2008,80612.0,N,Homo sapiens,Intermediate,17146.0,,9606.0,CHEMBL615348,1.0,,1.0,,,,,388.0,123.0,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected
,BAO_0000219,F,,2008/R,80613.0,N,Homo sapiens,Intermediate,10797.0,,9606.0,CHEMBL827085,1.0,,1.0,,,,,561.0,124.0,In vitro inhibition of 2008/R ovarian cancer cell line
,BAO_0000219,F,,2008/R,80613.0,N,Homo sapiens,Intermediate,10797.0,,9606.0,CHEMBL615349,1.0,,1.0,,,,,561.0,125.0,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable
,BAO_0000219,F,,2008/S,80614.0,N,Homo sapiens,Intermediate,10797.0,,9606.0,CHEMBL615350,1.0,,1.0,,,,,389.0,126.0,In vitro inhibition of 2008/S ovarian cancer cell line
,BAO_0000219,F,,2008/S,80614.0,N,Homo sapiens,Intermediate,10797.0,,9606.0,CHEMBL615351,1.0,,1.0,,,,,389.0,127.0,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable
,BAO_0000220,B,,,100256.0,S,Homo sapiens,Expert,4823.0,,9606.0,CHEMBL615352,1.0,,2.0,,,,,,128.0,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome
,BAO_0000220,B,,,100256.0,S,Homo sapiens,Intermediate,12912.0,,9606.0,CHEMBL615353,1.0,,2.0,,,,,,129.0,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain
,BAO_0000220,B,,,100256.0,S,,Expert,2957.0,,,CHEMBL615354,1.0,,2.0,,,,,,130.0,Inhibition of chymotrypsin-like activity of 20S proteasome
,BAO_0000220,B,,,100256.0,S,,Expert,2957.0,,,CHEMBL615355,1.0,,2.0,,,,,,131.0,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM
,BAO_0000220,B,,,100256.0,S,,Intermediate,3260.0,,,CHEMBL615356,1.0,,2.0,,,,,,132.0,Inhibitory activity against 20S proteosome
,BAO_0000019,B,,,22226.0,U,Homo sapiens,Autocuration,3451.0,,9606.0,CHEMBL615357,1.0,,0.0,,,,,,133.0,Compound was tested for inhibitory activity against tryptase
,BAO_0000219,F,,HepG2,81020.0,N,Homo sapiens,Intermediate,13885.0,,9606.0,CHEMBL615358,1.0,,1.0,,,,,726.0,134.0,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line
,BAO_0000219,F,,HepG2,81020.0,N,Homo sapiens,Intermediate,13885.0,,9606.0,CHEMBL827086,1.0,,1.0,,,,,726.0,135.0,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line
,BAO_0000019,B,,,22226.0,U,,Autocuration,3676.0,,,CHEMBL615359,1.0,,0.0,,,,,,136.0,Compound was tested for the inhibition of Alpha-glucosidase
,BAO_0000357,B,,,235.0,H,,Autocuration,6043.0,,,CHEMBL615360,1.0,,8.0,,,,,,137.0,Inhibitory concentration against human neutrophil elastase (HNE)
,BAO_0000218,F,,,22226.0,U,Rattus norvegicus,Autocuration,11140.0,,10116.0,CHEMBL615361,1.0,,0.0,Heart,,,948.0,,138.0,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat
,BAO_0000019,F,,,19640.0,H,,Autocuration,10543.0,,,CHEMBL615362,1.0,,8.0,,,,,,139.0,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates
,BAO_0000019,F,,,19640.0,H,,Expert,10543.0,,,CHEMBL615363,1.0,,8.0,,,,,,140.0,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates
,BAO_0000357,B,,,19640.0,H,,Autocuration,10543.0,,,CHEMBL615364,1.0,,8.0,,,,,,141.0,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates
,BAO_0000019,F,,,19640.0,H,,Expert,10543.0,,,CHEMBL615365,1.0,,8.0,,,,,,142.0,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates
,BAO_0000219,F,,P338,80360.0,N,Mus musculus,Intermediate,11365.0,,10090.0,CHEMBL615366,1.0,,1.0,,,,,524.0,143.0,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines
,BAO_0000219,F,,P338,80360.0,N,Mus musculus,Intermediate,11365.0,,10090.0,CHEMBL615367,1.0,,1.0,,,,,524.0,144.0,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines
,BAO_0000219,F,,PBL,80384.0,N,Homo sapiens,Intermediate,11803.0,,9606.0,CHEMBL615368,1.0,,1.0,,,,,554.0,145.0,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).
,BAO_0000019,F,,,22226.0,U,Ovis aries,Autocuration,11803.0,,9940.0,CHEMBL615369,1.0,,0.0,,,,,,146.0,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells
,BAO_0000019,F,,,22226.0,U,Ovis aries,Autocuration,11803.0,,9940.0,CHEMBL615370,1.0,,0.0,,,,,,147.0,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.
,BAO_0000357,B,,,191.0,H,,Autocuration,12278.0,,,CHEMBL615673,1.0,,8.0,,,,,,148.0,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C)
,BAO_0000019,F,,,22226.0,U,Homo sapiens,Autocuration,8249.0,,9606.0,CHEMBL615674,1.0,,0.0,,,,,,149.0,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5
,BAO_0000019,F,,,22226.0,U,Homo sapiens,Autocuration,8249.0,,9606.0,CHEMBL615675,1.0,,0.0,,,,,,150.0,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6
,BAO_0000219,F,,CCRF-CEM,22226.0,U,Homo sapiens,Autocuration,8249.0,,9606.0,CHEMBL615676,1.0,,0.0,,,,,635.0,151.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7
,BAO_0000219,F,,CCRF-CEM,22226.0,U,Homo sapiens,Autocuration,8249.0,,9606.0,CHEMBL615677,1.0,,0.0,,,,,635.0,152.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4
,BAO_0000219,F,,CCRF-CEM,22226.0,U,Homo sapiens,Autocuration,8249.0,,9606.0,CHEMBL615678,1.0,,0.0,,,,,635.0,153.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5
,BAO_0000219,F,,CCRF-CEM,22226.0,U,Homo sapiens,Autocuration,8249.0,,9606.0,CHEMBL615679,1.0,,0.0,,,,,635.0,154.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6
,BAO_0000019,F,,,22226.0,U,Homo sapiens,Autocuration,8249.0,,9606.0,CHEMBL615680,1.0,,0.0,,,,,,155.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.
,BAO_0000019,F,,,22226.0,U,Homo sapiens,Autocuration,8249.0,,9606.0,CHEMBL615681,1.0,,0.0,,,,,,156.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4
,BAO_0000249,B,,,104290.0,H,,Autocuration,16992.0,,,CHEMBL857972,1.0,,6.0,,,,,,157.0,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain
,BAO_0000218,F,,,50264.0,N,Streptococcus pyogenes,Intermediate,10543.0,,1314.0,CHEMBL857899,1.0,,1.0,,,,,,158.0,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse
,BAO_0000218,F,,,50527.0,N,Human herpesvirus 3,Intermediate,17833.0,,10335.0,CHEMBL615371,1.0,,1.0,,,,,,159.0,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV)
,BAO_0000218,F,,HEL,50527.0,N,vericilla zoster virus,Expert,17290.0,,10335.0,CHEMBL615372,1.0,,1.0,,,,,468.0,160.0,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.
,BAO_0000218,F,,,50527.0,N,vericilla zoster virus,Intermediate,17290.0,,10335.0,CHEMBL615373,1.0,,1.0,,,,,,161.0,Antiviral activity against 07/1 strain of VZV; ND: No data
,BAO_0000218,F,,,50527.0,N,vericilla zoster virus,Intermediate,17290.0,,10335.0,CHEMBL615374,1.0,,1.0,,,,,,162.0,Antiviral activity against 07/1 strain of VZV; ND=No data
,BAO_0000218,F,,,50145.0,N,escherichia cloac,Intermediate,10932.0,,561.0,CHEMBL615375,1.0,,1.0,,,,,,163.0,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)"
,BAO_0000019,B,,,22226.0,U,,Autocuration,9707.0,,,CHEMBL615376,1.0,,0.0,,,,,,164.0,Ratio of Ki at A2 to Ki at A1 receptors
,BAO_0000249,B,,,11143.0,H,Candida albicans,Expert,2346.0,,5476.0,CHEMBL615377,1.0,,8.0,,,,,,165.0,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay."
,BAO_0000357,B,,,18077.0,H,Candida glabrata CBS 138,Expert,2205.0,,284593.0,CHEMBL615378,1.0,,8.0,,,,,,166.0,"Inhibition of 1,3-beta-glucan synthase"
,BAO_0000219,F,,1-87 tumor cell line,80609.0,N,Homo sapiens,Intermediate,11900.0,,9606.0,CHEMBL615379,1.0,,1.0,,,,,832.0,167.0,Inhibition of growth of 1-87 human tumor cell line
,BAO_0000219,B,,,12166.0,D,Rattus norvegicus,Expert,14864.0,,10116.0,CHEMBL615380,1.0,,9.0,,,,,,168.0,Inhibition of 1-lipoxygenase (LOX)in RBL cells
,BAO_0000357,B,,,100171.0,D,Glycine max,Autocuration,16474.0,,3847.0,CHEMBL615381,1.0,,9.0,,,,,,169.0,Inhibitory activity against soybean 1-lipoxygenase (SLO)
,BAO_0000357,B,,,100171.0,D,Glycine max,Autocuration,16474.0,,3847.0,CHEMBL615382,1.0,,9.0,,,,,,170.0,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect
,BAO_0000357,B,,,100171.0,D,Glycine max,Autocuration,16474.0,,3847.0,CHEMBL615383,1.0,,9.0,,,,,,171.0,% inhibition against soybean 1-lipoxygenase (SLO)
,BAO_0000357,B,,,100171.0,D,Glycine max,Autocuration,16474.0,,3847.0,CHEMBL615384,1.0,,9.0,,,,,,172.0,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition
,BAO_0000357,B,,,100171.0,D,Glycine max,Autocuration,3094.0,,3847.0,CHEMBL615385,1.0,,9.0,,,,,,173.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90
,BAO_0000357,B,,,100171.0,D,Glycine max,Autocuration,3094.0,,3847.0,CHEMBL615386,1.0,,9.0,,,,,,174.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99
,BAO_0000357,B,,,100171.0,D,Glycine max,Autocuration,3094.0,,3847.0,CHEMBL615387,1.0,,9.0,,,,,,175.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75
,BAO_0000357,B,,,100171.0,D,Glycine max,Autocuration,3094.0,,3847.0,CHEMBL615388,1.0,,9.0,,,,,,176.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65
,BAO_0000357,B,,,100171.0,D,Glycine max,Autocuration,3094.0,,3847.0,CHEMBL615214,1.0,,9.0,,,,,,177.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50
,BAO_0000357,B,,,100171.0,D,Glycine max,Autocuration,3094.0,,3847.0,CHEMBL827087,1.0,,9.0,,,,,,178.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24
,BAO_0000357,B,,,100171.0,D,Glycine max,Autocuration,3094.0,,3847.0,CHEMBL615215,1.0,,9.0,,,,,,179.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13
,BAO_0000357,B,,,100171.0,D,Glycine max,Autocuration,3094.0,,3847.0,CHEMBL615216,1.0,,9.0,,,,,,180.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11
,BAO_0000357,B,,,100171.0,D,Glycine max,Autocuration,3094.0,,3847.0,CHEMBL615217,1.0,,9.0,,,,,,181.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5
,BAO_0000357,B,,,100171.0,D,Glycine max,Autocuration,3094.0,,3847.0,CHEMBL615218,1.0,,9.0,,,,,,182.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3
,BAO_0000357,B,,,100171.0,D,Glycine max,Autocuration,3094.0,,3847.0,CHEMBL615219,1.0,,9.0,,,,,,183.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1
,BAO_0000019,B,,,22226.0,U,Mus musculus,Autocuration,10413.0,,10090.0,CHEMBL615220,1.0,,0.0,,,,,,184.0,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM
,BAO_0000219,F,,C3H 10T1/2,80049.0,N,Mus musculus,Intermediate,16929.0,,10090.0,CHEMBL615221,1.0,,1.0,,,,,294.0,185.0,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity)
,BAO_0000019,F,,,22226.0,U,,Intermediate,1229.0,,,CHEMBL615222,1.0,,0.0,,,,,,186.0,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive
,BAO_0000357,B,,,11489.0,H,,Autocuration,16587.0,,,CHEMBL615223,1.0,,8.0,,,,,,187.0,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA)
,BAO_0000357,B,,,11862.0,H,,Autocuration,16587.0,,,CHEMBL615224,1.0,,8.0,,,,,,188.0,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA)
,BAO_0000357,B,,,11862.0,H,,Autocuration,16587.0,,,CHEMBL615225,1.0,,8.0,,,,,,189.0,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).
,BAO_0000357,B,,,11489.0,H,,Autocuration,16587.0,,,CHEMBL615226,1.0,,8.0,,,,,,190.0,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2
,BAO_0000357,B,,,11862.0,H,,Autocuration,16587.0,,,CHEMBL615227,1.0,,8.0,,,,,,191.0,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition
,BAO_0000019,F,,,12347.0,D,Bos taurus,Expert,8058.0,,9913.0,CHEMBL615228,1.0,,9.0,,,,,,192.0,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase
,BAO_0000357,B,,,100120.0,D,Rattus norvegicus,Expert,9065.0,,10116.0,CHEMBL615229,1.0,,9.0,,,,,,193.0,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect
,BAO_0000357,B,,,100120.0,D,Rattus norvegicus,Expert,8865.0,,10116.0,CHEMBL615230,1.0,,9.0,Adrenal gland,,,2369.0,,194.0,Inhibition of 11 beta-hydroxylase from rat adrenal gland
,BAO_0000357,B,,,100120.0,D,Rattus norvegicus,Expert,9066.0,,10116.0,CHEMBL615231,1.0,,9.0,,,,,,195.0,Inhibition of rat adrenal 11-beta-hydroxylase
,BAO_0000357,B,,,100120.0,D,Rattus norvegicus,Expert,8394.0,,10116.0,CHEMBL884520,1.0,,9.0,,,,,,196.0,Inhibition of rat adrenal 11-beta-hydroxylase
,BAO_0000357,B,,,100120.0,D,Rattus norvegicus,Expert,8394.0,,10116.0,CHEMBL615232,1.0,,9.0,,,,,,197.0,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M
,BAO_0000019,B,,,10328.0,H,,Autocuration,6431.0,,,CHEMBL615233,1.0,,8.0,,,,,,198.0,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone
,BAO_0000357,B,,,11490.0,H,,Autocuration,6431.0,,,CHEMBL827088,1.0,,8.0,,,,,,199.0,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol
,BAO_0000357,B,,,11490.0,H,,Autocuration,6431.0,,,CHEMBL615234,1.0,,8.0,,,,,,200.0,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol
,BAO_0000019,F,,,11134.0,H,,Autocuration,9295.0,,,CHEMBL615235,1.0,,8.0,,,,,,201.0,Compound was tested for the percent of inhibition against 12-LO at 10 uM
,BAO_0000019,B,,,12052.0,H,,Autocuration,10193.0,,,CHEMBL615236,1.0,,8.0,,,,,,202.0,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM
,BAO_0000019,B,,,11134.0,H,,Autocuration,13622.0,,,CHEMBL615237,1.0,,8.0,,,,,,203.0,Compound was tested in vitro for inhibition of 12-LO human platelet
,BAO_0000019,F,,,11134.0,H,,Autocuration,12079.0,,,CHEMBL615238,1.0,,8.0,,,,,,204.0,Inhibitory concentration against human platelet 12-lipoxygenase
,BAO_0000019,B,,,11134.0,H,,Autocuration,13622.0,,,CHEMBL615239,1.0,,8.0,,,,,,205.0,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet
,BAO_0000019,F,,,11134.0,D,Homo sapiens,Autocuration,12079.0,,9606.0,CHEMBL615240,1.0,,9.0,,,,,,206.0,Inhibitory concentration against human platelet 12-lipoxygenase
,BAO_0000019,B,,,11835.0,H,,Expert,13500.0,,,CHEMBL615241,1.0,,8.0,,,,,,207.0,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates
,BAO_0000357,B,,,11601.0,H,,Expert,13723.0,,,CHEMBL615242,1.0,,8.0,,,,,,208.0,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase
,BAO_0000019,B,,,11134.0,H,,Autocuration,16474.0,,,CHEMBL615243,1.0,,8.0,,,,,,209.0,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO)
,BAO_0000019,B,,,11134.0,H,,Autocuration,1630.0,,,CHEMBL615244,1.0,,8.0,,,,,,210.0,Inhibitory activity against human platelet 12-lipoxygenase
,BAO_0000019,B,,,11134.0,H,,Autocuration,167.0,,,CHEMBL615245,1.0,,8.0,,,,,,211.0,Inhibitory activity against human platelet 12-lipoxygenase was evaluated
,BAO_0000019,B,,,11134.0,H,,Autocuration,16474.0,,,CHEMBL615246,1.0,,8.0,,,,,,212.0,% inhibition against human platelet 12-lipoxygenase (12-HLO)
,BAO_0000019,B,,,11134.0,H,,Autocuration,167.0,,,CHEMBL615247,1.0,,8.0,,,,,,213.0,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM
,BAO_0000019,B,,,11134.0,H,,Autocuration,16474.0,,,CHEMBL615248,1.0,,8.0,,,,,,214.0,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition
,BAO_0000357,B,,,11601.0,H,,Autocuration,10091.0,,,CHEMBL615249,1.0,,8.0,,,,,,215.0,Inhibitory activity towards porcine 12-lipoxygenase
,BAO_0000357,B,,,11601.0,H,,Autocuration,11966.0,,,CHEMBL615250,1.0,,8.0,,,,,,216.0,Tested for inhibition against porcine 12-LO
,BAO_0000019,B,,,12052.0,H,,Autocuration,951.0,,,CHEMBL615251,1.0,,8.0,,,,,,217.0,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect
,BAO_0000019,B,,,12052.0,H,,Autocuration,10997.0,,,CHEMBL615252,1.0,,8.0,,,,,,218.0,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma
,BAO_0000019,B,,,12052.0,H,,Expert,10193.0,,,CHEMBL828340,1.0,,8.0,,,,,,219.0,In vitro inhibition of rat platelet 12-lipoxygenase
,BAO_0000019,B,,,12052.0,H,,Autocuration,10193.0,,,CHEMBL615253,1.0,,8.0,,,,,,220.0,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM
,BAO_0000019,B,,,12052.0,H,,Autocuration,10193.0,,,CHEMBL615254,1.0,,8.0,,,,,,221.0,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM
,BAO_0000019,B,,,12052.0,H,,Autocuration,10193.0,,,CHEMBL615255,1.0,,8.0,,,,,,222.0,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM
,BAO_0000019,B,,,12052.0,H,,Autocuration,10193.0,,,CHEMBL615256,1.0,,8.0,,,,,,223.0,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM
,BAO_0000019,B,,,12052.0,H,,Autocuration,10193.0,,,CHEMBL615257,1.0,,8.0,,,,,,224.0,In vitro inhibitory activity against rat platelet 12-lipoxygenase
,BAO_0000019,B,,,12052.0,H,,Autocuration,11087.0,,,CHEMBL615258,1.0,,8.0,,,,,,225.0,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM
,BAO_0000219,F,,41M,80007.0,N,Homo sapiens,Intermediate,15569.0,,9606.0,CHEMBL615259,1.0,,1.0,,,,,621.0,226.0,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure
,BAO_0000219,F,,41M,80007.0,N,Homo sapiens,Expert,12989.0,,9606.0,CHEMBL615260,1.0,,1.0,,,,,621.0,227.0,In vitro antitumor activity against 41M cell line.
,BAO_0000219,F,,41M,80007.0,N,Homo sapiens,Intermediate,16745.0,,9606.0,CHEMBL615261,1.0,,1.0,,,,,621.0,228.0,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.
,BAO_0000219,F,,41M,80007.0,N,Homo sapiens,Intermediate,15569.0,,9606.0,CHEMBL615262,1.0,,1.0,,,,,621.0,229.0,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure
,BAO_0000219,F,,41M,80007.0,N,Homo sapiens,Expert,12989.0,,9606.0,CHEMBL615263,1.0,,1.0,,,,,621.0,230.0,In vitro antitumor activity against 41McisR cell line.
,BAO_0000219,F,,41M,80007.0,N,Homo sapiens,Expert,12989.0,,9606.0,CHEMBL838393,1.0,,1.0,,,,,621.0,231.0,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line
,BAO_0000219,F,,41M,80007.0,N,Homo sapiens,Intermediate,16745.0,,9606.0,CHEMBL615264,1.0,,1.0,,,,,621.0,232.0,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay
,BAO_0000357,B,,,84.0,D,Homo sapiens,Expert,6210.0,,9606.0,CHEMBL615265,1.0,,9.0,,,,,,233.0,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I)
,BAO_0000357,B,,,68.0,D,Homo sapiens,Expert,6210.0,,9606.0,CHEMBL615266,1.0,,9.0,,,,,,234.0,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II)
,BAO_0000357,B,,,68.0,H,,Expert,6226.0,,,CHEMBL615267,1.0,,8.0,,,,,,235.0,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II)
,BAO_0000357,B,,,10201.0,H,,Expert,17855.0,,,CHEMBL615268,1.0,,8.0,,,,,,236.0,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase
,BAO_0000357,B,,,10201.0,H,,Expert,17855.0,,,CHEMBL615269,1.0,,8.0,,,,,,237.0,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined
,BAO_0000357,B,,,10201.0,H,,Expert,17855.0,,,CHEMBL615270,1.0,,8.0,,,,,,238.0,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase
,BAO_0000357,B,,,12220.0,H,,Autocuration,10413.0,,,CHEMBL615271,1.0,,8.0,,,,,,239.0,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM"
,BAO_0000357,B,,,11303.0,H,Escherichia coli,Autocuration,10413.0,,562.0,CHEMBL615272,1.0,,8.0,,,,,,240.0,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested"
,BAO_0000357,B,,,11303.0,H,Escherichia coli,Autocuration,10413.0,,562.0,CHEMBL615103,1.0,,8.0,,,,,,241.0,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested"
,BAO_0000357,B,,,11303.0,H,Escherichia coli,Autocuration,10413.0,,562.0,CHEMBL615104,1.0,,8.0,,,,,,242.0,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested"
,BAO_0000357,B,,,12220.0,H,,Autocuration,10413.0,,,CHEMBL615105,1.0,,8.0,,,,,,243.0,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM"
,BAO_0000357,B,,,12220.0,H,,Autocuration,10413.0,,,CHEMBL872866,1.0,,8.0,,,,,,244.0,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM"
,BAO_0000357,B,,,11303.0,H,Sus scrofa,Autocuration,7587.0,,9823.0,CHEMBL615106,1.0,,8.0,,,,,,245.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration"
,BAO_0000019,B,,,11303.0,H,Sus scrofa,Autocuration,7587.0,,9823.0,CHEMBL615107,1.0,,8.0,,,,,,246.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme."
,BAO_0000357,B,,,11303.0,H,Sus scrofa,Autocuration,7587.0,,9823.0,CHEMBL615108,1.0,,8.0,,,,,,247.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration"
,BAO_0000357,B,,,11303.0,H,Sus scrofa,Autocuration,7587.0,,9823.0,CHEMBL615109,1.0,,8.0,,,,,,248.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration"
,BAO_0000357,B,,,11303.0,H,Sus scrofa,Autocuration,7587.0,,9823.0,CHEMBL615110,1.0,,8.0,,,,,,249.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration"
,BAO_0000019,B,,,11303.0,H,Sus scrofa,Autocuration,7587.0,,9823.0,CHEMBL840105,1.0,,8.0,,,,,,250.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration"
,BAO_0000019,B,,,11303.0,H,Sus scrofa,Autocuration,7587.0,,9823.0,CHEMBL615111,1.0,,8.0,,,,,,251.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration"
,BAO_0000019,B,,,11303.0,H,Sus scrofa,Autocuration,7587.0,,9823.0,CHEMBL615112,1.0,,8.0,,,,,,252.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration"
,BAO_0000019,B,,,11303.0,H,Sus scrofa,Autocuration,7587.0,,9823.0,CHEMBL615113,1.0,,8.0,,,,,,253.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration"
,BAO_0000019,B,,,11303.0,H,Sus scrofa,Autocuration,7587.0,,9823.0,CHEMBL615114,1.0,,8.0,,,,,,254.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme."
,BAO_0000357,B,,,11303.0,H,Sus scrofa,Autocuration,7587.0,,9823.0,CHEMBL615115,1.0,,8.0,,,,,,255.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration"
,BAO_0000019,B,,,11303.0,H,Sus scrofa,Autocuration,7587.0,,9823.0,CHEMBL615116,1.0,,8.0,,,,,,256.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration"
,BAO_0000357,B,,,11303.0,H,,Autocuration,7323.0,,,CHEMBL615698,1.0,,8.0,,,,,,257.0,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate"
,BAO_0000019,B,,,22226.0,U,Sus scrofa,Autocuration,7587.0,,9823.0,CHEMBL615699,1.0,,0.0,,,,,,258.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration"
,BAO_0000019,B,,,22226.0,U,Sus scrofa,Autocuration,7587.0,,9823.0,CHEMBL615700,1.0,,0.0,,,,,,259.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme."
,BAO_0000357,B,,,100249.0,H,Saccharomyces cerevisiae,Expert,13750.0,,4932.0,CHEMBL615701,1.0,,8.0,,,,,,260.0,Inhibition of 5-Desaturase involved in ergosterol biosynthesis
,BAO_0000019,B,,,22226.0,U,Rattus norvegicus,Autocuration,7662.0,,10116.0,CHEMBL615702,1.0,,0.0,,,,,,261.0,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase
,BAO_0000019,B,,,22226.0,U,Rattus norvegicus,Autocuration,7662.0,,10116.0,CHEMBL615703,1.0,,0.0,,,,,,262.0,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase
,BAO_0000019,B,,,22226.0,U,Rattus norvegicus,Autocuration,7662.0,,10116.0,CHEMBL615704,1.0,,0.0,,,,,,263.0,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor"
,BAO_0000019,F,,,104698.0,H,,Autocuration,12211.0,,,CHEMBL615705,1.0,,6.0,,,,,,264.0,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat"
,BAO_0000019,F,,,104698.0,H,,Autocuration,12211.0,,,CHEMBL615706,1.0,,6.0,,,,,,265.0,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat"
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,12211.0,,10141.0,CHEMBL615707,1.0,,9.0,Ileum,,,2116.0,,266.0,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig
,BAO_0000019,F,,,10623.0,H,,Expert,12211.0,,,CHEMBL615708,1.0,,8.0,,,,,,267.0,Stimulatory activity of intragastric pressure was tested in the rat
,BAO_0000357,B,,,121.0,H,,Autocuration,15453.0,,,CHEMBL615709,1.0,,8.0,,,,,,268.0,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.
,BAO_0000218,F,,,22226.0,U,Rattus norvegicus,Autocuration,11884.0,,10116.0,CHEMBL615710,1.0,,0.0,,,,,,269.0,Dose to reduce neuronal firing against 5-HT cells in rats (iv)
,BAO_0000019,F,,,12688.0,H,,Autocuration,7185.0,,,CHEMBL615711,1.0,,8.0,,,,,,270.0,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor
,BAO_0000357,B,,,121.0,D,Homo sapiens,Expert,6876.0,,9606.0,CHEMBL615712,1.0,,9.0,,,,,,271.0,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine
,BAO_0000357,B,,,121.0,D,Homo sapiens,Expert,6876.0,,9606.0,CHEMBL836325,1.0,,9.0,,,,,,272.0,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data
,BAO_0000019,F,,,12198.0,H,,Autocuration,11863.0,,,CHEMBL615713,1.0,,8.0,,,,,,273.0,Inhibition of high affinity 5-HT uptake at concentration of 1 uM
,BAO_0000357,B,,,12198.0,H,,Autocuration,11863.0,,,CHEMBL615714,1.0,,8.0,,,,,,274.0,Inhibition constant of high-affinity 5-HT uptake
,BAO_0000019,F,,,12198.0,H,,Autocuration,11863.0,,,CHEMBL615715,1.0,,8.0,,,,,,275.0,Michaelis-Menten constant was reported for high affinity transport of 5-HT
,BAO_0000019,F,,,12198.0,H,,Autocuration,11863.0,,,CHEMBL615716,1.0,,8.0,,,,,,276.0,Maximum rate was determined for high affinity transport of 5-HT
,BAO_0000019,F,,,104714.0,H,,Autocuration,4639.0,,,CHEMBL615717,1.0,,4.0,,,,,,277.0,Compound was tested for agonistic activity against 5-HT uptake
,BAO_0000019,B,,,10577.0,H,,Expert,15796.0,,,CHEMBL881818,1.0,,8.0,,,,,,278.0,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay
,BAO_0000357,B,,,105.0,H,Bos taurus,Expert,15796.0,,9913.0,CHEMBL884540,1.0,,8.0,,,,,,279.0,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay
,BAO_0000224,B,,,104744.0,D,Rattus norvegicus,Autocuration,12801.0,,10116.0,CHEMBL615718,1.0,,5.0,,,,,,280.0,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand
,BAO_0000224,B,,,104744.0,H,,Autocuration,12801.0,,,CHEMBL615719,1.0,,4.0,,,,,,281.0,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand
,BAO_0000249,B,,,104744.0,H,,Autocuration,12120.0,Membranes,,CHEMBL615720,1.0,,4.0,,,,,,282.0,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M
,BAO_0000249,B,,,104744.0,H,,Autocuration,12120.0,Membranes,,CHEMBL615721,1.0,,4.0,,,,,,283.0,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.
,BAO_0000019,B,,,104744.0,H,,Autocuration,11963.0,,,CHEMBL615722,1.0,,4.0,,,,,,284.0,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex
,BAO_0000019,F,,,51.0,H,,Autocuration,11701.0,,,CHEMBL615723,1.0,,8.0,,,,,,285.0,Dose required to reduce neuronal firing of 5-HT1A cells by 50%
,BAO_0000221,B,,,51.0,H,,Autocuration,9995.0,,,CHEMBL615724,1.0,,8.0,Hippocampus,,,10000000.0,,286.0,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
,BAO_0000221,B,,,51.0,H,,Autocuration,9995.0,,,CHEMBL615725,1.0,,8.0,Hippocampus,,,10000000.0,,287.0,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus
,BAO_0000221,B,,,51.0,H,,Autocuration,9995.0,,,CHEMBL615726,1.0,,8.0,Hippocampus,,,10000000.0,,288.0,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
,BAO_0000218,F,In vivo,,10576.0,H,,Autocuration,16394.0,,,CHEMBL615727,1.0,,8.0,,,,,,289.0,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52)
,BAO_0000019,F,,,105570.0,D,Cavia porcellus,Intermediate,11574.0,,10141.0,CHEMBL615728,1.0,,9.0,,,,,,290.0,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.
,BAO_0000219,B,,CHO,279.0,H,,Autocuration,15779.0,,,CHEMBL857971,1.0,,8.0,,,,,449.0,291.0,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.
,BAO_0000357,B,,,107.0,H,,Autocuration,15363.0,,,CHEMBL615729,1.0,,8.0,,,,,,292.0,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor
,BAO_0000019,F,,,12687.0,D,Rattus norvegicus,Expert,15363.0,,10116.0,CHEMBL615730,1.0,,9.0,,,,,,293.0,Efficacy against 5-hydroxytryptamine 2A receptor
,BAO_0000019,F,,,12687.0,H,,Expert,15329.0,,,CHEMBL615731,1.0,,8.0,,,,,,294.0,Intrinsic activity towards 5-HT2A receptor of rat tail artery
,BAO_0000019,F,,,12687.0,H,,Expert,15329.0,,,CHEMBL615732,1.0,,8.0,,,,,,295.0,Relative potency towards 5-HT2A receptor of rat tail artery
,BAO_0000019,F,,,12687.0,H,,Expert,15329.0,,,CHEMBL615733,1.0,,8.0,,,,,,296.0,Blocking 5-HT2A receptor-mediated contractions of rat tail artery
,BAO_0000019,F,,,12687.0,H,,Expert,15329.0,,,CHEMBL615734,1.0,,8.0,,,,,,297.0,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery
,BAO_0000019,F,,,12687.0,H,,Autocuration,15329.0,,,CHEMBL615735,1.0,,8.0,,,,,,298.0,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.
,BAO_0000019,F,,,12687.0,H,,Expert,15329.0,,,CHEMBL615736,1.0,,8.0,,,,,,299.0,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,273.0,,10141.0,CHEMBL615737,1.0,,9.0,Ileum,,,2116.0,,300.0,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,273.0,,10141.0,CHEMBL615738,1.0,,9.0,Ileum,,,2116.0,,301.0,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI)
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,273.0,,10141.0,CHEMBL615739,1.0,,9.0,Ileum,,,2116.0,,302.0,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.
,BAO_0000357,B,,,10623.0,H,,Autocuration,12092.0,,,CHEMBL615278,1.0,,8.0,,,,,,303.0,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.
,BAO_0000019,F,,,10623.0,D,Rattus norvegicus,Expert,1317.0,,10116.0,CHEMBL615279,1.0,,9.0,,,,,,304.0,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae
,BAO_0000357,B,,,168.0,H,,Expert,12409.0,,,CHEMBL615280,1.0,,8.0,,,,,,305.0,Binding affinity against 5-hydroxytryptamine 4 receptor
,BAO_0000019,B,,,22226.0,U,Gallus gallus,Autocuration,11126.0,,9031.0,CHEMBL615281,1.0,,0.0,,,,,,306.0,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine
,BAO_0000019,F,,,22226.0,U,Homo sapiens,Autocuration,11126.0,,9606.0,CHEMBL615282,1.0,,0.0,,,,,,307.0,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity
,BAO_0000019,F,,,22226.0,U,Homo sapiens,Autocuration,11126.0,,9606.0,CHEMBL615283,1.0,,0.0,,,,,,308.0,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control
,BAO_0000219,B,,HL-60,80156.0,N,Homo sapiens,Autocuration,11126.0,,9606.0,CHEMBL615284,1.0,,1.0,,,,,649.0,309.0,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells
,BAO_0000019,B,,,22226.0,U,Homo sapiens,Autocuration,11126.0,,9606.0,CHEMBL615285,1.0,,0.0,,,,,,310.0,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity
,BAO_0000019,B,,,22226.0,U,Homo sapiens,Autocuration,11126.0,,9606.0,CHEMBL615286,1.0,,0.0,,,,,,311.0,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control
,BAO_0000219,B,,Oocytes,104703.0,D,Homo sapiens,Autocuration,17807.0,,9606.0,CHEMBL615287,1.0,,7.0,,,,,,312.0,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes
,BAO_0000220,F,,,100256.0,S,,Intermediate,16575.0,,,CHEMBL615288,1.0,,2.0,,,,,,313.0,Chymotryptic inhibitory activity against 26S proteasome
,BAO_0000220,B,,,100256.0,S,,Intermediate,15407.0,,,CHEMBL615289,1.0,,2.0,,,,,,314.0,Inhibitory activity against 26S proteasome degradation of IkB
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,10797.0,,9606.0,CHEMBL615290,1.0,,1.0,,,,,478.0,315.0,In vitro inhibition of 2780/DOX ovarian cancer cell line
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,10797.0,,9606.0,CHEMBL884522,1.0,,1.0,,,,,478.0,316.0,In vitro inhibition of 2780/S ovarian cancer cell line
,BAO_0000019,F,,,22226.0,U,Homo sapiens,Autocuration,3469.0,,9606.0,CHEMBL615291,1.0,,0.0,,,,,,317.0,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells
,BAO_0000225,B,,,22222.0,M,,Intermediate,16037.0,,,CHEMBL615292,1.0,,3.0,,,,,,318.0,Association constant for binding to AATT 28-mer AATT hairpin
,BAO_0000225,B,,,22222.0,M,,Intermediate,16037.0,,,CHEMBL615293,1.0,,3.0,,,,,,319.0,Kinetically Defined Association Constant for 28-mer AATT hairpin.
,BAO_0000225,B,,,22222.0,M,,Intermediate,16037.0,,,CHEMBL615294,1.0,,3.0,,,,,,320.0,Reaction Rate Parameter for 28-mer AATT hairpin
,BAO_0000225,B,,,22222.0,M,,Intermediate,16037.0,,,CHEMBL615295,1.0,,3.0,,,,,,321.0,Reaction Rate Parameter for 28-mer AATT hairpin
,BAO_0000019,F,,,22226.0,U,Homo sapiens,Autocuration,16524.0,,9606.0,CHEMBL825021,1.0,,0.0,,,,,,322.0,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1)
,BAO_0000019,F,,,22226.0,U,Homo sapiens,Autocuration,16524.0,,9606.0,CHEMBL615296,1.0,,0.0,,,,,,323.0,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2)
,BAO_0000019,F,,,22226.0,U,Homo sapiens,Autocuration,16524.0,,9606.0,CHEMBL615297,1.0,,0.0,,,,,,324.0,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1
,BAO_0000019,F,,,22226.0,U,Cricetulus griseus,Autocuration,16758.0,,10029.0,CHEMBL615298,1.0,,0.0,,,,,,325.0,Cytotoxicity against cell line 2SC/20 determined by MTT test
,BAO_0000019,F,,,22226.0,U,Cricetulus griseus,Autocuration,16758.0,,10029.0,CHEMBL615299,1.0,,0.0,,,,,,326.0,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test
,BAO_0000019,F,,,22226.0,U,Cricetulus griseus,Autocuration,16758.0,,10029.0,CHEMBL615300,1.0,,0.0,,,,,,327.0,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test
,BAO_0000357,B,,,241.0,H,,Autocuration,14360.0,,,CHEMBL615301,1.0,,8.0,,,,,,328.0,Binding affinity on 3 beta-hydroxysteroid dehydrogenase
,BAO_0000357,B,,,241.0,D,Homo sapiens,Expert,14360.0,,9606.0,CHEMBL615302,1.0,,9.0,,,,,,329.0,Binding affinity for 3-beta-hydroxysteroid dehydrogenase
,BAO_0000019,B,,,22226.0,U,Rattus norvegicus,Autocuration,9964.0,,10116.0,CHEMBL615303,1.0,,0.0,,,,,,330.0,Selectivity ratio of ID50 in liver and heart
,BAO_0000019,B,,,12132.0,H,,Autocuration,9964.0,,,CHEMBL615304,1.0,,8.0,,,,,,331.0,"Selectivity, ratio of relative ID50 in liver and heart"
,BAO_0000019,B,,,12132.0,H,,Autocuration,9964.0,,,CHEMBL615305,1.0,,8.0,,,,,,332.0,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3
,BAO_0000218,B,,,12132.0,H,,Autocuration,9964.0,,,CHEMBL615306,1.0,,8.0,,,,,,333.0,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor"
,BAO_0000218,B,,,12132.0,H,,Autocuration,9964.0,,,CHEMBL615307,1.0,,8.0,,,,,,334.0,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor"
,BAO_0000218,B,In vivo,,12132.0,H,,Autocuration,9964.0,,,CHEMBL615308,1.0,,8.0,,,,,,335.0,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor"
,BAO_0000218,F,In vivo,,12132.0,H,,Autocuration,9964.0,,,CHEMBL615309,1.0,,8.0,,,,,,336.0,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor"
,BAO_0000019,B,,,22226.0,U,,Autocuration,9964.0,,,CHEMBL615310,1.0,,0.0,,,,,,337.0,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine"
,BAO_0000019,B,,,12132.0,H,,Autocuration,9964.0,,,CHEMBL615311,1.0,,8.0,,,,,,338.0,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3
,BAO_0000019,B,,,22226.0,U,Homo sapiens,Autocuration,9964.0,,9606.0,CHEMBL615312,1.0,,0.0,,,,,,339.0,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart"
,BAO_0000019,B,,,12132.0,H,,Autocuration,9964.0,,,CHEMBL615313,1.0,,8.0,,,,,,340.0,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3
,BAO_0000019,F,,,12132.0,H,,Autocuration,9964.0,,,CHEMBL615314,1.0,,8.0,,,,,,341.0,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3
,BAO_0000019,B,,,12132.0,H,,Autocuration,9964.0,,,CHEMBL615315,1.0,,8.0,,,,,,342.0,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor"
,BAO_0000218,B,,,22226.0,U,Rattus norvegicus,Autocuration,9964.0,,10116.0,CHEMBL615316,1.0,,0.0,,,,,,343.0,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration"
,BAO_0000218,B,In vivo,,12132.0,H,,Autocuration,9964.0,,,CHEMBL615317,1.0,,8.0,,,,,,344.0,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3
,BAO_0000218,B,,,12132.0,H,,Autocuration,9964.0,,,CHEMBL615318,1.0,,8.0,,,,,,345.0,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor"
,BAO_0000218,B,,,22226.0,U,Rattus norvegicus,Autocuration,9964.0,,10116.0,CHEMBL615319,1.0,,0.0,,,,,,346.0,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration"
,BAO_0000019,B,,,12132.0,H,,Autocuration,9964.0,,,CHEMBL615320,1.0,,8.0,,,,,,347.0,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor"
,BAO_0000019,F,,,12132.0,H,,Autocuration,9964.0,,,CHEMBL615321,1.0,,8.0,,,,,,348.0,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor"
,BAO_0000019,B,,,22226.0,U,Rattus norvegicus,Autocuration,3796.0,,10116.0,CHEMBL615322,1.0,,0.0,,,,,,349.0,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor"
,BAO_0000357,B,,,19690.0,H,Escherichia coli,Autocuration,4251.0,,562.0,CHEMBL615323,1.0,,8.0,,,,,,350.0,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli
,BAO_0000357,B,,,19690.0,H,Escherichia coli,Autocuration,4251.0,,562.0,CHEMBL615407,1.0,,8.0,,,,,,351.0,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli
,BAO_0000357,B,,,19690.0,H,Escherichia coli,Autocuration,4251.0,,562.0,CHEMBL857267,1.0,,8.0,,,,,,352.0,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli
,BAO_0000357,B,,,19690.0,H,Escherichia coli,Autocuration,4251.0,,562.0,CHEMBL615408,1.0,,8.0,,,,,,353.0,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli
,BAO_0000357,B,,,19690.0,H,,Autocuration,166.0,,,CHEMBL615409,1.0,,8.0,,,,,,354.0,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible
,BAO_0000357,B,,,19690.0,H,,Autocuration,17861.0,,,CHEMBL615410,1.0,,8.0,,,,,,355.0,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase
,BAO_0000357,B,,,19690.0,H,,Autocuration,166.0,,,CHEMBL615411,1.0,,8.0,,,,,,356.0,Inhibition constant against 3-dehydroquinate synthase
,BAO_0000357,B,,,19690.0,H,,Autocuration,166.0,,,CHEMBL615412,1.0,,8.0,,,,,,357.0,Association rate constant against 3-dehydroquinate synthase
,BAO_0000357,B,,,19690.0,H,,Autocuration,166.0,,,CHEMBL615413,1.0,,8.0,,,,,,358.0,Rate constant against 3-dehydroquinate synthase
,BAO_0000019,B,,,22226.0,U,,Autocuration,3548.0,,,CHEMBL615414,1.0,,0.0,,,,,,359.0,Inhibitory activity against fuc-TVII
,BAO_0000251,B,,,12236.0,D,Rattus norvegicus,Autocuration,9877.0,Microsomes,10116.0,CHEMBL615415,1.0,,9.0,Liver,,,2107.0,,360.0,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes
,BAO_0000251,B,,,12236.0,D,Rattus norvegicus,Autocuration,9877.0,Microsomes,10116.0,CHEMBL615416,1.0,,9.0,Liver,,,2107.0,,361.0,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes
,BAO_0000251,B,,,12236.0,D,Rattus norvegicus,Autocuration,9877.0,Microsomes,10116.0,CHEMBL615417,1.0,,9.0,Liver,,,2107.0,,362.0,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes
,BAO_0000251,B,,,12236.0,D,Rattus norvegicus,Autocuration,9877.0,Microsomes,10116.0,CHEMBL615418,1.0,,9.0,Liver,,,2107.0,,363.0,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes
,BAO_0000251,B,,,12236.0,D,Rattus norvegicus,Autocuration,9877.0,Microsomes,10116.0,CHEMBL615419,1.0,,9.0,Liver,,,2107.0,,364.0,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes
,BAO_0000251,B,,,12236.0,D,Rattus norvegicus,Autocuration,9877.0,Microsomes,10116.0,CHEMBL615420,1.0,,9.0,Liver,,,2107.0,,365.0,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes
,BAO_0000251,B,,,12236.0,D,Rattus norvegicus,Autocuration,9877.0,Microsomes,10116.0,CHEMBL615421,1.0,,9.0,Liver,,,2107.0,,366.0,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM
,BAO_0000251,B,,,12236.0,D,Rattus norvegicus,Autocuration,9877.0,Microsomes,10116.0,CHEMBL615422,1.0,,9.0,Liver,,,2107.0,,367.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM
,BAO_0000251,B,,,12236.0,D,Rattus norvegicus,Autocuration,9877.0,Microsomes,10116.0,CHEMBL615423,1.0,,9.0,Liver,,,2107.0,,368.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM
,BAO_0000251,B,,,12236.0,D,Rattus norvegicus,Autocuration,9877.0,Microsomes,10116.0,CHEMBL872868,1.0,,9.0,Liver,,,2107.0,,369.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM
,BAO_0000251,B,,,12236.0,D,Rattus norvegicus,Autocuration,9877.0,Microsomes,10116.0,CHEMBL615424,1.0,,9.0,Liver,,,2107.0,,370.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM
,BAO_0000224,B,,,104832.0,H,,Autocuration,3003.0,,,CHEMBL825022,1.0,,4.0,,,,,,371.0,Inhibitory activity against 3-phosphoglycerate kinase.
,BAO_0000224,B,,,104832.0,H,,Autocuration,3003.0,,,CHEMBL615425,1.0,,4.0,,,,,,372.0,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1
,BAO_0000224,B,,,104832.0,H,,Autocuration,3003.0,,,CHEMBL615426,1.0,,4.0,,,,,,373.0,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase"
,BAO_0000357,B,,,10612.0,D,Homo sapiens,Expert,17185.0,,9606.0,CHEMBL615427,1.0,,9.0,,,,,,374.0,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM
,BAO_0000219,F,,3677 melanoma cell line,80616.0,N,Homo sapiens,Intermediate,6072.0,,9606.0,CHEMBL615428,1.0,,1.0,,,,,844.0,375.0,Cytotoxicity on 3677 melanoma cells
,BAO_0000219,F,,3677 melanoma cell line,80616.0,N,Homo sapiens,Intermediate,6072.0,,9606.0,CHEMBL615429,1.0,,1.0,,,,,844.0,376.0,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL
,BAO_0000219,F,,MC-38,80617.0,N,Mus musculus,Intermediate,5018.0,,10090.0,CHEMBL615430,1.0,,1.0,,,,,700.0,377.0,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay
,BAO_0000019,F,,,22226.0,U,Homo sapiens,Intermediate,2852.0,,9606.0,CHEMBL615431,1.0,,0.0,,,,,,378.0,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines
,BAO_0000218,F,,B16,22226.0,U,,Autocuration,8663.0,,,CHEMBL615432,1.0,,0.0,,,,,798.0,379.0,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested
,BAO_0000218,F,,B16,22226.0,U,,Autocuration,8663.0,,,CHEMBL615433,1.0,,0.0,,,,,798.0,380.0,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.
,BAO_0000019,F,,,12464.0,D,Human rhinovirus 14,Expert,3245.0,,12131.0,CHEMBL615434,1.0,,9.0,,,,,,381.0,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease
,BAO_0000218,F,,,50085.0,N,Human rhinovirus sp.,Intermediate,3245.0,,169066.0,CHEMBL615435,1.0,,1.0,,,,,,382.0,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM
,BAO_0000218,F,,,50679.0,N,human rhinovirus type 14,Intermediate,3877.0,,169066.0,CHEMBL615436,1.0,,1.0,,,,,,383.0,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI
,BAO_0000218,F,,,50679.0,N,human rhinovirus type 14,Intermediate,3877.0,,169066.0,CHEMBL615437,1.0,,1.0,,,,,,384.0,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact
,BAO_0000019,F,,,12464.0,D,Human rhinovirus 14,Expert,5861.0,,12131.0,CHEMBL615438,1.0,,9.0,,,,,,385.0,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay
,BAO_0000019,F,,,12464.0,D,Human rhinovirus 14,Expert,5861.0,,12131.0,CHEMBL615439,1.0,,9.0,,,,,,386.0,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay
,BAO_0000019,F,,,12464.0,D,Human rhinovirus 14,Expert,5861.0,,12131.0,CHEMBL615440,1.0,,9.0,,,,,,387.0,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay
,BAO_0000019,F,,,12464.0,D,Human rhinovirus 14,Expert,5861.0,,12131.0,CHEMBL615441,1.0,,9.0,,,,,,388.0,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive
,BAO_0000218,F,,,50665.0,N,Enterovirus,Intermediate,13748.0,,12059.0,CHEMBL615641,1.0,,1.0,,,,,,389.0,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease
,BAO_0000218,F,,,50665.0,N,Enterovirus,Intermediate,13748.0,,12059.0,CHEMBL872065,1.0,,1.0,,,,,,390.0,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease
,BAO_0000218,F,,,50665.0,N,Enterovirus,Intermediate,13748.0,,12059.0,CHEMBL825023,1.0,,1.0,,,,,,391.0,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease
,BAO_0000218,F,,,50665.0,N,Enterovirus,Intermediate,13748.0,,12059.0,CHEMBL615642,1.0,,1.0,,,,,,392.0,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease
,BAO_0000357,B,,,12464.0,H,Human rhinovirus B,Expert,13748.0,,147712.0,CHEMBL615643,1.0,,8.0,,,,,,393.0,Inhibition of human rhinovirus 3C protease
,BAO_0000019,B,,,22226.0,U,Homo sapiens,Autocuration,17699.0,,9606.0,CHEMBL615644,1.0,,0.0,,,,,,394.0,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited
,BAO_0000218,F,,3EM 37,80619.0,N,Mus musculus,Intermediate,7145.0,,10090.0,CHEMBL615645,1.0,,1.0,,,,,833.0,395.0,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5)
,BAO_0000218,F,,3EM 37,80619.0,N,Mus musculus,Intermediate,7145.0,,10090.0,CHEMBL615646,1.0,,1.0,,,,,833.0,396.0,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16)
,BAO_0000218,F,,3EM 37,80619.0,N,Mus musculus,Intermediate,7145.0,,10090.0,CHEMBL615647,1.0,,1.0,,,,,833.0,397.0,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10)
,BAO_0000218,F,,3EM 37,80619.0,N,Mus musculus,Intermediate,7145.0,,10090.0,CHEMBL615648,1.0,,1.0,,,,,833.0,398.0,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6)
,BAO_0000218,F,,3EM 37,80619.0,N,Mus musculus,Intermediate,7145.0,,10090.0,CHEMBL615649,1.0,,1.0,,,,,833.0,399.0,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg
,BAO_0000218,F,,3EM 37,80619.0,N,Mus musculus,Intermediate,7145.0,,10090.0,CHEMBL615650,1.0,,1.0,,,,,833.0,400.0,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg
,BAO_0000218,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,5325.0,,10090.0,CHEMBL615651,1.0,,1.0,,,,,847.0,401.0,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor
,BAO_0000218,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,5325.0,,10090.0,CHEMBL615652,1.0,,1.0,,,,,847.0,402.0,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor
,BAO_0000218,F,,3LL cell line,80620.0,N,Mus musculus,Expert,5325.0,,10090.0,CHEMBL615653,1.0,,1.0,,,,,847.0,403.0,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615654,1.0,,1.0,,,,,847.0,404.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615655,1.0,,1.0,,,,,847.0,405.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL825024,1.0,,1.0,,,,,847.0,406.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615656,1.0,,1.0,,,,,847.0,407.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615657,1.0,,1.0,,,,,847.0,408.0,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615658,1.0,,1.0,,,,,847.0,409.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615659,1.0,,1.0,,,,,847.0,410.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615660,1.0,,1.0,,,,,847.0,411.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615661,1.0,,1.0,,,,,847.0,412.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615662,1.0,,1.0,,,,,847.0,413.0,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615663,1.0,,1.0,,,,,847.0,414.0,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615664,1.0,,1.0,,,,,847.0,415.0,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615665,1.0,,1.0,,,,,847.0,416.0,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615666,1.0,,1.0,,,,,847.0,417.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615667,1.0,,1.0,,,,,847.0,418.0,putrescine levels in 3LL cells after the treatment of 1 uM of Compound
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615668,1.0,,1.0,,,,,847.0,419.0,putrescine levels in 3LL cells after the treatment of 10 uM of Compound
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615669,1.0,,1.0,,,,,847.0,420.0,putrescine levels in 3LL cells after the treatment of 250 uM of Compound
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615670,1.0,,1.0,,,,,847.0,421.0,putrescine levels in 3LL cells after the treatment of 50 uM of Compound
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL836739,1.0,,1.0,,,,,847.0,422.0,spermidine levels in 3LL cells after the treatment of 1 uM of Compound
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615671,1.0,,1.0,,,,,847.0,423.0,spermidine levels in 3LL cells after the treatment of 10 uM of Compound
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615672,1.0,,1.0,,,,,847.0,424.0,spermidine levels in 3LL cells after the treatment of 250 uM of Compound
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615791,1.0,,1.0,,,,,847.0,425.0,spermidine levels in 3LL cells after the treatment of 50 uM of Compound
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615792,1.0,,1.0,,,,,847.0,426.0,spermine levels in 3LL cells after the treatment of 1 uM of Compound
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615793,1.0,,1.0,,,,,847.0,427.0,spermine levels in 3LL cells after the treatment of 10 uM of Compound
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615794,1.0,,1.0,,,,,847.0,428.0,spermine levels in 3LL cells after the treatment of 250 uM of Compound
,BAO_0000219,F,,3LL cell line,80620.0,N,Mus musculus,Intermediate,16169.0,,10090.0,CHEMBL615795,1.0,,1.0,,,,,847.0,429.0,spermine levels in 3LL cells after the treatment of 50 uM of Compound
,BAO_0000219,F,,3LLD122,80621.0,N,Homo sapiens,Intermediate,15547.0,,9606.0,CHEMBL615590,1.0,,1.0,,,,,971.0,430.0,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%
,BAO_0000218,F,,,22226.0,U,,Autocuration,8663.0,,,CHEMBL615591,1.0,,0.0,,,,,,431.0,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity
,BAO_0000218,F,,,22226.0,U,,Autocuration,8663.0,,,CHEMBL615592,1.0,,0.0,,,,,,432.0,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.
,BAO_0000218,F,,,22226.0,U,,Autocuration,8663.0,,,CHEMBL615593,1.0,,0.0,,,,,,433.0,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested
,BAO_0000218,F,,,22226.0,U,,Autocuration,8663.0,,,CHEMBL615594,1.0,,0.0,,,,,,434.0,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,4504.0,,10090.0,CHEMBL615595,1.0,,1.0,,,,,723.0,435.0,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,4504.0,,10090.0,CHEMBL615596,1.0,,1.0,,,,,723.0,436.0,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts
,BAO_0000219,F,,NIH3T3,11169.0,H,,Expert,12695.0,,,CHEMBL615597,1.0,,8.0,,,,,723.0,437.0,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,12695.0,,10090.0,CHEMBL615598,1.0,,1.0,,,,,723.0,438.0,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,12695.0,,10090.0,CHEMBL615599,1.0,,1.0,,,,,723.0,439.0,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Expert,17642.0,,10090.0,CHEMBL615600,1.0,,1.0,,,,,723.0,440.0,Effective dose against murine 3T3 fibroblasts cells
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Expert,17642.0,,10090.0,CHEMBL615601,1.0,,1.0,,,,,723.0,441.0,Dose required against murine 3T3 fibroblasts cells; 1-10 uM
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Expert,12340.0,,10090.0,CHEMBL615602,1.0,,1.0,,,,,723.0,442.0,Cytotoxic effect on 3T3 cells
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Expert,12340.0,,10090.0,CHEMBL615603,1.0,,1.0,,,,,723.0,443.0,Cytotoxic effect on 3T3 cells
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,12716.0,,10090.0,CHEMBL615604,1.0,,1.0,,,,,723.0,444.0,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,6277.0,,10090.0,CHEMBL615605,1.0,,1.0,,,,,723.0,445.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,6277.0,,10090.0,CHEMBL615606,1.0,,1.0,,,,,723.0,446.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Expert,6277.0,,10090.0,CHEMBL884526,1.0,,1.0,,,,,723.0,447.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Expert,6277.0,,10090.0,CHEMBL615607,1.0,,1.0,,,,,723.0,448.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,6277.0,,10090.0,CHEMBL615608,1.0,,1.0,,,,,723.0,449.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Expert,6277.0,,10090.0,CHEMBL615609,1.0,,1.0,,,,,723.0,450.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Expert,6277.0,,10090.0,CHEMBL615682,1.0,,1.0,,,,,723.0,451.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,6277.0,,10090.0,CHEMBL615683,1.0,,1.0,,,,,723.0,452.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested
,BAO_0000218,F,,NIH3T3,80951.0,N,Mus musculus,Expert,17780.0,,10090.0,CHEMBL615684,1.0,,1.0,,,,,723.0,453.0,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models
,BAO_0000219,F,,,104860.0,D,Mus musculus,Autocuration,12751.0,,10090.0,CHEMBL615685,1.0,,7.0,,,,,,454.0,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Expert,12380.0,,10090.0,CHEMBL615686,1.0,,1.0,,,,,723.0,455.0,Inhibition of Swiss 3T3 Mouse fibroblast proliferation
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,14892.0,,10090.0,CHEMBL615687,1.0,,1.0,,,,,723.0,456.0,Inhibitory activity against 3T3 cell line
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,12695.0,,10090.0,CHEMBL884523,1.0,,1.0,,,,,723.0,457.0,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured
,BAO_0000019,F,,,11169.0,H,,Expert,12695.0,,,CHEMBL615688,1.0,,8.0,,,,,,458.0,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,12695.0,,10090.0,CHEMBL615689,1.0,,1.0,,,,,723.0,459.0,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,12695.0,,10090.0,CHEMBL615690,1.0,,1.0,,,,,723.0,460.0,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured
,BAO_0000019,F,,,11169.0,H,,Expert,12695.0,,,CHEMBL615691,1.0,,8.0,,,,,,461.0,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells
,BAO_0000019,F,,,11169.0,H,,Expert,12695.0,,,CHEMBL615692,1.0,,8.0,,,,,,462.0,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,6277.0,,10090.0,CHEMBL615693,1.0,,1.0,,,,,723.0,463.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Expert,6277.0,,10090.0,CHEMBL615324,1.0,,1.0,,,,,723.0,464.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data
,BAO_0000219,F,,NIH3T3,9.0,D,Homo sapiens,Expert,4959.0,,9606.0,CHEMBL615325,1.0,,9.0,,,,,723.0,465.0,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells
,BAO_0000219,F,,NIH3T3,9.0,D,Homo sapiens,Expert,4959.0,,9606.0,CHEMBL615490,1.0,,9.0,,,,,723.0,466.0,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested)
,BAO_0000219,F,,NIH3T3,188.0,D,Homo sapiens,Expert,4959.0,,9606.0,CHEMBL615491,1.0,,9.0,,,,,723.0,467.0,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells
,BAO_0000219,F,,NIH3T3,188.0,D,Homo sapiens,Expert,4959.0,,9606.0,CHEMBL615492,1.0,,9.0,,,,,723.0,468.0,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested)
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,12082.0,,10090.0,CHEMBL615493,1.0,,1.0,,,,,723.0,469.0,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,12082.0,,10090.0,CHEMBL615494,1.0,,1.0,,,,,723.0,470.0,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,12082.0,,10090.0,CHEMBL615495,1.0,,1.0,,,,,723.0,471.0,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,12082.0,,10090.0,CHEMBL615496,1.0,,1.0,,,,,723.0,472.0,Inhibitory concentration was calculated on 3T3 cells by using growth assay
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,2643.0,,10090.0,CHEMBL615497,1.0,,1.0,,,,,723.0,473.0,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Expert,11926.0,,10090.0,CHEMBL615498,1.0,,1.0,,,,,723.0,474.0,Inhibition of Swiss 3T3 mouse fibroblast proliferation
,BAO_0000219,A,,NIH3T3,80951.0,N,Mus musculus,Intermediate,15204.0,,10090.0,CHEMBL615499,1.0,,1.0,,,,,723.0,475.0,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Expert,15992.0,,10090.0,CHEMBL835522,1.0,,1.0,,,,,723.0,476.0,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,16279.0,,10090.0,CHEMBL615500,1.0,,1.0,,,,,723.0,477.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,16279.0,,10090.0,CHEMBL615501,1.0,,1.0,,,,,723.0,478.0,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014)
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,16279.0,,10090.0,CHEMBL615502,1.0,,1.0,,,,,723.0,479.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014)
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,16279.0,,10090.0,CHEMBL615503,1.0,,1.0,,,,,723.0,480.0,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014)
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,16279.0,,10090.0,CHEMBL615504,1.0,,1.0,,,,,723.0,481.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014)
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,16279.0,,10090.0,CHEMBL615505,1.0,,1.0,,,,,723.0,482.0,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014)
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Expert,12831.0,,10090.0,CHEMBL615506,1.0,,1.0,,,,,723.0,483.0,Inhibition of swiss 3T3 mouse fibroblast proliferation
,BAO_0000219,F,,NIH3T3,80951.0,N,Mus musculus,Intermediate,13497.0,,10090.0,CHEMBL615507,1.0,,1.0,,,,,723.0,484.0,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.
,BAO_0000218,F,,3T3-L1,80006.0,N,,Intermediate,13715.0,,,CHEMBL615508,1.0,,1.0,,,,,620.0,485.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.
,BAO_0000219,F,,3T3-L1,80006.0,N,Mus musculus,Intermediate,13618.0,,10090.0,CHEMBL615509,1.0,,1.0,,,,,620.0,486.0,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation
,BAO_0000219,F,,3T3-L1,80006.0,N,Mus musculus,Intermediate,11902.0,,10090.0,CHEMBL615510,1.0,,1.0,,,,,620.0,487.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM
,BAO_0000219,F,,3T3-L1,80006.0,N,Mus musculus,Intermediate,11902.0,,10090.0,CHEMBL615511,1.0,,1.0,,,,,620.0,488.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM
,BAO_0000219,F,,3T3-L1,80006.0,N,Mus musculus,Intermediate,11902.0,,10090.0,CHEMBL615512,1.0,,1.0,,,,,620.0,489.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM
,BAO_0000218,F,,3T3-L1,80006.0,N,Mus musculus,Intermediate,14840.0,,10090.0,CHEMBL615513,1.0,,1.0,,,,,620.0,490.0,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr"
,BAO_0000218,F,,3T3-L1,80006.0,N,Mus musculus,Intermediate,14840.0,,10090.0,CHEMBL615514,1.0,,1.0,,,,,620.0,491.0,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr"
,BAO_0000219,F,,3T3-L1,80006.0,N,,Intermediate,13715.0,,,CHEMBL615515,1.0,,1.0,,,,,620.0,492.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes
,BAO_0000219,F,,3T3-L1,80006.0,N,,Intermediate,13715.0,,,CHEMBL615516,1.0,,1.0,,,,,620.0,493.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M
,BAO_0000219,F,,3T3-L1,80006.0,N,,Intermediate,13715.0,,,CHEMBL615517,1.0,,1.0,,,,,620.0,494.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M
,BAO_0000219,F,,3T3-L1,80006.0,N,,Intermediate,13715.0,,,CHEMBL615518,1.0,,1.0,,,,,620.0,495.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M
,BAO_0000219,F,,3T3-L1,80006.0,N,,Intermediate,13715.0,,,CHEMBL615519,1.0,,1.0,,,,,620.0,496.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M
,BAO_0000218,F,,3T3-L1,80006.0,N,,Intermediate,13715.0,,,CHEMBL615520,1.0,,1.0,,,,,620.0,497.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.
,BAO_0000218,F,,3T3-L1,80006.0,N,,Intermediate,13715.0,,,CHEMBL615521,1.0,,1.0,,,,,620.0,498.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.
,BAO_0000218,F,,3T3-L1,80006.0,N,,Intermediate,13715.0,,,CHEMBL615522,1.0,,1.0,,,,,620.0,499.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.
,BAO_0000218,F,,3T3-L1,80006.0,N,,Intermediate,13715.0,,,CHEMBL615523,1.0,,1.0,,,,,620.0,500.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.
,BAO_0000218,F,,3T3-L1,80006.0,N,,Expert,13715.0,,,CHEMBL615524,1.0,,1.0,,,,,620.0,501.0,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.
,BAO_0000218,F,,3T3-L1,80006.0,N,,Expert,13715.0,,,CHEMBL615525,1.0,,1.0,,,,,620.0,502.0,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.
,BAO_0000218,F,,3T3-L1,80006.0,N,,Intermediate,13715.0,,,CHEMBL615526,1.0,,1.0,,,,,620.0,503.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.
,BAO_0000218,F,,3T3-L1,80006.0,N,,Intermediate,13715.0,,,CHEMBL615527,1.0,,1.0,,,,,620.0,504.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.
,BAO_0000218,F,,3T3-L1,80006.0,N,,Intermediate,13715.0,,,CHEMBL615528,1.0,,1.0,,,,,620.0,505.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.
,BAO_0000218,F,,3T3-L1,80006.0,N,,Expert,13715.0,,,CHEMBL615529,1.0,,1.0,,,,,620.0,506.0,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.
,BAO_0000218,F,,3T3-L1,80006.0,N,,Expert,13715.0,,,CHEMBL615530,1.0,,1.0,,,,,620.0,507.0,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.
,BAO_0000218,F,,3T3-L1,80006.0,N,,Expert,13715.0,,,CHEMBL615531,1.0,,1.0,,,,,620.0,508.0,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.
,BAO_0000219,F,,3T3-L1,80006.0,N,,Intermediate,13715.0,,,CHEMBL615532,1.0,,1.0,,,,,620.0,509.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M
,BAO_0000219,F,,3T3-L1,80006.0,N,,Intermediate,13715.0,,,CHEMBL615533,1.0,,1.0,,,,,620.0,510.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M
,BAO_0000219,F,,3T3-L1,80006.0,N,,Intermediate,13715.0,,,CHEMBL615534,1.0,,1.0,,,,,620.0,511.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M
,BAO_0000218,F,,3T3-L1,80006.0,N,,Intermediate,13715.0,,,CHEMBL615535,1.0,,1.0,,,,,620.0,512.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.
,BAO_0000218,F,,3T3-L1,80006.0,N,,Intermediate,13715.0,,,CHEMBL615536,1.0,,1.0,,,,,620.0,513.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.
,BAO_0000218,F,,3T3-L1,80006.0,N,,Intermediate,13715.0,,,CHEMBL615537,1.0,,1.0,,,,,620.0,514.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.
,BAO_0000218,F,,3T3-L1,80006.0,N,,Intermediate,13715.0,,,CHEMBL615538,1.0,,1.0,,,,,620.0,515.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.
,BAO_0000218,F,,3T3-L1,80006.0,N,,Intermediate,13715.0,,,CHEMBL836166,1.0,,1.0,,,,,620.0,516.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.
,BAO_0000219,F,,3T3-L1,11214.0,H,,Expert,6411.0,,,CHEMBL615539,1.0,,8.0,,,,,620.0,517.0,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells
,BAO_0000219,F,,3T3-L1,80006.0,N,Mus musculus,Intermediate,6411.0,,10090.0,CHEMBL615540,1.0,,1.0,,,,,620.0,518.0,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data
,BAO_0000219,F,,3T3-L1,11214.0,H,,Expert,6411.0,,,CHEMBL615541,1.0,,8.0,,,,,620.0,519.0,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active
,BAO_0000219,F,,3T3-L1,80006.0,N,Mus musculus,Expert,3966.0,,10090.0,CHEMBL615542,1.0,,1.0,,,,,620.0,520.0,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone
,BAO_0000219,F,,3T3-L1,80006.0,N,Mus musculus,Intermediate,3966.0,,10090.0,CHEMBL615543,1.0,,1.0,,,,,620.0,521.0,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone
,BAO_0000219,F,,3T3-L1,80006.0,N,Mus musculus,Expert,15556.0,,10090.0,CHEMBL615544,1.0,,1.0,,,,,620.0,522.0,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone
,BAO_0000219,F,,3T3-L1,80006.0,N,Mus musculus,Expert,5845.0,,10090.0,CHEMBL615545,1.0,,1.0,,,,,620.0,523.0,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells
,BAO_0000219,F,,3T3-L1,80006.0,N,Mus musculus,Expert,14422.0,,10090.0,CHEMBL615546,1.0,,1.0,,,,,620.0,524.0,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells
,BAO_0000219,F,,3T3-L1,80006.0,N,Mus musculus,Expert,5845.0,,10090.0,CHEMBL615547,1.0,,1.0,,,,,620.0,525.0,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells
,BAO_0000219,F,,3T3-L1,80006.0,N,Mus musculus,Expert,14508.0,,10090.0,CHEMBL615548,1.0,,1.0,,,,,620.0,526.0,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.
,BAO_0000219,F,,3T3-L1,80006.0,N,Mus musculus,Expert,14508.0,,10090.0,CHEMBL615549,1.0,,1.0,,,,,620.0,527.0,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.
,BAO_0000219,F,,3T3-L1,80006.0,N,Mus musculus,Expert,14508.0,,10090.0,CHEMBL615550,1.0,,1.0,,,,,620.0,528.0,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.
,BAO_0000219,F,,3Y1 cell line,80622.0,N,Rattus norvegicus,Intermediate,6349.0,,10116.0,CHEMBL615551,1.0,,1.0,,,,,1118.0,529.0,Inhibitory activity against rat fibroblast (3Y1) cell line
,BAO_0000219,F,,3Y1 cell line,80622.0,N,Rattus norvegicus,Expert,15899.0,,10116.0,CHEMBL615552,1.0,,1.0,,,,,1118.0,530.0,Mean concentration causing inhibition of cell growth in 3Y1 cells.
,BAO_0000219,F,,3Y1 cell line,80622.0,N,Rattus norvegicus,Expert,15899.0,,10116.0,CHEMBL615553,1.0,,1.0,,,,,1118.0,531.0,Cytotoxicity in 3Y1 cells.
,BAO_0000219,F,,3Y1 cell line,80622.0,N,Rattus norvegicus,Expert,15899.0,,10116.0,CHEMBL615554,1.0,,1.0,,,,,1118.0,532.0,Cytostatic effect in 3Y1 cells.
,BAO_0000219,F,,3Y1 cell line,80622.0,N,Rattus norvegicus,Intermediate,15899.0,,10116.0,CHEMBL615555,1.0,,1.0,,,,,1118.0,533.0,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect"
,BAO_0000219,F,,3Y1 cell line,80622.0,N,Rattus norvegicus,Expert,17038.0,,10116.0,CHEMBL615556,1.0,,1.0,,,,,1118.0,534.0,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure
,BAO_0000019,B,,,22226.0,U,,Autocuration,12421.0,,,CHEMBL615557,1.0,,0.0,,,,,,535.0,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase
,BAO_0000019,B,,,22226.0,U,,Autocuration,12947.0,,,CHEMBL615558,1.0,,0.0,,,,,,536.0,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase
,BAO_0000019,B,,,22226.0,U,,Autocuration,12947.0,,,CHEMBL872066,1.0,,0.0,,,,,,537.0,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase
,BAO_0000019,B,,,11607.0,D,Sus scrofa,Expert,4896.0,,9823.0,CHEMBL615559,1.0,,9.0,,,,,,538.0,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method
,BAO_0000019,B,,,11607.0,H,,Autocuration,6148.0,,,CHEMBL615560,1.0,,8.0,,,,,,539.0,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver
,BAO_0000019,B,,,11607.0,H,,Autocuration,16432.0,,,CHEMBL615561,1.0,,8.0,,,,,,540.0,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme
,BAO_0000019,B,,,11607.0,H,,Expert,4978.0,,,CHEMBL857062,1.0,,8.0,,,,,,541.0,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver
,BAO_0000019,B,,,11607.0,H,,Expert,4978.0,,,CHEMBL615562,1.0,,8.0,,,,,,542.0,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value)
,BAO_0000019,B,,,11607.0,H,,Autocuration,3723.0,,,CHEMBL615563,1.0,,8.0,,,,,,543.0,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method
,BAO_0000357,B,,,11607.0,H,,Autocuration,3518.0,,,CHEMBL615564,1.0,,8.0,,,,,,544.0,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD)
,BAO_0000019,B,,,11607.0,H,,Autocuration,4164.0,,,CHEMBL615565,1.0,,8.0,,,,,,545.0,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method
,BAO_0000019,B,,,11607.0,H,,Autocuration,3518.0,,,CHEMBL615566,1.0,,8.0,,,,,,546.0,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated
,BAO_0000019,B,,,11607.0,D,Sus scrofa,Expert,4164.0,,9823.0,CHEMBL615567,1.0,,9.0,,,,,,547.0,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method
,BAO_0000019,B,,,11607.0,H,,Autocuration,3518.0,,,CHEMBL615568,1.0,,8.0,,,,,,548.0,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.
,BAO_0000357,B,,,11607.0,H,,Autocuration,3518.0,,,CHEMBL615569,1.0,,8.0,,,,,,549.0,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM)
,BAO_0000019,B,,,11607.0,H,,Autocuration,4978.0,,,CHEMBL615570,1.0,,8.0,,,,,,550.0,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver
,BAO_0000019,B,,,11607.0,H,,Autocuration,4978.0,,,CHEMBL615571,1.0,,8.0,,,,,,551.0,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value)
,BAO_0000224,B,,,104733.0,H,,Autocuration,6455.0,,,CHEMBL615572,1.0,,4.0,,,,,,552.0,Binding affinity against melatonin (MT1) receptor (pC1)
,BAO_0000019,B,,,22226.0,U,,Autocuration,2222.0,,,CHEMBL615573,1.0,,0.0,,,,,,553.0,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor
,BAO_0000019,B,,,22226.0,U,,Autocuration,13020.0,,,CHEMBL615574,1.0,,0.0,,,,,,554.0,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M
,BAO_0000019,B,,,22226.0,U,,Autocuration,13021.0,,,CHEMBL615575,1.0,,0.0,,,,,,555.0,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system
,BAO_0000357,B,,,10619.0,H,,Autocuration,14532.0,,,CHEMBL615576,1.0,,8.0,,,,,,556.0,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration
,BAO_0000357,B,,,10619.0,H,,Autocuration,14118.0,,,CHEMBL615577,1.0,,8.0,,,,,,557.0,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand
,BAO_0000221,B,,,51.0,H,,Autocuration,11884.0,,,CHEMBL615578,1.0,,8.0,Hippocampus,,,10000000.0,,558.0,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT
,BAO_0000357,B,,,51.0,H,,Expert,13969.0,,,CHEMBL615579,1.0,,8.0,,,,,,559.0,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand
,BAO_0000357,B,,,51.0,H,,Expert,13392.0,,,CHEMBL615580,1.0,,8.0,,,,,,560.0,Binding affinity for 5-hydroxytryptamine 1A receptor
,BAO_0000019,B,,,51.0,H,,Expert,14430.0,,,CHEMBL615581,1.0,,8.0,,,,,,561.0,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT
,BAO_0000221,B,,,51.0,H,,Autocuration,12248.0,,,CHEMBL615582,1.0,,8.0,Hippocampus,,,10000000.0,,562.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus
,BAO_0000221,B,,,51.0,H,,Autocuration,12249.0,,,CHEMBL615583,1.0,,8.0,Hippocampus,,,10000000.0,,563.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus
,BAO_0000221,B,,,51.0,H,,Autocuration,9995.0,,,CHEMBL615584,1.0,,8.0,Hippocampus,,,10000000.0,,564.0,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus
,BAO_0000221,B,,,51.0,H,,Autocuration,9995.0,,,CHEMBL833691,1.0,,8.0,Hippocampus,,,10000000.0,,565.0,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
,BAO_0000221,B,,,51.0,H,,Autocuration,9995.0,,,CHEMBL615585,1.0,,8.0,Hippocampus,,,10000000.0,,566.0,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus
,BAO_0000221,B,,,51.0,H,,Autocuration,9995.0,,,CHEMBL615586,1.0,,8.0,Hippocampus,,,10000000.0,,567.0,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus
,BAO_0000221,B,,,51.0,H,,Autocuration,9995.0,,,CHEMBL884524,1.0,,8.0,Hippocampus,,,10000000.0,,568.0,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
,BAO_0000221,B,,,51.0,H,,Autocuration,12249.0,,,CHEMBL615587,1.0,,8.0,Hippocampus,,,10000000.0,,569.0,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus
,BAO_0000221,B,,,51.0,H,,Autocuration,11799.0,,,CHEMBL615588,1.0,,8.0,Hippocampus,,,10000000.0,,570.0,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand"
,BAO_0000249,B,,,10576.0,D,Rattus norvegicus,Expert,14331.0,Membranes,10116.0,CHEMBL615589,1.0,,9.0,,,,,,571.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes
,BAO_0000221,B,,,51.0,H,Bos taurus,Expert,11884.0,,9913.0,CHEMBL615442,1.0,,8.0,Hippocampus,,,10000000.0,,572.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.
,BAO_0000221,B,,,51.0,H,,Autocuration,14331.0,,,CHEMBL615443,1.0,,8.0,Hippocampus,,,10000000.0,,573.0,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined
,BAO_0000221,B,,,51.0,H,,Autocuration,11701.0,,,CHEMBL615444,1.0,,8.0,Hippocampus,,,10000000.0,,574.0,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus
,BAO_0000221,B,,,51.0,H,,Expert,11701.0,,,CHEMBL615445,1.0,,8.0,Hippocampus,,,10000000.0,,575.0,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.
,BAO_0000221,B,,,51.0,H,,Autocuration,12248.0,,,CHEMBL615446,1.0,,8.0,Hippocampus,,,10000000.0,,576.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus
,BAO_0000219,B,,CHO,51.0,H,,Autocuration,12248.0,,,CHEMBL615447,1.0,,8.0,,,,,449.0,577.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells
,BAO_0000221,B,,,51.0,H,,Expert,12248.0,,,CHEMBL615448,1.0,,8.0,Hippocampus,,,10000000.0,,578.0,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus
,BAO_0000221,B,,,51.0,H,,Expert,12249.0,,,CHEMBL615449,1.0,,8.0,Hippocampus,,,10000000.0,,579.0,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus
,BAO_0000219,B,,CHO,51.0,H,,Autocuration,12248.0,,,CHEMBL615450,1.0,,8.0,,,,,449.0,580.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells
,BAO_0000221,B,,,51.0,H,,Expert,11799.0,,,CHEMBL615451,1.0,,8.0,Hippocampus,,,10000000.0,,581.0,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand"
,BAO_0000357,B,,,51.0,H,,Autocuration,634.0,,,CHEMBL615452,1.0,,8.0,,,,,,582.0,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand
,BAO_0000221,B,,,51.0,H,,Autocuration,9995.0,,,CHEMBL615453,1.0,,8.0,Hippocampus,,,10000000.0,,583.0,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus
,BAO_0000221,B,,,51.0,H,,Autocuration,9995.0,,,CHEMBL615454,1.0,,8.0,Hippocampus,,,10000000.0,,584.0,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
,BAO_0000221,B,,,51.0,H,,Autocuration,9995.0,,,CHEMBL615455,1.0,,8.0,Hippocampus,,,10000000.0,,585.0,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus
,BAO_0000221,B,,,51.0,H,,Autocuration,9995.0,,,CHEMBL615456,1.0,,8.0,Hippocampus,,,10000000.0,,586.0,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
,BAO_0000221,B,,,51.0,H,,Autocuration,9995.0,,,CHEMBL615457,1.0,,8.0,Hippocampus,,,10000000.0,,587.0,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus
,BAO_0000218,B,,,51.0,H,,Expert,12210.0,,,CHEMBL615458,1.0,,8.0,Hippocampus,,,10000000.0,,588.0,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.
,BAO_0000221,B,,,51.0,H,,Expert,13311.0,,,CHEMBL615459,1.0,,8.0,Hippocampus,,,10000000.0,,589.0,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus
,BAO_0000219,B,,CHO,51.0,D,Homo sapiens,Expert,2331.0,,9606.0,CHEMBL615460,1.0,,9.0,,,,,449.0,590.0,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells."
,BAO_0000019,F,,,51.0,H,Cavia porcellus,Autocuration,1375.0,,10141.0,CHEMBL615461,1.0,,8.0,,,,,,591.0,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig
,BAO_0000019,F,,,51.0,H,Cavia porcellus,Autocuration,1375.0,,10141.0,CHEMBL615462,1.0,,8.0,,,,,,592.0,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested
,BAO_0000221,F,,,51.0,H,Cavia porcellus,Autocuration,11574.0,,10141.0,CHEMBL615463,1.0,,8.0,Hippocampus,,,10000000.0,,593.0,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.
,BAO_0000221,B,,,51.0,H,Cavia porcellus,Autocuration,12867.0,,10141.0,CHEMBL615464,1.0,,8.0,Ileum,,,2116.0,,594.0,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.
,BAO_0000221,B,,,51.0,H,Cavia porcellus,Autocuration,12867.0,,10141.0,CHEMBL615465,1.0,,8.0,Ileum,,,2116.0,,595.0,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM
,BAO_0000221,B,,,51.0,H,Cavia porcellus,Autocuration,12867.0,,10141.0,CHEMBL615466,1.0,,8.0,Ileum,,,2116.0,,596.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.
,BAO_0000221,B,,,51.0,H,Cavia porcellus,Autocuration,12867.0,,10141.0,CHEMBL615467,1.0,,8.0,Ileum,,,2116.0,,597.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM
,BAO_0000221,B,,,51.0,H,Cavia porcellus,Autocuration,12867.0,,10141.0,CHEMBL615468,1.0,,8.0,Ileum,,,2116.0,,598.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM
,BAO_0000221,B,,,51.0,H,Cavia porcellus,Autocuration,12867.0,,10141.0,CHEMBL615469,1.0,,8.0,Ileum,,,2116.0,,599.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM
,BAO_0000357,B,,,51.0,H,Cavia porcellus,Autocuration,11574.0,,10141.0,CHEMBL615470,1.0,,8.0,,,,,,600.0,Binding affinity against 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,H,Cavia porcellus,Autocuration,13114.0,,10141.0,CHEMBL615471,1.0,,8.0,,,,,,601.0,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,H,Cavia porcellus,Autocuration,13181.0,,10141.0,CHEMBL615472,1.0,,8.0,,,,,,602.0,Binding affinity was determined against 5-hydroxytryptamine 1A receptor
,BAO_0000221,B,,,106.0,H,Cavia porcellus,Autocuration,10639.0,,10141.0,CHEMBL883242,1.0,,8.0,Hippocampus,,,10000000.0,,603.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus
,BAO_0000221,F,,,106.0,H,Cavia porcellus,Autocuration,10639.0,,10141.0,CHEMBL615473,1.0,,8.0,Hippocampus,,,10000000.0,,604.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus
,BAO_0000218,B,,CHO,11863.0,H,Cricetulus griseus,Autocuration,11883.0,,10029.0,CHEMBL615474,1.0,,8.0,,,,,449.0,605.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc)
,BAO_0000357,B,,,51.0,H,,Autocuration,17785.0,,,CHEMBL615475,1.0,,8.0,,,,,,606.0,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor
,BAO_0000219,F,,HeLa,51.0,H,,Autocuration,1558.0,,,CHEMBL615476,1.0,,8.0,,,,,308.0,607.0,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370
,BAO_0000219,F,,HeLa,51.0,H,,Autocuration,1558.0,,,CHEMBL615477,1.0,,8.0,,,,,308.0,608.0,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320
,BAO_0000019,F,,,51.0,H,,Autocuration,15740.0,,,CHEMBL615478,1.0,,8.0,,,,,,609.0,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,17624.0,,,CHEMBL615160,1.0,,8.0,,,,,449.0,610.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor
,BAO_0000219,F,,CHO,51.0,H,,Expert,17624.0,,,CHEMBL615161,1.0,,8.0,,,,,449.0,611.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,17624.0,,,CHEMBL615162,1.0,,8.0,,,,,449.0,612.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,17624.0,,,CHEMBL615163,1.0,,8.0,,,,,449.0,613.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined
,BAO_0000219,B,,CHO,51.0,H,,Expert,17624.0,,,CHEMBL615164,1.0,,8.0,,,,,449.0,614.0,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells
,BAO_0000219,B,,CHO,51.0,H,,Expert,17624.0,,,CHEMBL615165,1.0,,8.0,,,,,449.0,615.0,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells
,BAO_0000219,B,,CHO,51.0,H,,Autocuration,17624.0,,,CHEMBL615166,1.0,,8.0,,,,,449.0,616.0,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined
,BAO_0000219,F,,,51.0,H,,Autocuration,14256.0,,,CHEMBL615167,1.0,,8.0,,,,,,617.0,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP
,BAO_0000219,B,,HeLa,51.0,D,Homo sapiens,Expert,3445.0,,9606.0,CHEMBL615168,1.0,,9.0,,,,,308.0,618.0,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells
,BAO_0000219,B,,HeLa,51.0,D,Homo sapiens,Expert,3445.0,,9606.0,CHEMBL615169,1.0,,9.0,,,,,308.0,619.0,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse
,BAO_0000219,B,,CHO,51.0,D,Homo sapiens,Expert,17200.0,,9606.0,CHEMBL615170,1.0,,9.0,,,,,449.0,620.0,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor
,BAO_0000219,B,,CHO,51.0,D,Homo sapiens,Expert,17200.0,,9606.0,CHEMBL615171,1.0,,9.0,,,,,449.0,621.0,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined
,BAO_0000019,F,,,51.0,H,,Autocuration,15180.0,,,CHEMBL615694,1.0,,8.0,,,,,,622.0,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor
,BAO_0000019,F,,,51.0,H,,Autocuration,15180.0,,,CHEMBL615695,1.0,,8.0,,,,,,623.0,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor
,BAO_0000019,F,,,51.0,H,,Autocuration,16026.0,,,CHEMBL615696,1.0,,8.0,,,,,,624.0,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor"
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,2759.0,,,CHEMBL615697,1.0,,8.0,,,,,449.0,625.0,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor
,BAO_0000219,F,,CHO,51.0,D,Homo sapiens,Expert,2759.0,,9606.0,CHEMBL859410,1.0,,9.0,,,,,449.0,626.0,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1)
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,2759.0,,,CHEMBL615841,1.0,,8.0,,,,,449.0,627.0,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2)
,BAO_0000219,F,,CHO,51.0,D,Homo sapiens,Expert,2759.0,,9606.0,CHEMBL615842,1.0,,9.0,,,,,449.0,628.0,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2)
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,2759.0,,,CHEMBL835003,1.0,,8.0,,,,,449.0,629.0,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,2759.0,,,CHEMBL615843,1.0,,8.0,,,,,449.0,630.0,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1)
,BAO_0000219,F,,CHO,51.0,D,Homo sapiens,Expert,2759.0,,9606.0,CHEMBL615979,1.0,,9.0,,,,,449.0,631.0,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1)
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,2759.0,,,CHEMBL615980,1.0,,8.0,,,,,449.0,632.0,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2)
,BAO_0000219,F,,CHO,51.0,D,Homo sapiens,Expert,2759.0,,9606.0,CHEMBL615981,1.0,,9.0,,,,,449.0,633.0,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2)
,BAO_0000019,F,,,51.0,D,Homo sapiens,Expert,3445.0,,9606.0,CHEMBL615982,1.0,,9.0,,,,,,634.0,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response
,BAO_0000019,F,,,51.0,D,Homo sapiens,Expert,5272.0,,9606.0,CHEMBL615983,1.0,,9.0,,,,,,635.0,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,"
,BAO_0000019,F,,,51.0,D,Homo sapiens,Expert,5272.0,,9606.0,CHEMBL615984,1.0,,9.0,,,,,,636.0,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data"
,BAO_0000019,F,,,51.0,D,Homo sapiens,Expert,5272.0,,9606.0,CHEMBL615985,1.0,,9.0,,,,,,637.0,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,"
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,17624.0,,,CHEMBL615986,1.0,,8.0,,,,,449.0,638.0,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,17624.0,,,CHEMBL615987,1.0,,8.0,,,,,449.0,639.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,17624.0,,,CHEMBL615988,1.0,,8.0,,,,,449.0,640.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined
,BAO_0000219,F,,CHO,51.0,H,,Expert,17624.0,,,CHEMBL615989,1.0,,8.0,,,,,449.0,641.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,17624.0,,,CHEMBL615990,1.0,,8.0,,,,,449.0,642.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,17624.0,,,CHEMBL615991,1.0,,8.0,,,,,449.0,643.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,17624.0,,,CHEMBL615992,1.0,,8.0,,,,,449.0,644.0,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,17624.0,,,CHEMBL615993,1.0,,8.0,,,,,449.0,645.0,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined
,BAO_0000219,F,,CHO,51.0,H,,Expert,17624.0,,,CHEMBL615994,1.0,,8.0,,,,,449.0,646.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,17624.0,,,CHEMBL615995,1.0,,8.0,,,,,449.0,647.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,17624.0,,,CHEMBL615996,1.0,,8.0,,,,,449.0,648.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,17624.0,,,CHEMBL615997,1.0,,8.0,,,,,449.0,649.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined
,BAO_0000019,F,,,51.0,H,,Autocuration,6563.0,,,CHEMBL615998,1.0,,8.0,,,,,,650.0,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay"
,BAO_0000019,F,,,51.0,H,,Autocuration,6563.0,,,CHEMBL615999,1.0,,8.0,,,,,,651.0,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay"
,BAO_0000019,F,,,51.0,H,,Autocuration,6563.0,,,CHEMBL616000,1.0,,8.0,,,,,,652.0,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay
,BAO_0000219,F,,HEK293,51.0,H,,Autocuration,17296.0,,,CHEMBL616001,1.0,,8.0,,,,,722.0,653.0,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S
,BAO_0000019,F,,,51.0,D,Homo sapiens,Expert,6876.0,,9606.0,CHEMBL616002,1.0,,9.0,,,,,,654.0,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine"
,BAO_0000019,F,,,51.0,H,,Expert,6876.0,,,CHEMBL616003,1.0,,8.0,,,,,,655.0,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined"
,BAO_0000019,F,,,51.0,D,Homo sapiens,Expert,5272.0,,9606.0,CHEMBL616004,1.0,,9.0,,,,,,656.0,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor
,BAO_0000019,F,,,51.0,D,Homo sapiens,Expert,5272.0,,9606.0,CHEMBL616005,1.0,,9.0,,,,,,657.0,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data
,BAO_0000019,F,,,51.0,H,,Autocuration,5548.0,,,CHEMBL616006,1.0,,8.0,,,,,,658.0,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined"
,BAO_0000019,F,,,51.0,H,,Expert,5548.0,,,CHEMBL616007,1.0,,8.0,,,,,,659.0,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding"
,BAO_0000019,F,,,51.0,H,,Autocuration,5548.0,,,CHEMBL616008,1.0,,8.0,,,,,,660.0,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined"
,BAO_0000019,F,,,51.0,H,,Autocuration,5548.0,,,CHEMBL616009,1.0,,8.0,,,,,,661.0,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined"
,BAO_0000019,F,,,51.0,H,,Expert,5929.0,,,CHEMBL616010,1.0,,8.0,,,,,,662.0,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding"
,BAO_0000019,F,,,51.0,D,Homo sapiens,Expert,5929.0,,9606.0,CHEMBL616011,1.0,,9.0,,,,,,663.0,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined"
,BAO_0000019,F,,,51.0,D,Homo sapiens,Expert,5929.0,,9606.0,CHEMBL615740,1.0,,9.0,,,,,,664.0,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined"
,BAO_0000019,F,,,51.0,H,,Autocuration,16245.0,,,CHEMBL615741,1.0,,8.0,,,,,,665.0,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor"
,BAO_0000019,F,,,51.0,H,,Expert,5640.0,,,CHEMBL615742,1.0,,8.0,,,,,,666.0,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors."
,BAO_0000019,F,,,51.0,H,,Autocuration,5640.0,,,CHEMBL615743,1.0,,8.0,,,,,,667.0,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined"
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,14509.0,,,CHEMBL615744,1.0,,8.0,,,,,449.0,668.0,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay
,BAO_0000219,F,,CHO,51.0,H,,Expert,14509.0,,,CHEMBL615745,1.0,,8.0,,,,,449.0,669.0,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.
,BAO_0000357,B,,,51.0,H,,Autocuration,15331.0,,,CHEMBL615746,1.0,,8.0,,,,,,670.0,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique
,BAO_0000357,B,,,51.0,H,,Autocuration,15331.0,,,CHEMBL615747,1.0,,8.0,,,,,,671.0,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique
,BAO_0000019,F,,,51.0,H,,Autocuration,6563.0,,,CHEMBL615748,1.0,,8.0,,,,,,672.0,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay"
,BAO_0000019,F,,,51.0,H,,Autocuration,6563.0,,,CHEMBL615749,1.0,,8.0,,,,,,673.0,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available"
,BAO_0000019,F,,,51.0,H,,Autocuration,6563.0,,,CHEMBL615750,1.0,,8.0,,,,,,674.0,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay
,BAO_0000019,F,,,51.0,D,Homo sapiens,Expert,6563.0,,9606.0,CHEMBL616259,1.0,,9.0,,,,,,675.0,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor
,BAO_0000019,F,,,51.0,H,,Autocuration,6563.0,,,CHEMBL616260,1.0,,8.0,,,,,,676.0,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay"
,BAO_0000019,F,,,51.0,D,Homo sapiens,Expert,5272.0,,9606.0,CHEMBL616261,1.0,,9.0,,,,,,677.0,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro
,BAO_0000019,F,,,51.0,D,Homo sapiens,Expert,5272.0,,9606.0,CHEMBL616262,1.0,,9.0,,,,,,678.0,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,"
,BAO_0000019,F,,,51.0,D,Homo sapiens,Expert,5272.0,,9606.0,CHEMBL616263,1.0,,9.0,,,,,,679.0,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data"
,BAO_0000019,F,,,51.0,D,Homo sapiens,Expert,5272.0,,9606.0,CHEMBL616264,1.0,,9.0,,,,,,680.0,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data
,BAO_0000019,F,,,51.0,D,Homo sapiens,Expert,5272.0,,9606.0,CHEMBL616265,1.0,,9.0,,,,,,681.0,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro
,BAO_0000019,F,,,51.0,D,Homo sapiens,Expert,5272.0,,9606.0,CHEMBL616266,1.0,,9.0,,,,,,682.0,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,"
,BAO_0000019,F,,,51.0,D,Homo sapiens,Expert,5272.0,,9606.0,CHEMBL616267,1.0,,9.0,,,,,,683.0,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data"
,BAO_0000019,F,,,51.0,D,Homo sapiens,Expert,5272.0,,9606.0,CHEMBL616268,1.0,,9.0,,,,,,684.0,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data
,BAO_0000357,B,,,51.0,D,Homo sapiens,Expert,16146.0,,9606.0,CHEMBL616269,1.0,,9.0,,,,,,685.0,Inhibition of human 5-hydroxytryptamine 1A receptor
,BAO_0000219,B,,CHO,51.0,H,,Autocuration,17624.0,,,CHEMBL884528,1.0,,8.0,,,,,449.0,686.0,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells
,BAO_0000219,B,,HEK293,105.0,D,,Expert,13706.0,,,CHEMBL616270,1.0,,9.0,,,,,722.0,687.0,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells
,BAO_0000219,B,,CHO,51.0,H,,Autocuration,15250.0,,,CHEMBL616271,1.0,,8.0,,,,,449.0,688.0,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,17624.0,,,CHEMBL616272,1.0,,8.0,,,,,449.0,689.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,H,,Expert,6861.0,,,CHEMBL616273,1.0,,8.0,,,,,,690.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay
,BAO_0000357,B,,,51.0,D,Homo sapiens,Expert,17200.0,,9606.0,CHEMBL616274,1.0,,9.0,,,,,,691.0,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor
,BAO_0000219,B,,CHO,51.0,H,,Autocuration,17624.0,,,CHEMBL616275,1.0,,8.0,,,,,449.0,692.0,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells
,BAO_0000219,B,,CHO,51.0,H,,Autocuration,17624.0,,,CHEMBL616276,1.0,,8.0,,,,,449.0,693.0,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells
,BAO_0000218,F,In vivo,,22226.0,U,Rattus norvegicus,Autocuration,12058.0,,10116.0,CHEMBL616277,1.0,,0.0,,,,,,694.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration
,BAO_0000218,F,In vivo,,22226.0,U,Rattus norvegicus,Autocuration,12058.0,,10116.0,CHEMBL616278,1.0,,0.0,,,,,,695.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive
,BAO_0000218,F,In vivo,,22226.0,U,Rattus norvegicus,Autocuration,12058.0,,10116.0,CHEMBL616279,1.0,,0.0,,,,,,696.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration
,BAO_0000218,F,In vivo,,22226.0,U,Rattus norvegicus,Autocuration,12058.0,,10116.0,CHEMBL616280,1.0,,0.0,,,,,,697.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive
,BAO_0000218,F,In vivo,,22226.0,U,Rattus norvegicus,Autocuration,12058.0,,10116.0,CHEMBL616281,1.0,,0.0,,,,,,698.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested
,BAO_0000218,F,In vivo,,22226.0,U,Rattus norvegicus,Autocuration,12058.0,,10116.0,CHEMBL616282,1.0,,0.0,,,,,,699.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive
,BAO_0000218,F,In vivo,,22226.0,U,Rattus norvegicus,Autocuration,12058.0,,10116.0,CHEMBL616283,1.0,,0.0,,,,,,700.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration
,BAO_0000218,F,In vivo,,22226.0,U,Rattus norvegicus,Autocuration,12058.0,,10116.0,CHEMBL616284,1.0,,0.0,,,,,,701.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive
,BAO_0000218,F,In vivo,,22226.0,U,Rattus norvegicus,Autocuration,12058.0,,10116.0,CHEMBL616285,1.0,,0.0,,,,,,702.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration
,BAO_0000218,F,In vivo,,22226.0,U,Rattus norvegicus,Autocuration,12058.0,,10116.0,CHEMBL616286,1.0,,0.0,,,,,,703.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive
,BAO_0000218,F,In vivo,,22226.0,U,Rattus norvegicus,Autocuration,12058.0,,10116.0,CHEMBL616287,1.0,,0.0,,,,,,704.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested
,BAO_0000218,F,In vivo,,22226.0,U,Rattus norvegicus,Autocuration,12058.0,,10116.0,CHEMBL616288,1.0,,0.0,,,,,,705.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration
,BAO_0000218,F,In vivo,,22226.0,U,Rattus norvegicus,Autocuration,12058.0,,10116.0,CHEMBL616289,1.0,,0.0,,,,,,706.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive
,BAO_0000218,F,In vivo,,22226.0,U,Rattus norvegicus,Autocuration,12058.0,,10116.0,CHEMBL615610,1.0,,0.0,,,,,,707.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested
,BAO_0000218,F,In vivo,,22226.0,U,Rattus norvegicus,Autocuration,12058.0,,10116.0,CHEMBL615611,1.0,,0.0,,,,,,708.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration
,BAO_0000218,F,In vivo,,22226.0,U,Rattus norvegicus,Autocuration,12058.0,,10116.0,CHEMBL615612,1.0,,0.0,,,,,,709.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive
,BAO_0000218,F,In vivo,,22226.0,U,Rattus norvegicus,Autocuration,12058.0,,10116.0,CHEMBL615613,1.0,,0.0,,,,,,710.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested
,BAO_0000218,F,In vivo,,22226.0,U,Rattus norvegicus,Autocuration,12058.0,,10116.0,CHEMBL615614,1.0,,0.0,,,,,,711.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested
,BAO_0000218,F,In vivo,,22226.0,U,Rattus norvegicus,Autocuration,12058.0,,10116.0,CHEMBL615615,1.0,,0.0,,,,,,712.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration
,BAO_0000019,B,,,105093.0,H,,Autocuration,11440.0,,,CHEMBL615616,1.0,,4.0,,,,,,713.0,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.
,BAO_0000249,B,,,11923.0,H,,Autocuration,6238.0,,,CHEMBL615617,1.0,,8.0,Hypothalamus,,,1898.0,,714.0,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand
,BAO_0000019,B,,,10577.0,H,,Autocuration,10046.0,,,CHEMBL615618,1.0,,8.0,,,,,,715.0,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data
,BAO_0000019,B,,,10577.0,H,,Autocuration,10046.0,,,CHEMBL615619,1.0,,8.0,,,,,,716.0,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.
,BAO_0000019,B,,,10577.0,H,,Expert,10046.0,,,CHEMBL615620,1.0,,8.0,,,,,,717.0,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.
,BAO_0000357,B,,,55.0,H,,Autocuration,167.0,,,CHEMBL615621,1.0,,8.0,,,,,,718.0,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated"
,BAO_0000357,B,,,55.0,H,,Autocuration,167.0,,,CHEMBL615622,1.0,,8.0,,,,,,719.0,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated"
,BAO_0000019,F,,,12166.0,H,,Autocuration,11520.0,,,CHEMBL615623,1.0,,8.0,,,,,,720.0,Compound was evaluated for the inhibition of 5-LO (lipoxygenase)
,BAO_0000019,F,,,12166.0,H,,Autocuration,11520.0,,,CHEMBL615624,1.0,,8.0,,,,,,721.0,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).
,BAO_0000019,F,,,12166.0,H,,Autocuration,11520.0,,,CHEMBL615625,1.0,,8.0,,,,,,722.0,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).
,BAO_0000019,F,,,12166.0,H,,Autocuration,11520.0,,,CHEMBL767045,1.0,,8.0,,,,,,723.0,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).
,BAO_0000019,F,,,55.0,H,Cavia porcellus,Autocuration,135.0,,10141.0,CHEMBL615626,1.0,,8.0,,,,,,724.0,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN
,BAO_0000019,F,,,55.0,H,Cavia porcellus,Autocuration,135.0,,10141.0,CHEMBL615627,1.0,,8.0,,,,,,725.0,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity
,BAO_0000019,B,,,55.0,H,Cavia porcellus,Autocuration,11311.0,,10141.0,CHEMBL615628,1.0,,8.0,,,,,,726.0,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes
,BAO_0000357,B,,,55.0,H,Cavia porcellus,Autocuration,10193.0,,10141.0,CHEMBL615629,1.0,,8.0,,,,,,727.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM
,BAO_0000357,B,,,55.0,D,Homo sapiens,Expert,12281.0,,9606.0,CHEMBL615630,1.0,,9.0,,,,,,728.0,Inhibitory concentration against 5-lipoxygenase from human whole blood
,BAO_0000219,B,,,55.0,H,,Autocuration,11311.0,,,CHEMBL615631,1.0,,8.0,,,,,,729.0,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS]
,BAO_0000218,F,,,17087.0,H,,Autocuration,12576.0,,,CHEMBL615632,1.0,,8.0,,,,,,730.0,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg
,BAO_0000357,B,,,17087.0,H,,Autocuration,12281.0,,,CHEMBL615633,1.0,,8.0,,,,,,731.0,Inhibitory concentration against 5-lipoxygenase from mouse macrophage
,BAO_0000218,F,,,17087.0,H,,Autocuration,12576.0,,,CHEMBL615634,1.0,,8.0,,,,,,732.0,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg
,BAO_0000019,B,,,55.0,H,Sus scrofa,Expert,11089.0,,9823.0,CHEMBL615635,1.0,,8.0,,,,,,733.0,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.
,BAO_0000357,B,,,12166.0,H,,Expert,11006.0,,,CHEMBL615636,1.0,,8.0,,,,,,734.0,In vitro inhibition of rat 5-Lipoxygenase
,BAO_0000357,B,,,12166.0,D,Rattus norvegicus,Expert,11481.0,,10116.0,CHEMBL615637,1.0,,9.0,,,,,,735.0,Inhibitory activity against 5-Lipoxygenase
,BAO_0000219,B,,RBL-1,12166.0,H,,Expert,10864.0,,,CHEMBL615638,1.0,,8.0,,,,,702.0,736.0,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,3595.0,,,CHEMBL615639,1.0,,8.0,,,,,702.0,737.0,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1)
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,11311.0,,,CHEMBL615640,1.0,,8.0,,,,,702.0,738.0,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1
,BAO_0000019,B,,,12166.0,H,,Autocuration,11311.0,,,CHEMBL615796,1.0,,8.0,,,,,,739.0,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood
,BAO_0000219,B,,,12166.0,H,,Autocuration,11311.0,,,CHEMBL615845,1.0,,8.0,,,,,,740.0,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS]
,BAO_0000357,B,,,12166.0,H,,Autocuration,11006.0,,,CHEMBL615846,1.0,,8.0,,,,,,741.0,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,3595.0,,,CHEMBL615847,1.0,,8.0,,,,,702.0,742.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM
,BAO_0000357,B,,,12166.0,H,,Autocuration,11311.0,,,CHEMBL615848,1.0,,8.0,,,,,,743.0,The compound was tested for inhibition of isolated 5-Lipoxygenase
,BAO_0000019,B,,,22226.0,U,Rattus norvegicus,Autocuration,11481.0,,10116.0,CHEMBL615849,1.0,,0.0,,,,,,744.0,Ratio of IC50 against 5-LO and COX
,BAO_0000357,B,,,12166.0,H,,Autocuration,11006.0,,,CHEMBL615850,1.0,,8.0,,,,,,745.0,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM
,BAO_0000357,B,,,12166.0,H,,Autocuration,11006.0,,,CHEMBL615851,1.0,,8.0,,,,,,746.0,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%
,BAO_0000219,B,,,12166.0,H,,Autocuration,11311.0,,,CHEMBL615852,1.0,,8.0,,,,,,747.0,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration
,BAO_0000019,F,,,12166.0,H,,Autocuration,11006.0,,,CHEMBL615853,1.0,,8.0,,,,,,748.0,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo
,BAO_0000357,B,,,120.0,H,,Autocuration,4288.0,,,CHEMBL884527,1.0,,8.0,Prostate gland,,,2367.0,,749.0,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates
,BAO_0000019,B,,,22226.0,U,Columba livia,Autocuration,7587.0,,8932.0,CHEMBL872871,1.0,,0.0,,,,,,750.0,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration
,BAO_0000019,B,,,22226.0,U,Columba livia,Autocuration,7587.0,,8932.0,CHEMBL615854,1.0,,0.0,,,,,,751.0,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration
,BAO_0000019,B,,,22226.0,U,Columba livia,Autocuration,7587.0,,8932.0,CHEMBL767046,1.0,,0.0,,,,,,752.0,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.
,BAO_0000357,B,,,10732.0,H,,Autocuration,11249.0,,,CHEMBL615855,1.0,,8.0,,,,,,753.0,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM
,BAO_0000019,F,,,12198.0,D,Rattus norvegicus,Expert,8003.0,,10116.0,CHEMBL615856,1.0,,9.0,,,,,,754.0,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested
,BAO_0000019,F,,,12198.0,D,Rattus norvegicus,Expert,8003.0,,10116.0,CHEMBL615857,1.0,,9.0,,,,,,755.0,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT)
,BAO_0000019,F,,,12198.0,D,Rattus norvegicus,Expert,8003.0,,10116.0,CHEMBL615858,1.0,,9.0,,,,,,756.0,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT)
,BAO_0000221,B,,,10576.0,H,,Expert,12416.0,,,CHEMBL615859,1.0,,8.0,Hippocampus,,,10000000.0,,757.0,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus
,BAO_0000357,B,,,51.0,H,,Autocuration,16293.0,,,CHEMBL615860,1.0,,8.0,,,,,,758.0,Binding affinity towards human 5-hydroxytryptamine 1 receptor
,BAO_0000019,B,,,22226.0,U,Oryctolagus cuniculus,Autocuration,13047.0,,9986.0,CHEMBL615861,1.0,,0.0,,,,,,759.0,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.
,BAO_0000019,B,,,22226.0,U,Oryctolagus cuniculus,Autocuration,13047.0,,9986.0,CHEMBL615862,1.0,,0.0,,,,,,760.0,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.
,BAO_0000019,B,,,22226.0,U,Oryctolagus cuniculus,Autocuration,13047.0,,9986.0,CHEMBL615863,1.0,,0.0,,,,,,761.0,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.
,BAO_0000019,B,,,22226.0,U,Oryctolagus cuniculus,Autocuration,13047.0,,9986.0,CHEMBL615864,1.0,,0.0,,,,,,762.0,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.
,BAO_0000221,B,,,104744.0,H,,Autocuration,10085.0,,,CHEMBL615865,1.0,,4.0,Hippocampus,,,10000000.0,,763.0,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT
,BAO_0000221,B,,,104744.0,H,,Autocuration,10085.0,,,CHEMBL615866,1.0,,4.0,Hippocampus,,,10000000.0,,764.0,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT
,BAO_0000221,B,,,104744.0,H,,Autocuration,10085.0,,,CHEMBL615867,1.0,,4.0,Hippocampus,,,10000000.0,,765.0,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT
,BAO_0000249,B,,,104744.0,H,,Autocuration,9841.0,Membranes,,CHEMBL615868,1.0,,4.0,,,,,,766.0,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes
,BAO_0000249,B,,,104744.0,D,Rattus norvegicus,Autocuration,8822.0,,10116.0,CHEMBL615869,1.0,,5.0,,,,,,767.0,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat
,BAO_0000019,B,,,104744.0,D,Rattus norvegicus,Autocuration,9806.0,,10116.0,CHEMBL615870,1.0,,5.0,,,,,,768.0,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand
,BAO_0000019,B,,,104744.0,D,Rattus norvegicus,Autocuration,9806.0,,10116.0,CHEMBL615871,1.0,,5.0,,,,,,769.0,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates
,BAO_0000224,B,,,104744.0,H,,Autocuration,8868.0,,,CHEMBL615872,1.0,,4.0,,,,,,770.0,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay
,BAO_0000221,B,,,104744.0,H,,Autocuration,9036.0,,,CHEMBL833492,1.0,,4.0,Hippocampus,,,10000000.0,,771.0,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT
,BAO_0000221,B,,,104744.0,H,,Autocuration,11374.0,,,CHEMBL615873,1.0,,4.0,Hippocampus,,,10000000.0,,772.0,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus
,BAO_0000224,B,,,104744.0,H,,Autocuration,10881.0,,,CHEMBL615479,1.0,,4.0,,,,,,773.0,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.
,BAO_0000019,B,,,104744.0,H,,Autocuration,8822.0,,,CHEMBL615480,1.0,,4.0,,,,,,774.0,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat
,BAO_0000249,B,,,104744.0,D,Rattus norvegicus,Autocuration,9806.0,,10116.0,CHEMBL615481,1.0,,5.0,,,,,,775.0,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.
,BAO_0000019,B,,,104744.0,H,,Autocuration,15463.0,,,CHEMBL872869,1.0,,4.0,,,,,,776.0,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex
,BAO_0000019,B,,,104744.0,H,,Autocuration,15463.0,,,CHEMBL615482,1.0,,4.0,,,,,,777.0,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex
,BAO_0000221,B,,,104744.0,H,,Autocuration,14542.0,,,CHEMBL615483,1.0,,4.0,Brain,,,955.0,,778.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM
,BAO_0000221,B,,,104744.0,H,,Autocuration,14542.0,,,CHEMBL615484,1.0,,4.0,Brain,,,955.0,,779.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM
,BAO_0000019,B,,,104744.0,H,,Autocuration,8569.0,,,CHEMBL615485,1.0,,4.0,,,,,,780.0,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM
,BAO_0000224,B,,,104744.0,D,Rattus norvegicus,Autocuration,10062.0,,10116.0,CHEMBL615486,1.0,,5.0,,,,,,781.0,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor
,BAO_0000224,B,,,104744.0,H,,Autocuration,4771.0,,,CHEMBL615487,1.0,,4.0,,,,,,782.0,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor
,BAO_0000224,B,,,104744.0,H,,Autocuration,10062.0,,,CHEMBL615488,1.0,,4.0,,,,,,783.0,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor
,BAO_0000224,B,,,104744.0,H,,Autocuration,10062.0,,,CHEMBL615489,1.0,,4.0,,,,,,784.0,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor
,BAO_0000224,B,,,104744.0,H,,Autocuration,10062.0,,,CHEMBL615389,1.0,,4.0,,,,,,785.0,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor
,BAO_0000019,B,,,104744.0,H,,Autocuration,15463.0,,,CHEMBL615390,1.0,,4.0,,,,,,786.0,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand
,BAO_0000019,B,,,104744.0,H,,Autocuration,15463.0,,,CHEMBL615391,1.0,,4.0,,,,,,787.0,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand
,BAO_0000224,B,,,104744.0,H,,Autocuration,9098.0,,,CHEMBL615392,1.0,,4.0,,,,,,788.0,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined
,BAO_0000019,B,,,22226.0,U,Rattus norvegicus,Autocuration,3070.0,,10116.0,CHEMBL615393,1.0,,0.0,,,,,,789.0,Affinity for 5-hydroxytryptamine 1 receptor
,BAO_0000221,B,,,104744.0,H,,Autocuration,14542.0,,,CHEMBL615394,1.0,,4.0,Brain,,,955.0,,790.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex
,BAO_0000221,B,,,104744.0,H,,Autocuration,14542.0,,,CHEMBL615395,1.0,,4.0,Brain,,,955.0,,791.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM
,BAO_0000224,B,,,104744.0,H,,Autocuration,6398.0,,,CHEMBL615396,1.0,,4.0,,,,,,792.0,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding
,BAO_0000221,B,,,104744.0,H,,Autocuration,1344.0,,,CHEMBL615397,1.0,,4.0,Brain,,,955.0,,793.0,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay
,BAO_0000019,B,,,104744.0,H,,Autocuration,11963.0,,,CHEMBL615398,1.0,,4.0,,,,,,794.0,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex
,BAO_0000019,B,,,22226.0,U,Rattus norvegicus,Autocuration,8908.0,,10116.0,CHEMBL615399,1.0,,0.0,,,,,,795.0,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex
,BAO_0000019,B,,,104744.0,H,,Autocuration,9098.0,,,CHEMBL615400,1.0,,4.0,,,,,,796.0,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.
,BAO_0000019,B,,,104744.0,D,Rattus norvegicus,Autocuration,8841.0,,10116.0,CHEMBL615401,1.0,,5.0,,,,,,797.0,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex
,BAO_0000019,B,,,22226.0,U,Rattus norvegicus,Autocuration,8814.0,,10116.0,CHEMBL615402,1.0,,0.0,,,,,,798.0,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates
,BAO_0000019,B,,,104744.0,H,,Autocuration,11752.0,,,CHEMBL615403,1.0,,4.0,,,,,,799.0,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex
,BAO_0000221,B,,,104744.0,H,,Autocuration,11642.0,,,CHEMBL615404,1.0,,4.0,Brain,,,955.0,,800.0,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue
,BAO_0000019,B,,,104744.0,H,,Autocuration,11642.0,,,CHEMBL615781,1.0,,4.0,,,,,,801.0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex
,BAO_0000220,B,,,104744.0,H,,Autocuration,9231.0,,,CHEMBL615782,1.0,,4.0,Brain,,,955.0,,802.0,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes
,BAO_0000221,B,,,104744.0,H,,Autocuration,11351.0,,,CHEMBL615783,1.0,,4.0,Brain,,,955.0,,803.0,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.
,BAO_0000019,B,,,22226.0,U,,Autocuration,4639.0,,,CHEMBL873481,1.0,,0.0,,,,,,804.0,Compound was tested for binding affinity against 5-HT1 receptor
,BAO_0000019,B,,,22226.0,U,,Autocuration,1205.0,,,CHEMBL615784,1.0,,0.0,,,,,,805.0,Inhibitory concentration against 5-hydroxytryptamine 1 receptor
,BAO_0000357,B,,,10576.0,H,,Expert,10025.0,,,CHEMBL615785,1.0,,8.0,,,,,,806.0,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM
,BAO_0000249,F,,,10576.0,H,,Autocuration,13241.0,,,CHEMBL615786,1.0,,8.0,,,,,,807.0,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor"
,BAO_0000218,F,In vivo,,10576.0,H,,Autocuration,16245.0,,,CHEMBL615787,1.0,,8.0,,,,,,808.0,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration
,BAO_0000218,F,In vivo,,10576.0,H,,Autocuration,16245.0,,,CHEMBL615788,1.0,,8.0,,,,,,809.0,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration
,BAO_0000019,F,,,10576.0,H,,Autocuration,12438.0,,,CHEMBL767044,1.0,,8.0,,,,,,810.0,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor
,BAO_0000218,F,In vivo,,10576.0,H,,Autocuration,16245.0,,,CHEMBL615789,1.0,,8.0,,,,,,811.0,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration
,BAO_0000218,F,In vivo,,10576.0,H,,Autocuration,16245.0,,,CHEMBL615790,1.0,,8.0,,,,,,812.0,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration
,BAO_0000019,F,,,10576.0,H,,Autocuration,15740.0,,,CHEMBL615813,1.0,,8.0,,,,,,813.0,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats
,BAO_0000219,F,,,10576.0,H,,Autocuration,15535.0,,,CHEMBL615814,1.0,,8.0,,,,,,814.0,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration
,BAO_0000219,F,,,51.0,H,,Expert,15535.0,,,CHEMBL615815,1.0,,8.0,,,,,,815.0,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT
,BAO_0000219,F,,,10576.0,H,,Autocuration,15535.0,,,CHEMBL615816,1.0,,8.0,,,,,,816.0,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect
,BAO_0000249,B,,,10576.0,H,,Expert,9888.0,,,CHEMBL615817,1.0,,8.0,,,,,,817.0,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values
,BAO_0000221,B,,,10576.0,H,,Autocuration,10085.0,,,CHEMBL615818,1.0,,8.0,Hippocampus,,,10000000.0,,818.0,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT
,BAO_0000221,B,,,10576.0,H,,Autocuration,10085.0,,,CHEMBL615819,1.0,,8.0,Hippocampus,,,10000000.0,,819.0,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT
,BAO_0000249,B,,,10576.0,H,,Expert,17331.0,Membranes,,CHEMBL615820,1.0,,8.0,,,,,,820.0,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes
,BAO_0000221,B,,,10576.0,D,Rattus norvegicus,Expert,10845.0,,10116.0,CHEMBL615821,1.0,,9.0,Hippocampus,,,10000000.0,,821.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT
,BAO_0000221,B,,,10576.0,D,Rattus norvegicus,Expert,10845.0,,10116.0,CHEMBL615822,1.0,,9.0,Hippocampus,,,10000000.0,,822.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT
,BAO_0000221,B,,,10576.0,H,,Expert,10845.0,,,CHEMBL615823,1.0,,8.0,Hippocampus,,,10000000.0,,823.0,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand
,BAO_0000221,B,,,10576.0,D,Rattus norvegicus,Expert,10845.0,,10116.0,CHEMBL615824,1.0,,9.0,Hippocampus,,,10000000.0,,824.0,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive
,BAO_0000221,B,,,10576.0,D,Rattus norvegicus,Expert,10845.0,,10116.0,CHEMBL615825,1.0,,9.0,Hippocampus,,,10000000.0,,825.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT
,BAO_0000357,B,,,10576.0,H,,Expert,13730.0,,,CHEMBL615826,1.0,,8.0,,,,,,826.0,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand
,BAO_0000249,B,,,10576.0,H,,Expert,13508.0,,,CHEMBL615827,1.0,,8.0,,,,,,827.0,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand
,BAO_0000249,B,,,10576.0,H,,Expert,13508.0,,,CHEMBL615828,1.0,,8.0,Hippocampus,,,10000000.0,,828.0,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand
,BAO_0000221,B,,,10576.0,H,,Expert,12073.0,,,CHEMBL615829,1.0,,8.0,Hippocampus,,,10000000.0,,829.0,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus
,BAO_0000221,B,,,10576.0,H,,Autocuration,4671.0,,,CHEMBL615830,1.0,,8.0,Hippocampus,,,10000000.0,,830.0,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand
,BAO_0000221,B,,,10576.0,H,,Expert,13631.0,,,CHEMBL615831,1.0,,8.0,Hippocampus,,,10000000.0,,831.0,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand
,BAO_0000357,B,,,10576.0,H,,Autocuration,12438.0,,,CHEMBL615832,1.0,,8.0,,,,,,832.0,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor
,BAO_0000019,B,,,10576.0,H,,Autocuration,10483.0,,,CHEMBL615833,1.0,,8.0,,,,,,833.0,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand
,BAO_0000221,B,,,10576.0,H,,Autocuration,10483.0,,,CHEMBL615834,1.0,,8.0,Hippocampus,,,10000000.0,,834.0,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand
,BAO_0000249,B,,,10576.0,H,,Intermediate,12352.0,,,CHEMBL615835,1.0,,8.0,,,,,,835.0,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes
,BAO_0000249,B,,,10576.0,H,,Autocuration,14732.0,,,CHEMBL615836,1.0,,8.0,Hippocampus,,,10000000.0,,836.0,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.
,BAO_0000019,B,,,10576.0,D,Rattus norvegicus,Expert,11049.0,,10116.0,CHEMBL615837,1.0,,9.0,,,,,,837.0,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.
,BAO_0000019,B,,,10576.0,D,Rattus norvegicus,Expert,11049.0,,10116.0,CHEMBL615838,1.0,,9.0,,,,,,838.0,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined
,BAO_0000249,B,,,10576.0,H,,Expert,13657.0,,,CHEMBL615839,1.0,,8.0,,,,,,839.0,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)"
,BAO_0000019,B,,,10576.0,H,,Autocuration,11473.0,,,CHEMBL884525,1.0,,8.0,,,,,,840.0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand
,BAO_0000249,B,,,10576.0,H,,Autocuration,2014.0,,,CHEMBL615840,1.0,,8.0,,,,,,841.0,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes
,BAO_0000221,B,,,10576.0,H,,Expert,3086.0,,,CHEMBL615405,1.0,,8.0,Hippocampus,,,10000000.0,,842.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus
,BAO_0000019,B,,,10576.0,H,,Expert,15854.0,,,CHEMBL615406,1.0,,8.0,,,,,,843.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.
,BAO_0000221,B,,,10576.0,H,,Expert,10922.0,,,CHEMBL615900,1.0,,8.0,Hippocampus,,,10000000.0,,844.0,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue
,BAO_0000221,B,,,10576.0,H,,Expert,13346.0,,,CHEMBL615901,1.0,,8.0,Hippocampus,,,10000000.0,,845.0,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.
,BAO_0000357,B,,,10576.0,H,,Expert,15311.0,,,CHEMBL615902,1.0,,8.0,,,,,,846.0,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.
,BAO_0000221,B,,,10576.0,H,,Autocuration,10922.0,,,CHEMBL615903,1.0,,8.0,Hippocampus,,,10000000.0,,847.0,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue
,BAO_0000357,B,,,10576.0,H,,Autocuration,10025.0,,,CHEMBL615904,1.0,,8.0,,,,,,848.0,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM
,BAO_0000357,B,,,10576.0,H,,Expert,10025.0,,,CHEMBL615905,1.0,,8.0,,,,,,849.0,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM
,BAO_0000019,B,,,10576.0,H,,Autocuration,9742.0,,,CHEMBL615906,1.0,,8.0,,,,,,850.0,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat
,BAO_0000019,F,,,10576.0,H,,Autocuration,9742.0,,,CHEMBL615907,1.0,,8.0,,,,,,851.0,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat
,BAO_0000019,B,,,10576.0,H,,Expert,12304.0,,,CHEMBL615908,1.0,,8.0,,,,,,852.0,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex
,BAO_0000221,B,,,10576.0,H,,Autocuration,15789.0,,,CHEMBL615909,1.0,,8.0,Hippocampus,,,10000000.0,,853.0,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus
,BAO_0000019,B,,,10576.0,H,,Autocuration,9912.0,,,CHEMBL615910,1.0,,8.0,,,,,,854.0,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand"
,BAO_0000019,B,,,10576.0,H,,Autocuration,9912.0,,,CHEMBL615911,1.0,,8.0,,,,,,855.0,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand."
,BAO_0000019,B,,,10576.0,H,,Autocuration,9912.0,,,CHEMBL615912,1.0,,8.0,,,,,,856.0,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand"
,BAO_0000019,B,,,10576.0,H,,Expert,16693.0,,,CHEMBL615913,1.0,,8.0,,,,,,857.0,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand
,BAO_0000357,B,,,10576.0,H,,Expert,13276.0,,,CHEMBL615914,1.0,,8.0,,,,,,858.0,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.
,BAO_0000221,B,,,10576.0,H,,Autocuration,12678.0,,,CHEMBL615915,1.0,,8.0,Hippocampus,,,10000000.0,,859.0,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate
,BAO_0000357,B,,,10576.0,H,,Autocuration,11825.0,,,CHEMBL615916,1.0,,8.0,,,,,,860.0,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated
,BAO_0000357,B,,,10576.0,H,,Expert,12443.0,,,CHEMBL615917,1.0,,8.0,,,,,,861.0,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin
,BAO_0000357,B,,,10576.0,H,,Expert,13830.0,,,CHEMBL615918,1.0,,8.0,,,,,,862.0,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor
,BAO_0000249,B,,,10576.0,H,,Expert,14286.0,,,CHEMBL615919,1.0,,8.0,Hippocampus,,,10000000.0,,863.0,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.
,BAO_0000221,B,,,10576.0,D,Rattus norvegicus,Expert,14356.0,,10116.0,CHEMBL615920,1.0,,9.0,Hippocampus,,,10000000.0,,864.0,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus
,BAO_0000357,B,,,10576.0,H,,Autocuration,15306.0,,,CHEMBL615921,1.0,,8.0,,,,,,865.0,Inhibition concentration against 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,10576.0,H,,Expert,15306.0,,,CHEMBL615922,1.0,,8.0,,,,,,866.0,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration)
,BAO_0000249,F,,,10576.0,D,Rattus norvegicus,Expert,16616.0,,10116.0,CHEMBL881290,1.0,,9.0,,,,,,867.0,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes"
,BAO_0000221,B,,,10576.0,H,,Autocuration,3651.0,,,CHEMBL615923,1.0,,8.0,Hippocampus,,,10000000.0,,868.0,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%"
,BAO_0000221,F,,,10576.0,H,,Autocuration,14331.0,,,CHEMBL615924,1.0,,8.0,Hippocampus,,,10000000.0,,869.0,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus
,BAO_0000221,F,,,10576.0,H,,Autocuration,14331.0,,,CHEMBL615925,1.0,,8.0,Hippocampus,,,10000000.0,,870.0,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus
,BAO_0000357,B,,,10576.0,D,Rattus norvegicus,Expert,14178.0,,10116.0,CHEMBL615926,1.0,,9.0,,,,,,871.0,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor
,BAO_0000019,B,,,10576.0,D,Rattus norvegicus,Expert,10639.0,,10116.0,CHEMBL615927,1.0,,9.0,,,,,,872.0,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor
,BAO_0000221,B,,,10576.0,H,,Autocuration,12306.0,,,CHEMBL615928,1.0,,8.0,Hippocampus,,,10000000.0,,873.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates
,BAO_0000357,B,,,10576.0,D,Rattus norvegicus,Expert,1348.0,,10116.0,CHEMBL615929,1.0,,9.0,,,,,,874.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype
,BAO_0000221,B,,,10576.0,H,,Autocuration,13605.0,,,CHEMBL615930,1.0,,8.0,Hippocampus,,,10000000.0,,875.0,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus
,BAO_0000219,B,,CHO,51.0,H,,Autocuration,17624.0,,,CHEMBL615931,1.0,,8.0,,,,,449.0,876.0,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,17624.0,,,CHEMBL615932,1.0,,8.0,,,,,449.0,877.0,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,17624.0,,,CHEMBL615933,1.0,,8.0,,,,,449.0,878.0,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,H,,Autocuration,15267.0,,,CHEMBL615934,1.0,,8.0,,,,,,879.0,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,H,,Autocuration,16532.0,,,CHEMBL615935,1.0,,8.0,,,,,,880.0,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested
,BAO_0000019,F,,,51.0,H,,Autocuration,6563.0,,,CHEMBL615936,1.0,,8.0,,,,,,881.0,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay"
,BAO_0000219,B,,CHO,51.0,H,,Autocuration,4751.0,,,CHEMBL615937,1.0,,8.0,,,,,449.0,882.0,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM
,BAO_0000357,B,,,51.0,H,,Autocuration,15463.0,,,CHEMBL615938,1.0,,8.0,,,,,,883.0,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,H,,Autocuration,3805.0,,,CHEMBL615797,1.0,,8.0,,,,,,884.0,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM)
,BAO_0000357,B,,,51.0,H,,Autocuration,5640.0,,,CHEMBL615798,1.0,,8.0,,,,,,885.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
,BAO_0000357,B,,,51.0,H,,Autocuration,6563.0,,,CHEMBL872870,1.0,,8.0,,,,,,886.0,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration
,BAO_0000357,B,,,51.0,H,,Autocuration,5548.0,,,CHEMBL615799,1.0,,8.0,,,,,,887.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration
,BAO_0000357,B,,,51.0,H,,Autocuration,6347.0,,,CHEMBL615800,1.0,,8.0,,,,,,888.0,Percent binding affinity against 5-hydroxytryptamine 1A receptor
,BAO_0000219,F,,HEK293,51.0,H,,Autocuration,17296.0,,,CHEMBL615801,1.0,,8.0,,,,,722.0,889.0,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S
,BAO_0000019,B,,,51.0,H,,Autocuration,13047.0,,,CHEMBL615802,1.0,,8.0,,,,,,890.0,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium
,BAO_0000357,B,,,51.0,H,,Autocuration,15740.0,,,CHEMBL615803,1.0,,8.0,,,,,,891.0,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor
,BAO_0000019,F,,,51.0,H,,Expert,5640.0,,,CHEMBL835002,1.0,,8.0,,,,,,892.0,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors."
,BAO_0000019,F,,,51.0,H,,Autocuration,5640.0,,,CHEMBL615804,1.0,,8.0,,,,,,893.0,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined"
,BAO_0000219,B,,HeLa,51.0,H,,Expert,17211.0,,,CHEMBL615805,1.0,,8.0,,,,,308.0,894.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor
,BAO_0000219,B,,CHO,51.0,H,,Autocuration,4751.0,,,CHEMBL615806,1.0,,8.0,,,,,449.0,895.0,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,D,Homo sapiens,Expert,6491.0,,9606.0,CHEMBL615807,1.0,,9.0,,,,,,896.0,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor
,BAO_0000357,B,,,51.0,H,,Autocuration,4707.0,,,CHEMBL615808,1.0,,8.0,,,,,,897.0,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand
,BAO_0000357,B,,,51.0,D,Homo sapiens,Expert,13910.0,,9606.0,CHEMBL615809,1.0,,9.0,,,,,,898.0,Binding affinity against 5-hydroxytryptamine 1A receptor
,BAO_0000219,B,,HeLa,51.0,H,,Autocuration,16190.0,,,CHEMBL615810,1.0,,8.0,,,,,308.0,899.0,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT
,BAO_0000357,B,,,51.0,H,,Autocuration,16633.0,,,CHEMBL615811,1.0,,8.0,,,,,,900.0,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
,BAO_0000219,B,,CHO,51.0,H,,Autocuration,11898.0,,,CHEMBL615812,1.0,,8.0,,,,,449.0,901.0,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells
,BAO_0000219,B,,CHO,51.0,H,,Autocuration,11898.0,,,CHEMBL615751,1.0,,8.0,,,,,449.0,902.0,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells
,BAO_0000357,B,,,51.0,H,,Autocuration,14331.0,,,CHEMBL615752,1.0,,8.0,,,,,,903.0,Binding affinity against human 5-hydroxytryptamine 1A receptor
,BAO_0000219,B,,CHO,51.0,H,,Expert,17624.0,,,CHEMBL615753,1.0,,8.0,,,,,449.0,904.0,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand
,BAO_0000219,B,,CHO,51.0,H,,Autocuration,17624.0,,,CHEMBL615754,1.0,,8.0,,,,,449.0,905.0,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined
,BAO_0000357,B,,,51.0,H,,Autocuration,3307.0,,,CHEMBL615755,1.0,,8.0,,,,,,906.0,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor
,BAO_0000219,B,,CHO,51.0,D,Homo sapiens,Expert,6563.0,,9606.0,CHEMBL615756,1.0,,9.0,,,,,449.0,907.0,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells
,BAO_0000019,B,,,51.0,H,,Autocuration,14165.0,,,CHEMBL615757,1.0,,8.0,,,,,,908.0,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand
,BAO_0000357,B,,,51.0,H,,Autocuration,5732.0,,,CHEMBL615758,1.0,,8.0,,,,,,909.0,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined
,BAO_0000357,B,,,51.0,H,,Expert,13366.0,,,CHEMBL615759,1.0,,8.0,,,,,,910.0,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.
,BAO_0000357,B,,,51.0,H,,Autocuration,17626.0,,,CHEMBL615760,1.0,,8.0,,,,,,911.0,Binding affinity towards human 5-hydroxytryptamine 1A receptor
,BAO_0000219,B,,HeLa,51.0,H,,Expert,6588.0,,,CHEMBL615761,1.0,,8.0,,,,,308.0,912.0,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells
,BAO_0000357,B,,,51.0,H,,Autocuration,16209.0,,,CHEMBL872104,1.0,,8.0,,,,,,913.0,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand
,BAO_0000357,B,,,51.0,H,,Autocuration,15463.0,,,CHEMBL615762,1.0,,8.0,,,,,,914.0,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand
,BAO_0000357,B,,,51.0,H,,Autocuration,15463.0,,,CHEMBL615763,1.0,,8.0,,,,,,915.0,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand
,BAO_0000357,B,,,51.0,H,,Autocuration,14770.0,,,CHEMBL615764,1.0,,8.0,,,,,,916.0,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.
,BAO_0000219,B,,Cell line,51.0,H,,Autocuration,16245.0,,,CHEMBL615765,1.0,,8.0,,,,,1167.0,917.0,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La)
,BAO_0000019,B,,,51.0,H,,Autocuration,16245.0,,,CHEMBL615766,1.0,,8.0,,,,,,918.0,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La)
,BAO_0000357,B,,,51.0,H,,Autocuration,5548.0,,,CHEMBL615767,1.0,,8.0,,,,,,919.0,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand
,BAO_0000357,B,,,51.0,H,,Expert,5548.0,,,CHEMBL615768,1.0,,8.0,,,,,,920.0,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
,BAO_0000357,B,,,51.0,H,,Autocuration,5548.0,,,CHEMBL615769,1.0,,8.0,,,,,,921.0,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
,BAO_0000357,B,,,51.0,H,,Expert,6876.0,,,CHEMBL615770,1.0,,8.0,,,,,,922.0,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT
,BAO_0000357,B,,,51.0,H,,Autocuration,2598.0,,,CHEMBL615771,1.0,,8.0,,,,,,923.0,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
,BAO_0000357,B,,,51.0,H,,Expert,17785.0,,,CHEMBL615772,1.0,,8.0,,,,,,924.0,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand
,BAO_0000357,B,,,51.0,H,,Autocuration,6013.0,,,CHEMBL615773,1.0,,8.0,,,,,,925.0,Binding affinity towards 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,H,,Expert,5929.0,,,CHEMBL615774,1.0,,8.0,,,,,,926.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand
,BAO_0000357,B,,,51.0,H,,Autocuration,16633.0,,,CHEMBL615775,1.0,,8.0,,,,,,927.0,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
,BAO_0000357,B,,,51.0,H,,Autocuration,1558.0,,,CHEMBL615776,1.0,,8.0,,,,,,928.0,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined
,BAO_0000357,B,,,51.0,H,,Expert,16026.0,,,CHEMBL615777,1.0,,8.0,,,,,,929.0,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
,BAO_0000219,B,,,51.0,H,,Autocuration,12469.0,,,CHEMBL615778,1.0,,8.0,,,,,,930.0,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT
,BAO_0000357,B,,,51.0,D,Homo sapiens,Expert,15874.0,,9606.0,CHEMBL615779,1.0,,9.0,,,,,,931.0,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT
,BAO_0000357,B,,,51.0,H,,Autocuration,15874.0,,,CHEMBL615780,1.0,,8.0,,,,,,932.0,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT
,BAO_0000357,B,,,51.0,H,,Autocuration,3935.0,,,CHEMBL616298,1.0,,8.0,,,,,,933.0,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,H,,Autocuration,15818.0,,,CHEMBL616299,1.0,,8.0,,,,,,934.0,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor
,BAO_0000219,B,,CHO-K1,51.0,H,,Autocuration,13706.0,,,CHEMBL616300,1.0,,8.0,,,,,485.0,935.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.
,BAO_0000219,F,,CHO-K1,51.0,H,,Expert,13729.0,,,CHEMBL616301,1.0,,8.0,,,,,485.0,936.0,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells
,BAO_0000019,B,,,51.0,H,,Autocuration,15413.0,,,CHEMBL616302,1.0,,8.0,,,,,,937.0,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor
,BAO_0000019,B,,,51.0,H,,Autocuration,15413.0,,,CHEMBL616117,1.0,,8.0,,,,,,938.0,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1)
,BAO_0000019,B,,,51.0,H,,Autocuration,15413.0,,,CHEMBL616118,1.0,,8.0,,,,,,939.0,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2)
,BAO_0000019,B,,,51.0,H,,Autocuration,15413.0,,,CHEMBL616119,1.0,,8.0,,,,,,940.0,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay
,BAO_0000219,B,,HeLa,51.0,D,Homo sapiens,Expert,3445.0,,9606.0,CHEMBL616120,1.0,,9.0,,,,,308.0,941.0,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells
,BAO_0000357,B,,,51.0,H,,Autocuration,15740.0,,,CHEMBL616121,1.0,,8.0,,,,,,942.0,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,H,,Autocuration,15740.0,,,CHEMBL616122,1.0,,8.0,,,,,,943.0,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor
,BAO_0000357,B,,,51.0,H,,Autocuration,17626.0,,,CHEMBL616123,1.0,,8.0,,,,,,944.0,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,D,Homo sapiens,Expert,4234.0,,9606.0,CHEMBL616124,1.0,,9.0,,,,,,945.0,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,H,,Expert,5640.0,,,CHEMBL616125,1.0,,8.0,,,,,,946.0,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.
,BAO_0000357,B,,,51.0,H,Rattus norvegicus,Expert,5272.0,,10116.0,CHEMBL616126,1.0,,8.0,,,,,,947.0,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT
,BAO_0000219,B,,CHO,51.0,H,,Autocuration,4622.0,,,CHEMBL616127,1.0,,8.0,,,,,449.0,948.0,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand
,BAO_0000019,B,,,51.0,H,,Expert,17085.0,,,CHEMBL616128,1.0,,8.0,,,,,,949.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,H,,Autocuration,3025.0,,,CHEMBL616129,1.0,,8.0,,,,,,950.0,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand
,BAO_0000357,B,,,51.0,H,,Expert,15315.0,,,CHEMBL616130,1.0,,8.0,,,,,,951.0,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,H,,Autocuration,15267.0,,,CHEMBL616131,1.0,,8.0,,,,,,952.0,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant
,BAO_0000219,B,,HeLa,51.0,H,,Autocuration,17158.0,,,CHEMBL616132,1.0,,8.0,,,,,308.0,953.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells
,BAO_0000219,B,,HeLa,51.0,D,Homo sapiens,Expert,14214.0,,9606.0,CHEMBL616133,1.0,,9.0,,,,,308.0,954.0,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells
,BAO_0000357,B,,,51.0,H,,Autocuration,17133.0,,,CHEMBL616134,1.0,,8.0,,,,,,955.0,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
,BAO_0000357,B,,,51.0,H,,Autocuration,16532.0,,,CHEMBL616135,1.0,,8.0,,,,,,956.0,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT
,BAO_0000357,B,,,51.0,D,Homo sapiens,Expert,2391.0,,9606.0,CHEMBL616136,1.0,,9.0,,,,,,957.0,Affinity for 5-hydroxytryptamine 1A receptor subtype
,BAO_0000019,B,,,51.0,H,,Autocuration,14447.0,,,CHEMBL616137,1.0,,8.0,,,,,,958.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes
,BAO_0000019,B,,,51.0,H,,Autocuration,14447.0,,,CHEMBL872105,1.0,,8.0,,,,,,959.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.
,BAO_0000357,B,,,51.0,H,,Autocuration,15086.0,,,CHEMBL616138,1.0,,8.0,,,,,,960.0,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor
,BAO_0000357,B,,,51.0,D,Homo sapiens,Expert,13051.0,,9606.0,CHEMBL616139,1.0,,9.0,,,,,,961.0,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor
,BAO_0000019,F,,,51.0,H,,Autocuration,16026.0,,,CHEMBL616140,1.0,,8.0,,,,,,962.0,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active"
,BAO_0000019,B,,,51.0,H,,Expert,17085.0,,,CHEMBL616141,1.0,,8.0,,,,,,963.0,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined
,BAO_0000357,B,,,51.0,H,,Autocuration,17133.0,,,CHEMBL616142,1.0,,8.0,,,,,,964.0,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
,BAO_0000357,B,,,51.0,H,,Autocuration,17133.0,,,CHEMBL616143,1.0,,8.0,,,,,,965.0,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined
,BAO_0000219,B,,HeLa,51.0,H,,Autocuration,17211.0,,,CHEMBL616144,1.0,,8.0,,,,,308.0,966.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested
,BAO_0000219,B,,HeLa,51.0,H,,Autocuration,17211.0,,,CHEMBL616145,1.0,,8.0,,,,,308.0,967.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested
,BAO_0000219,B,,HeLa,51.0,H,,Autocuration,17211.0,,,CHEMBL616012,1.0,,8.0,,,,,308.0,968.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested
,BAO_0000219,B,,HeLa,51.0,H,,Autocuration,17211.0,,,CHEMBL616013,1.0,,8.0,,,,,308.0,969.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested
,BAO_0000019,F,,,51.0,H,,Autocuration,16394.0,,,CHEMBL616014,1.0,,8.0,,,,,,970.0,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested"
,BAO_0000019,F,,,51.0,H,,Autocuration,16394.0,,,CHEMBL616015,1.0,,8.0,,,,,,971.0,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested"
,BAO_0000019,F,,,51.0,H,,Autocuration,16394.0,,,CHEMBL616016,1.0,,8.0,,,,,,972.0,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested"
,BAO_0000218,F,In vivo,,51.0,H,,Autocuration,16394.0,,,CHEMBL616017,1.0,,8.0,,,,,,973.0,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested
,BAO_0000019,B,,,51.0,H,,Autocuration,16394.0,,,CHEMBL616018,1.0,,8.0,,,,,,974.0,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested
,BAO_0000019,F,,,51.0,H,,Autocuration,15740.0,,,CHEMBL616019,1.0,,8.0,,,,,,975.0,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested
,BAO_0000019,F,,,51.0,H,,Autocuration,15740.0,,,CHEMBL616020,1.0,,8.0,,,,,,976.0,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested
,BAO_0000357,B,,,51.0,H,,Autocuration,15740.0,,,CHEMBL858018,1.0,,8.0,,,,,,977.0,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor
,BAO_0000219,F,,HEK293,51.0,H,,Autocuration,17296.0,,,CHEMBL616021,1.0,,8.0,,,,,722.0,978.0,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S
,BAO_0000019,F,,,51.0,H,,Expert,5640.0,,,CHEMBL616022,1.0,,8.0,,,,,,979.0,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM."
,BAO_0000019,F,,,51.0,H,,Autocuration,5640.0,,,CHEMBL616023,1.0,,8.0,,,,,,980.0,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined"
,BAO_0000019,F,,,51.0,H,,Autocuration,5640.0,,,CHEMBL616024,1.0,,8.0,,,,,,981.0,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined"
,BAO_0000019,F,,,51.0,H,,Autocuration,5640.0,,,CHEMBL616025,1.0,,8.0,,,,,,982.0,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined"
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,2759.0,,,CHEMBL616026,1.0,,8.0,,,,,449.0,983.0,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor
,BAO_0000019,F,,,51.0,H,,Autocuration,16394.0,,,CHEMBL616027,1.0,,8.0,,,,,,984.0,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT"
,BAO_0000019,F,,,51.0,D,Homo sapiens,Expert,16394.0,,9606.0,CHEMBL616028,1.0,,9.0,,,,,,985.0,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT"
,BAO_0000019,F,,,51.0,D,Homo sapiens,Expert,3445.0,,9606.0,CHEMBL616029,1.0,,9.0,,,,,,986.0,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response
,BAO_0000219,B,,CHO,51.0,H,,Expert,4316.0,,,CHEMBL616030,1.0,,8.0,,,,,449.0,987.0,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT
,BAO_0000019,B,,,51.0,H,,Expert,4316.0,,,CHEMBL616031,1.0,,8.0,,,,,,988.0,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.
,BAO_0000019,F,,,51.0,D,Homo sapiens,Expert,15180.0,,9606.0,CHEMBL616032,1.0,,9.0,,,,,,989.0,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype
,BAO_0000019,F,,,51.0,D,Homo sapiens,Expert,15180.0,,9606.0,CHEMBL616033,1.0,,9.0,,,,,,990.0,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype
,BAO_0000019,F,,,51.0,H,,Autocuration,15042.0,,,CHEMBL616034,1.0,,8.0,,,,,,991.0,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.
,BAO_0000019,F,,,51.0,H,,Autocuration,15042.0,,,CHEMBL616035,1.0,,8.0,,,,,,992.0,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.
,BAO_0000019,F,,,51.0,H,,Autocuration,15042.0,,,CHEMBL616036,1.0,,8.0,,,,,,993.0,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor
,BAO_0000019,F,,,51.0,H,,Autocuration,15042.0,,,CHEMBL616037,1.0,,8.0,,,,,,994.0,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.
,BAO_0000019,F,,,51.0,H,,Autocuration,15042.0,,,CHEMBL616038,1.0,,8.0,,,,,,995.0,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.
,BAO_0000019,F,,,51.0,H,,Autocuration,15042.0,,,CHEMBL616039,1.0,,8.0,,,,,,996.0,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.
,BAO_0000019,F,,,51.0,H,,Autocuration,15042.0,,,CHEMBL616040,1.0,,8.0,,,,,,997.0,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor
,BAO_0000219,F,,HeLa,51.0,D,Homo sapiens,Expert,15180.0,,9606.0,CHEMBL616041,1.0,,9.0,,,,,308.0,998.0,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells
,BAO_0000219,F,,HeLa,51.0,D,Homo sapiens,Expert,15180.0,,9606.0,CHEMBL616042,1.0,,9.0,,,,,308.0,999.0,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells
,BAO_0000219,F,,HeLa,51.0,D,Homo sapiens,Expert,15180.0,,9606.0,CHEMBL616043,1.0,,9.0,,,,,308.0,1000.0,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells
,BAO_0000019,F,,,51.0,H,,Autocuration,16245.0,,,CHEMBL616044,1.0,,8.0,,,,,,1001.0,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor"
,BAO_0000019,F,,,51.0,H,,Autocuration,16026.0,,,CHEMBL616045,1.0,,8.0,,,,,,1002.0,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor"
,BAO_0000219,F,,HEK293,51.0,H,,Autocuration,17296.0,,,CHEMBL616046,1.0,,8.0,,,,,722.0,1003.0,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,2759.0,,,CHEMBL616047,1.0,,8.0,,,,,449.0,1004.0,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2)
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,2759.0,,,CHEMBL616048,1.0,,8.0,,,,,449.0,1005.0,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells
,BAO_0000219,F,,CHO,51.0,D,Homo sapiens,Expert,2759.0,,9606.0,CHEMBL616049,1.0,,9.0,,,,,449.0,1006.0,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1)
,BAO_0000219,F,,CHO,51.0,H,,Autocuration,2759.0,,,CHEMBL616050,1.0,,8.0,,,,,449.0,1007.0,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2)
,BAO_0000219,F,,,51.0,H,,Expert,15419.0,,,CHEMBL616051,1.0,,8.0,,,,,,1008.0,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor
,BAO_0000219,F,,,51.0,H,,Autocuration,15419.0,,,CHEMBL616212,1.0,,8.0,,,,,,1009.0,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested
,BAO_0000019,F,,,51.0,H,,Autocuration,16026.0,,,CHEMBL616213,1.0,,8.0,,,,,,1010.0,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor"
,BAO_0000219,B,In vitro,,51.0,H,,Expert,1414.0,,,CHEMBL616214,1.0,,8.0,,,,,,1011.0,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells
,BAO_0000219,B,In vitro,,51.0,H,,Expert,1414.0,,,CHEMBL616215,1.0,,8.0,,,,,,1012.0,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells
,BAO_0000357,B,,,51.0,H,,Autocuration,12861.0,,,CHEMBL616216,1.0,,8.0,,,,,,1013.0,Binding activity radioligand.
,BAO_0000019,B,,,51.0,H,,Autocuration,12861.0,,,CHEMBL616217,1.0,,8.0,,,,,,1014.0,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.
,BAO_0000357,B,,,51.0,H,,Autocuration,5104.0,,,CHEMBL616218,1.0,,8.0,,,,,,1015.0,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,H,,Autocuration,5105.0,,,CHEMBL616219,1.0,,8.0,,,,,,1016.0,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,H,,Autocuration,16312.0,,,CHEMBL616220,1.0,,8.0,,,,,,1017.0,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,D,Homo sapiens,Expert,15180.0,,9606.0,CHEMBL833493,1.0,,9.0,,,,,,1018.0,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,H,,Autocuration,5033.0,,,CHEMBL616221,1.0,,8.0,,,,,,1019.0,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor
,BAO_0000219,B,,CHO,51.0,D,Homo sapiens,Expert,16909.0,,9606.0,CHEMBL616222,1.0,,9.0,,,,,449.0,1020.0,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A
,BAO_0000019,F,,,51.0,H,,Autocuration,2590.0,,,CHEMBL616223,1.0,,8.0,,,,,,1021.0,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor
,BAO_0000019,F,,,51.0,H,,Autocuration,2590.0,,,CHEMBL616224,1.0,,8.0,,,,,,1022.0,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined
,BAO_0000019,B,,,51.0,H,,Expert,16394.0,,,CHEMBL616225,1.0,,8.0,,,,,,1023.0,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line
,BAO_0000219,B,,HEK293,51.0,D,Homo sapiens,Expert,4540.0,,9606.0,CHEMBL616226,1.0,,9.0,,,,,722.0,1024.0,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand
,BAO_0000219,B,,HEK293,51.0,H,,Autocuration,17296.0,,,CHEMBL616227,1.0,,8.0,,,,,722.0,1025.0,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells
,BAO_0000219,B,,HEK293,51.0,H,,Autocuration,17296.0,,,CHEMBL616228,1.0,,8.0,,,,,722.0,1026.0,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand
,BAO_0000219,B,,HEK293,51.0,H,,Autocuration,15779.0,,,CHEMBL616229,1.0,,8.0,,,,,722.0,1027.0,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;
,BAO_0000219,B,,HEK293,51.0,H,,Autocuration,15779.0,,,CHEMBL616230,1.0,,8.0,,,,,722.0,1028.0,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data
,BAO_0000219,B,,HEK293,51.0,H,,Autocuration,15779.0,,,CHEMBL616231,1.0,,8.0,,,,,722.0,1029.0,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.
,BAO_0000357,B,,,51.0,H,,Autocuration,6166.0,,,CHEMBL616232,1.0,,8.0,,,,,,1030.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand
,BAO_0000219,B,,HEK293,51.0,H,,Autocuration,15779.0,,,CHEMBL616233,1.0,,8.0,,,,,722.0,1031.0,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;
,BAO_0000219,B,,HEK293,51.0,H,,Autocuration,4199.0,,,CHEMBL857973,1.0,,8.0,,,,,722.0,1032.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand
,BAO_0000219,B,,,51.0,H,,Autocuration,15316.0,,,CHEMBL616234,1.0,,8.0,,,,,,1033.0,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells
,BAO_0000357,B,,,51.0,H,,Autocuration,14875.0,,,CHEMBL616235,1.0,,8.0,,,,,,1034.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor
,BAO_0000219,B,,HeLa,51.0,H,,Expert,14727.0,,,CHEMBL616236,1.0,,8.0,,,,,308.0,1035.0,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.
,BAO_0000019,B,,,51.0,H,,Expert,14727.0,,,CHEMBL616237,1.0,,8.0,,,,,,1036.0,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.
,BAO_0000219,B,,HEK293,51.0,H,,Autocuration,15146.0,,,CHEMBL616238,1.0,,8.0,,,,,722.0,1037.0,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT
,BAO_0000219,B,,HEK293,51.0,H,,Autocuration,5213.0,,,CHEMBL616239,1.0,,8.0,,,,,722.0,1038.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand
,BAO_0000219,B,,,51.0,H,,Autocuration,16429.0,,,CHEMBL616240,1.0,,8.0,,,,,,1039.0,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand
,BAO_0000219,B,,HeLa,51.0,D,Homo sapiens,Expert,15042.0,,9606.0,CHEMBL616241,1.0,,9.0,,,,,308.0,1040.0,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.
,BAO_0000219,B,,HEK293,51.0,H,,Autocuration,14818.0,,,CHEMBL616242,1.0,,8.0,,,,,722.0,1041.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.
,BAO_0000219,B,,HEK293,51.0,H,,Autocuration,4829.0,,,CHEMBL616243,1.0,,8.0,,,,,722.0,1042.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand"
,BAO_0000357,B,,,51.0,D,,Expert,17200.0,,,CHEMBL616244,1.0,,9.0,,,,,,1043.0,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,D,Homo sapiens,Autocuration,13051.0,,9606.0,CHEMBL616245,1.0,,9.0,,,,,,1044.0,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,106.0,H,,Autocuration,5486.0,,,CHEMBL616246,1.0,,8.0,,,,,,1045.0,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell
,BAO_0000357,B,,,105.0,H,,Autocuration,5254.0,,,CHEMBL616247,1.0,,8.0,,,,,,1046.0,Binding affinity against 5-HT1D receptor
,BAO_0000357,B,,,105.0,H,,Autocuration,5254.0,,,CHEMBL616248,1.0,,8.0,,,,,,1047.0,Binding affinity against 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,107.0,H,,Autocuration,15331.0,,,CHEMBL616249,1.0,,8.0,,,,,,1048.0,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique
,BAO_0000357,B,,,10576.0,H,Homo sapiens,Autocuration,13506.0,,9606.0,CHEMBL616250,1.0,,8.0,,,,,,1049.0,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay
,BAO_0000357,B,,,51.0,H,,Autocuration,15267.0,,,CHEMBL616251,1.0,,8.0,,,,,,1050.0,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor
,BAO_0000218,F,In vivo,,11863.0,H,,Autocuration,16616.0,,,CHEMBL616252,1.0,,8.0,,,,,,1051.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound
,BAO_0000218,F,In vivo,,11863.0,H,,Autocuration,16616.0,,,CHEMBL616253,1.0,,8.0,,,,,,1052.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound
,BAO_0000218,F,In vivo,,11863.0,H,,Autocuration,16616.0,,,CHEMBL616254,1.0,,8.0,,,,,,1053.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound
,BAO_0000218,F,,,11863.0,D,Mus musculus,Expert,16616.0,,10090.0,CHEMBL616255,1.0,,9.0,,,,,,1054.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min
,BAO_0000218,F,,,11863.0,D,Mus musculus,Expert,16616.0,,10090.0,CHEMBL832872,1.0,,9.0,,,,,,1055.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min
,BAO_0000218,F,,,11863.0,D,Mus musculus,Expert,16616.0,,10090.0,CHEMBL616256,1.0,,9.0,,,,,,1056.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min
,BAO_0000218,F,,,11863.0,D,Mus musculus,Expert,16616.0,,10090.0,CHEMBL616257,1.0,,9.0,,,,,,1057.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min
,BAO_0000218,F,,,11863.0,D,Mus musculus,Expert,16616.0,,10090.0,CHEMBL616258,1.0,,9.0,,,,,,1058.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min
,BAO_0000218,F,,,11863.0,D,Mus musculus,Expert,16616.0,,10090.0,CHEMBL616384,1.0,,9.0,,,,,,1059.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min
,BAO_0000221,B,,,11863.0,H,,Autocuration,10297.0,,,CHEMBL616385,1.0,,8.0,Hippocampus,,,10000000.0,,1060.0,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus
,BAO_0000357,B,,,11863.0,H,,Expert,13704.0,,,CHEMBL616386,1.0,,8.0,,,,,,1061.0,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.
,BAO_0000221,B,,,11863.0,D,Mus musculus,Expert,10297.0,,10090.0,CHEMBL616387,1.0,,9.0,Hippocampus,,,10000000.0,,1062.0,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus
,BAO_0000221,B,,,11863.0,H,,Autocuration,10297.0,,,CHEMBL616388,1.0,,8.0,Hippocampus,,,10000000.0,,1063.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined
,BAO_0000221,B,,,11863.0,D,Mus musculus,Expert,10297.0,,10090.0,CHEMBL616389,1.0,,9.0,Hippocampus,,,10000000.0,,1064.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus
,BAO_0000221,B,,,11863.0,H,,Autocuration,10297.0,,,CHEMBL616390,1.0,,8.0,Hippocampus,,,10000000.0,,1065.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined
,BAO_0000357,B,,,11863.0,H,,Autocuration,217.0,,,CHEMBL616391,1.0,,8.0,,,,,,1066.0,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand
,BAO_0000221,B,,,11863.0,D,Mus musculus,Expert,10297.0,,10090.0,CHEMBL616392,1.0,,9.0,Hippocampus,,,10000000.0,,1067.0,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus
,BAO_0000357,B,,,51.0,H,Sus scrofa,Autocuration,4921.0,,9823.0,CHEMBL616393,1.0,,8.0,,,,,,1068.0,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,H,Sus scrofa,Autocuration,4921.0,,9823.0,CHEMBL616394,1.0,,8.0,,,,,,1069.0,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined
,BAO_0000019,B,,,51.0,H,Sus scrofa,Autocuration,4996.0,,9823.0,CHEMBL616395,1.0,,8.0,,,,,,1070.0,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates
,BAO_0000357,B,,,51.0,H,Sus scrofa,Autocuration,12918.0,,9823.0,CHEMBL616396,1.0,,8.0,,,,,,1071.0,Compound was evaluated for the binding affinity at 5- HT1A receptor
,BAO_0000019,B,,,51.0,H,Sus scrofa,Autocuration,5333.0,,9823.0,CHEMBL872907,1.0,,8.0,,,,,,1072.0,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate
,BAO_0000019,B,,,51.0,H,Sus scrofa,Autocuration,4437.0,,9823.0,CHEMBL616397,1.0,,8.0,,,,,,1073.0,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate
,BAO_0000019,B,,,51.0,H,Sus scrofa,Autocuration,1742.0,,9823.0,CHEMBL616398,1.0,,8.0,,,,,,1074.0,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex
,BAO_0000357,B,,,51.0,H,Sus scrofa,Expert,16688.0,,9823.0,CHEMBL616399,1.0,,8.0,,,,,,1075.0,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,H,Sus scrofa,Autocuration,12861.0,,9823.0,CHEMBL857065,1.0,,8.0,,,,,,1076.0,Binding activity radioligand.
,BAO_0000019,B,,,51.0,H,Sus scrofa,Expert,12861.0,,9823.0,CHEMBL616400,1.0,,8.0,,,,,,1077.0,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.
,BAO_0000019,B,,,51.0,H,Sus scrofa,Autocuration,12861.0,,9823.0,CHEMBL616401,1.0,,8.0,,,,,,1078.0,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.
,BAO_0000019,B,,,10624.0,H,,Expert,12490.0,,,CHEMBL616402,1.0,,8.0,,,,,,1079.0,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex
,BAO_0000019,B,,,51.0,H,Sus scrofa,Expert,11828.0,,9823.0,CHEMBL616403,1.0,,8.0,,,,,,1080.0,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor
,BAO_0000221,B,,,51.0,H,Sus scrofa,Autocuration,11866.0,,9823.0,CHEMBL616404,1.0,,8.0,Hippocampus,,,10000000.0,,1081.0,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT
,BAO_0000249,B,,,51.0,H,Sus scrofa,Autocuration,12827.0,,9823.0,CHEMBL616405,1.0,,8.0,,,,,,1082.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT
,BAO_0000019,B,,,51.0,H,Sus scrofa,Autocuration,12918.0,,9823.0,CHEMBL616406,1.0,,8.0,,,,,,1083.0,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT
,BAO_0000019,F,,,51.0,H,Sus scrofa,Expert,12919.0,,9823.0,CHEMBL616407,1.0,,8.0,,,,,,1084.0,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT
,BAO_0000019,B,,,51.0,H,Oryctolagus cuniculus,Autocuration,13047.0,,9986.0,CHEMBL616408,1.0,,8.0,,,,,,1085.0,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium
,BAO_0000249,B,,,10576.0,D,Rattus norvegicus,Expert,15796.0,,10116.0,CHEMBL616409,1.0,,9.0,,,,,,1086.0,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays
,BAO_0000221,B,,,10576.0,D,Rattus norvegicus,Expert,3651.0,,10116.0,CHEMBL616410,1.0,,9.0,Hippocampus,,,10000000.0,,1087.0,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active"
,BAO_0000357,B,,,10576.0,H,,Autocuration,188.0,,,CHEMBL616411,1.0,,8.0,,,,,,1088.0,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity
,BAO_0000249,F,,,10576.0,D,Rattus norvegicus,Expert,16616.0,Membranes,10116.0,CHEMBL616412,1.0,,9.0,,,,,,1089.0,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes"
,BAO_0000249,F,,,10576.0,D,Rattus norvegicus,Expert,16616.0,Membranes,10116.0,CHEMBL616413,1.0,,9.0,Hippocampus,,,10000000.0,,1090.0,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes"
,BAO_0000221,B,,,10576.0,H,,Autocuration,12306.0,,,CHEMBL616414,1.0,,8.0,Hippocampus,,,10000000.0,,1091.0,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates
,BAO_0000221,B,,,10576.0,D,Rattus norvegicus,Expert,17167.0,,10116.0,CHEMBL616415,1.0,,9.0,Hippocampus,,,10000000.0,,1092.0,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding
,BAO_0000019,B,,,10576.0,H,,Autocuration,14776.0,,,CHEMBL616416,1.0,,8.0,,,,,,1093.0,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.
,BAO_0000357,B,,,10576.0,H,,Expert,12158.0,,,CHEMBL616417,1.0,,8.0,,,,,,1094.0,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.
,BAO_0000357,B,,,10576.0,H,,Autocuration,13481.0,,,CHEMBL616418,1.0,,8.0,,,,,,1095.0,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay
,BAO_0000219,B,In vitro,,10576.0,H,,Autocuration,13427.0,,,CHEMBL616419,1.0,,8.0,,,,,,1096.0,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.
,BAO_0000357,B,,,10576.0,H,,Autocuration,10210.0,,,CHEMBL616420,1.0,,8.0,,,,,,1097.0,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT
,BAO_0000249,B,,,10576.0,H,,Autocuration,10205.0,Membranes,,CHEMBL616421,1.0,,8.0,,,,,,1098.0,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes
,BAO_0000249,B,,,10576.0,H,,Autocuration,10205.0,Membranes,,CHEMBL616422,1.0,,8.0,,,,,,1099.0,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes
,BAO_0000249,B,,,10576.0,H,,Expert,10205.0,Membranes,,CHEMBL616423,1.0,,8.0,,,,,,1100.0,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.
,BAO_0000357,B,,,10576.0,D,Rattus norvegicus,Expert,12280.0,,10116.0,CHEMBL616424,1.0,,9.0,,,,,,1101.0,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT
,BAO_0000357,B,,,10576.0,H,,Expert,17386.0,,,CHEMBL616425,1.0,,8.0,,,,,,1102.0,Binding affinity to the rat 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,10576.0,H,,Expert,13654.0,,,CHEMBL616426,1.0,,8.0,,,,,,1103.0,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.
,BAO_0000221,B,,,10576.0,H,,Autocuration,14423.0,,,CHEMBL616427,1.0,,8.0,Hippocampus,,,10000000.0,,1104.0,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.
,BAO_0000221,B,,,10576.0,H,,Autocuration,15412.0,,,CHEMBL616428,1.0,,8.0,Hippocampus,,,10000000.0,,1105.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.
,BAO_0000221,B,,,10576.0,H,,Autocuration,12073.0,,,CHEMBL616290,1.0,,8.0,Hippocampus,,,10000000.0,,1106.0,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus
,BAO_0000357,B,,,10576.0,D,Rattus norvegicus,Expert,4101.0,,10116.0,CHEMBL616052,1.0,,9.0,,,,,,1107.0,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,10576.0,H,,Autocuration,10062.0,,,CHEMBL616053,1.0,,8.0,,,,,,1108.0,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor
,BAO_0000249,B,,,10576.0,H,,Autocuration,6238.0,,,CHEMBL616054,1.0,,8.0,,,,,,1109.0,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand
,BAO_0000357,B,,,10576.0,H,,Autocuration,16273.0,,,CHEMBL616055,1.0,,8.0,,,,,,1110.0,Binding affinity towards 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,10576.0,H,,Autocuration,11139.0,,,CHEMBL616056,1.0,,8.0,,,,,,1111.0,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay
,BAO_0000019,B,,,10576.0,H,,Expert,16796.0,,,CHEMBL616057,1.0,,8.0,,,,,,1112.0,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes
,BAO_0000221,B,,,10576.0,D,Rattus norvegicus,Expert,9548.0,,10116.0,CHEMBL616058,1.0,,9.0,Brain,,,955.0,,1113.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain
,BAO_0000221,B,,,10576.0,H,,Autocuration,10381.0,,,CHEMBL616059,1.0,,8.0,Brain,,,955.0,,1114.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain
,BAO_0000249,B,,,10576.0,H,,Autocuration,13408.0,,,CHEMBL616060,1.0,,8.0,,,,,,1115.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand
,BAO_0000221,B,,,10576.0,D,Rattus norvegicus,Expert,13825.0,,10116.0,CHEMBL616061,1.0,,9.0,Hippocampus,,,10000000.0,,1116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT
,BAO_0000221,B,,,10576.0,H,,Expert,11147.0,,,CHEMBL616062,1.0,,8.0,Hippocampus,,,10000000.0,,1117.0,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand
,BAO_0000249,B,,,10576.0,H,,Autocuration,10552.0,,,CHEMBL616063,1.0,,8.0,,,,,,1118.0,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand
,BAO_0000249,B,,,10576.0,H,,Autocuration,10552.0,,,CHEMBL616064,1.0,,8.0,Striatum,,,2435.0,,1119.0,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand"
,BAO_0000249,B,,,10576.0,D,Rattus norvegicus,Expert,17136.0,Membranes,10116.0,CHEMBL616065,1.0,,9.0,,,,,,1120.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes
,BAO_0000249,B,,,10576.0,D,Rattus norvegicus,Expert,5778.0,Membranes,10116.0,CHEMBL616066,1.0,,9.0,,,,,,1121.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes
,BAO_0000221,B,,,10576.0,H,,Autocuration,13481.0,,,CHEMBL616067,1.0,,8.0,Hippocampus,,,10000000.0,,1122.0,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
,BAO_0000221,B,,,10576.0,H,,Autocuration,13481.0,,,CHEMBL616068,1.0,,8.0,Hippocampus,,,10000000.0,,1123.0,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested
,BAO_0000221,B,,,10576.0,H,,Intermediate,13630.0,,,CHEMBL616069,1.0,,8.0,Hippocampus,,,10000000.0,,1124.0,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand
,BAO_0000249,B,,,10576.0,H,,Expert,16245.0,,,CHEMBL616070,1.0,,8.0,,,,,,1125.0,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes
,BAO_0000221,B,,,10576.0,H,,Autocuration,14509.0,,,CHEMBL616071,1.0,,8.0,Hippocampus,,,10000000.0,,1126.0,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand
,BAO_0000221,B,,,10576.0,H,,Expert,14509.0,,,CHEMBL616072,1.0,,8.0,Hippocampus,,,10000000.0,,1127.0,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.
,BAO_0000221,B,,,10576.0,H,,Autocuration,14509.0,,,CHEMBL616073,1.0,,8.0,Hippocampus,,,10000000.0,,1128.0,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined
,BAO_0000221,B,,,10576.0,H,,Autocuration,14509.0,,,CHEMBL616074,1.0,,8.0,Hippocampus,,,10000000.0,,1129.0,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined
,BAO_0000019,B,,,10576.0,H,,Expert,14256.0,,,CHEMBL616075,1.0,,8.0,,,,,,1130.0,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.
,BAO_0000357,B,,,10576.0,H,,Autocuration,11139.0,,,CHEMBL616076,1.0,,8.0,,,,,,1131.0,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor
,BAO_0000019,B,,,10576.0,D,Rattus norvegicus,Expert,11047.0,,10116.0,CHEMBL616077,1.0,,9.0,,,,,,1132.0,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined
,BAO_0000019,B,,,10576.0,D,Rattus norvegicus,Expert,11047.0,,10116.0,CHEMBL616078,1.0,,9.0,,,,,,1133.0,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes
,BAO_0000019,B,,,10576.0,D,Rattus norvegicus,Expert,11047.0,,10116.0,CHEMBL616079,1.0,,9.0,,,,,,1134.0,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined
,BAO_0000219,B,,CHO-K1,10576.0,D,Rattus norvegicus,Expert,2395.0,,10116.0,CHEMBL616080,1.0,,9.0,,,,,485.0,1135.0,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells
,BAO_0000357,B,,,10576.0,H,,Autocuration,9699.0,,,CHEMBL616081,1.0,,8.0,,,,,,1136.0,Binding affinity towards 5-hydroxytryptamine 1A receptor
,BAO_0000221,B,,,10576.0,D,Rattus norvegicus,Expert,12028.0,,10116.0,CHEMBL616082,1.0,,9.0,Hippocampus,,,10000000.0,,1137.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain
,BAO_0000221,B,,,10576.0,H,,Autocuration,12028.0,,,CHEMBL616083,1.0,,8.0,Hippocampus,,,10000000.0,,1138.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain
,BAO_0000019,B,,,10576.0,H,,Autocuration,5815.0,,,CHEMBL616084,1.0,,8.0,,,,,,1139.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex
,BAO_0000019,B,,,10576.0,H,,Expert,16616.0,,,CHEMBL616085,1.0,,8.0,,,,,,1140.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates
,BAO_0000019,B,,,10576.0,H,,Autocuration,5815.0,,,CHEMBL616086,1.0,,8.0,,,,,,1141.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT
,BAO_0000221,B,,,10576.0,H,,Autocuration,2761.0,,,CHEMBL616087,1.0,,8.0,Hippocampus,,,10000000.0,,1142.0,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate"
,BAO_0000357,B,,,10576.0,H,,Expert,13133.0,,,CHEMBL616088,1.0,,8.0,,,,,,1143.0,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101
,BAO_0000019,B,,,10576.0,H,,Autocuration,10444.0,,,CHEMBL616089,1.0,,8.0,,,,,,1144.0,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.
,BAO_0000357,B,,,10576.0,D,Rattus norvegicus,Expert,13278.0,,10116.0,CHEMBL616090,1.0,,9.0,,,,,,1145.0,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides
,BAO_0000357,B,,,10576.0,H,,Autocuration,15874.0,,,CHEMBL616091,1.0,,8.0,,,,,,1146.0,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT
,BAO_0000249,B,,,10576.0,H,,Autocuration,10552.0,Membranes,,CHEMBL616092,1.0,,8.0,Striatum,,,2435.0,,1147.0,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand"
,BAO_0000357,B,,,10576.0,H,,Autocuration,11130.0,,,CHEMBL616093,1.0,,8.0,,,,,,1148.0,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro)
,BAO_0000218,B,In vivo,,10576.0,H,,Autocuration,11130.0,,,CHEMBL616094,1.0,,8.0,,,,,,1149.0,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo)
,BAO_0000221,B,,,10576.0,H,,Autocuration,14542.0,,,CHEMBL616095,1.0,,8.0,Brain,,,955.0,,1150.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex
,BAO_0000357,B,,,10576.0,D,Rattus norvegicus,Expert,13670.0,,10116.0,CHEMBL616096,1.0,,9.0,,,,,,1151.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor
,BAO_0000249,B,,,10576.0,H,,Expert,9888.0,,,CHEMBL616097,1.0,,8.0,,,,,,1152.0,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes
,BAO_0000249,B,,,10576.0,D,Rattus norvegicus,Expert,3678.0,Membranes,10116.0,CHEMBL616098,1.0,,9.0,,,,,,1153.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes
,BAO_0000221,B,,,10576.0,H,,Autocuration,11332.0,,,CHEMBL616099,1.0,,8.0,Hippocampus,,,10000000.0,,1154.0,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand
,BAO_0000221,B,,,10576.0,H,,Autocuration,11332.0,,,CHEMBL616100,1.0,,8.0,Hippocampus,,,10000000.0,,1155.0,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand
,BAO_0000357,B,,,10576.0,H,,Expert,1185.0,,,CHEMBL616101,1.0,,8.0,,,,,,1156.0,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor
,BAO_0000249,B,,,10576.0,H,,Expert,2014.0,,,CHEMBL616102,1.0,,8.0,,,,,,1157.0,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.
,BAO_0000357,B,,,10576.0,H,,Autocuration,1185.0,,,CHEMBL616103,1.0,,8.0,,,,,,1158.0,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor
,BAO_0000019,B,,,10576.0,H,,Expert,14429.0,,,CHEMBL616104,1.0,,8.0,,,,,,1159.0,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex
,BAO_0000019,B,,,10576.0,H,,Expert,16288.0,,,CHEMBL616105,1.0,,8.0,,,,,,1160.0,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand"
,BAO_0000019,B,,,10576.0,D,Rattus norvegicus,Expert,5432.0,,10116.0,CHEMBL616106,1.0,,9.0,,,,,,1161.0,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor
,BAO_0000019,B,,,10576.0,H,,Autocuration,14429.0,,,CHEMBL616107,1.0,,8.0,,,,,,1162.0,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex
,BAO_0000357,B,,,10576.0,H,,Expert,13672.0,,,CHEMBL616108,1.0,,8.0,,,,,,1163.0,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.
,BAO_0000221,B,,,10576.0,H,,Expert,11296.0,,,CHEMBL616109,1.0,,8.0,Hippocampus,,,10000000.0,,1164.0,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus
,BAO_0000357,B,,,10576.0,H,,Autocuration,11296.0,,,CHEMBL616110,1.0,,8.0,,,,,,1165.0,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.
,BAO_0000219,B,,CHO,10576.0,H,,Expert,14749.0,,,CHEMBL616111,1.0,,8.0,,,,,449.0,1166.0,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.
,BAO_0000019,B,,,10576.0,H,,Expert,15086.0,,,CHEMBL616112,1.0,,8.0,,,,,,1167.0,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand
,BAO_0000221,B,,,10576.0,H,,Autocuration,13462.0,,,CHEMBL616113,1.0,,8.0,Hippocampus,,,10000000.0,,1168.0,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.
,BAO_0000019,B,,,10576.0,H,,Autocuration,15363.0,,,CHEMBL616114,1.0,,8.0,,,,,,1169.0,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor
,BAO_0000019,B,,,10576.0,H,,Autocuration,15363.0,,,CHEMBL616115,1.0,,8.0,,,,,,1170.0,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,10576.0,H,,Autocuration,10796.0,,,CHEMBL616116,1.0,,8.0,,,,,,1171.0,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor
,BAO_0000221,B,,,10576.0,H,,Expert,12816.0,,,CHEMBL615844,1.0,,8.0,Brain,,,955.0,,1172.0,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand
,BAO_0000221,B,,,10576.0,H,,Expert,13542.0,,,CHEMBL615939,1.0,,8.0,Hippocampus,,,10000000.0,,1173.0,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor
,BAO_0000019,B,,,10576.0,H,,Expert,13308.0,,,CHEMBL615940,1.0,,8.0,,,,,,1174.0,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.
,BAO_0000221,B,,,10576.0,H,,Expert,13541.0,,,CHEMBL615941,1.0,,8.0,Hippocampus,,,10000000.0,,1175.0,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.
,BAO_0000221,B,,,10576.0,H,,Autocuration,10058.0,,,CHEMBL615942,1.0,,8.0,Hippocampus,,,10000000.0,,1176.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12
,BAO_0000221,B,,,10576.0,H,,Autocuration,10058.0,,,CHEMBL615943,1.0,,8.0,Hippocampus,,,10000000.0,,1177.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus
,BAO_0000221,B,,,10576.0,H,,Autocuration,10058.0,,,CHEMBL615944,1.0,,8.0,Hippocampus,,,10000000.0,,1178.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17
,BAO_0000221,B,,,10576.0,H,,Autocuration,10058.0,,,CHEMBL615945,1.0,,8.0,Hippocampus,,,10000000.0,,1179.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841
,BAO_0000221,B,,,10576.0,H,,Autocuration,10058.0,,,CHEMBL615946,1.0,,8.0,Hippocampus,,,10000000.0,,1180.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.
,BAO_0000221,B,,,10576.0,H,,Autocuration,10058.0,,,CHEMBL615947,1.0,,8.0,Hippocampus,,,10000000.0,,1181.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.
,BAO_0000221,B,,,10576.0,H,,Autocuration,10058.0,,,CHEMBL615948,1.0,,8.0,Hippocampus,,,10000000.0,,1182.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736
,BAO_0000221,B,,,10576.0,H,,Autocuration,10058.0,,,CHEMBL615949,1.0,,8.0,Hippocampus,,,10000000.0,,1183.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84
,BAO_0000221,B,,,10576.0,H,,Autocuration,10058.0,,,CHEMBL615950,1.0,,8.0,Hippocampus,,,10000000.0,,1184.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59
,BAO_0000221,B,,,10576.0,H,,Autocuration,10058.0,,,CHEMBL615951,1.0,,8.0,Hippocampus,,,10000000.0,,1185.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5
,BAO_0000221,B,,,10576.0,H,,Autocuration,10058.0,,,CHEMBL615952,1.0,,8.0,Hippocampus,,,10000000.0,,1186.0,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31
,BAO_0000221,B,,,10576.0,H,,Autocuration,10058.0,,,CHEMBL615953,1.0,,8.0,Hippocampus,,,10000000.0,,1187.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42
,BAO_0000221,B,,,10576.0,H,,Autocuration,10058.0,,,CHEMBL615954,1.0,,8.0,Hippocampus,,,10000000.0,,1188.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13
,BAO_0000221,B,,,10576.0,D,Rattus norvegicus,Expert,10058.0,,10116.0,CHEMBL615955,1.0,,9.0,Hippocampus,,,10000000.0,,1189.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus
,BAO_0000221,B,,,10576.0,H,,Autocuration,10058.0,,,CHEMBL615956,1.0,,8.0,Hippocampus,,,10000000.0,,1190.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.
,BAO_0000221,B,,,10576.0,H,,Autocuration,10058.0,,,CHEMBL615957,1.0,,8.0,Hippocampus,,,10000000.0,,1191.0,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27
,BAO_0000019,B,,,10576.0,H,,Expert,12879.0,,,CHEMBL615958,1.0,,8.0,,,,,,1192.0,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.
,BAO_0000019,B,,,10576.0,H,,Expert,11964.0,,,CHEMBL615959,1.0,,8.0,,,,,,1193.0,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate
,BAO_0000019,B,,,10576.0,H,,Autocuration,11964.0,,,CHEMBL615960,1.0,,8.0,,,,,,1194.0,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1)
,BAO_0000019,B,,,10576.0,H,,Autocuration,11964.0,,,CHEMBL615961,1.0,,8.0,,,,,,1195.0,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2)
,BAO_0000221,B,,,10576.0,H,,Expert,9548.0,,,CHEMBL615962,1.0,,8.0,Brain,,,955.0,,1196.0,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain
,BAO_0000019,B,,,10576.0,H,,Expert,9098.0,,,CHEMBL615963,1.0,,8.0,,,,,,1197.0,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.
,BAO_0000019,B,,,10576.0,H,,Autocuration,9098.0,,,CHEMBL615964,1.0,,8.0,,,,,,1198.0,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.
,BAO_0000019,B,,,10576.0,H,,Autocuration,9098.0,,,CHEMBL615965,1.0,,8.0,,,,,,1199.0,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data
,BAO_0000219,B,,CHO,10576.0,H,,Expert,13248.0,,,CHEMBL615966,1.0,,8.0,,,,,449.0,1200.0,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells
,BAO_0000249,B,,,10576.0,H,,Expert,3147.0,,,CHEMBL615967,1.0,,8.0,,,,,,1201.0,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes
,BAO_0000019,B,,,10576.0,H,,Expert,13949.0,,,CHEMBL615968,1.0,,8.0,,,,,,1202.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.
,BAO_0000218,B,,CHO,10576.0,H,,Autocuration,11883.0,,,CHEMBL615969,1.0,,8.0,,,,,449.0,1203.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc)
,BAO_0000218,B,,,10576.0,H,,Autocuration,11883.0,,,CHEMBL615970,1.0,,8.0,,,,,,1204.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc)
,BAO_0000357,B,,,10576.0,D,Rattus norvegicus,Expert,11883.0,,10116.0,CHEMBL615971,1.0,,9.0,,,,,,1205.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT
,BAO_0000249,B,,,10576.0,H,,Expert,15535.0,Membranes,,CHEMBL615972,1.0,,8.0,,,,,,1206.0,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes
,BAO_0000249,B,,,10576.0,H,,Autocuration,15535.0,,,CHEMBL615973,1.0,,8.0,,,,,,1207.0,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex
,BAO_0000249,B,,,10576.0,H,,Autocuration,15535.0,,,CHEMBL615974,1.0,,8.0,,,,,,1208.0,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex
,BAO_0000219,B,,CHO,51.0,D,Homo sapiens,Expert,16372.0,,9606.0,CHEMBL615975,1.0,,9.0,,,,,449.0,1209.0,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells
,BAO_0000249,B,,,10576.0,H,,Expert,14608.0,,,CHEMBL615976,1.0,,8.0,,,,,,1210.0,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.
,BAO_0000221,B,,,10576.0,D,Rattus norvegicus,Expert,4795.0,,10116.0,CHEMBL872106,1.0,,9.0,Hippocampus,,,10000000.0,,1211.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus
,BAO_0000357,B,,,10576.0,H,,Autocuration,13863.0,,,CHEMBL615977,1.0,,8.0,,,,,,1212.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand
,BAO_0000357,B,,,10576.0,H,,Autocuration,13863.0,,,CHEMBL615978,1.0,,8.0,,,,,,1213.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230
,BAO_0000357,B,,,10576.0,H,,Autocuration,13863.0,,,CHEMBL616166,1.0,,8.0,,,,,,1214.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14
,BAO_0000357,B,,,10576.0,H,,Autocuration,13863.0,,,CHEMBL616167,1.0,,8.0,,,,,,1215.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20
,BAO_0000357,B,,,10576.0,H,,Autocuration,13863.0,,,CHEMBL616168,1.0,,8.0,,,,,,1216.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430
,BAO_0000357,B,,,10576.0,H,,Autocuration,13863.0,,,CHEMBL616169,1.0,,8.0,,,,,,1217.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224
,BAO_0000357,B,,,10576.0,H,,Autocuration,13863.0,,,CHEMBL616170,1.0,,8.0,,,,,,1218.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503
,BAO_0000357,B,,,10576.0,H,,Autocuration,13863.0,,,CHEMBL616171,1.0,,8.0,,,,,,1219.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23
,BAO_0000357,B,,,10576.0,H,,Autocuration,13863.0,,,CHEMBL616172,1.0,,8.0,,,,,,1220.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2
,BAO_0000357,B,,,10576.0,H,,Autocuration,13863.0,,,CHEMBL616173,1.0,,8.0,,,,,,1221.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6
,BAO_0000357,B,,,10576.0,H,,Autocuration,13863.0,,,CHEMBL616174,1.0,,8.0,,,,,,1222.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23
,BAO_0000357,B,,,10576.0,H,,Autocuration,13863.0,,,CHEMBL616175,1.0,,8.0,,,,,,1223.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28
,BAO_0000357,B,,,10576.0,H,,Autocuration,13863.0,,,CHEMBL616176,1.0,,8.0,,,,,,1224.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760
,BAO_0000357,B,,,10576.0,H,,Autocuration,13863.0,,,CHEMBL616177,1.0,,8.0,,,,,,1225.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87
,BAO_0000357,B,,,10576.0,H,,Autocuration,13863.0,,,CHEMBL616178,1.0,,8.0,,,,,,1226.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2
,BAO_0000019,B,,,10576.0,H,,Autocuration,9742.0,,,CHEMBL616179,1.0,,8.0,,,,,,1227.0,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat
,BAO_0000357,B,,,10576.0,H,,Autocuration,12073.0,,,CHEMBL616180,1.0,,8.0,,,,,,1228.0,Inhibitory concentration against 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,10576.0,H,,Autocuration,4101.0,,,CHEMBL616181,1.0,,8.0,,,,,,1229.0,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT
,BAO_0000019,B,,,10576.0,H,,Autocuration,15360.0,,,CHEMBL616182,1.0,,8.0,,,,,,1230.0,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat
,BAO_0000221,B,,,10576.0,H,,Autocuration,11576.0,,,CHEMBL616183,1.0,,8.0,Hippocampus,,,10000000.0,,1231.0,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor
,BAO_0000019,B,,,10576.0,H,,Expert,5834.0,,,CHEMBL615874,1.0,,8.0,,,,,,1232.0,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe
,BAO_0000219,B,,CHO-K1,10576.0,D,Rattus norvegicus,Expert,2395.0,,10116.0,CHEMBL615875,1.0,,9.0,,,,,485.0,1233.0,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells
,BAO_0000019,B,,,10576.0,H,,Autocuration,1375.0,,,CHEMBL615876,1.0,,8.0,,,,,,1234.0,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand
,BAO_0000019,B,,,10576.0,H,,Autocuration,1375.0,,,CHEMBL615877,1.0,,8.0,,,,,,1235.0,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested
,BAO_0000357,B,,,10576.0,H,,Autocuration,3967.0,,,CHEMBL615878,1.0,,8.0,,,,,,1236.0,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats)
,BAO_0000357,B,,,10576.0,H,,Expert,12884.0,,,CHEMBL615879,1.0,,8.0,,,,,,1237.0,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. 
,BAO_0000357,B,,,10576.0,H,,Expert,2343.0,,,CHEMBL615880,1.0,,8.0,,,,,,1238.0,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay
,BAO_0000019,B,,,10576.0,H,,Autocuration,11511.0,,,CHEMBL615881,1.0,,8.0,,,,,,1239.0,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand"
,BAO_0000019,B,,,10576.0,D,Rattus norvegicus,Expert,11511.0,,10116.0,CHEMBL615882,1.0,,9.0,,,,,,1240.0,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand"
,BAO_0000218,F,In vivo,,10576.0,H,,Autocuration,16394.0,,,CHEMBL615883,1.0,,8.0,,,,,,1241.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat
,BAO_0000218,F,In vivo,,10576.0,H,,Autocuration,16394.0,,,CHEMBL615884,1.0,,8.0,,,,,,1242.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20)
,BAO_0000218,F,In vivo,,10576.0,H,,Autocuration,16394.0,,,CHEMBL615885,1.0,,8.0,,,,,,1243.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60)
,BAO_0000218,F,In vivo,,10576.0,H,,Autocuration,16394.0,,,CHEMBL615886,1.0,,8.0,,,,,,1244.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80)
,BAO_0000218,F,In vivo,,10576.0,H,,Autocuration,16394.0,,,CHEMBL615887,1.0,,8.0,,,,,,1245.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27)
,BAO_0000218,F,In vivo,,10576.0,H,,Autocuration,16394.0,,,CHEMBL615888,1.0,,8.0,,,,,,1246.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70)
,BAO_0000218,F,In vivo,,10576.0,H,,Autocuration,16394.0,,,CHEMBL615889,1.0,,8.0,,,,,,1247.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4)
,BAO_0000218,F,In vivo,,10576.0,H,,Autocuration,16394.0,,,CHEMBL615890,1.0,,8.0,,,,,,1248.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51)
,BAO_0000218,F,In vivo,,10576.0,H,,Autocuration,16394.0,,,CHEMBL615891,1.0,,8.0,,,,,,1249.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30)
,BAO_0000218,F,In vivo,,10576.0,H,,Autocuration,16394.0,,,CHEMBL615892,1.0,,8.0,,,,,,1250.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60)
,BAO_0000218,F,In vivo,,10576.0,H,,Autocuration,16394.0,,,CHEMBL615893,1.0,,8.0,,,,,,1251.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87)
,BAO_0000218,F,In vivo,,10576.0,H,,Autocuration,16394.0,,,CHEMBL615894,1.0,,8.0,,,,,,1252.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80)
,BAO_0000218,F,In vivo,,10576.0,H,,Autocuration,16394.0,,,CHEMBL615895,1.0,,8.0,,,,,,1253.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5)
,BAO_0000218,F,In vivo,,10576.0,H,,Autocuration,16394.0,,,CHEMBL615896,1.0,,8.0,,,,,,1254.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5)
,BAO_0000218,F,In vivo,,10576.0,H,,Autocuration,16394.0,,,CHEMBL615897,1.0,,8.0,,,,,,1255.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable
,BAO_0000249,F,,,10576.0,D,Rattus norvegicus,Expert,16616.0,Membranes,10116.0,CHEMBL615898,1.0,,9.0,,,,,,1256.0,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes"
,BAO_0000019,B,,,10576.0,H,,Autocuration,16796.0,,,CHEMBL615899,1.0,,8.0,,,,,,1257.0,% inhibition towards 5-HT1A receptor from rat hippocampal membranes
,BAO_0000019,B,,,10576.0,H,,Autocuration,16796.0,,,CHEMBL616291,1.0,,8.0,,,,,,1258.0,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes
,BAO_0000357,B,,,10576.0,H,,Autocuration,15629.0,,,CHEMBL616292,1.0,,8.0,,,,,,1259.0,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.
,BAO_0000249,F,,,10576.0,H,,Autocuration,13241.0,,,CHEMBL616293,1.0,,8.0,,,,,,1260.0,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor"
,BAO_0000221,B,,,10576.0,H,,Expert,12073.0,,,CHEMBL616294,1.0,,8.0,Hippocampus,,,10000000.0,,1261.0,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus
,BAO_0000249,B,,,10576.0,H,,Autocuration,14286.0,,,CHEMBL616295,1.0,,8.0,Hippocampus,,,10000000.0,,1262.0,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane
,BAO_0000221,B,,,10576.0,H,,Autocuration,14542.0,,,CHEMBL616296,1.0,,8.0,Brain,,,955.0,,1263.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM
,BAO_0000019,F,,,10576.0,H,,Autocuration,13630.0,,,CHEMBL616297,1.0,,8.0,,,,,,1264.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.
,BAO_0000019,F,,,10576.0,H,,Autocuration,13630.0,,,CHEMBL616605,1.0,,8.0,,,,,,1265.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.
,BAO_0000019,F,,,10576.0,H,,Autocuration,13630.0,,,CHEMBL616606,1.0,,8.0,,,,,,1266.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.
,BAO_0000019,F,,,10576.0,H,,Autocuration,13630.0,,,CHEMBL616607,1.0,,8.0,,,,,,1267.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM
,BAO_0000019,F,,,10576.0,H,,Expert,13630.0,,,CHEMBL616608,1.0,,8.0,,,,,,1268.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM
,BAO_0000019,F,,,10576.0,H,,Autocuration,13630.0,,,CHEMBL616609,1.0,,8.0,,,,,,1269.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.
,BAO_0000019,F,,,10576.0,D,Rattus norvegicus,Expert,13630.0,,10116.0,CHEMBL616610,1.0,,9.0,,,,,,1270.0,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose
,BAO_0000019,F,,,10576.0,H,,Autocuration,13630.0,,,CHEMBL616611,1.0,,8.0,,,,,,1271.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.
,BAO_0000019,F,,,10576.0,H,,Expert,13630.0,,,CHEMBL616612,1.0,,8.0,,,,,,1272.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.
,BAO_0000019,F,,,10576.0,H,,Autocuration,13630.0,,,CHEMBL616613,1.0,,8.0,,,,,,1273.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.
,BAO_0000019,F,,,10576.0,H,,Expert,13630.0,,,CHEMBL616614,1.0,,8.0,,,,,,1274.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM
,BAO_0000019,F,,,10576.0,H,,Autocuration,13630.0,,,CHEMBL616615,1.0,,8.0,,,,,,1275.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.
,BAO_0000019,F,,,10576.0,H,,Expert,13630.0,,,CHEMBL616616,1.0,,8.0,,,,,,1276.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM
,BAO_0000019,F,,,10576.0,H,,Autocuration,13630.0,,,CHEMBL616617,1.0,,8.0,,,,,,1277.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.
,BAO_0000019,F,,,10576.0,H,,Autocuration,13630.0,,,CHEMBL616618,1.0,,8.0,,,,,,1278.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.
,BAO_0000019,F,,,10576.0,H,,Autocuration,13630.0,,,CHEMBL616619,1.0,,8.0,,,,,,1279.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.
,BAO_0000019,F,,,10576.0,H,,Expert,13630.0,,,CHEMBL616620,1.0,,8.0,,,,,,1280.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.
,BAO_0000019,F,,,10576.0,H,,Expert,13630.0,,,CHEMBL616621,1.0,,8.0,,,,,,1281.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.
,BAO_0000019,F,,,10576.0,H,,Autocuration,13630.0,,,CHEMBL616622,1.0,,8.0,,,,,,1282.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM
,BAO_0000019,F,,,10576.0,H,,Expert,13630.0,,,CHEMBL616146,1.0,,8.0,,,,,,1283.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM
,BAO_0000019,F,,,10576.0,H,,Autocuration,13630.0,,,CHEMBL832873,1.0,,8.0,,,,,,1284.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.
,BAO_0000019,F,,,10576.0,H,,Autocuration,13630.0,,,CHEMBL616147,1.0,,8.0,,,,,,1285.0,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM
,BAO_0000019,F,,,10576.0,H,,Autocuration,13630.0,,,CHEMBL872872,1.0,,8.0,,,,,,1286.0,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.
,BAO_0000019,F,,,10576.0,H,,Autocuration,13630.0,,,CHEMBL616148,1.0,,8.0,,,,,,1287.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM
,BAO_0000221,B,,,10576.0,H,,Autocuration,9783.0,,,CHEMBL616149,1.0,,8.0,Hippocampus,,,10000000.0,,1288.0,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue
,BAO_0000221,B,,,10576.0,H,,Expert,9783.0,,,CHEMBL616150,1.0,,8.0,Hippocampus,,,10000000.0,,1289.0,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM
,BAO_0000249,B,,,10576.0,D,Rattus norvegicus,Expert,14331.0,Membranes,10116.0,CHEMBL616151,1.0,,9.0,,,,,,1290.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M
,BAO_0000221,B,,,10576.0,H,,Expert,15260.0,,,CHEMBL872873,1.0,,8.0,Hippocampus,,,10000000.0,,1291.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM
,BAO_0000221,B,,,10576.0,H,,Autocuration,15260.0,,,CHEMBL616670,1.0,,8.0,Hippocampus,,,10000000.0,,1292.0,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration
,BAO_0000221,B,,,10576.0,H,,Autocuration,15260.0,,,CHEMBL616671,1.0,,8.0,Hippocampus,,,10000000.0,,1293.0,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration
,BAO_0000249,F,,,10576.0,D,Rattus norvegicus,Expert,16616.0,,10116.0,CHEMBL884861,1.0,,9.0,,,,,,1294.0,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes"
,BAO_0000357,B,,,10576.0,H,,Autocuration,15629.0,,,CHEMBL616672,1.0,,8.0,,,,,,1295.0,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor
,BAO_0000019,B,,,10576.0,H,,Autocuration,15086.0,,,CHEMBL616673,1.0,,8.0,,,,,,1296.0,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.
,BAO_0000019,F,,,10576.0,H,,Expert,5717.0,,,CHEMBL616674,1.0,,8.0,,,,,,1297.0,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.
,BAO_0000357,B,,,10576.0,H,,Autocuration,12652.0,,,CHEMBL616675,1.0,,8.0,,,,,,1298.0,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT
,BAO_0000221,B,,,10576.0,H,,Autocuration,14608.0,,,CHEMBL616676,1.0,,8.0,Hippocampus,,,10000000.0,,1299.0,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations
,BAO_0000221,B,,,10576.0,H,,Autocuration,12306.0,,,CHEMBL616677,1.0,,8.0,Hippocampus,,,10000000.0,,1300.0,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates
,BAO_0000221,B,,,10576.0,H,,Autocuration,12306.0,,,CHEMBL616678,1.0,,8.0,Hippocampus,,,10000000.0,,1301.0,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates
,BAO_0000357,B,,,10576.0,D,Rattus norvegicus,Expert,15247.0,,10116.0,CHEMBL616679,1.0,,9.0,,,,,,1302.0,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor
,BAO_0000221,B,,,10576.0,H,,Expert,17529.0,,,CHEMBL616680,1.0,,8.0,Hippocampus,,,10000000.0,,1303.0,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand
,BAO_0000221,B,,,10576.0,H,,Autocuration,14826.0,,,CHEMBL616681,1.0,,8.0,Hippocampus,,,10000000.0,,1304.0,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus
,BAO_0000221,B,,,10576.0,H,,Autocuration,14826.0,,,CHEMBL616682,1.0,,8.0,Hippocampus,,,10000000.0,,1305.0,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus
,BAO_0000221,B,,,10576.0,H,,Autocuration,13241.0,,,CHEMBL616683,1.0,,8.0,Hippocampus,,,10000000.0,,1306.0,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor
,BAO_0000221,B,,,10576.0,H,,Autocuration,14093.0,,,CHEMBL616684,1.0,,8.0,Hippocampus,,,10000000.0,,1307.0,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor
,BAO_0000221,B,,,10576.0,H,,Autocuration,14093.0,,,CHEMBL616685,1.0,,8.0,Hippocampus,,,10000000.0,,1308.0,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested
,BAO_0000221,B,,,10576.0,H,,Autocuration,14442.0,,,CHEMBL616686,1.0,,8.0,Brain,,,955.0,,1309.0,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined
,BAO_0000357,B,,,10576.0,H,,Autocuration,9919.0,,,CHEMBL616687,1.0,,8.0,,,,,,1310.0,Affinity for 5-hydroxytryptamine 1A receptor site
,BAO_0000357,B,,,10576.0,H,,Autocuration,9919.0,,,CHEMBL616688,1.0,,8.0,,,,,,1311.0,Affinity for 5-hydroxytryptamine 1A receptor site
,BAO_0000221,B,,,10576.0,H,,Autocuration,11440.0,,,CHEMBL616689,1.0,,8.0,Hippocampus,,,10000000.0,,1312.0,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.
,BAO_0000357,B,,,10576.0,H,,Autocuration,11257.0,,,CHEMBL616690,1.0,,8.0,,,,,,1313.0,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT
,BAO_0000357,B,,,10576.0,H,,Expert,10330.0,,,CHEMBL616691,1.0,,8.0,,,,,,1314.0,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand
,BAO_0000221,B,,,10576.0,D,Rattus norvegicus,Expert,17331.0,,10116.0,CHEMBL616692,1.0,,9.0,Hippocampus,,,10000000.0,,1315.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes
,BAO_0000249,B,,,10576.0,H,,Expert,16567.0,,,CHEMBL616693,1.0,,8.0,,,,,,1316.0,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane
,BAO_0000019,B,,,10576.0,D,Rattus norvegicus,Expert,12058.0,,10116.0,CHEMBL616694,1.0,,9.0,,,,,,1317.0,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand"
,BAO_0000221,B,,,10576.0,H,,Autocuration,9699.0,,,CHEMBL616695,1.0,,8.0,Hippocampus,,,10000000.0,,1318.0,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue
,BAO_0000357,B,,,10576.0,H,,Autocuration,9547.0,,,CHEMBL616696,1.0,,8.0,,,,,,1319.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay
,BAO_0000357,B,,,10576.0,H,,Autocuration,10330.0,,,CHEMBL616697,1.0,,8.0,,,,,,1320.0,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand
,BAO_0000357,B,,,10576.0,H,,Autocuration,14331.0,,,CHEMBL616698,1.0,,8.0,,,,,,1321.0,Binding affinity against rat 5-hydroxytryptamine 1A receptor
,BAO_0000019,B,,,10576.0,D,Rattus norvegicus,Expert,14060.0,,10116.0,CHEMBL616949,1.0,,9.0,,,,,,1322.0,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor
,BAO_0000221,B,,,10576.0,H,,Autocuration,14744.0,,,CHEMBL616950,1.0,,8.0,Hippocampus,,,10000000.0,,1323.0,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates
,BAO_0000357,B,,,10576.0,H,,Autocuration,13506.0,,,CHEMBL832875,1.0,,8.0,,,,,,1324.0,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay
,BAO_0000221,B,,,10576.0,H,,Expert,10862.0,,,CHEMBL616951,1.0,,8.0,Brain,,,955.0,,1325.0,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.
,BAO_0000221,B,,,10576.0,H,,Expert,10862.0,,,CHEMBL616952,1.0,,8.0,Brain,,,955.0,,1326.0,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.
,BAO_0000357,B,,,10576.0,H,,Expert,10062.0,,,CHEMBL616953,1.0,,8.0,,,,,,1327.0,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.
,BAO_0000357,B,,,10576.0,H,,Autocuration,12073.0,,,CHEMBL616954,1.0,,8.0,,,,,,1328.0,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat
,BAO_0000357,B,,,106.0,H,,Autocuration,14875.0,,,CHEMBL616955,1.0,,8.0,,,,,,1329.0,GTPgammaS radioligand binding assay
,BAO_0000357,B,,,106.0,H,,Autocuration,2391.0,,,CHEMBL616956,1.0,,8.0,,,,,,1330.0,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined
,BAO_0000019,F,,,106.0,H,,Autocuration,2391.0,,,CHEMBL616957,1.0,,8.0,,,,,,1331.0,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist
,BAO_0000019,F,,,106.0,H,,Autocuration,2391.0,,,CHEMBL616958,1.0,,8.0,,,,,,1332.0,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist
,BAO_0000357,B,,,106.0,H,,Autocuration,2391.0,,,CHEMBL616959,1.0,,8.0,,,,,,1333.0,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor
,BAO_0000357,B,,,106.0,H,,Autocuration,2391.0,,,CHEMBL616960,1.0,,8.0,,,,,,1334.0,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined
,BAO_0000019,F,,,106.0,H,,Autocuration,2391.0,,,CHEMBL616961,1.0,,8.0,,,,,,1335.0,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist
,BAO_0000219,B,,HeLa,106.0,H,,Expert,17211.0,,,CHEMBL616962,1.0,,8.0,,,,,308.0,1336.0,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor
,BAO_0000219,B,,HeLa,106.0,H,,Autocuration,17211.0,,,CHEMBL616963,1.0,,8.0,,,,,308.0,1337.0,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor
,BAO_0000357,B,,,106.0,D,Homo sapiens,Expert,6491.0,,9606.0,CHEMBL616524,1.0,,9.0,,,,,,1338.0,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor
,BAO_0000219,B,,CHO,106.0,H,,Autocuration,16190.0,,,CHEMBL616525,1.0,,8.0,,,,,449.0,1339.0,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand
,BAO_0000019,B,,,106.0,H,,Autocuration,14165.0,,,CHEMBL872908,1.0,,8.0,,,,,,1340.0,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand
,BAO_0000019,B,,,106.0,H,,Autocuration,14165.0,,,CHEMBL616526,1.0,,8.0,,,,,,1341.0,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand
,BAO_0000357,B,,,106.0,D,Homo sapiens,Expert,4234.0,,9606.0,CHEMBL616527,1.0,,9.0,,,,,,1342.0,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor
,BAO_0000219,B,,,106.0,H,,Expert,6328.0,,,CHEMBL616528,1.0,,8.0,,,,,,1343.0,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand
,BAO_0000357,B,,,106.0,H,,Autocuration,14770.0,,,CHEMBL616529,1.0,,8.0,,,,,,1344.0,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.
,BAO_0000357,B,,,106.0,H,,Autocuration,2598.0,,,CHEMBL616530,1.0,,8.0,,,,,,1345.0,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand
,BAO_0000357,B,,,106.0,H,,Expert,6897.0,,,CHEMBL616531,1.0,,8.0,,,,,,1346.0,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor
,BAO_0000357,B,,,106.0,H,,Autocuration,6897.0,,,CHEMBL616532,1.0,,8.0,,,,,,1347.0,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor
,BAO_0000357,B,,,106.0,H,,Autocuration,6013.0,,,CHEMBL616533,1.0,,8.0,,,,,,1348.0,Binding affinity towards 5-hydroxytryptamine 1B receptor
,BAO_0000357,B,,,106.0,H,,Expert,5843.0,,,CHEMBL616534,1.0,,8.0,,,,,,1349.0,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor
,BAO_0000357,B,,,106.0,H,,Expert,14454.0,,,CHEMBL616535,1.0,,8.0,,,,,,1350.0,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand
,BAO_0000357,B,,,106.0,H,,Autocuration,16209.0,,,CHEMBL616536,1.0,,8.0,,,,,,1351.0,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand
,BAO_0000357,B,,,106.0,H,,Autocuration,3935.0,,,CHEMBL616537,1.0,,8.0,,,,,,1352.0,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor
,BAO_0000219,F,,CHO-K1,106.0,H,,Expert,13729.0,,,CHEMBL616538,1.0,,8.0,,,,,485.0,1353.0,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells
,BAO_0000019,F,,,106.0,H,,Expert,14251.0,,,CHEMBL616539,1.0,,8.0,,,,,,1354.0,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor
,BAO_0000019,B,,,106.0,H,,Expert,17085.0,,,CHEMBL616540,1.0,,8.0,,,,,,1355.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor
,BAO_0000357,B,,,106.0,H,,Autocuration,3025.0,,,CHEMBL616429,1.0,,8.0,,,,,,1356.0,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand
,BAO_0000357,B,,,106.0,H,,Expert,15315.0,,,CHEMBL616430,1.0,,8.0,,,,,,1357.0,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor
,BAO_0000219,B,,,106.0,D,Homo sapiens,Expert,14214.0,,9606.0,CHEMBL616431,1.0,,9.0,,,,,,1358.0,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells
,BAO_0000357,B,,,106.0,D,Homo sapiens,Expert,3804.0,,9606.0,CHEMBL616432,1.0,,9.0,,,,,,1359.0,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor
,BAO_0000357,B,,,106.0,D,Homo sapiens,Expert,2391.0,,9606.0,CHEMBL616433,1.0,,9.0,,,,,,1360.0,Affinity for 5-hydroxytryptamine 1B receptor subtype
,BAO_0000357,B,,,106.0,D,Homo sapiens,Expert,4175.0,,9606.0,CHEMBL616434,1.0,,9.0,,,,,,1361.0,Binding affinity for human 5-hydroxytryptamine 1B receptor
,BAO_0000219,B,,CHO,106.0,H,,Autocuration,17296.0,,,CHEMBL616435,1.0,,8.0,,,,,449.0,1362.0,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined
,BAO_0000019,B,,,106.0,H,,Expert,17085.0,,,CHEMBL616436,1.0,,8.0,,,,,,1363.0,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined
,BAO_0000219,B,,HeLa,106.0,H,,Autocuration,17211.0,,,CHEMBL616437,1.0,,8.0,,,,,308.0,1364.0,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested
,BAO_0000219,B,,HeLa,106.0,H,,Autocuration,17211.0,,,CHEMBL616438,1.0,,8.0,,,,,308.0,1365.0,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested
,BAO_0000219,B,,HeLa,106.0,H,,Autocuration,17211.0,,,CHEMBL616439,1.0,,8.0,,,,,308.0,1366.0,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested
,BAO_0000357,B,,,106.0,D,Homo sapiens,Expert,15926.0,,9606.0,CHEMBL616440,1.0,,9.0,,,,,,1367.0,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested
,BAO_0000219,B,,CHO-K1,106.0,H,,Autocuration,16312.0,,,CHEMBL616441,1.0,,8.0,,,,,485.0,1368.0,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested
,BAO_0000357,B,,,106.0,H,,Expert,5843.0,,,CHEMBL616442,1.0,,8.0,,,,,,1369.0,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor
,BAO_0000357,B,,,106.0,H,,Autocuration,5843.0,,,CHEMBL616443,1.0,,8.0,,,,,,1370.0,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor
,BAO_0000219,B,,CHO-K1,106.0,H,,Expert,16312.0,,,CHEMBL616444,1.0,,8.0,,,,,485.0,1371.0,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor
,BAO_0000357,B,,,106.0,D,Homo sapiens,Expert,15926.0,,9606.0,CHEMBL616445,1.0,,9.0,,,,,,1372.0,Binding activity against human 5-hydroxytryptamine 1B receptor
,BAO_0000357,B,,,106.0,D,Homo sapiens,Expert,15926.0,,9606.0,CHEMBL616446,1.0,,9.0,,,,,,1373.0,Binding activity against human 5-hydroxytryptamine 1B receptor
,BAO_0000219,B,,CHO,106.0,D,Homo sapiens,Expert,4540.0,,9606.0,CHEMBL616447,1.0,,9.0,,,,,449.0,1374.0,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand
,BAO_0000357,B,,,106.0,H,,Autocuration,6166.0,,,CHEMBL616448,1.0,,8.0,,,,,,1375.0,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined
,BAO_0000219,B,,CHO,106.0,H,,Autocuration,17296.0,,,CHEMBL616449,1.0,,8.0,,,,,449.0,1376.0,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand
,BAO_0000219,B,,CHO,106.0,H,,Autocuration,17296.0,,,CHEMBL616450,1.0,,8.0,,,,,449.0,1377.0,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells
,BAO_0000219,B,,CHO,106.0,H,,Autocuration,17296.0,,,CHEMBL857974,1.0,,8.0,,,,,449.0,1378.0,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand
,BAO_0000219,B,,CHO,106.0,H,,Autocuration,15779.0,,,CHEMBL616451,1.0,,8.0,,,,,449.0,1379.0,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand
,BAO_0000219,B,,CHO,106.0,H,,Autocuration,15779.0,,,CHEMBL616452,1.0,,8.0,,,,,449.0,1380.0,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand
,BAO_0000219,B,,CHO,106.0,H,,Autocuration,15779.0,,,CHEMBL616453,1.0,,8.0,,,,,449.0,1381.0,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.
,BAO_0000219,B,,CHO,106.0,H,,Autocuration,4199.0,,,CHEMBL616454,1.0,,8.0,,,,,449.0,1382.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand
,BAO_0000357,B,,,106.0,D,Homo sapiens,Expert,14875.0,,9606.0,CHEMBL616455,1.0,,9.0,,,,,,1383.0,Binding affinity for human 5-hydroxytryptamine 1B receptor
,BAO_0000219,B,,CHO,106.0,H,,Autocuration,15146.0,,,CHEMBL616456,1.0,,8.0,,,,,449.0,1384.0,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT
,BAO_0000357,B,,,106.0,H,,Autocuration,5213.0,,,CHEMBL616457,1.0,,8.0,,,,,,1385.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand
,BAO_0000219,B,,CHO,106.0,H,,Autocuration,14818.0,,,CHEMBL616458,1.0,,8.0,,,,,449.0,1386.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT
,BAO_0000219,B,,CHO,106.0,H,,Autocuration,4829.0,,,CHEMBL616459,1.0,,8.0,,,,,449.0,1387.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand"
,BAO_0000019,F,,,106.0,H,,Expert,14454.0,,,CHEMBL616460,1.0,,8.0,,,,,,1388.0,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM
,BAO_0000019,F,,,106.0,H,,Expert,14454.0,,,CHEMBL616461,1.0,,8.0,,,,,,1389.0,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM
,BAO_0000219,F,,CHO,106.0,H,,Autocuration,14875.0,,,CHEMBL616462,1.0,,8.0,,,,,449.0,1390.0,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor"
,BAO_0000219,F,,CHO,106.0,H,,Autocuration,14875.0,,,CHEMBL616463,1.0,,8.0,,,,,449.0,1391.0,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor"
,BAO_0000019,F,,,105.0,H,,Autocuration,15250.0,,,CHEMBL616464,1.0,,8.0,,,,,,1392.0,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT."
,BAO_0000219,B,,CHO,105.0,H,,Autocuration,15250.0,,,CHEMBL616465,1.0,,8.0,,,,,449.0,1393.0,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.
,BAO_0000357,B,,,17105.0,H,,Autocuration,15086.0,,,CHEMBL832874,1.0,,8.0,,,,,,1394.0,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor
,BAO_0000019,F,,,106.0,H,Oryctolagus cuniculus,Autocuration,3025.0,,9986.0,CHEMBL616184,1.0,,8.0,,,,,,1395.0,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model
,BAO_0000019,B,,,106.0,H,Oryctolagus cuniculus,Autocuration,14998.0,,9986.0,CHEMBL616185,1.0,,8.0,,,,,,1396.0,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).
,BAO_0000019,B,,,106.0,H,Oryctolagus cuniculus,Intermediate,14998.0,,9986.0,CHEMBL616186,1.0,,8.0,,,,,,1397.0,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)"
,BAO_0000019,B,,,106.0,H,Oryctolagus cuniculus,Autocuration,14998.0,,9986.0,CHEMBL616187,1.0,,8.0,,,,,,1398.0,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).
,BAO_0000357,B,,,10577.0,H,,Expert,13969.0,,,CHEMBL616188,1.0,,8.0,,,,,,1399.0,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand
,BAO_0000357,B,,,10577.0,D,,Intermediate,13392.0,,,CHEMBL873475,1.0,,9.0,,,,,,1400.0,Binding affinity for 5-hydroxytryptamine 1B receptor
,BAO_0000019,B,,,10577.0,D,Rattus norvegicus,Expert,3651.0,,10116.0,CHEMBL616189,1.0,,9.0,Striatum,,,2435.0,,1401.0,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active
,BAO_0000357,B,,,10577.0,H,,Expert,10025.0,,,CHEMBL616190,1.0,,8.0,,,,,,1402.0,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM
,BAO_0000357,B,,,10576.0,H,,Autocuration,13863.0,,,CHEMBL616191,1.0,,8.0,,,,,,1403.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77
,BAO_0000357,B,,,10576.0,H,,Autocuration,13863.0,,,CHEMBL616192,1.0,,8.0,,,,,,1404.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95
,BAO_0000357,B,,,10576.0,H,,Autocuration,13863.0,,,CHEMBL616193,1.0,,8.0,,,,,,1405.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980
,BAO_0000357,B,,,10576.0,H,,Autocuration,13863.0,,,CHEMBL616194,1.0,,8.0,,,,,,1406.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140
,BAO_0000357,B,,,10576.0,H,,Autocuration,13863.0,,,CHEMBL616195,1.0,,8.0,,,,,,1407.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130
,BAO_0000357,B,,,10576.0,H,,Autocuration,13863.0,,,CHEMBL616196,1.0,,8.0,,,,,,1408.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280
,BAO_0000249,B,,,10576.0,H,,Autocuration,4622.0,,,CHEMBL616197,1.0,,8.0,Hippocampus,,,10000000.0,,1409.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.
,BAO_0000019,B,,,10576.0,H,,Intermediate,14911.0,,,CHEMBL616198,1.0,,8.0,,,,,,1410.0,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand
,BAO_0000221,B,,,10576.0,H,,Autocuration,12678.0,,,CHEMBL616199,1.0,,8.0,Hippocampus,,,10000000.0,,1411.0,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate
,BAO_0000221,B,,,10576.0,H,,Expert,12678.0,,,CHEMBL616200,1.0,,8.0,Hippocampus,,,10000000.0,,1412.0,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.
,BAO_0000221,B,,,10576.0,H,,Expert,14235.0,,,CHEMBL616201,1.0,,8.0,Hippocampus,,,10000000.0,,1413.0,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand
,BAO_0000221,B,,,10576.0,H,,Expert,14949.0,,,CHEMBL616202,1.0,,8.0,Hippocampus,,,10000000.0,,1414.0,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates
,BAO_0000221,B,,,10576.0,H,,Expert,14949.0,,,CHEMBL616203,1.0,,8.0,Hippocampus,,,10000000.0,,1415.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates
,BAO_0000221,B,,,10576.0,H,,Expert,14949.0,,,CHEMBL616204,1.0,,8.0,Hippocampus,,,10000000.0,,1416.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined
,BAO_0000221,B,,,10576.0,H,,Expert,14949.0,,,CHEMBL616205,1.0,,8.0,Hippocampus,,,10000000.0,,1417.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined
,BAO_0000221,B,,,10576.0,H,,Expert,14949.0,,,CHEMBL616206,1.0,,8.0,Hippocampus,,,10000000.0,,1418.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined
,BAO_0000249,B,,,10576.0,H,,Expert,16118.0,,,CHEMBL616207,1.0,,8.0,,,,,,1419.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes
,BAO_0000249,B,,,10576.0,H,,Autocuration,3268.0,,,CHEMBL616208,1.0,,8.0,,,,,,1420.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes
,BAO_0000249,B,,,10576.0,H,,Autocuration,3268.0,,,CHEMBL616209,1.0,,8.0,,,,,,1421.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive
,BAO_0000357,B,,,10576.0,H,,Expert,16117.0,,,CHEMBL616210,1.0,,8.0,,,,,,1422.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT
,BAO_0000221,B,,,10576.0,H,,Expert,9783.0,,,CHEMBL616211,1.0,,8.0,Hippocampus,,,10000000.0,,1423.0,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.
,BAO_0000221,B,,,10576.0,H,,Autocuration,9783.0,,,CHEMBL616504,1.0,,8.0,Hippocampus,,,10000000.0,,1424.0,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested
,BAO_0000221,B,,,10576.0,D,Rattus norvegicus,Expert,14356.0,,10116.0,CHEMBL616505,1.0,,9.0,Hippocampus,,,10000000.0,,1425.0,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor
,BAO_0000019,F,,,10576.0,H,,Autocuration,15740.0,,,CHEMBL616506,1.0,,8.0,,,,,,1426.0,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor
,BAO_0000221,B,,,10576.0,H,,Autocuration,12306.0,,,CHEMBL872107,1.0,,8.0,Hippocampus,,,10000000.0,,1427.0,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates
,BAO_0000221,B,,,10576.0,D,Rattus norvegicus,Expert,13348.0,,10116.0,CHEMBL616507,1.0,,9.0,Hippocampus,,,10000000.0,,1428.0,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin
,BAO_0000249,B,,,10576.0,H,,Autocuration,10394.0,,,CHEMBL616303,1.0,,8.0,,,,,,1429.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand
,BAO_0000221,B,,,10576.0,H,,Autocuration,15260.0,,,CHEMBL616304,1.0,,8.0,Hippocampus,,,10000000.0,,1430.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue
,BAO_0000221,B,,,10576.0,H,,Expert,10046.0,,,CHEMBL616305,1.0,,8.0,Hippocampus,,,10000000.0,,1431.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.
,BAO_0000221,F,,,10576.0,H,,Intermediate,15260.0,,,CHEMBL616306,1.0,,8.0,Hippocampus,,,10000000.0,,1432.0,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,10576.0,H,,Autocuration,12851.0,,,CHEMBL616307,1.0,,8.0,,,,,,1433.0,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor
,BAO_0000221,B,,,10576.0,D,Rattus norvegicus,Expert,2148.0,,10116.0,CHEMBL881829,1.0,,9.0,Hippocampus,,,10000000.0,,1434.0,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus
,BAO_0000357,B,,,10576.0,H,,Expert,13134.0,,,CHEMBL616308,1.0,,8.0,,,,,,1435.0,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.
,BAO_0000019,B,,,10576.0,H,,Autocuration,12462.0,,,CHEMBL616309,1.0,,8.0,,,,,,1436.0,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain
,BAO_0000019,B,,,10576.0,H,,Expert,12462.0,,,CHEMBL616310,1.0,,8.0,,,,,,1437.0,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue
,BAO_0000219,B,,CHO,10576.0,H,,Autocuration,12462.0,,,CHEMBL616311,1.0,,8.0,,,,,449.0,1438.0,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells
,BAO_0000357,B,,,10576.0,H,,Expert,11933.0,,,CHEMBL616312,1.0,,8.0,,,,,,1439.0,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand
,BAO_0000357,B,,,10576.0,H,,Autocuration,11933.0,,,CHEMBL616313,1.0,,8.0,,,,,,1440.0,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined
,BAO_0000221,B,,,10576.0,D,Rattus norvegicus,Expert,403.0,,10116.0,CHEMBL616314,1.0,,9.0,Hippocampus,,,10000000.0,,1441.0,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor
,BAO_0000221,B,,,10576.0,H,,Autocuration,15538.0,,,CHEMBL616315,1.0,,8.0,Hippocampus,,,10000000.0,,1442.0,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus
,BAO_0000221,B,,,10576.0,H,,Autocuration,15538.0,,,CHEMBL616567,1.0,,8.0,Hippocampus,,,10000000.0,,1443.0,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active
,BAO_0000221,B,,,10576.0,H,,Autocuration,15538.0,,,CHEMBL616568,1.0,,8.0,Hippocampus,,,10000000.0,,1444.0,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined
,BAO_0000019,B,,,10576.0,H,,Intermediate,12464.0,,,CHEMBL616569,1.0,,8.0,,,,,,1445.0,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates
,BAO_0000357,B,,,10576.0,H,,Expert,1455.0,,,CHEMBL616570,1.0,,8.0,,,,,,1446.0,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.
,BAO_0000357,B,,,10576.0,H,,Autocuration,12652.0,,,CHEMBL616571,1.0,,8.0,,,,,,1447.0,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT
,BAO_0000221,B,,,10576.0,H,,Autocuration,12639.0,,,CHEMBL616572,1.0,,8.0,Hippocampus,,,10000000.0,,1448.0,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal
,BAO_0000249,B,,,10576.0,H,,Expert,13949.0,,,CHEMBL616573,1.0,,8.0,,,,,,1449.0,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.
,BAO_0000357,B,,,10576.0,D,Rattus norvegicus,Expert,12463.0,,10116.0,CHEMBL616574,1.0,,9.0,,,,,,1450.0,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT
,BAO_0000221,B,,,10576.0,H,,Expert,14829.0,,,CHEMBL616575,1.0,,8.0,Hippocampus,,,10000000.0,,1451.0,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation
,BAO_0000221,B,,,10576.0,H,,Autocuration,14829.0,,,CHEMBL872108,1.0,,8.0,Hippocampus,,,10000000.0,,1452.0,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined
,BAO_0000357,B,,,10576.0,H,,Autocuration,12092.0,,,CHEMBL616576,1.0,,8.0,,,,,,1453.0,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.
,BAO_0000249,B,,,10576.0,H,,Autocuration,403.0,,,CHEMBL616577,1.0,,8.0,,,,,,1454.0,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2
,BAO_0000249,B,,,10576.0,H,,Autocuration,403.0,,,CHEMBL616578,1.0,,8.0,,,,,,1455.0,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S
,BAO_0000357,B,,,10576.0,H,,Expert,3967.0,,,CHEMBL616579,1.0,,8.0,,,,,,1456.0,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.
,BAO_0000019,B,,,10576.0,D,Rattus norvegicus,Expert,12771.0,,10116.0,CHEMBL616580,1.0,,9.0,,,,,,1457.0,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations
,BAO_0000019,B,,,10576.0,H,,Autocuration,15086.0,,,CHEMBL616581,1.0,,8.0,,,,,,1458.0,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.
,BAO_0000221,B,,,10576.0,H,,Autocuration,14909.0,,,CHEMBL616582,1.0,,8.0,Hippocampus,,,10000000.0,,1459.0,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus
,BAO_0000221,B,,,10576.0,H,,Expert,14949.0,,,CHEMBL616583,1.0,,8.0,Hippocampus,,,10000000.0,,1460.0,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus
,BAO_0000221,B,,,10576.0,D,Rattus norvegicus,Expert,2309.0,,10116.0,CHEMBL616584,1.0,,9.0,Hippocampus,,,10000000.0,,1461.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT
,BAO_0000357,B,,,10576.0,H,,Expert,4170.0,,,CHEMBL616585,1.0,,8.0,,,,,,1462.0,Binding affinity towards 5-hydroxytryptamine 1A receptor
,BAO_0000221,B,,,10576.0,D,Rattus norvegicus,Expert,11642.0,,10116.0,CHEMBL616586,1.0,,9.0,Hippocampus,,,10000000.0,,1463.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus
,BAO_0000221,B,,,10576.0,H,,Autocuration,11642.0,,,CHEMBL616587,1.0,,8.0,Hippocampus,,,10000000.0,,1464.0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus
,BAO_0000221,B,,,10576.0,H,,Autocuration,12953.0,,,CHEMBL616588,1.0,,8.0,Hippocampus,,,10000000.0,,1465.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand
,BAO_0000221,B,,,10576.0,H,,Autocuration,12953.0,,,CHEMBL616589,1.0,,8.0,Hippocampus,,,10000000.0,,1466.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.
,BAO_0000221,B,,,10576.0,H,,Expert,12953.0,,,CHEMBL616590,1.0,,8.0,Hippocampus,,,10000000.0,,1467.0,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand
,BAO_0000219,B,,CHO,10576.0,H,,Expert,12903.0,,,CHEMBL616591,1.0,,8.0,,,,,449.0,1468.0,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand."
,BAO_0000357,B,,,10576.0,H,,Expert,12536.0,,,CHEMBL616592,1.0,,8.0,,,,,,1469.0,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,10576.0,H,,Autocuration,10058.0,,,CHEMBL616593,1.0,,8.0,,,,,,1470.0,The inhibition activity of 5-HT1A at 1 uM
,BAO_0000219,B,,CHO-K1,10576.0,H,,Expert,12902.0,,,CHEMBL616594,1.0,,8.0,,,,,485.0,1471.0,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand."
,BAO_0000249,B,,,10576.0,H,,Expert,14057.0,,,CHEMBL616595,1.0,,8.0,,,,,,1472.0,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane
,BAO_0000357,B,,,10576.0,H,,Autocuration,11296.0,,,CHEMBL616596,1.0,,8.0,,,,,,1473.0,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.
,BAO_0000221,B,,,10576.0,H,,Autocuration,11296.0,,,CHEMBL616597,1.0,,8.0,Hippocampus,,,10000000.0,,1474.0,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus
,BAO_0000221,B,,,10576.0,H,,Expert,11296.0,,,CHEMBL616598,1.0,,8.0,Hippocampus,,,10000000.0,,1475.0,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus
,BAO_0000249,F,,,10576.0,D,Rattus norvegicus,Expert,16616.0,Membranes,10116.0,CHEMBL616599,1.0,,9.0,,,,,,1476.0,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes
,BAO_0000249,F,,,10576.0,D,Rattus norvegicus,Expert,16616.0,Membranes,10116.0,CHEMBL616600,1.0,,9.0,Hippocampus,,,10000000.0,,1477.0,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes"
,BAO_0000019,B,,,10576.0,H,,Autocuration,16567.0,,,CHEMBL616601,1.0,,8.0,,,,,,1478.0,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.
,BAO_0000019,B,,,10576.0,H,,Autocuration,16567.0,,,CHEMBL616602,1.0,,8.0,,,,,,1479.0,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.
,BAO_0000019,B,,,10576.0,H,,Autocuration,16567.0,,,CHEMBL616603,1.0,,8.0,,,,,,1480.0,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.
,BAO_0000019,B,,,10576.0,H,,Autocuration,16567.0,,,CHEMBL616604,1.0,,8.0,,,,,,1481.0,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.
,BAO_0000249,B,,,10576.0,H,,Autocuration,17136.0,,,CHEMBL616316,1.0,,8.0,,,,,,1482.0,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data
,BAO_0000249,B,,,10576.0,H,,Autocuration,17136.0,,,CHEMBL616317,1.0,,8.0,,,,,,1483.0,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined
,BAO_0000019,B,,,10576.0,D,Rattus norvegicus,Expert,16616.0,,10116.0,CHEMBL616318,1.0,,9.0,,,,,,1484.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data
,BAO_0000221,B,,,10576.0,H,,Autocuration,17331.0,,,CHEMBL616319,1.0,,8.0,Hippocampus,,,10000000.0,,1485.0,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes
,BAO_0000221,B,,,10576.0,H,,Autocuration,17331.0,,,CHEMBL616320,1.0,,8.0,Hippocampus,,,10000000.0,,1486.0,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested
,BAO_0000221,B,,,10576.0,D,Rattus norvegicus,Expert,17167.0,,10116.0,CHEMBL616321,1.0,,9.0,Hippocampus,,,10000000.0,,1487.0,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested
,BAO_0000019,F,,,10576.0,H,,Autocuration,15740.0,,,CHEMBL616322,1.0,,8.0,,,,,,1488.0,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested
,BAO_0000019,F,,,10576.0,H,,Autocuration,15740.0,,,CHEMBL616323,1.0,,8.0,,,,,,1489.0,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested
,BAO_0000357,B,,,10576.0,H,,Autocuration,4671.0,,,CHEMBL616324,1.0,,8.0,,,,,,1490.0,Ratio of binding affinity to 5-HT 1A and D2 receptor
,BAO_0000221,B,,,10576.0,H,,Autocuration,10058.0,,,CHEMBL616325,1.0,,8.0,Hippocampus,,,10000000.0,,1491.0,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM
,BAO_0000221,B,,,10576.0,H,,Autocuration,10058.0,,,CHEMBL616326,1.0,,8.0,Hippocampus,,,10000000.0,,1492.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM
,BAO_0000221,B,,,10576.0,H,,Autocuration,10058.0,,,CHEMBL616327,1.0,,8.0,Hippocampus,,,10000000.0,,1493.0,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.
,BAO_0000357,B,,,10576.0,H,,Autocuration,12073.0,,,CHEMBL616328,1.0,,8.0,,,,,,1494.0,Percentage inhibition against 5-hydroxytryptamine 1A receptor
,BAO_0000249,B,,,10576.0,H,,Autocuration,2759.0,,,CHEMBL858110,1.0,,8.0,,,,,,1495.0,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1)
,BAO_0000249,F,,,10576.0,H,,Autocuration,2759.0,,,CHEMBL616329,1.0,,8.0,,,,,,1496.0,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1)
,BAO_0000249,B,,,10576.0,H,,Autocuration,2759.0,,,CHEMBL616330,1.0,,8.0,,,,,,1497.0,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2)
,BAO_0000249,F,,,10576.0,H,,Autocuration,2759.0,,,CHEMBL616331,1.0,,8.0,,,,,,1498.0,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2)
,BAO_0000249,F,,,10576.0,H,,Autocuration,2759.0,,,CHEMBL616332,1.0,,8.0,,,,,,1499.0,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.
,BAO_0000249,B,,,10576.0,H,,Autocuration,9737.0,,,CHEMBL857063,1.0,,8.0,Brain,,,955.0,,1500.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.
,BAO_0000019,B,,,10576.0,H,,Autocuration,9737.0,,,CHEMBL616333,1.0,,8.0,,,,,,1501.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand
,BAO_0000019,F,,,10576.0,H,,Expert,5717.0,,,CHEMBL616334,1.0,,8.0,,,,,,1502.0,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.
,BAO_0000221,B,,,10576.0,H,,Autocuration,12253.0,,,CHEMBL616335,1.0,,8.0,Hippocampus,,,10000000.0,,1503.0,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus
,BAO_0000019,B,,,10576.0,H,,Autocuration,14025.0,,,CHEMBL616336,1.0,,8.0,,,,,,1504.0,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.
,BAO_0000249,B,,,10576.0,H,,Expert,10425.0,,,CHEMBL616337,1.0,,8.0,,,,,,1505.0,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.
,BAO_0000019,B,,,10576.0,H,,Autocuration,14998.0,,,CHEMBL616338,1.0,,8.0,,,,,,1506.0,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.
,BAO_0000221,B,,,10576.0,H,,Autocuration,13694.0,,,CHEMBL616339,1.0,,8.0,Hippocampus,,,10000000.0,,1507.0,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay
,BAO_0000221,B,,,10576.0,H,,Autocuration,13694.0,,,CHEMBL616340,1.0,,8.0,Hippocampus,,,10000000.0,,1508.0,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay
,BAO_0000357,B,,,10576.0,H,,Autocuration,4342.0,,,CHEMBL616341,1.0,,8.0,,,,,,1509.0,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined
,BAO_0000357,B,,,10576.0,D,Rattus norvegicus,Expert,12936.0,,10116.0,CHEMBL616342,1.0,,9.0,,,,,,1510.0,Binding affinity against rat 5-hydroxytryptamine 1A receptor
,BAO_0000019,B,,,10576.0,D,Rattus norvegicus,Expert,13144.0,,10116.0,CHEMBL616343,1.0,,9.0,,,,,,1511.0,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates
,BAO_0000019,B,,,10576.0,H,,Expert,13343.0,,,CHEMBL616344,1.0,,8.0,,,,,,1512.0,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement
,BAO_0000357,B,,,10576.0,H,,Expert,12132.0,,,CHEMBL616345,1.0,,8.0,,,,,,1513.0,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.
,BAO_0000019,B,,,10576.0,H,,Expert,15419.0,,,CHEMBL616346,1.0,,8.0,,,,,,1514.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand
,BAO_0000221,B,,,10576.0,H,,Autocuration,1479.0,,,CHEMBL616347,1.0,,8.0,Hippocampus,,,10000000.0,,1515.0,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus
,BAO_0000019,B,,,10576.0,H,,Expert,14287.0,,,CHEMBL616348,1.0,,8.0,,,,,,1516.0,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane
,BAO_0000357,B,,,10576.0,H,,Expert,13116.0,,,CHEMBL616349,1.0,,8.0,,,,,,1517.0,Binding affinity at 5-hydroxytryptamine 1A receptor
,BAO_0000249,B,,,10576.0,D,Rattus norvegicus,Expert,2759.0,Membranes,10116.0,CHEMBL616152,1.0,,9.0,,,,,,1518.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes
,BAO_0000249,B,,,10576.0,H,,Autocuration,2759.0,,,CHEMBL616153,1.0,,8.0,,,,,,1519.0,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.
,BAO_0000019,B,,,10576.0,H,,Expert,14748.0,,,CHEMBL616154,1.0,,8.0,,,,,,1520.0,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand"
,BAO_0000019,B,,,10576.0,H,,Autocuration,12304.0,,,CHEMBL616155,1.0,,8.0,,,,,,1521.0,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex
,BAO_0000221,B,,,10576.0,D,Rattus norvegicus,Expert,12409.0,,10116.0,CHEMBL616156,1.0,,9.0,Hippocampus,,,10000000.0,,1522.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT
,BAO_0000221,B,,,10576.0,D,Rattus norvegicus,Expert,12409.0,,10116.0,CHEMBL616157,1.0,,9.0,Hippocampus,,,10000000.0,,1523.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT
,BAO_0000221,B,,,10576.0,H,,Autocuration,13267.0,,,CHEMBL616158,1.0,,8.0,Hippocampus,,,10000000.0,,1524.0,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand
,BAO_0000357,B,,,10576.0,H,,Autocuration,15194.0,,,CHEMBL616159,1.0,,8.0,,,,,,1525.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.
,BAO_0000357,B,,,10576.0,H,,Expert,14256.0,,,CHEMBL616160,1.0,,8.0,,,,,,1526.0,pKi value against rat 5-hydroxytryptamine 1A receptor.
,BAO_0000019,B,,,10576.0,H,,Autocuration,16567.0,,,CHEMBL616161,1.0,,8.0,,,,,,1527.0,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.
,BAO_0000019,F,,,10576.0,H,,Autocuration,15740.0,,,CHEMBL616162,1.0,,8.0,,,,,,1528.0,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested
,BAO_0000357,B,,,12687.0,D,Rattus norvegicus,Expert,13278.0,,10116.0,CHEMBL616163,1.0,,9.0,,,,,,1529.0,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides
,BAO_0000249,B,,,10626.0,H,,Expert,1970.0,Membranes,,CHEMBL616164,1.0,,8.0,,,,,,1530.0,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes
,BAO_0000221,B,,,10576.0,H,,Autocuration,10034.0,,,CHEMBL616165,1.0,,8.0,Brain,,,955.0,,1531.0,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated
,BAO_0000019,B,,,51.0,H,Rattus norvegicus,Autocuration,13348.0,,10116.0,CHEMBL616355,1.0,,8.0,,,,,,1532.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker
,BAO_0000019,F,,,10576.0,H,,Autocuration,13630.0,,,CHEMBL616356,1.0,,8.0,,,,,,1533.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.
,BAO_0000221,B,,,10576.0,H,,Autocuration,10862.0,,,CHEMBL616357,1.0,,8.0,Brain,,,955.0,,1534.0,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.
,BAO_0000019,B,,,10576.0,H,,Autocuration,12058.0,,,CHEMBL616358,1.0,,8.0,,,,,,1535.0,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand"
,BAO_0000357,B,,,51.0,H,,Autocuration,4639.0,,,CHEMBL616359,1.0,,8.0,,,,,,1536.0,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,H,,Expert,15453.0,,,CHEMBL616360,1.0,,8.0,,,,,,1537.0,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT
,BAO_0000357,B,,,51.0,H,,Expert,4820.0,,,CHEMBL616361,1.0,,8.0,,,,,,1538.0,Binding affinity towards 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,H,,Autocuration,1089.0,,,CHEMBL616362,1.0,,8.0,,,,,,1539.0,Tested for binding affinity for 5-hydroxytryptamine 1A receptor
,BAO_0000249,B,,,51.0,H,,Autocuration,386.0,Brain membranes,,CHEMBL616363,1.0,,8.0,,,,,,1540.0,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes
,BAO_0000357,B,,,51.0,H,,Autocuration,6011.0,,,CHEMBL616364,1.0,,8.0,,,,,,1541.0,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration
,BAO_0000357,B,,,51.0,H,,Autocuration,5014.0,,,CHEMBL616365,1.0,,8.0,,,,,,1542.0,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,H,,Expert,4402.0,,,CHEMBL616366,1.0,,8.0,,,,,,1543.0,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand
,BAO_0000357,B,,,51.0,H,,Expert,17066.0,,,CHEMBL872906,1.0,,8.0,,,,,,1544.0,Binding affinity towards 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,H,,Autocuration,17515.0,,,CHEMBL616367,1.0,,8.0,,,,,,1545.0,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM
,BAO_0000357,B,,,51.0,H,,Autocuration,2474.0,,,CHEMBL616368,1.0,,8.0,,,,,,1546.0,Binding affinity against 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,51.0,H,,Autocuration,4775.0,,,CHEMBL616369,1.0,,8.0,,,,,,1547.0,Binding affinity to 5-hydroxytryptamine 1A receptor was determined
,BAO_0000357,B,,,51.0,D,Homo sapiens,Expert,14294.0,,9606.0,CHEMBL616370,1.0,,9.0,,,,,,1548.0,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.
,BAO_0000357,B,,,51.0,D,Homo sapiens,Expert,14294.0,,9606.0,CHEMBL616371,1.0,,9.0,,,,,,1549.0,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive
,BAO_0000219,B,,CHO,51.0,H,,Autocuration,12249.0,,,CHEMBL616372,1.0,,8.0,,,,,449.0,1550.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells
,BAO_0000219,B,,,51.0,H,,Expert,11376.0,,,CHEMBL616373,1.0,,8.0,,,,,,1551.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes
,BAO_0000218,B,In vivo,,51.0,H,,Autocuration,2474.0,,,CHEMBL616374,1.0,,8.0,,,,,,1552.0,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
,BAO_0000221,B,,,51.0,H,,Autocuration,13311.0,,,CHEMBL616375,1.0,,8.0,Hippocampus,,,10000000.0,,1553.0,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus
,BAO_0000357,B,,,51.0,H,,Autocuration,4373.0,,,CHEMBL616376,1.0,,8.0,,,,,,1554.0,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined
,BAO_0000357,B,,,51.0,H,,Expert,1633.0,,,CHEMBL857064,1.0,,8.0,,,,,,1555.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.
,BAO_0000357,B,,,51.0,H,,Autocuration,11866.0,,,CHEMBL616377,1.0,,8.0,,,,,,1556.0,Binding affinity for 5-hydroxytryptamine 1A receptor was determined
,BAO_0000357,B,,,51.0,H,,Autocuration,4373.0,,,CHEMBL616378,1.0,,8.0,,,,,,1557.0,Binding affinity for 5-hydroxytryptamine 1A receptor was determined
,BAO_0000357,B,,,51.0,H,,Autocuration,4687.0,,,CHEMBL616379,1.0,,8.0,,,,,,1558.0,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,11863.0,H,,Autocuration,16946.0,,,CHEMBL616380,1.0,,8.0,,,,,,1559.0,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,11863.0,H,,Autocuration,13291.0,,,CHEMBL616381,1.0,,8.0,,,,,,1560.0,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand
,BAO_0000357,B,,,11863.0,H,,Autocuration,14159.0,,,CHEMBL616382,1.0,,8.0,,,,,,1561.0,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,11863.0,H,,Autocuration,10812.0,,,CHEMBL616383,1.0,,8.0,,,,,,1562.0,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand
,BAO_0000219,B,,CHO,11863.0,D,Mus musculus,Expert,3032.0,,10090.0,CHEMBL616350,1.0,,9.0,,,,,449.0,1563.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells
,BAO_0000357,B,,,11863.0,H,,Autocuration,16655.0,,,CHEMBL616351,1.0,,8.0,,,,,,1564.0,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,11863.0,H,,Autocuration,14532.0,,,CHEMBL616352,1.0,,8.0,,,,,,1565.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration
,BAO_0000357,B,,,11863.0,H,,Autocuration,13944.0,,,CHEMBL616353,1.0,,8.0,,,,,,1566.0,Binding affinity against 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,11863.0,H,,Autocuration,13033.0,,,CHEMBL616354,1.0,,8.0,,,,,,1567.0,Binding affinity against serotonergic 5-HT1a receptor
,BAO_0000357,B,,,11863.0,H,,Autocuration,10321.0,,,CHEMBL616508,1.0,,8.0,,,,,,1568.0,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand
,BAO_0000357,B,,,11863.0,D,Mus musculus,Expert,2968.0,,10090.0,CHEMBL616559,1.0,,9.0,,,,,,1569.0,Binding affinity for 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,11863.0,H,,Autocuration,13964.0,,,CHEMBL616560,1.0,,8.0,,,,,,1570.0,Binding affinity at 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,11863.0,H,,Autocuration,15527.0,,,CHEMBL616561,1.0,,8.0,,,,,,1571.0,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand."
,BAO_0000219,B,,CHO,11863.0,H,,Autocuration,12248.0,,,CHEMBL616562,1.0,,8.0,,,,,449.0,1572.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells
,BAO_0000219,B,,CHO,11863.0,H,,Autocuration,12249.0,,,CHEMBL616563,1.0,,8.0,,,,,449.0,1573.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells
,BAO_0000357,B,,,11863.0,H,,Autocuration,15120.0,,,CHEMBL616564,1.0,,8.0,,,,,,1574.0,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,11863.0,H,,Autocuration,13313.0,,,CHEMBL616565,1.0,,8.0,,,,,,1575.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand
,BAO_0000218,B,,,11863.0,H,,Autocuration,2613.0,,,CHEMBL616566,1.0,,8.0,,,,,,1576.0,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,11863.0,H,,Autocuration,16700.0,,,CHEMBL616989,1.0,,8.0,,,,,,1577.0,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity
,BAO_0000357,B,,,11863.0,H,,Autocuration,2201.0,,,CHEMBL857975,1.0,,8.0,,,,,,1578.0,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,11863.0,D,Mus musculus,Expert,1274.0,,10090.0,CHEMBL616990,1.0,,9.0,,,,,,1579.0,Binding affinity against 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,11863.0,H,,Autocuration,1317.0,,,CHEMBL616991,1.0,,8.0,,,,,,1580.0,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay
,BAO_0000357,B,,,11863.0,H,,Autocuration,12146.0,,,CHEMBL616992,1.0,,8.0,,,,,,1581.0,Tested against 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,11863.0,H,,Autocuration,14059.0,,,CHEMBL616993,1.0,,8.0,,,,,,1582.0,The compound's binding affinity against 5-hydroxytryptamine 1A receptor
,BAO_0000019,B,,,106.0,H,Oryctolagus cuniculus,Expert,14025.0,,9986.0,CHEMBL616994,1.0,,8.0,,,,,,1583.0,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein
,BAO_0000019,B,,,106.0,H,Oryctolagus cuniculus,Autocuration,14025.0,,9986.0,CHEMBL616995,1.0,,8.0,,,,,,1584.0,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable
,BAO_0000219,B,,HEK293,105571.0,D,Gorilla gorilla,Intermediate,14447.0,,9593.0,CHEMBL616996,1.0,,9.0,,,,,722.0,1585.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells
,BAO_0000218,F,In vivo,,106.0,H,Cavia porcellus,Autocuration,3025.0,,10141.0,CHEMBL616997,1.0,,8.0,,,,,,1586.0,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration
,BAO_0000218,F,In vivo,,106.0,H,Cavia porcellus,Autocuration,3025.0,,10141.0,CHEMBL616998,1.0,,8.0,,,,,,1587.0,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration
,BAO_0000019,F,,,106.0,H,Cavia porcellus,Autocuration,15329.0,,10141.0,CHEMBL616999,1.0,,8.0,,,,,,1588.0,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery
,BAO_0000019,F,,,106.0,H,Cavia porcellus,Autocuration,15329.0,,10141.0,CHEMBL617000,1.0,,8.0,,,,,,1589.0,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined
,BAO_0000019,F,,,106.0,H,Cavia porcellus,Autocuration,15847.0,,10141.0,CHEMBL617001,1.0,,8.0,,,,,,1590.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig
,BAO_0000019,F,,,106.0,H,Cavia porcellus,Autocuration,15847.0,,10141.0,CHEMBL858111,1.0,,8.0,,,,,,1591.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done
,BAO_0000019,F,,,106.0,H,,Autocuration,14165.0,,,CHEMBL617002,1.0,,8.0,,,,,,1592.0,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding
,BAO_0000019,F,,,106.0,H,,Autocuration,14214.0,,,CHEMBL617003,1.0,,8.0,,,,,,1593.0,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT)
,BAO_0000019,F,,,106.0,H,,Autocuration,14214.0,,,CHEMBL617004,1.0,,8.0,,,,,,1594.0,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT)
,BAO_0000019,F,,,106.0,D,Homo sapiens,Expert,14214.0,,9606.0,CHEMBL617005,1.0,,9.0,,,,,,1595.0,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation
,BAO_0000219,F,,CHO-K1,106.0,D,Homo sapiens,Expert,13729.0,,9606.0,CHEMBL616623,1.0,,9.0,,,,,485.0,1596.0,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells
,BAO_0000219,F,,CHO,106.0,H,,Autocuration,3025.0,,,CHEMBL616624,1.0,,8.0,,,,,449.0,1597.0,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines
,BAO_0000357,B,,,106.0,H,,Autocuration,2391.0,,,CHEMBL883243,1.0,,8.0,,,,,,1598.0,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor
,BAO_0000019,F,,,106.0,H,,Autocuration,2391.0,,,CHEMBL616625,1.0,,8.0,,,,,,1599.0,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist
,BAO_0000219,F,,CHO,106.0,H,,Expert,14956.0,,,CHEMBL616626,1.0,,8.0,,,,,449.0,1600.0,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor"
,BAO_0000219,F,,CHO,106.0,H,,Autocuration,2598.0,,,CHEMBL616627,1.0,,8.0,,,,,449.0,1601.0,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line
,BAO_0000219,F,,CHO,106.0,H,,Autocuration,2598.0,,,CHEMBL616628,1.0,,8.0,,,,,449.0,1602.0,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist
,BAO_0000219,F,,CHO,106.0,H,,Autocuration,2598.0,,,CHEMBL616629,1.0,,8.0,,,,,449.0,1603.0,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist
,BAO_0000219,F,,CHO,106.0,H,,Autocuration,2598.0,,,CHEMBL616630,1.0,,8.0,,,,,449.0,1604.0,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist
,BAO_0000019,F,,,106.0,H,,Expert,14956.0,,,CHEMBL616631,1.0,,8.0,,,,,,1605.0,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand"
,BAO_0000019,F,,,106.0,H,,Autocuration,14956.0,,,CHEMBL616632,1.0,,8.0,,,,,,1606.0,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand"
,BAO_0000357,B,,,106.0,D,Homo sapiens,Expert,14214.0,,9606.0,CHEMBL616633,1.0,,9.0,,,,,,1607.0,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor
,BAO_0000219,B,,CHO,106.0,H,,Expert,3463.0,,,CHEMBL616634,1.0,,8.0,,,,,449.0,1608.0,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro
,BAO_0000357,B,,,106.0,H,,Autocuration,15331.0,,,CHEMBL616635,1.0,,8.0,,,,,,1609.0,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique
,BAO_0000357,B,,,106.0,D,Homo sapiens,Expert,16146.0,,9606.0,CHEMBL885358,1.0,,9.0,,,,,,1610.0,Binding affinity against 5-hydroxytryptamine 1B receptor
,BAO_0000219,B,,CHO,106.0,D,Homo sapiens,Expert,14159.0,,9606.0,CHEMBL616636,1.0,,9.0,,,,,449.0,1611.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells
,BAO_0000219,B,,CHO,106.0,H,,Expert,14158.0,,,CHEMBL616637,1.0,,8.0,,,,,449.0,1612.0,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.
,BAO_0000357,B,,,106.0,H,,Autocuration,14159.0,,,CHEMBL616638,1.0,,8.0,,,,,,1613.0,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor
,BAO_0000219,B,,CHO,106.0,H,,Expert,15250.0,,,CHEMBL616639,1.0,,8.0,,,,,449.0,1614.0,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells
,BAO_0000219,B,,CHO,106.0,H,,Expert,15250.0,,,CHEMBL616640,1.0,,8.0,,,,,449.0,1615.0,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.
,BAO_0000219,B,,CHO,106.0,H,,Expert,15331.0,,,CHEMBL616641,1.0,,8.0,,,,,449.0,1616.0,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells
,BAO_0000219,B,,CHO,106.0,H,,Expert,15332.0,,,CHEMBL616642,1.0,,8.0,,,,,449.0,1617.0,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.
,BAO_0000219,B,,CHO,106.0,H,,Expert,14956.0,,,CHEMBL616643,1.0,,8.0,,,,,449.0,1618.0,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells
,BAO_0000357,B,,,106.0,H,,Autocuration,3805.0,,,CHEMBL616644,1.0,,8.0,,,,,,1619.0,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM)
,BAO_0000357,B,,,106.0,H,,Autocuration,14875.0,,,CHEMBL616645,1.0,,8.0,,,,,,1620.0,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response
,BAO_0000019,F,,,105.0,H,Oryctolagus cuniculus,Autocuration,14454.0,,9986.0,CHEMBL616646,1.0,,8.0,,,,,,1621.0,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV)
,BAO_0000019,F,,,105.0,H,Oryctolagus cuniculus,Expert,14454.0,,9986.0,CHEMBL616647,1.0,,8.0,,,,,,1622.0,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV)
,BAO_0000357,B,,,105.0,H,,Autocuration,16288.0,,,CHEMBL616509,1.0,,8.0,,,,,,1623.0,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9)
,BAO_0000357,B,,,105.0,H,,Autocuration,16288.0,,,CHEMBL616510,1.0,,8.0,,,,,,1624.0,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9)
,BAO_0000357,B,,,105.0,H,,Autocuration,16312.0,,,CHEMBL616511,1.0,,8.0,,,,,,1625.0,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor
,BAO_0000357,B,,,105.0,H,Bos taurus,Expert,1348.0,,9913.0,CHEMBL616512,1.0,,8.0,,,,,,1626.0,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype
,BAO_0000357,B,,,105.0,H,Bos taurus,Autocuration,5834.0,,9913.0,CHEMBL616513,1.0,,8.0,,,,,,1627.0,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT
,BAO_0000019,B,,,105.0,H,Bos taurus,Autocuration,13366.0,,9913.0,CHEMBL616514,1.0,,8.0,Striatum,,,2435.0,,1628.0,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate
,BAO_0000357,B,,,105.0,H,Bos taurus,Expert,1414.0,,9913.0,CHEMBL616515,1.0,,8.0,,,,,,1629.0,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra
,BAO_0000019,B,,,105.0,H,Bos taurus,Autocuration,14998.0,,9913.0,CHEMBL616516,1.0,,8.0,,,,,,1630.0,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.
,BAO_0000357,B,,,105.0,H,Bos taurus,Autocuration,11473.0,,9913.0,CHEMBL616517,1.0,,8.0,,,,,,1631.0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand
,BAO_0000357,B,,,105.0,H,Bos taurus,Autocuration,11473.0,,9913.0,CHEMBL616518,1.0,,8.0,,,,,,1632.0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand
,BAO_0000357,B,,,105.0,H,Bos taurus,Autocuration,10639.0,,9913.0,CHEMBL616519,1.0,,8.0,,,,,,1633.0,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand
,BAO_0000357,B,,,105.0,H,Bos taurus,Autocuration,10639.0,,9913.0,CHEMBL616520,1.0,,8.0,,,,,,1634.0,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand
,BAO_0000357,B,,,105.0,H,Bos taurus,Autocuration,1375.0,,9913.0,CHEMBL616521,1.0,,8.0,,,,,,1635.0,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand
,BAO_0000357,B,,,105.0,H,Bos taurus,Autocuration,1375.0,,9913.0,CHEMBL616522,1.0,,8.0,,,,,,1636.0,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested
,BAO_0000357,B,,,105.0,H,Bos taurus,Autocuration,16532.0,,9913.0,CHEMBL884531,1.0,,8.0,,,,,,1637.0,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested
,BAO_0000357,B,,,105.0,H,Bos taurus,Autocuration,11147.0,,9913.0,CHEMBL616523,1.0,,8.0,,,,,,1638.0,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand
,BAO_0000019,B,,,105.0,H,Bos taurus,Autocuration,13366.0,,9913.0,CHEMBL616731,1.0,,8.0,Striatum,,,2435.0,,1639.0,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate
,BAO_0000019,B,,,105.0,H,Bos taurus,Autocuration,10444.0,,9913.0,CHEMBL616732,1.0,,8.0,,,,,,1640.0,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate
,BAO_0000357,B,,,105.0,H,Bos taurus,Autocuration,16532.0,,9913.0,CHEMBL616733,1.0,,8.0,,,,,,1641.0,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT
,BAO_0000357,B,,,105.0,H,Bos taurus,Autocuration,16532.0,,9913.0,CHEMBL616734,1.0,,8.0,,,,,,1642.0,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested
,BAO_0000249,B,,,105.0,H,Bos taurus,Autocuration,12827.0,,9913.0,CHEMBL616735,1.0,,8.0,,,,,,1643.0,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP
,BAO_0000249,B,,,105.0,H,Bos taurus,Autocuration,12827.0,,9913.0,CHEMBL616736,1.0,,8.0,,,,,,1644.0,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined
,BAO_0000019,F,,,105.0,H,Bos taurus,Expert,12919.0,,9913.0,CHEMBL616737,1.0,,8.0,,,,,,1645.0,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI
,BAO_0000019,B,,,105.0,H,Bos taurus,Autocuration,14025.0,,9913.0,CHEMBL616738,1.0,,8.0,,,,,,1646.0,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate
,BAO_0000019,F,,,105.0,H,Bos taurus,Expert,12919.0,,9913.0,CHEMBL616739,1.0,,8.0,,,,,,1647.0,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI
,BAO_0000019,F,,,105.0,H,Bos taurus,Expert,12919.0,,9913.0,CHEMBL616740,1.0,,8.0,,,,,,1648.0,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI
,BAO_0000019,F,,,105.0,H,Bos taurus,Expert,12919.0,,9913.0,CHEMBL616741,1.0,,8.0,,,,,,1649.0,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI
,BAO_0000219,B,,HEK293,105.0,H,Gorilla gorilla,Autocuration,14447.0,,9593.0,CHEMBL616742,1.0,,8.0,,,,,722.0,1650.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells
,BAO_0000019,B,,,105570.0,D,Cavia porcellus,Intermediate,1375.0,,10141.0,CHEMBL616743,1.0,,9.0,,,,,,1651.0,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra
,BAO_0000019,B,,,105570.0,D,Cavia porcellus,Intermediate,1375.0,,10141.0,CHEMBL616744,1.0,,9.0,,,,,,1652.0,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested
,BAO_0000019,F,,,105570.0,D,Cavia porcellus,Intermediate,12409.0,,10141.0,CHEMBL616745,1.0,,9.0,,,,,,1653.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611
,BAO_0000019,F,,,105570.0,D,Cavia porcellus,Intermediate,12409.0,,10141.0,CHEMBL616746,1.0,,9.0,,,,,,1654.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611
,BAO_0000019,F,,,105570.0,D,Cavia porcellus,Intermediate,12409.0,,10141.0,CHEMBL616747,1.0,,9.0,,,,,,1655.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9
,BAO_0000019,F,,,105570.0,D,Cavia porcellus,Intermediate,12409.0,,10141.0,CHEMBL616748,1.0,,9.0,,,,,,1656.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4
,BAO_0000019,F,,,105570.0,D,Cavia porcellus,Intermediate,12409.0,,10141.0,CHEMBL616648,1.0,,9.0,,,,,,1657.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2
,BAO_0000357,B,,,105570.0,D,Cavia porcellus,Intermediate,11574.0,,10141.0,CHEMBL616649,1.0,,9.0,,,,,,1658.0,Binding affinity against 5-hydroxytryptamine 1D receptor
,BAO_0000357,B,,,105570.0,D,Cavia porcellus,Intermediate,1558.0,,10141.0,CHEMBL616650,1.0,,9.0,,,,,,1659.0,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined
,BAO_0000218,F,,,105570.0,D,Cavia porcellus,Intermediate,12409.0,,10141.0,CHEMBL616651,1.0,,9.0,,,,,,1660.0,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611
,BAO_0000218,F,,,105570.0,D,Cavia porcellus,Intermediate,12409.0,,10141.0,CHEMBL616652,1.0,,9.0,,,,,,1661.0,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611
,BAO_0000218,F,,,105570.0,D,Cavia porcellus,Intermediate,12409.0,,10141.0,CHEMBL616653,1.0,,9.0,,,,,,1662.0,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611
,BAO_0000218,F,,,105570.0,D,Cavia porcellus,Intermediate,12409.0,,10141.0,CHEMBL616654,1.0,,9.0,,,,,,1663.0,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig
,BAO_0000019,B,,,105570.0,D,Cavia porcellus,Intermediate,12253.0,,10141.0,CHEMBL616655,1.0,,9.0,,,,,,1664.0,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex
,BAO_0000357,B,,,105570.0,D,Cavia porcellus,Intermediate,12936.0,,10141.0,CHEMBL616656,1.0,,9.0,,,,,,1665.0,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor
,BAO_0000019,B,,,105.0,H,Cavia porcellus,Autocuration,13181.0,,10141.0,CHEMBL616657,1.0,,8.0,,,,,,1666.0,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes
,BAO_0000357,B,,,105570.0,D,Cavia porcellus,Intermediate,12409.0,,10141.0,CHEMBL616658,1.0,,9.0,Striatum,,,2435.0,,1667.0,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine
,BAO_0000357,B,,,105570.0,D,Cavia porcellus,Intermediate,10639.0,,10141.0,CHEMBL616659,1.0,,9.0,,,,,,1668.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra
,BAO_0000357,B,,,51.0,H,,Autocuration,5254.0,,,CHEMBL616660,1.0,,8.0,,,,,,1669.0,Binding affinity against 5-hydroxytryptamine 1D receptor
,BAO_0000357,B,,,106.0,H,,Autocuration,13051.0,,,CHEMBL616661,1.0,,8.0,,,,,,1670.0,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta
,BAO_0000019,F,,,105.0,H,,Expert,3463.0,,,CHEMBL616662,1.0,,8.0,,,,,,1671.0,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor
,BAO_0000019,F,,,105.0,H,,Autocuration,15315.0,,,CHEMBL616663,1.0,,8.0,,,,,,1672.0,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor
,BAO_0000019,F,,,105.0,H,,Autocuration,6011.0,,,CHEMBL616664,1.0,,8.0,,,,,,1673.0,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor
,BAO_0000219,F,,CHO,105.0,D,Homo sapiens,Expert,14159.0,,9606.0,CHEMBL881820,1.0,,9.0,,,,,449.0,1674.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor"
,BAO_0000219,F,,CHO,105.0,H,,Autocuration,14159.0,,,CHEMBL616665,1.0,,8.0,,,,,449.0,1675.0,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor."
,BAO_0000219,B,,CHO,105.0,H,,Expert,15250.0,,,CHEMBL616666,1.0,,8.0,,,,,449.0,1676.0,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor
,BAO_0000219,B,,CHO,105.0,H,,Autocuration,15250.0,,,CHEMBL616667,1.0,,8.0,,,,,449.0,1677.0,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor
,BAO_0000219,F,,CHO,105.0,H,,Expert,15331.0,,,CHEMBL616668,1.0,,8.0,,,,,449.0,1678.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor"
,BAO_0000219,F,,CHO,105.0,D,Homo sapiens,Expert,15332.0,,9606.0,CHEMBL616669,1.0,,9.0,,,,,449.0,1679.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor"
,BAO_0000219,F,,CHO,105.0,H,,Expert,15332.0,,,CHEMBL617040,1.0,,8.0,,,,,449.0,1680.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor."
,BAO_0000219,F,,CHO,105.0,H,,Autocuration,3294.0,,,CHEMBL617041,1.0,,8.0,,,,,449.0,1681.0,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor"
,BAO_0000219,F,,CHO,105.0,H,,Expert,14158.0,,,CHEMBL617042,1.0,,8.0,,,,,449.0,1682.0,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor."
,BAO_0000219,F,,CHO,105.0,H,,Expert,14956.0,,,CHEMBL617043,1.0,,8.0,,,,,449.0,1683.0,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor"
,BAO_0000019,F,,,105.0,H,,Autocuration,12469.0,,,CHEMBL617044,1.0,,8.0,,,,,,1684.0,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor
,BAO_0000219,F,,CHO,105.0,H,,Expert,3463.0,,,CHEMBL617045,1.0,,8.0,,,,,449.0,1685.0,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor
,BAO_0000219,F,,CHO,105.0,D,Homo sapiens,Expert,15250.0,,9606.0,CHEMBL617046,1.0,,9.0,,,,,449.0,1686.0,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT"
,BAO_0000219,F,,CHO,105.0,D,Homo sapiens,Expert,15250.0,,9606.0,CHEMBL617047,1.0,,9.0,,,,,449.0,1687.0,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT"
,BAO_0000019,F,,,105.0,H,,Expert,14956.0,,,CHEMBL617048,1.0,,8.0,,,,,,1688.0,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand"
,BAO_0000019,F,,,105.0,H,,Autocuration,14159.0,,,CHEMBL616897,1.0,,8.0,,,,,,1689.0,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor."
,BAO_0000019,F,,,105.0,D,Homo sapiens,Expert,14159.0,,9606.0,CHEMBL616898,1.0,,9.0,,,,,,1690.0,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT"
,BAO_0000219,F,,CHO,105.0,D,Homo sapiens,Expert,14499.0,,9606.0,CHEMBL858201,1.0,,9.0,,,,,449.0,1691.0,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor
,BAO_0000019,F,,,105.0,H,,Autocuration,15315.0,,,CHEMBL616899,1.0,,8.0,,,,,,1692.0,Intrinsic activity for 5-hydroxytryptamine 1D receptor
,BAO_0000219,B,In vitro,,105.0,H,,Autocuration,3294.0,,,CHEMBL616900,1.0,,8.0,,,,,,1693.0,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells)
,BAO_0000219,B,,CHO,105.0,H,,Expert,3463.0,,,CHEMBL616901,1.0,,8.0,,,,,449.0,1694.0,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro
,BAO_0000357,B,,,105.0,H,,Autocuration,15331.0,,,CHEMBL616902,1.0,,8.0,,,,,,1695.0,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique
,BAO_0000219,B,,CHO,105.0,D,Homo sapiens,Expert,14159.0,,9606.0,CHEMBL616903,1.0,,9.0,,,,,449.0,1696.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells
,BAO_0000219,B,,CHO,105.0,H,,Expert,14158.0,,,CHEMBL616904,1.0,,8.0,,,,,449.0,1697.0,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.
,BAO_0000357,B,,,105.0,H,,Autocuration,14159.0,,,CHEMBL616905,1.0,,8.0,,,,,,1698.0,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor
,BAO_0000219,B,,CHO,105.0,H,,Expert,15250.0,,,CHEMBL616906,1.0,,8.0,,,,,449.0,1699.0,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.
,BAO_0000219,B,,CHO,105.0,H,,Expert,15250.0,,,CHEMBL616907,1.0,,8.0,,,,,449.0,1700.0,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells
,BAO_0000219,B,,CHO,105.0,H,,Expert,15331.0,,,CHEMBL616908,1.0,,8.0,,,,,449.0,1701.0,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells
,BAO_0000219,B,,CHO,105.0,D,Homo sapiens,Expert,15332.0,,9606.0,CHEMBL616909,1.0,,9.0,,,,,449.0,1702.0,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells
,BAO_0000219,B,,CHO,105.0,D,Homo sapiens,Expert,14499.0,,9606.0,CHEMBL616910,1.0,,9.0,,,,,449.0,1703.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells
,BAO_0000219,B,,CHO,105.0,H,,Expert,15332.0,,,CHEMBL616911,1.0,,8.0,,,,,449.0,1704.0,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells
,BAO_0000219,B,,CHO,105.0,H,,Expert,14956.0,,,CHEMBL616912,1.0,,8.0,,,,,449.0,1705.0,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells
,BAO_0000357,B,,,105.0,H,,Autocuration,3805.0,,,CHEMBL616913,1.0,,8.0,,,,,,1706.0,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM)
,BAO_0000219,B,,CHO,105.0,D,Homo sapiens,Expert,6011.0,,9606.0,CHEMBL616914,1.0,,9.0,,,,,449.0,1707.0,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM
,BAO_0000219,B,,CHO,105.0,H,,Autocuration,16190.0,,,CHEMBL616915,1.0,,8.0,,,,,449.0,1708.0,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand
,BAO_0000019,B,,,105.0,H,,Autocuration,14165.0,,,CHEMBL616916,1.0,,8.0,,,,,,1709.0,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand
,BAO_0000357,B,,,105.0,D,Homo sapiens,Expert,4234.0,,9606.0,CHEMBL616917,1.0,,9.0,,,,,,1710.0,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor
,BAO_0000357,B,,,105.0,H,,Autocuration,15527.0,,,CHEMBL616918,1.0,,8.0,,,,,,1711.0,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand."
,BAO_0000219,B,,,105.0,H,,Expert,6328.0,,,CHEMBL616919,1.0,,8.0,,,,,,1712.0,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand
,BAO_0000357,B,,,105.0,H,,Autocuration,16209.0,,,CHEMBL616920,1.0,,8.0,,,,,,1713.0,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand
,BAO_0000357,B,,,105.0,H,,Autocuration,14770.0,,,CHEMBL872914,1.0,,8.0,,,,,,1714.0,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.
,BAO_0000357,B,,,105.0,H,,Autocuration,2598.0,,,CHEMBL616921,1.0,,8.0,,,,,,1715.0,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand
,BAO_0000357,B,,,105.0,H,,Expert,6897.0,,,CHEMBL616922,1.0,,8.0,,,,,,1716.0,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor
,BAO_0000357,B,,,105.0,H,,Autocuration,6013.0,,,CHEMBL616923,1.0,,8.0,,,,,,1717.0,Binding affinity towards 5-hydroxytryptamine 1D receptor
,BAO_0000357,B,,,105.0,H,,Expert,5843.0,,,CHEMBL616924,1.0,,8.0,,,,,,1718.0,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor
,BAO_0000357,B,,,105.0,H,,Expert,14454.0,,,CHEMBL875909,1.0,,8.0,,,,,,1719.0,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand
,BAO_0000357,B,,,105.0,H,,Autocuration,14454.0,,,CHEMBL616925,1.0,,8.0,,,,,,1720.0,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined
,BAO_0000357,B,,,105.0,H,,Autocuration,14454.0,,,CHEMBL616926,1.0,,8.0,,,,,,1721.0,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined
,BAO_0000357,B,,,105.0,H,,Autocuration,15818.0,,,CHEMBL616927,1.0,,8.0,,,,,,1722.0,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor
,BAO_0000219,F,,CHO-K1,105.0,H,,Expert,13729.0,,,CHEMBL616928,1.0,,8.0,,,,,485.0,1723.0,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells
,BAO_0000219,B,In vitro,,105.0,D,Homo sapiens,Expert,6011.0,,9606.0,CHEMBL616929,1.0,,9.0,,,,,,1724.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells)
,BAO_0000357,B,,,105.0,D,Homo sapiens,Expert,4234.0,,9606.0,CHEMBL616930,1.0,,9.0,,,,,,1725.0,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor
,BAO_0000019,B,,,105.0,H,,Expert,17085.0,,,CHEMBL616931,1.0,,8.0,,,,,,1726.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor
,BAO_0000357,B,,,105.0,H,,Autocuration,3025.0,,,CHEMBL616932,1.0,,8.0,,,,,,1727.0,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand
,BAO_0000357,B,,,105.0,H,,Expert,15315.0,,,CHEMBL616933,1.0,,8.0,,,,,,1728.0,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor
,BAO_0000219,B,,,105.0,D,Homo sapiens,Expert,14214.0,,9606.0,CHEMBL616934,1.0,,9.0,,,,,,1729.0,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells
,BAO_0000357,B,,,105.0,D,Homo sapiens,Expert,3804.0,,9606.0,CHEMBL616935,1.0,,9.0,,,,,,1730.0,Binding affinity for human 5-hydroxytryptamine 1D receptor
,BAO_0000357,B,,,105.0,H,,Autocuration,16700.0,,,CHEMBL616936,1.0,,8.0,,,,,,1731.0,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity
,BAO_0000357,B,,,105.0,D,Homo sapiens,Expert,2391.0,,9606.0,CHEMBL616937,1.0,,9.0,,,,,,1732.0,Affinity for 5-hydroxytryptamine 1D receptor subtype
,BAO_0000357,B,,,105.0,D,Homo sapiens,Expert,4175.0,,9606.0,CHEMBL616938,1.0,,9.0,,,,,,1733.0,Binding affinity for human 5-hydroxytryptamine 1D receptor
,BAO_0000019,B,,,105.0,H,,Autocuration,17085.0,,,CHEMBL616939,1.0,,8.0,,,,,,1734.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor
,BAO_0000019,B,,,105.0,H,,Expert,17085.0,,,CHEMBL616940,1.0,,8.0,,,,,,1735.0,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined
,BAO_0000357,B,,,105.0,D,Homo sapiens,Expert,15926.0,,9606.0,CHEMBL616941,1.0,,9.0,,,,,,1736.0,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested
,BAO_0000219,B,,CHO-K1,105.0,H,,Autocuration,16312.0,,,CHEMBL616942,1.0,,8.0,,,,,485.0,1737.0,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested
,BAO_0000219,B,,CHO-K1,105.0,H,,Autocuration,16312.0,,,CHEMBL616943,1.0,,8.0,,,,,485.0,1738.0,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested
,BAO_0000219,B,,CHO,104802.0,H,,Autocuration,14956.0,,,CHEMBL616944,1.0,,4.0,,,,,449.0,1739.0,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells
,BAO_0000019,F,,,105.0,H,,Autocuration,3294.0,,,CHEMBL616945,1.0,,8.0,,,,,,1740.0,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT"
,BAO_0000357,B,,,105.0,H,,Autocuration,12861.0,,,CHEMBL616946,1.0,,8.0,,,,,,1741.0,Binding activity radioligand.
,BAO_0000019,B,,,105.0,H,,Autocuration,12861.0,,,CHEMBL616947,1.0,,8.0,,,,,,1742.0,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.
,BAO_0000219,B,,CHO-K1,105.0,H,,Expert,16312.0,,,CHEMBL616948,1.0,,8.0,,,,,485.0,1743.0,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor
,BAO_0000357,B,,,105.0,H,,Autocuration,5104.0,,,CHEMBL616851,1.0,,8.0,,,,,,1744.0,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor
,BAO_0000357,B,,,105.0,H,,Autocuration,5105.0,,,CHEMBL616852,1.0,,8.0,,,,,,1745.0,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor
,BAO_0000357,B,,,105.0,H,,Autocuration,14499.0,,,CHEMBL616853,1.0,,8.0,,,,,,1746.0,Measured as -log Ka on 5-hydroxytryptamine 1D receptor
,BAO_0000357,B,,,105.0,D,Homo sapiens,Expert,15926.0,,9606.0,CHEMBL616854,1.0,,9.0,,,,,,1747.0,Binding activity against human 5-hydroxytryptamine 1D receptor
,BAO_0000219,B,,CHO,105.0,D,Homo sapiens,Expert,4540.0,,9606.0,CHEMBL616855,1.0,,9.0,,,,,449.0,1748.0,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand
,BAO_0000219,B,,CHO,105.0,H,,Autocuration,15779.0,,,CHEMBL616856,1.0,,8.0,,,,,449.0,1749.0,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.
,BAO_0000219,B,,CHO,105.0,H,,Autocuration,15779.0,,,CHEMBL616857,1.0,,8.0,,,,,449.0,1750.0,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.
,BAO_0000357,B,,,105.0,H,,Autocuration,6166.0,,,CHEMBL616858,1.0,,8.0,,,,,,1751.0,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor
,BAO_0000219,B,,CHO,105.0,H,,Autocuration,15779.0,,,CHEMBL616859,1.0,,8.0,,,,,449.0,1752.0,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.
,BAO_0000219,B,,CHO,105.0,H,,Autocuration,15779.0,,,CHEMBL616860,1.0,,8.0,,,,,449.0,1753.0,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.
,BAO_0000219,B,,HEK293,105.0,H,,Autocuration,17451.0,,,CHEMBL616861,1.0,,8.0,,,,,722.0,1754.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand
,BAO_0000219,B,,HEK293,105.0,H,,Autocuration,17451.0,,,CHEMBL616541,1.0,,8.0,,,,,722.0,1755.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand
,BAO_0000219,B,,HEK293,105.0,H,,Autocuration,17451.0,,,CHEMBL616542,1.0,,8.0,,,,,722.0,1756.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined
,BAO_0000219,B,,CHO,105.0,H,,Autocuration,4199.0,,,CHEMBL616543,1.0,,8.0,,,,,449.0,1757.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand
,BAO_0000357,B,,,105.0,D,Homo sapiens,Expert,14875.0,,9606.0,CHEMBL616544,1.0,,9.0,,,,,,1758.0,Binding affinity for human 5-hydroxytryptamine 1D receptor
,BAO_0000219,B,,CHO,105.0,H,,Autocuration,15146.0,,,CHEMBL616545,1.0,,8.0,,,,,449.0,1759.0,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT
,BAO_0000357,B,,,105.0,H,,Autocuration,5213.0,,,CHEMBL616546,1.0,,8.0,,,,,,1760.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand
,BAO_0000219,B,,CHO,105.0,H,,Autocuration,14818.0,,,CHEMBL616547,1.0,,8.0,,,,,449.0,1761.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.
,BAO_0000219,B,,CHO,105.0,H,,Autocuration,4829.0,,,CHEMBL616548,1.0,,8.0,,,,,449.0,1762.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand"
,BAO_0000019,F,,,105.0,H,,Expert,14454.0,,,CHEMBL616549,1.0,,8.0,,,,,,1763.0,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM
,BAO_0000019,F,,,105.0,H,,Expert,14454.0,,,CHEMBL616550,1.0,,8.0,,,,,,1764.0,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM
,BAO_0000357,B,,,108.0,H,,Autocuration,5254.0,,,CHEMBL857066,1.0,,8.0,,,,,,1765.0,Binding affinity against 5-HT2C receptor
,BAO_0000357,B,,,108.0,H,,Autocuration,5254.0,,,CHEMBL616551,1.0,,8.0,,,,,,1766.0,Binding affinity against 5-hydroxytryptamine 1D receptor
,BAO_0000357,B,,,10577.0,H,,Autocuration,10639.0,,,CHEMBL616552,1.0,,8.0,,,,,,1767.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra
,BAO_0000019,F,,,10577.0,H,,Autocuration,10639.0,,,CHEMBL832876,1.0,,8.0,,,,,,1768.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra
,BAO_0000019,B,,,10577.0,H,,Expert,12352.0,,,CHEMBL616553,1.0,,8.0,,,,,,1769.0,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus"
,BAO_0000357,B,,,10577.0,H,,Autocuration,9098.0,,,CHEMBL616554,1.0,,8.0,,,,,,1770.0,Binding affinity towards 5-HT1B was determined
,BAO_0000019,B,,,10577.0,H,,Expert,14430.0,,,CHEMBL616555,1.0,,8.0,,,,,,1771.0,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT
,BAO_0000019,B,,,10577.0,H,,Expert,13657.0,,,CHEMBL616556,1.0,,8.0,,,,,,1772.0,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB"
,BAO_0000019,B,,,10577.0,H,,Autocuration,13657.0,,,CHEMBL616557,1.0,,8.0,,,,,,1773.0,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB."
,BAO_0000019,B,,,10577.0,H,,Expert,15854.0,,,CHEMBL616558,1.0,,8.0,,,,,,1774.0,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.
,BAO_0000019,B,,,10577.0,D,Rattus norvegicus,Expert,10639.0,,10116.0,CHEMBL616749,1.0,,9.0,,,,,,1775.0,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT
,BAO_0000357,B,,,10577.0,H,,Autocuration,10025.0,,,CHEMBL616750,1.0,,8.0,,,,,,1776.0,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM
,BAO_0000357,B,,,10577.0,H,,Autocuration,10025.0,,,CHEMBL616751,1.0,,8.0,,,,,,1777.0,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM"
,BAO_0000249,B,,,10577.0,H,,Autocuration,14286.0,,,CHEMBL616752,1.0,,8.0,,,,,,1778.0,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane
,BAO_0000019,B,,,10577.0,H,,Autocuration,3651.0,,,CHEMBL616753,1.0,,8.0,Striatum,,,2435.0,,1779.0,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%
,BAO_0000357,B,,,10577.0,D,Rattus norvegicus,Expert,14178.0,,10116.0,CHEMBL616754,1.0,,9.0,,,,,,1780.0,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor
,BAO_0000019,B,,,10577.0,H,,Autocuration,10639.0,,,CHEMBL616755,1.0,,8.0,,,,,,1781.0,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.
,BAO_0000019,B,,,10577.0,H,,Autocuration,13605.0,,,CHEMBL616756,1.0,,8.0,Striatum,,,2435.0,,1782.0,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum
,BAO_0000019,B,,,10577.0,H,,Autocuration,5834.0,,,CHEMBL616757,1.0,,8.0,Striatum,,,2435.0,,1783.0,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT
,BAO_0000357,B,,,10577.0,H,,Autocuration,10922.0,,,CHEMBL616758,1.0,,8.0,Striatum,,,2435.0,,1784.0,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue
,BAO_0000249,B,,,10577.0,H,,Autocuration,14286.0,,,CHEMBL616759,1.0,,8.0,,,,,,1785.0,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane
,BAO_0000357,B,,,10577.0,H,,Autocuration,11825.0,,,CHEMBL616760,1.0,,8.0,,,,,,1786.0,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M
,BAO_0000019,B,,,10577.0,H,,Autocuration,14826.0,,,CHEMBL616761,1.0,,8.0,Striatum,,,2435.0,,1787.0,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum
,BAO_0000019,B,,,10577.0,H,,Autocuration,9699.0,,,CHEMBL616762,1.0,,8.0,Striatum,,,2435.0,,1788.0,Binding affinity against 5-HT1B serotonin receptor in rat striatum
,BAO_0000019,B,,,10577.0,H,,Autocuration,14423.0,,,CHEMBL616763,1.0,,8.0,,,,,,1789.0,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex
,BAO_0000357,B,,,10577.0,H,,Expert,10062.0,,,CHEMBL872909,1.0,,8.0,,,,,,1790.0,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.
,BAO_0000357,B,,,10577.0,H,,Autocuration,10062.0,,,CHEMBL616764,1.0,,8.0,,,,,,1791.0,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor
,BAO_0000357,B,,,10577.0,D,Rattus norvegicus,Expert,12280.0,,10116.0,CHEMBL616765,1.0,,9.0,,,,,,1792.0,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor
,BAO_0000357,B,,,10577.0,H,,Autocuration,15412.0,,,CHEMBL616766,1.0,,8.0,Striatum,,,2435.0,,1793.0,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum
,BAO_0000357,B,,,10577.0,H,,Autocuration,15412.0,,,CHEMBL616767,1.0,,8.0,Striatum,,,2435.0,,1794.0,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.
,BAO_0000357,B,,,10577.0,H,,Autocuration,10062.0,,,CHEMBL616768,1.0,,8.0,,,,,,1795.0,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor
,BAO_0000357,B,,,10577.0,H,,Autocuration,11147.0,,,CHEMBL616769,1.0,,8.0,,,,,,1796.0,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand
,BAO_0000019,B,,,10577.0,H,,Autocuration,9547.0,,,CHEMBL616770,1.0,,8.0,,,,,,1797.0,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay
,BAO_0000019,B,,,10577.0,H,,Autocuration,10444.0,,,CHEMBL616771,1.0,,8.0,,,,,,1798.0,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.
,BAO_0000019,B,,,10577.0,H,,Autocuration,12469.0,,,CHEMBL616772,1.0,,8.0,Striatum,,,2435.0,,1799.0,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT
,BAO_0000019,B,,,10577.0,H,,Expert,9098.0,,,CHEMBL616773,1.0,,8.0,,,,,,1800.0,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.
,BAO_0000019,B,,,10577.0,H,,Autocuration,9098.0,,,CHEMBL616774,1.0,,8.0,,,,,,1801.0,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.
,BAO_0000357,B,,,10577.0,H,,Autocuration,9699.0,,,CHEMBL616775,1.0,,8.0,,,,,,1802.0,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor
,BAO_0000249,B,,,10577.0,H,,Autocuration,10394.0,,,CHEMBL616776,1.0,,8.0,,,,,,1803.0,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand
,BAO_0000357,B,,,10577.0,H,,Autocuration,12092.0,,,CHEMBL616777,1.0,,8.0,,,,,,1804.0,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.
,BAO_0000357,B,,,10577.0,H,,Autocuration,16700.0,,,CHEMBL616778,1.0,,8.0,,,,,,1805.0,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity
,BAO_0000249,B,,,10577.0,D,Rattus norvegicus,Expert,403.0,,10116.0,CHEMBL616779,1.0,,9.0,,,,,,1806.0,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand
,BAO_0000357,B,,,10577.0,D,Rattus norvegicus,Expert,12771.0,,10116.0,CHEMBL616780,1.0,,9.0,,,,,,1807.0,Binding affinity towards 5-hydroxytryptamine 1B receptor
,BAO_0000019,B,,,10577.0,H,,Autocuration,11642.0,,,CHEMBL616781,1.0,,8.0,,,,,,1808.0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex
,BAO_0000357,B,,,10577.0,H,,Autocuration,12953.0,,,CHEMBL616782,1.0,,8.0,,,,,,1809.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand
,BAO_0000357,B,,,10577.0,H,,Autocuration,12953.0,,,CHEMBL616783,1.0,,8.0,,,,,,1810.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.
,BAO_0000019,B,,,10577.0,H,,Expert,12953.0,,,CHEMBL616784,1.0,,8.0,Striatum,,,2435.0,,1811.0,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand
,BAO_0000357,B,,,10577.0,H,,Autocuration,12953.0,,,CHEMBL616785,1.0,,8.0,,,,,,1812.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM
,BAO_0000249,B,,,10577.0,H,,Autocuration,9737.0,,,CHEMBL857067,1.0,,8.0,Brain,,,955.0,,1813.0,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.
,BAO_0000019,B,,,10577.0,H,,Autocuration,9737.0,,,CHEMBL616786,1.0,,8.0,,,,,,1814.0,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand
,BAO_0000249,B,,,10577.0,H,,Autocuration,9737.0,,,CHEMBL616787,1.0,,8.0,Brain,,,955.0,,1815.0,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.
,BAO_0000357,B,,,10577.0,H,,Autocuration,12827.0,,,CHEMBL616788,1.0,,8.0,,,,,,1816.0,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine
,BAO_0000357,B,,,10577.0,H,,Autocuration,5033.0,,,CHEMBL616789,1.0,,8.0,,,,,,1817.0,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor
,BAO_0000019,B,,,10577.0,D,Rattus norvegicus,Expert,9786.0,,10116.0,CHEMBL616790,1.0,,9.0,,,,,,1818.0,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate
,BAO_0000357,B,,,10577.0,H,,Expert,13116.0,,,CHEMBL616791,1.0,,8.0,,,,,,1819.0,Binding affinity at 5-hydroxytryptamine 1B receptor
,BAO_0000019,B,,,10577.0,H,,Autocuration,16429.0,,,CHEMBL616792,1.0,,8.0,,,,,,1820.0,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand
,BAO_0000249,B,,,10577.0,D,Rattus norvegicus,Expert,12409.0,,10116.0,CHEMBL616793,1.0,,9.0,,,,,,1821.0,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol
,BAO_0000357,B,,,10577.0,H,,Autocuration,15194.0,,,CHEMBL616794,1.0,,8.0,,,,,,1822.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand
,BAO_0000357,B,,,10577.0,H,,Autocuration,15194.0,,,CHEMBL616795,1.0,,8.0,,,,,,1823.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.
,BAO_0000019,B,,,104686.0,H,,Autocuration,5486.0,,,CHEMBL616796,1.0,,4.0,,,,,,1824.0,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex
,BAO_0000357,B,,,106.0,H,,Autocuration,4639.0,,,CHEMBL616797,1.0,,8.0,,,,,,1825.0,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor
,BAO_0000249,B,,,106.0,H,,Autocuration,386.0,Brain membranes,,CHEMBL616798,1.0,,8.0,,,,,,1826.0,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes
,BAO_0000357,B,,,106.0,H,,Autocuration,2474.0,,,CHEMBL616799,1.0,,8.0,,,,,,1827.0,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand
,BAO_0000357,B,,,106.0,H,,Autocuration,6011.0,,,CHEMBL616800,1.0,,8.0,,,,,,1828.0,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration
,BAO_0000357,B,,,106.0,H,,Autocuration,5014.0,,,CHEMBL616801,1.0,,8.0,,,,,,1829.0,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor
,BAO_0000357,B,,,106.0,H,,Autocuration,17515.0,,,CHEMBL616802,1.0,,8.0,,,,,,1830.0,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM
,BAO_0000357,B,,,106.0,H,,Autocuration,4373.0,,,CHEMBL616803,1.0,,8.0,,,,,,1831.0,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined
,BAO_0000357,B,,,106.0,H,,Expert,1633.0,,,CHEMBL857068,1.0,,8.0,,,,,,1832.0,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.
,BAO_0000357,B,,,106.0,H,,Autocuration,1633.0,,,CHEMBL616804,1.0,,8.0,,,,,,1833.0,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.
,BAO_0000357,B,,,106.0,H,,Autocuration,4373.0,,,CHEMBL616805,1.0,,8.0,,,,,,1834.0,Binding affinity for 5-hydroxytryptamine 1B receptor was determined
,BAO_0000357,B,,,106.0,H,,Autocuration,4687.0,,,CHEMBL616806,1.0,,8.0,,,,,,1835.0,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor
,BAO_0000357,B,,,106.0,H,,Autocuration,11574.0,,,CHEMBL616807,1.0,,8.0,,,,,,1836.0,Binding affinity against 5-hydroxytryptamine 1B receptor
,BAO_0000357,B,,,106.0,H,,Autocuration,10321.0,,,CHEMBL616808,1.0,,8.0,,,,,,1837.0,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand
,BAO_0000357,B,,,106.0,H,,Autocuration,15527.0,,,CHEMBL616809,1.0,,8.0,,,,,,1838.0,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.
,BAO_0000357,B,,,106.0,H,,Autocuration,17200.0,,,CHEMBL616810,1.0,,8.0,,,,,,1839.0,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand
,BAO_0000224,B,,,104802.0,H,,Autocuration,14423.0,,,CHEMBL616811,1.0,,4.0,,,,,,1840.0,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.
,BAO_0000357,B,,,108.0,H,Bos taurus,Autocuration,5834.0,,9913.0,CHEMBL616812,1.0,,8.0,,,,,,1841.0,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine
,BAO_0000357,B,,,108.0,H,Sus scrofa,Autocuration,11473.0,,9823.0,CHEMBL616813,1.0,,8.0,,,,,,1842.0,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand
,BAO_0000357,B,,,108.0,H,Sus scrofa,Autocuration,11473.0,,9823.0,CHEMBL616814,1.0,,8.0,,,,,,1843.0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand
,BAO_0000357,B,,,108.0,H,Sus scrofa,Autocuration,10639.0,,9823.0,CHEMBL616815,1.0,,8.0,,,,,,1844.0,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand
,BAO_0000357,B,,,108.0,H,Sus scrofa,Autocuration,10639.0,,9823.0,CHEMBL616816,1.0,,8.0,,,,,,1845.0,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand
,BAO_0000357,B,,,108.0,H,Sus scrofa,Autocuration,14331.0,,9823.0,CHEMBL616817,1.0,,8.0,,,,,,1846.0,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined
,BAO_0000357,B,,,108.0,H,Sus scrofa,Autocuration,10796.0,,9823.0,CHEMBL616818,1.0,,8.0,,,,,,1847.0,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor
,BAO_0000357,B,,,108.0,H,Sus scrofa,Expert,9098.0,,9823.0,CHEMBL616819,1.0,,8.0,,,,,,1848.0,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.
,BAO_0000357,B,,,108.0,H,Sus scrofa,Expert,14331.0,,9823.0,CHEMBL616820,1.0,,8.0,,,,,,1849.0,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus
,BAO_0000019,B,,,108.0,H,Sus scrofa,Expert,11828.0,,9823.0,CHEMBL616821,1.0,,8.0,,,,,,1850.0,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor
,BAO_0000357,B,,,108.0,H,Sus scrofa,Autocuration,11866.0,,9823.0,CHEMBL616822,1.0,,8.0,,,,,,1851.0,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT
,BAO_0000019,B,,,108.0,H,Oryctolagus cuniculus,Autocuration,13047.0,,9986.0,CHEMBL616823,1.0,,8.0,,,,,,1852.0,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.
,BAO_0000357,B,,,12689.0,D,Rattus norvegicus,Autocuration,188.0,,10116.0,CHEMBL616824,1.0,,9.0,,,,,,1853.0,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity
,BAO_0000357,B,,,12689.0,D,Rattus norvegicus,Autocuration,11825.0,,10116.0,CHEMBL616825,1.0,,9.0,,,,,,1854.0,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M
,BAO_0000357,B,,,12689.0,D,Rattus norvegicus,Autocuration,11825.0,,10116.0,CHEMBL616826,1.0,,9.0,,,,,,1855.0,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M
,BAO_0000019,B,,,12689.0,D,Rattus norvegicus,Expert,11624.0,,10116.0,CHEMBL616827,1.0,,9.0,,,,,,1856.0,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand
,BAO_0000357,B,,,12689.0,D,Rattus norvegicus,Autocuration,11139.0,,10116.0,CHEMBL616828,1.0,,9.0,,,,,,1857.0,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay
,BAO_0000357,B,,,12689.0,D,Rattus norvegicus,Autocuration,11147.0,,10116.0,CHEMBL616829,1.0,,9.0,,,,,,1858.0,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand
,BAO_0000019,B,,,12689.0,D,Rattus norvegicus,Autocuration,10444.0,,10116.0,CHEMBL616830,1.0,,9.0,,,,,,1859.0,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.
,BAO_0000357,B,,,12689.0,D,Rattus norvegicus,Expert,11624.0,,10116.0,CHEMBL616831,1.0,,9.0,,,,,,1860.0,Binding affinity against 5-hydroxytryptamine 1C receptor
,BAO_0000019,B,,,12689.0,D,Rattus norvegicus,Autocuration,11662.0,,10116.0,CHEMBL616832,1.0,,9.0,,,,,,1861.0,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand"
,BAO_0000019,B,,,12689.0,D,Rattus norvegicus,Autocuration,11662.0,,10116.0,CHEMBL616833,1.0,,9.0,,,,,,1862.0,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand"
,BAO_0000019,B,,,12689.0,D,Rattus norvegicus,Expert,11662.0,,10116.0,CHEMBL616834,1.0,,9.0,,,,,,1863.0,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand"
,BAO_0000019,B,,,12689.0,D,Rattus norvegicus,Autocuration,11662.0,,10116.0,CHEMBL829595,1.0,,9.0,,,,,,1864.0,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand"
,BAO_0000357,B,,,12689.0,D,Rattus norvegicus,Autocuration,9098.0,,10116.0,CHEMBL616835,1.0,,9.0,,,,,,1865.0,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.
,BAO_0000249,B,,,12689.0,D,Rattus norvegicus,Autocuration,10394.0,,10116.0,CHEMBL872910,1.0,,9.0,,,,,,1866.0,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand
,BAO_0000357,B,,,12689.0,H,,Expert,11933.0,,,CHEMBL616836,1.0,,8.0,,,,,,1867.0,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand
,BAO_0000357,B,,,12689.0,D,Rattus norvegicus,Autocuration,12092.0,,10116.0,CHEMBL616837,1.0,,9.0,,,,,,1868.0,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.
,BAO_0000019,B,,,12689.0,D,Rattus norvegicus,Autocuration,12253.0,,10116.0,CHEMBL616466,1.0,,9.0,,,,,,1869.0,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex
,BAO_0000219,B,,HEK293,12689.0,D,Rattus norvegicus,Autocuration,12253.0,,10116.0,CHEMBL616467,1.0,,9.0,,,,,722.0,1870.0,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells
,BAO_0000357,B,,,108.0,H,,Autocuration,1558.0,,,CHEMBL616468,1.0,,8.0,,,,,,1871.0,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor
,BAO_0000357,B,,,108.0,H,,Autocuration,2474.0,,,CHEMBL616469,1.0,,8.0,,,,,,1872.0,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand
,BAO_0000357,B,,,108.0,H,,Autocuration,2474.0,,,CHEMBL616470,1.0,,8.0,,,,,,1873.0,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand
,BAO_0000357,B,,,12689.0,H,,Autocuration,11574.0,,,CHEMBL616471,1.0,,8.0,,,,,,1874.0,Binding affinity against 5-hydroxytryptamine 1C receptor
,BAO_0000357,B,,,12689.0,H,,Autocuration,1558.0,,,CHEMBL616472,1.0,,8.0,,,,,,1875.0,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor
,BAO_0000357,B,,,12689.0,H,,Autocuration,13944.0,,,CHEMBL616473,1.0,,8.0,,,,,,1876.0,Binding affinity against 5-hydroxytryptamine 1C receptor
,BAO_0000357,B,,,12689.0,H,,Autocuration,13033.0,,,CHEMBL616474,1.0,,8.0,,,,,,1877.0,Binding affinity against serotonergic 5-HT1c receptor
,BAO_0000357,B,,,12689.0,H,,Autocuration,10321.0,,,CHEMBL616475,1.0,,8.0,,,,,,1878.0,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand
,BAO_0000357,B,,,12689.0,H,,Autocuration,11866.0,,,CHEMBL616476,1.0,,8.0,,,,,,1879.0,Binding affinity for 5-hydroxytryptamine 1C receptor was determined
,BAO_0000019,B,,,105.0,H,Oryctolagus cuniculus,Autocuration,14454.0,,9986.0,CHEMBL616477,1.0,,8.0,,,,,,1880.0,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV)
,BAO_0000224,B,,,104686.0,H,,Autocuration,11574.0,,,CHEMBL616478,1.0,,4.0,,,,,,1881.0,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.
,BAO_0000224,B,,,104686.0,H,,Autocuration,11574.0,,,CHEMBL616479,1.0,,4.0,,,,,,1882.0,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.
,BAO_0000019,B,,,104686.0,H,,Autocuration,13631.0,,,CHEMBL616480,1.0,,4.0,,,,,,1883.0,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand
,BAO_0000019,B,,,104686.0,D,Rattus norvegicus,Autocuration,9630.0,,10116.0,CHEMBL616481,1.0,,5.0,,,,,,1884.0,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein
,BAO_0000249,B,,,104686.0,D,Rattus norvegicus,Autocuration,8822.0,,10116.0,CHEMBL616482,1.0,,5.0,,,,,,1885.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes
,BAO_0000221,B,,,104686.0,D,Rattus norvegicus,Autocuration,9064.0,,10116.0,CHEMBL884713,1.0,,5.0,Brain,,,955.0,,1886.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol
,BAO_0000224,B,,,104686.0,H,,Autocuration,8868.0,,,CHEMBL616483,1.0,,4.0,,,,,,1887.0,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay
,BAO_0000224,B,,,104686.0,H,,Autocuration,9064.0,,,CHEMBL616484,1.0,,4.0,,,,,,1888.0,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol
,BAO_0000019,B,,,104686.0,H,,Autocuration,9806.0,,,CHEMBL616485,1.0,,4.0,,,,,,1889.0,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.
,BAO_0000224,B,,,104686.0,H,,Autocuration,9098.0,,,CHEMBL616486,1.0,,4.0,,,,,,1890.0,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined
,BAO_0000224,B,,,104686.0,H,,Autocuration,8868.0,,,CHEMBL616487,1.0,,4.0,,,,,,1891.0,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay
,BAO_0000224,B,,,104686.0,H,,Autocuration,12765.0,,,CHEMBL616488,1.0,,4.0,,,,,,1892.0,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.
,BAO_0000019,B,,,104686.0,H,,Autocuration,11049.0,,,CHEMBL616489,1.0,,4.0,,,,,,1893.0,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.
,BAO_0000019,B,,,104686.0,H,,Autocuration,11049.0,,,CHEMBL616490,1.0,,4.0,,,,,,1894.0,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.
,BAO_0000019,B,,,104686.0,H,,Autocuration,11049.0,,,CHEMBL616491,1.0,,4.0,,,,,,1895.0,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined
,BAO_0000019,B,,,104686.0,H,,Autocuration,11049.0,,,CHEMBL616492,1.0,,4.0,,,,,,1896.0,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined
,BAO_0000019,B,,,104686.0,H,,Autocuration,11049.0,,,CHEMBL616493,1.0,,4.0,,,,,,1897.0,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.
,BAO_0000019,B,,,104686.0,H,,Autocuration,11473.0,,,CHEMBL616494,1.0,,4.0,,,,,,1898.0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand
,BAO_0000019,B,,,104686.0,H,,Autocuration,11473.0,,,CHEMBL616495,1.0,,4.0,,,,,,1899.0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand
,BAO_0000019,B,,,104686.0,H,,Autocuration,3086.0,,,CHEMBL616496,1.0,,4.0,,,,,,1900.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex
,BAO_0000019,B,,,104686.0,H,,Autocuration,11049.0,,,CHEMBL616497,1.0,,4.0,,,,,,1901.0,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.
,BAO_0000019,B,,,104686.0,H,,Autocuration,11049.0,,,CHEMBL616498,1.0,,4.0,,,,,,1902.0,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.
,BAO_0000019,B,,,104686.0,H,,Autocuration,10639.0,,,CHEMBL616499,1.0,,4.0,,,,,,1903.0,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand
,BAO_0000019,B,,,104686.0,H,,Autocuration,10922.0,,,CHEMBL616500,1.0,,4.0,,,,,,1904.0,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.
,BAO_0000221,B,,,104686.0,D,Rattus norvegicus,Autocuration,9064.0,,10116.0,CHEMBL616501,1.0,,5.0,Brain,,,955.0,,1905.0,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol
,BAO_0000221,B,,,104686.0,H,,Autocuration,10748.0,,,CHEMBL616502,1.0,,4.0,Brain,,,955.0,,1906.0,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.
,BAO_0000249,B,,,104686.0,H,,Autocuration,11614.0,Membranes,,CHEMBL884529,1.0,,4.0,,,,,,1907.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.
,BAO_0000249,B,,,104686.0,H,,Autocuration,11615.0,Membranes,,CHEMBL616503,1.0,,4.0,,,,,,1908.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes
,BAO_0000224,B,,,104686.0,H,,Autocuration,11615.0,,,CHEMBL616964,1.0,,4.0,,,,,,1909.0,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor
,BAO_0000249,B,,,104686.0,H,,Autocuration,11614.0,Membranes,,CHEMBL616965,1.0,,4.0,,,,,,1910.0,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.
,BAO_0000224,B,,,104686.0,H,,Autocuration,11702.0,,,CHEMBL616966,1.0,,4.0,,,,,,1911.0,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.
,BAO_0000224,B,,,104686.0,H,,Autocuration,11702.0,,,CHEMBL616967,1.0,,4.0,,,,,,1912.0,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested
,BAO_0000224,B,,,104686.0,D,Rattus norvegicus,Autocuration,11702.0,,10116.0,CHEMBL616968,1.0,,5.0,,,,,,1913.0,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104686.0,H,,Autocuration,11702.0,,,CHEMBL616969,1.0,,4.0,,,,,,1914.0,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested
,BAO_0000019,B,,,104686.0,H,,Autocuration,13346.0,,,CHEMBL884530,1.0,,4.0,,,,,,1915.0,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.
,BAO_0000224,B,,,104686.0,H,,Autocuration,10025.0,,,CHEMBL616970,1.0,,4.0,,,,,,1916.0,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104686.0,H,,Autocuration,10025.0,,,CHEMBL616971,1.0,,4.0,,,,,,1917.0,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM
,BAO_0000224,B,,,104686.0,H,,Autocuration,10025.0,,,CHEMBL616972,1.0,,4.0,,,,,,1918.0,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM"
,BAO_0000224,B,,,104686.0,H,,Autocuration,9036.0,,,CHEMBL616973,1.0,,4.0,,,,,,1919.0,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone
,BAO_0000224,B,,,104686.0,H,,Autocuration,9036.0,,,CHEMBL616974,1.0,,4.0,,,,,,1920.0,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive
,BAO_0000019,B,,,104686.0,H,,Autocuration,9161.0,,,CHEMBL616975,1.0,,4.0,,,,,,1921.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.
,BAO_0000019,B,,,104686.0,H,,Autocuration,12304.0,,,CHEMBL616976,1.0,,4.0,,,,,,1922.0,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex
,BAO_0000224,B,,,104686.0,H,,Autocuration,13276.0,,,CHEMBL616977,1.0,,4.0,,,,,,1923.0,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.
,BAO_0000224,B,,,104686.0,H,,Autocuration,11825.0,,,CHEMBL616978,1.0,,4.0,,,,,,1924.0,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M
,BAO_0000224,B,,,104686.0,H,,Autocuration,12443.0,,,CHEMBL616979,1.0,,4.0,,,,,,1925.0,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin
,BAO_0000224,B,,,104686.0,H,,Autocuration,13830.0,,,CHEMBL616980,1.0,,4.0,,,,,,1926.0,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor
,BAO_0000249,B,,,104686.0,H,,Autocuration,9592.0,Membranes,,CHEMBL616981,1.0,,4.0,,,,,,1927.0,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes
,BAO_0000249,B,,,104686.0,H,,Autocuration,9592.0,Membranes,,CHEMBL616982,1.0,,4.0,,,,,,1928.0,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested
,BAO_0000224,B,,,104686.0,H,,Autocuration,10881.0,,,CHEMBL616983,1.0,,4.0,,,,,,1929.0,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.
,BAO_0000019,B,,,104686.0,H,,Autocuration,13605.0,,,CHEMBL616984,1.0,,4.0,,,,,,1930.0,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex
,BAO_0000224,B,,,104686.0,D,Rattus norvegicus,Autocuration,11624.0,,10116.0,CHEMBL616985,1.0,,5.0,,,,,,1931.0,Inhibitory activity against 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104686.0,H,,Autocuration,4101.0,,,CHEMBL616986,1.0,,4.0,,,,,,1932.0,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin
,BAO_0000224,B,,,104686.0,H,,Autocuration,4101.0,,,CHEMBL616987,1.0,,4.0,,,,,,1933.0,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin
,BAO_0000019,B,,,104686.0,H,,Autocuration,15360.0,,,CHEMBL616988,1.0,,4.0,,,,,,1934.0,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat
,BAO_0000019,B,,,104686.0,H,,Autocuration,11576.0,,,CHEMBL617243,1.0,,4.0,,,,,,1935.0,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex
,BAO_0000019,B,,,104686.0,H,,Autocuration,5834.0,,,CHEMBL617244,1.0,,4.0,,,,,,1936.0,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone
,BAO_0000219,B,,CHO-K1,104686.0,D,Rattus norvegicus,Autocuration,2395.0,,10116.0,CHEMBL617245,1.0,,5.0,,,,,485.0,1937.0,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells
,BAO_0000249,B,,,104686.0,H,,Autocuration,11965.0,Membranes,,CHEMBL617246,1.0,,4.0,,,,,,1938.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes
,BAO_0000224,B,,,104686.0,H,,Autocuration,3967.0,,,CHEMBL617546,1.0,,4.0,,,,,,1939.0,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats)
,BAO_0000249,B,,,104686.0,H,,Autocuration,11130.0,Brain membranes,,CHEMBL617547,1.0,,4.0,,,,,,1940.0,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro)
,BAO_0000219,B,In vitro,,104686.0,H,,Autocuration,13427.0,,,CHEMBL617548,1.0,,4.0,,,,,,1941.0,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.
,BAO_0000224,B,,,104686.0,H,,Autocuration,9443.0,,,CHEMBL617549,1.0,,4.0,,,,,,1942.0,Binding affinity towards 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104686.0,H,,Autocuration,9443.0,,,CHEMBL617550,1.0,,4.0,,,,,,1943.0,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration
,BAO_0000224,B,,,104686.0,H,,Autocuration,11825.0,,,CHEMBL617551,1.0,,4.0,,,,,,1944.0,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M
,BAO_0000249,B,,,104686.0,H,,Autocuration,12120.0,Membranes,,CHEMBL617552,1.0,,4.0,,,,,,1945.0,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M
,BAO_0000249,B,,,104686.0,H,,Autocuration,12120.0,Membranes,,CHEMBL617553,1.0,,4.0,,,,,,1946.0,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.
,BAO_0000019,F,,,104686.0,H,,Autocuration,11963.0,,,CHEMBL617554,1.0,,4.0,Thoracic aorta,,,1515.0,,1947.0,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta
,BAO_0000019,B,,,104686.0,H,,Autocuration,9069.0,,,CHEMBL617555,1.0,,4.0,,,,,,1948.0,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104686.0,H,,Autocuration,8868.0,,,CHEMBL617556,1.0,,4.0,,,,,,1949.0,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis
,BAO_0000357,B,,,10624.0,H,,Autocuration,17200.0,,,CHEMBL617557,1.0,,8.0,,,,,,1950.0,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand
,BAO_0000357,B,,,10624.0,H,,Autocuration,17200.0,,,CHEMBL617558,1.0,,8.0,,,,,,1951.0,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand
,BAO_0000357,B,,,17106.0,H,,Expert,13969.0,,,CHEMBL617559,1.0,,8.0,,,,,,1952.0,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand
,BAO_0000357,B,,,17106.0,D,,Expert,13392.0,,,CHEMBL617560,1.0,,9.0,,,,,,1953.0,Binding affinity for 5-hydroxytryptamine 1D receptor
,BAO_0000249,B,,,17106.0,H,,Autocuration,1742.0,,,CHEMBL617561,1.0,,8.0,,,,,,1954.0,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes
,BAO_0000249,B,,,17106.0,H,,Autocuration,1742.0,,,CHEMBL617562,1.0,,8.0,,,,,,1955.0,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes
,BAO_0000357,B,,,17106.0,H,,Autocuration,14331.0,,,CHEMBL617563,1.0,,8.0,Striatum,,,2435.0,,1956.0,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex
,BAO_0000019,F,,,17106.0,H,,Autocuration,12861.0,,,CHEMBL617564,1.0,,8.0,,,,,,1957.0,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor
,BAO_0000019,B,,,17106.0,H,,Expert,12861.0,,,CHEMBL617565,1.0,,8.0,,,,,,1958.0,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand
,BAO_0000357,B,,,17106.0,H,,Autocuration,12861.0,,,CHEMBL856076,1.0,,8.0,,,,,,1959.0,Binding activity radioligand.
,BAO_0000019,B,,,17106.0,H,,Autocuration,12861.0,,,CHEMBL617566,1.0,,8.0,,,,,,1960.0,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.
,BAO_0000019,B,,,17106.0,H,,Expert,12861.0,,,CHEMBL875911,1.0,,8.0,,,,,,1961.0,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.
,BAO_0000019,B,,,17106.0,H,,Autocuration,12861.0,,,CHEMBL617567,1.0,,8.0,,,,,,1962.0,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available
,BAO_0000249,B,,,17106.0,H,,Autocuration,675.0,,,CHEMBL617568,1.0,,8.0,,,,,,1963.0,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes
,BAO_0000019,B,,,17106.0,H,,Expert,12490.0,,,CHEMBL617569,1.0,,8.0,,,,,,1964.0,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane
,BAO_0000249,B,,,17106.0,H,,Expert,11828.0,,,CHEMBL617570,1.0,,8.0,,,,,,1965.0,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane
,BAO_0000357,B,,,17106.0,H,,Autocuration,11866.0,,,CHEMBL617571,1.0,,8.0,,,,,,1966.0,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT
,BAO_0000357,B,,,105.0,H,Sus scrofa,Autocuration,773.0,,9823.0,CHEMBL617572,1.0,,8.0,,,,,,1967.0,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate
,BAO_0000357,B,,,105.0,H,Oryctolagus cuniculus,Expert,13047.0,,9986.0,CHEMBL617573,1.0,,8.0,,,,,,1968.0,The compound was tested for intrinsic activity against 5-HT1D receptor
,BAO_0000019,B,,,105.0,H,Oryctolagus cuniculus,Autocuration,13047.0,,9986.0,CHEMBL617574,1.0,,8.0,,,,,,1969.0,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.
,BAO_0000357,B,,,105.0,H,Oryctolagus cuniculus,Expert,13047.0,,9986.0,CHEMBL617575,1.0,,8.0,,,,,,1970.0,The compound was tested for binding affinity against 5-HT1D receptor
,BAO_0000357,B,,,10578.0,H,,Autocuration,188.0,,,CHEMBL617576,1.0,,8.0,,,,,,1971.0,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity
,BAO_0000019,F,,,10578.0,H,,Autocuration,10639.0,,,CHEMBL617577,1.0,,8.0,,,,,,1972.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra
,BAO_0000019,F,,,10578.0,H,,Autocuration,12438.0,,,CHEMBL617578,1.0,,8.0,,,,,,1973.0,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor
,BAO_0000357,B,,,10578.0,H,,Autocuration,12438.0,,,CHEMBL617579,1.0,,8.0,,,,,,1974.0,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor
,BAO_0000019,B,,,10578.0,H,,Expert,15854.0,,,CHEMBL617580,1.0,,8.0,,,,,,1975.0,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.
,BAO_0000249,B,,,10578.0,H,,Autocuration,10394.0,,,CHEMBL617581,1.0,,8.0,,,,,,1976.0,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand
,BAO_0000357,B,,,10578.0,H,,Autocuration,12092.0,,,CHEMBL617582,1.0,,8.0,,,,,,1977.0,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.
,BAO_0000019,B,,,10578.0,H,,Expert,3389.0,,,CHEMBL617583,1.0,,8.0,,,,,,1978.0,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.
,BAO_0000357,B,,,105.0,H,,Autocuration,6011.0,,,CHEMBL617584,1.0,,8.0,,,,,,1979.0,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration
,BAO_0000357,B,,,105.0,H,,Autocuration,4639.0,,,CHEMBL617585,1.0,,8.0,,,,,,1980.0,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor
,BAO_0000357,B,,,105.0,H,,Autocuration,2474.0,,,CHEMBL875912,1.0,,8.0,,,,,,1981.0,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand
,BAO_0000357,B,,,105.0,H,,Autocuration,5014.0,,,CHEMBL617586,1.0,,8.0,,,,,,1982.0,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor
,BAO_0000357,B,,,105.0,H,,Autocuration,17515.0,,,CHEMBL617587,1.0,,8.0,,,,,,1983.0,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM
,BAO_0000357,B,,,105.0,H,,Autocuration,11866.0,,,CHEMBL617588,1.0,,8.0,,,,,,1984.0,Binding affinity for 5-hydroxytryptamine 1D receptor was determined
,BAO_0000357,B,,,105.0,H,,Autocuration,4687.0,,,CHEMBL857980,1.0,,8.0,,,,,,1985.0,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor
,BAO_0000357,B,,,105.0,H,,Autocuration,12146.0,,,CHEMBL617589,1.0,,8.0,,,,,,1986.0,Tested against 5-hydroxytryptamine 1D receptor
,BAO_0000357,B,,,105.0,H,,Autocuration,10321.0,,,CHEMBL617590,1.0,,8.0,,,,,,1987.0,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand
,BAO_0000219,B,,HEK293,105.0,H,,Autocuration,13267.0,,,CHEMBL617591,1.0,,8.0,,,,,722.0,1988.0,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand
,BAO_0000357,B,,,105.0,D,Homo sapiens,Expert,1274.0,,9606.0,CHEMBL617592,1.0,,9.0,,,,,,1989.0,Binding affinity against 5-Hydroxytryptamine 1D receptor
,BAO_0000357,B,,,105.0,H,,Autocuration,15250.0,,,CHEMBL617593,1.0,,8.0,,,,,,1990.0,
,BAO_0000219,B,,CHO-K1,106.0,H,,Autocuration,13706.0,,,CHEMBL617594,1.0,,8.0,,,,,485.0,1991.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.
,BAO_0000219,B,,CHO-K1,105.0,H,,Autocuration,13706.0,,,CHEMBL617595,1.0,,8.0,,,,,485.0,1992.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.
,BAO_0000219,B,,HEK293,105.0,H,,Autocuration,13706.0,,,CHEMBL617596,1.0,,8.0,,,,,722.0,1993.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.
,BAO_0000219,B,,HEK293,105.0,H,,Autocuration,13706.0,,,CHEMBL617597,1.0,,8.0,,,,,722.0,1994.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested
,BAO_0000019,B,,,105.0,H,,Autocuration,13047.0,,,CHEMBL617598,1.0,,8.0,,,,,,1995.0,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.
,BAO_0000357,B,,,105.0,H,,Autocuration,13366.0,,,CHEMBL872916,1.0,,8.0,,,,,,1996.0,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human
,BAO_0000357,B,,,105.0,H,,Expert,13366.0,,,CHEMBL617599,1.0,,8.0,,,,,,1997.0,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.
,BAO_0000357,B,,,105.0,H,,Autocuration,1558.0,,,CHEMBL617091,1.0,,8.0,,,,,,1998.0,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined
,BAO_0000219,B,,CHO-K1,105.0,H,,Expert,12902.0,,,CHEMBL617092,1.0,,8.0,,,,,485.0,1999.0,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand."
,BAO_0000219,B,,CHO-K1,105.0,H,,Autocuration,13706.0,,,CHEMBL617093,1.0,,8.0,,,,,485.0,2000.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.
,BAO_0000019,F,,,105.0,H,,Autocuration,13706.0,,,CHEMBL617094,1.0,,8.0,,,,,,2001.0,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.
,BAO_0000019,F,,,105.0,H,,Autocuration,13706.0,,,CHEMBL617095,1.0,,8.0,,,,,,2002.0,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.
,BAO_0000019,F,,,105.0,H,,Autocuration,14251.0,,,CHEMBL617096,1.0,,8.0,,,,,,2003.0,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.
,BAO_0000019,F,,,105.0,H,,Autocuration,14251.0,,,CHEMBL617097,1.0,,8.0,,,,,,2004.0,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.
,BAO_0000019,F,,,105.0,H,,Autocuration,14251.0,,,CHEMBL617098,1.0,,8.0,,,,,,2005.0,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.
,BAO_0000357,B,,,105.0,H,,Autocuration,13313.0,,,CHEMBL617301,1.0,,8.0,,,,,,2006.0,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand
,BAO_0000357,B,,,105.0,H,,Autocuration,13313.0,,,CHEMBL617302,1.0,,8.0,,,,,,2007.0,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand
,BAO_0000357,B,,,105.0,H,,Autocuration,13366.0,,,CHEMBL617303,1.0,,8.0,,,,,,2008.0,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha
,BAO_0000357,B,,,105.0,H,,Expert,13051.0,,,CHEMBL617304,1.0,,8.0,,,,,,2009.0,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha
,BAO_0000219,B,,CHO,105.0,H,,Expert,12903.0,,,CHEMBL617305,1.0,,8.0,,,,,449.0,2010.0,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand"
,BAO_0000219,B,,,105.0,D,Homo sapiens,Autocuration,12469.0,,9606.0,CHEMBL617306,1.0,,9.0,,,,,,2011.0,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT
,BAO_0000357,B,,,17106.0,H,,Autocuration,5619.0,,,CHEMBL617307,1.0,,8.0,,,,,,2012.0,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay
,BAO_0000019,B,,,105.0,H,Oryctolagus cuniculus,Autocuration,13047.0,,9986.0,CHEMBL617308,1.0,,8.0,,,,,,2013.0,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.
,BAO_0000357,B,,,105.0,H,,Autocuration,16633.0,,,CHEMBL617309,1.0,,8.0,,,,,,2014.0,Binding affinities against 5-hydroxytryptamine 1D receptor alpha
,BAO_0000357,B,,,105.0,H,,Autocuration,16633.0,,,CHEMBL617310,1.0,,8.0,,,,,,2015.0,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha
,BAO_0000357,B,,,105.0,H,,Autocuration,16633.0,,,CHEMBL617311,1.0,,8.0,,,,,,2016.0,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha
,BAO_0000357,B,,,105.0,H,,Autocuration,16633.0,,,CHEMBL617312,1.0,,8.0,,,,,,2017.0,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand
,BAO_0000357,B,,,105.0,H,,Autocuration,3269.0,,,CHEMBL617313,1.0,,8.0,,,,,,2018.0,Affinity against 5-hydroxytryptamine 1D receptor alpha
,BAO_0000357,B,,,105.0,H,,Expert,12409.0,,,CHEMBL617314,1.0,,8.0,,,,,,2019.0,Binding affinity against 5-hydroxytryptamine 1D receptor alpha
,BAO_0000019,F,,,106.0,H,,Autocuration,13706.0,,,CHEMBL617315,1.0,,8.0,,,,,,2020.0,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.
,BAO_0000219,B,,HEK293,106.0,H,,Autocuration,13706.0,,,CHEMBL617316,1.0,,8.0,,,,,722.0,2021.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.
,BAO_0000219,B,,HEK293,106.0,H,,Autocuration,13706.0,,,CHEMBL617317,1.0,,8.0,,,,,722.0,2022.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested
,BAO_0000219,B,,CHO,106.0,H,,Autocuration,12903.0,,,CHEMBL617318,1.0,,8.0,,,,,449.0,2023.0,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand"
,BAO_0000019,B,,,106.0,H,,Autocuration,13047.0,,,CHEMBL617319,1.0,,8.0,,,,,,2024.0,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.
,BAO_0000357,B,,,106.0,D,,Expert,13366.0,,,CHEMBL617320,1.0,,9.0,,,,,,2025.0,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta
,BAO_0000357,B,,,106.0,D,,Expert,13366.0,,,CHEMBL617321,1.0,,9.0,,,,,,2026.0,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta
,BAO_0000357,B,,,106.0,D,,Expert,13366.0,,,CHEMBL617322,1.0,,9.0,,,,,,2027.0,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta
,BAO_0000357,B,,,106.0,H,,Autocuration,13366.0,,,CHEMBL616862,1.0,,8.0,,,,,,2028.0,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand
,BAO_0000357,B,,,106.0,H,,Autocuration,13366.0,,,CHEMBL616863,1.0,,8.0,,,,,,2029.0,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand
,BAO_0000219,B,,CHO,106.0,H,,Autocuration,12469.0,,,CHEMBL616864,1.0,,8.0,,,,,449.0,2030.0,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT
,BAO_0000219,B,,CHO-K1,106.0,H,,Autocuration,13706.0,,,CHEMBL616865,1.0,,8.0,,,,,485.0,2031.0,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.
,BAO_0000219,B,,CHO-K1,106.0,H,,Autocuration,13706.0,,,CHEMBL616866,1.0,,8.0,,,,,485.0,2032.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.
,BAO_0000019,F,,,106.0,H,,Autocuration,13706.0,,,CHEMBL616867,1.0,,8.0,,,,,,2033.0,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.
,BAO_0000219,B,,CHO-K1,106.0,H,,Expert,12902.0,,,CHEMBL616868,1.0,,8.0,,,,,485.0,2034.0,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand."
,BAO_0000357,B,,,105.0,H,,Expert,13051.0,,,CHEMBL616869,1.0,,8.0,,,,,,2035.0,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta
,BAO_0000219,B,,CHO,106.0,H,,Expert,12903.0,,,CHEMBL616870,1.0,,8.0,,,,,449.0,2036.0,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand"
,BAO_0000219,F,,CHO-K1,105.0,H,,Autocuration,1558.0,,,CHEMBL616871,1.0,,8.0,,,,,485.0,2037.0,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55
,BAO_0000219,F,,CHO-K1,105.0,H,,Autocuration,1558.0,,,CHEMBL616872,1.0,,8.0,,,,,485.0,2038.0,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0
,BAO_0000219,F,,CHO-K1,105.0,H,,Autocuration,1558.0,,,CHEMBL616873,1.0,,8.0,,,,,485.0,2039.0,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5
,BAO_0000219,F,,CHO-K1,105.0,H,,Autocuration,1558.0,,,CHEMBL616838,1.0,,8.0,,,,,485.0,2040.0,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70
,BAO_0000357,B,,,105.0,H,,Autocuration,1558.0,,,CHEMBL616839,1.0,,8.0,,,,,,2041.0,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined
,BAO_0000019,B,,,106.0,H,Oryctolagus cuniculus,Autocuration,13047.0,,9986.0,CHEMBL616840,1.0,,8.0,,,,,,2042.0,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.
,BAO_0000357,B,,,105.0,H,,Autocuration,13313.0,,,CHEMBL616841,1.0,,8.0,,,,,,2043.0,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand
,BAO_0000357,B,,,105.0,H,,Autocuration,13313.0,,,CHEMBL616842,1.0,,8.0,,,,,,2044.0,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand
,BAO_0000357,B,,,105.0,H,,Expert,12409.0,,,CHEMBL857976,1.0,,8.0,,,,,,2045.0,Binding affinity against 5-hydroxytryptamine 1D receptor beta
,BAO_0000219,B,,CHO,10618.0,H,,Autocuration,15250.0,,,CHEMBL616843,1.0,,8.0,,,,,449.0,2046.0,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells
,BAO_0000357,B,,,10618.0,D,Homo sapiens,Expert,1348.0,,9606.0,CHEMBL616844,1.0,,9.0,,,,,,2047.0,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype
,BAO_0000357,B,,,10618.0,H,,Autocuration,1348.0,,,CHEMBL616845,1.0,,8.0,,,,,,2048.0,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available
,BAO_0000357,B,,,10618.0,D,Homo sapiens,Expert,4234.0,,9606.0,CHEMBL616846,1.0,,9.0,,,,,,2049.0,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor
,BAO_0000357,B,,,10618.0,H,,Autocuration,16209.0,,,CHEMBL616847,1.0,,8.0,,,,,,2050.0,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand
,BAO_0000019,B,,,10618.0,H,,Autocuration,10444.0,,,CHEMBL616848,1.0,,8.0,,,,,,2051.0,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate
,BAO_0000357,B,,,10618.0,H,,Autocuration,3935.0,,,CHEMBL616849,1.0,,8.0,,,,,,2052.0,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor
,BAO_0000357,B,,,10618.0,H,,Autocuration,15818.0,,,CHEMBL872911,1.0,,8.0,,,,,,2053.0,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor
,BAO_0000019,B,,,10618.0,H,,Autocuration,17085.0,,,CHEMBL616850,1.0,,8.0,,,,,,2054.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor
,BAO_0000219,B,,CHO,10618.0,D,Homo sapiens,Expert,12936.0,,9606.0,CHEMBL616699,1.0,,9.0,,,,,449.0,2055.0,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells
,BAO_0000357,B,,,10618.0,H,,Autocuration,6166.0,,,CHEMBL616700,1.0,,8.0,,,,,,2056.0,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined
,BAO_0000219,B,,CHO,10618.0,H,,Autocuration,15779.0,,,CHEMBL616701,1.0,,8.0,,,,,449.0,2057.0,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.
,BAO_0000219,B,,CHO,10618.0,H,,Autocuration,15779.0,,,CHEMBL616702,1.0,,8.0,,,,,449.0,2058.0,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.
,BAO_0000219,B,,CHO,10618.0,H,,Autocuration,15779.0,,,CHEMBL616703,1.0,,8.0,,,,,449.0,2059.0,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.
,BAO_0000357,B,,,10618.0,H,,Autocuration,13181.0,,,CHEMBL616704,1.0,,8.0,,,,,,2060.0,Binding affinity was determined against 5-hydroxytryptamine 1D receptor
,BAO_0000219,B,,CHO,10618.0,H,,Autocuration,4199.0,,,CHEMBL616705,1.0,,8.0,,,,,449.0,2061.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand
,BAO_0000357,B,,,10618.0,H,,Autocuration,14875.0,,,CHEMBL616706,1.0,,8.0,,,,,,2062.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor
,BAO_0000219,B,,CHO,10618.0,H,,Autocuration,15146.0,,,CHEMBL616707,1.0,,8.0,,,,,449.0,2063.0,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT
,BAO_0000357,B,,,10618.0,H,,Autocuration,5213.0,,,CHEMBL616708,1.0,,8.0,,,,,,2064.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand
,BAO_0000357,B,,,10618.0,H,,Autocuration,12146.0,,,CHEMBL616709,1.0,,8.0,,,,,,2065.0,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand
,BAO_0000219,B,,CHO,10618.0,H,,Autocuration,13267.0,,,CHEMBL616710,1.0,,8.0,,,,,449.0,2066.0,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand
,BAO_0000219,B,,CHO,10618.0,H,,Autocuration,14818.0,,,CHEMBL616711,1.0,,8.0,,,,,449.0,2067.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.
,BAO_0000219,B,,CHO,10618.0,H,,Autocuration,4829.0,,,CHEMBL616712,1.0,,8.0,,,,,449.0,2068.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand"
,BAO_0000357,B,,,10618.0,H,,Autocuration,4373.0,,,CHEMBL616713,1.0,,8.0,,,,,,2069.0,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined
,BAO_0000357,B,,,10618.0,H,,Autocuration,4373.0,,,CHEMBL616714,1.0,,8.0,,,,,,2070.0,Binding affinity for 5-hydroxytryptamine 1E receptor was determined
,BAO_0000357,B,,,10618.0,H,,Autocuration,14159.0,,,CHEMBL616715,1.0,,8.0,,,,,,2071.0,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor
,BAO_0000357,B,,,10618.0,H,,Autocuration,16633.0,,,CHEMBL616716,1.0,,8.0,,,,,,2072.0,Binding affinity towards 5-hydroxytryptamine 1E receptor
,BAO_0000019,F,,,279.0,H,,Autocuration,17085.0,,,CHEMBL616717,1.0,,8.0,,,,,,2073.0,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor"
,BAO_0000019,F,,,279.0,H,,Expert,17085.0,,,CHEMBL616718,1.0,,8.0,,,,,,2074.0,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor"
,BAO_0000019,F,,,279.0,H,,Autocuration,16209.0,,,CHEMBL875905,1.0,,8.0,,,,,,2075.0,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor
,BAO_0000019,F,,,279.0,H,,Autocuration,16209.0,,,CHEMBL616719,1.0,,8.0,,,,,,2076.0,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor
,BAO_0000019,F,,,279.0,H,,Expert,17085.0,,,CHEMBL616720,1.0,,8.0,,,,,,2077.0,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor"
,BAO_0000357,B,,,279.0,H,,Autocuration,14159.0,,,CHEMBL616721,1.0,,8.0,,,,,,2078.0,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor
,BAO_0000219,B,,CHO,279.0,H,,Autocuration,15250.0,,,CHEMBL616722,1.0,,8.0,,,,,449.0,2079.0,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells
,BAO_0000357,B,,,279.0,H,,Autocuration,3805.0,,,CHEMBL616723,1.0,,8.0,,,,,,2080.0,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM)
,BAO_0000219,B,,CHO,279.0,H,,Autocuration,16190.0,,,CHEMBL616724,1.0,,8.0,,,,,449.0,2081.0,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand
,BAO_0000357,B,,,279.0,H,,Autocuration,16190.0,,,CHEMBL616725,1.0,,8.0,,,,,,2082.0,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand
,BAO_0000357,B,,,279.0,H,,Autocuration,16209.0,,,CHEMBL616726,1.0,,8.0,,,,,,2083.0,Binding affinity towards human 5-hydroxytryptamine 1F receptor
,BAO_0000357,B,,,279.0,H,,Autocuration,16209.0,,,CHEMBL616727,1.0,,8.0,,,,,,2084.0,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined
,BAO_0000357,B,,,279.0,H,,Autocuration,16209.0,,,CHEMBL616728,1.0,,8.0,,,,,,2085.0,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand
,BAO_0000357,B,,,279.0,H,,Autocuration,6866.0,,,CHEMBL616729,1.0,,8.0,,,,,,2086.0,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor
,BAO_0000019,B,,,279.0,H,,Expert,17085.0,,,CHEMBL616730,1.0,,8.0,,,,,,2087.0,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor
,BAO_0000357,B,,,279.0,H,,Autocuration,16312.0,,,CHEMBL617125,1.0,,8.0,,,,,,2088.0,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor
,BAO_0000357,B,,,279.0,H,,Autocuration,6166.0,,,CHEMBL857977,1.0,,8.0,,,,,,2089.0,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined
,BAO_0000219,B,,CHO,279.0,H,,Autocuration,15779.0,,,CHEMBL617126,1.0,,8.0,,,,,449.0,2090.0,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.
,BAO_0000219,B,,CHO,279.0,H,,Autocuration,4199.0,,,CHEMBL617127,1.0,,8.0,,,,,449.0,2091.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand
,BAO_0000357,B,,,279.0,H,,Autocuration,14875.0,,,CHEMBL617128,1.0,,8.0,,,,,,2092.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor
,BAO_0000219,B,,CHO,279.0,H,,Autocuration,15146.0,,,CHEMBL617129,1.0,,8.0,,,,,449.0,2093.0,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT
,BAO_0000357,B,,,279.0,H,,Autocuration,5213.0,,,CHEMBL617130,1.0,,8.0,,,,,,2094.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand
,BAO_0000219,B,,CHO,279.0,H,,Autocuration,14818.0,,,CHEMBL617131,1.0,,8.0,,,,,449.0,2095.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.
,BAO_0000219,B,,CHO,279.0,H,,Autocuration,4829.0,,,CHEMBL617132,1.0,,8.0,,,,,449.0,2096.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand"
,BAO_0000219,B,,CHO,279.0,H,,Autocuration,4829.0,,,CHEMBL617133,1.0,,8.0,,,,,449.0,2097.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand"
,BAO_0000357,B,,,279.0,H,,Autocuration,4373.0,,,CHEMBL617134,1.0,,8.0,,,,,,2098.0,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined
,BAO_0000357,B,,,279.0,H,,Autocuration,4373.0,,,CHEMBL617135,1.0,,8.0,,,,,,2099.0,Binding affinity for 5-hydroxytryptamine 1F receptor was determined
,BAO_0000357,B,,,279.0,H,,Autocuration,5014.0,,,CHEMBL617136,1.0,,8.0,,,,,,2100.0,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor
,BAO_0000019,B,,,104686.0,H,,Autocuration,11662.0,,,CHEMBL617137,1.0,,4.0,,,,,,2101.0,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand"
,BAO_0000019,B,,,104686.0,H,,Autocuration,11662.0,,,CHEMBL617138,1.0,,4.0,,,,,,2102.0,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand"
,BAO_0000019,B,,,104686.0,H,,Autocuration,11662.0,,,CHEMBL617139,1.0,,4.0,,,,,,2103.0,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined"
,BAO_0000019,B,,,12687.0,H,,Autocuration,14093.0,,,CHEMBL617140,1.0,,8.0,,,,,,2104.0,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor
,BAO_0000218,F,In vivo,,104686.0,H,,Autocuration,11200.0,,,CHEMBL617141,1.0,,4.0,,,,,,2105.0,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration"
,BAO_0000019,F,,,104686.0,H,,Autocuration,11200.0,,,CHEMBL858112,1.0,,4.0,,,,,,2106.0,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips
,BAO_0000019,B,,,17005.0,H,,Intermediate,12352.0,,,CHEMBL617142,1.0,,8.0,,,,,,2107.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex
,BAO_0000019,B,,,22226.0,U,Bos taurus,Autocuration,13657.0,,9913.0,CHEMBL617143,1.0,,0.0,,,,,,2108.0,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB"
,BAO_0000019,B,,,22226.0,U,Bos taurus,Autocuration,14331.0,,9913.0,CHEMBL617144,1.0,,0.0,,,,,,2109.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M
,BAO_0000019,B,,,22226.0,U,Bos taurus,Autocuration,14331.0,,9913.0,CHEMBL617145,1.0,,0.0,,,,,,2110.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex
,BAO_0000019,B,,,22226.0,U,,Autocuration,14331.0,,,CHEMBL617146,1.0,,0.0,,,,,,2111.0,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined
,BAO_0000019,B,,,104784.0,H,Cavia porcellus,Autocuration,12685.0,,10141.0,CHEMBL617147,1.0,,4.0,,,,,,2112.0,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex
,BAO_0000019,B,,,104784.0,H,Cavia porcellus,Autocuration,14389.0,,10141.0,CHEMBL617148,1.0,,4.0,,,,,,2113.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes
,BAO_0000019,B,,,104784.0,H,Cavia porcellus,Autocuration,14386.0,,10141.0,CHEMBL617149,1.0,,4.0,,,,,,2114.0,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex
,BAO_0000224,B,,,104784.0,H,,Autocuration,5732.0,,,CHEMBL617150,1.0,,4.0,,,,,,2115.0,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined
,BAO_0000224,B,,,104784.0,H,,Autocuration,16293.0,,,CHEMBL617151,1.0,,4.0,,,,,,2116.0,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined
,BAO_0000224,B,,,104784.0,H,,Autocuration,2078.0,,,CHEMBL617201,1.0,,4.0,,,,,,2117.0,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor
,BAO_0000357,B,,,10209.0,H,,Autocuration,5486.0,,,CHEMBL617202,1.0,,8.0,,,,,,2118.0,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell
,BAO_0000218,B,In vivo,,104826.0,H,,Autocuration,11820.0,,,CHEMBL617203,1.0,,4.0,,,,,,2119.0,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin
,BAO_0000019,B,,,104826.0,H,,Autocuration,10297.0,,,CHEMBL617204,1.0,,4.0,,,,,,2120.0,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex
,BAO_0000224,B,,,104826.0,H,,Autocuration,13704.0,,,CHEMBL617205,1.0,,4.0,,,,,,2121.0,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.
,BAO_0000019,B,,,104826.0,D,Mus musculus,Autocuration,10297.0,,10090.0,CHEMBL617206,1.0,,5.0,,,,,,2122.0,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex
,BAO_0000218,B,In vivo,,104826.0,H,,Autocuration,11820.0,,,CHEMBL617207,1.0,,4.0,,,,,,2123.0,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin
,BAO_0000019,B,,,104826.0,D,Mus musculus,Autocuration,10297.0,,10090.0,CHEMBL617208,1.0,,5.0,,,,,,2124.0,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex
,BAO_0000224,B,,,104826.0,H,,Autocuration,11555.0,,,CHEMBL617209,1.0,,4.0,,,,,,2125.0,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104826.0,H,,Autocuration,11555.0,,,CHEMBL617210,1.0,,4.0,,,,,,2126.0,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors
,BAO_0000224,B,,,104826.0,H,,Autocuration,11555.0,,,CHEMBL617211,1.0,,4.0,,,,,,2127.0,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data
,BAO_0000019,B,,,104826.0,D,Mus musculus,Autocuration,10297.0,,10090.0,CHEMBL617212,1.0,,5.0,,,,,,2128.0,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex
,BAO_0000224,B,,,104784.0,H,Sus scrofa,Autocuration,16688.0,,9823.0,CHEMBL617213,1.0,,4.0,,,,,,2129.0,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin
,BAO_0000224,B,,,104784.0,H,Sus scrofa,Autocuration,16688.0,,9823.0,CHEMBL617214,1.0,,4.0,,,,,,2130.0,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin
,BAO_0000221,B,,,22226.0,U,,Autocuration,5333.0,,,CHEMBL617215,1.0,,0.0,,,,,,2131.0,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate
,BAO_0000221,B,,,22226.0,U,,Autocuration,4437.0,,,CHEMBL617216,1.0,,0.0,,,,,,2132.0,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate
,BAO_0000357,B,,,17005.0,H,Sus scrofa,Autocuration,5033.0,,9823.0,CHEMBL617217,1.0,,8.0,,,,,,2133.0,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor
,BAO_0000019,B,,,104686.0,H,,Autocuration,15267.0,,,CHEMBL617218,1.0,,4.0,,,,,,2134.0,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor
,BAO_0000019,B,,,104686.0,H,,Autocuration,15267.0,,,CHEMBL872913,1.0,,4.0,,,,,,2135.0,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor
,BAO_0000019,B,,,104826.0,H,,Autocuration,11820.0,,,CHEMBL617219,1.0,,4.0,,,,,,2136.0,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.
,BAO_0000224,B,,,104686.0,H,,Autocuration,9069.0,,,CHEMBL873482,1.0,,4.0,,,,,,2137.0,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor
,BAO_0000019,B,,,104686.0,D,Rattus norvegicus,Autocuration,9162.0,,10116.0,CHEMBL617220,1.0,,5.0,,,,,,2138.0,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data
,BAO_0000019,B,,,104686.0,H,,Autocuration,9162.0,,,CHEMBL617221,1.0,,4.0,,,,,,2139.0,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.
,BAO_0000019,B,,,104686.0,H,,Autocuration,9162.0,,,CHEMBL617222,1.0,,4.0,,,,,,2140.0,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity
,BAO_0000019,F,,,104686.0,H,,Autocuration,10428.0,,,CHEMBL875906,1.0,,4.0,,,,,,2141.0,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein
,BAO_0000019,B,,,104686.0,H,,Autocuration,9628.0,,,CHEMBL617223,1.0,,4.0,,,,,,2142.0,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein
,BAO_0000224,B,,,104686.0,H,,Autocuration,12704.0,,,CHEMBL617224,1.0,,4.0,,,,,,2143.0,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104686.0,D,Rattus norvegicus,Autocuration,15453.0,,10116.0,CHEMBL617225,1.0,,5.0,,,,,,2144.0,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin
,BAO_0000224,B,,,104686.0,H,,Autocuration,188.0,,,CHEMBL617226,1.0,,4.0,,,,,,2145.0,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity
,BAO_0000224,B,,,104686.0,H,,Autocuration,10349.0,,,CHEMBL617227,1.0,,4.0,,,,,,2146.0,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.
,BAO_0000224,B,,,104686.0,H,,Autocuration,10349.0,,,CHEMBL617228,1.0,,4.0,,,,,,2147.0,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.
,BAO_0000224,B,,,104686.0,H,,Autocuration,8868.0,,,CHEMBL617229,1.0,,4.0,,,,,,2148.0,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis
,BAO_0000224,B,,,104686.0,H,,Autocuration,10025.0,,,CHEMBL617230,1.0,,4.0,,,,,,2149.0,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM
,BAO_0000224,B,,,104686.0,H,,Autocuration,10025.0,,,CHEMBL617231,1.0,,4.0,,,,,,2150.0,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM"
,BAO_0000224,B,,,104686.0,H,,Autocuration,11702.0,,,CHEMBL617232,1.0,,4.0,,,,,,2151.0,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor
,BAO_0000224,B,,,104686.0,H,,Autocuration,11702.0,,,CHEMBL617233,1.0,,4.0,,,,,,2152.0,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104686.0,H,,Autocuration,11702.0,,,CHEMBL617234,1.0,,4.0,,,,,,2153.0,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested
,BAO_0000019,F,,,104686.0,H,,Autocuration,11702.0,,,CHEMBL617235,1.0,,4.0,,,,,,2154.0,Compound was tested for the inhibition of quipazine induced head twitches in rats
,BAO_0000019,F,,,104686.0,H,,Autocuration,11702.0,,,CHEMBL617236,1.0,,4.0,,,,,,2155.0,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested
,BAO_0000221,B,,,104686.0,H,,Autocuration,10085.0,,,CHEMBL617237,1.0,,4.0,Hippocampus,,,10000000.0,,2156.0,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone
,BAO_0000221,B,,,104686.0,H,,Autocuration,10085.0,,,CHEMBL617238,1.0,,4.0,Hippocampus,,,10000000.0,,2157.0,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone
,BAO_0000221,B,,,104686.0,D,Rattus norvegicus,Autocuration,9630.0,,10116.0,CHEMBL617239,1.0,,5.0,Brain,,,955.0,,2158.0,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain
,BAO_0000019,B,,,104686.0,H,,Autocuration,11070.0,,,CHEMBL617240,1.0,,4.0,,,,,,2159.0,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex
,BAO_0000249,B,,,104686.0,H,,Autocuration,9841.0,Membranes,,CHEMBL617241,1.0,,4.0,,,,,,2160.0,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes
,BAO_0000249,B,,,104686.0,H,,Autocuration,9841.0,Membranes,,CHEMBL875907,1.0,,4.0,,,,,,2161.0,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes
,BAO_0000019,B,,,104686.0,H,,Autocuration,13291.0,,,CHEMBL617242,1.0,,4.0,,,,,,2162.0,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.
,BAO_0000019,F,,,104686.0,H,,Autocuration,10590.0,,,CHEMBL617152,1.0,,4.0,,,,,,2163.0,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.
,BAO_0000221,B,,,104686.0,D,Rattus norvegicus,Autocuration,9064.0,,10116.0,CHEMBL617153,1.0,,5.0,Brain,,,955.0,,2164.0,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol
,BAO_0000249,B,,,104686.0,D,Rattus norvegicus,Autocuration,12268.0,Membranes,10116.0,CHEMBL617154,1.0,,5.0,,,,,,2165.0,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes
,BAO_0000221,B,,,104686.0,H,,Autocuration,13508.0,,,CHEMBL617155,1.0,,4.0,Brain,,,955.0,,2166.0,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand
,BAO_0000019,F,,,104686.0,H,,Autocuration,11279.0,,,CHEMBL617156,1.0,,4.0,,,,,,2167.0,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.
,BAO_0000019,F,,,104686.0,H,,Autocuration,11200.0,,,CHEMBL617157,1.0,,4.0,,,,,,2168.0,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips
,BAO_0000019,F,,,104686.0,H,,Autocuration,11200.0,,,CHEMBL617158,1.0,,4.0,,,,,,2169.0,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips
,BAO_0000019,F,,,104686.0,H,,Autocuration,11200.0,,,CHEMBL617159,1.0,,4.0,,,,,,2170.0,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism
,BAO_0000019,F,,,104686.0,H,,Autocuration,11200.0,,,CHEMBL617160,1.0,,4.0,,,,,,2171.0,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism
,BAO_0000019,F,,,104686.0,H,,Autocuration,11200.0,,,CHEMBL858113,1.0,,4.0,,,,,,2172.0,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips
,BAO_0000220,B,,,104686.0,H,,Autocuration,9231.0,,,CHEMBL617247,1.0,,4.0,Brain,,,955.0,,2173.0,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes
,BAO_0000019,B,,,104686.0,H,,Autocuration,9737.0,,,CHEMBL617248,1.0,,4.0,,,,,,2174.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand
,BAO_0000249,B,,,104686.0,H,,Autocuration,9737.0,,,CHEMBL617249,1.0,,4.0,Brain,,,955.0,,2175.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.
,BAO_0000019,B,,,104686.0,H,,Autocuration,9737.0,,,CHEMBL617250,1.0,,4.0,,,,,,2176.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex
,BAO_0000019,B,,,104686.0,H,,Autocuration,9737.0,,,CHEMBL617251,1.0,,4.0,,,,,,2177.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand
,BAO_0000019,B,,,104686.0,D,Rattus norvegicus,Autocuration,11828.0,,10116.0,CHEMBL617252,1.0,,5.0,,,,,,2178.0,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor
,BAO_0000019,B,,,104686.0,H,,Autocuration,12253.0,,,CHEMBL617006,1.0,,4.0,,,,,,2179.0,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex
,BAO_0000019,B,,,104686.0,H,,Autocuration,12253.0,,,CHEMBL617007,1.0,,4.0,,,,,,2180.0,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex
,BAO_0000019,F,,,104686.0,H,,Autocuration,11279.0,,,CHEMBL617008,1.0,,4.0,,,,,,2181.0,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery."
,BAO_0000019,B,,,104686.0,H,,Autocuration,11866.0,,,CHEMBL617009,1.0,,4.0,,,,,,2182.0,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin
,BAO_0000224,B,,,104686.0,D,Rattus norvegicus,Autocuration,14424.0,,10116.0,CHEMBL617010,1.0,,5.0,,,,,,2183.0,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta
,BAO_0000019,B,,,104686.0,D,Rattus norvegicus,Autocuration,15180.0,,10116.0,CHEMBL857978,1.0,,5.0,,,,,,2184.0,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor
,BAO_0000019,B,,,104686.0,D,Rattus norvegicus,Autocuration,15180.0,,10116.0,CHEMBL617011,1.0,,5.0,,,,,,2185.0,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor
,BAO_0000019,B,,,104686.0,D,Rattus norvegicus,Autocuration,9786.0,,10116.0,CHEMBL617012,1.0,,5.0,,,,,,2186.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate
,BAO_0000224,B,,,104686.0,H,,Autocuration,12132.0,,,CHEMBL617013,1.0,,4.0,,,,,,2187.0,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.
,BAO_0000249,B,,,104686.0,H,,Autocuration,5486.0,,,CHEMBL617014,1.0,,4.0,,,,,,2188.0,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane
,BAO_0000019,B,,,104686.0,H,,Autocuration,15316.0,,,CHEMBL617015,1.0,,4.0,,,,,,2189.0,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor
,BAO_0000019,B,,,104686.0,H,,Autocuration,16429.0,,,CHEMBL617016,1.0,,4.0,,,,,,2190.0,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand
,BAO_0000224,B,,,104686.0,H,,Autocuration,14617.0,,,CHEMBL617017,1.0,,4.0,,,,,,2191.0,pKi value for 5-hydroxytryptamine 2 receptor binding site
,BAO_0000221,B,,,104686.0,H,,Autocuration,11351.0,,,CHEMBL617018,1.0,,4.0,Brain,,,955.0,,2192.0,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.
,BAO_0000019,F,,,104686.0,H,,Autocuration,11279.0,,,CHEMBL617019,1.0,,4.0,,,,,,2193.0,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.
,BAO_0000019,B,,,105075.0,H,,Autocuration,9523.0,,,CHEMBL617020,1.0,,4.0,,,,,,2194.0,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex
,BAO_0000019,B,,,105075.0,H,,Autocuration,9523.0,,,CHEMBL617021,1.0,,4.0,,,,,,2195.0,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex
,BAO_0000019,B,,,105075.0,H,,Autocuration,9523.0,,,CHEMBL617022,1.0,,4.0,,,,,,2196.0,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex
,BAO_0000019,B,,,105075.0,H,,Autocuration,9523.0,,,CHEMBL617023,1.0,,4.0,,,,,,2197.0,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex
,BAO_0000019,B,,,105075.0,H,,Autocuration,9523.0,,,CHEMBL617024,1.0,,4.0,,,,,,2198.0,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex
,BAO_0000019,B,,,105075.0,H,,Autocuration,9523.0,,,CHEMBL617025,1.0,,4.0,,,,,,2199.0,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex
,BAO_0000224,B,,,105075.0,H,,Autocuration,9523.0,,,CHEMBL617026,1.0,,4.0,,,,,,2200.0,Hill coefficient of compound was determined
,BAO_0000019,B,,,22226.0,U,,Autocuration,4771.0,,,CHEMBL617027,1.0,,0.0,,,,,,2201.0,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor
,BAO_0000019,B,,,104686.0,D,Rattus norvegicus,Autocuration,5033.0,,10116.0,CHEMBL617028,1.0,,5.0,,,,,,2202.0,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane
,BAO_0000019,B,,,12687.0,H,,Expert,10845.0,,,CHEMBL617029,1.0,,8.0,,,,,,2203.0,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand
,BAO_0000019,B,,,12687.0,H,,Expert,10845.0,,,CHEMBL875908,1.0,,8.0,,,,,,2204.0,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive
,BAO_0000357,B,,,12687.0,H,,Autocuration,16288.0,,,CHEMBL617030,1.0,,8.0,,,,,,2205.0,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09)
,BAO_0000019,B,,,12687.0,H,,Autocuration,16288.0,,,CHEMBL617031,1.0,,8.0,,,,,,2206.0,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09)
,BAO_0000019,B,,,12687.0,H,,Autocuration,16190.0,,,CHEMBL617032,1.0,,8.0,,,,,,2207.0,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand
,BAO_0000224,B,,,104686.0,D,Rattus norvegicus,Autocuration,12463.0,,10116.0,CHEMBL617033,1.0,,5.0,,,,,,2208.0,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin
,BAO_0000224,B,,,104686.0,H,,Autocuration,9699.0,,,CHEMBL617034,1.0,,4.0,,,,,,2209.0,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand"
,BAO_0000224,B,,,104686.0,H,,Autocuration,9699.0,,,CHEMBL617035,1.0,,4.0,,,,,,2210.0,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand
,BAO_0000019,B,,,104686.0,H,,Autocuration,11662.0,,,CHEMBL617036,1.0,,4.0,,,,,,2211.0,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined"
,BAO_0000224,B,,,104784.0,H,,Autocuration,1205.0,,,CHEMBL617037,1.0,,4.0,,,,,,2212.0,Inhibitory concentration against 5-hydroxytryptamine 2 receptor
,BAO_0000219,B,,,22226.0,U,,Autocuration,11376.0,,,CHEMBL617038,1.0,,0.0,,,,,,2213.0,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand
,BAO_0000219,B,,,104784.0,H,,Autocuration,11376.0,,,CHEMBL617039,1.0,,4.0,,,,,,2214.0,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)"
,BAO_0000224,B,,,104784.0,H,,Autocuration,4639.0,,,CHEMBL617161,1.0,,4.0,,,,,,2215.0,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104784.0,H,,Autocuration,2222.0,,,CHEMBL617162,1.0,,4.0,,,,,,2216.0,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104784.0,H,,Autocuration,1558.0,,,CHEMBL617163,1.0,,4.0,,,,,,2217.0,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104784.0,H,,Autocuration,1089.0,,,CHEMBL617164,1.0,,4.0,,,,,,2218.0,Tested for binding affinity for 5-hydroxytryptamine 2 receptor
,BAO_0000249,B,,,104784.0,H,,Autocuration,386.0,Brain membranes,,CHEMBL617165,1.0,,4.0,,,,,,2219.0,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes
,BAO_0000224,B,,,104784.0,H,,Autocuration,2474.0,,,CHEMBL617166,1.0,,4.0,,,,,,2220.0,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand
,BAO_0000224,B,,,104784.0,H,,Autocuration,17066.0,,,CHEMBL617167,1.0,,4.0,,,,,,2221.0,Binding affinity towards 5-HT2 receptor
,BAO_0000224,B,,,104784.0,H,,Autocuration,959.0,,,CHEMBL872912,1.0,,4.0,,,,,,2222.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104784.0,H,,Autocuration,6398.0,,,CHEMBL617168,1.0,,4.0,,,,,,2223.0,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding
,BAO_0000224,B,,,104686.0,H,,Autocuration,11889.0,,,CHEMBL617169,1.0,,4.0,,,,,,2224.0,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.
,BAO_0000224,B,,,104784.0,H,,Autocuration,4221.0,,,CHEMBL617170,1.0,,4.0,,,,,,2225.0,In vitro binding affinity for 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104784.0,H,,Autocuration,11026.0,,,CHEMBL617171,1.0,,4.0,,,,,,2226.0,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand
,BAO_0000224,B,,,104784.0,H,,Autocuration,11866.0,,,CHEMBL617172,1.0,,4.0,,,,,,2227.0,Binding affinity for 5-hydroxytryptamine 2 receptor was determined
,BAO_0000224,B,,,104784.0,H,,Autocuration,4221.0,,,CHEMBL617173,1.0,,4.0,,,,,,2228.0,In vitro binding affinity for 5-hydroxytryptamine 2 receptor
,BAO_0000019,B,,,22226.0,U,,Autocuration,13950.0,,,CHEMBL617174,1.0,,0.0,,,,,,2229.0,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104784.0,H,,Autocuration,1263.0,,,CHEMBL617175,1.0,,4.0,,,,,,2230.0,5-hydroxytryptamine 2 receptor binding affinity
,BAO_0000357,B,,,17005.0,H,,Autocuration,13291.0,,,CHEMBL617176,1.0,,8.0,,,,,,2231.0,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand
,BAO_0000357,B,,,17005.0,H,,Autocuration,10812.0,,,CHEMBL617177,1.0,,8.0,,,,,,2232.0,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand
,BAO_0000224,B,,,104784.0,H,,Autocuration,13020.0,,,CHEMBL617178,1.0,,4.0,,,,,,2233.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M
,BAO_0000224,B,,,104784.0,H,,Autocuration,13021.0,,,CHEMBL617179,1.0,,4.0,,,,,,2234.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system
,BAO_0000224,B,,,104784.0,H,,Autocuration,13020.0,,,CHEMBL617180,1.0,,4.0,,,,,,2235.0,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M
,BAO_0000357,B,,,17005.0,H,,Autocuration,14532.0,,,CHEMBL617181,1.0,,8.0,,,,,,2236.0,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration
,BAO_0000357,B,,,17005.0,H,,Autocuration,13944.0,,,CHEMBL617182,1.0,,8.0,,,,,,2237.0,Binding affinity against 5-hydroxytryptamine 2 receptor
,BAO_0000357,B,,,17005.0,H,,Autocuration,14331.0,,,CHEMBL617183,1.0,,8.0,,,,,,2238.0,Binding affinity against 5-hydroxytryptamine 2 receptor
,BAO_0000357,B,,,17005.0,H,,Autocuration,14118.0,,,CHEMBL617184,1.0,,8.0,,,,,,2239.0,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand
,BAO_0000357,B,,,17005.0,H,,Autocuration,13033.0,,,CHEMBL617185,1.0,,8.0,,,,,,2240.0,Binding affinity against serotonergic 5-HT2 receptor
,BAO_0000357,B,,,17005.0,H,,Autocuration,10321.0,,,CHEMBL617186,1.0,,8.0,,,,,,2241.0,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand
,BAO_0000357,B,,,17005.0,H,,Autocuration,12918.0,,,CHEMBL617187,1.0,,8.0,,,,,,2242.0,Compound was evaluated for the binding affinity at 5- HT2 receptor
,BAO_0000357,B,,,17005.0,H,,Autocuration,15120.0,,,CHEMBL617188,1.0,,8.0,,,,,,2243.0,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor
,BAO_0000218,B,,,17005.0,H,,Autocuration,2613.0,,,CHEMBL617189,1.0,,8.0,,,,,,2244.0,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104784.0,D,Homo sapiens,Autocuration,13378.0,,9606.0,CHEMBL617190,1.0,,5.0,,,,,,2245.0,Inhibitory activity against cloned human 5-HT2 receptor
,BAO_0000219,B,,CHO,104784.0,D,Homo sapiens,Autocuration,2331.0,,9606.0,CHEMBL617191,1.0,,5.0,,,,,449.0,2246.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells"
,BAO_0000219,B,,CHO,104784.0,D,Homo sapiens,Autocuration,2331.0,,9606.0,CHEMBL617192,1.0,,5.0,,,,,449.0,2247.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells."
,BAO_0000219,B,,CHO,104784.0,D,Homo sapiens,Autocuration,2331.0,,9606.0,CHEMBL617193,1.0,,5.0,,,,,449.0,2248.0,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive"
,BAO_0000219,B,,CHO,104784.0,D,Homo sapiens,Autocuration,2331.0,,9606.0,CHEMBL617194,1.0,,5.0,,,,,449.0,2249.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested"
,BAO_0000224,B,,,104784.0,H,,Autocuration,4170.0,,,CHEMBL617195,1.0,,4.0,,,,,,2250.0,Binding affinity towards 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104784.0,H,,Autocuration,15453.0,,,CHEMBL881830,1.0,,4.0,,,,,,2251.0,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin
,BAO_0000357,B,,,17005.0,H,,Autocuration,1479.0,,,CHEMBL617196,1.0,,8.0,,,,,,2252.0,Binding affinity towards 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104686.0,H,,Autocuration,11139.0,,,CHEMBL617197,1.0,,4.0,,,,,,2253.0,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay
,BAO_0000357,B,,,17005.0,H,,Expert,13969.0,,,CHEMBL617198,1.0,,8.0,,,,,,2254.0,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand
,BAO_0000357,B,,,17005.0,H,,Expert,13392.0,,,CHEMBL873476,1.0,,8.0,,,,,,2255.0,Binding affinity towards 5-hydroxytryptamine 2A receptor
,BAO_0000019,B,,,17005.0,H,,Expert,14430.0,,,CHEMBL617199,1.0,,8.0,,,,,,2256.0,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin
,BAO_0000357,B,,,107.0,H,Cavia porcellus,Autocuration,13181.0,,10141.0,CHEMBL617200,1.0,,8.0,,,,,,2257.0,Binding affinity was determined against 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,51.0,H,,Autocuration,17200.0,,,CHEMBL617484,1.0,,8.0,,,,,,2258.0,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand
,BAO_0000357,B,,,107.0,H,,Autocuration,17200.0,,,CHEMBL617485,1.0,,8.0,,,,,,2259.0,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand
,BAO_0000357,B,,,51.0,H,,Autocuration,17200.0,,,CHEMBL617486,1.0,,8.0,,,,,,2260.0,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand
,BAO_0000357,B,,,107.0,H,,Autocuration,13463.0,,,CHEMBL858022,1.0,,8.0,,,,,,2261.0,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand
,BAO_0000219,B,,CHO,107.0,H,,Autocuration,6347.0,,,CHEMBL617049,1.0,,8.0,,,,,449.0,2262.0,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand
,BAO_0000219,F,,CHO,107.0,D,Homo sapiens,Expert,6857.0,,9606.0,CHEMBL617050,1.0,,9.0,,,,,449.0,2263.0,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader
,BAO_0000219,F,,,107.0,H,,Autocuration,4176.0,,,CHEMBL617051,1.0,,8.0,,,,,,2264.0,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line
,BAO_0000219,F,,,107.0,H,,Autocuration,4176.0,,,CHEMBL617052,1.0,,8.0,,,,,,2265.0,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data
,BAO_0000219,F,,,107.0,H,,Autocuration,4176.0,,,CHEMBL617053,1.0,,8.0,,,,,,2266.0,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line
,BAO_0000219,B,,CHO,107.0,H,,Autocuration,6347.0,,,CHEMBL617054,1.0,,8.0,,,,,449.0,2267.0,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax"
,BAO_0000219,B,,CHO,107.0,H,,Autocuration,6347.0,,,CHEMBL617055,1.0,,8.0,,,,,449.0,2268.0,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax"
,BAO_0000357,B,,,107.0,H,,Autocuration,15331.0,,,CHEMBL882924,1.0,,8.0,,,,,,2269.0,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique
,BAO_0000357,B,,,107.0,D,Homo sapiens,Expert,16146.0,,9606.0,CHEMBL617056,1.0,,9.0,,,,,,2270.0,Inhibition of human 5-hydroxytryptamine 2A receptor
,BAO_0000219,B,,CHO,107.0,H,,Autocuration,15250.0,,,CHEMBL617057,1.0,,8.0,,,,,449.0,2271.0,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells
,BAO_0000219,B,,,107.0,H,,Expert,13631.0,,,CHEMBL617058,1.0,,8.0,,,,,,2272.0,Inhibitory concentration against human 5-HT2A receptor in BEK cells
,BAO_0000357,B,,,107.0,H,,Autocuration,3805.0,,,CHEMBL617059,1.0,,8.0,,,,,,2273.0,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM)
,BAO_0000219,B,,CHO,107.0,H,,Autocuration,4011.0,,,CHEMBL617060,1.0,,8.0,,,,,449.0,2274.0,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined
,BAO_0000219,B,,CHO,107.0,H,,Expert,4012.0,,,CHEMBL617061,1.0,,8.0,,,,,449.0,2275.0,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.
,BAO_0000219,B,,L929,107.0,H,,Expert,6366.0,,,CHEMBL617062,1.0,,8.0,,,,,307.0,2276.0,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells
,BAO_0000219,B,,CHO,107.0,H,,Expert,15949.0,,,CHEMBL617063,1.0,,8.0,,,,,449.0,2277.0,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells
,BAO_0000019,F,,,107.0,H,,Autocuration,14093.0,,,CHEMBL617064,1.0,,8.0,,,,,,2278.0,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand
,BAO_0000019,F,,,107.0,H,,Autocuration,13481.0,,,CHEMBL617065,1.0,,8.0,,,,,,2279.0,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand
,BAO_0000219,B,,CHO,107.0,H,,Autocuration,6347.0,,,CHEMBL617066,1.0,,8.0,,,,,449.0,2280.0,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand
,BAO_0000219,B,,CHO,107.0,H,,Autocuration,6347.0,,,CHEMBL617067,1.0,,8.0,,,,,449.0,2281.0,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done
,BAO_0000019,F,,,107.0,H,,Autocuration,14093.0,,,CHEMBL617068,1.0,,8.0,,,,,,2282.0,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand
,BAO_0000019,F,,,107.0,H,,Autocuration,14093.0,,,CHEMBL617069,1.0,,8.0,,,,,,2283.0,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested
,BAO_0000019,F,,,107.0,H,,Autocuration,13481.0,,,CHEMBL617070,1.0,,8.0,,,,,,2284.0,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
,BAO_0000357,B,,,107.0,H,,Autocuration,14442.0,,,CHEMBL617071,1.0,,8.0,,,,,,2285.0,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand
,BAO_0000357,B,,,107.0,H,,Autocuration,14442.0,,,CHEMBL872915,1.0,,8.0,,,,,,2286.0,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
,BAO_0000357,B,,,107.0,H,,Autocuration,14755.0,,,CHEMBL617072,1.0,,8.0,,,,,,2287.0,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.
,BAO_0000357,B,,,107.0,H,,Autocuration,16441.0,,,CHEMBL617073,1.0,,8.0,,,,,,2288.0,Binding affinity against 5-hydroxytryptamine 2A receptor in humans
,BAO_0000357,B,,,107.0,H,,Autocuration,14744.0,,,CHEMBL617074,1.0,,8.0,,,,,,2289.0,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand
,BAO_0000219,B,,CHO,107.0,H,,Expert,16659.0,,,CHEMBL617075,1.0,,8.0,,,,,449.0,2290.0,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells
,BAO_0000357,B,,,107.0,H,,Autocuration,3307.0,,,CHEMBL617076,1.0,,8.0,,,,,,2291.0,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor
,BAO_0000019,B,,,107.0,D,Homo sapiens,Expert,6857.0,,9606.0,CHEMBL617077,1.0,,9.0,,,,,,2292.0,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line
,BAO_0000357,B,,,107.0,H,,Expert,5635.0,,,CHEMBL617078,1.0,,8.0,,,,,,2293.0,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.
,BAO_0000357,B,,,107.0,D,Homo sapiens,Expert,4234.0,,9606.0,CHEMBL617079,1.0,,9.0,,,,,,2294.0,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,107.0,H,,Autocuration,15527.0,,,CHEMBL617080,1.0,,8.0,,,,,,2295.0,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.
,BAO_0000219,B,,CHO,107.0,H,,Expert,6588.0,,,CHEMBL617081,1.0,,8.0,,,,,449.0,2296.0,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells
,BAO_0000219,B,,,107.0,H,,Expert,13631.0,,,CHEMBL617082,1.0,,8.0,,,,,,2297.0,Binding affinity towards human 5-HT2A receptor in BEK cells
,BAO_0000357,B,,,107.0,H,,Autocuration,17723.0,,,CHEMBL617083,1.0,,8.0,,,,,,2298.0,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,107.0,H,,Autocuration,14770.0,,,CHEMBL617084,1.0,,8.0,,,,,,2299.0,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.
,BAO_0000357,B,,,107.0,D,Homo sapiens,Expert,16293.0,,9606.0,CHEMBL617085,1.0,,9.0,,,,,,2300.0,Binding affinity for human 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,107.0,H,,Autocuration,16209.0,,,CHEMBL617086,1.0,,8.0,,,,,,2301.0,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand
,BAO_0000219,B,,,107.0,H,,Autocuration,12469.0,,,CHEMBL617087,1.0,,8.0,,,,,,2302.0,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin
,BAO_0000357,B,,,107.0,H,,Autocuration,15363.0,,,CHEMBL617088,1.0,,8.0,,,,,,2303.0,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,107.0,H,,Autocuration,15363.0,,,CHEMBL617089,1.0,,8.0,,,,,,2304.0,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor
,BAO_0000019,B,,,107.0,H,,Expert,16441.0,,,CHEMBL617090,1.0,,8.0,,,,,,2305.0,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand"
,BAO_0000357,B,,,107.0,H,,Autocuration,8.0,,,CHEMBL617513,1.0,,8.0,,,,,,2306.0,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand
,BAO_0000219,B,,HEK293,107.0,H,,Autocuration,4176.0,,,CHEMBL617514,1.0,,8.0,,,,,722.0,2307.0,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand
,BAO_0000019,B,,,107.0,H,,Autocuration,17085.0,,,CHEMBL617515,1.0,,8.0,,,,,,2308.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,107.0,H,,Autocuration,17200.0,,,CHEMBL617516,1.0,,8.0,,,,,,2309.0,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand
,BAO_0000357,B,,,107.0,D,Homo sapiens,Expert,17200.0,,9606.0,CHEMBL617517,1.0,,9.0,,,,,,2310.0,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand
,BAO_0000219,B,,CHO,107.0,D,Homo sapiens,Expert,4013.0,,9606.0,CHEMBL617518,1.0,,9.0,,,,,449.0,2311.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells
,BAO_0000357,B,,,107.0,H,,Autocuration,5088.0,,,CHEMBL617519,1.0,,8.0,,,,,,2312.0,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,107.0,D,Homo sapiens,Expert,5088.0,,9606.0,CHEMBL617520,1.0,,9.0,,,,,,2313.0,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,107.0,H,,Autocuration,5088.0,,,CHEMBL617521,1.0,,8.0,,,,,,2314.0,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained
,BAO_0000357,B,,,107.0,D,Homo sapiens,Expert,5088.0,,9606.0,CHEMBL617522,1.0,,9.0,,,,,,2315.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,107.0,H,,Autocuration,5088.0,,,CHEMBL617523,1.0,,8.0,,,,,,2316.0,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand
,BAO_0000357,B,,,107.0,H,,Autocuration,5088.0,,,CHEMBL617524,1.0,,8.0,,,,,,2317.0,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand
,BAO_0000019,B,,,104686.0,H,,Autocuration,9786.0,,,CHEMBL617525,1.0,,4.0,,,,,,2318.0,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate
,BAO_0000019,B,,,104686.0,D,Rattus norvegicus,Autocuration,9205.0,,10116.0,CHEMBL617526,1.0,,5.0,,,,,,2319.0,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat
,BAO_0000224,B,,,104686.0,H,,Autocuration,11257.0,,,CHEMBL617527,1.0,,4.0,,,,,,2320.0,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI
,BAO_0000019,B,,,104686.0,H,,Autocuration,9362.0,,,CHEMBL617528,1.0,,4.0,,,,,,2321.0,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates
,BAO_0000019,B,,,104686.0,H,,Autocuration,9362.0,,,CHEMBL617529,1.0,,4.0,,,,,,2322.0,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates
,BAO_0000224,B,,,104686.0,H,,Autocuration,10590.0,,,CHEMBL617530,1.0,,4.0,,,,,,2323.0,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.
,BAO_0000019,B,,,104686.0,H,,Autocuration,10468.0,,,CHEMBL617531,1.0,,4.0,,,,,,2324.0,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand
,BAO_0000019,B,,,104686.0,H,,Autocuration,13050.0,,,CHEMBL617532,1.0,,4.0,,,,,,2325.0,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand
,BAO_0000019,B,,,104686.0,H,,Autocuration,11624.0,,,CHEMBL617533,1.0,,4.0,,,,,,2326.0,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand
,BAO_0000019,B,,,104686.0,H,,Autocuration,10468.0,,,CHEMBL617534,1.0,,4.0,,,,,,2327.0,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand
,BAO_0000224,B,,,104686.0,H,,Autocuration,10330.0,,,CHEMBL617535,1.0,,4.0,,,,,,2328.0,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand
,BAO_0000224,B,,,104686.0,H,,Autocuration,10062.0,,,CHEMBL617536,1.0,,4.0,,,,,,2329.0,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.
,BAO_0000224,B,,,104686.0,H,,Autocuration,11642.0,,,CHEMBL617537,1.0,,4.0,,,,,,2330.0,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104686.0,H,,Autocuration,10062.0,,,CHEMBL617538,1.0,,4.0,,,,,,2331.0,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor
,BAO_0000219,B,In vitro,,104686.0,H,,Autocuration,13427.0,,,CHEMBL617539,1.0,,4.0,,,,,,2332.0,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.
,BAO_0000224,B,,,104686.0,D,Rattus norvegicus,Autocuration,12280.0,,10116.0,CHEMBL617540,1.0,,5.0,,,,,,2333.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104686.0,D,Rattus norvegicus,Autocuration,4101.0,,10116.0,CHEMBL617541,1.0,,5.0,,,,,,2334.0,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin
,BAO_0000224,B,,,104686.0,H,,Autocuration,10062.0,,,CHEMBL617542,1.0,,4.0,,,,,,2335.0,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104686.0,H,,Autocuration,11147.0,,,CHEMBL617543,1.0,,4.0,,,,,,2336.0,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as
,BAO_0000219,B,,CHO-K1,104686.0,D,Rattus norvegicus,Autocuration,2395.0,,10116.0,CHEMBL617544,1.0,,5.0,,,,,485.0,2337.0,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells
,BAO_0000219,B,,CHO-K1,104686.0,D,Rattus norvegicus,Autocuration,2395.0,,10116.0,CHEMBL617545,1.0,,5.0,,,,,485.0,2338.0,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells
,BAO_0000019,B,,,104686.0,D,Rattus norvegicus,Autocuration,9098.0,,10116.0,CHEMBL617413,1.0,,5.0,,,,,,2339.0,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand
,BAO_0000019,B,,,104686.0,H,,Autocuration,9098.0,,,CHEMBL617414,1.0,,4.0,,,,,,2340.0,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.
,BAO_0000019,B,,,104686.0,D,Rattus norvegicus,Autocuration,9098.0,,10116.0,CHEMBL617415,1.0,,5.0,,,,,,2341.0,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.
,BAO_0000224,B,,,104686.0,H,,Autocuration,9443.0,,,CHEMBL617416,1.0,,4.0,,,,,,2342.0,Binding affinity towards 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104686.0,H,,Autocuration,9443.0,,,CHEMBL617417,1.0,,4.0,,,,,,2343.0,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration
,BAO_0000019,B,,,104686.0,H,,Autocuration,9699.0,,,CHEMBL617418,1.0,,4.0,,,,,,2344.0,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex"
,BAO_0000019,B,,,104686.0,H,,Autocuration,9699.0,,,CHEMBL617419,1.0,,4.0,,,,,,2345.0,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex
,BAO_0000224,B,,,104686.0,H,,Autocuration,9098.0,,,CHEMBL617420,1.0,,4.0,,,,,,2346.0,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined
,BAO_0000224,B,,,104686.0,D,Rattus norvegicus,Autocuration,3070.0,,10116.0,CHEMBL617421,1.0,,5.0,,,,,,2347.0,Affinity for 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104686.0,H,,Autocuration,9547.0,,,CHEMBL617422,1.0,,4.0,,,,,,2348.0,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay
,BAO_0000019,B,,,104686.0,H,,Autocuration,10444.0,,,CHEMBL617423,1.0,,4.0,,,,,,2349.0,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.
,BAO_0000019,B,,,104686.0,H,,Autocuration,14617.0,,,CHEMBL617424,1.0,,4.0,,,,,,2350.0,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate
,BAO_0000019,B,,,104686.0,H,,Autocuration,14617.0,,,CHEMBL617425,1.0,,4.0,,,,,,2351.0,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate
,BAO_0000224,B,,,104686.0,H,,Autocuration,11130.0,,,CHEMBL617426,1.0,,4.0,,,,,,2352.0,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro)
,BAO_0000218,B,In vivo,,104686.0,H,,Autocuration,11130.0,,,CHEMBL617427,1.0,,4.0,,,,,,2353.0,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo)
,BAO_0000221,B,,,104686.0,H,,Autocuration,14542.0,,,CHEMBL617428,1.0,,4.0,Brain,,,955.0,,2354.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain
,BAO_0000224,B,,,104686.0,H,,Autocuration,2797.0,,,CHEMBL617429,1.0,,4.0,,,,,,2355.0,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat
,BAO_0000019,B,,,104686.0,H,,Autocuration,11332.0,,,CHEMBL617430,1.0,,4.0,,,,,,2356.0,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand
,BAO_0000019,B,,,104686.0,H,,Autocuration,11332.0,,,CHEMBL617431,1.0,,4.0,,,,,,2357.0,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand
,BAO_0000019,B,,,104686.0,H,,Autocuration,10752.0,,,CHEMBL617432,1.0,,4.0,Frontal cortex,,,1870.0,,2358.0,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.
,BAO_0000224,B,,,104686.0,H,,Autocuration,1185.0,,,CHEMBL617433,1.0,,4.0,,,,,,2359.0,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104686.0,H,,Autocuration,1185.0,,,CHEMBL617434,1.0,,4.0,,,,,,2360.0,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104686.0,D,Rattus norvegicus,Autocuration,11624.0,,10116.0,CHEMBL617435,1.0,,5.0,,,,,,2361.0,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor
,BAO_0000019,B,,,104686.0,H,,Autocuration,1344.0,,,CHEMBL617436,1.0,,4.0,,,,,,2362.0,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay
,BAO_0000019,B,,,104686.0,D,Rattus norvegicus,Autocuration,15453.0,,10116.0,CHEMBL617437,1.0,,5.0,Striatum,,,2435.0,,2363.0,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203
,BAO_0000019,B,,,104686.0,H,,Autocuration,11662.0,,,CHEMBL617438,1.0,,4.0,,,,,,2364.0,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand"
,BAO_0000019,B,,,104686.0,H,,Autocuration,11662.0,,,CHEMBL617439,1.0,,4.0,,,,,,2365.0,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined"
,BAO_0000224,B,,,104686.0,H,,Autocuration,10796.0,,,CHEMBL617440,1.0,,4.0,,,,,,2366.0,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104686.0,H,,Autocuration,9069.0,,,CHEMBL617441,1.0,,4.0,,,,,,2367.0,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor
,BAO_0000019,B,,,104686.0,D,Rattus norvegicus,Autocuration,8814.0,,10116.0,CHEMBL872918,1.0,,5.0,,,,,,2368.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates
,BAO_0000019,B,,,104686.0,D,Rattus norvegicus,Autocuration,8908.0,,10116.0,CHEMBL617442,1.0,,5.0,,,,,,2369.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex
,BAO_0000019,B,,,104686.0,H,,Autocuration,9098.0,,,CHEMBL617443,1.0,,4.0,,,,,,2370.0,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.
,BAO_0000019,B,,,104686.0,H,,Autocuration,9098.0,,,CHEMBL617444,1.0,,4.0,,,,,,2371.0,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand
,BAO_0000019,B,,,104686.0,H,,Autocuration,9098.0,,,CHEMBL617445,1.0,,4.0,,,,,,2372.0,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.
,BAO_0000019,B,,,104686.0,H,,Autocuration,9098.0,,,CHEMBL617446,1.0,,4.0,,,,,,2373.0,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.
,BAO_0000249,B,,,104686.0,H,,Autocuration,9098.0,,,CHEMBL617447,1.0,,4.0,,,,,,2374.0,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.
,BAO_0000019,B,,,104686.0,H,,Autocuration,9098.0,,,CHEMBL617448,1.0,,4.0,,,,,,2375.0,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined
,BAO_0000019,B,,,104686.0,H,,Autocuration,9098.0,,,CHEMBL617449,1.0,,4.0,,,,,,2376.0,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data
,BAO_0000019,B,,,104686.0,H,,Autocuration,9161.0,,,CHEMBL617450,1.0,,4.0,,,,,,2377.0,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.
,BAO_0000019,B,,,104686.0,H,,Autocuration,9161.0,,,CHEMBL617451,1.0,,4.0,,,,,,2378.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263
,BAO_0000019,B,,,104686.0,H,,Autocuration,9161.0,,,CHEMBL617452,1.0,,4.0,,,,,,2379.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3
,BAO_0000019,B,,,104686.0,H,,Autocuration,9161.0,,,CHEMBL617453,1.0,,4.0,,,,,,2380.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.
,BAO_0000019,B,,,104686.0,H,,Autocuration,9161.0,,,CHEMBL617660,1.0,,4.0,,,,,,2381.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980
,BAO_0000019,B,,,104686.0,H,,Autocuration,9161.0,,,CHEMBL617661,1.0,,4.0,,,,,,2382.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299
,BAO_0000019,B,,,104686.0,H,,Autocuration,9161.0,,,CHEMBL617662,1.0,,4.0,,,,,,2383.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66
,BAO_0000019,B,,,104686.0,H,,Autocuration,9161.0,,,CHEMBL872919,1.0,,4.0,,,,,,2384.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220
,BAO_0000019,B,,,104686.0,H,,Autocuration,9161.0,,,CHEMBL617663,1.0,,4.0,,,,,,2385.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341
,BAO_0000019,B,,,104686.0,H,,Autocuration,9161.0,,,CHEMBL617664,1.0,,4.0,,,,,,2386.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187
,BAO_0000019,B,,,104686.0,H,,Autocuration,9161.0,,,CHEMBL617665,1.0,,4.0,,,,,,2387.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132
,BAO_0000019,B,,,104686.0,H,,Autocuration,9161.0,,,CHEMBL617666,1.0,,4.0,,,,,,2388.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75
,BAO_0000019,B,,,104686.0,H,,Autocuration,12094.0,,,CHEMBL617667,1.0,,4.0,,,,,,2389.0,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells
,BAO_0000249,B,,,104686.0,H,,Autocuration,12018.0,,,CHEMBL617668,1.0,,4.0,,,,,,2390.0,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.
,BAO_0000249,B,,,104686.0,H,,Autocuration,10394.0,,,CHEMBL617669,1.0,,4.0,,,,,,2391.0,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand
,BAO_0000224,B,,,104686.0,H,,Autocuration,15260.0,,,CHEMBL617670,1.0,,4.0,,,,,,2392.0,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104686.0,D,Rattus norvegicus,Autocuration,11624.0,,10116.0,CHEMBL617671,1.0,,5.0,,,,,,2393.0,Inhibitory constant against 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104686.0,H,,Autocuration,13654.0,,,CHEMBL617672,1.0,,4.0,,,,,,2394.0,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor
,BAO_0000019,B,,,104686.0,H,,Autocuration,9541.0,,,CHEMBL617673,1.0,,4.0,,,,,,2395.0,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum
,BAO_0000224,B,,,104686.0,H,,Autocuration,11933.0,,,CHEMBL617674,1.0,,4.0,,,,,,2396.0,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand
,BAO_0000019,B,,,104686.0,H,,Autocuration,15538.0,,,CHEMBL617675,1.0,,4.0,,,,,,2397.0,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex
,BAO_0000019,B,,,104686.0,H,,Autocuration,15538.0,,,CHEMBL617676,1.0,,4.0,,,,,,2398.0,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active
,BAO_0000019,B,,,104686.0,H,,Autocuration,15538.0,,,CHEMBL617677,1.0,,4.0,,,,,,2399.0,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined
,BAO_0000019,B,,,104686.0,D,,Autocuration,8841.0,,,CHEMBL617678,1.0,,5.0,,,,,,2400.0,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor
,BAO_0000224,B,,,104686.0,H,,Autocuration,1455.0,,,CHEMBL617679,1.0,,4.0,,,,,,2401.0,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.
,BAO_0000224,B,,,104686.0,H,,Autocuration,1455.0,,,CHEMBL617680,1.0,,4.0,,,,,,2402.0,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay
,BAO_0000019,B,,,104686.0,H,,Autocuration,11752.0,,,CHEMBL617681,1.0,,4.0,,,,,,2403.0,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain
,BAO_0000221,B,,,104686.0,H,,Autocuration,11642.0,,,CHEMBL617682,1.0,,4.0,Brain,,,955.0,,2404.0,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue
,BAO_0000224,B,,,104686.0,H,,Autocuration,12092.0,,,CHEMBL617683,1.0,,4.0,,,,,,2405.0,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.
,BAO_0000224,B,,,104686.0,H,,Autocuration,3967.0,,,CHEMBL617684,1.0,,4.0,,,,,,2406.0,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.
,BAO_0000224,B,,,104686.0,D,Rattus norvegicus,Autocuration,12771.0,,10116.0,CHEMBL617685,1.0,,5.0,,,,,,2407.0,Binding affinity towards 5-hydroxytryptamine 2 receptor
,BAO_0000019,B,,,104686.0,H,,Autocuration,11642.0,,,CHEMBL617686,1.0,,4.0,,,,,,2408.0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex
,BAO_0000224,B,,,104686.0,H,,Autocuration,11628.0,,,CHEMBL617687,1.0,,4.0,,,,,,2409.0,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand
,BAO_0000224,B,,,104686.0,H,,Autocuration,13654.0,,,CHEMBL617688,1.0,,4.0,,,,,,2410.0,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor
,BAO_0000019,F,,,104686.0,H,,Autocuration,11200.0,,,CHEMBL617689,1.0,,4.0,,,,,,2411.0,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips
,BAO_0000019,F,,,104686.0,H,,Autocuration,11200.0,,,CHEMBL617690,1.0,,4.0,,,,,,2412.0,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips
,BAO_0000218,F,In vivo,,104686.0,H,,Autocuration,11200.0,,,CHEMBL617691,1.0,,4.0,,,,,,2413.0,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration"
,BAO_0000218,F,In vivo,,104686.0,H,,Autocuration,11200.0,,,CHEMBL617692,1.0,,4.0,,,,,,2414.0,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration"
,BAO_0000218,F,In vivo,,104686.0,H,,Autocuration,11200.0,,,CHEMBL617693,1.0,,4.0,,,,,,2415.0,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration"
,BAO_0000218,F,In vivo,,104686.0,H,,Autocuration,11200.0,,,CHEMBL617694,1.0,,4.0,,,,,,2416.0,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration"
,BAO_0000221,B,,,12687.0,H,,Expert,15436.0,,,CHEMBL857985,1.0,,8.0,Brain,,,955.0,,2417.0,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin
,BAO_0000019,B,,,12687.0,D,Rattus norvegicus,Expert,15436.0,,10116.0,CHEMBL617695,1.0,,9.0,,,,,,2418.0,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin
,BAO_0000019,B,,,12687.0,H,,Autocuration,14025.0,,,CHEMBL617696,1.0,,8.0,,,,,,2419.0,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates
,BAO_0000357,B,,,12687.0,H,,Autocuration,4342.0,,,CHEMBL617697,1.0,,8.0,,,,,,2420.0,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined
,BAO_0000019,B,,,12687.0,D,Rattus norvegicus,Expert,13735.0,,10116.0,CHEMBL617257,1.0,,9.0,,,,,,2421.0,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex
,BAO_0000357,B,,,12687.0,D,Rattus norvegicus,Expert,5816.0,,10116.0,CHEMBL617258,1.0,,9.0,,,,,,2422.0,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin
,BAO_0000019,B,,,12687.0,H,,Expert,14287.0,,,CHEMBL617259,1.0,,8.0,,,,,,2423.0,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane
,BAO_0000357,B,,,12687.0,H,,Autocuration,15738.0,,,CHEMBL617260,1.0,,8.0,,,,,,2424.0,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor
,BAO_0000357,B,,,12687.0,D,Rattus norvegicus,Expert,15738.0,,10116.0,CHEMBL617261,1.0,,9.0,,,,,,2425.0,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor
,BAO_0000019,B,,,12687.0,H,,Autocuration,15026.0,,,CHEMBL617262,1.0,,8.0,,,,,,2426.0,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand
,BAO_0000019,B,,,12687.0,H,,Expert,16647.0,,,CHEMBL617263,1.0,,8.0,,,,,,2427.0,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate
,BAO_0000019,B,,,12687.0,H,,Autocuration,16647.0,,,CHEMBL617264,1.0,,8.0,,,,,,2428.0,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate
,BAO_0000019,B,,,12687.0,D,Rattus norvegicus,Expert,13345.0,,10116.0,CHEMBL617265,1.0,,9.0,,,,,,2429.0,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor
,BAO_0000249,B,,,12687.0,H,,Autocuration,1543.0,Membranes,,CHEMBL617266,1.0,,8.0,,,,,,2430.0,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor
,BAO_0000019,B,,,12687.0,H,,Autocuration,12444.0,,,CHEMBL617267,1.0,,8.0,,,,,,2431.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane
,BAO_0000019,B,,,12687.0,H,,Expert,16404.0,,,CHEMBL617268,1.0,,8.0,,,,,,2432.0,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex
,BAO_0000219,B,,CHO,12687.0,H,,Autocuration,16404.0,,,CHEMBL617269,1.0,,8.0,,,,,449.0,2433.0,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells
,BAO_0000357,B,,,12687.0,H,,Expert,15577.0,,,CHEMBL617323,1.0,,8.0,,,,,,2434.0,Kinetic inhibition constant evaluated by measuring serotonergic activity
,BAO_0000357,B,,,12687.0,H,,Autocuration,15577.0,,,CHEMBL617324,1.0,,8.0,,,,,,2435.0,Serotonergic activity of the compound.
,BAO_0000249,B,,,12687.0,H,,Autocuration,2495.0,,,CHEMBL617325,1.0,,8.0,,,,,,2436.0,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes
,BAO_0000019,B,,,12687.0,D,Rattus norvegicus,Expert,15042.0,,10116.0,CHEMBL617326,1.0,,9.0,,,,,,2437.0,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.
,BAO_0000249,B,,,12687.0,H,,Expert,15026.0,,,CHEMBL617327,1.0,,8.0,,,,,,2438.0,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.
,BAO_0000019,F,,,12687.0,D,Rattus norvegicus,Expert,12919.0,,10116.0,CHEMBL617328,1.0,,9.0,,,,,,2439.0,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin
,BAO_0000019,F,,,12687.0,D,Rattus norvegicus,Expert,12919.0,,10116.0,CHEMBL617329,1.0,,9.0,,,,,,2440.0,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin
,BAO_0000019,F,,,12687.0,D,Rattus norvegicus,Expert,12919.0,,10116.0,CHEMBL617330,1.0,,9.0,,,,,,2441.0,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin
,BAO_0000357,B,,,12687.0,H,,Autocuration,15194.0,,,CHEMBL617331,1.0,,8.0,,,,,,2442.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
,BAO_0000357,B,,,12687.0,H,,Autocuration,15194.0,,,CHEMBL617332,1.0,,8.0,,,,,,2443.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.
,BAO_0000357,B,,,107.0,H,,Expert,4820.0,,,CHEMBL617333,1.0,,8.0,,,,,,2444.0,Binding affinity towards 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,107.0,H,,Autocuration,6736.0,,,CHEMBL617334,1.0,,8.0,,,,,,2445.0,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin
,BAO_0000357,B,,,107.0,H,,Autocuration,5163.0,,,CHEMBL617335,1.0,,8.0,,,,,,2446.0,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L
,BAO_0000357,B,,,107.0,H,,Autocuration,5163.0,,,CHEMBL617336,1.0,,8.0,,,,,,2447.0,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L
,BAO_0000357,B,,,107.0,H,,Autocuration,6011.0,,,CHEMBL617337,1.0,,8.0,,,,,,2448.0,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration
,BAO_0000357,B,,,107.0,D,Homo sapiens,Expert,14294.0,,9606.0,CHEMBL617338,1.0,,9.0,,,,,,2449.0,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM
,BAO_0000357,B,,,107.0,H,,Autocuration,5014.0,,,CHEMBL617339,1.0,,8.0,,,,,,2450.0,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,107.0,H,,Expert,17066.0,,,CHEMBL617340,1.0,,8.0,,,,,,2451.0,Binding affinity towards 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,107.0,H,,Autocuration,17515.0,,,CHEMBL617341,1.0,,8.0,,,,,,2452.0,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM
,BAO_0000357,B,,,107.0,H,,Expert,6736.0,,,CHEMBL617342,1.0,,8.0,,,,,,2453.0,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,107.0,H,,Expert,5163.0,,,CHEMBL617343,1.0,,8.0,,,,,,2454.0,Affinity for 5-hydroxytryptamine 2A receptor
,BAO_0000219,B,,NIH3T3,107.0,H,,Expert,16911.0,,,CHEMBL617344,1.0,,8.0,,,,,723.0,2455.0,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).
,BAO_0000357,B,,,107.0,H,,Expert,6841.0,,,CHEMBL617345,1.0,,8.0,,,,,,2456.0,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin
,BAO_0000357,B,,,107.0,H,,Expert,6119.0,,,CHEMBL617346,1.0,,8.0,,,,,,2457.0,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.
,BAO_0000357,B,,,107.0,H,,Autocuration,3962.0,,,CHEMBL617347,1.0,,8.0,,,,,,2458.0,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,107.0,H,,Autocuration,4373.0,,,CHEMBL617348,1.0,,8.0,,,,,,2459.0,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined
,BAO_0000357,B,,,107.0,H,,Autocuration,4373.0,,,CHEMBL617349,1.0,,8.0,,,,,,2460.0,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined
,BAO_0000019,F,,,107.0,H,,Autocuration,3962.0,,,CHEMBL617350,1.0,,8.0,,,,,,2461.0,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,107.0,H,,Expert,1633.0,,,CHEMBL872339,1.0,,8.0,,,,,,2462.0,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin
,BAO_0000357,B,,,107.0,H,,Autocuration,4373.0,,,CHEMBL617351,1.0,,8.0,,,,,,2463.0,Binding affinity for 5-hydroxytryptamine 2A receptor was determined
,BAO_0000357,B,,,107.0,H,,Expert,6576.0,,,CHEMBL617352,1.0,,8.0,,,,,,2464.0,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,107.0,H,,Autocuration,4687.0,,,CHEMBL617353,1.0,,8.0,,,,,,2465.0,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,107.0,H,,Autocuration,16946.0,,,CHEMBL617354,1.0,,8.0,,,,,,2466.0,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,107.0,H,,Autocuration,14159.0,,,CHEMBL617355,1.0,,8.0,,,,,,2467.0,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor
,BAO_0000219,B,,CHO,107.0,H,Mus musculus,Expert,3032.0,,10090.0,CHEMBL617356,1.0,,8.0,,,,,449.0,2468.0,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells
,BAO_0000357,B,,,107.0,H,,Autocuration,16655.0,,,CHEMBL617357,1.0,,8.0,,,,,,2469.0,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,107.0,H,,Autocuration,13964.0,,,CHEMBL617358,1.0,,8.0,,,,,,2470.0,Binding affinity at 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,107.0,H,,Expert,16989.0,,,CHEMBL617359,1.0,,8.0,,,,,,2471.0,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,107.0,H,,Autocuration,16117.0,,,CHEMBL617360,1.0,,8.0,,,,,,2472.0,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined
,BAO_0000357,B,,,107.0,H,,Autocuration,16700.0,,,CHEMBL875913,1.0,,8.0,,,,,,2473.0,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity
,BAO_0000357,B,,,107.0,H,,Autocuration,3269.0,,,CHEMBL617361,1.0,,8.0,,,,,,2474.0,Affinity against 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,107.0,D,Homo sapiens,Expert,1274.0,,9606.0,CHEMBL617362,1.0,,9.0,,,,,,2475.0,Binding affinity against 5-Hydroxytryptamine 2A receptor
,BAO_0000357,B,,,107.0,H,,Autocuration,1317.0,,,CHEMBL617363,1.0,,8.0,,,,,,2476.0,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay
,BAO_0000357,B,,,107.0,H,,Autocuration,12146.0,,,CHEMBL617364,1.0,,8.0,,,,,,2477.0,Tested against 5-hydroxytryptamine 2A receptor
,BAO_0000224,B,,,105075.0,H,,Autocuration,12652.0,,,CHEMBL617365,1.0,,4.0,,,,,,2478.0,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin
,BAO_0000224,B,,,105075.0,H,,Autocuration,12652.0,,,CHEMBL617366,1.0,,4.0,,,,,,2479.0,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin
,BAO_0000224,B,,,105075.0,H,,Autocuration,12652.0,,,CHEMBL617367,1.0,,4.0,,,,,,2480.0,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI
,BAO_0000224,B,,,105075.0,H,,Autocuration,12652.0,,,CHEMBL617368,1.0,,4.0,,,,,,2481.0,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin
,BAO_0000357,B,,,107.0,H,,Autocuration,16647.0,,,CHEMBL617369,1.0,,8.0,,,,,,2482.0,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 )
,BAO_0000219,B,,HEK293,227.0,D,Homo sapiens,Expert,15851.0,,9606.0,CHEMBL617370,1.0,,9.0,,,,,722.0,2483.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data
,BAO_0000219,F,,CHO,227.0,D,Homo sapiens,Expert,6857.0,,9606.0,CHEMBL617371,1.0,,9.0,,,,,449.0,2484.0,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader
,BAO_0000357,B,,,227.0,H,,Autocuration,3805.0,,,CHEMBL617372,1.0,,8.0,,,,,,2485.0,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM)
,BAO_0000357,B,,,227.0,D,Homo sapiens,Expert,6491.0,,9606.0,CHEMBL617373,1.0,,9.0,,,,,,2486.0,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor
,BAO_0000019,F,,,227.0,H,,Autocuration,14093.0,,,CHEMBL617374,1.0,,8.0,,,,,,2487.0,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand
,BAO_0000019,F,,,227.0,H,,Autocuration,13481.0,,,CHEMBL617375,1.0,,8.0,,,,,,2488.0,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand
,BAO_0000019,F,,,227.0,H,,Autocuration,14093.0,,,CHEMBL617376,1.0,,8.0,,,,,,2489.0,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand
,BAO_0000019,F,,,227.0,H,,Autocuration,14093.0,,,CHEMBL617377,1.0,,8.0,,,,,,2490.0,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested
,BAO_0000019,F,,,227.0,H,,Autocuration,14093.0,,,CHEMBL617378,1.0,,8.0,,,,,,2491.0,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand
,BAO_0000019,F,,,227.0,H,,Autocuration,13481.0,,,CHEMBL617379,1.0,,8.0,,,,,,2492.0,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand
,BAO_0000357,B,,,227.0,H,,Autocuration,14442.0,,,CHEMBL617380,1.0,,8.0,,,,,,2493.0,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand
,BAO_0000357,B,,,227.0,H,,Autocuration,14442.0,,,CHEMBL617381,1.0,,8.0,,,,,,2494.0,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand
,BAO_0000357,B,,,227.0,H,,Autocuration,14442.0,,,CHEMBL617382,1.0,,8.0,,,,,,2495.0,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand
,BAO_0000357,B,,,107.0,H,,Autocuration,12369.0,,,CHEMBL617383,1.0,,8.0,,,,,,2496.0,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,107.0,H,,Expert,12369.0,,,CHEMBL617384,1.0,,8.0,,,,,,2497.0,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.
,BAO_0000357,B,,,107.0,H,,Expert,12369.0,,,CHEMBL617385,1.0,,8.0,,,,,,2498.0,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.
,BAO_0000019,B,,,107.0,H,,Autocuration,14447.0,,,CHEMBL617386,1.0,,8.0,,,,,,2499.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes
,BAO_0000019,B,,,107.0,H,,Autocuration,14447.0,,,CHEMBL617387,1.0,,8.0,,,,,,2500.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.
,BAO_0000219,B,,NIH3T3,107.0,H,,Autocuration,17451.0,,,CHEMBL617388,1.0,,8.0,,,,,723.0,2501.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined
,BAO_0000219,F,,CHO,107.0,H,,Autocuration,6857.0,,,CHEMBL617389,1.0,,8.0,,,,,449.0,2502.0,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT
,BAO_0000219,F,,CHO,107.0,D,Homo sapiens,Expert,6857.0,,9606.0,CHEMBL617390,1.0,,9.0,,,,,449.0,2503.0,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT
,BAO_0000224,B,,,104817.0,H,,Autocuration,5635.0,,,CHEMBL617391,1.0,,4.0,,,,,,2504.0,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.
,BAO_0000357,B,,,107.0,H,,Autocuration,12861.0,,,CHEMBL617392,1.0,,8.0,,,,,,2505.0,Binding activity radioligand.
,BAO_0000019,B,,,107.0,H,,Autocuration,12861.0,,,CHEMBL617393,1.0,,8.0,,,,,,2506.0,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.
,BAO_0000219,B,,L929,107.0,H,,Autocuration,5105.0,,,CHEMBL617394,1.0,,8.0,,,,,307.0,2507.0,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand
,BAO_0000219,B,,L929,107.0,H,,Expert,5104.0,,,CHEMBL617395,1.0,,8.0,,,,,307.0,2508.0,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand
,BAO_0000219,B,,L929,107.0,H,,Expert,5105.0,,,CHEMBL617396,1.0,,8.0,,,,,307.0,2509.0,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.
,BAO_0000219,B,,L929,107.0,H,,Autocuration,5105.0,,,CHEMBL617397,1.0,,8.0,,,,,307.0,2510.0,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested
,BAO_0000357,B,,,107.0,H,,Autocuration,5254.0,,,CHEMBL617398,1.0,,8.0,,,,,,2511.0,Binding affinity against 5-HT2A receptor
,BAO_0000357,B,,,107.0,H,,Autocuration,5254.0,,,CHEMBL617399,1.0,,8.0,,,,,,2512.0,Binding affinity against 5-hydroxytryptamine 2A receptor
,BAO_0000219,B,,HEK293,107.0,H,,Autocuration,13267.0,,,CHEMBL617400,1.0,,8.0,,,,,722.0,2513.0,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand
,BAO_0000219,B,,HEK293,107.0,H,,Autocuration,13267.0,,,CHEMBL617401,1.0,,8.0,,,,,722.0,2514.0,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand
,BAO_0000219,B,,HEK293,107.0,D,Homo sapiens,Expert,14157.0,,9606.0,CHEMBL617402,1.0,,9.0,,,,,722.0,2515.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells
,BAO_0000219,B,,HEK293,107.0,D,Homo sapiens,Expert,12936.0,,9606.0,CHEMBL617403,1.0,,9.0,,,,,722.0,2516.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin
,BAO_0000357,B,,,107.0,H,,Expert,14068.0,,,CHEMBL617404,1.0,,8.0,,,,,,2517.0,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT
,BAO_0000219,B,,HEK293,107.0,D,Homo sapiens,Expert,12936.0,,9606.0,CHEMBL857981,1.0,,9.0,,,,,722.0,2518.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin
,BAO_0000219,B,,HEK293,107.0,D,Homo sapiens,Expert,12936.0,,9606.0,CHEMBL617405,1.0,,9.0,,,,,722.0,2519.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin
,BAO_0000219,B,,HEK293,107.0,D,Homo sapiens,Expert,4540.0,,9606.0,CHEMBL617253,1.0,,9.0,,,,,722.0,2520.0,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand
,BAO_0000357,B,,,107.0,H,,Expert,6166.0,,,CHEMBL617254,1.0,,8.0,,,,,,2521.0,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.
,BAO_0000219,B,,HEK293,107.0,H,,Autocuration,17296.0,,,CHEMBL617255,1.0,,8.0,,,,,722.0,2522.0,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand
,BAO_0000219,B,,HEK293,107.0,H,,Autocuration,17296.0,,,CHEMBL617256,1.0,,8.0,,,,,722.0,2523.0,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand
,BAO_0000219,B,,HEK293,107.0,H,,Autocuration,17296.0,,,CHEMBL616874,1.0,,8.0,,,,,722.0,2524.0,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand
,BAO_0000219,B,,HEK293,107.0,D,Homo sapiens,Expert,15779.0,,9606.0,CHEMBL616875,1.0,,9.0,,,,,722.0,2525.0,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.
,BAO_0000219,B,,HEK293,107.0,H,,Expert,14391.0,,,CHEMBL616876,1.0,,8.0,,,,,722.0,2526.0,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand
,BAO_0000219,B,,HEK293,107.0,H,,Expert,15851.0,,,CHEMBL616877,1.0,,8.0,,,,,722.0,2527.0,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand."
,BAO_0000219,B,,HEK293,107.0,D,Homo sapiens,Expert,15851.0,,9606.0,CHEMBL616878,1.0,,9.0,,,,,722.0,2528.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble
,BAO_0000219,B,,HEK293,107.0,H,,Expert,3832.0,,,CHEMBL616879,1.0,,8.0,,,,,722.0,2529.0,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin
,BAO_0000219,B,,HEK293,107.0,H,,Expert,3833.0,,,CHEMBL616880,1.0,,8.0,,,,,722.0,2530.0,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.
,BAO_0000219,B,,HEK293,107.0,D,Homo sapiens,Expert,12936.0,,9606.0,CHEMBL616881,1.0,,9.0,,,,,722.0,2531.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin
,BAO_0000219,B,,NIH3T3,107.0,H,,Autocuration,17451.0,,,CHEMBL616882,1.0,,8.0,,,,,723.0,2532.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand
,BAO_0000219,B,,NIH3T3,107.0,H,,Autocuration,17451.0,,,CHEMBL616883,1.0,,8.0,,,,,723.0,2533.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined
,BAO_0000219,B,,NIH3T3,107.0,H,,Autocuration,17451.0,,,CHEMBL616884,1.0,,8.0,,,,,723.0,2534.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined
,BAO_0000219,B,,HEK293,107.0,H,,Autocuration,4199.0,,,CHEMBL616885,1.0,,8.0,,,,,722.0,2535.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand
,BAO_0000219,B,,CHO-K1,107.0,H,,Autocuration,1883.0,,,CHEMBL616886,1.0,,8.0,,,,,485.0,2536.0,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells
,BAO_0000219,B,,CHO-K1,107.0,H,,Expert,1883.0,,,CHEMBL616887,1.0,,8.0,,,,,485.0,2537.0,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.
,BAO_0000357,B,,,107.0,D,Homo sapiens,Expert,14875.0,,9606.0,CHEMBL616888,1.0,,9.0,,,,,,2538.0,Binding affinity for human 5-hydroxytryptamine 2A receptor
,BAO_0000219,B,,HEK293,107.0,H,,Autocuration,15146.0,,,CHEMBL616889,1.0,,8.0,,,,,722.0,2539.0,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin
,BAO_0000219,B,,HEK293,107.0,H,,Autocuration,5213.0,,,CHEMBL616890,1.0,,8.0,,,,,722.0,2540.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand
,BAO_0000219,B,,CHO,107.0,D,Homo sapiens,Expert,16404.0,,9606.0,CHEMBL616891,1.0,,9.0,,,,,449.0,2541.0,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells
,BAO_0000219,B,,HEK293,107.0,H,,Autocuration,14818.0,,,CHEMBL616892,1.0,,8.0,,,,,722.0,2542.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.
,BAO_0000219,B,,HEK293,107.0,H,,Autocuration,4829.0,,,CHEMBL616893,1.0,,8.0,,,,,722.0,2543.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand"
,BAO_0000219,F,,NIH3T3,10620.0,H,,Autocuration,12652.0,,,CHEMBL616894,1.0,,8.0,,,,,723.0,2544.0,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells
,BAO_0000219,B,,NIH3T3,107.0,H,,Expert,4682.0,,,CHEMBL616895,1.0,,8.0,,,,,723.0,2545.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells
,BAO_0000019,F,,,10620.0,H,,Autocuration,12652.0,,,CHEMBL616896,1.0,,8.0,,,,,,2546.0,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,10621.0,H,,Autocuration,4921.0,,,CHEMBL617099,1.0,,8.0,,,,,,2547.0,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,10621.0,H,,Autocuration,4921.0,,,CHEMBL617100,1.0,,8.0,,,,,,2548.0,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined
,BAO_0000357,B,,,107.0,H,Oryctolagus cuniculus,Autocuration,16312.0,,9986.0,CHEMBL884532,1.0,,8.0,,,,,,2549.0,Binding affinity against rabbit aorta 5-HT2A receptor
,BAO_0000357,B,,,107.0,H,Oryctolagus cuniculus,Expert,14998.0,,9986.0,CHEMBL617101,1.0,,8.0,,,,,,2550.0,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations
,BAO_0000357,B,,,107.0,H,Oryctolagus cuniculus,Expert,14025.0,,9986.0,CHEMBL617102,1.0,,8.0,,,,,,2551.0,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta
,BAO_0000019,B,,,107.0,H,Oryctolagus cuniculus,Autocuration,13047.0,,9986.0,CHEMBL617103,1.0,,8.0,,,,,,2552.0,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.
,BAO_0000357,B,,,107.0,H,Oryctolagus cuniculus,Expert,13047.0,,9986.0,CHEMBL617104,1.0,,8.0,,,,,,2553.0,The compound was tested for binding affinity against 5-HT2A receptor
,BAO_0000219,B,,CHO-K1,10576.0,H,,Autocuration,1883.0,,,CHEMBL857979,1.0,,8.0,,,,,485.0,2554.0,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.
,BAO_0000019,B,,,12687.0,H,,Autocuration,13463.0,,,CHEMBL857502,1.0,,8.0,,,,,,2555.0,Binding affinity analysed towards 5-HT 2A in rat jugular vein
,BAO_0000019,B,,,12687.0,H,,Autocuration,13463.0,,,CHEMBL617105,1.0,,8.0,,,,,,2556.0,Binding affinity analysed towards 5-HT 2A in rat jugular vein.
,BAO_0000019,B,,,12687.0,H,,Autocuration,13463.0,,,CHEMBL858021,1.0,,8.0,Stomach,,,945.0,,2557.0,Binding affinity analysed on 5-HT 2A in rat stomach fundus.
,BAO_0000019,B,,,12687.0,D,Rattus norvegicus,Expert,13463.0,,10116.0,CHEMBL875910,1.0,,9.0,Stomach,,,945.0,,2558.0,Binding affinity for 5-HT 2A in rat stomach fundus
,BAO_0000019,B,,,12687.0,H,,Autocuration,13463.0,,,CHEMBL617106,1.0,,8.0,,,,,,2559.0,Binding affinity analysed towards 5-HT 2A in rat jugular vein.
,BAO_0000219,B,,NIH3T3,12687.0,H,,Expert,16326.0,,,CHEMBL617107,1.0,,8.0,,,,,723.0,2560.0,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor
,BAO_0000019,F,,,12687.0,H,,Autocuration,14093.0,,,CHEMBL617108,1.0,,8.0,,,,,,2561.0,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor
,BAO_0000019,F,,,12687.0,H,,Autocuration,14093.0,,,CHEMBL617109,1.0,,8.0,,,,,,2562.0,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,12687.0,H,,Autocuration,15740.0,,,CHEMBL617110,1.0,,8.0,,,,,,2563.0,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,12687.0,H,,Autocuration,16633.0,,,CHEMBL617111,1.0,,8.0,,,,,,2564.0,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation
,BAO_0000019,F,,,12687.0,D,Rattus norvegicus,Expert,17200.0,,10116.0,CHEMBL617112,1.0,,9.0,,,,,,2565.0,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells
,BAO_0000357,B,,,12687.0,H,,Autocuration,17133.0,,,CHEMBL617113,1.0,,8.0,,,,,,2566.0,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,12687.0,H,,Autocuration,17133.0,,,CHEMBL617114,1.0,,8.0,,,,,,2567.0,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,12687.0,H,,Autocuration,17133.0,,,CHEMBL617115,1.0,,8.0,,,,,,2568.0,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor
,BAO_0000219,F,,,12687.0,H,,Autocuration,17200.0,,,CHEMBL617116,1.0,,8.0,,,,,,2569.0,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells
,BAO_0000019,F,,,12687.0,H,,Autocuration,15363.0,,,CHEMBL617117,1.0,,8.0,,,,,,2570.0,Efficacy at 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,12687.0,H,,Autocuration,17200.0,,,CHEMBL617118,1.0,,8.0,,,,,,2571.0,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax)
,BAO_0000357,B,,,12687.0,D,Rattus norvegicus,Expert,17200.0,,10116.0,CHEMBL617119,1.0,,9.0,,,,,,2572.0,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax)
,BAO_0000357,B,,,12687.0,D,Rattus norvegicus,Expert,17200.0,,10116.0,CHEMBL617120,1.0,,9.0,,,,,,2573.0,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax)
,BAO_0000219,F,,,12687.0,D,Rattus norvegicus,Expert,17200.0,,10116.0,CHEMBL617121,1.0,,9.0,,,,,,2574.0,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells
,BAO_0000219,F,,,12687.0,H,,Autocuration,17200.0,,,CHEMBL617122,1.0,,8.0,,,,,,2575.0,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells
,BAO_0000019,B,,,12687.0,H,,Autocuration,17211.0,,,CHEMBL617123,1.0,,8.0,,,,,,2576.0,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor
,BAO_0000019,B,,,12687.0,H,,Expert,17331.0,,,CHEMBL617124,1.0,,8.0,,,,,,2577.0,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes
,BAO_0000249,B,,,12687.0,H,,Expert,13565.0,,,CHEMBL617600,1.0,,8.0,,,,,,2578.0,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes
,BAO_0000357,B,,,12687.0,H,,Expert,13730.0,,,CHEMBL617601,1.0,,8.0,,,,,,2579.0,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand
,BAO_0000019,B,,,12687.0,H,,Expert,12416.0,,,CHEMBL882923,1.0,,8.0,,,,,,2580.0,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex
,BAO_0000357,B,,,12687.0,H,,Autocuration,15295.0,,,CHEMBL617602,1.0,,8.0,,,,,,2581.0,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor
,BAO_0000019,B,,,12687.0,H,,Autocuration,1742.0,,,CHEMBL617603,1.0,,8.0,,,,,,2582.0,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates
,BAO_0000357,B,,,12687.0,H,,Autocuration,15295.0,,,CHEMBL617604,1.0,,8.0,,,,,,2583.0,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor
,BAO_0000019,B,,,12687.0,H,,Expert,14970.0,,,CHEMBL617605,1.0,,8.0,,,,,,2584.0,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand
,BAO_0000019,B,,,12687.0,H,,Expert,16693.0,,,CHEMBL617606,1.0,,8.0,,,,,,2585.0,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand
,BAO_0000019,B,,,12687.0,D,Rattus norvegicus,Expert,14776.0,,10116.0,CHEMBL617607,1.0,,9.0,,,,,,2586.0,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor
,BAO_0000249,B,,,12687.0,H,,Autocuration,14286.0,,,CHEMBL617455,1.0,,8.0,,,,,,2587.0,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane
,BAO_0000019,B,,,12687.0,D,Rattus norvegicus,Expert,17200.0,,10116.0,CHEMBL617456,1.0,,9.0,,,,,,2588.0,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex
,BAO_0000357,B,,,12687.0,H,,Expert,15306.0,,,CHEMBL617457,1.0,,8.0,,,,,,2589.0,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration)
,BAO_0000357,B,,,12687.0,D,Rattus norvegicus,Expert,14178.0,,10116.0,CHEMBL617458,1.0,,9.0,,,,,,2590.0,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor
,BAO_0000019,B,,,12687.0,D,Rattus norvegicus,Expert,14229.0,,10116.0,CHEMBL617459,1.0,,9.0,,,,,,2591.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain
,BAO_0000357,B,,,12687.0,H,,Expert,12884.0,,,CHEMBL617460,1.0,,8.0,,,,,,2592.0,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. 
,BAO_0000357,B,,,12687.0,H,,Expert,13149.0,,,CHEMBL617461,1.0,,8.0,,,,,,2593.0,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values."
,BAO_0000019,B,,,12687.0,D,Rattus norvegicus,Expert,15295.0,,10116.0,CHEMBL617462,1.0,,9.0,,,,,,2594.0,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M
,BAO_0000357,B,,,12687.0,H,,Autocuration,15740.0,,,CHEMBL617463,1.0,,8.0,,,,,,2595.0,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.
,BAO_0000019,B,,,12687.0,H,,Autocuration,15185.0,,,CHEMBL617464,1.0,,8.0,,,,,,2596.0,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI)."
,BAO_0000019,B,,,12687.0,H,,Autocuration,15185.0,,,CHEMBL617465,1.0,,8.0,,,,,,2597.0,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate."
,BAO_0000019,B,,,12687.0,H,,Expert,17529.0,,,CHEMBL617466,1.0,,8.0,,,,,,2598.0,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand
,BAO_0000019,B,,,12687.0,H,,Autocuration,14826.0,,,CHEMBL617467,1.0,,8.0,,,,,,2599.0,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex
,BAO_0000019,B,,,12687.0,H,,Expert,17211.0,,,CHEMBL617468,1.0,,8.0,,,,,,2600.0,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors
,BAO_0000019,B,,,12687.0,H,,Autocuration,14826.0,,,CHEMBL617469,1.0,,8.0,,,,,,2601.0,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex
,BAO_0000019,B,,,12687.0,H,,Autocuration,14093.0,,,CHEMBL617470,1.0,,8.0,,,,,,2602.0,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor
,BAO_0000019,B,,,12687.0,H,,Autocuration,14093.0,,,CHEMBL617471,1.0,,8.0,,,,,,2603.0,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested
,BAO_0000219,B,,NIH3T3,12687.0,H,,Expert,13246.0,,,CHEMBL617472,1.0,,8.0,,,,,723.0,2604.0,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes
,BAO_0000357,B,,,12687.0,H,,Expert,13246.0,,,CHEMBL617473,1.0,,8.0,,,,,,2605.0,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.
,BAO_0000019,B,,,12687.0,D,Rattus norvegicus,Expert,15436.0,,10116.0,CHEMBL617474,1.0,,9.0,,,,,,2606.0,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin
,BAO_0000019,B,,,12687.0,D,Rattus norvegicus,Expert,15436.0,,10116.0,CHEMBL617475,1.0,,9.0,,,,,,2607.0,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin
,BAO_0000221,B,,,12687.0,H,,Autocuration,14442.0,,,CHEMBL617476,1.0,,8.0,Brain,,,955.0,,2608.0,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined
,BAO_0000357,B,,,12687.0,H,,Expert,12457.0,,,CHEMBL617477,1.0,,8.0,,,,,,2609.0,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor
,BAO_0000219,B,,NIH3T3,12687.0,H,,Expert,12457.0,,,CHEMBL617478,1.0,,8.0,,,,,723.0,2610.0,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor
,BAO_0000221,F,,,12687.0,H,,Autocuration,14755.0,,,CHEMBL617479,1.0,,8.0,,,,,,2611.0,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates."
,BAO_0000357,B,,,12687.0,H,,Autocuration,4707.0,,,CHEMBL617480,1.0,,8.0,,,,,,2612.0,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand
,BAO_0000357,B,,,12687.0,H,,Expert,13297.0,,,CHEMBL617481,1.0,,8.0,,,,,,2613.0,Binding affinity against 5-hydroxytryptamine 2A receptor
,BAO_0000019,B,,,12687.0,H,,Expert,17331.0,,,CHEMBL617482,1.0,,8.0,,,,,,2614.0,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes
,BAO_0000019,B,,,12687.0,H,,Autocuration,4664.0,,,CHEMBL617483,1.0,,8.0,,,,,,2615.0,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand
,BAO_0000357,B,,,12687.0,H,,Autocuration,16633.0,,,CHEMBL621528,1.0,,8.0,,,,,,2616.0,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand
,BAO_0000219,B,,NIH3T3,12687.0,D,Rattus norvegicus,Expert,4664.0,,10116.0,CHEMBL621529,1.0,,9.0,,,,,723.0,2617.0,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin
,BAO_0000357,B,,,12687.0,H,,Expert,16133.0,,,CHEMBL621530,1.0,,8.0,,,,,,2618.0,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand
,BAO_0000357,B,,,12687.0,H,,Expert,16133.0,,,CHEMBL621531,1.0,,8.0,,,,,,2619.0,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
,BAO_0000019,B,,,12687.0,D,Rattus norvegicus,Expert,14060.0,,10116.0,CHEMBL621532,1.0,,9.0,,,,,,2620.0,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,12687.0,H,,Expert,16326.0,,,CHEMBL621533,1.0,,8.0,,,,,,2621.0,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand
,BAO_0000219,B,,CHO,12687.0,H,,Expert,16659.0,,,CHEMBL621534,1.0,,8.0,,,,,449.0,2622.0,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells
,BAO_0000019,B,,,12687.0,H,,Autocuration,14776.0,,,CHEMBL621535,1.0,,8.0,,,,,,2623.0,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.
,BAO_0000357,B,,,12687.0,H,,Autocuration,13481.0,,,CHEMBL621536,1.0,,8.0,,,,,,2624.0,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay
,BAO_0000357,B,,,12687.0,H,,Autocuration,17386.0,,,CHEMBL621537,1.0,,8.0,,,,,,2625.0,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,12687.0,D,Rattus norvegicus,Expert,6611.0,,10116.0,CHEMBL621538,1.0,,9.0,,,,,,2626.0,Binding affinity for 5-hydroxytryptamine 2A receptor
,BAO_0000019,B,,,12687.0,H,,Autocuration,14423.0,,,CHEMBL621539,1.0,,8.0,,,,,,2627.0,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.
,BAO_0000019,B,,,12687.0,H,,Autocuration,15412.0,,,CHEMBL621540,1.0,,8.0,,,,,,2628.0,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex
,BAO_0000019,B,,,12687.0,H,,Autocuration,15412.0,,,CHEMBL621541,1.0,,8.0,,,,,,2629.0,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.
,BAO_0000019,B,,,12687.0,H,,Autocuration,6238.0,,,CHEMBL621542,1.0,,8.0,,,,,,2630.0,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand
,BAO_0000357,B,,,12687.0,H,,Expert,6648.0,,,CHEMBL621543,1.0,,8.0,,,,,,2631.0,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.
,BAO_0000357,B,,,12687.0,H,,Expert,5667.0,,,CHEMBL621544,1.0,,8.0,,,,,,2632.0,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand
,BAO_0000357,B,,,12687.0,D,Rattus norvegicus,Expert,6611.0,,10116.0,CHEMBL621545,1.0,,9.0,,,,,,2633.0,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor
,BAO_0000357,B,,,12687.0,H,,Autocuration,13481.0,,,CHEMBL621546,1.0,,8.0,,,,,,2634.0,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
,BAO_0000357,B,,,12687.0,H,,Autocuration,13481.0,,,CHEMBL621547,1.0,,8.0,,,,,,2635.0,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested
,BAO_0000219,B,,NIH3T3,12687.0,H,,Expert,15558.0,,,CHEMBL618692,1.0,,8.0,,,,,723.0,2636.0,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,12687.0,H,,Autocuration,6013.0,,,CHEMBL618693,1.0,,8.0,,,,,,2637.0,Binding affinity towards 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,12687.0,H,,Autocuration,16633.0,,,CHEMBL872922,1.0,,8.0,,,,,,2638.0,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand
,BAO_0000357,B,,,12687.0,H,,Autocuration,6013.0,,,CHEMBL618694,1.0,,8.0,,,,,,2639.0,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand
,BAO_0000357,B,,,12687.0,D,Rattus norvegicus,Expert,6013.0,,10116.0,CHEMBL618695,1.0,,9.0,,,,,,2640.0,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB
,BAO_0000357,B,,,12687.0,H,,Autocuration,6013.0,,,CHEMBL618696,1.0,,8.0,,,,,,2641.0,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data
,BAO_0000357,B,,,12687.0,H,,Expert,6013.0,,,CHEMBL618697,1.0,,8.0,,,,,,2642.0,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.
,BAO_0000357,B,,,12687.0,H,,Autocuration,6013.0,,,CHEMBL618892,1.0,,8.0,,,,,,2643.0,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand
,BAO_0000357,B,,,12687.0,H,,Autocuration,6013.0,,,CHEMBL618893,1.0,,8.0,,,,,,2644.0,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand
,BAO_0000357,B,,,12687.0,H,,Autocuration,16293.0,,,CHEMBL618894,1.0,,8.0,,,,,,2645.0,Binding affinity towards rat 5-hydroxytryptamine 2A receptor
,BAO_0000219,B,,NIH3T3,12687.0,H,,Expert,17175.0,,,CHEMBL618895,1.0,,8.0,,,,,723.0,2646.0,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand
,BAO_0000357,B,,,12687.0,D,Rattus norvegicus,Expert,13278.0,,10116.0,CHEMBL618896,1.0,,9.0,,,,,,2647.0,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides
,BAO_0000019,B,,,12687.0,H,,Autocuration,3682.0,,,CHEMBL618897,1.0,,8.0,Caudate-putamen,,,5383.0,,2648.0,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain
,BAO_0000357,B,,,12687.0,H,,Autocuration,2014.0,,,CHEMBL618898,1.0,,8.0,,,,,,2649.0,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand
,BAO_0000357,B,,,12687.0,H,,Autocuration,2014.0,,,CHEMBL618899,1.0,,8.0,,,,,,2650.0,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined
,BAO_0000357,B,,,12687.0,H,,Autocuration,4932.0,,,CHEMBL618900,1.0,,8.0,,,,,,2651.0,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture
,BAO_0000019,B,,,12687.0,H,,Autocuration,4932.0,,,CHEMBL618901,1.0,,8.0,,,,,,2652.0,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate
,BAO_0000357,B,,,12687.0,H,,Autocuration,3935.0,,,CHEMBL618902,1.0,,8.0,,,,,,2653.0,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor
,BAO_0000221,B,,,12687.0,D,Rattus norvegicus,Expert,5432.0,,10116.0,CHEMBL618903,1.0,,9.0,Hippocampus,,,10000000.0,,2654.0,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,12687.0,H,,Autocuration,15818.0,,,CHEMBL618904,1.0,,8.0,,,,,,2655.0,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,12687.0,H,,Autocuration,13672.0,,,CHEMBL618905,1.0,,8.0,,,,,,2656.0,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.
,BAO_0000357,B,,,12687.0,H,,Autocuration,13672.0,,,CHEMBL618906,1.0,,8.0,,,,,,2657.0,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.
,BAO_0000219,B,,NIH3T3,12687.0,H,,Expert,14749.0,,,CHEMBL618907,1.0,,8.0,,,,,723.0,2658.0,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.
,BAO_0000019,B,,,12687.0,H,,Autocuration,13462.0,,,CHEMBL618908,1.0,,8.0,,,,,,2659.0,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.
,BAO_0000357,B,,,12687.0,H,,Autocuration,15740.0,,,CHEMBL617909,1.0,,8.0,,,,,,2660.0,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor
,BAO_0000019,B,,,12687.0,H,,Expert,16647.0,,,CHEMBL617910,1.0,,8.0,,,,,,2661.0,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate
,BAO_0000221,B,,,12687.0,H,,Autocuration,13345.0,,,CHEMBL617911,1.0,,8.0,Brain,,,955.0,,2662.0,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.
,BAO_0000249,B,,,12687.0,H,,Autocuration,16740.0,,,CHEMBL872923,1.0,,8.0,,,,,,2663.0,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane
,BAO_0000249,B,,,12687.0,H,,Autocuration,16740.0,,,CHEMBL617912,1.0,,8.0,,,,,,2664.0,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane
,BAO_0000019,B,,,12687.0,D,Rattus norvegicus,Expert,15535.0,,10116.0,CHEMBL617913,1.0,,9.0,,,,,,2665.0,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex
,BAO_0000249,B,,,12687.0,H,,Expert,16740.0,,,CHEMBL617914,1.0,,8.0,,,,,,2666.0,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane
,BAO_0000249,B,,,12687.0,H,,Autocuration,16740.0,,,CHEMBL617915,1.0,,8.0,,,,,,2667.0,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane
,BAO_0000249,B,,,12687.0,H,,Autocuration,16740.0,,,CHEMBL617916,1.0,,8.0,,,,,,2668.0,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane
,BAO_0000019,B,,,12687.0,D,Rattus norvegicus,Expert,4795.0,,10116.0,CHEMBL617917,1.0,,9.0,,,,,,2669.0,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor
,BAO_0000019,B,,,12687.0,H,,Expert,8.0,,,CHEMBL617918,1.0,,8.0,,,,,,2670.0,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand
,BAO_0000019,B,,,12687.0,H,,Autocuration,8.0,,,CHEMBL617919,1.0,,8.0,,,,,,2671.0,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M
,BAO_0000019,B,,,12687.0,D,Rattus norvegicus,Expert,17200.0,,10116.0,CHEMBL617920,1.0,,9.0,,,,,,2672.0,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex
,BAO_0000019,B,,,12687.0,D,Rattus norvegicus,Expert,2148.0,,10116.0,CHEMBL617921,1.0,,9.0,,,,,,2673.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex
,BAO_0000224,B,,,105102.0,D,Rattus norvegicus,Expert,13345.0,,10116.0,CHEMBL617922,1.0,,5.0,,,,,,2674.0,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki"
,BAO_0000357,B,,,12687.0,H,,Autocuration,5088.0,,,CHEMBL617923,1.0,,8.0,,,,,,2675.0,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand
,BAO_0000357,B,,,12687.0,H,,Autocuration,5088.0,,,CHEMBL617924,1.0,,8.0,,,,,,2676.0,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
,BAO_0000357,B,,,12687.0,H,,Autocuration,17133.0,,,CHEMBL617925,1.0,,8.0,,,,,,2677.0,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand
,BAO_0000357,B,,,12687.0,D,Rattus norvegicus,Expert,17133.0,,10116.0,CHEMBL617926,1.0,,9.0,,,,,,2678.0,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI
,BAO_0000357,B,,,12687.0,H,,Autocuration,16532.0,,,CHEMBL617927,1.0,,8.0,,,,,,2679.0,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin
,BAO_0000357,B,,,12687.0,H,,Autocuration,15086.0,,,CHEMBL617928,1.0,,8.0,,,,,,2680.0,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor
,BAO_0000019,B,,,12687.0,D,Rattus norvegicus,Expert,2309.0,,10116.0,CHEMBL617929,1.0,,9.0,,,,,,2681.0,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin
,BAO_0000019,B,,,12687.0,H,,Expert,12953.0,,,CHEMBL617930,1.0,,8.0,,,,,,2682.0,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.
,BAO_0000019,B,,,12687.0,H,,Autocuration,12953.0,,,CHEMBL617931,1.0,,8.0,,,,,,2683.0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM
,BAO_0000019,B,,,12687.0,H,,Autocuration,12953.0,,,CHEMBL617932,1.0,,8.0,,,,,,2684.0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM
,BAO_0000219,B,,CHO,12687.0,H,,Autocuration,16659.0,,,CHEMBL617933,1.0,,8.0,,,,,449.0,2685.0,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data
,BAO_0000019,B,,,12687.0,H,,Autocuration,16740.0,,,CHEMBL617934,1.0,,8.0,,,,,,2686.0,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data
,BAO_0000019,B,,,12687.0,H,,Autocuration,16740.0,,,CHEMBL617935,1.0,,8.0,,,,,,2687.0,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data
,BAO_0000357,B,,,12687.0,H,,Autocuration,17133.0,,,CHEMBL617936,1.0,,8.0,,,,,,2688.0,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined
,BAO_0000019,B,,,12687.0,H,,Autocuration,17211.0,,,CHEMBL617937,1.0,,8.0,,,,,,2689.0,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested
,BAO_0000019,B,,,12687.0,H,,Autocuration,17331.0,,,CHEMBL617938,1.0,,8.0,,,,,,2690.0,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested
,BAO_0000218,B,,,12687.0,H,,Autocuration,16633.0,,,CHEMBL617939,1.0,,8.0,,,,,,2691.0,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63
,BAO_0000218,B,,,12687.0,H,,Autocuration,16633.0,,,CHEMBL617940,1.0,,8.0,,,,,,2692.0,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg
,BAO_0000218,B,,,12687.0,H,,Autocuration,16633.0,,,CHEMBL617941,1.0,,8.0,,,,,,2693.0,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg
,BAO_0000357,B,,,12687.0,H,,Expert,15026.0,,,CHEMBL617942,1.0,,8.0,,,,,,2694.0,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor
,BAO_0000357,B,,,12687.0,H,,Expert,15026.0,,,CHEMBL617943,1.0,,8.0,,,,,,2695.0,Ratio of pKi of 5-HT2A to that of D2 receptor
,BAO_0000224,B,,,105093.0,H,,Expert,16404.0,,,CHEMBL617944,1.0,,4.0,,,,,,2696.0,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor
,BAO_0000224,B,,,105093.0,H,,Expert,16404.0,,,CHEMBL617945,1.0,,4.0,,,,,,2697.0,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor
,BAO_0000224,B,,,105075.0,H,,Expert,16404.0,,,CHEMBL617946,1.0,,4.0,,,,,,2698.0,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,12687.0,H,,Autocuration,16404.0,,,CHEMBL617947,1.0,,8.0,,,,,,2699.0,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data
,BAO_0000357,B,,,12687.0,H,,Expert,16326.0,,,CHEMBL617948,1.0,,8.0,,,,,,2700.0,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM
,BAO_0000019,F,,,12687.0,H,,Autocuration,15847.0,,,CHEMBL858116,1.0,,8.0,,,,,,2701.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat
,BAO_0000019,F,,,12687.0,H,,Autocuration,15847.0,,,CHEMBL617949,1.0,,8.0,,,,,,2702.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done
,BAO_0000019,F,,,12687.0,H,,Autocuration,15329.0,,,CHEMBL617950,1.0,,8.0,,,,,,2703.0,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery
,BAO_0000019,F,,,12687.0,H,,Expert,16404.0,,,CHEMBL617951,1.0,,8.0,Thoracic aorta,,,1515.0,,2704.0,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta
,BAO_0000019,F,,,12687.0,H,,Expert,16404.0,,,CHEMBL617952,1.0,,8.0,Thoracic aorta,,,1515.0,,2705.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta
,BAO_0000019,F,,,12687.0,H,,Autocuration,16404.0,,,CHEMBL617953,1.0,,8.0,Thoracic aorta,,,1515.0,,2706.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.
,BAO_0000357,B,,,12687.0,H,,Autocuration,12861.0,,,CHEMBL617954,1.0,,8.0,,,,,,2707.0,Binding activity radioligand.
,BAO_0000019,B,,,12687.0,H,,Expert,12861.0,,,CHEMBL617955,1.0,,8.0,,,,,,2708.0,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.
,BAO_0000019,B,,,12687.0,H,,Autocuration,12861.0,,,CHEMBL857071,1.0,,8.0,,,,,,2709.0,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available
,BAO_0000019,B,,,12687.0,H,,Expert,12490.0,,,CHEMBL617270,1.0,,8.0,,,,,,2710.0,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate
,BAO_0000219,B,,N1E-115,12687.0,H,,Autocuration,12827.0,,,CHEMBL617271,1.0,,8.0,,,,,339.0,2711.0,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930
,BAO_0000219,B,,N1E-115,12687.0,H,,Autocuration,12827.0,,,CHEMBL617272,1.0,,8.0,,,,,339.0,2712.0,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined
,BAO_0000019,B,,,12687.0,H,,Autocuration,12918.0,,,CHEMBL617273,1.0,,8.0,,,,,,2713.0,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin
,BAO_0000019,F,,,12687.0,D,Rattus norvegicus,Expert,12919.0,,10116.0,CHEMBL617274,1.0,,9.0,,,,,,2714.0,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin
,BAO_0000357,B,,,108.0,H,,Autocuration,17723.0,,,CHEMBL617275,1.0,,8.0,,,,,,2715.0,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,H,,Autocuration,6013.0,,,CHEMBL617276,1.0,,8.0,,,,,,2716.0,Binding affinity towards 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,H,,Autocuration,16293.0,,,CHEMBL617277,1.0,,8.0,,,,,,2717.0,Binding affinity towards human 5-hydroxytryptamine 2C receptor
,BAO_0000019,B,,,108.0,H,,Expert,3857.0,,,CHEMBL617278,1.0,,8.0,,,,,,2718.0,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor
,BAO_0000019,B,,,108.0,H,,Expert,3857.0,,,CHEMBL617279,1.0,,8.0,,,,,,2719.0,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined
,BAO_0000019,B,,,108.0,H,,Expert,3857.0,,,CHEMBL617280,1.0,,8.0,,,,,,2720.0,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,H,,Autocuration,15363.0,,,CHEMBL617281,1.0,,8.0,,,,,,2721.0,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,H,,Autocuration,15363.0,,,CHEMBL617282,1.0,,8.0,,,,,,2722.0,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor
,BAO_0000019,B,,,108.0,H,,Expert,16441.0,,,CHEMBL617283,1.0,,8.0,,,,,,2723.0,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine
,BAO_0000019,B,,,108.0,H,,Expert,16441.0,,,CHEMBL617284,1.0,,8.0,,,,,,2724.0,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.
,BAO_0000219,B,,HEK293,108.0,H,,Autocuration,4176.0,,,CHEMBL617285,1.0,,8.0,,,,,722.0,2725.0,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand
,BAO_0000019,B,,,108.0,H,,Autocuration,17085.0,,,CHEMBL617286,1.0,,8.0,,,,,,2726.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,D,Homo sapiens,Expert,17200.0,,9606.0,CHEMBL617287,1.0,,9.0,,,,,,2727.0,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand
,BAO_0000357,B,,,108.0,H,,Expert,5088.0,,,CHEMBL617288,1.0,,8.0,,,,,,2728.0,Binding affinity towards human 5-hydroxytryptamine 2C receptor.
,BAO_0000357,B,,,108.0,H,,Autocuration,5088.0,,,CHEMBL617289,1.0,,8.0,,,,,,2729.0,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand
,BAO_0000357,B,,,108.0,H,,Autocuration,5088.0,,,CHEMBL872917,1.0,,8.0,,,,,,2730.0,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand
,BAO_0000357,B,,,108.0,H,,Autocuration,5088.0,,,CHEMBL617290,1.0,,8.0,,,,,,2731.0,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand
,BAO_0000219,B,,CHO,108.0,H,,Autocuration,16659.0,,,CHEMBL617291,1.0,,8.0,,,,,449.0,2732.0,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells
,BAO_0000219,B,,CHO,108.0,H,,Autocuration,16659.0,,,CHEMBL617292,1.0,,8.0,,,,,449.0,2733.0,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data
,BAO_0000219,B,,NIH3T3,108.0,H,,Autocuration,17451.0,,,CHEMBL617293,1.0,,8.0,,,,,723.0,2734.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined
,BAO_0000219,F,,CHO,108.0,D,Homo sapiens,Expert,6857.0,,9606.0,CHEMBL617294,1.0,,9.0,,,,,449.0,2735.0,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT
,BAO_0000019,B,,,108.0,H,,Expert,3857.0,,,CHEMBL617295,1.0,,8.0,,,,,,2736.0,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM
,BAO_0000357,B,,,108.0,H,,Autocuration,12861.0,,,CHEMBL617296,1.0,,8.0,,,,,,2737.0,Binding activity radioligand.
,BAO_0000019,B,,,108.0,H,,Autocuration,12861.0,,,CHEMBL617297,1.0,,8.0,,,,,,2738.0,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.
,BAO_0000219,B,,CHO,108.0,H,,Expert,5104.0,,,CHEMBL617298,1.0,,8.0,,,,,449.0,2739.0,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand
,BAO_0000219,B,,CHO,108.0,H,,Expert,5105.0,,,CHEMBL617299,1.0,,8.0,,,,,449.0,2740.0,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.
,BAO_0000219,B,,CHO,108.0,H,,Autocuration,5105.0,,,CHEMBL617300,1.0,,8.0,,,,,449.0,2741.0,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested
,BAO_0000357,B,,,108.0,H,,Autocuration,5254.0,,,CHEMBL617454,1.0,,8.0,,,,,,2742.0,Binding affinity against 5-HT2C receptor
,BAO_0000219,B,,HEK293,108.0,H,,Autocuration,13267.0,,,CHEMBL617505,1.0,,8.0,,,,,722.0,2743.0,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand
,BAO_0000219,B,,HEK293,108.0,D,Homo sapiens,Expert,14157.0,,9606.0,CHEMBL617506,1.0,,9.0,,,,,722.0,2744.0,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells
,BAO_0000219,B,,HEK293,108.0,D,Homo sapiens,Expert,12936.0,,9606.0,CHEMBL617507,1.0,,9.0,,,,,722.0,2745.0,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine
,BAO_0000357,B,,,108.0,H,,Expert,14068.0,,,CHEMBL617508,1.0,,8.0,,,,,,2746.0,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB
,BAO_0000219,B,,HEK293,108.0,D,Homo sapiens,Expert,12936.0,,9606.0,CHEMBL857982,1.0,,9.0,,,,,722.0,2747.0,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine
,BAO_0000219,B,,HEK293,108.0,D,Homo sapiens,Expert,4540.0,,9606.0,CHEMBL617509,1.0,,9.0,,,,,722.0,2748.0,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand
,BAO_0000219,B,,HEK293,108.0,D,Homo sapiens,Expert,4540.0,,9606.0,CHEMBL617510,1.0,,9.0,,,,,722.0,2749.0,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined
,BAO_0000357,B,,,108.0,H,,Autocuration,6166.0,,,CHEMBL617511,1.0,,8.0,,,,,,2750.0,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined
,BAO_0000219,B,,HEK293,108.0,H,,Autocuration,17296.0,,,CHEMBL617512,1.0,,8.0,,,,,722.0,2751.0,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand
,BAO_0000219,B,,HEK293,108.0,H,,Autocuration,17296.0,,,CHEMBL617749,1.0,,8.0,,,,,722.0,2752.0,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand
,BAO_0000219,B,,HEK293,108.0,H,,Autocuration,15779.0,,,CHEMBL617750,1.0,,8.0,,,,,722.0,2753.0,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.
,BAO_0000219,B,,HEK293,108.0,H,,Autocuration,15779.0,,,CHEMBL617751,1.0,,8.0,,,,,722.0,2754.0,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.
,BAO_0000219,B,,HEK293,108.0,H,,Expert,14391.0,,,CHEMBL617752,1.0,,8.0,,,,,722.0,2755.0,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand
,BAO_0000219,B,,HEK293,108.0,H,,Autocuration,15779.0,,,CHEMBL617753,1.0,,8.0,,,,,722.0,2756.0,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand"
,BAO_0000219,B,,HEK293,108.0,H,,Expert,15851.0,,,CHEMBL617754,1.0,,8.0,,,,,722.0,2757.0,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand."
,BAO_0000219,B,,HEK293,108.0,D,Homo sapiens,Expert,15851.0,,9606.0,CHEMBL617755,1.0,,9.0,,,,,722.0,2758.0,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble
,BAO_0000219,B,,HEK293,108.0,H,,Autocuration,15779.0,,,CHEMBL617756,1.0,,8.0,,,,,722.0,2759.0,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data"
,BAO_0000219,B,,HEK293,108.0,H,,Expert,3832.0,,,CHEMBL617757,1.0,,8.0,,,,,722.0,2760.0,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine
,BAO_0000219,B,,HEK293,108.0,H,,Expert,3833.0,,,CHEMBL617758,1.0,,8.0,,,,,722.0,2761.0,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.
,BAO_0000219,B,,NIH3T3,108.0,H,,Autocuration,17451.0,,,CHEMBL617759,1.0,,8.0,,,,,723.0,2762.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand
,BAO_0000219,B,,HEK293,108.0,H,,Autocuration,4199.0,,,CHEMBL617760,1.0,,8.0,,,,,722.0,2763.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand
,BAO_0000219,B,,CHO-K1,108.0,H,,Expert,1883.0,,,CHEMBL617761,1.0,,8.0,,,,,485.0,2764.0,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells
,BAO_0000357,B,,,108.0,D,Homo sapiens,Expert,4321.0,,9606.0,CHEMBL617762,1.0,,9.0,,,,,,2765.0,Binding affinity against 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,H,,Autocuration,14875.0,,,CHEMBL617763,1.0,,8.0,,,,,,2766.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor
,BAO_0000219,B,,HEK293,108.0,H,,Autocuration,15146.0,,,CHEMBL857983,1.0,,8.0,,,,,722.0,2767.0,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine
,BAO_0000219,B,,HEK293,108.0,H,,Autocuration,5213.0,,,CHEMBL617764,1.0,,8.0,,,,,722.0,2768.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand
,BAO_0000219,B,,HeLa,108.0,H,,Autocuration,16404.0,,,CHEMBL617765,1.0,,8.0,,,,,308.0,2769.0,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells
,BAO_0000019,F,,,108.0,H,,Autocuration,13267.0,,,CHEMBL617766,1.0,,8.0,,,,,,2770.0,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor
,BAO_0000221,F,,,108.0,H,,Autocuration,13267.0,,,CHEMBL617767,1.0,,8.0,Hippocampus,,,10000000.0,,2771.0,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand
,BAO_0000219,B,,HEK293,108.0,H,,Autocuration,14818.0,,,CHEMBL617768,1.0,,8.0,,,,,722.0,2772.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.
,BAO_0000219,B,,HEK293,108.0,H,,Autocuration,4829.0,,,CHEMBL617769,1.0,,8.0,,,,,722.0,2773.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand"
,BAO_0000357,B,,,11864.0,H,,Autocuration,13463.0,,,CHEMBL858023,1.0,,8.0,,,,,,2774.0,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand
,BAO_0000019,B,,,11864.0,H,,Autocuration,13463.0,,,CHEMBL617770,1.0,,8.0,Stomach,,,945.0,,2775.0,Binding affinity analysed on 5-HT 2C in rat stomach fundus
,BAO_0000019,B,,,11864.0,H,,Autocuration,13463.0,,,CHEMBL617771,1.0,,8.0,Stomach,,,945.0,,2776.0,Binding affinity analysed towards 5-HT 2C in rat stomach fundus
,BAO_0000219,F,,A9,11864.0,H,,Autocuration,12652.0,,,CHEMBL617772,1.0,,8.0,,,,,625.0,2777.0,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells
,BAO_0000219,B,,NIH3T3,11864.0,H,,Autocuration,4682.0,,,CHEMBL617773,1.0,,8.0,,,,,723.0,2778.0,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells
,BAO_0000219,B,,NIH3T3,11864.0,H,,Autocuration,4682.0,,,CHEMBL617850,1.0,,8.0,,,,,723.0,2779.0,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells
,BAO_0000219,B,,NIH3T3,11864.0,H,,Autocuration,4682.0,,,CHEMBL617851,1.0,,8.0,,,,,723.0,2780.0,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells
,BAO_0000019,F,,,11864.0,H,,Autocuration,12652.0,,,CHEMBL617852,1.0,,8.0,,,,,,2781.0,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor
,BAO_0000019,B,,,12689.0,H,Mus musculus,Autocuration,13463.0,,10090.0,CHEMBL858024,1.0,,8.0,Stomach,,,945.0,,2782.0,Binding affinity analysed on 5-HT 2C in rat stomach fundus.
,BAO_0000019,B,,,12689.0,D,Rattus norvegicus,Expert,13463.0,,10116.0,CHEMBL617853,1.0,,9.0,Stomach,,,945.0,,2783.0,Binding affinity towards 5-HT 2C receptor in rat stomach fundus
,BAO_0000357,B,,,108.0,H,,Expert,13969.0,,,CHEMBL617854,1.0,,8.0,,,,,,2784.0,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand
,BAO_0000357,B,,,108.0,H,Sus scrofa,Expert,13392.0,,9823.0,CHEMBL873477,1.0,,8.0,,,,,,2785.0,Binding affinity for 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,H,,Expert,13392.0,,,CHEMBL617855,1.0,,8.0,,,,,,2786.0,Binding affinity towards 5-hydroxytryptamine 2C receptor
,BAO_0000019,B,,,108.0,H,,Expert,14430.0,,,CHEMBL617856,1.0,,8.0,,,,,,2787.0,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine
,BAO_0000019,B,,,108.0,H,,Autocuration,1742.0,,,CHEMBL617857,1.0,,8.0,,,,,,2788.0,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex
,BAO_0000249,B,,,108.0,H,,Autocuration,14286.0,,,CHEMBL617858,1.0,,8.0,,,,,,2789.0,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane
,BAO_0000357,B,,,108.0,H,,Autocuration,5619.0,,,CHEMBL617859,1.0,,8.0,,,,,,2790.0,Binding affinity towards pig 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,H,,Autocuration,15086.0,,,CHEMBL617860,1.0,,8.0,,,,,,2791.0,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,H,,Autocuration,12861.0,,,CHEMBL617861,1.0,,8.0,,,,,,2792.0,Binding activity radioligand.
,BAO_0000019,B,,,108.0,H,,Expert,12861.0,,,CHEMBL617862,1.0,,8.0,,,,,,2793.0,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.
,BAO_0000019,B,,,108.0,H,,Autocuration,12861.0,,,CHEMBL617863,1.0,,8.0,,,,,,2794.0,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available
,BAO_0000249,B,,,108.0,H,,Autocuration,12827.0,,,CHEMBL617864,1.0,,8.0,,,,,,2795.0,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT
,BAO_0000249,B,,,108.0,H,,Autocuration,12827.0,,,CHEMBL617649,1.0,,8.0,,,,,,2796.0,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined
,BAO_0000019,F,,,108.0,H,Sus scrofa,Expert,12919.0,,9823.0,CHEMBL617650,1.0,,8.0,,,,,,2797.0,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine
,BAO_0000019,F,,,108.0,H,Sus scrofa,Expert,12919.0,,9823.0,CHEMBL617651,1.0,,8.0,,,,,,2798.0,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine
,BAO_0000357,B,,,108.0,H,Sus scrofa,Autocuration,16429.0,,9823.0,CHEMBL617652,1.0,,8.0,,,,,,2799.0,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand
,BAO_0000019,B,,,108.0,H,Sus scrofa,Autocuration,773.0,,9823.0,CHEMBL857072,1.0,,8.0,,,,,,2800.0,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex
,BAO_0000357,B,,,108.0,H,Sus scrofa,Autocuration,5033.0,,9823.0,CHEMBL617653,1.0,,8.0,,,,,,2801.0,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor
,BAO_0000019,B,,,12687.0,H,,Autocuration,12861.0,,,CHEMBL617654,1.0,,8.0,,,,,,2802.0,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.
,BAO_0000019,F,,,12689.0,H,,Autocuration,14093.0,,,CHEMBL617655,1.0,,8.0,,,,,,2803.0,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,12689.0,H,,Expert,14970.0,,,CHEMBL617656,1.0,,8.0,,,,,,2804.0,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand
,BAO_0000357,B,,,12689.0,H,,Autocuration,14970.0,,,CHEMBL617657,1.0,,8.0,,,,,,2805.0,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand
,BAO_0000357,B,,,12689.0,H,,Autocuration,14970.0,,,CHEMBL617658,1.0,,8.0,,,,,,2806.0,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested
,BAO_0000357,B,,,12689.0,D,Rattus norvegicus,Expert,14178.0,,10116.0,CHEMBL617659,1.0,,9.0,,,,,,2807.0,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,12689.0,D,Rattus norvegicus,Expert,14178.0,,10116.0,CHEMBL617838,1.0,,9.0,,,,,,2808.0,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor
,BAO_0000249,B,,,12689.0,D,Rattus norvegicus,Expert,14229.0,Brain membranes,10116.0,CHEMBL617839,1.0,,9.0,,,,,,2809.0,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes
,BAO_0000357,B,,,12689.0,H,,Autocuration,16532.0,,,CHEMBL617840,1.0,,8.0,,,,,,2810.0,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested
,BAO_0000019,B,,,12689.0,H,,Autocuration,14826.0,,,CHEMBL617841,1.0,,8.0,,,,,,2811.0,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex
,BAO_0000019,B,,,12689.0,H,,Autocuration,17211.0,,,CHEMBL875915,1.0,,8.0,,,,,,2812.0,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor
,BAO_0000219,B,In vitro,,12689.0,H,,Expert,17211.0,,,CHEMBL617842,1.0,,8.0,,,,,,2813.0,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells
,BAO_0000219,B,,NIH3T3,12689.0,H,,Expert,13246.0,,,CHEMBL617843,1.0,,8.0,,,,,723.0,2814.0,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes
,BAO_0000357,B,,,12689.0,H,,Expert,13246.0,,,CHEMBL617844,1.0,,8.0,,,,,,2815.0,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.
,BAO_0000357,B,,,12689.0,H,,Expert,12457.0,,,CHEMBL617845,1.0,,8.0,,,,,,2816.0,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor
,BAO_0000219,B,,NIH3T3,12689.0,H,,Expert,12457.0,,,CHEMBL617846,1.0,,8.0,,,,,723.0,2817.0,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,12689.0,H,,Autocuration,4707.0,,,CHEMBL617847,1.0,,8.0,,,,,,2818.0,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand
,BAO_0000357,B,,,12689.0,H,,Expert,13297.0,,,CHEMBL617848,1.0,,8.0,,,,,,2819.0,Binding affinity against 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,12689.0,H,,Autocuration,16633.0,,,CHEMBL617849,1.0,,8.0,,,,,,2820.0,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand
,BAO_0000357,B,,,12689.0,H,,Expert,16133.0,,,CHEMBL621507,1.0,,8.0,,,,,,2821.0,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand
,BAO_0000357,B,,,12689.0,H,,Expert,16326.0,,,CHEMBL621508,1.0,,8.0,,,,,,2822.0,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand
,BAO_0000019,B,,,12689.0,H,,Autocuration,14423.0,,,CHEMBL621509,1.0,,8.0,,,,,,2823.0,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.
,BAO_0000019,B,,,12689.0,H,,Autocuration,15412.0,,,CHEMBL621510,1.0,,8.0,,,,,,2824.0,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex
,BAO_0000019,B,,,12689.0,H,,Autocuration,15412.0,,,CHEMBL621511,1.0,,8.0,,,,,,2825.0,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.
,BAO_0000219,B,,A9,12689.0,H,,Expert,15558.0,,,CHEMBL621512,1.0,,8.0,,,,,625.0,2826.0,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,12689.0,H,,Autocuration,16633.0,,,CHEMBL621513,1.0,,8.0,,,,,,2827.0,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand
,BAO_0000357,B,,,12689.0,H,,Expert,6013.0,,,CHEMBL621514,1.0,,8.0,,,,,,2828.0,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.
,BAO_0000219,B,In vitro,,12689.0,H,,Expert,17175.0,,,CHEMBL621515,1.0,,8.0,,,,,,2829.0,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand
,BAO_0000219,B,,,12689.0,H,,Autocuration,12469.0,,,CHEMBL621516,1.0,,8.0,,,,,,2830.0,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine
,BAO_0000019,B,,,12689.0,H,,Autocuration,3682.0,,,CHEMBL621517,1.0,,8.0,Caudate-putamen,,,5383.0,,2831.0,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain
,BAO_0000357,B,,,12689.0,H,,Autocuration,4932.0,,,CHEMBL621518,1.0,,8.0,,,,,,2832.0,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture
,BAO_0000019,B,,,12689.0,H,,Autocuration,4932.0,,,CHEMBL621519,1.0,,8.0,,,,,,2833.0,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data
,BAO_0000357,B,,,12689.0,H,,Autocuration,3935.0,,,CHEMBL621520,1.0,,8.0,,,,,,2834.0,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,12689.0,H,,Autocuration,15818.0,,,CHEMBL621521,1.0,,8.0,,,,,,2835.0,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,12689.0,H,,Autocuration,15818.0,,,CHEMBL621522,1.0,,8.0,,,,,,2836.0,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor
,BAO_0000219,B,,,12689.0,H,,Expert,14749.0,,,CHEMBL621523,1.0,,8.0,,,,,,2837.0,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.
,BAO_0000357,B,,,12689.0,H,,Autocuration,15740.0,,,CHEMBL621524,1.0,,8.0,,,,,,2838.0,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,12689.0,D,Rattus norvegicus,Expert,17133.0,,10116.0,CHEMBL621525,1.0,,9.0,,,,,,2839.0,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI
,BAO_0000357,B,,,12689.0,H,,Autocuration,16532.0,,,CHEMBL872921,1.0,,8.0,,,,,,2840.0,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine
,BAO_0000357,B,,,12689.0,H,,Autocuration,12369.0,,,CHEMBL621526,1.0,,8.0,,,,,,2841.0,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor
,BAO_0000219,B,,,12689.0,H,,Expert,12369.0,,,CHEMBL621527,1.0,,8.0,,,,,,2842.0,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.
,BAO_0000019,B,,,12689.0,D,Rattus norvegicus,Expert,2309.0,,10116.0,CHEMBL617865,1.0,,9.0,,,,,,2843.0,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine
,BAO_0000357,B,,,12689.0,H,,Autocuration,12953.0,,,CHEMBL617866,1.0,,8.0,,,,,,2844.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor
,BAO_0000019,B,,,12689.0,H,,Autocuration,12953.0,,,CHEMBL617867,1.0,,8.0,,,,,,2845.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM
,BAO_0000357,B,,,12689.0,H,,Autocuration,12953.0,,,CHEMBL617487,1.0,,8.0,,,,,,2846.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM
,BAO_0000357,B,,,12689.0,H,,Expert,12953.0,,,CHEMBL617488,1.0,,8.0,,,,,,2847.0,Binding affinity for 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,12689.0,H,,Autocuration,17133.0,,,CHEMBL617489,1.0,,8.0,,,,,,2848.0,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined
,BAO_0000019,B,,,12689.0,H,,Autocuration,17211.0,,,CHEMBL617490,1.0,,8.0,,,,,,2849.0,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested
,BAO_0000019,B,,,12689.0,H,,Autocuration,17211.0,,,CHEMBL617491,1.0,,8.0,,,,,,2850.0,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested
,BAO_0000019,B,,,12689.0,H,,Autocuration,14025.0,,,CHEMBL617492,1.0,,8.0,,,,,,2851.0,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.
,BAO_0000019,B,,,12689.0,H,,Autocuration,14998.0,,,CHEMBL617493,1.0,,8.0,,,,,,2852.0,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.
,BAO_0000357,B,,,12689.0,H,,Autocuration,4342.0,,,CHEMBL617494,1.0,,8.0,,,,,,2853.0,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined
,BAO_0000019,B,,,12689.0,D,Rattus norvegicus,Expert,13735.0,,10116.0,CHEMBL617495,1.0,,9.0,,,,,,2854.0,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293
,BAO_0000357,B,,,12689.0,H,,Autocuration,13181.0,,,CHEMBL617496,1.0,,8.0,,,,,,2855.0,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand
,BAO_0000219,B,,CHO-K1,12689.0,H,,Autocuration,1883.0,,,CHEMBL617497,1.0,,8.0,,,,,485.0,2856.0,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.
,BAO_0000357,B,,,12689.0,H,,Autocuration,15194.0,,,CHEMBL617498,1.0,,8.0,,,,,,2857.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand
,BAO_0000357,B,,,12689.0,H,,Autocuration,15194.0,,,CHEMBL617499,1.0,,8.0,,,,,,2858.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.
,BAO_0000019,F,,,12689.0,H,,Autocuration,14579.0,,,CHEMBL617500,1.0,,8.0,,,,,,2859.0,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,H,,Autocuration,4639.0,,,CHEMBL617501,1.0,,8.0,,,,,,2860.0,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,H,,Expert,4820.0,,,CHEMBL617502,1.0,,8.0,,,,,,2861.0,Binding affinity towards 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,227.0,H,,Autocuration,14442.0,,,CHEMBL617503,1.0,,8.0,,,,,,2862.0,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested
,BAO_0000357,B,,,227.0,H,,Autocuration,14755.0,,,CHEMBL617504,1.0,,8.0,,,,,,2863.0,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.
,BAO_0000357,B,,,227.0,H,,Autocuration,14744.0,,,CHEMBL617406,1.0,,8.0,,,,,,2864.0,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand
,BAO_0000019,B,,,227.0,D,Homo sapiens,Expert,6857.0,,9606.0,CHEMBL617407,1.0,,9.0,,,,,,2865.0,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line
,BAO_0000357,B,,,227.0,H,,Autocuration,16209.0,,,CHEMBL617408,1.0,,8.0,,,,,,2866.0,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand
,BAO_0000357,B,,,227.0,H,,Autocuration,15363.0,,,CHEMBL617409,1.0,,8.0,,,,,,2867.0,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor
,BAO_0000357,B,,,227.0,H,,Autocuration,15363.0,,,CHEMBL617410,1.0,,8.0,,,,,,2868.0,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor
,BAO_0000357,B,,,227.0,H,,Autocuration,15363.0,,,CHEMBL617411,1.0,,8.0,,,,,,2869.0,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor
,BAO_0000019,B,,,227.0,H,,Autocuration,17085.0,,,CHEMBL617412,1.0,,8.0,,,,,,2870.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor
,BAO_0000357,B,,,227.0,D,Homo sapiens,Expert,17200.0,,9606.0,CHEMBL617774,1.0,,9.0,,,,,,2871.0,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand
,BAO_0000219,B,,HEK293,227.0,D,Homo sapiens,Expert,15851.0,,9606.0,CHEMBL617775,1.0,,9.0,,,,,722.0,2872.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data
,BAO_0000219,B,,HEK293,227.0,D,Homo sapiens,Expert,15851.0,,9606.0,CHEMBL617776,1.0,,9.0,,,,,722.0,2873.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data
,BAO_0000219,F,,CHO,227.0,D,Homo sapiens,Expert,6857.0,,9606.0,CHEMBL617777,1.0,,9.0,,,,,449.0,2874.0,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT
,BAO_0000219,F,,CHO,227.0,D,Homo sapiens,Expert,6857.0,,9606.0,CHEMBL617778,1.0,,9.0,,,,,449.0,2875.0,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT
,BAO_0000219,B,,HEK293,227.0,H,,Autocuration,15779.0,,,CHEMBL617779,1.0,,8.0,,,,,722.0,2876.0,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand"
,BAO_0000219,B,,HEK293,227.0,H,,Expert,15851.0,,,CHEMBL617780,1.0,,8.0,,,,,722.0,2877.0,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.
,BAO_0000219,B,,HEK293,227.0,H,,Autocuration,15779.0,,,CHEMBL617781,1.0,,8.0,,,,,722.0,2878.0,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data"
,BAO_0000219,B,,HEK293,227.0,D,Homo sapiens,Expert,14157.0,,9606.0,CHEMBL617782,1.0,,9.0,,,,,722.0,2879.0,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells
,BAO_0000219,B,,HEK293,227.0,D,Homo sapiens,Expert,4540.0,,9606.0,CHEMBL617783,1.0,,9.0,,,,,722.0,2880.0,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand
,BAO_0000357,B,,,227.0,H,,Autocuration,6166.0,,,CHEMBL617784,1.0,,8.0,,,,,,2881.0,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined
,BAO_0000219,B,,HEK293,227.0,H,,Autocuration,15779.0,,,CHEMBL617785,1.0,,8.0,,,,,722.0,2882.0,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.
,BAO_0000219,B,,HEK293,227.0,H,,Expert,14391.0,,,CHEMBL857984,1.0,,8.0,,,,,722.0,2883.0,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand
,BAO_0000219,B,,HEK293,227.0,H,,Expert,3832.0,,,CHEMBL617786,1.0,,8.0,,,,,722.0,2884.0,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT
,BAO_0000219,B,,HEK293,227.0,H,,Expert,3833.0,,,CHEMBL617787,1.0,,8.0,,,,,722.0,2885.0,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.
,BAO_0000219,B,,HEK293,227.0,D,Homo sapiens,Expert,15851.0,,9606.0,CHEMBL617788,1.0,,9.0,,,,,722.0,2886.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells
,BAO_0000219,B,,HEK293,227.0,D,Homo sapiens,Expert,15851.0,,9606.0,CHEMBL617789,1.0,,9.0,,,,,722.0,2887.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble
,BAO_0000219,B,,HEK293,227.0,H,,Autocuration,4199.0,,,CHEMBL617790,1.0,,8.0,,,,,722.0,2888.0,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand
,BAO_0000219,B,,CHO-K1,227.0,H,,Expert,1883.0,,,CHEMBL617791,1.0,,8.0,,,,,485.0,2889.0,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells
,BAO_0000357,B,,,227.0,H,,Expert,4321.0,,,CHEMBL617608,1.0,,8.0,,,,,,2890.0,Binding affinity against 5-hydroxytryptamine 2B receptor
,BAO_0000219,B,,HEK293,227.0,H,,Autocuration,15146.0,,,CHEMBL617609,1.0,,8.0,,,,,722.0,2891.0,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT
,BAO_0000219,B,,HEK293,227.0,H,,Autocuration,5213.0,,,CHEMBL617610,1.0,,8.0,,,,,722.0,2892.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand
,BAO_0000219,B,,HEK293,227.0,H,,Autocuration,14818.0,,,CHEMBL617611,1.0,,8.0,,,,,722.0,2893.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.
,BAO_0000219,B,,HEK293,227.0,H,,Autocuration,4829.0,,,CHEMBL617612,1.0,,8.0,,,,,722.0,2894.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand"
,BAO_0000219,B,,HEK293,227.0,H,,Autocuration,4829.0,,,CHEMBL617613,1.0,,8.0,,,,,722.0,2895.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand"
,BAO_0000019,B,,,227.0,H,Oryctolagus cuniculus,Autocuration,14025.0,,9986.0,CHEMBL617614,1.0,,8.0,,,,,,2896.0,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.
,BAO_0000019,B,,,12688.0,H,,Expert,13463.0,,,CHEMBL617615,1.0,,8.0,Stomach,,,945.0,,2897.0,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus
,BAO_0000357,B,,,12688.0,H,,Expert,7259.0,,,CHEMBL858114,1.0,,8.0,Stomach,,,945.0,,2898.0,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus
,BAO_0000357,B,,,12688.0,H,,Autocuration,7259.0,,,CHEMBL617616,1.0,,8.0,Stomach,,,945.0,,2899.0,Affinity against serotonergic receptor in the isolated rat stomach fundus
,BAO_0000019,F,,,12688.0,D,Rattus norvegicus,Expert,7185.0,,10116.0,CHEMBL617617,1.0,,9.0,Stomach,,,945.0,,2900.0,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation
,BAO_0000019,F,,,12688.0,D,Rattus norvegicus,Expert,7185.0,,10116.0,CHEMBL875914,1.0,,9.0,,,,,,2901.0,Antagonistic against 5-hydroxytryptamine 2B receptor
,BAO_0000019,F,,,12688.0,H,,Autocuration,13267.0,,,CHEMBL617618,1.0,,8.0,Stomach,,,945.0,,2902.0,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus
,BAO_0000357,B,,,12688.0,D,Rattus norvegicus,Expert,13735.0,,10116.0,CHEMBL617619,1.0,,9.0,Stomach,,,945.0,,2903.0,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus
,BAO_0000019,F,,,12688.0,H,,Autocuration,15738.0,,,CHEMBL617620,1.0,,8.0,,,,,,2904.0,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor
,BAO_0000019,F,,,12688.0,H,,Autocuration,15738.0,,,CHEMBL617621,1.0,,8.0,,,,,,2905.0,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data
,BAO_0000019,F,,,12688.0,H,,Autocuration,15738.0,,,CHEMBL617622,1.0,,8.0,,,,,,2906.0,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor
,BAO_0000357,B,,,12688.0,D,Rattus norvegicus,Expert,12936.0,,10116.0,CHEMBL617623,1.0,,9.0,Stomach,,,945.0,,2907.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor
,BAO_0000357,B,,,12688.0,D,Rattus norvegicus,Expert,12936.0,,10116.0,CHEMBL617624,1.0,,9.0,Stomach,,,945.0,,2908.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor
,BAO_0000357,B,,,12688.0,D,Rattus norvegicus,Expert,12936.0,,10116.0,CHEMBL617625,1.0,,9.0,Stomach,,,945.0,,2909.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor
,BAO_0000357,B,,,12688.0,D,Rattus norvegicus,Expert,12936.0,,10116.0,CHEMBL617626,1.0,,9.0,Stomach,,,945.0,,2910.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor
,BAO_0000019,F,,,12688.0,H,,Autocuration,16404.0,,,CHEMBL617627,1.0,,8.0,Stomach,,,945.0,,2911.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus
,BAO_0000019,F,,,12688.0,H,,Expert,16404.0,,,CHEMBL617628,1.0,,8.0,Stomach,,,945.0,,2912.0,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus
,BAO_0000019,F,,,12688.0,H,,Autocuration,16404.0,,,CHEMBL617629,1.0,,8.0,Stomach,,,945.0,,2913.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.
,BAO_0000019,F,,,12688.0,H,,Autocuration,16404.0,,,CHEMBL858115,1.0,,8.0,Stomach,,,945.0,,2914.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.
,BAO_0000019,F,,,12688.0,D,Rattus norvegicus,Expert,16404.0,,10116.0,CHEMBL617630,1.0,,9.0,Stomach,,,945.0,,2915.0,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined
,BAO_0000019,F,,,12688.0,H,,Autocuration,16404.0,,,CHEMBL617631,1.0,,8.0,Thoracic aorta,,,1515.0,,2916.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined
,BAO_0000357,B,,,12688.0,H,,Autocuration,7483.0,,,CHEMBL617632,1.0,,8.0,,,,,,2917.0,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot
,BAO_0000357,B,,,12688.0,H,,Expert,7483.0,,,CHEMBL617633,1.0,,8.0,,,,,,2918.0,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus
,BAO_0000357,B,,,12688.0,H,,Autocuration,7483.0,,,CHEMBL617634,1.0,,8.0,,,,,,2919.0,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot
,BAO_0000357,B,,,12688.0,H,,Autocuration,7483.0,,,CHEMBL617635,1.0,,8.0,,,,,,2920.0,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot
,BAO_0000019,F,,,12688.0,D,Rattus norvegicus,Autocuration,16404.0,,10116.0,CHEMBL617637,1.0,,9.0,Stomach,,,945.0,,2922.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus
,BAO_0000357,B,,,227.0,H,,Autocuration,6347.0,,,CHEMBL617638,1.0,,8.0,,,,,,2923.0,Binding affinity against 5-hydroxytryptamine 1A receptor
,BAO_0000357,B,,,227.0,H,,Autocuration,4373.0,,,CHEMBL617639,1.0,,8.0,,,,,,2924.0,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined
,BAO_0000357,B,,,227.0,H,,Autocuration,4373.0,,,CHEMBL617640,1.0,,8.0,,,,,,2925.0,Binding affinity for 5-hydroxytryptamine 2B receptor was determined
,BAO_0000357,B,,,227.0,H,,Autocuration,4687.0,,,CHEMBL617641,1.0,,8.0,,,,,,2926.0,Evaluated for the binding affinity to 5-HT 2B receptor
,BAO_0000357,B,,,227.0,H,,Autocuration,16946.0,,,CHEMBL617642,1.0,,8.0,,,,,,2927.0,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor
,BAO_0000357,B,,,227.0,H,,Autocuration,16633.0,,,CHEMBL617643,1.0,,8.0,,,,,,2928.0,Binding affinities against 5-hydroxytryptamine 2B receptor
,BAO_0000357,B,,,227.0,H,,Autocuration,16633.0,,,CHEMBL617644,1.0,,8.0,,,,,,2929.0,Binding affinities towards 5-hydroxytryptamine 2B receptor
,BAO_0000357,B,,,227.0,H,,Autocuration,16633.0,,,CHEMBL617645,1.0,,8.0,,,,,,2930.0,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand
,BAO_0000357,B,,,108.0,H,,Expert,15026.0,,,CHEMBL617646,1.0,,8.0,,,,,,2931.0,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.
,BAO_0000357,B,,,108.0,H,Bos taurus,Autocuration,15738.0,,9913.0,CHEMBL617647,1.0,,8.0,,,,,,2932.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor
,BAO_0000357,B,,,108.0,H,Bos taurus,Autocuration,15738.0,,9913.0,CHEMBL617648,1.0,,8.0,,,,,,2933.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M
,BAO_0000357,B,,,108.0,H,Bos taurus,Autocuration,15738.0,,9913.0,CHEMBL617875,1.0,,8.0,,,,,,2934.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M
,BAO_0000357,B,,,108.0,H,Bos taurus,Autocuration,15738.0,,9913.0,CHEMBL617876,1.0,,8.0,,,,,,2935.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M
,BAO_0000357,B,,,108.0,H,Bos taurus,Expert,16404.0,,9913.0,CHEMBL617877,1.0,,8.0,,,,,,2936.0,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus
,BAO_0000357,B,,,108.0,H,Bos taurus,Expert,15026.0,,9913.0,CHEMBL617878,1.0,,8.0,,,,,,2937.0,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.
,BAO_0000357,B,,,108.0,H,Bos taurus,Autocuration,15738.0,,9913.0,CHEMBL617879,1.0,,8.0,,,,,,2938.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor
,BAO_0000019,B,,,108.0,H,Cavia porcellus,Autocuration,16312.0,,10141.0,CHEMBL617880,1.0,,8.0,,,,,,2939.0,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Intermediate,5486.0,,10141.0,CHEMBL617881,1.0,,9.0,Striatum,,,2435.0,,2940.0,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum
,BAO_0000357,B,,,51.0,H,,Autocuration,5254.0,,,CHEMBL857073,1.0,,8.0,,,,,,2941.0,Binding affinity against 5-HT1A receptor
,BAO_0000219,F,,CHO,108.0,H,,Expert,3857.0,,,CHEMBL617882,1.0,,8.0,,,,,449.0,2942.0,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed
,BAO_0000219,F,,CHO,108.0,D,Homo sapiens,Expert,6857.0,,9606.0,CHEMBL617883,1.0,,9.0,,,,,449.0,2943.0,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader
,BAO_0000219,F,,,108.0,H,,Autocuration,4176.0,,,CHEMBL617884,1.0,,8.0,,,,,,2944.0,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line
,BAO_0000219,B,,CHO,108.0,H,,Autocuration,6347.0,,,CHEMBL617885,1.0,,8.0,,,,,449.0,2945.0,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand
,BAO_0000219,B,,CHO,108.0,H,,Autocuration,6347.0,,,CHEMBL617886,1.0,,8.0,,,,,449.0,2946.0,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax"
,BAO_0000357,B,,,108.0,D,Homo sapiens,Expert,16146.0,,9606.0,CHEMBL617887,1.0,,9.0,,,,,,2947.0,Inhibition of human 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,H,,Autocuration,3805.0,,,CHEMBL617888,1.0,,8.0,,,,,,2948.0,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM)
,BAO_0000019,B,,,108.0,H,,Autocuration,3857.0,,,CHEMBL617889,1.0,,8.0,,,,,,2949.0,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM
,BAO_0000357,B,,,108.0,H,,Autocuration,5635.0,,,CHEMBL617890,1.0,,8.0,,,,,,2950.0,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,H,,Autocuration,5635.0,,,CHEMBL617891,1.0,,8.0,,,,,,2951.0,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined
,BAO_0000357,B,,,108.0,H,,Autocuration,5635.0,,,CHEMBL617892,1.0,,8.0,,,,,,2952.0,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined
,BAO_0000219,B,,CHO,108.0,H,,Expert,4012.0,,,CHEMBL617893,1.0,,8.0,,,,,449.0,2953.0,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.
,BAO_0000219,B,,CHO,108.0,H,,Expert,6366.0,,,CHEMBL617894,1.0,,8.0,,,,,449.0,2954.0,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells
,BAO_0000219,B,,CHO,108.0,H,,Expert,15949.0,,,CHEMBL617895,1.0,,8.0,,,,,449.0,2955.0,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells
,BAO_0000219,B,,CHO,108.0,H,,Autocuration,17211.0,,,CHEMBL617896,1.0,,8.0,,,,,449.0,2956.0,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,D,Homo sapiens,Expert,6491.0,,9606.0,CHEMBL617897,1.0,,9.0,,,,,,2957.0,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor
,BAO_0000019,F,,,108.0,H,,Autocuration,14093.0,,,CHEMBL617898,1.0,,8.0,,,,,,2958.0,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand
,BAO_0000019,F,,,108.0,H,,Autocuration,13481.0,,,CHEMBL617899,1.0,,8.0,,,,,,2959.0,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand
,BAO_0000219,B,,CHO,108.0,H,Rattus norvegicus,Expert,6347.0,,10116.0,CHEMBL617900,1.0,,8.0,,,,,449.0,2960.0,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI 
,BAO_0000019,F,,,108.0,H,,Autocuration,14093.0,,,CHEMBL617901,1.0,,8.0,,,,,,2961.0,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand
,BAO_0000019,F,,,108.0,H,,Autocuration,14093.0,,,CHEMBL617902,1.0,,8.0,,,,,,2962.0,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested
,BAO_0000019,F,,,108.0,H,,Autocuration,13481.0,,,CHEMBL617903,1.0,,8.0,,,,,,2963.0,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand
,BAO_0000357,B,,,108.0,H,,Autocuration,14442.0,,,CHEMBL617904,1.0,,8.0,,,,,,2964.0,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand
,BAO_0000357,B,,,108.0,H,,Autocuration,14442.0,,,CHEMBL617905,1.0,,8.0,,,,,,2965.0,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand
,BAO_0000357,B,,,108.0,H,,Autocuration,14442.0,,,CHEMBL617906,1.0,,8.0,,,,,,2966.0,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested
,BAO_0000357,B,,,108.0,H,,Autocuration,14755.0,,,CHEMBL617907,1.0,,8.0,,,,,,2967.0,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.
,BAO_0000357,B,,,108.0,H,,Autocuration,14744.0,,,CHEMBL617908,1.0,,8.0,,,,,,2968.0,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand
,BAO_0000219,B,,CHO,108.0,H,,Expert,16659.0,,,CHEMBL620617,1.0,,8.0,,,,,449.0,2969.0,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells
,BAO_0000019,B,,,108.0,D,Homo sapiens,Expert,6857.0,,9606.0,CHEMBL620618,1.0,,9.0,,,,,,2970.0,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line
,BAO_0000357,B,,,108.0,H,,Expert,5635.0,,,CHEMBL620619,1.0,,8.0,,,,,,2971.0,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.
,BAO_0000357,B,,,108.0,D,Homo sapiens,Expert,4234.0,,9606.0,CHEMBL620620,1.0,,9.0,,,,,,2972.0,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,H,,Autocuration,16209.0,,,CHEMBL620621,1.0,,8.0,,,,,,2973.0,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand
,BAO_0000249,B,,,104698.0,D,Rattus norvegicus,Autocuration,5778.0,Membranes,10116.0,CHEMBL872920,1.0,,7.0,,,,,,2974.0,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes
,BAO_0000223,B,,,104698.0,H,,Autocuration,5094.0,,,CHEMBL620622,1.0,,6.0,,,,,,2975.0,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated
,BAO_0000019,B,,,104698.0,D,Rattus norvegicus,Autocuration,809.0,,10116.0,CHEMBL620623,1.0,,7.0,,,,,,2976.0,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex
,BAO_0000019,B,,,104698.0,H,,Autocuration,1578.0,,,CHEMBL620624,1.0,,6.0,,,,,,2977.0,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex
,BAO_0000019,B,,,104698.0,H,,Autocuration,809.0,,,CHEMBL620625,1.0,,6.0,,,,,,2978.0,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested
,BAO_0000219,B,,,104698.0,H,,Autocuration,12469.0,,,CHEMBL620626,1.0,,6.0,,,,,,2979.0,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630
,BAO_0000019,B,,,104698.0,H,,Autocuration,14290.0,,,CHEMBL621307,1.0,,6.0,,,,,,2980.0,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex
,BAO_0000019,B,,,104698.0,H,,Autocuration,14290.0,,,CHEMBL621308,1.0,,6.0,,,,,,2981.0,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.
,BAO_0000223,B,,,104698.0,H,,Autocuration,10609.0,,,CHEMBL621309,1.0,,6.0,,,,,,2982.0,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT
,BAO_0000223,B,,,104698.0,H,,Autocuration,10609.0,,,CHEMBL621310,1.0,,6.0,,,,,,2983.0,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630
,BAO_0000223,B,,,104698.0,H,,Autocuration,10609.0,,,CHEMBL621311,1.0,,6.0,,,,,,2984.0,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin
,BAO_0000249,B,,,104698.0,H,,Autocuration,15253.0,,,CHEMBL621502,1.0,,6.0,,,,,,2985.0,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes."
,BAO_0000249,B,,,104698.0,H,,Autocuration,15253.0,,,CHEMBL621503,1.0,,6.0,,,,,,2986.0,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes."
,BAO_0000249,B,,,104698.0,H,,Autocuration,11683.0,Membranes,,CHEMBL621504,1.0,,6.0,,,,,,2987.0,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.
,BAO_0000223,B,,,104698.0,H,,Autocuration,12092.0,,,CHEMBL621505,1.0,,6.0,,,,,,2988.0,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor
,BAO_0000019,B,,,104698.0,H,,Autocuration,1946.0,,,CHEMBL621506,1.0,,6.0,,,,,,2989.0,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.
,BAO_0000223,B,,,104698.0,H,,Autocuration,11623.0,,,CHEMBL619781,1.0,,6.0,,,,,,2990.0,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.
,BAO_0000223,B,,,104698.0,H,,Autocuration,11623.0,,,CHEMBL619782,1.0,,6.0,,,,,,2991.0,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. 
,BAO_0000019,B,,,104698.0,H,,Autocuration,14788.0,,,CHEMBL619783,1.0,,6.0,,,,,,2992.0,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex
,BAO_0000019,B,,,104698.0,D,Rattus norvegicus,Autocuration,5432.0,,10116.0,CHEMBL619784,1.0,,7.0,,,,,,2993.0,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor
,BAO_0000249,B,,,104698.0,H,,Autocuration,14826.0,,,CHEMBL619785,1.0,,6.0,,,,,,2994.0,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane
,BAO_0000223,B,,,104698.0,H,,Autocuration,2222.0,,,CHEMBL619786,1.0,,6.0,,,,,,2995.0,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor
,BAO_0000019,B,,,104698.0,H,,Autocuration,11963.0,,,CHEMBL619787,1.0,,6.0,,,,,,2996.0,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex
,BAO_0000019,B,,,104698.0,H,,Autocuration,14145.0,,,CHEMBL872925,1.0,,6.0,,,,,,2997.0,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex
,BAO_0000019,B,,,104698.0,H,,Autocuration,17819.0,,,CHEMBL619788,1.0,,6.0,,,,,,2998.0,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.
,BAO_0000249,B,,,104698.0,H,,Autocuration,10394.0,,,CHEMBL619789,1.0,,6.0,,,,,,2999.0,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand
,BAO_0000249,B,,,104698.0,H,,Autocuration,10394.0,,,CHEMBL619790,1.0,,6.0,,,,,,3000.0,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand
,BAO_0000019,B,,,104698.0,H,,Autocuration,15034.0,,,CHEMBL619791,1.0,,6.0,,,,,,3001.0,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand
,BAO_0000019,B,,,104698.0,H,,Autocuration,691.0,,,CHEMBL619792,1.0,,6.0,,,,,,3002.0,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.
,BAO_0000249,B,,,104698.0,H,,Autocuration,12092.0,Membranes,,CHEMBL619793,1.0,,6.0,,,,,,3003.0,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes
,BAO_0000223,B,,,104698.0,D,Rattus norvegicus,Autocuration,11752.0,,10116.0,CHEMBL619794,1.0,,7.0,,,,,,3004.0,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor
,BAO_0000221,B,,,104698.0,H,,Autocuration,11752.0,,,CHEMBL619795,1.0,,6.0,Brain,,,955.0,,3005.0,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices
,BAO_0000019,B,,,104698.0,H,,Autocuration,301.0,,,CHEMBL619796,1.0,,6.0,,,,,,3006.0,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.
,BAO_0000223,B,,,104698.0,H,,Autocuration,16532.0,,,CHEMBL620448,1.0,,6.0,,,,,,3007.0,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584
,BAO_0000223,B,,,104698.0,H,,Autocuration,16532.0,,,CHEMBL620449,1.0,,6.0,,,,,,3008.0,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested
,BAO_0000223,B,,,104698.0,H,,Autocuration,12092.0,,,CHEMBL620450,1.0,,6.0,,,,,,3009.0,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.
,BAO_0000223,B,,,104698.0,H,,Autocuration,11684.0,,,CHEMBL620451,1.0,,6.0,,,,,,3010.0,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630
,BAO_0000223,B,,,104698.0,H,,Autocuration,11684.0,,,CHEMBL620631,1.0,,6.0,,,,,,3011.0,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.
,BAO_0000019,B,,,104698.0,H,,Autocuration,12953.0,,,CHEMBL620632,1.0,,6.0,,,,,,3012.0,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand
,BAO_0000019,B,,,104698.0,H,,Autocuration,12953.0,,,CHEMBL620633,1.0,,6.0,,,,,,3013.0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active
,BAO_0000223,B,,,104698.0,H,,Autocuration,12953.0,,,CHEMBL620634,1.0,,6.0,,,,,,3014.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM
,BAO_0000019,B,,,104698.0,H,,Autocuration,12861.0,,,CHEMBL620635,1.0,,6.0,,,,,,3015.0,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL620636,1.0,,6.0,,,,,,3016.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL620637,1.0,,6.0,,,,,,3017.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL620638,1.0,,6.0,,,,,,3018.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL620639,1.0,,6.0,,,,,,3019.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL620640,1.0,,6.0,,,,,,3020.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL620641,1.0,,6.0,,,,,,3021.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL620642,1.0,,6.0,,,,,,3022.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL620643,1.0,,6.0,,,,,,3023.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL620644,1.0,,6.0,,,,,,3024.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL620645,1.0,,6.0,,,,,,3025.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL620646,1.0,,6.0,,,,,,3026.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL620647,1.0,,6.0,,,,,,3027.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL620648,1.0,,6.0,,,,,,3028.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL620649,1.0,,6.0,,,,,,3029.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL620650,1.0,,6.0,,,,,,3030.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL620651,1.0,,6.0,,,,,,3031.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL872875,1.0,,6.0,,,,,,3032.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL620652,1.0,,6.0,,,,,,3033.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats
,BAO_0000019,F,,,104698.0,H,,Autocuration,10609.0,,,CHEMBL620653,1.0,,6.0,,,,,,3034.0,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart
,BAO_0000019,B,,,104698.0,H,,Autocuration,12861.0,,,CHEMBL857076,1.0,,6.0,,,,,,3035.0,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.
,BAO_0000019,B,,,104698.0,D,Rattus norvegicus,Autocuration,12861.0,,10116.0,CHEMBL620654,1.0,,7.0,,,,,,3036.0,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor
,BAO_0000223,B,,,104698.0,H,,Autocuration,12861.0,,,CHEMBL620655,1.0,,6.0,,,,,,3037.0,Binding activity radioligand.
,BAO_0000249,B,,,104698.0,H,,Autocuration,10728.0,Brain membranes,,CHEMBL620656,1.0,,6.0,,,,,,3038.0,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes
,BAO_0000249,B,,,104698.0,H,,Autocuration,10728.0,Brain membranes,,CHEMBL620657,1.0,,6.0,,,,,,3039.0,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.
,BAO_0000357,B,,,108.0,H,,Autocuration,5163.0,,,CHEMBL620658,1.0,,8.0,,,,,,3040.0,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L
,BAO_0000357,B,,,108.0,H,,Autocuration,5163.0,,,CHEMBL620659,1.0,,8.0,,,,,,3041.0,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L
,BAO_0000357,B,,,108.0,H,,Autocuration,6011.0,,,CHEMBL620660,1.0,,8.0,,,,,,3042.0,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration
,BAO_0000357,B,,,108.0,H,,Autocuration,5014.0,,,CHEMBL620661,1.0,,8.0,,,,,,3043.0,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,H,,Autocuration,5635.0,,,CHEMBL620662,1.0,,8.0,,,,,,3044.0,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,H,,Expert,5163.0,,,CHEMBL620663,1.0,,8.0,,,,,,3045.0,Affinity for 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,H,,Autocuration,6841.0,,,CHEMBL620664,1.0,,8.0,,,,,,3046.0,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand
,BAO_0000357,B,,,108.0,H,,Expert,6119.0,,,CHEMBL620665,1.0,,8.0,,,,,,3047.0,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.
,BAO_0000357,B,,,108.0,H,,Autocuration,4373.0,,,CHEMBL620666,1.0,,8.0,,,,,,3048.0,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined
,BAO_0000357,B,,,108.0,H,,Autocuration,1633.0,,,CHEMBL620667,1.0,,8.0,,,,,,3049.0,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin
,BAO_0000357,B,,,108.0,H,,Expert,1633.0,,,CHEMBL620668,1.0,,8.0,,,,,,3050.0,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine
,BAO_0000357,B,,,108.0,H,,Autocuration,4373.0,,,CHEMBL620669,1.0,,8.0,,,,,,3051.0,Binding affinity for 5-hydroxytryptamine 2C receptor was determined
,BAO_0000357,B,,,108.0,H,,Expert,6576.0,,,CHEMBL620670,1.0,,8.0,,,,,,3052.0,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,H,,Autocuration,4687.0,,,CHEMBL620671,1.0,,8.0,,,,,,3053.0,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,H,,Autocuration,12146.0,,,CHEMBL620672,1.0,,8.0,,,,,,3054.0,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1
,BAO_0000357,B,,,108.0,H,,Autocuration,12146.0,,,CHEMBL620673,1.0,,8.0,,,,,,3055.0,Tested against 5-hydroxytryptamine 2C receptor in experiment 2
,BAO_0000357,B,,,108.0,H,,Autocuration,16946.0,,,CHEMBL620674,1.0,,8.0,,,,,,3056.0,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,H,,Autocuration,14159.0,,,CHEMBL620675,1.0,,8.0,,,,,,3057.0,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,H,,Autocuration,16700.0,,,CHEMBL620676,1.0,,8.0,,,,,,3058.0,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity
,BAO_0000357,B,,,108.0,H,,Autocuration,3269.0,,,CHEMBL621382,1.0,,8.0,,,,,,3059.0,Affinity against 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,D,Homo sapiens,Expert,1274.0,,9606.0,CHEMBL621383,1.0,,9.0,,,,,,3060.0,Binding affinity against 5-hydroxytryptamine 2C receptor
,BAO_0000357,B,,,108.0,H,,Autocuration,1317.0,,,CHEMBL621384,1.0,,8.0,,,,,,3061.0,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay
,BAO_0000357,B,,,144.0,H,Bos taurus,Autocuration,5834.0,,9913.0,CHEMBL621385,1.0,,8.0,,,,,,3062.0,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630
,BAO_0000357,B,,,144.0,H,Bos taurus,Autocuration,11147.0,,9913.0,CHEMBL617989,1.0,,8.0,,,,,,3063.0,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand
,BAO_0000019,F,,,104714.0,H,Cavia porcellus,Expert,14145.0,,10141.0,CHEMBL617990,1.0,,4.0,,,,,,3064.0,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay
,BAO_0000221,B,,,104714.0,H,Cavia porcellus,Autocuration,10561.0,,10141.0,CHEMBL875085,1.0,,4.0,Ileum,,,2116.0,,3065.0,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum
,BAO_0000019,F,,,104714.0,H,Cavia porcellus,Autocuration,15847.0,,10141.0,CHEMBL617991,1.0,,4.0,,,,,,3066.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig
,BAO_0000019,F,,,104714.0,H,Cavia porcellus,Autocuration,15847.0,,10141.0,CHEMBL617992,1.0,,4.0,,,,,,3067.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done
,BAO_0000221,B,,,104714.0,H,Cavia porcellus,Autocuration,10561.0,,10141.0,CHEMBL617993,1.0,,4.0,Ileum,,,2116.0,,3068.0,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum
,BAO_0000221,B,,,104714.0,H,Cavia porcellus,Autocuration,11454.0,,10141.0,CHEMBL617994,1.0,,4.0,Ileum,,,2116.0,,3069.0,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.
,BAO_0000019,F,,,104714.0,H,Cavia porcellus,Autocuration,4639.0,,10141.0,CHEMBL617995,1.0,,4.0,,,,,,3070.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM
,BAO_0000019,F,,,104714.0,H,Cavia porcellus,Autocuration,4639.0,,10141.0,CHEMBL617996,1.0,,4.0,,,,,,3071.0,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM
,BAO_0000019,F,,,104714.0,H,Cavia porcellus,Autocuration,4639.0,,10141.0,CHEMBL617997,1.0,,4.0,,,,,,3072.0,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM
,BAO_0000019,F,,,104714.0,H,Cavia porcellus,Autocuration,4639.0,,10141.0,CHEMBL617998,1.0,,4.0,,,,,,3073.0,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222
,BAO_0000019,F,,,104714.0,H,Cavia porcellus,Autocuration,4639.0,,10141.0,CHEMBL617999,1.0,,4.0,,,,,,3074.0,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM
,BAO_0000019,F,,,104714.0,H,Cavia porcellus,Autocuration,4639.0,,10141.0,CHEMBL618000,1.0,,4.0,,,,,,3075.0,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM
,BAO_0000221,F,,,104714.0,H,Cavia porcellus,Autocuration,15253.0,,10141.0,CHEMBL617815,1.0,,4.0,Ileum,,,2116.0,,3076.0,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum"
,BAO_0000221,F,,,104714.0,H,Cavia porcellus,Autocuration,15253.0,,10141.0,CHEMBL617816,1.0,,4.0,Ileum,,,2116.0,,3077.0,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum."
,BAO_0000221,F,,,104714.0,H,Cavia porcellus,Autocuration,11963.0,,10141.0,CHEMBL617817,1.0,,4.0,Ileum,,,2116.0,,3078.0,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum
,BAO_0000221,B,,,104714.0,H,Cavia porcellus,Autocuration,1946.0,,10141.0,CHEMBL617818,1.0,,4.0,Ileum,,,2116.0,,3079.0,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum
,BAO_0000221,B,,,104714.0,H,Cavia porcellus,Autocuration,1946.0,,10141.0,CHEMBL617819,1.0,,4.0,Ileum,,,2116.0,,3080.0,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested
,BAO_0000223,B,,,104714.0,H,Cavia porcellus,Autocuration,12045.0,,10141.0,CHEMBL617820,1.0,,4.0,,,,,,3081.0,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15
,BAO_0000221,B,,,104714.0,H,Cavia porcellus,Autocuration,1559.0,,10141.0,CHEMBL617821,1.0,,4.0,Ileum,,,2116.0,,3082.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum
,BAO_0000221,F,,,104714.0,H,Cavia porcellus,Autocuration,273.0,,10141.0,CHEMBL617822,1.0,,4.0,Ileum,,,2116.0,,3083.0,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI)
,BAO_0000221,F,,,104714.0,H,Cavia porcellus,Autocuration,273.0,,10141.0,CHEMBL617823,1.0,,4.0,Ileum,,,2116.0,,3084.0,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI)
,BAO_0000221,F,,,104714.0,H,Cavia porcellus,Autocuration,188.0,,10141.0,CHEMBL617824,1.0,,4.0,Ileum,,,2116.0,,3085.0,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum
,BAO_0000221,F,,,104714.0,H,Cavia porcellus,Autocuration,12919.0,,10141.0,CHEMBL617825,1.0,,4.0,Ileum,,,2116.0,,3086.0,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay
,BAO_0000221,F,,,104714.0,H,Cavia porcellus,Autocuration,12918.0,,10141.0,CHEMBL617826,1.0,,4.0,Ileum,,,2116.0,,3087.0,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay
,BAO_0000221,B,,,104714.0,H,Cavia porcellus,Autocuration,1559.0,,10141.0,CHEMBL617827,1.0,,4.0,Ileum,,,2116.0,,3088.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum
,BAO_0000221,F,,,104714.0,H,Cavia porcellus,Autocuration,273.0,,10141.0,CHEMBL617828,1.0,,4.0,Ileum,,,2116.0,,3089.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI)
,BAO_0000221,B,,,104714.0,H,Cavia porcellus,Autocuration,1559.0,,10141.0,CHEMBL617829,1.0,,4.0,Ileum,,,2116.0,,3090.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum
,BAO_0000221,B,,,104714.0,H,Cavia porcellus,Autocuration,1559.0,,10141.0,CHEMBL617830,1.0,,4.0,Ileum,,,2116.0,,3091.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined
,BAO_0000221,B,,,104714.0,H,Cavia porcellus,Autocuration,1559.0,,10141.0,CHEMBL617831,1.0,,4.0,Ileum,,,2116.0,,3092.0,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined
,BAO_0000221,B,,,104714.0,H,Cavia porcellus,Autocuration,14424.0,,10141.0,CHEMBL617832,1.0,,4.0,Ileum,,,2116.0,,3093.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.
,BAO_0000019,B,,,22226.0,U,Cavia porcellus,Autocuration,13181.0,,10141.0,CHEMBL617833,1.0,,0.0,,,,,,3094.0,Binding affinity was determined against 5-hydroxytryptamine 2A receptor
,BAO_0000357,B,,,51.0,H,,Autocuration,5486.0,,,CHEMBL617834,1.0,,8.0,,,,,,3095.0,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell
,BAO_0000223,B,,,104714.0,D,Homo sapiens,Expert,6491.0,,9606.0,CHEMBL617835,1.0,,5.0,,,,,,3096.0,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor
,BAO_0000223,B,,,104714.0,H,,Autocuration,6013.0,,,CHEMBL617836,1.0,,4.0,,,,,,3097.0,Binding affinity towards 5-HT3 receptor
,BAO_0000223,B,,,104714.0,H,,Autocuration,12861.0,,,CHEMBL617837,1.0,,4.0,,,,,,3098.0,Binding activity radioligand.
,BAO_0000019,B,,,104714.0,H,,Autocuration,12861.0,,,CHEMBL620392,1.0,,4.0,,,,,,3099.0,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.
,BAO_0000223,B,,,104714.0,H,,Autocuration,5104.0,,,CHEMBL620393,1.0,,4.0,,,,,,3100.0,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor
,BAO_0000223,B,,,104714.0,H,,Autocuration,5105.0,,,CHEMBL620394,1.0,,4.0,,,,,,3101.0,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor
,BAO_0000223,B,,,104714.0,H,,Autocuration,5104.0,,,CHEMBL620395,1.0,,4.0,,,,,,3102.0,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested
,BAO_0000019,B,,,22226.0,U,,Autocuration,3935.0,,,CHEMBL620396,1.0,,0.0,,,,,,3103.0,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor
,BAO_0000219,B,,NG108-15,105030.0,H,,Expert,13657.0,,,CHEMBL620582,1.0,,4.0,,,,,433.0,3104.0,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells
,BAO_0000218,B,In vivo,,105030.0,H,,Autocuration,10369.0,,,CHEMBL620583,1.0,,4.0,,,,,,3105.0,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)"
,BAO_0000019,B,,,105030.0,H,,Autocuration,10369.0,,,CHEMBL620584,1.0,,4.0,,,,,,3106.0,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro)
,BAO_0000224,B,,,105030.0,H,,Autocuration,12918.0,,,CHEMBL620585,1.0,,4.0,,,,,,3107.0,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype
,BAO_0000224,B,,,105030.0,H,,Autocuration,12918.0,,,CHEMBL620586,1.0,,4.0,,,,,,3108.0,Compound was evaluated for the binding affinity at 5- HT3 receptor
,BAO_0000019,B,,,105030.0,H,,Autocuration,10369.0,,,CHEMBL620587,1.0,,4.0,,,,,,3109.0,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro)
,BAO_0000019,B,,,105030.0,H,,Autocuration,773.0,,,CHEMBL620588,1.0,,4.0,,,,,,3110.0,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates
,BAO_0000218,F,,,105030.0,H,,Autocuration,12918.0,,,CHEMBL620589,1.0,,4.0,,,,,,3111.0,5-hydroxytryptamine 3 receptor agonism in mouse
,BAO_0000219,B,,,105030.0,H,,Autocuration,10561.0,,,CHEMBL620590,1.0,,4.0,,,,,,3112.0,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells
,BAO_0000019,B,,,105030.0,H,,Autocuration,12827.0,,,CHEMBL617956,1.0,,4.0,,,,,,3113.0,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin
,BAO_0000019,B,,,105030.0,H,,Autocuration,12827.0,,,CHEMBL617957,1.0,,4.0,,,,,,3114.0,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin
,BAO_0000224,B,,,105030.0,H,,Autocuration,12918.0,,,CHEMBL617958,1.0,,4.0,,,,,,3115.0,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron
,BAO_0000219,B,,,105030.0,H,,Autocuration,273.0,,,CHEMBL617959,1.0,,4.0,,,,,,3116.0,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand
,BAO_0000219,B,,,105030.0,H,,Autocuration,273.0,,,CHEMBL617960,1.0,,4.0,,,,,,3117.0,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand
,BAO_0000224,B,,,105030.0,H,,Autocuration,10561.0,,,CHEMBL617961,1.0,,4.0,,,,,,3118.0,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart
,BAO_0000219,B,In vitro,,105030.0,H,,Autocuration,5033.0,,,CHEMBL617962,1.0,,4.0,,,,,,3119.0,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells
,BAO_0000219,B,,N1E-115,105030.0,H,,Autocuration,16429.0,,,CHEMBL617963,1.0,,4.0,,,,,339.0,3120.0,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand
,BAO_0000019,B,,,11765.0,H,,Autocuration,10322.0,,,CHEMBL617964,1.0,,8.0,,,,,,3121.0,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells
,BAO_0000219,B,,,11765.0,H,,Autocuration,14331.0,,,CHEMBL617965,1.0,,8.0,,,,,,3122.0,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15
,BAO_0000357,B,,,10630.0,D,Mus musculus,Autocuration,13462.0,,10090.0,CHEMBL617966,1.0,,9.0,,,,,,3123.0,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.
,BAO_0000019,B,,,17106.0,H,,Autocuration,12861.0,,,CHEMBL857074,1.0,,8.0,,,,,,3124.0,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.
,BAO_0000357,B,,,144.0,H,Sus scrofa,Autocuration,15086.0,,9823.0,CHEMBL617967,1.0,,8.0,,,,,,3125.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor
,BAO_0000357,B,,,144.0,H,Sus scrofa,Autocuration,12861.0,,9823.0,CHEMBL617968,1.0,,8.0,,,,,,3126.0,Binding activity radioligand.
,BAO_0000223,B,,,104714.0,H,Oryctolagus cuniculus,Autocuration,10561.0,,9986.0,CHEMBL617969,1.0,,4.0,,,,,,3127.0,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus
,BAO_0000223,B,,,104714.0,H,Oryctolagus cuniculus,Autocuration,10561.0,,9986.0,CHEMBL617970,1.0,,4.0,,,,,,3128.0,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart
,BAO_0000223,B,,,104714.0,H,Oryctolagus cuniculus,Autocuration,10561.0,,9986.0,CHEMBL617971,1.0,,4.0,,,,,,3129.0,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart
,BAO_0000019,B,,,104714.0,H,Oryctolagus cuniculus,Autocuration,10561.0,,9986.0,CHEMBL617972,1.0,,4.0,,,,,,3130.0,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex
,BAO_0000019,F,,,104714.0,H,Oryctolagus cuniculus,Autocuration,273.0,,9986.0,CHEMBL617973,1.0,,4.0,,,,,,3131.0,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH)
,BAO_0000019,F,,,104714.0,H,Oryctolagus cuniculus,Autocuration,273.0,,9986.0,CHEMBL617974,1.0,,4.0,,,,,,3132.0,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN)
,BAO_0000221,F,,,104714.0,H,Oryctolagus cuniculus,Autocuration,273.0,,9986.0,CHEMBL617975,1.0,,4.0,Ileum,,,2116.0,,3133.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI)
,BAO_0000019,F,,,104714.0,H,Oryctolagus cuniculus,Autocuration,273.0,,9986.0,CHEMBL617976,1.0,,4.0,,,,,,3134.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH)
,BAO_0000019,F,,,104714.0,H,Oryctolagus cuniculus,Autocuration,273.0,,9986.0,CHEMBL617977,1.0,,4.0,,,,,,3135.0,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN)
,BAO_0000019,F,,,104714.0,H,Oryctolagus cuniculus,Autocuration,273.0,,9986.0,CHEMBL617978,1.0,,4.0,,,,,,3136.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH)
,BAO_0000019,F,,,104714.0,H,Oryctolagus cuniculus,Autocuration,273.0,,9986.0,CHEMBL617979,1.0,,4.0,,,,,,3137.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN)
,BAO_0000219,B,,CHO,104714.0,H,Oryctolagus cuniculus,Autocuration,13047.0,,9986.0,CHEMBL617980,1.0,,4.0,,,,,449.0,3138.0,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand
,BAO_0000019,B,,,104698.0,D,Rattus norvegicus,Autocuration,1650.0,,10116.0,CHEMBL617981,1.0,,7.0,,,,,,3139.0,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor
,BAO_0000019,B,,,12020.0,H,,Autocuration,16288.0,,,CHEMBL617982,1.0,,8.0,,,,,,3140.0,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01)
,BAO_0000357,B,,,12020.0,H,,Autocuration,16288.0,,,CHEMBL617983,1.0,,8.0,,,,,,3141.0,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01)
,BAO_0000019,B,,,104698.0,D,Rattus norvegicus,Autocuration,10254.0,,10116.0,CHEMBL617984,1.0,,7.0,,,,,,3142.0,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells
,BAO_0000019,B,,,104698.0,H,,Autocuration,14532.0,,,CHEMBL617985,1.0,,6.0,,,,,,3143.0,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630"
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,13392.0,,,CHEMBL617986,1.0,,6.0,Heart,,,948.0,,3144.0,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate"
,BAO_0000019,F,,,104698.0,H,,Autocuration,13392.0,,,CHEMBL617987,1.0,,6.0,Heart,,,948.0,,3145.0,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate"
,BAO_0000019,F,,,104698.0,H,,Autocuration,13392.0,,,CHEMBL617988,1.0,,6.0,Heart,,,948.0,,3146.0,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate"
,BAO_0000019,F,,,104698.0,H,,Autocuration,13392.0,,,CHEMBL617792,1.0,,6.0,Heart,,,948.0,,3147.0,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate"
,BAO_0000019,F,,,104698.0,H,,Autocuration,13392.0,,,CHEMBL617793,1.0,,6.0,Heart,,,948.0,,3148.0,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate"
,BAO_0000019,F,,,104698.0,H,,Autocuration,13392.0,,,CHEMBL617794,1.0,,6.0,,,,,,3149.0,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia"
,BAO_0000019,F,,,104698.0,H,,Autocuration,13392.0,,,CHEMBL617795,1.0,,6.0,,,,,,3150.0,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia"
,BAO_0000019,F,,,104698.0,H,,Autocuration,13392.0,,,CHEMBL617796,1.0,,6.0,,,,,,3151.0,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia"
,BAO_0000019,F,,,104698.0,H,,Autocuration,13392.0,,,CHEMBL617797,1.0,,6.0,,,,,,3152.0,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia"
,BAO_0000218,F,In vivo,,104698.0,D,Rattus norvegicus,Autocuration,1089.0,,10116.0,CHEMBL617798,1.0,,7.0,,,,,,3153.0,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism)
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,1089.0,,,CHEMBL617799,1.0,,6.0,,,,,,3154.0,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor)
,BAO_0000218,F,In vivo,,104698.0,D,Rattus norvegicus,Autocuration,11454.0,,10116.0,CHEMBL617800,1.0,,7.0,,,,,,3155.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats
,BAO_0000019,F,,,104698.0,D,Rattus norvegicus,Autocuration,11454.0,,10116.0,CHEMBL617801,1.0,,7.0,,,,,,3156.0,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+
,BAO_0000218,F,In vivo,,104698.0,D,Rattus norvegicus,Autocuration,12205.0,,10116.0,CHEMBL617802,1.0,,7.0,,,,,,3157.0,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration
,BAO_0000019,F,,,104698.0,D,Rattus norvegicus,Autocuration,1089.0,,10116.0,CHEMBL617803,1.0,,7.0,,,,,,3158.0,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism)
,BAO_0000019,B,,,104698.0,H,,Autocuration,5094.0,,,CHEMBL617804,1.0,,6.0,,,,,,3159.0,Binding affinity towards 5-HT3 receptor in rat was evaluated
,BAO_0000019,B,,,104698.0,D,Rattus norvegicus,Autocuration,2622.0,,10116.0,CHEMBL617805,1.0,,7.0,,,,,,3160.0,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor
,BAO_0000223,B,,,104698.0,H,,Autocuration,245.0,,,CHEMBL617806,1.0,,6.0,,,,,,3161.0,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor
,BAO_0000019,B,,,104698.0,H,,Autocuration,14788.0,,,CHEMBL617807,1.0,,6.0,,,,,,3162.0,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.
,BAO_0000019,B,,,104698.0,H,,Autocuration,14788.0,,,CHEMBL617808,1.0,,6.0,,,,,,3163.0,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex
,BAO_0000249,B,,,104698.0,H,,Autocuration,3020.0,,,CHEMBL617809,1.0,,6.0,,,,,,3164.0,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand
,BAO_0000019,B,,,104698.0,H,,Autocuration,1742.0,,,CHEMBL617810,1.0,,6.0,,,,,,3165.0,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates
,BAO_0000249,B,,,104698.0,H,,Autocuration,17394.0,,,CHEMBL617811,1.0,,6.0,Brain,,,955.0,,3166.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane
,BAO_0000221,B,,,104698.0,H,,Autocuration,17394.0,,,CHEMBL617812,1.0,,6.0,Brain,,,955.0,,3167.0,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane
,BAO_0000249,B,,,104698.0,H,,Autocuration,17394.0,,,CHEMBL617813,1.0,,6.0,,,,,,3168.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane
,BAO_0000249,B,,,104698.0,H,,Autocuration,14286.0,,,CHEMBL617814,1.0,,6.0,,,,,,3169.0,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane
,BAO_0000019,B,,,104698.0,H,,Autocuration,14178.0,,,CHEMBL617698,1.0,,6.0,,,,,,3170.0,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.
,BAO_0000019,B,,,104698.0,D,Rattus norvegicus,Autocuration,14178.0,,10116.0,CHEMBL617699,1.0,,7.0,,,,,,3171.0,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm
,BAO_0000019,B,,,104698.0,D,Rattus norvegicus,Autocuration,14178.0,,10116.0,CHEMBL617700,1.0,,7.0,,,,,,3172.0,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM
,BAO_0000223,B,,,104698.0,D,Rattus norvegicus,Autocuration,14178.0,,10116.0,CHEMBL617701,1.0,,7.0,,,,,,3173.0,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor
,BAO_0000019,B,,,104698.0,H,,Autocuration,15034.0,,,CHEMBL617702,1.0,,6.0,,,,,,3174.0,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand
,BAO_0000249,B,,,104698.0,H,,Autocuration,1089.0,Membranes,,CHEMBL617703,1.0,,6.0,,,,,,3175.0,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50"
,BAO_0000019,B,,,104698.0,D,Rattus norvegicus,Autocuration,1089.0,,10116.0,CHEMBL617704,1.0,,7.0,,,,,,3176.0,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor
,BAO_0000223,B,,,104698.0,H,,Autocuration,16532.0,,,CHEMBL617705,1.0,,6.0,,,,,,3177.0,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested
,BAO_0000223,B,,,104698.0,D,Rattus norvegicus,Autocuration,12801.0,,10116.0,CHEMBL617706,1.0,,7.0,,,,,,3178.0,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor
,BAO_0000219,B,,NG108-15,104698.0,H,,Autocuration,15194.0,,,CHEMBL617707,1.0,,6.0,,,,,433.0,3179.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand)
,BAO_0000219,B,,NG108-15,104698.0,H,,Autocuration,15194.0,,,CHEMBL617708,1.0,,6.0,,,,,433.0,3180.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand
,BAO_0000019,B,,,104698.0,H,,Autocuration,15194.0,,,CHEMBL617709,1.0,,6.0,,,,,,3181.0,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand
,BAO_0000019,B,,,104698.0,H,,Autocuration,15194.0,,,CHEMBL617710,1.0,,6.0,,,,,,3182.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active
,BAO_0000019,B,,,104698.0,H,,Autocuration,15194.0,,,CHEMBL882925,1.0,,6.0,,,,,,3183.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active
,BAO_0000019,B,,,104698.0,H,,Autocuration,15194.0,,,CHEMBL617711,1.0,,6.0,,,,,,3184.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active
,BAO_0000019,F,,,104698.0,H,,Autocuration,10610.0,,,CHEMBL617712,1.0,,6.0,,,,,,3185.0,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats
,BAO_0000019,F,,,104698.0,D,Rattus norvegicus,Autocuration,10355.0,,10116.0,CHEMBL617713,1.0,,7.0,,,,,,3186.0,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat
,BAO_0000019,F,,,104698.0,H,,Autocuration,691.0,,,CHEMBL617714,1.0,,6.0,,,,,,3187.0,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously"
,BAO_0000218,F,,,104698.0,H,,Autocuration,10611.0,,,CHEMBL617715,1.0,,6.0,,,,,,3188.0,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,12801.0,,,CHEMBL617716,1.0,,6.0,,,,,,3189.0,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats
,BAO_0000218,F,,,104698.0,H,,Autocuration,10609.0,,,CHEMBL617717,1.0,,6.0,,,,,,3190.0,Inhibition of 5-HT evoked reflex bradycardia in rat.
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617718,1.0,,6.0,,,,,,3191.0,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617719,1.0,,6.0,,,,,,3192.0,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617720,1.0,,6.0,,,,,,3193.0,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats)
,BAO_0000218,F,In vivo,,104698.0,D,Rattus norvegicus,Autocuration,11454.0,,10116.0,CHEMBL617721,1.0,,7.0,,,,,,3194.0,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617722,1.0,,6.0,,,,,,3195.0,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617723,1.0,,6.0,,,,,,3196.0,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617724,1.0,,6.0,,,,,,3197.0,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617725,1.0,,6.0,,,,,,3198.0,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617726,1.0,,6.0,,,,,,3199.0,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617727,1.0,,6.0,,,,,,3200.0,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617728,1.0,,6.0,,,,,,3201.0,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617729,1.0,,6.0,,,,,,3202.0,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617730,1.0,,6.0,,,,,,3203.0,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617731,1.0,,6.0,,,,,,3204.0,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617732,1.0,,6.0,,,,,,3205.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617733,1.0,,6.0,,,,,,3206.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617734,1.0,,6.0,,,,,,3207.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL872874,1.0,,6.0,,,,,,3208.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617735,1.0,,6.0,,,,,,3209.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617736,1.0,,6.0,,,,,,3210.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617737,1.0,,6.0,,,,,,3211.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617738,1.0,,6.0,,,,,,3212.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617739,1.0,,6.0,,,,,,3213.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617740,1.0,,6.0,,,,,,3214.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617741,1.0,,6.0,,,,,,3215.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617742,1.0,,6.0,,,,,,3216.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617743,1.0,,6.0,,,,,,3217.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617744,1.0,,6.0,,,,,,3218.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,11454.0,,,CHEMBL617745,1.0,,6.0,,,,,,3219.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats
,BAO_0000218,F,,,104698.0,H,,Autocuration,670.0,,,CHEMBL617746,1.0,,6.0,,,,,,3220.0,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)"
,BAO_0000218,F,,,104698.0,H,,Autocuration,670.0,,,CHEMBL617747,1.0,,6.0,,,,,,3221.0,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested"
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,10321.0,,,CHEMBL617748,1.0,,6.0,,,,,,3222.0,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,10321.0,,,CHEMBL618909,1.0,,6.0,,,,,,3223.0,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,10321.0,,,CHEMBL618910,1.0,,6.0,,,,,,3224.0,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,10321.0,,,CHEMBL618911,1.0,,6.0,,,,,,3225.0,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,10321.0,,,CHEMBL618912,1.0,,6.0,,,,,,3226.0,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg
,BAO_0000218,F,In vivo,,104698.0,H,,Autocuration,10322.0,,,CHEMBL618913,1.0,,6.0,,,,,,3227.0,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg)
,BAO_0000019,F,,,104698.0,H,,Autocuration,15412.0,,,CHEMBL618914,1.0,,6.0,,,,,,3228.0,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist
,BAO_0000019,F,,,104698.0,H,,Autocuration,15412.0,,,CHEMBL618915,1.0,,6.0,,,,,,3229.0,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist
,BAO_0000223,B,,,104698.0,D,Rattus norvegicus,Autocuration,15412.0,,10116.0,CHEMBL618916,1.0,,7.0,,,,,,3230.0,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor
,BAO_0000019,F,,,104698.0,H,,Autocuration,15412.0,,,CHEMBL618917,1.0,,6.0,,,,,,3231.0,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist
,BAO_0000221,B,,,104698.0,D,,Intermediate,15412.0,,,CHEMBL618918,1.0,,7.0,Hippocampus,,,10000000.0,,3232.0,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue
,BAO_0000019,B,,,104698.0,D,Rattus norvegicus,Autocuration,15412.0,,10116.0,CHEMBL618919,1.0,,7.0,,,,,,3233.0,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane
,BAO_0000019,B,,,104698.0,D,Rattus norvegicus,Autocuration,17394.0,,10116.0,CHEMBL618920,1.0,,7.0,,,,,,3234.0,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor
,BAO_0000223,B,,,104698.0,H,,Autocuration,12457.0,,,CHEMBL618921,1.0,,6.0,,,,,,3235.0,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor
,BAO_0000019,B,,,104698.0,H,,Autocuration,12457.0,,,CHEMBL618922,1.0,,6.0,,,,,,3236.0,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor
,BAO_0000019,B,,,104698.0,H,,Autocuration,12205.0,,,CHEMBL618923,1.0,,6.0,,,,,,3237.0,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.
,BAO_0000019,B,,,104698.0,H,,Autocuration,14532.0,,,CHEMBL618924,1.0,,6.0,,,,,,3238.0,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices
,BAO_0000019,B,,,104698.0,H,,Autocuration,1122.0,,,CHEMBL618925,1.0,,6.0,,,,,,3239.0,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand
,BAO_0000019,B,,,104698.0,H,,Autocuration,5094.0,,,CHEMBL618926,1.0,,6.0,,,,,,3240.0,Binding affinity towards 5-HT3 receptor in rat was evaluated
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,809.0,,10141.0,CHEMBL618927,1.0,,9.0,Ileum,,,2116.0,,3241.0,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,809.0,,10141.0,CHEMBL618928,1.0,,9.0,Ileum,,,2116.0,,3242.0,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,14290.0,,10141.0,CHEMBL618929,1.0,,9.0,Ileum,,,2116.0,,3243.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum"
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,14290.0,,10141.0,CHEMBL618930,1.0,,9.0,Ileum,,,2116.0,,3244.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M"
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,14290.0,,10141.0,CHEMBL618931,1.0,,9.0,Ileum,,,2116.0,,3245.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested"
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,14290.0,,10141.0,CHEMBL619594,1.0,,9.0,Ileum,,,2116.0,,3246.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested"
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,14290.0,,10141.0,CHEMBL619595,1.0,,9.0,Ileum,,,2116.0,,3247.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation"
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,13961.0,,10141.0,CHEMBL619596,1.0,,9.0,Ileum,,,2116.0,,3248.0,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,13961.0,,10141.0,CHEMBL619755,1.0,,9.0,Ileum,,,2116.0,,3249.0,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,809.0,,10141.0,CHEMBL619756,1.0,,9.0,Ileum,,,2116.0,,3250.0,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,809.0,,10141.0,CHEMBL619757,1.0,,9.0,Ileum,,,2116.0,,3251.0,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,809.0,,10141.0,CHEMBL619758,1.0,,9.0,Ileum,,,2116.0,,3252.0,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,14290.0,,10141.0,CHEMBL619759,1.0,,9.0,Ileum,,,2116.0,,3253.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum"
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,14290.0,,10141.0,CHEMBL619760,1.0,,9.0,Ileum,,,2116.0,,3254.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M"
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,14290.0,,10141.0,CHEMBL619761,1.0,,9.0,Ileum,,,2116.0,,3255.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M"
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,14290.0,,10141.0,CHEMBL619762,1.0,,9.0,Ileum,,,2116.0,,3256.0,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,14290.0,,10141.0,CHEMBL619763,1.0,,9.0,Ileum,,,2116.0,,3257.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested"
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,14290.0,,10141.0,CHEMBL617868,1.0,,9.0,Ileum,,,2116.0,,3258.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested"
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Intermediate,15034.0,,10141.0,CHEMBL617869,1.0,,9.0,,,,,,3259.0,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum
,BAO_0000249,B,,,20033.0,D,Cavia porcellus,Intermediate,5094.0,,10141.0,CHEMBL882926,1.0,,9.0,Striatum,,,2435.0,,3260.0,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated
,BAO_0000249,B,,,20033.0,D,Cavia porcellus,Intermediate,5094.0,,10141.0,CHEMBL617870,1.0,,9.0,Striatum,,,2435.0,,3261.0,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Intermediate,5399.0,,10141.0,CHEMBL617871,1.0,,9.0,Striatum,,,2435.0,,3262.0,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Intermediate,17394.0,,10141.0,CHEMBL617872,1.0,,9.0,Striatum,,,2435.0,,3263.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Intermediate,17394.0,,10141.0,CHEMBL617873,1.0,,9.0,Striatum,,,2435.0,,3264.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Intermediate,17394.0,,10141.0,CHEMBL617874,1.0,,9.0,Striatum,,,2435.0,,3265.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,13961.0,,10141.0,CHEMBL619067,1.0,,9.0,Ileum,,,2116.0,,3266.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,13961.0,,10141.0,CHEMBL619068,1.0,,9.0,Ileum,,,2116.0,,3267.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,13961.0,,10141.0,CHEMBL619069,1.0,,9.0,Ileum,,,2116.0,,3268.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Intermediate,16946.0,,10141.0,CHEMBL619070,1.0,,9.0,,,,,,3269.0,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Intermediate,16946.0,,10141.0,CHEMBL619071,1.0,,9.0,,,,,,3270.0,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig
,BAO_0000019,F,,,20033.0,D,Cavia porcellus,Intermediate,15034.0,,10141.0,CHEMBL619072,1.0,,9.0,,,,,,3271.0,Agonistic activity against 5-hydroxytryptamine 4 receptor
,BAO_0000019,F,,,20033.0,D,Cavia porcellus,Intermediate,15034.0,,10141.0,CHEMBL619073,1.0,,9.0,,,,,,3272.0,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested
,BAO_0000019,F,,,20033.0,D,Cavia porcellus,Intermediate,12918.0,,10141.0,CHEMBL619074,1.0,,9.0,,,,,,3273.0,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Intermediate,16946.0,,10141.0,CHEMBL619075,1.0,,9.0,,,,,,3274.0,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Intermediate,17394.0,,10141.0,CHEMBL619076,1.0,,9.0,Striatum,,,2435.0,,3275.0,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Intermediate,15034.0,,10141.0,CHEMBL619077,1.0,,9.0,Striatum,,,2435.0,,3276.0,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand
,BAO_0000249,B,,,20033.0,D,Cavia porcellus,Intermediate,5094.0,,10141.0,CHEMBL619078,1.0,,9.0,Striatum,,,2435.0,,3277.0,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated
,BAO_0000249,B,,,20033.0,D,Cavia porcellus,Intermediate,5094.0,,10141.0,CHEMBL619079,1.0,,9.0,Striatum,,,2435.0,,3278.0,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated
,BAO_0000221,B,,,20033.0,D,Cavia porcellus,Intermediate,17358.0,,10141.0,CHEMBL619080,1.0,,9.0,Ileum,,,2116.0,,3279.0,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Expert,12953.0,,10141.0,CHEMBL619081,1.0,,9.0,,,,,,3280.0,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Intermediate,12953.0,,10141.0,CHEMBL619082,1.0,,9.0,,,,,,3281.0,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Intermediate,12953.0,,10141.0,CHEMBL619083,1.0,,9.0,,,,,,3282.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Intermediate,12953.0,,10141.0,CHEMBL619084,1.0,,9.0,,,,,,3283.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,273.0,,10141.0,CHEMBL859397,1.0,,9.0,Ileum,,,2116.0,,3284.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,12918.0,,10141.0,CHEMBL619085,1.0,,9.0,Ileum,,,2116.0,,3285.0,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,12919.0,,10141.0,CHEMBL619086,1.0,,9.0,Ileum,,,2116.0,,3286.0,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,273.0,,10141.0,CHEMBL619087,1.0,,9.0,Ileum,,,2116.0,,3287.0,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,273.0,,10141.0,CHEMBL619088,1.0,,9.0,Ileum,,,2116.0,,3288.0,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Intermediate,13181.0,,10141.0,CHEMBL619089,1.0,,9.0,,,,,,3289.0,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP
,BAO_0000357,B,,,168.0,H,Cavia porcellus,Autocuration,13181.0,,10141.0,CHEMBL619090,1.0,,8.0,,,,,,3290.0,Binding affinity was determined against 5-hydroxytryptamine 3 receptor
,BAO_0000019,F,,,20033.0,D,Cavia porcellus,Intermediate,15034.0,,10141.0,CHEMBL619091,1.0,,9.0,,,,,,3291.0,Antagonistic activity against 5-hydroxytryptamine 4 receptor
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Intermediate,5033.0,,10141.0,CHEMBL619092,1.0,,9.0,,,,,,3292.0,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor
,BAO_0000019,B,,,20033.0,D,Cavia porcellus,Intermediate,1980.0,,10141.0,CHEMBL619093,1.0,,9.0,,,,,,3293.0,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.
,BAO_0000219,B,,HEK293,168.0,H,Cavia porcellus,Autocuration,13181.0,,10141.0,CHEMBL619094,1.0,,8.0,,,,,722.0,3294.0,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine
,BAO_0000019,B,,,20033.0,D,Cavia porcellus,Intermediate,14287.0,,10141.0,CHEMBL619095,1.0,,9.0,,,,,,3295.0,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Intermediate,1317.0,,10141.0,CHEMBL857988,1.0,,9.0,,,,,,3296.0,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Intermediate,15316.0,,10141.0,CHEMBL619096,1.0,,9.0,,,,,,3297.0,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Intermediate,16429.0,,10141.0,CHEMBL619097,1.0,,9.0,Striatum,,,2435.0,,3298.0,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand
,BAO_0000221,B,,,20033.0,D,Cavia porcellus,Intermediate,14818.0,,10141.0,CHEMBL619098,1.0,,9.0,Hippocampus,,,10000000.0,,3299.0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Intermediate,15194.0,,10141.0,CHEMBL619751,1.0,,9.0,,,,,,3300.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Intermediate,15194.0,,10141.0,CHEMBL619752,1.0,,9.0,,,,,,3301.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,13961.0,,10141.0,CHEMBL875096,1.0,,9.0,Ileum,,,2116.0,,3302.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.
,BAO_0000357,B,,,108.0,H,,Autocuration,5486.0,,,CHEMBL619004,1.0,,8.0,,,,,,3303.0,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell
,BAO_0000357,B,,,168.0,H,,Autocuration,16209.0,,,CHEMBL619005,1.0,,8.0,,,,,,3304.0,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand
,BAO_0000019,B,,,168.0,H,,Autocuration,17085.0,,,CHEMBL619006,1.0,,8.0,,,,,,3305.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor
,BAO_0000219,B,,HeLa,168.0,H,,Autocuration,4199.0,,,CHEMBL619007,1.0,,8.0,,,,,308.0,3306.0,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand
,BAO_0000357,B,,,168.0,H,,Autocuration,15146.0,,,CHEMBL619008,1.0,,8.0,,,,,,3307.0,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor
,BAO_0000357,B,,,168.0,H,,Autocuration,5213.0,,,CHEMBL619009,1.0,,8.0,,,,,,3308.0,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor
,BAO_0000219,B,,HeLa,168.0,H,,Autocuration,4829.0,,,CHEMBL619010,1.0,,8.0,,,,,308.0,3309.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand"
,BAO_0000357,B,,,10622.0,H,,Autocuration,17358.0,,,CHEMBL619011,1.0,,8.0,,,,,,3310.0,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons
,BAO_0000357,B,,,10622.0,H,,Autocuration,17358.0,,,CHEMBL619012,1.0,,8.0,,,,,,3311.0,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive
,BAO_0000219,B,,,10622.0,H,,Autocuration,16946.0,,,CHEMBL619013,1.0,,8.0,,,,,,3312.0,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells
,BAO_0000357,B,,,10622.0,H,,Autocuration,17358.0,,,CHEMBL619014,1.0,,8.0,,,,,,3313.0,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons
,BAO_0000019,F,,,11249.0,H,,Autocuration,268.0,,,CHEMBL857503,1.0,,8.0,Cardiac atrium,,,2081.0,,3314.0,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model
,BAO_0000019,F,,,11249.0,H,,Autocuration,268.0,,,CHEMBL619015,1.0,,8.0,Cardiac atrium,,,2081.0,,3315.0,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM
,BAO_0000357,B,,,11249.0,H,,Autocuration,15086.0,,,CHEMBL619016,1.0,,8.0,,,,,,3316.0,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor
,BAO_0000221,B,,,11249.0,H,,Autocuration,14875.0,,,CHEMBL619017,1.0,,8.0,Hippocampus,,,10000000.0,,3317.0,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor
,BAO_0000221,B,,,168.0,H,Sus scrofa,Autocuration,13267.0,,9823.0,CHEMBL619018,1.0,,8.0,Hippocampus,,,10000000.0,,3318.0,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand
,BAO_0000019,B,,,168.0,H,Oryctolagus cuniculus,Autocuration,13047.0,,9986.0,CHEMBL619019,1.0,,8.0,,,,,,3319.0,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.
,BAO_0000357,B,,,10623.0,D,Rattus norvegicus,Expert,1650.0,,10116.0,CHEMBL619020,1.0,,9.0,,,,,,3320.0,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor
,BAO_0000019,F,,,10623.0,H,,Autocuration,567.0,,,CHEMBL619021,1.0,,8.0,,,,,,3321.0,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae
,BAO_0000357,B,,,10623.0,H,,Autocuration,17358.0,,,CHEMBL619022,1.0,,8.0,,,,,,3322.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus
,BAO_0000357,B,,,10623.0,H,,Autocuration,188.0,,,CHEMBL619023,1.0,,8.0,,,,,,3323.0,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity
,BAO_0000019,F,,,10623.0,H,,Autocuration,670.0,,,CHEMBL619024,1.0,,8.0,,,,,,3324.0,lntrinsic activity relative to 5-HT receptor
,BAO_0000019,F,,,10623.0,H,,Autocuration,204.0,,,CHEMBL619025,1.0,,8.0,,,,,,3325.0,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay
,BAO_0000019,F,,,10623.0,H,,Expert,1946.0,,,CHEMBL619026,1.0,,8.0,,,,,,3326.0,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.
,BAO_0000019,F,,,10623.0,H,,Autocuration,6398.0,,,CHEMBL619027,1.0,,8.0,,,,,,3327.0,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay
,BAO_0000019,F,,,10623.0,H,,Autocuration,6398.0,,,CHEMBL619028,1.0,,8.0,,,,,,3328.0,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive
,BAO_0000019,F,,,10623.0,H,,Autocuration,17358.0,,,CHEMBL619029,1.0,,8.0,,,,,,3329.0,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae
,BAO_0000019,F,,,10623.0,H,,Autocuration,6398.0,,,CHEMBL619030,1.0,,8.0,,,,,,3330.0,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture
,BAO_0000357,B,,,10623.0,H,,Expert,11752.0,,,CHEMBL619031,1.0,,8.0,,,,,,3331.0,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae
,BAO_0000019,F,,,10623.0,H,,Autocuration,809.0,,,CHEMBL619032,1.0,,8.0,,,,,,3332.0,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae
,BAO_0000357,B,,,10623.0,D,Rattus norvegicus,Expert,14178.0,,10116.0,CHEMBL619033,1.0,,9.0,,,,,,3333.0,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor
,BAO_0000357,B,,,10623.0,H,,Autocuration,567.0,,,CHEMBL619034,1.0,,8.0,,,,,,3334.0,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae
,BAO_0000357,B,,,10623.0,H,,Autocuration,1946.0,,,CHEMBL619035,1.0,,8.0,,,,,,3335.0,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.
,BAO_0000357,B,,,10623.0,H,,Autocuration,1946.0,,,CHEMBL619036,1.0,,8.0,,,,,,3336.0,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration
,BAO_0000019,B,,,10623.0,D,Rattus norvegicus,Expert,13961.0,,10116.0,CHEMBL619037,1.0,,9.0,,,,,,3337.0,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum
,BAO_0000249,B,,,10623.0,H,,Autocuration,6238.0,,,CHEMBL619038,1.0,,8.0,Striatum,,,2435.0,,3338.0,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand
,BAO_0000249,B,,,10623.0,H,,Autocuration,14290.0,,,CHEMBL619039,1.0,,8.0,,,,,,3339.0,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested
,BAO_0000249,B,,,10623.0,H,,Expert,14290.0,,,CHEMBL619040,1.0,,8.0,,,,,,3340.0,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand
,BAO_0000019,B,,,10623.0,D,Rattus norvegicus,Expert,809.0,,10116.0,CHEMBL619041,1.0,,9.0,Striatum,,,2435.0,,3341.0,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum
,BAO_0000019,B,,,10623.0,H,,Autocuration,1578.0,,,CHEMBL619042,1.0,,8.0,Striatum,,,2435.0,,3342.0,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum
,BAO_0000249,B,,,10623.0,H,,Expert,16709.0,,,CHEMBL619043,1.0,,8.0,Striatum,,,2435.0,,3343.0,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane
,BAO_0000019,B,,,10623.0,H,,Expert,1946.0,,,CHEMBL619044,1.0,,8.0,Striatum,,,2435.0,,3344.0,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.
,BAO_0000249,B,,,10623.0,H,,Expert,15253.0,,,CHEMBL619045,1.0,,8.0,Striatum,,,2435.0,,3345.0,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.
,BAO_0000249,B,,,10623.0,H,,Expert,4535.0,,,CHEMBL619046,1.0,,8.0,Striatum,,,2435.0,,3346.0,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane
,BAO_0000249,B,,,10623.0,H,,Expert,13961.0,,,CHEMBL619047,1.0,,8.0,,,,,,3347.0,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.
,BAO_0000221,F,,,10623.0,H,,Autocuration,17358.0,,,CHEMBL619048,1.0,,8.0,Brain,,,955.0,,3348.0,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain
,BAO_0000019,F,,,10623.0,H,,Autocuration,15847.0,,,CHEMBL859398,1.0,,8.0,,,,,,3349.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat
,BAO_0000019,F,,,10623.0,H,,Autocuration,15847.0,,,CHEMBL619049,1.0,,8.0,,,,,,3350.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done
,BAO_0000019,F,,,10623.0,H,,Autocuration,670.0,,,CHEMBL857886,1.0,,8.0,,,,,,3351.0,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae
,BAO_0000019,F,,,10623.0,H,,Autocuration,670.0,,,CHEMBL619050,1.0,,8.0,,,,,,3352.0,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested
,BAO_0000019,F,,,10623.0,H,,Autocuration,1317.0,,,CHEMBL620591,1.0,,8.0,,,,,,3353.0,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae
,BAO_0000357,B,,,10623.0,D,Rattus norvegicus,Expert,12936.0,,10116.0,CHEMBL620592,1.0,,9.0,,,,,,3354.0,Binding affinity against rat 5-hydroxytryptamine 4 receptor
,BAO_0000249,B,,,10623.0,H,,Expert,4535.0,,,CHEMBL620593,1.0,,8.0,Striatum,,,2435.0,,3355.0,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane
,BAO_0000019,F,,,10623.0,D,Rattus norvegicus,Expert,14424.0,,10116.0,CHEMBL620594,1.0,,9.0,,,,,,3356.0,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.
,BAO_0000019,F,,,10623.0,H,,Expert,14424.0,,,CHEMBL875079,1.0,,8.0,,,,,,3357.0,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.
,BAO_0000019,F,,,10623.0,H,,Expert,14424.0,,,CHEMBL620595,1.0,,8.0,,,,,,3358.0,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.
,BAO_0000019,F,,,10623.0,D,Rattus norvegicus,Expert,14424.0,,10116.0,CHEMBL620596,1.0,,9.0,,,,,,3359.0,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.
,BAO_0000019,F,,,10623.0,H,,Autocuration,14424.0,,,CHEMBL620597,1.0,,8.0,,,,,,3360.0,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.
,BAO_0000019,F,,,10623.0,H,,Expert,14424.0,,,CHEMBL620598,1.0,,8.0,,,,,,3361.0,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.
,BAO_0000218,F,,,10623.0,H,,Expert,14424.0,,,CHEMBL620599,1.0,,8.0,,,,,,3362.0,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.)
,BAO_0000019,F,,,10623.0,H,,Autocuration,14424.0,,,CHEMBL620600,1.0,,8.0,,,,,,3363.0,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.
,BAO_0000019,F,,,168.0,H,Rattus norvegicus,Autocuration,1980.0,,10116.0,CHEMBL620601,1.0,,8.0,,,,,,3364.0,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae
,BAO_0000019,F,,,168.0,H,,Autocuration,4639.0,,,CHEMBL620602,1.0,,8.0,,,,,,3365.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM
,BAO_0000357,B,,,168.0,H,,Autocuration,17358.0,,,CHEMBL620603,1.0,,8.0,,,,,,3366.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor
,BAO_0000357,B,,,168.0,H,,Autocuration,17358.0,,,CHEMBL620604,1.0,,8.0,,,,,,3367.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor.
,BAO_0000357,B,,,168.0,H,,Autocuration,17358.0,,,CHEMBL620605,1.0,,8.0,,,,,,3368.0,Compound was tested for 5-hydroxytryptamine 4 binding affinity
,BAO_0000357,B,,,168.0,H,,Autocuration,1558.0,,,CHEMBL620606,1.0,,8.0,,,,,,3369.0,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor
,BAO_0000019,F,,,168.0,H,,Autocuration,17358.0,,,CHEMBL620607,1.0,,8.0,,,,,,3370.0,Tested for 5-hydroxytryptamine 4 receptor antagonist activity
,BAO_0000357,B,,,168.0,H,,Autocuration,16117.0,,,CHEMBL620608,1.0,,8.0,,,,,,3371.0,In vitro binding affinity towards 5-HT4 receptor was determined
,BAO_0000019,F,,,168.0,H,,Autocuration,17358.0,,,CHEMBL620609,1.0,,8.0,,,,,,3372.0,Tested for 5-hydroxytryptamine 4 receptor antagonist activity
,BAO_0000019,F,,,168.0,H,,Autocuration,17358.0,,,CHEMBL620610,1.0,,8.0,,,,,,3373.0,Tested for agonist activity against 5-hydroxytryptamine 4 receptor
,BAO_0000357,B,,,168.0,H,,Autocuration,17358.0,,,CHEMBL620611,1.0,,8.0,,,,,,3374.0,Tested for selectivity for 5-hydroxytryptamine 4 receptor
,BAO_0000357,B,,,168.0,H,,Autocuration,17358.0,,,CHEMBL620612,1.0,,8.0,,,,,,3375.0,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride
,BAO_0000357,B,,,168.0,H,,Autocuration,17358.0,,,CHEMBL620613,1.0,,8.0,,,,,,3376.0,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride
,BAO_0000357,B,,,168.0,H,,Autocuration,17358.0,,,CHEMBL620614,1.0,,8.0,,,,,,3377.0,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride
,BAO_0000357,B,,,168.0,H,,Expert,1274.0,,,CHEMBL620615,1.0,,8.0,,,,,,3378.0,Binding affinity against 5-Hydroxytryptamine 4 receptor
,BAO_0000249,B,,,104698.0,H,,Autocuration,10728.0,Brain membranes,,CHEMBL857075,1.0,,6.0,,,,,,3379.0,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes
,BAO_0000249,B,,,104698.0,H,,Autocuration,11695.0,Brain membranes,,CHEMBL620616,1.0,,6.0,,,,,,3380.0,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes
,BAO_0000249,B,,,104698.0,H,,Autocuration,11695.0,Brain membranes,,CHEMBL619411,1.0,,6.0,,,,,,3381.0,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes
,BAO_0000019,B,,,104698.0,H,,Autocuration,12490.0,,,CHEMBL619412,1.0,,6.0,,,,,,3382.0,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate
,BAO_0000019,B,,,104698.0,D,Rattus norvegicus,Autocuration,11828.0,,10116.0,CHEMBL619413,1.0,,7.0,,,,,,3383.0,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor
,BAO_0000221,B,,,104698.0,H,,Autocuration,12253.0,,,CHEMBL619414,1.0,,6.0,Hippocampus,,,10000000.0,,3384.0,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex
,BAO_0000019,B,,,104698.0,H,,Autocuration,10561.0,,,CHEMBL619415,1.0,,6.0,,,,,,3385.0,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex
,BAO_0000019,B,,,104698.0,H,,Autocuration,10561.0,,,CHEMBL619416,1.0,,6.0,,,,,,3386.0,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex
,BAO_0000019,F,,,104698.0,H,,Autocuration,14432.0,,,CHEMBL619417,1.0,,6.0,,,,,,3387.0,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist
,BAO_0000223,B,,,104698.0,D,Rattus norvegicus,Autocuration,12936.0,,10116.0,CHEMBL619418,1.0,,7.0,,,,,,3388.0,Binding affinity against rat 5-hydroxytryptamine 3 receptor
,BAO_0000223,B,,,104698.0,D,Rattus norvegicus,Autocuration,1274.0,,10116.0,CHEMBL619419,1.0,,7.0,,,,,,3389.0,Binding affinity against 5-Hydroxytryptamine 3 receptor
,BAO_0000019,B,,,104698.0,H,,Autocuration,1980.0,,,CHEMBL619420,1.0,,6.0,,,,,,3390.0,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex
,BAO_0000249,B,,,104698.0,H,,Autocuration,670.0,,,CHEMBL619421,1.0,,6.0,,,,,,3391.0,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.
,BAO_0000019,B,,,104698.0,D,Rattus norvegicus,Autocuration,968.0,,10116.0,CHEMBL619422,1.0,,7.0,,,,,,3392.0,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex
,BAO_0000019,B,,,104698.0,H,,Autocuration,14287.0,,,CHEMBL619423,1.0,,6.0,,,,,,3393.0,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex
,BAO_0000019,B,,,104698.0,H,,Autocuration,567.0,,,CHEMBL875080,1.0,,6.0,,,,,,3394.0,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex
,BAO_0000019,B,,,104698.0,H,,Autocuration,13267.0,,,CHEMBL619424,1.0,,6.0,,,,,,3395.0,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand
,BAO_0000249,B,,,104698.0,H,,Autocuration,14826.0,,,CHEMBL619425,1.0,,6.0,,,,,,3396.0,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.
,BAO_0000223,B,,,104698.0,H,,Autocuration,15194.0,,,CHEMBL619426,1.0,,6.0,,,,,,3397.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand
,BAO_0000223,B,,,104698.0,H,,Autocuration,15194.0,,,CHEMBL619427,1.0,,6.0,,,,,,3398.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.
,BAO_0000223,B,,,104698.0,D,Rattus norvegicus,Autocuration,10394.0,,10116.0,CHEMBL619645,1.0,,7.0,,,,,,3399.0,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor
,BAO_0000249,B,,,10576.0,D,,Expert,13657.0,,,CHEMBL619646,1.0,,9.0,,,,,,3400.0,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding"
,BAO_0000221,F,,,12020.0,H,,Autocuration,1879.0,,,CHEMBL619647,1.0,,8.0,Brain,,,955.0,,3401.0,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.
,BAO_0000019,F,,,12020.0,H,,Autocuration,1879.0,,,CHEMBL619648,1.0,,8.0,,,,,,3402.0,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor
,BAO_0000019,F,,,12020.0,H,,Autocuration,1879.0,,,CHEMBL619165,1.0,,8.0,,,,,,3403.0,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.
,BAO_0000218,F,In vivo,,12020.0,H,,Autocuration,204.0,,,CHEMBL620719,1.0,,8.0,,,,,,3404.0,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor
,BAO_0000019,B,,,12020.0,H,,Autocuration,1879.0,,,CHEMBL872924,1.0,,8.0,,,,,,3405.0,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.
,BAO_0000357,B,,,12020.0,H,,Autocuration,1879.0,,,CHEMBL620720,1.0,,8.0,,,,,,3406.0,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor
,BAO_0000019,B,,,12020.0,H,,Autocuration,1879.0,,,CHEMBL620721,1.0,,8.0,,,,,,3407.0,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.
,BAO_0000019,B,,,12020.0,H,,Autocuration,1879.0,,,CHEMBL620722,1.0,,8.0,,,,,,3408.0,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.
,BAO_0000019,B,,,104698.0,H,,Autocuration,10641.0,,,CHEMBL620723,1.0,,6.0,,,,,,3409.0,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex"
,BAO_0000019,B,,,12020.0,H,,Autocuration,773.0,,,CHEMBL620724,1.0,,8.0,,,,,,3410.0,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates
,BAO_0000249,B,,,104698.0,H,,Autocuration,11952.0,,,CHEMBL620725,1.0,,6.0,,,,,,3411.0,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine
,BAO_0000019,F,,,12020.0,D,Rattus norvegicus,Autocuration,14145.0,,10116.0,CHEMBL620726,1.0,,9.0,,,,,,3412.0,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.
,BAO_0000357,B,,,144.0,H,,Expert,17066.0,,,CHEMBL620727,1.0,,8.0,,,,,,3413.0,Binding affinity towards 5-hydroxytryptamine 3 receptor
,BAO_0000223,B,,,104714.0,H,,Autocuration,6398.0,,,CHEMBL620728,1.0,,4.0,,,,,,3414.0,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding
,BAO_0000019,B,,,22226.0,U,,Autocuration,10321.0,,,CHEMBL620729,1.0,,0.0,,,,,,3415.0,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells
,BAO_0000019,F,,,104714.0,H,,Autocuration,511.0,,,CHEMBL858288,1.0,,4.0,,,,,,3416.0,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex
,BAO_0000223,B,,,104714.0,H,,Autocuration,4639.0,,,CHEMBL620730,1.0,,4.0,,,,,,3417.0,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor
,BAO_0000223,B,,,104714.0,H,,Autocuration,4639.0,,,CHEMBL620731,1.0,,4.0,,,,,,3418.0,Binding affinity towards 5-hydroxytryptamine 3 receptor
,BAO_0000019,F,,,104714.0,H,Cavia porcellus,Autocuration,4639.0,,10141.0,CHEMBL620732,1.0,,4.0,,,,,,3419.0,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM
,BAO_0000019,F,,,104714.0,H,Cavia porcellus,Autocuration,4639.0,,10141.0,CHEMBL618042,1.0,,4.0,,,,,,3420.0,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM
,BAO_0000019,F,,,104714.0,H,Cavia porcellus,Autocuration,4639.0,,10141.0,CHEMBL618043,1.0,,4.0,,,,,,3421.0,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM
,BAO_0000223,B,,,104714.0,H,,Autocuration,1558.0,,,CHEMBL618044,1.0,,4.0,,,,,,3422.0,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor
,BAO_0000019,F,,,104714.0,H,,Autocuration,268.0,,,CHEMBL618045,1.0,,4.0,,,,,,3423.0,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection
,BAO_0000223,B,,,104714.0,H,,Autocuration,2474.0,,,CHEMBL618046,1.0,,4.0,,,,,,3424.0,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand
,BAO_0000019,F,,,104714.0,H,,Autocuration,5067.0,,,CHEMBL618047,1.0,,4.0,,,,,,3425.0,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist
,BAO_0000019,F,,,104714.0,H,,Autocuration,5067.0,,,CHEMBL875084,1.0,,4.0,,,,,,3426.0,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist
,BAO_0000019,F,,,104714.0,H,,Autocuration,5067.0,,,CHEMBL618048,1.0,,4.0,,,,,,3427.0,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist
,BAO_0000223,B,,,104714.0,H,,Autocuration,5067.0,,,CHEMBL618049,1.0,,4.0,,,,,,3428.0,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available
,BAO_0000019,F,,,104714.0,H,,Autocuration,5067.0,,,CHEMBL619764,1.0,,4.0,,,,,,3429.0,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist
,BAO_0000019,F,,,104714.0,H,,Autocuration,5067.0,,,CHEMBL619765,1.0,,4.0,,,,,,3430.0,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist
,BAO_0000019,F,,,104714.0,H,,Autocuration,5067.0,,,CHEMBL619766,1.0,,4.0,,,,,,3431.0,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist
,BAO_0000223,B,,,104714.0,H,,Autocuration,5067.0,,,CHEMBL619767,1.0,,4.0,,,,,,3432.0,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active
,BAO_0000223,B,,,104714.0,H,,Autocuration,5067.0,,,CHEMBL619768,1.0,,4.0,,,,,,3433.0,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available
,BAO_0000019,F,,,104714.0,H,,Autocuration,5067.0,,,CHEMBL619769,1.0,,4.0,,,,,,3434.0,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist
,BAO_0000223,B,,,104714.0,H,,Autocuration,5067.0,,,CHEMBL619770,1.0,,4.0,,,,,,3435.0,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available
,BAO_0000223,B,,,104714.0,H,,Autocuration,5067.0,,,CHEMBL619771,1.0,,4.0,,,,,,3436.0,Binding affinity towards 5-hydroxytryptamine 3 receptor
,BAO_0000219,B,,,104714.0,H,,Autocuration,14331.0,,,CHEMBL619772,1.0,,4.0,,,,,,3437.0,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined
,BAO_0000223,B,,,104714.0,H,,Autocuration,5067.0,,,CHEMBL619773,1.0,,4.0,,,,,,3438.0,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active
,BAO_0000219,B,,NG108-15,104714.0,H,,Autocuration,6179.0,,,CHEMBL619774,1.0,,4.0,,,,,433.0,3439.0,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630
,BAO_0000019,B,,,104714.0,H,,Autocuration,4265.0,,,CHEMBL875083,1.0,,4.0,,,,,,3440.0,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.
,BAO_0000219,B,,NG108-15,104714.0,H,,Autocuration,4265.0,,,CHEMBL620718,1.0,,4.0,,,,,433.0,3441.0,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand
,BAO_0000223,B,,,104714.0,H,,Autocuration,17358.0,,,CHEMBL618127,1.0,,4.0,,,,,,3442.0,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity
,BAO_0000223,B,,,104714.0,H,,Autocuration,17358.0,,,CHEMBL618128,1.0,,4.0,,,,,,3443.0,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity
,BAO_0000219,B,In vitro,,104714.0,H,,Autocuration,13628.0,,,CHEMBL618129,1.0,,4.0,,,,,,3444.0,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells
,BAO_0000223,B,,,104714.0,H,,Autocuration,4612.0,,,CHEMBL618130,1.0,,4.0,,,,,,3445.0,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined
,BAO_0000019,F,,,104714.0,H,,Autocuration,17358.0,,,CHEMBL618131,1.0,,4.0,,,,,,3446.0,Tested for 5-hydroxytryptamine 3 receptor antagonist activity
,BAO_0000019,F,,,104714.0,H,Cavia porcellus,Autocuration,4639.0,,10141.0,CHEMBL618132,1.0,,4.0,,,,,,3447.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM
,BAO_0000019,F,,,104714.0,H,Cavia porcellus,Autocuration,4639.0,,10141.0,CHEMBL618133,1.0,,4.0,,,,,,3448.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM
,BAO_0000019,F,,,104714.0,H,Cavia porcellus,Autocuration,4639.0,,10141.0,CHEMBL618134,1.0,,4.0,,,,,,3449.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222
,BAO_0000019,F,,,104714.0,H,Cavia porcellus,Autocuration,4639.0,,10141.0,CHEMBL618135,1.0,,4.0,,,,,,3450.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM
,BAO_0000223,B,,,104714.0,H,,Autocuration,511.0,,,CHEMBL618136,1.0,,4.0,,,,,,3451.0,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.
,BAO_0000223,B,,,104714.0,H,,Autocuration,1479.0,,,CHEMBL618137,1.0,,4.0,,,,,,3452.0,Binding affinity towards 5-hydroxytryptamine 3 receptor
,BAO_0000223,B,,,104714.0,H,,Autocuration,1317.0,,,CHEMBL618138,1.0,,4.0,,,,,,3453.0,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay
,BAO_0000223,B,,,104714.0,H,,Autocuration,12146.0,,,CHEMBL618139,1.0,,4.0,,,,,,3454.0,Tested against 5-hydroxytryptamine 3 receptor in experiment 1
,BAO_0000223,B,,,104714.0,H,,Autocuration,12146.0,,,CHEMBL618140,1.0,,4.0,,,,,,3455.0,Tested against 5-hydroxytryptamine 3 receptor in experiment 2
,BAO_0000223,B,,,104714.0,H,,Autocuration,13969.0,,,CHEMBL618141,1.0,,4.0,,,,,,3456.0,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand
,BAO_0000357,B,,,108.0,H,,Expert,13392.0,,,CHEMBL873478,1.0,,8.0,,,,,,3457.0,Binding affinity for 5-hydroxytryptamine 2C receptor
,BAO_0000223,B,,,104698.0,H,,Autocuration,13392.0,,,CHEMBL618142,1.0,,6.0,,,,,,3458.0,Binding affinity towards 5-hydroxytryptamine 3 receptor
,BAO_0000357,B,,,144.0,H,,Autocuration,14159.0,,,CHEMBL618143,1.0,,8.0,,,,,,3459.0,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor
,BAO_0000357,B,,,144.0,H,,Autocuration,1558.0,,,CHEMBL618144,1.0,,8.0,,,,,,3460.0,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor
,BAO_0000357,B,,,144.0,H,,Autocuration,16655.0,,,CHEMBL618145,1.0,,8.0,,,,,,3461.0,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor
,BAO_0000223,B,,,104714.0,H,,Autocuration,13020.0,,,CHEMBL618146,1.0,,4.0,,,,,,3462.0,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M
,BAO_0000223,B,,,104714.0,H,,Autocuration,13021.0,,,CHEMBL618147,1.0,,4.0,,,,,,3463.0,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system
,BAO_0000223,B,,,104714.0,H,,Autocuration,13020.0,,,CHEMBL618148,1.0,,4.0,,,,,,3464.0,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M
,BAO_0000019,B,,,144.0,H,,Autocuration,10321.0,,,CHEMBL618149,1.0,,8.0,,,,,,3465.0,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells
,BAO_0000357,B,,,144.0,H,,Autocuration,15818.0,,,CHEMBL872927,1.0,,8.0,,,,,,3466.0,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor
,BAO_0000357,B,,,144.0,H,,Autocuration,15818.0,,,CHEMBL618150,1.0,,8.0,,,,,,3467.0,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor
,BAO_0000357,B,,,144.0,H,,Autocuration,17358.0,,,CHEMBL618151,1.0,,8.0,,,,,,3468.0,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity
,BAO_0000357,B,,,144.0,H,,Autocuration,2222.0,,,CHEMBL875094,1.0,,8.0,,,,,,3469.0,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor
,BAO_0000019,B,,,144.0,H,,Autocuration,10322.0,,,CHEMBL618152,1.0,,8.0,,,,,,3470.0,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells
,BAO_0000357,B,,,144.0,H,,Autocuration,16117.0,,,CHEMBL618153,1.0,,8.0,,,,,,3471.0,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined
,BAO_0000357,B,,,144.0,H,,Autocuration,17200.0,,,CHEMBL618888,1.0,,8.0,,,,,,3472.0,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand
,BAO_0000019,F,,,144.0,H,,Autocuration,17358.0,,,CHEMBL618889,1.0,,8.0,,,,,,3473.0,Tested for 5-hydroxytryptamine 3 receptor agonist activity
,BAO_0000357,B,,,144.0,H,,Autocuration,16700.0,,,CHEMBL618890,1.0,,8.0,,,,,,3474.0,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity
,BAO_0000019,B,,,144.0,H,,Autocuration,1980.0,,,CHEMBL618891,1.0,,8.0,,,,,,3475.0,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes
,BAO_0000019,B,,,144.0,H,,Autocuration,1980.0,,,CHEMBL619054,1.0,,8.0,,,,,,3476.0,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes
,BAO_0000223,B,,,104714.0,H,,Autocuration,12409.0,,,CHEMBL619055,1.0,,4.0,,,,,,3477.0,Binding affinity against the 5-hydroxytryptamine 3 receptor
,BAO_0000357,B,,,144.0,H,,Autocuration,4365.0,,,CHEMBL619056,1.0,,8.0,,,,,,3478.0,Binding affinity against human 5-hydroxytryptamine 3A receptor
,BAO_0000019,F,,,144.0,H,,Autocuration,4365.0,,,CHEMBL619057,1.0,,8.0,,,,,,3479.0,Percent efficacy against 5-hydroxytryptamine 3A receptor
,BAO_0000357,B,,,144.0,H,,Autocuration,4365.0,,,CHEMBL619058,1.0,,8.0,,,,,,3480.0,Binding affinity against human 5-hydroxytryptamine 3A receptor
,BAO_0000219,F,,Oocytes,12020.0,D,Rattus norvegicus,Expert,6769.0,,10116.0,CHEMBL619059,1.0,,9.0,,,,,,3481.0,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes
,BAO_0000219,F,,Oocytes,12020.0,D,Rattus norvegicus,Expert,6769.0,,10116.0,CHEMBL619060,1.0,,9.0,,,,,,3482.0,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes
,BAO_0000219,F,,Oocytes,12020.0,D,Rattus norvegicus,Expert,6769.0,,10116.0,CHEMBL875095,1.0,,9.0,,,,,,3483.0,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,809.0,,10141.0,CHEMBL619061,1.0,,9.0,Ileum,,,2116.0,,3484.0,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum
,BAO_0000221,F,,,20033.0,D,Cavia porcellus,Intermediate,809.0,,10141.0,CHEMBL619062,1.0,,9.0,Ileum,,,2116.0,,3485.0,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum
,BAO_0000019,F,,,20033.0,D,Cavia porcellus,Intermediate,14290.0,,10141.0,CHEMBL619063,1.0,,9.0,,,,,,3486.0,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response
,BAO_0000221,B,,,20033.0,D,Cavia porcellus,Intermediate,17358.0,,10141.0,CHEMBL619064,1.0,,9.0,Ileum,,,2116.0,,3487.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Intermediate,17358.0,,10141.0,CHEMBL619065,1.0,,9.0,,,,,,3488.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation
,BAO_0000221,B,,,20033.0,D,Cavia porcellus,Intermediate,17358.0,,10141.0,CHEMBL619066,1.0,,9.0,Ileum,,,2116.0,,3489.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation
,BAO_0000221,B,,,10209.0,H,,Autocuration,17386.0,,,CHEMBL619775,1.0,,8.0,Ileum,,,2116.0,,3490.0,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization
,BAO_0000357,B,,,10209.0,H,,Autocuration,3269.0,,,CHEMBL619776,1.0,,8.0,,,,,,3491.0,Affinity against 5-hydroxytryptamine 7 receptor
,BAO_0000224,B,,,104841.0,H,Cavia porcellus,Autocuration,7721.0,,10141.0,CHEMBL619777,1.0,,4.0,,,,,,3492.0,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand
,BAO_0000224,B,,,104841.0,H,Cavia porcellus,Autocuration,7721.0,,10141.0,CHEMBL619778,1.0,,4.0,,,,,,3493.0,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand
,BAO_0000221,B,,,104841.0,H,Cavia porcellus,Autocuration,9117.0,,10141.0,CHEMBL619779,1.0,,4.0,Ileum,,,2116.0,,3494.0,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect
,BAO_0000224,B,,,104841.0,H,Cavia porcellus,Autocuration,7721.0,,10141.0,CHEMBL619780,1.0,,4.0,,,,,,3495.0,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd."
,BAO_0000224,B,,,104841.0,H,Cavia porcellus,Autocuration,7721.0,,10141.0,CHEMBL619166,1.0,,4.0,,,,,,3496.0,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd."
,BAO_0000019,F,,,104841.0,H,Cavia porcellus,Autocuration,15796.0,,10141.0,CHEMBL619167,1.0,,4.0,,,,,,3497.0,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.
,BAO_0000019,F,,,104841.0,H,Cavia porcellus,Autocuration,15796.0,,10141.0,CHEMBL619168,1.0,,4.0,,,,,,3498.0,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.
,BAO_0000219,B,,,168.0,D,Homo sapiens,Expert,15650.0,,9606.0,CHEMBL619169,1.0,,9.0,Cardiac atrium,,,2081.0,,3499.0,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes
,BAO_0000219,B,,,168.0,D,Homo sapiens,Expert,15650.0,,9606.0,CHEMBL619170,1.0,,9.0,Cardiac atrium,,,2081.0,,3500.0,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes
,BAO_0000019,F,,,104841.0,D,Homo sapiens,Autocuration,6866.0,,9606.0,CHEMBL619171,1.0,,5.0,,,,,,3501.0,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine"
,BAO_0000219,F,,,168.0,D,Homo sapiens,Expert,15650.0,,9606.0,CHEMBL619172,1.0,,9.0,Cardiac atrium,,,2081.0,,3502.0,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes"
,BAO_0000019,B,,,22226.0,U,Mus musculus,Autocuration,10063.0,,10090.0,CHEMBL619173,1.0,,0.0,,,,,,3503.0,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice
,BAO_0000019,B,,,22226.0,U,Mus musculus,Autocuration,12665.0,,10090.0,CHEMBL619174,1.0,,0.0,,,,,,3504.0,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration
,BAO_0000019,B,,,104705.0,H,,Autocuration,7504.0,,,CHEMBL619175,1.0,,4.0,,,,,,3505.0,5-hydroxytryptamine receptor binding affinity was determined in rats
,BAO_0000224,B,,,104705.0,H,,Autocuration,7504.0,,,CHEMBL619176,1.0,,4.0,,,,,,3506.0,Binding affinity at rat 5-hydroxytryptamine receptor.
,BAO_0000019,B,,,104705.0,H,,Autocuration,7038.0,,,CHEMBL619177,1.0,,4.0,,,,,,3507.0,Affinity against 5-hydroxytryptamine receptors in rat fundus model
,BAO_0000224,B,,,104705.0,H,,Autocuration,7626.0,,,CHEMBL619178,1.0,,4.0,,,,,,3508.0,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation
,BAO_0000224,B,,,104705.0,H,,Autocuration,7626.0,,,CHEMBL619179,1.0,,4.0,,,,,,3509.0,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined
,BAO_0000019,F,,,104705.0,H,,Autocuration,7185.0,,,CHEMBL619180,1.0,,4.0,Stomach,,,945.0,,3510.0,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation
,BAO_0000019,F,,,104705.0,H,,Autocuration,7185.0,,,CHEMBL619181,1.0,,4.0,Stomach,,,945.0,,3511.0,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).
,BAO_0000019,F,,,104705.0,H,,Autocuration,7185.0,,,CHEMBL619182,1.0,,4.0,,,,,,3512.0,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor
,BAO_0000224,B,,,104705.0,H,,Autocuration,6960.0,,,CHEMBL619183,1.0,,4.0,,,,,,3513.0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2
,BAO_0000224,B,,,104705.0,H,,Autocuration,6960.0,,,CHEMBL619184,1.0,,4.0,,,,,,3514.0,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot."
,BAO_0000221,B,,,10576.0,H,,Autocuration,12416.0,,,CHEMBL619185,1.0,,8.0,Hippocampus,,,10000000.0,,3515.0,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus
,BAO_0000357,B,,,12198.0,H,,Expert,15753.0,,,CHEMBL619186,1.0,,8.0,,,,,,3516.0,Binding affinity for rat 5-hydroxytryptamine transporter.
,BAO_0000019,B,,,104705.0,H,,Autocuration,8062.0,,,CHEMBL619187,1.0,,4.0,,,,,,3517.0,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.
,BAO_0000019,B,,,104705.0,D,Rattus norvegicus,Autocuration,9036.0,,10116.0,CHEMBL619188,1.0,,5.0,,,,,,3518.0,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT
,BAO_0000224,B,,,104705.0,D,Rattus norvegicus,Autocuration,15067.0,,10116.0,CHEMBL619189,1.0,,5.0,,,,,,3519.0,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor
,BAO_0000019,F,,,12198.0,D,Rattus norvegicus,Expert,15753.0,,10116.0,CHEMBL619190,1.0,,9.0,Brain,,,955.0,,3520.0,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum
,BAO_0000221,F,,,12198.0,D,Rattus norvegicus,Expert,15753.0,,10116.0,CHEMBL619191,1.0,,9.0,Cerebellum,,,2037.0,,3521.0,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.
,BAO_0000019,B,,,104705.0,D,Rattus norvegicus,Autocuration,15295.0,,10116.0,CHEMBL619192,1.0,,5.0,,,,,,3522.0,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M
,BAO_0000224,B,,,104705.0,D,Rattus norvegicus,Autocuration,6347.0,,10116.0,CHEMBL619193,1.0,,5.0,,,,,,3523.0,Percent binding affinity against 5-hydroxytryptamine receptor
,BAO_0000019,B,,,22226.0,U,,Autocuration,6763.0,,,CHEMBL619194,1.0,,0.0,,,,,,3524.0,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex
,BAO_0000224,B,,,104705.0,D,Rattus norvegicus,Autocuration,12092.0,,10116.0,CHEMBL619195,1.0,,5.0,,,,,,3525.0,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.
,BAO_0000224,B,,,104705.0,D,Rattus norvegicus,Autocuration,1579.0,,10116.0,CHEMBL619196,1.0,,5.0,,,,,,3526.0,Affinity against 5-hydroxytryptamine receptor was determined
,BAO_0000019,B,,,104705.0,D,Rattus norvegicus,Autocuration,1579.0,,10116.0,CHEMBL619197,1.0,,5.0,Stomach,,,945.0,,3527.0,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip
,BAO_0000219,B,In vitro,,121.0,D,Homo sapiens,Expert,5963.0,,9606.0,CHEMBL619198,1.0,,9.0,,,,,,3528.0,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT
,BAO_0000219,B,In vitro,,121.0,D,Homo sapiens,Expert,5963.0,,9606.0,CHEMBL875081,1.0,,9.0,,,,,,3529.0,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT
,BAO_0000357,B,,,18065.0,H,,Autocuration,5030.0,,,CHEMBL884712,1.0,,8.0,,,,,,3530.0,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete
,BAO_0000357,B,,,121.0,H,,Expert,15796.0,,,CHEMBL884710,1.0,,8.0,,,,,,3531.0,Inhibition of 5-hydroxytryptamine reuptake
,BAO_0000019,F,,,18065.0,H,,Autocuration,15413.0,,,CHEMBL619199,1.0,,8.0,,,,,,3532.0,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding"
,BAO_0000019,F,,,18065.0,H,,Autocuration,15413.0,,,CHEMBL619200,1.0,,8.0,,,,,,3533.0,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)"
,BAO_0000019,F,,,18065.0,H,,Autocuration,15413.0,,,CHEMBL619201,1.0,,8.0,,,,,,3534.0,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)"
,BAO_0000019,F,,,18065.0,H,,Autocuration,12409.0,,,CHEMBL619202,1.0,,8.0,,,,,,3535.0,Tested for 5-hydroxytryptamine receptor uptake
,BAO_0000219,B,,CHO,51.0,D,Homo sapiens,Expert,16909.0,,9606.0,CHEMBL619203,1.0,,9.0,,,,,449.0,3536.0,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A
,BAO_0000019,F,,,51.0,D,Homo sapiens,Expert,16909.0,,9606.0,CHEMBL619204,1.0,,9.0,,,,,,3537.0,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype
,BAO_0000249,B,,,10576.0,H,Homo sapiens,Autocuration,15629.0,,9606.0,CHEMBL619205,1.0,,8.0,,,,,,3538.0,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.
,BAO_0000357,B,,,10576.0,H,,Autocuration,15629.0,,,CHEMBL619206,1.0,,8.0,,,,,,3539.0,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A
,BAO_0000249,B,,,10576.0,H,,Expert,15629.0,,,CHEMBL619207,1.0,,8.0,,,,,,3540.0,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.
,BAO_0000019,F,,,10825.0,H,,Autocuration,10034.0,,,CHEMBL619208,1.0,,8.0,Striatum,,,2435.0,,3541.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg
,BAO_0000019,F,,,10825.0,H,,Autocuration,10034.0,,,CHEMBL619209,1.0,,8.0,Striatum,,,2435.0,,3542.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg
,BAO_0000019,F,,,10825.0,H,,Autocuration,10034.0,,,CHEMBL619210,1.0,,8.0,Striatum,,,2435.0,,3543.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg
,BAO_0000019,F,,,10825.0,H,,Autocuration,10034.0,,,CHEMBL619211,1.0,,8.0,Striatum,,,2435.0,,3544.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg
,BAO_0000019,F,,,10825.0,H,,Autocuration,10034.0,,,CHEMBL619212,1.0,,8.0,Striatum,,,2435.0,,3545.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg
,BAO_0000019,F,,,10825.0,H,,Autocuration,10034.0,,,CHEMBL620681,1.0,,8.0,Striatum,,,2435.0,,3546.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg
,BAO_0000019,F,,,10825.0,H,,Autocuration,10034.0,,,CHEMBL620682,1.0,,8.0,Striatum,,,2435.0,,3547.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg
,BAO_0000019,F,,,10825.0,H,,Autocuration,10034.0,,,CHEMBL620683,1.0,,8.0,Striatum,,,2435.0,,3548.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg
,BAO_0000019,F,,,10825.0,H,,Autocuration,10034.0,,,CHEMBL620684,1.0,,8.0,Striatum,,,2435.0,,3549.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg
,BAO_0000019,F,,,10825.0,H,,Autocuration,10034.0,,,CHEMBL620685,1.0,,8.0,Striatum,,,2435.0,,3550.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg
,BAO_0000019,F,,,10825.0,H,,Autocuration,10034.0,,,CHEMBL620686,1.0,,8.0,Striatum,,,2435.0,,3551.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg
,BAO_0000019,F,,,10825.0,H,,Autocuration,10034.0,,,CHEMBL620687,1.0,,8.0,Limbic system,,,349.0,,3552.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg
,BAO_0000019,F,,,10825.0,H,,Autocuration,10034.0,,,CHEMBL620688,1.0,,8.0,Limbic system,,,349.0,,3553.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg
,BAO_0000019,F,,,10825.0,H,,Autocuration,10034.0,,,CHEMBL620689,1.0,,8.0,Limbic system,,,349.0,,3554.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg
,BAO_0000019,F,,,10825.0,H,,Autocuration,10034.0,,,CHEMBL620690,1.0,,8.0,Limbic system,,,349.0,,3555.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg
,BAO_0000019,F,,,10825.0,H,,Autocuration,10034.0,,,CHEMBL620691,1.0,,8.0,Limbic system,,,349.0,,3556.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg
,BAO_0000019,F,,,10825.0,H,,Autocuration,10034.0,,,CHEMBL620692,1.0,,8.0,Limbic system,,,349.0,,3557.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg
,BAO_0000019,F,,,10825.0,H,,Autocuration,10034.0,,,CHEMBL620693,1.0,,8.0,Limbic system,,,349.0,,3558.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg
,BAO_0000357,B,,,168.0,H,,Expert,1274.0,,,CHEMBL620694,1.0,,8.0,,,,,,3559.0,Binding affinity against 5-hydroxytryptamine 4 receptor
,BAO_0000019,F,,,168.0,H,,Autocuration,17358.0,,,CHEMBL857986,1.0,,8.0,,,,,,3560.0,Tested for 5-hydroxytryptamine 4 receptor antagonist activity
,BAO_0000357,B,,,168.0,H,,Autocuration,14532.0,,,CHEMBL620695,1.0,,8.0,,,,,,3561.0,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration
,BAO_0000357,B,,,168.0,H,,Expert,16989.0,,,CHEMBL620696,1.0,,8.0,,,,,,3562.0,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor
,BAO_0000357,B,,,168.0,H,,Autocuration,17200.0,,,CHEMBL620697,1.0,,8.0,,,,,,3563.0,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand
,BAO_0000357,B,,,168.0,H,,Autocuration,15779.0,,,CHEMBL620698,1.0,,8.0,,,,,,3564.0,Binding affinity towards 5-hydroxytryptamine 4 receptor
,BAO_0000357,B,,,168.0,H,,Autocuration,15779.0,,,CHEMBL620699,1.0,,8.0,,,,,,3565.0,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.
,BAO_0000357,B,,,168.0,H,,Autocuration,15779.0,,,CHEMBL620700,1.0,,8.0,,,,,,3566.0,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.
,BAO_0000219,B,,COS-7,168.0,H,,Autocuration,15650.0,,,CHEMBL620701,1.0,,8.0,,,,,643.0,3567.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells
,BAO_0000219,B,,COS-7,168.0,H,,Autocuration,15650.0,,,CHEMBL875082,1.0,,8.0,,,,,643.0,3568.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells
,BAO_0000219,B,,COS-7,168.0,H,,Autocuration,15650.0,,,CHEMBL620702,1.0,,8.0,,,,,643.0,3569.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells
,BAO_0000219,B,,COS-7,168.0,H,,Autocuration,15650.0,,,CHEMBL620703,1.0,,8.0,,,,,643.0,3570.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells
,BAO_0000219,B,,C6,168.0,H,,Autocuration,17046.0,,,CHEMBL620704,1.0,,8.0,,,,,673.0,3571.0,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand
,BAO_0000219,B,,C6,168.0,H,,Expert,17046.0,,,CHEMBL620705,1.0,,8.0,,,,,673.0,3572.0,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand
,BAO_0000219,B,,C6,168.0,H,,Expert,15650.0,,,CHEMBL620706,1.0,,8.0,,,,,673.0,3573.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808
,BAO_0000219,B,,C6,168.0,H,,Expert,17046.0,,,CHEMBL620707,1.0,,8.0,,,,,673.0,3574.0,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined
,BAO_0000357,B,,,10624.0,H,,Expert,17066.0,,,CHEMBL620708,1.0,,8.0,,,,,,3575.0,Binding affinity towards 5-hydroxytryptamine 5 receptor
,BAO_0000357,B,,,105.0,H,,Autocuration,17200.0,,,CHEMBL620709,1.0,,8.0,,,,,,3576.0,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand
,BAO_0000357,B,,,10624.0,D,Homo sapiens,Expert,16146.0,,9606.0,CHEMBL620710,1.0,,9.0,,,,,,3577.0,Binding affinity against 5-hydroxytryptamine 5A receptor
,BAO_0000219,B,,CHO,10624.0,H,,Autocuration,15250.0,,,CHEMBL620711,1.0,,8.0,,,,,449.0,3578.0,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells
,BAO_0000357,B,,,10624.0,D,Homo sapiens,Expert,6491.0,,9606.0,CHEMBL620712,1.0,,9.0,,,,,,3579.0,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor
,BAO_0000357,B,,,10624.0,D,Homo sapiens,Expert,17066.0,,9606.0,CHEMBL620713,1.0,,9.0,,,,,,3580.0,Binding affinity towards human 5-hydroxytryptamine 5A receptor
,BAO_0000357,B,,,10624.0,D,Homo sapiens,Expert,17066.0,,9606.0,CHEMBL620714,1.0,,9.0,,,,,,3581.0,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand
,BAO_0000357,B,,,10624.0,D,Homo sapiens,Expert,4234.0,,9606.0,CHEMBL620715,1.0,,9.0,,,,,,3582.0,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor
,BAO_0000357,B,,,10624.0,H,,Autocuration,6013.0,,,CHEMBL620716,1.0,,8.0,,,,,,3583.0,Binding affinity towards 5-HT5A receptor
,BAO_0000357,B,,,10624.0,H,,Expert,17175.0,,,CHEMBL620717,1.0,,8.0,,,,,,3584.0,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand
,BAO_0000357,B,,,10624.0,H,,Autocuration,15818.0,,,CHEMBL618072,1.0,,8.0,,,,,,3585.0,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor
,BAO_0000357,B,,,10624.0,H,,Autocuration,6166.0,,,CHEMBL857987,1.0,,8.0,,,,,,3586.0,Binding affinity towards cloned human 5-HT5A receptor was determined
,BAO_0000219,B,,HEK293,10624.0,H,,Autocuration,15779.0,,,CHEMBL618073,1.0,,8.0,,,,,722.0,3587.0,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.
,BAO_0000219,B,,HEK293,10624.0,H,,Autocuration,15779.0,,,CHEMBL618074,1.0,,8.0,,,,,722.0,3588.0,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.
,BAO_0000219,B,,HEK293,10624.0,H,,Autocuration,5213.0,,,CHEMBL618075,1.0,,8.0,,,,,722.0,3589.0,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand )
,BAO_0000357,B,,,10625.0,D,Mus musculus,Expert,17066.0,,10090.0,CHEMBL618076,1.0,,9.0,,,,,,3590.0,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor
,BAO_0000357,B,,,10625.0,D,Mus musculus,Expert,17066.0,,10090.0,CHEMBL618077,1.0,,9.0,,,,,,3591.0,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand
,BAO_0000357,B,,,10625.0,D,Mus musculus,Expert,17066.0,,10090.0,CHEMBL618078,1.0,,9.0,,,,,,3592.0,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand
,BAO_0000357,B,,,10625.0,D,Mus musculus,Expert,17066.0,,10090.0,CHEMBL881821,1.0,,9.0,,,,,,3593.0,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand
,BAO_0000357,B,,,10625.0,D,Mus musculus,Expert,17066.0,,10090.0,CHEMBL618079,1.0,,9.0,,,,,,3594.0,Binding affinity towards murine 5-hydroxytryptamine 5A receptor
,BAO_0000357,B,,,10625.0,H,,Expert,17175.0,,,CHEMBL618080,1.0,,8.0,,,,,,3595.0,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand
,BAO_0000219,B,,HEK293,10576.0,H,,Autocuration,16190.0,,,CHEMBL618081,1.0,,8.0,,,,,722.0,3596.0,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand
,BAO_0000219,B,,HEK293,10626.0,H,,Autocuration,16190.0,,,CHEMBL618082,1.0,,8.0,,,,,722.0,3597.0,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand
,BAO_0000357,B,,,10624.0,H,,Expert,4820.0,,,CHEMBL618083,1.0,,8.0,,,,,,3598.0,Binding affinity towards 5-HT5a receptor
,BAO_0000357,B,,,10624.0,D,Homo sapiens,Expert,17066.0,,9606.0,CHEMBL618084,1.0,,9.0,,,,,,3599.0,Binding affinity towards 5-hydroxytryptamine 5A receptor
,BAO_0000357,B,,,10624.0,H,,Expert,17066.0,,,CHEMBL618085,1.0,,8.0,,,,,,3600.0,Binding affinity for rodent 5-hydroxytryptamine 5A receptor
,BAO_0000357,B,,,10624.0,H,,Expert,17175.0,,,CHEMBL618086,1.0,,8.0,,,,,,3601.0,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand
,BAO_0000357,B,,,10624.0,H,,Autocuration,16633.0,,,CHEMBL875092,1.0,,8.0,,,,,,3602.0,Binding affinities against 5-hydroxytryptamine 5A receptor
,BAO_0000357,B,,,10624.0,H,,Autocuration,16633.0,,,CHEMBL618087,1.0,,8.0,,,,,,3603.0,Binding affinities towards 5-hydroxytryptamine 5A receptor
,BAO_0000357,B,,,10624.0,H,,Autocuration,16700.0,,,CHEMBL872926,1.0,,8.0,,,,,,3604.0,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity
,BAO_0000019,F,,,104714.0,H,Cavia porcellus,Autocuration,4639.0,,10141.0,CHEMBL618088,1.0,,4.0,,,,,,3605.0,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM
,BAO_0000223,B,,,104714.0,H,,Autocuration,5486.0,,,CHEMBL618089,1.0,,4.0,,,,,,3606.0,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell
,BAO_0000357,B,,,10627.0,D,Homo sapiens,Expert,16146.0,,9606.0,CHEMBL618090,1.0,,9.0,,,,,,3607.0,Inhibition of human 5-hydroxytryptamine 6 receptor
,BAO_0000357,B,,,10627.0,D,Homo sapiens,Expert,17273.0,,9606.0,CHEMBL618091,1.0,,9.0,,,,,,3608.0,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand
,BAO_0000357,B,,,10627.0,H,,Autocuration,17687.0,,,CHEMBL618092,1.0,,8.0,,,,,,3609.0,Inhibition against human 5-hydroxytryptamine 6 receptor
,BAO_0000357,B,,,10627.0,D,Homo sapiens,Expert,6491.0,,9606.0,CHEMBL618093,1.0,,9.0,,,,,,3610.0,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor
,BAO_0000219,B,,HeLa,10627.0,H,,Expert,16190.0,,,CHEMBL618094,1.0,,8.0,,,,,308.0,3611.0,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.
,BAO_0000357,B,,,10627.0,D,Homo sapiens,Expert,17066.0,,9606.0,CHEMBL618095,1.0,,9.0,,,,,,3612.0,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor
,BAO_0000357,B,,,10627.0,D,Homo sapiens,Expert,17066.0,,9606.0,CHEMBL875093,1.0,,9.0,,,,,,3613.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor
,BAO_0000357,B,,,10627.0,D,Homo sapiens,Expert,17066.0,,9606.0,CHEMBL618096,1.0,,9.0,,,,,,3614.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand
,BAO_0000357,B,,,10627.0,D,Homo sapiens,Expert,17066.0,,9606.0,CHEMBL618118,1.0,,9.0,,,,,,3615.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand
,BAO_0000357,B,,,10627.0,D,Homo sapiens,Expert,3555.0,,9606.0,CHEMBL618119,1.0,,9.0,,,,,,3616.0,Binding affinity against 5-hydroxytryptamine 6 receptor
,BAO_0000357,B,,,10627.0,H,,Expert,5808.0,,,CHEMBL618120,1.0,,8.0,,,,,,3617.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor
,BAO_0000357,B,,,10627.0,H,,Autocuration,6013.0,,,CHEMBL618121,1.0,,8.0,,,,,,3618.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor
,BAO_0000219,B,,HEK293,10627.0,H,,Expert,15818.0,,,CHEMBL618122,1.0,,8.0,,,,,722.0,3619.0,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand"
,BAO_0000357,B,,,10627.0,H,,Autocuration,16209.0,,,CHEMBL618123,1.0,,8.0,,,,,,3620.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand
,BAO_0000219,B,,HEK293,10627.0,H,,Expert,3935.0,,,CHEMBL618124,1.0,,8.0,,,,,722.0,3621.0,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand
,BAO_0000357,B,,,10627.0,H,,Autocuration,15818.0,,,CHEMBL618125,1.0,,8.0,,,,,,3622.0,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor
,BAO_0000219,B,,HEK293,10627.0,D,Homo sapiens,Expert,3805.0,,9606.0,CHEMBL618126,1.0,,9.0,,,,,722.0,3623.0,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells
,BAO_0000019,B,,,10627.0,H,,Expert,16441.0,,,CHEMBL618236,1.0,,8.0,,,,,,3624.0,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD
,BAO_0000019,B,,,10627.0,H,,Expert,16441.0,,,CHEMBL618237,1.0,,8.0,,,,,,3625.0,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.
,BAO_0000219,B,,COS-7,10627.0,H,,Expert,6786.0,,,CHEMBL618238,1.0,,8.0,,,,,643.0,3626.0,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells
,BAO_0000357,B,,,10627.0,D,Homo sapiens,Expert,4234.0,,9606.0,CHEMBL618239,1.0,,9.0,,,,,,3627.0,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor
,BAO_0000019,B,,,10627.0,H,,Autocuration,17085.0,,,CHEMBL618240,1.0,,8.0,,,,,,3628.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor
,BAO_0000357,B,,,10627.0,H,,Autocuration,17200.0,,,CHEMBL618241,1.0,,8.0,,,,,,3629.0,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand
,BAO_0000219,B,,HEK293,10627.0,H,,Autocuration,17451.0,,,CHEMBL859399,1.0,,8.0,,,,,722.0,3630.0,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells
,BAO_0000019,F,,,10627.0,H,,Autocuration,3935.0,,,CHEMBL618242,1.0,,8.0,,,,,,3631.0,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase
,BAO_0000357,B,,,10627.0,H,,Autocuration,5033.0,,,CHEMBL857991,1.0,,8.0,,,,,,3632.0,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor
,BAO_0000357,B,,,10627.0,H,,Expert,4540.0,,,CHEMBL619951,1.0,,8.0,,,,,,3633.0,Binding affinity against human 5-hydroxytryptamine 6 receptor
,BAO_0000219,B,,HeLa,10627.0,D,Homo sapiens,Expert,4540.0,,9606.0,CHEMBL619952,1.0,,9.0,,,,,308.0,3634.0,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand
,BAO_0000219,B,,HeLa,10627.0,D,Homo sapiens,Expert,4540.0,,9606.0,CHEMBL619953,1.0,,9.0,,,,,308.0,3635.0,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand
,BAO_0000219,B,,HeLa,10627.0,H,,Autocuration,17296.0,,,CHEMBL619954,1.0,,8.0,,,,,308.0,3636.0,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells
,BAO_0000219,B,,HeLa,10627.0,H,,Autocuration,17296.0,,,CHEMBL619955,1.0,,8.0,,,,,308.0,3637.0,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand
,BAO_0000219,B,,HeLa,10627.0,H,,Autocuration,17296.0,,,CHEMBL619956,1.0,,8.0,,,,,308.0,3638.0,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand
,BAO_0000219,B,,CHO,10627.0,H,,Autocuration,15779.0,,,CHEMBL619957,1.0,,8.0,,,,,449.0,3639.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand
,BAO_0000219,B,,HEK293,10627.0,H,,Autocuration,15779.0,,,CHEMBL619958,1.0,,8.0,,,,,722.0,3640.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.
,BAO_0000219,B,,HEK293,10627.0,H,,Autocuration,15779.0,,,CHEMBL620627,1.0,,8.0,,,,,722.0,3641.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.
,BAO_0000219,B,,HEK293,10627.0,H,,Autocuration,15779.0,,,CHEMBL620628,1.0,,8.0,,,,,722.0,3642.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.
,BAO_0000219,B,,HeLa,10627.0,H,,Autocuration,15779.0,,,CHEMBL620629,1.0,,8.0,,,,,308.0,3643.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.
,BAO_0000357,B,,,10627.0,H,,Autocuration,6166.0,,,CHEMBL620630,1.0,,8.0,,,,,,3644.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor
,BAO_0000219,B,,HeLa,10627.0,H,,Autocuration,17451.0,,,CHEMBL620782,1.0,,8.0,,,,,308.0,3645.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand
,BAO_0000357,B,,,10627.0,H,,Autocuration,15316.0,,,CHEMBL620783,1.0,,8.0,,,,,,3646.0,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor
,BAO_0000357,B,,,10627.0,H,,Expert,4199.0,,,CHEMBL620784,1.0,,8.0,,,,,,3647.0,Binding affinity against human 5-hydroxytryptamine 6 receptor
,BAO_0000219,B,,HeLa,10627.0,H,,Expert,15146.0,,,CHEMBL620785,1.0,,8.0,,,,,308.0,3648.0,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD
,BAO_0000357,B,,,10627.0,H,,Autocuration,5213.0,,,CHEMBL857992,1.0,,8.0,,,,,,3649.0,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand )
,BAO_0000219,B,,,10627.0,H,,Autocuration,16429.0,,,CHEMBL620786,1.0,,8.0,,,,,,3650.0,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand
,BAO_0000219,B,,HeLa,10627.0,H,,Autocuration,14818.0,,,CHEMBL620787,1.0,,8.0,,,,,308.0,3651.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.
,BAO_0000219,B,,HeLa,10627.0,H,,Autocuration,4829.0,,,CHEMBL620788,1.0,,8.0,,,,,308.0,3652.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3"
,BAO_0000219,B,,HeLa,10627.0,H,,Autocuration,4829.0,,,CHEMBL620789,1.0,,8.0,,,,,308.0,3653.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9"
,BAO_0000219,B,,HeLa,10627.0,H,,Autocuration,4829.0,,,CHEMBL620790,1.0,,8.0,,,,,308.0,3654.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3"
,BAO_0000219,B,,CHO,10628.0,H,,Autocuration,15250.0,,,CHEMBL620791,1.0,,8.0,,,,,449.0,3655.0,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells
,BAO_0000019,B,,,10628.0,H,,Autocuration,14423.0,,,CHEMBL620792,1.0,,8.0,,,,,,3656.0,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.
,BAO_0000357,B,,,10628.0,H,,Autocuration,15086.0,,,CHEMBL620793,1.0,,8.0,,,,,,3657.0,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor
,BAO_0000357,B,,,10628.0,H,,Autocuration,4342.0,,,CHEMBL620794,1.0,,8.0,,,,,,3658.0,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined
,BAO_0000219,B,,HeLa,10627.0,D,Homo sapiens,Autocuration,16190.0,,9606.0,CHEMBL620795,1.0,,9.0,,,,,308.0,3659.0,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells
,BAO_0000357,B,,,10627.0,H,,Expert,4820.0,,,CHEMBL620796,1.0,,8.0,,,,,,3660.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor
,BAO_0000357,B,,,10627.0,H,,Autocuration,4639.0,,,CHEMBL620797,1.0,,8.0,,,,,,3661.0,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M
,BAO_0000019,F,,,10627.0,D,Homo sapiens,Expert,17066.0,,9606.0,CHEMBL620798,1.0,,9.0,,,,,,3662.0,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay
,BAO_0000357,B,,,10627.0,H,,Autocuration,6011.0,,,CHEMBL620799,1.0,,8.0,,,,,,3663.0,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration
,BAO_0000357,B,,,10627.0,H,,Expert,17066.0,,,CHEMBL620800,1.0,,8.0,,,,,,3664.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor
,BAO_0000357,B,,,10627.0,H,,Autocuration,17515.0,,,CHEMBL620801,1.0,,8.0,,,,,,3665.0,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM
,BAO_0000357,B,,,10627.0,H,,Autocuration,5014.0,,,CHEMBL875100,1.0,,8.0,,,,,,3666.0,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor
,BAO_0000357,B,,,10627.0,H,,Autocuration,4373.0,,,CHEMBL620802,1.0,,8.0,,,,,,3667.0,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined
,BAO_0000019,F,,,10627.0,H,,Expert,17066.0,,,CHEMBL620803,1.0,,8.0,,,,,,3668.0,Antagonistic activity towards 5-hydroxytryptamine 6 receptor
,BAO_0000019,F,,,10627.0,H,,Expert,17066.0,,,CHEMBL620804,1.0,,8.0,,,,,,3669.0,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay
,BAO_0000357,B,,,10627.0,H,,Autocuration,4373.0,,,CHEMBL620805,1.0,,8.0,,,,,,3670.0,Binding affinity for 5-hydroxytryptamine 6 receptor was determined
,BAO_0000357,B,,,10627.0,H,,Autocuration,4687.0,,,CHEMBL620806,1.0,,8.0,,,,,,3671.0,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor
,BAO_0000357,B,,,10627.0,H,,Autocuration,16946.0,,,CHEMBL620807,1.0,,8.0,,,,,,3672.0,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M
,BAO_0000357,B,,,10627.0,H,,Autocuration,16946.0,,,CHEMBL620808,1.0,,8.0,,,,,,3673.0,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M
,BAO_0000357,B,,,10627.0,H,,Autocuration,16633.0,,,CHEMBL620809,1.0,,8.0,,,,,,3674.0,Binding affinities against 5-hydroxytryptamine 6 receptor
,BAO_0000357,B,,,10627.0,H,,Autocuration,16633.0,,,CHEMBL620810,1.0,,8.0,,,,,,3675.0,Binding affinities towards 5-hydroxytryptamine 6 receptor
,BAO_0000357,B,,,10627.0,D,Homo sapiens,Expert,17066.0,,9606.0,CHEMBL620811,1.0,,9.0,,,,,,3676.0,Binding affinity towards 5-hydroxytryptamine 6 receptor
,BAO_0000357,B,,,10627.0,H,,Autocuration,16700.0,,,CHEMBL620812,1.0,,8.0,,,,,,3677.0,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity
,BAO_0000357,B,,,10627.0,H,,Autocuration,3269.0,,,CHEMBL620813,1.0,,8.0,,,,,,3678.0,Affinity against 5-hydroxytryptamine 6 receptor
,BAO_0000357,B,,,10627.0,H,,Autocuration,5486.0,,,CHEMBL620814,1.0,,8.0,,,,,,3679.0,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT]
,BAO_0000357,B,,,10209.0,D,Homo sapiens,Expert,16146.0,,9606.0,CHEMBL620815,1.0,,9.0,,,,,,3680.0,Inhibition of human 5-hydroxytryptamine 7 receptor
,BAO_0000219,B,,HEK293,10209.0,H,,Autocuration,5014.0,,,CHEMBL620816,1.0,,8.0,,,,,722.0,3681.0,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD
,BAO_0000357,B,,,10209.0,H,,Autocuration,15463.0,,,CHEMBL620817,1.0,,8.0,,,,,,3682.0,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor
,BAO_0000357,B,,,10209.0,H,,Autocuration,3805.0,,,CHEMBL620818,1.0,,8.0,,,,,,3683.0,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM)
,BAO_0000219,B,,HEK293,10209.0,H,,Expert,5014.0,,,CHEMBL620819,1.0,,8.0,,,,,722.0,3684.0,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells
,BAO_0000357,B,,,10209.0,D,Homo sapiens,Expert,6491.0,,9606.0,CHEMBL620820,1.0,,9.0,,,,,,3685.0,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor
,BAO_0000219,B,,CHO,10209.0,H,,Autocuration,16190.0,,,CHEMBL620821,1.0,,8.0,,,,,449.0,3686.0,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT
,BAO_0000357,B,,,10209.0,D,Homo sapiens,Expert,17066.0,,9606.0,CHEMBL620822,1.0,,9.0,,,,,,3687.0,Binding affinity towards human 5-hydroxytryptamine 7 receptor
,BAO_0000357,B,,,10209.0,D,Homo sapiens,Expert,17066.0,,9606.0,CHEMBL620823,1.0,,9.0,,,,,,3688.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor
,BAO_0000357,B,,,10209.0,D,Homo sapiens,Expert,3555.0,,9606.0,CHEMBL620824,1.0,,9.0,,,,,,3689.0,Binding affinity against 5-hydroxytryptamine 7 receptor
,BAO_0000219,B,,CHO,10209.0,H,,Expert,6588.0,,,CHEMBL620825,1.0,,8.0,,,,,449.0,3690.0,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells
,BAO_0000357,B,,,10209.0,H,,Autocuration,15463.0,,,CHEMBL872930,1.0,,8.0,,,,,,3691.0,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand
,BAO_0000357,B,,,10209.0,H,,Autocuration,6013.0,,,CHEMBL620826,1.0,,8.0,,,,,,3692.0,Binding affinity towards 5-hydroxytryptamine 7 receptor
,BAO_0000357,B,,,10209.0,H,,Autocuration,16209.0,,,CHEMBL620827,1.0,,8.0,,,,,,3693.0,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand
,BAO_0000357,B,,,10209.0,H,,Autocuration,3935.0,,,CHEMBL620828,1.0,,8.0,,,,,,3694.0,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor
,BAO_0000357,B,,,10209.0,H,,Autocuration,15818.0,,,CHEMBL620829,1.0,,8.0,,,,,,3695.0,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor
,BAO_0000219,B,,HEK293,10209.0,H,,Expert,5014.0,,,CHEMBL620830,1.0,,8.0,,,,,722.0,3696.0,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD
,BAO_0000019,B,,,10209.0,H,,Expert,16441.0,,,CHEMBL620831,1.0,,8.0,,,,,,3697.0,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD
,BAO_0000019,B,,,10209.0,H,,Expert,16441.0,,,CHEMBL620832,1.0,,8.0,,,,,,3698.0,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.
,BAO_0000357,B,,,10209.0,D,Homo sapiens,Expert,4234.0,,9606.0,CHEMBL621548,1.0,,9.0,,,,,,3699.0,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor
,BAO_0000019,B,,,10209.0,H,,Autocuration,17085.0,,,CHEMBL621549,1.0,,8.0,,,,,,3700.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor
,BAO_0000357,B,,,10209.0,H,,Autocuration,17200.0,,,CHEMBL621550,1.0,,8.0,,,,,,3701.0,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand
,BAO_0000219,B,,CHO,10209.0,H,,Autocuration,17451.0,,,CHEMBL621551,1.0,,8.0,,,,,449.0,3702.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined
,BAO_0000019,B,,,10209.0,H,,Autocuration,17085.0,,,CHEMBL621552,1.0,,8.0,,,,,,3703.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined
,BAO_0000357,B,,,10209.0,H,,Autocuration,5104.0,,,CHEMBL857077,1.0,,8.0,,,,,,3704.0,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor
,BAO_0000357,B,,,10209.0,H,,Autocuration,5104.0,,,CHEMBL618158,1.0,,8.0,,,,,,3705.0,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested
,BAO_0000219,B,,COS-7,10209.0,D,Homo sapiens,Expert,5033.0,,9606.0,CHEMBL618159,1.0,,9.0,,,,,643.0,3706.0,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells
,BAO_0000219,B,,COS-7,10209.0,H,,Autocuration,5486.0,,,CHEMBL875101,1.0,,8.0,,,,,643.0,3707.0,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells
,BAO_0000219,B,,HEK293,10209.0,D,Homo sapiens,Expert,4540.0,,9606.0,CHEMBL618160,1.0,,9.0,,,,,722.0,3708.0,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand
,BAO_0000357,B,,,10209.0,H,,Expert,6166.0,,,CHEMBL618161,1.0,,8.0,,,,,,3709.0,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.
,BAO_0000219,B,,HEK293,10209.0,H,,Expert,17342.0,,,CHEMBL618162,1.0,,8.0,,,,,722.0,3710.0,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand
,BAO_0000357,B,,,10209.0,H,,Expert,17342.0,,,CHEMBL618163,1.0,,8.0,,,,,,3711.0,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand
,BAO_0000357,B,,,10209.0,H,,Autocuration,17296.0,,,CHEMBL618164,1.0,,8.0,,,,,,3712.0,Binding affinity against 5-hydroxytryptamine 7 human receptors
,BAO_0000219,B,,,10209.0,H,,Expert,16429.0,,,CHEMBL618165,1.0,,8.0,,,,,,3713.0,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand
,BAO_0000219,B,,HEK293,10209.0,H,,Autocuration,15779.0,,,CHEMBL618166,1.0,,8.0,,,,,722.0,3714.0,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.
,BAO_0000219,B,,HEK293,10209.0,H,,Autocuration,15779.0,,,CHEMBL857989,1.0,,8.0,,,,,722.0,3715.0,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.
,BAO_0000219,B,,HEK293,10209.0,H,,Autocuration,15779.0,,,CHEMBL619888,1.0,,8.0,,,,,722.0,3716.0,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.
,BAO_0000219,B,,HEK293,10209.0,H,,Autocuration,15779.0,,,CHEMBL619889,1.0,,8.0,,,,,722.0,3717.0,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.
,BAO_0000219,B,,HEK293,10209.0,H,,Autocuration,15779.0,,,CHEMBL619890,1.0,,8.0,,,,,722.0,3718.0,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.
,BAO_0000219,B,,CHO,10209.0,H,,Autocuration,17451.0,,,CHEMBL619891,1.0,,8.0,,,,,449.0,3719.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand
,BAO_0000219,B,,HEK293,10209.0,H,,Autocuration,4199.0,,,CHEMBL619892,1.0,,8.0,,,,,722.0,3720.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3)
,BAO_0000219,B,,HEK293,10209.0,D,,Expert,4199.0,,,CHEMBL619893,1.0,,9.0,,,,,722.0,3721.0,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells
,BAO_0000219,B,,HEK293,10209.0,H,,Autocuration,4199.0,,,CHEMBL619894,1.0,,8.0,,,,,722.0,3722.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6)
,BAO_0000219,B,,HEK293,10209.0,D,,Intermediate,3680.0,,,CHEMBL619895,1.0,,9.0,,,,,722.0,3723.0,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells
,BAO_0000357,B,,,10209.0,D,,Intermediate,3680.0,,,CHEMBL619896,1.0,,9.0,,,,,,3724.0,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand
,BAO_0000219,B,,COS-7,10209.0,H,,Autocuration,15316.0,,,CHEMBL619897,1.0,,8.0,,,,,643.0,3725.0,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.
,BAO_0000219,B,,HEK293,10209.0,H,,Autocuration,15146.0,,,CHEMBL619898,1.0,,8.0,,,,,722.0,3726.0,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT
,BAO_0000219,B,,HEK293,10209.0,H,,Expert,5213.0,,,CHEMBL619899,1.0,,8.0,,,,,722.0,3727.0,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand
,BAO_0000219,B,,HEK293,10209.0,H,,Autocuration,5213.0,,,CHEMBL619900,1.0,,8.0,,,,,722.0,3728.0,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand )
,BAO_0000219,B,,HEK293,10209.0,D,Homo sapiens,Expert,14818.0,,9606.0,CHEMBL619901,1.0,,9.0,,,,,722.0,3729.0,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT
,BAO_0000219,B,,HEK293,10209.0,H,,Autocuration,14818.0,,,CHEMBL620580,1.0,,8.0,,,,,722.0,3730.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. 
,BAO_0000219,B,,HEK293,10209.0,H,,Autocuration,14818.0,,,CHEMBL620581,1.0,,8.0,,,,,722.0,3731.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.
,BAO_0000219,B,,HEK293,10209.0,H,,Autocuration,4829.0,,,CHEMBL620733,1.0,,8.0,,,,,722.0,3732.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand"
,BAO_0000357,B,,,10209.0,D,Homo sapiens,Autocuration,17200.0,,9606.0,CHEMBL620734,1.0,,9.0,,,,,,3733.0,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined
,BAO_0000357,B,,,10022.0,D,Mus musculus,Expert,17066.0,,10090.0,CHEMBL620735,1.0,,9.0,,,,,,3734.0,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand
,BAO_0000019,B,,,10209.0,H,Oryctolagus cuniculus,Autocuration,14025.0,,9986.0,CHEMBL620736,1.0,,8.0,,,,,,3735.0,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.
,BAO_0000219,B,,CHO,11923.0,H,,Autocuration,15250.0,,,CHEMBL620737,1.0,,8.0,,,,,449.0,3736.0,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells
,BAO_0000219,B,,CHO,11923.0,H,,Autocuration,16372.0,,,CHEMBL620738,1.0,,8.0,,,,,449.0,3737.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM
,BAO_0000219,B,,CHO,11923.0,H,,Autocuration,16372.0,,,CHEMBL620739,1.0,,8.0,,,,,449.0,3738.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM
,BAO_0000219,B,,CHO,11923.0,H,,Autocuration,16372.0,,,CHEMBL620740,1.0,,8.0,,,,,449.0,3739.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM
,BAO_0000219,B,,CHO,11923.0,H,,Autocuration,16372.0,,,CHEMBL620741,1.0,,8.0,,,,,449.0,3740.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.
,BAO_0000219,B,,CHO,11923.0,H,,Autocuration,16372.0,,,CHEMBL620742,1.0,,8.0,,,,,449.0,3741.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.
,BAO_0000219,B,,CHO,11923.0,H,,Autocuration,16372.0,,,CHEMBL620743,1.0,,8.0,,,,,449.0,3742.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT
,BAO_0000219,B,,CHO,11923.0,H,,Autocuration,16372.0,,,CHEMBL620744,1.0,,8.0,,,,,449.0,3743.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM
,BAO_0000219,B,,CHO,11923.0,H,,Autocuration,16372.0,,,CHEMBL620745,1.0,,8.0,,,,,449.0,3744.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM
,BAO_0000219,B,,CHO,11923.0,H,,Autocuration,16372.0,,,CHEMBL620746,1.0,,8.0,,,,,449.0,3745.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM
,BAO_0000219,B,,CHO,11923.0,H,,Autocuration,16372.0,,,CHEMBL620747,1.0,,8.0,,,,,449.0,3746.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.
,BAO_0000219,B,,CHO,11923.0,H,,Autocuration,16372.0,,,CHEMBL620748,1.0,,8.0,,,,,449.0,3747.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.
,BAO_0000219,B,,CHO,11923.0,H,,Autocuration,16372.0,,,CHEMBL620749,1.0,,8.0,,,,,449.0,3748.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.
,BAO_0000357,B,,,11923.0,H,,Expert,17066.0,,,CHEMBL620750,1.0,,8.0,,,,,,3749.0,Binding affinity towards rat 5-hydroxytryptamine 7 receptor
,BAO_0000357,B,,,11923.0,D,Rattus norvegicus,Expert,17066.0,,10116.0,CHEMBL620751,1.0,,9.0,,,,,,3750.0,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand
,BAO_0000357,B,,,11923.0,H,,Expert,17386.0,,,CHEMBL620752,1.0,,8.0,,,,,,3751.0,Binding affinity to the rat 5-hydroxytryptamine 7 receptor
,BAO_0000019,B,,,11923.0,H,,Autocuration,14423.0,,,CHEMBL872929,1.0,,8.0,,,,,,3752.0,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.
,BAO_0000357,B,,,11923.0,D,Rattus norvegicus,Expert,15874.0,,10116.0,CHEMBL620753,1.0,,9.0,,,,,,3753.0,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT
,BAO_0000357,B,,,11923.0,D,Rattus norvegicus,Expert,15874.0,,10116.0,CHEMBL620754,1.0,,9.0,,,,,,3754.0,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor
,BAO_0000219,B,,CHO,11923.0,D,Rattus norvegicus,Expert,16372.0,,10116.0,CHEMBL620755,1.0,,9.0,,,,,449.0,3755.0,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells
,BAO_0000357,B,,,11923.0,H,,Autocuration,4622.0,,,CHEMBL620756,1.0,,8.0,,,,,,3756.0,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand
,BAO_0000357,B,,,11923.0,H,,Autocuration,15086.0,,,CHEMBL620757,1.0,,8.0,,,,,,3757.0,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor
,BAO_0000219,B,,CHO,11923.0,H,,Autocuration,16372.0,,,CHEMBL620758,1.0,,8.0,,,,,449.0,3758.0,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested"
,BAO_0000219,B,,CHO,11923.0,H,,Autocuration,16372.0,,,CHEMBL620759,1.0,,8.0,,,,,449.0,3759.0,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested"
,BAO_0000219,B,,CHO,11923.0,H,,Autocuration,16372.0,,,CHEMBL620760,1.0,,8.0,,,,,449.0,3760.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested
,BAO_0000219,B,,CHO,11923.0,H,,Autocuration,16372.0,,,CHEMBL620761,1.0,,8.0,,,,,449.0,3761.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested
,BAO_0000221,F,,,11923.0,H,,Autocuration,17386.0,,,CHEMBL620762,1.0,,8.0,Ileum,,,2116.0,,3762.0,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization
,BAO_0000221,F,,,11923.0,H,,Autocuration,17386.0,,,CHEMBL620763,1.0,,8.0,Ileum,,,2116.0,,3763.0,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization
,BAO_0000221,F,,,11923.0,H,,Autocuration,17386.0,,,CHEMBL620764,1.0,,8.0,Ileum,,,2116.0,,3764.0,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization
,BAO_0000249,B,,,11923.0,D,Rattus norvegicus,Expert,5831.0,Membranes,10116.0,CHEMBL857990,1.0,,9.0,,,,,,3765.0,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes
,BAO_0000357,B,,,11923.0,H,,Autocuration,4342.0,,,CHEMBL620765,1.0,,8.0,,,,,,3766.0,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined
,BAO_0000357,B,,,11923.0,H,,Expert,17319.0,,,CHEMBL620766,1.0,,8.0,,,,,,3767.0,Binding affinity at rat 5-hydroxytryptamine 7 receptor.
,BAO_0000019,B,,,11923.0,H,,Expert,17342.0,,,CHEMBL620767,1.0,,8.0,Hypothalamus,,,1898.0,,3768.0,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.
,BAO_0000357,B,,,11923.0,H,,Autocuration,17342.0,,,CHEMBL620768,1.0,,8.0,,,,,,3769.0,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand
,BAO_0000249,B,,,11923.0,H,,Expert,3680.0,,,CHEMBL619051,1.0,,8.0,Hypothalamus,,,1898.0,,3770.0,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes
,BAO_0000357,B,,,11923.0,H,,Expert,3680.0,,,CHEMBL619052,1.0,,8.0,,,,,,3771.0,Binding affinity towards 5-hydroxytryptamine 7 receptor
,BAO_0000219,F,,HEK293,11923.0,D,Rattus norvegicus,Expert,17319.0,,10116.0,CHEMBL619053,1.0,,9.0,,,,,722.0,3772.0,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells
,BAO_0000219,F,,HEK293,11923.0,D,Rattus norvegicus,Expert,17319.0,,10116.0,CHEMBL619703,1.0,,9.0,,,,,722.0,3773.0,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active
,BAO_0000219,F,,HEK293,11923.0,D,Rattus norvegicus,Autocuration,17319.0,,10116.0,CHEMBL619704,1.0,,9.0,,,,,722.0,3774.0,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active
,BAO_0000357,B,,,10209.0,H,,Expert,4820.0,,,CHEMBL619851,1.0,,8.0,,,,,,3775.0,Binding affinity towards 5-hydroxytryptamine 7 receptor
,BAO_0000357,B,,,10209.0,H,,Autocuration,4639.0,,,CHEMBL619852,1.0,,8.0,,,,,,3776.0,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M
,BAO_0000357,B,,,10209.0,H,,Autocuration,6011.0,,,CHEMBL619853,1.0,,8.0,,,,,,3777.0,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration
,BAO_0000357,B,,,10209.0,D,Homo sapiens,Expert,17066.0,,9606.0,CHEMBL619854,1.0,,9.0,,,,,,3778.0,Binding affinity towards human 5-hydroxytryptamine 7 receptor
,BAO_0000357,B,,,10209.0,H,,Expert,17066.0,,,CHEMBL619855,1.0,,8.0,,,,,,3779.0,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor
,BAO_0000357,B,,,10209.0,H,,Autocuration,17515.0,,,CHEMBL619856,1.0,,8.0,,,,,,3780.0,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM
,BAO_0000357,B,,,10209.0,H,,Autocuration,4373.0,,,CHEMBL619857,1.0,,8.0,,,,,,3781.0,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined
,BAO_0000019,F,,,10209.0,H,,Expert,17066.0,,,CHEMBL619858,1.0,,8.0,,,,,,3782.0,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay
,BAO_0000357,B,,,10209.0,H,,Autocuration,4373.0,,,CHEMBL619859,1.0,,8.0,,,,,,3783.0,Binding affinity for 5-hydroxytryptamine 7 receptor was determined
,BAO_0000357,B,,,10209.0,H,,Autocuration,4373.0,,,CHEMBL619860,1.0,,8.0,,,,,,3784.0,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined
,BAO_0000357,B,,,10209.0,H,,Autocuration,4687.0,,,CHEMBL619861,1.0,,8.0,,,,,,3785.0,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor
,BAO_0000357,B,,,10209.0,H,,Expert,17342.0,,,CHEMBL619862,1.0,,8.0,,,,,,3786.0,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor
,BAO_0000357,B,,,10209.0,H,,Autocuration,16946.0,,,CHEMBL619863,1.0,,8.0,,,,,,3787.0,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M
,BAO_0000357,B,,,10209.0,H,,Autocuration,16946.0,,,CHEMBL619864,1.0,,8.0,,,,,,3788.0,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M
,BAO_0000357,B,,,10209.0,H,,Autocuration,16633.0,,,CHEMBL872928,1.0,,8.0,,,,,,3789.0,Binding affinities against 5-hydroxytryptamine 7 receptor
,BAO_0000357,B,,,10209.0,H,,Autocuration,16633.0,,,CHEMBL619865,1.0,,8.0,,,,,,3790.0,Binding affinities towards 5-hydroxytryptamine 7 receptor
,BAO_0000357,B,,,10209.0,H,,Expert,17066.0,,,CHEMBL619866,1.0,,8.0,,,,,,3791.0,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor
,BAO_0000357,B,,,10209.0,H,,Autocuration,16700.0,,,CHEMBL619867,1.0,,8.0,,,,,,3792.0,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity
,BAO_0000221,B,,,10209.0,H,,Autocuration,17386.0,,,CHEMBL619868,1.0,,8.0,Ileum,,,2116.0,,3793.0,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization
,BAO_0000019,F,,,55.0,H,,Autocuration,14080.0,,,CHEMBL619869,1.0,,8.0,,,,,,3794.0,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay
,BAO_0000019,F,,,55.0,D,Homo sapiens,Expert,14080.0,,9606.0,CHEMBL619870,1.0,,9.0,,,,,,3795.0,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay
,BAO_0000357,B,,,55.0,H,,Autocuration,409.0,,,CHEMBL619871,1.0,,8.0,,,,,,3796.0,In vitro inhibition of human recombinant 5-lipoxygenase enzyme
,BAO_0000357,B,,,55.0,H,,Autocuration,409.0,,,CHEMBL619872,1.0,,8.0,,,,,,3797.0,In vitro inhibition of human recombinant lipoxygenase enzyme
,BAO_0000357,B,,,55.0,H,,Autocuration,409.0,,,CHEMBL619873,1.0,,8.0,,,,,,3798.0,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition
,BAO_0000357,B,,,55.0,H,,Expert,11090.0,,,CHEMBL619874,1.0,,8.0,Blood,,,178.0,,3799.0,Inhibition of 5-lipoxygenase in human whole blood.
,BAO_0000357,B,,,55.0,H,,Expert,11090.0,,,CHEMBL619875,1.0,,8.0,Blood,,,178.0,,3800.0,Inhibition of 5-lipoxygenase in human whole blood.
,BAO_0000357,B,,,55.0,H,,Autocuration,948.0,,,CHEMBL619876,1.0,,8.0,,,,,,3801.0,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE
,BAO_0000357,B,,,55.0,H,,Autocuration,948.0,,,CHEMBL619877,1.0,,8.0,,,,,,3802.0,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4)
,BAO_0000219,F,,,55.0,H,,Expert,13622.0,,,CHEMBL619878,1.0,,8.0,,,,,,3803.0,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.
,BAO_0000019,F,,,55.0,H,,Autocuration,13622.0,,,CHEMBL619879,1.0,,8.0,Blood,,,178.0,,3804.0,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood
,BAO_0000357,B,,,55.0,H,,Autocuration,9637.0,,,CHEMBL619880,1.0,,8.0,,,,,,3805.0,In vitro inhibition of 5-lipoxygenase from human polymorphs
,BAO_0000357,B,,,55.0,H,,Autocuration,11320.0,,,CHEMBL619881,1.0,,8.0,,,,,,3806.0,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase)
,BAO_0000357,B,,,55.0,H,,Expert,11320.0,,,CHEMBL619882,1.0,,8.0,,,,,,3807.0,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase
,BAO_0000357,B,,,55.0,H,,Autocuration,6838.0,,,CHEMBL619883,1.0,,8.0,,,,,,3808.0,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay
,BAO_0000357,B,,,55.0,D,Homo sapiens,Expert,17667.0,,9606.0,CHEMBL619884,1.0,,9.0,Blood,,,178.0,,3809.0,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB)
,BAO_0000357,B,,,55.0,H,,Autocuration,12703.0,,,CHEMBL619885,1.0,,8.0,,,,,,3810.0,In vitro potency against human 5-Lipoxygenase
,BAO_0000019,F,,,55.0,D,Homo sapiens,Expert,14312.0,,9606.0,CHEMBL619886,1.0,,9.0,,,,,,3811.0,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay
,BAO_0000019,F,,,55.0,H,,Autocuration,14312.0,,,CHEMBL619887,1.0,,8.0,Blood,,,178.0,,3812.0,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data
,BAO_0000019,F,,,55.0,H,,Autocuration,5364.0,,,CHEMBL875097,1.0,,8.0,,,,,,3813.0,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.
,BAO_0000219,B,,,55.0,H,,Autocuration,951.0,,,CHEMBL618001,1.0,,8.0,,,,,,3814.0,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE
,BAO_0000219,B,,,55.0,H,,Autocuration,951.0,,,CHEMBL618002,1.0,,8.0,,,,,,3815.0,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active
,BAO_0000219,B,,,55.0,H,,Autocuration,951.0,,,CHEMBL618003,1.0,,8.0,,,,,,3816.0,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4
,BAO_0000219,B,,,55.0,H,,Autocuration,951.0,,,CHEMBL618004,1.0,,8.0,,,,,,3817.0,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active
,BAO_0000219,B,,,55.0,H,,Autocuration,12365.0,,,CHEMBL618005,1.0,,8.0,,,,,,3818.0,Inhibition of human 5-lipoxygenase in human cells
,BAO_0000357,B,,,55.0,H,,Expert,10603.0,,,CHEMBL618006,1.0,,8.0,,,,,,3819.0,Inhibition of human neutrophil 5-lipoxygenase
,BAO_0000019,B,,,55.0,H,,Autocuration,10501.0,,,CHEMBL875086,1.0,,8.0,,,,,,3820.0,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells
,BAO_0000357,B,,,55.0,H,,Expert,12281.0,,,CHEMBL618007,1.0,,8.0,Blood,,,178.0,,3821.0,Inhibition of 5-lipoxygenase from human whole blood
,BAO_0000357,B,,,55.0,H,,Autocuration,2567.0,,,CHEMBL618008,1.0,,8.0,,,,,,3822.0,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils
,BAO_0000219,B,,,55.0,H,,Autocuration,2567.0,,,CHEMBL618009,1.0,,8.0,,,,,,3823.0,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils
,BAO_0000357,B,,,55.0,H,,Expert,10193.0,,,CHEMBL618010,1.0,,8.0,,,,,,3824.0,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase
,BAO_0000357,B,,,55.0,H,,Autocuration,10193.0,,,CHEMBL618011,1.0,,8.0,,,,,,3825.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM
,BAO_0000357,B,,,55.0,H,,Expert,13623.0,,,CHEMBL618012,1.0,,8.0,,,,,,3826.0,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase
,BAO_0000357,B,,,55.0,H,,Autocuration,12780.0,,,CHEMBL882927,1.0,,8.0,,,,,,3827.0,Tested against 5-lipoxygenase
,BAO_0000357,B,,,55.0,H,,Autocuration,12780.0,,,CHEMBL618013,1.0,,8.0,,,,,,3828.0,Tested for activity against 5-Lipoxygenase (5-LO)
,BAO_0000357,B,,,55.0,H,,Autocuration,12780.0,,,CHEMBL618014,1.0,,8.0,,,,,,3829.0,Tested for activity against 5-lipoxygenase
,BAO_0000357,B,,,55.0,H,,Autocuration,11966.0,,,CHEMBL618015,1.0,,8.0,,,,,,3830.0,Tested for inhibition of 5-HPETE production by human 5-LO
,BAO_0000019,F,,,55.0,H,,Autocuration,5364.0,,,CHEMBL618016,1.0,,8.0,,,,,,3831.0,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.
,BAO_0000357,B,,,55.0,H,,Expert,13165.0,,,CHEMBL618017,1.0,,8.0,,,,,,3832.0,Inhibition of Human 5-lipoxygenase
,BAO_0000019,B,,,55.0,H,,Autocuration,5364.0,,,CHEMBL618018,1.0,,8.0,,,,,,3833.0,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells
,BAO_0000219,B,,,55.0,H,,Autocuration,11311.0,,,CHEMBL875087,1.0,,8.0,,,,,,3834.0,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS]
,BAO_0000219,B,,,55.0,H,,Autocuration,11311.0,,,CHEMBL618019,1.0,,8.0,,,,,,3835.0,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS]
,BAO_0000019,B,,,55.0,H,,Autocuration,14863.0,,,CHEMBL618020,1.0,,8.0,,,,,,3836.0,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.
,BAO_0000019,B,,,55.0,H,,Autocuration,14863.0,,,CHEMBL618021,1.0,,8.0,,,,,,3837.0,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested
,BAO_0000357,B,,,55.0,H,,Autocuration,11087.0,,,CHEMBL618022,1.0,,8.0,Blood,,,178.0,,3838.0,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL)
,BAO_0000357,B,,,55.0,H,,Autocuration,455.0,,,CHEMBL618023,1.0,,8.0,,,,,,3839.0,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils
,BAO_0000357,B,,,55.0,H,,Autocuration,13183.0,,,CHEMBL618024,1.0,,8.0,,,,,,3840.0,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4)
,BAO_0000019,B,,,55.0,H,,Expert,10319.0,,,CHEMBL873950,1.0,,8.0,,,,,,3841.0,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells
,BAO_0000357,B,,,55.0,H,,Autocuration,10193.0,,,CHEMBL618025,1.0,,8.0,,,,,,3842.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM
,BAO_0000219,B,,,55.0,H,,Autocuration,951.0,,,CHEMBL618026,1.0,,8.0,,,,,,3843.0,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM
,BAO_0000219,B,,,55.0,H,,Autocuration,951.0,,,CHEMBL618027,1.0,,8.0,,,,,,3844.0,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive
,BAO_0000219,B,,,55.0,H,,Autocuration,951.0,,,CHEMBL618028,1.0,,8.0,,,,,,3845.0,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM
,BAO_0000219,B,,,55.0,H,,Autocuration,951.0,,,CHEMBL618029,1.0,,8.0,,,,,,3846.0,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive
,BAO_0000357,B,,,55.0,H,,Expert,9859.0,,,CHEMBL618030,1.0,,8.0,,,,,,3847.0,Inhibitory activity against 5-lipoxygenase at 10 uM concentration
,BAO_0000357,B,,,55.0,H,,Expert,9859.0,,,CHEMBL618031,1.0,,8.0,,,,,,3848.0,Inhibitory activity against 5-lipoxygenase at 1 uM concentration
,BAO_0000357,B,,,55.0,H,,Autocuration,9859.0,,,CHEMBL618032,1.0,,8.0,,,,,,3849.0,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration
,BAO_0000357,B,,,55.0,H,,Autocuration,2567.0,,,CHEMBL618033,1.0,,8.0,,,,,,3850.0,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils
,BAO_0000357,B,,,55.0,H,,Autocuration,10193.0,,,CHEMBL618034,1.0,,8.0,,,,,,3851.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM
,BAO_0000357,B,,,55.0,H,,Autocuration,10193.0,,,CHEMBL875088,1.0,,8.0,,,,,,3852.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM
,BAO_0000019,B,,,55.0,H,,Autocuration,949.0,,,CHEMBL618035,1.0,,8.0,,,,,,3853.0,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive
,BAO_0000019,B,,,55.0,H,,Autocuration,949.0,,,CHEMBL618036,1.0,,8.0,,,,,,3854.0,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90
,BAO_0000357,B,,,55.0,H,,Expert,10603.0,,,CHEMBL618037,1.0,,8.0,,,,,,3855.0,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM
,BAO_0000357,B,,,55.0,H,,Expert,10603.0,,,CHEMBL618038,1.0,,8.0,,,,,,3856.0,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM
,BAO_0000019,F,,,55.0,H,,Autocuration,10603.0,,,CHEMBL618761,1.0,,8.0,,,,,,3857.0,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM
,BAO_0000357,B,,,55.0,H,,Expert,10603.0,,,CHEMBL618762,1.0,,8.0,,,,,,3858.0,Inhibition of lipoxygenase at the concentration of 0.1 uM
,BAO_0000357,B,,,55.0,H,,Expert,10603.0,,,CHEMBL618763,1.0,,8.0,,,,,,3859.0,Inhibition of lipoxygenase at the concentration of 1 uM
,BAO_0000357,B,,,55.0,H,,Autocuration,10193.0,,,CHEMBL618764,1.0,,8.0,,,,,,3860.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell
,BAO_0000357,B,,,55.0,D,Homo sapiens,Expert,14580.0,,9606.0,CHEMBL618765,1.0,,9.0,,,,,,3861.0,Inhibition of 5-Lipoxygenase (5-LOX)
,BAO_0000357,B,,,17087.0,H,,Expert,11090.0,,,CHEMBL618766,1.0,,8.0,,,,,,3862.0,Inhibition of 5-lipoxygenase in mouse macrophages.
,BAO_0000357,B,,,17087.0,H,,Expert,11090.0,,,CHEMBL618767,1.0,,8.0,,,,,,3863.0,Inhibition of 5-lipoxygenase in mouse macrophages.
,BAO_0000357,B,,,17087.0,H,,Autocuration,6339.0,,,CHEMBL619380,1.0,,8.0,,,,,,3864.0,Inhibitory activity against lipoxygenase-2 in mice
,BAO_0000357,B,,,17087.0,H,,Expert,6339.0,,,CHEMBL619381,1.0,,8.0,,,,,,3865.0,Inhibitory activity against murine lipoxygenase-2.
,BAO_0000357,B,,,17087.0,D,Mus musculus,Expert,12281.0,,10090.0,CHEMBL619382,1.0,,9.0,,,,,,3866.0,Inhibition of 5-lipoxygenase from mouse macrophage
,BAO_0000357,B,,,17087.0,H,,Autocuration,11311.0,,,CHEMBL619383,1.0,,8.0,,,,,,3867.0,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages
,BAO_0000019,B,,,55.0,H,Sus scrofa,Autocuration,11089.0,,9823.0,CHEMBL619384,1.0,,8.0,,,,,,3868.0,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.
,BAO_0000019,B,,,55.0,H,Sus scrofa,Autocuration,10091.0,,9823.0,CHEMBL619385,1.0,,8.0,,,,,,3869.0,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes
,BAO_0000019,B,,,55.0,H,Oryctolagus cuniculus,Autocuration,14352.0,,9986.0,CHEMBL882928,1.0,,8.0,,,,,,3870.0,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes
,BAO_0000019,B,,,12166.0,D,Rattus norvegicus,Expert,13329.0,,10116.0,CHEMBL619386,1.0,,9.0,,,,,,3871.0,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE
,BAO_0000019,B,,,12166.0,H,,Autocuration,13329.0,,,CHEMBL619387,1.0,,8.0,,,,,,3872.0,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. "
,BAO_0000019,B,,,12166.0,H,,Autocuration,13329.0,,,CHEMBL619388,1.0,,8.0,,,,,,3873.0,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE."
,BAO_0000019,B,,,12166.0,H,,Autocuration,13329.0,,,CHEMBL619389,1.0,,8.0,,,,,,3874.0,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4."
,BAO_0000019,B,,,12166.0,H,,Expert,13329.0,,,CHEMBL619390,1.0,,8.0,,,,,,3875.0,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation)
,BAO_0000019,B,,,12166.0,H,,Expert,13329.0,,,CHEMBL619391,1.0,,8.0,,,,,,3876.0,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM"
,BAO_0000019,B,,,12166.0,H,,Autocuration,13329.0,,,CHEMBL619392,1.0,,8.0,,,,,,3877.0,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE
,BAO_0000019,B,,,12166.0,H,,Autocuration,11311.0,,,CHEMBL619393,1.0,,8.0,,,,,,3878.0,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo)
,BAO_0000019,B,,,12166.0,H,,Autocuration,11311.0,,,CHEMBL619394,1.0,,8.0,,,,,,3879.0,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,105.0,,,CHEMBL619395,1.0,,8.0,,,,,702.0,3880.0,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay"
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,105.0,,,CHEMBL619396,1.0,,8.0,,,,,702.0,3881.0,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay"
,BAO_0000357,B,,,12166.0,H,,Autocuration,9138.0,,,CHEMBL619397,1.0,,8.0,,,,,,3882.0,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO)
,BAO_0000357,B,,,12166.0,H,,Autocuration,9138.0,,,CHEMBL619398,1.0,,8.0,,,,,,3883.0,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),"
,BAO_0000357,B,,,12166.0,H,,Autocuration,9138.0,,,CHEMBL619399,1.0,,8.0,,,,,,3884.0,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),"
,BAO_0000357,B,,,12166.0,H,,Autocuration,14427.0,,,CHEMBL619400,1.0,,8.0,,,,,,3885.0,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined
,BAO_0000019,B,,,12166.0,H,,Autocuration,13329.0,,,CHEMBL619401,1.0,,8.0,,,,,,3886.0,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE."
,BAO_0000019,B,,,12166.0,H,,Autocuration,13329.0,,,CHEMBL619402,1.0,,8.0,,,,,,3887.0,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. "
,BAO_0000219,B,,RBL-2H3,12166.0,D,Rattus norvegicus,Expert,14427.0,,10116.0,CHEMBL619403,1.0,,9.0,,,,,663.0,3888.0,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells
,BAO_0000357,B,,,12166.0,H,,Autocuration,14427.0,,,CHEMBL619404,1.0,,8.0,,,,,,3889.0,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined
,BAO_0000357,B,,,12166.0,H,,Autocuration,14427.0,,,CHEMBL619405,1.0,,8.0,,,,,,3890.0,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.
,BAO_0000219,B,,RBL-1,12166.0,H,,Expert,10293.0,,,CHEMBL619406,1.0,,8.0,,,,,702.0,3891.0,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line
,BAO_0000219,B,,RBL-1,12166.0,D,Rattus norvegicus,Expert,338.0,,10116.0,CHEMBL619407,1.0,,9.0,,,,,702.0,3892.0,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells
,BAO_0000357,B,,,12166.0,H,,Autocuration,303.0,,,CHEMBL619408,1.0,,8.0,,,,,,3893.0,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase)
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,303.0,,,CHEMBL619409,1.0,,8.0,,,,,702.0,3894.0,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay
,BAO_0000219,B,,RBL-1,12166.0,H,,Expert,9247.0,,,CHEMBL619410,1.0,,8.0,,,,,702.0,3895.0,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9247.0,,,CHEMBL619753,1.0,,8.0,,,,,702.0,3896.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,137.0,,,CHEMBL619754,1.0,,8.0,,,,,702.0,3897.0,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase
,BAO_0000357,B,,,12166.0,H,,Expert,11481.0,,,CHEMBL619903,1.0,,8.0,,,,,,3898.0,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase
,BAO_0000357,B,,,12166.0,H,,Expert,11481.0,,,CHEMBL619904,1.0,,8.0,,,,,,3899.0,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration"
,BAO_0000357,B,,,12166.0,H,,Expert,9029.0,,,CHEMBL619905,1.0,,8.0,,,,,,3900.0,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro
,BAO_0000019,B,,,12166.0,H,,Autocuration,1701.0,,,CHEMBL619906,1.0,,8.0,,,,,,3901.0,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells
,BAO_0000019,B,,,12166.0,H,,Autocuration,1701.0,,,CHEMBL619907,1.0,,8.0,,,,,,3902.0,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active
,BAO_0000019,B,,,12166.0,H,,Autocuration,1701.0,,,CHEMBL619908,1.0,,8.0,,,,,,3903.0,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active
,BAO_0000019,B,,,12166.0,H,,Autocuration,1701.0,,,CHEMBL619909,1.0,,8.0,,,,,,3904.0,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data
,BAO_0000219,F,,RBL-1,12166.0,H,,Expert,13358.0,,,CHEMBL619910,1.0,,8.0,,,,,702.0,3905.0,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant
,BAO_0000219,B,,RBL-1,12166.0,H,,Expert,1175.0,,,CHEMBL882929,1.0,,8.0,,,,,702.0,3906.0,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells
,BAO_0000219,B,,RBL-1,12166.0,H,,Expert,8797.0,,,CHEMBL619911,1.0,,8.0,,,,,702.0,3907.0,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.
,BAO_0000019,B,,,12166.0,H,,Autocuration,8797.0,,,CHEMBL619912,1.0,,8.0,,,,,,3908.0,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data
,BAO_0000357,B,,,12166.0,D,Rattus norvegicus,Expert,577.0,,10116.0,CHEMBL619913,1.0,,9.0,,,,,,3909.0,Inhibition of rat basophilic leukemia cell 5-lipoxygenase
,BAO_0000219,B,,RBL-1,12166.0,H,,Expert,9295.0,,,CHEMBL619914,1.0,,8.0,,,,,702.0,3910.0,In vitro inhibitory activity against RBL-1 5-LO
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9295.0,,,CHEMBL619915,1.0,,8.0,,,,,702.0,3911.0,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM)
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9295.0,,,CHEMBL619916,1.0,,8.0,,,,,702.0,3912.0,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent)
,BAO_0000218,B,,,12166.0,H,,Autocuration,9295.0,,,CHEMBL619917,1.0,,8.0,,,,,,3913.0,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.
,BAO_0000357,B,,,12166.0,H,,Autocuration,9295.0,,,CHEMBL619918,1.0,,8.0,,,,,,3914.0,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme
,BAO_0000218,B,,,12166.0,H,,Autocuration,216.0,,,CHEMBL619919,1.0,,8.0,,,,,,3915.0,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,11090.0,,,CHEMBL883710,1.0,,8.0,,,,,702.0,3916.0,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.
,BAO_0000019,B,,,12166.0,H,,Autocuration,11090.0,,,CHEMBL619920,1.0,,8.0,Blood,,,178.0,,3917.0,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.
,BAO_0000357,B,,,12166.0,H,,Expert,10091.0,,,CHEMBL619921,1.0,,8.0,,,,,,3918.0,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase
,BAO_0000019,F,,,12166.0,H,,Autocuration,10274.0,,,CHEMBL619922,1.0,,8.0,,,,,,3919.0,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.
,BAO_0000219,F,,,12166.0,H,,Autocuration,13622.0,,,CHEMBL619923,1.0,,8.0,,,,,,3920.0,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes
,BAO_0000219,B,,RBL-1,12166.0,H,,Expert,12118.0,,,CHEMBL619924,1.0,,8.0,,,,,702.0,3921.0,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined
,BAO_0000357,B,,,12166.0,H,,Expert,12576.0,,,CHEMBL619925,1.0,,8.0,,,,,,3922.0,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay
,BAO_0000219,B,,RBL-1,12166.0,H,,Expert,9546.0,,,CHEMBL619926,1.0,,8.0,,,,,702.0,3923.0,In vitro inhibition of 5-lipoxygenase from RBL-1 cells
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9521.0,,,CHEMBL619927,1.0,,8.0,,,,,702.0,3924.0,In vitro inhibition of 5-lipoxygenase in RBL-1 cells
,BAO_0000219,B,,RBL-1,12166.0,H,,Expert,10626.0,,,CHEMBL619928,1.0,,8.0,,,,,702.0,3925.0,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL619929,1.0,,8.0,,,,,702.0,3926.0,In vitro inhibition of RBL-1 5-lipoxygenase
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL875089,1.0,,8.0,,,,,702.0,3927.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL619930,1.0,,8.0,,,,,702.0,3928.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL619931,1.0,,8.0,,,,,702.0,3929.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL619932,1.0,,8.0,,,,,702.0,3930.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL619933,1.0,,8.0,,,,,702.0,3931.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL619934,1.0,,8.0,,,,,702.0,3932.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL619935,1.0,,8.0,,,,,702.0,3933.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL619936,1.0,,8.0,,,,,702.0,3934.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL619937,1.0,,8.0,,,,,702.0,3935.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL619938,1.0,,8.0,,,,,702.0,3936.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL619939,1.0,,8.0,,,,,702.0,3937.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL619940,1.0,,8.0,,,,,702.0,3938.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL875090,1.0,,8.0,,,,,702.0,3939.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL619941,1.0,,8.0,,,,,702.0,3940.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL619942,1.0,,8.0,,,,,702.0,3941.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL883711,1.0,,8.0,,,,,702.0,3942.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL619943,1.0,,8.0,,,,,702.0,3943.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL619944,1.0,,8.0,,,,,702.0,3944.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL619945,1.0,,8.0,,,,,702.0,3945.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL619946,1.0,,8.0,,,,,702.0,3946.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL619947,1.0,,8.0,,,,,702.0,3947.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL619948,1.0,,8.0,,,,,702.0,3948.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL619949,1.0,,8.0,,,,,702.0,3949.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8
,BAO_0000019,B,,,12166.0,H,,Expert,9401.0,,,CHEMBL619950,1.0,,8.0,,,,,,3950.0,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.
,BAO_0000019,B,,,12166.0,H,,Autocuration,10325.0,,,CHEMBL618050,1.0,,8.0,,,,,,3951.0,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay
,BAO_0000219,F,,RBL-2H3,12166.0,H,,Expert,1556.0,,,CHEMBL875091,1.0,,8.0,,,,,663.0,3952.0,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.
,BAO_0000219,F,,RBL-2H3,12166.0,H,,Expert,1556.0,,,CHEMBL618051,1.0,,8.0,,,,,663.0,3953.0,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested
,BAO_0000219,B,,RBL-1,12166.0,D,Rattus norvegicus,Expert,961.0,,10116.0,CHEMBL618052,1.0,,9.0,,,,,702.0,3954.0,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells
,BAO_0000019,B,,,12166.0,H,,Autocuration,6838.0,,,CHEMBL618053,1.0,,8.0,,,,,,3955.0,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate
,BAO_0000019,B,,,12166.0,H,,Expert,10325.0,,,CHEMBL618054,1.0,,8.0,,,,,,3956.0,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay)
,BAO_0000219,B,,RBL-1,12166.0,D,Rattus norvegicus,Expert,9209.0,,10116.0,CHEMBL618055,1.0,,9.0,,,,,702.0,3957.0,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells
,BAO_0000219,B,,RBL-1,12166.0,H,,Expert,11520.0,,,CHEMBL618056,1.0,,8.0,,,,,702.0,3958.0,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.
,BAO_0000357,B,,,12166.0,H,,Autocuration,137.0,,,CHEMBL618057,1.0,,8.0,,,,,,3959.0,In vitro inhibitory activity against 5-lipoxygenase was determined
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,4717.0,,,CHEMBL618058,1.0,,8.0,,,,,702.0,3960.0,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells
,BAO_0000219,B,,RBL-1,12166.0,H,,Expert,10636.0,,,CHEMBL618059,1.0,,8.0,,,,,702.0,3961.0,Inhibition of 5-lipoxygenase in intact RBL-1 cell line
,BAO_0000019,F,,,12166.0,D,Rattus norvegicus,Expert,14312.0,,10116.0,CHEMBL618060,1.0,,9.0,,,,,,3962.0,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,1203.0,,,CHEMBL618061,1.0,,8.0,,,,,702.0,3963.0,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells
,BAO_0000019,B,,,12166.0,H,,Autocuration,1203.0,,,CHEMBL618062,1.0,,8.0,,,,,,3964.0,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells
,BAO_0000219,B,,RBL-1,12166.0,H,,Expert,13622.0,,,CHEMBL618063,1.0,,8.0,,,,,702.0,3965.0,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation
,BAO_0000357,B,,,12166.0,H,,Autocuration,9793.0,,,CHEMBL618064,1.0,,8.0,,,,,,3966.0,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration
,BAO_0000219,B,,RBL-1,12166.0,D,Rattus norvegicus,Expert,1143.0,,10116.0,CHEMBL618065,1.0,,9.0,,,,,702.0,3967.0,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes
,BAO_0000219,B,,RBL-1,12166.0,D,Rattus norvegicus,Expert,11854.0,,10116.0,CHEMBL618066,1.0,,9.0,,,,,702.0,3968.0,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,3595.0,,,CHEMBL618067,1.0,,8.0,,,,,702.0,3969.0,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1)
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,3595.0,,,CHEMBL618068,1.0,,8.0,,,,,702.0,3970.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)
,BAO_0000219,B,,RBL-1,12166.0,D,Rattus norvegicus,Expert,10501.0,,10116.0,CHEMBL618069,1.0,,9.0,,,,,702.0,3971.0,Inhibition of 5-lipoxygenase in rat RBL-1 cells
,BAO_0000219,B,,RBL-1,12166.0,H,,Expert,12526.0,,,CHEMBL618070,1.0,,8.0,,,,,702.0,3972.0,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187
,BAO_0000019,F,,,10825.0,H,,Autocuration,10034.0,,,CHEMBL618071,1.0,,8.0,Limbic system,,,349.0,,3973.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg
,BAO_0000019,F,,,10825.0,H,,Autocuration,10034.0,,,CHEMBL619247,1.0,,8.0,Limbic system,,,349.0,,3974.0,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg
,BAO_0000019,F,,,10825.0,H,,Autocuration,10034.0,,,CHEMBL619248,1.0,,8.0,,,,,,3975.0,Approximate dose levels for a half maximal reduction of 5-HTP levels
,BAO_0000221,B,,,10576.0,H,,Autocuration,10046.0,,,CHEMBL619249,1.0,,8.0,Hippocampus,,,10000000.0,,3976.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.
,BAO_0000221,B,,,10576.0,H,,Autocuration,10046.0,,,CHEMBL619250,1.0,,8.0,Hippocampus,,,10000000.0,,3977.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.
,BAO_0000019,B,,,10577.0,H,,Autocuration,10046.0,,,CHEMBL619251,1.0,,8.0,,,,,,3978.0,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.
,BAO_0000019,F,,,55.0,H,Canis lupus familiaris,Autocuration,12079.0,,9615.0,CHEMBL619252,1.0,,8.0,Blood,,,178.0,,3979.0,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood
,BAO_0000019,F,,,55.0,H,,Autocuration,12079.0,,,CHEMBL619253,1.0,,8.0,Blood,,,178.0,,3980.0,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood
,BAO_0000219,B,,,12166.0,H,,Autocuration,11311.0,,,CHEMBL619254,1.0,,8.0,,,,,,3981.0,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS]
,BAO_0000219,B,,,17140.0,H,,Expert,12338.0,,,CHEMBL619255,1.0,,8.0,,,,,,3982.0,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes
,BAO_0000219,B,,,17140.0,H,,Expert,12143.0,,,CHEMBL619256,1.0,,8.0,,,,,,3983.0,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).
,BAO_0000219,B,,,17140.0,H,,Autocuration,12143.0,,,CHEMBL875418,1.0,,8.0,,,,,,3984.0,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL)
,BAO_0000219,B,,,17140.0,H,,Expert,12143.0,,,CHEMBL619257,1.0,,8.0,,,,,,3985.0,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM
,BAO_0000219,B,,,17140.0,H,,Autocuration,12143.0,,,CHEMBL619258,1.0,,8.0,,,,,,3986.0,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM
,BAO_0000357,B,,,17140.0,H,,Expert,12365.0,,,CHEMBL619259,1.0,,8.0,,,,,,3987.0,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.
,BAO_0000357,B,,,17140.0,H,,Expert,13500.0,,,CHEMBL619260,1.0,,8.0,,,,,,3988.0,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL619261,1.0,,8.0,Blood,,,178.0,,3989.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL619263,1.0,,8.0,Blood,,,178.0,,3990.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL619264,1.0,,8.0,Blood,,,178.0,,3991.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL619265,1.0,,8.0,Blood,,,178.0,,3992.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL619266,1.0,,8.0,Blood,,,178.0,,3993.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL619902,1.0,,8.0,Blood,,,178.0,,3994.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620058,1.0,,8.0,Blood,,,178.0,,3995.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620059,1.0,,8.0,Blood,,,178.0,,3996.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620060,1.0,,8.0,Blood,,,178.0,,3997.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620061,1.0,,8.0,Blood,,,178.0,,3998.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620062,1.0,,8.0,Blood,,,178.0,,3999.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620063,1.0,,8.0,Blood,,,178.0,,4000.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620064,1.0,,8.0,Blood,,,178.0,,4001.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620065,1.0,,8.0,Blood,,,178.0,,4002.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620066,1.0,,8.0,Blood,,,178.0,,4003.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620067,1.0,,8.0,Blood,,,178.0,,4004.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620068,1.0,,8.0,Blood,,,178.0,,4005.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620069,1.0,,8.0,Blood,,,178.0,,4006.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620070,1.0,,8.0,Blood,,,178.0,,4007.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620071,1.0,,8.0,Blood,,,178.0,,4008.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620072,1.0,,8.0,Blood,,,178.0,,4009.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620036,1.0,,8.0,Blood,,,178.0,,4010.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL857702,1.0,,8.0,Blood,,,178.0,,4011.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620037,1.0,,8.0,Blood,,,178.0,,4012.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620038,1.0,,8.0,Blood,,,178.0,,4013.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620039,1.0,,8.0,Blood,,,178.0,,4014.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620040,1.0,,8.0,Blood,,,178.0,,4015.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620041,1.0,,8.0,Blood,,,178.0,,4016.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620042,1.0,,8.0,Blood,,,178.0,,4017.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620043,1.0,,8.0,Blood,,,178.0,,4018.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620044,1.0,,8.0,Blood,,,178.0,,4019.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620045,1.0,,8.0,Blood,,,178.0,,4020.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620046,1.0,,8.0,Blood,,,178.0,,4021.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620047,1.0,,8.0,Blood,,,178.0,,4022.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620048,1.0,,8.0,Blood,,,178.0,,4023.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL857703,1.0,,8.0,Blood,,,178.0,,4024.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620049,1.0,,8.0,Blood,,,178.0,,4025.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620050,1.0,,8.0,Blood,,,178.0,,4026.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL620051,1.0,,8.0,Blood,,,178.0,,4027.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL619213,1.0,,8.0,Blood,,,178.0,,4028.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL619214,1.0,,8.0,Blood,,,178.0,,4029.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL619804,1.0,,8.0,Blood,,,178.0,,4030.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL619805,1.0,,8.0,Blood,,,178.0,,4031.0,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL619806,1.0,,8.0,Blood,,,178.0,,4032.0,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL619807,1.0,,8.0,Blood,,,178.0,,4033.0,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,F,In vivo,,55.0,H,Canis lupus familiaris,Autocuration,12832.0,,9615.0,CHEMBL619808,1.0,,8.0,Blood,,,178.0,,4034.0,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000218,B,,,55.0,H,Canis lupus familiaris,Autocuration,3595.0,,9615.0,CHEMBL619809,1.0,,8.0,,,,,,4035.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r
,BAO_0000218,B,,,55.0,H,Canis lupus familiaris,Autocuration,3595.0,,9615.0,CHEMBL619810,1.0,,8.0,,,,,,4036.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine
,BAO_0000218,B,,,55.0,H,Canis lupus familiaris,Autocuration,3595.0,,9615.0,CHEMBL619811,1.0,,8.0,,,,,,4037.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr
,BAO_0000218,B,,,55.0,H,Canis lupus familiaris,Autocuration,3595.0,,9615.0,CHEMBL620769,1.0,,8.0,,,,,,4038.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine
,BAO_0000218,B,,,55.0,H,Canis lupus familiaris,Autocuration,3595.0,,9615.0,CHEMBL620770,1.0,,8.0,,,,,,4039.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr
,BAO_0000218,B,,,55.0,H,Canis lupus familiaris,Autocuration,3595.0,,9615.0,CHEMBL620771,1.0,,8.0,,,,,,4040.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine
,BAO_0000218,B,,,55.0,H,Canis lupus familiaris,Autocuration,3595.0,,9615.0,CHEMBL620772,1.0,,8.0,,,,,,4041.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr
,BAO_0000218,B,,,55.0,H,Canis lupus familiaris,Autocuration,3595.0,,9615.0,CHEMBL620773,1.0,,8.0,,,,,,4042.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine
,BAO_0000357,B,,,55.0,H,Cavia porcellus,Autocuration,9203.0,,10141.0,CHEMBL620774,1.0,,8.0,,,,,,4043.0,Ability to inhibit 5-lipoxygenase in guinea pig
,BAO_0000357,B,,,55.0,H,Cavia porcellus,Expert,82.0,,10141.0,CHEMBL620775,1.0,,8.0,,,,,,4044.0,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN)
,BAO_0000357,B,,,55.0,H,Cavia porcellus,Autocuration,11090.0,,10141.0,CHEMBL620776,1.0,,8.0,,,,,,4045.0,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.
,BAO_0000218,B,,,55.0,H,Cavia porcellus,Autocuration,12832.0,,10141.0,CHEMBL620777,1.0,,8.0,Blood,,,178.0,,4046.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg"
,BAO_0000357,B,,,55.0,H,Cavia porcellus,Autocuration,1065.0,,10141.0,CHEMBL620778,1.0,,8.0,,,,,,4047.0,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production
,BAO_0000357,B,,,55.0,H,Cavia porcellus,Autocuration,1065.0,,10141.0,CHEMBL620779,1.0,,8.0,,,,,,4048.0,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production
,BAO_0000019,B,,,55.0,H,Cavia porcellus,Expert,12832.0,,10141.0,CHEMBL621500,1.0,,8.0,,,,,,4049.0,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes
,BAO_0000019,B,,,55.0,H,Cavia porcellus,Expert,12832.0,,10141.0,CHEMBL621501,1.0,,8.0,,,,,,4050.0,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes
,BAO_0000019,B,,,55.0,H,Cavia porcellus,Autocuration,12832.0,,10141.0,CHEMBL618098,1.0,,8.0,,,,,,4051.0,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes
,BAO_0000019,B,,,55.0,H,Cavia porcellus,Autocuration,10504.0,,10141.0,CHEMBL618099,1.0,,8.0,,,,,,4052.0,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes
,BAO_0000357,B,,,55.0,H,Cavia porcellus,Autocuration,7788.0,,10141.0,CHEMBL618100,1.0,,8.0,,,,,,4053.0,Inhibitory activity against 5-lipoxygenase
,BAO_0000357,B,,,55.0,H,Cavia porcellus,Autocuration,10001.0,,10141.0,CHEMBL618101,1.0,,8.0,,,,,,4054.0,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte
,BAO_0000357,B,,,55.0,H,Cavia porcellus,Autocuration,10193.0,,10141.0,CHEMBL618102,1.0,,8.0,,,,,,4055.0,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant
,BAO_0000357,B,,,55.0,H,Cavia porcellus,Autocuration,13243.0,,10141.0,CHEMBL618103,1.0,,8.0,,,,,,4056.0,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase
,BAO_0000357,B,,,55.0,H,Cavia porcellus,Autocuration,13243.0,,10141.0,CHEMBL618104,1.0,,8.0,,,,,,4057.0,Inhibitory activity uM
,BAO_0000219,B,,,55.0,H,Cavia porcellus,Autocuration,969.0,,10141.0,CHEMBL883712,1.0,,8.0,,,,,,4058.0,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined
,BAO_0000357,B,,,55.0,H,Cavia porcellus,Autocuration,10001.0,,10141.0,CHEMBL618105,1.0,,8.0,,,,,,4059.0,Inhibitory activity against 5-lipoxygenase at 10 uM
,BAO_0000357,B,,,55.0,H,Cavia porcellus,Autocuration,7788.0,,10141.0,CHEMBL618106,1.0,,8.0,,,,,,4060.0,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM
,BAO_0000357,B,,,55.0,H,Cavia porcellus,Autocuration,10001.0,,10141.0,CHEMBL618107,1.0,,8.0,,,,,,4061.0,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM
,BAO_0000357,B,,,55.0,H,Cavia porcellus,Autocuration,10193.0,,10141.0,CHEMBL618108,1.0,,8.0,,,,,,4062.0,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM
,BAO_0000357,B,,,55.0,H,Cavia porcellus,Autocuration,13243.0,,10141.0,CHEMBL618109,1.0,,8.0,,,,,,4063.0,Inhibitory activity uM
,BAO_0000357,B,,,55.0,H,Cavia porcellus,Autocuration,13243.0,,10141.0,CHEMBL618110,1.0,,8.0,,,,,,4064.0,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM
,BAO_0000357,B,,,55.0,H,Cavia porcellus,Expert,13243.0,,10141.0,CHEMBL618111,1.0,,8.0,,,,,,4065.0,Inhibitory activity uM
,BAO_0000019,F,,,55.0,H,Cavia porcellus,Autocuration,13243.0,,10141.0,CHEMBL618112,1.0,,8.0,,,,,,4066.0,Inhibitory activity uM
,BAO_0000019,B,,,55.0,H,Cavia porcellus,Autocuration,10504.0,,10141.0,CHEMBL618113,1.0,,8.0,,,,,,4067.0,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes
,BAO_0000357,B,,,55.0,H,Cavia porcellus,Autocuration,7788.0,,10141.0,CHEMBL618114,1.0,,8.0,,,,,,4068.0,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM
,BAO_0000221,F,,,55.0,H,Cavia porcellus,Expert,10546.0,,10141.0,CHEMBL620871,1.0,,8.0,Ileum,,,2116.0,,4069.0,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum
,BAO_0000357,B,,,55.0,H,,Autocuration,13183.0,,,CHEMBL620872,1.0,,8.0,,,,,,4070.0,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4)
,BAO_0000357,B,,,55.0,H,,Autocuration,13183.0,,,CHEMBL620873,1.0,,8.0,,,,,,4071.0,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4)
,BAO_0000357,B,,,55.0,H,,Autocuration,2578.0,,,CHEMBL620874,1.0,,8.0,,,,,,4072.0,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO)
,BAO_0000357,B,,,55.0,H,,Expert,12780.0,,,CHEMBL620875,1.0,,8.0,,,,,,4073.0,In vitro inhibition of human 5-Lipoxygenase.
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL620876,1.0,,0.0,Liver,,,2107.0,,4074.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL620877,1.0,,0.0,Liver,,,2107.0,,4075.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL857854,1.0,,0.0,Liver,,,2107.0,,4076.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL620878,1.0,,0.0,Liver,,,2107.0,,4077.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL620879,1.0,,0.0,Liver,,,2107.0,,4078.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL620880,1.0,,0.0,Liver,,,2107.0,,4079.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL620881,1.0,,0.0,Liver,,,2107.0,,4080.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL620882,1.0,,0.0,Liver,,,2107.0,,4081.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL620883,1.0,,0.0,Liver,,,2107.0,,4082.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL620884,1.0,,0.0,Liver,,,2107.0,,4083.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL620885,1.0,,0.0,Liver,,,2107.0,,4084.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL620886,1.0,,0.0,Liver,,,2107.0,,4085.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL620887,1.0,,0.0,Liver,,,2107.0,,4086.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618039,1.0,,0.0,Liver,,,2107.0,,4087.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618040,1.0,,0.0,Liver,,,2107.0,,4088.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618041,1.0,,0.0,Liver,,,2107.0,,4089.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618216,1.0,,0.0,Liver,,,2107.0,,4090.0,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats"
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618217,1.0,,0.0,Liver,,,2107.0,,4091.0,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats"
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618218,1.0,,0.0,Liver,,,2107.0,,4092.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618219,1.0,,0.0,Liver,,,2107.0,,4093.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618220,1.0,,0.0,Liver,,,2107.0,,4094.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618221,1.0,,0.0,Liver,,,2107.0,,4095.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618222,1.0,,0.0,Liver,,,2107.0,,4096.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618223,1.0,,0.0,Liver,,,2107.0,,4097.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618224,1.0,,0.0,Liver,,,2107.0,,4098.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618225,1.0,,0.0,Liver,,,2107.0,,4099.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618226,1.0,,0.0,Liver,,,2107.0,,4100.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618227,1.0,,0.0,Liver,,,2107.0,,4101.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618228,1.0,,0.0,Liver,,,2107.0,,4102.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618229,1.0,,0.0,Liver,,,2107.0,,4103.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618230,1.0,,0.0,Liver,,,2107.0,,4104.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618231,1.0,,0.0,Liver,,,2107.0,,4105.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618232,1.0,,0.0,Liver,,,2107.0,,4106.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618233,1.0,,0.0,Liver,,,2107.0,,4107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618234,1.0,,0.0,Liver,,,2107.0,,4108.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618235,1.0,,0.0,Liver,,,2107.0,,4109.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618115,1.0,,0.0,Liver,,,2107.0,,4110.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618116,1.0,,0.0,Liver,,,2107.0,,4111.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL618117,1.0,,0.0,Liver,,,2107.0,,4112.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL619968,1.0,,0.0,Liver,,,2107.0,,4113.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL619969,1.0,,0.0,Liver,,,2107.0,,4114.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL619970,1.0,,0.0,Liver,,,2107.0,,4115.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL619971,1.0,,0.0,Liver,,,2107.0,,4116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL619972,1.0,,0.0,Liver,,,2107.0,,4117.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL619973,1.0,,0.0,Liver,,,2107.0,,4118.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL619974,1.0,,0.0,Liver,,,2107.0,,4119.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL619975,1.0,,0.0,Liver,,,2107.0,,4120.0,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL619976,1.0,,0.0,,,,,,4121.0,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL619977,1.0,,0.0,Liver,,,2107.0,,4122.0,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats"
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL619978,1.0,,0.0,Liver,,,2107.0,,4123.0,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats"
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL619979,1.0,,0.0,Liver,,,2107.0,,4124.0,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition"
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL619980,1.0,,0.0,Liver,,,2107.0,,4125.0,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats"
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL619981,1.0,,0.0,Liver,,,2107.0,,4126.0,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats"
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,10797.0,,9606.0,CHEMBL619982,1.0,,1.0,,,,,741.0,4127.0,In vitro inhibition of 7226/S myeloma cancer cell line
,BAO_0000219,F,,BEL-7404 tumor cell line,80698.0,N,Homo sapiens,Intermediate,6881.0,,9606.0,CHEMBL619983,1.0,,1.0,,,,,993.0,4128.0,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells)
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,3838.0,,9606.0,CHEMBL620031,1.0,,1.0,,,,,391.0,4129.0,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,3838.0,,9606.0,CHEMBL620032,1.0,,1.0,,,,,391.0,4130.0,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer
,BAO_0000219,F,,V79,81264.0,N,Cricetulus griseus,Expert,12981.0,,10029.0,CHEMBL620033,1.0,,1.0,,,,,505.0,4131.0,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.
,BAO_0000219,F,,V79,81264.0,N,Cricetulus griseus,Expert,12981.0,,10029.0,CHEMBL620034,1.0,,1.0,,,,,505.0,4132.0,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.
,BAO_0000219,F,,7800C1 cell line,80635.0,N,Rattus norvegicus,Intermediate,7653.0,,10116.0,CHEMBL620035,1.0,,1.0,,,,,1119.0,4133.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose
,BAO_0000219,F,,7800C1 cell line,80635.0,N,Rattus norvegicus,Intermediate,7653.0,,10116.0,CHEMBL618318,1.0,,1.0,,,,,1119.0,4134.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose
,BAO_0000219,F,,7800C1 cell line,80635.0,N,Rattus norvegicus,Intermediate,7653.0,,10116.0,CHEMBL618319,1.0,,1.0,,,,,1119.0,4135.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose
,BAO_0000219,F,,7800C1 cell line,80635.0,N,Rattus norvegicus,Intermediate,7653.0,,10116.0,CHEMBL618320,1.0,,1.0,,,,,1119.0,4136.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose
,BAO_0000219,F,,7800C1 cell line,80635.0,N,Rattus norvegicus,Intermediate,7653.0,,10116.0,CHEMBL618321,1.0,,1.0,,,,,1119.0,4137.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose
,BAO_0000219,F,,7800C1 cell line,80635.0,N,Rattus norvegicus,Intermediate,7653.0,,10116.0,CHEMBL883118,1.0,,1.0,,,,,1119.0,4138.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,17229.0,,9606.0,CHEMBL883795,1.0,,1.0,,,,,391.0,4139.0,In vitro antitumor activity against renal 786-0 tumor cell lines
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,12858.0,,9606.0,CHEMBL618322,1.0,,1.0,,,,,391.0,4140.0,Cytotoxic activity against 786-0 Renal cancer cell line
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,16325.0,,9606.0,CHEMBL618323,1.0,,1.0,,,,,391.0,4141.0,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,16325.0,,9606.0,CHEMBL618324,1.0,,1.0,,,,,391.0,4142.0,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,5858.0,,9606.0,CHEMBL618325,1.0,,1.0,,,,,391.0,4143.0,In vitro antitumor activity against human renal 786-0 cell line
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,16325.0,,9606.0,CHEMBL875416,1.0,,1.0,,,,,391.0,4144.0,Inhibition of Renal cancer in 786-0 cancer cell lines
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,14696.0,,9606.0,CHEMBL618326,1.0,,1.0,,,,,391.0,4145.0,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,3786.0,,9606.0,CHEMBL618327,1.0,,1.0,,,,,391.0,4146.0,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,14696.0,,9606.0,CHEMBL619215,1.0,,1.0,,,,,391.0,4147.0,inhibition of the growth of renal cancer(786-0) cell line
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,14769.0,,9606.0,CHEMBL619216,1.0,,1.0,,,,,391.0,4148.0,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells )
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,15354.0,,9606.0,CHEMBL619217,1.0,,1.0,,,,,391.0,4149.0,Compound was tested for the growth inhibition of 786-0 renal tumor cell line
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,14255.0,,9606.0,CHEMBL619218,1.0,,1.0,,,,,391.0,4150.0,The IC50 value was measured on 786-0 cell line in ovarian tumor
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,14255.0,,9606.0,CHEMBL619219,1.0,,1.0,,,,,391.0,4151.0,The IC50 value was measured on 786-0 cell line in ovarian tumor t
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,14255.0,,9606.0,CHEMBL619220,1.0,,1.0,,,,,391.0,4152.0,The IC50 value was measured on 786-0 cell line in renal tumor type.
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,14696.0,,9606.0,CHEMBL619221,1.0,,1.0,,,,,391.0,4153.0,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,12016.0,,9606.0,CHEMBL619222,1.0,,1.0,,,,,391.0,4154.0,Tested for cytotoxic activity against renal cancer 786-0 cell line
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,2597.0,,9606.0,CHEMBL857454,1.0,,1.0,,,,,391.0,4155.0,Compound was tested for growth inhibitory activity against 786-0 cell line
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,12526.0,,,CHEMBL619223,1.0,,8.0,,,,,702.0,4156.0,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,12526.0,,,CHEMBL619224,1.0,,8.0,,,,,702.0,4157.0,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive
,BAO_0000019,B,,,12166.0,H,,Autocuration,14799.0,,,CHEMBL619225,1.0,,8.0,,,,,,4158.0,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells
,BAO_0000219,B,,RBL-1,12166.0,H,,Expert,3595.0,,,CHEMBL619226,1.0,,8.0,,,,,702.0,4159.0,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1)
,BAO_0000219,B,,RBL-1,12166.0,H,,Expert,3595.0,,,CHEMBL619227,1.0,,8.0,,,,,702.0,4160.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)
,BAO_0000357,B,,,12166.0,H,,Autocuration,12767.0,,,CHEMBL619228,1.0,,8.0,,,,,,4161.0,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase
,BAO_0000219,B,,,12166.0,H,,Autocuration,10997.0,,,CHEMBL619229,1.0,,8.0,,,,,,4162.0,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,11388.0,,,CHEMBL619230,1.0,,8.0,,,,,702.0,4163.0,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line
,BAO_0000357,B,,,12166.0,H,,Autocuration,167.0,,,CHEMBL619231,1.0,,8.0,,,,,,4164.0,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated
,BAO_0000357,B,,,12166.0,H,,Autocuration,167.0,,,CHEMBL619232,1.0,,8.0,,,,,,4165.0,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated"
,BAO_0000357,B,,,12166.0,H,,Expert,13744.0,,,CHEMBL619233,1.0,,8.0,,,,,,4166.0,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.
,BAO_0000357,B,,,12166.0,H,,Autocuration,1630.0,,,CHEMBL619234,1.0,,8.0,,,,,,4167.0,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase
,BAO_0000357,B,,,12166.0,H,,Autocuration,1630.0,,,CHEMBL619235,1.0,,8.0,,,,,,4168.0,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO)
,BAO_0000019,B,,,12166.0,D,Rattus norvegicus,Expert,969.0,,10116.0,CHEMBL619236,1.0,,9.0,,,,,,4169.0,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production"
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,13621.0,,,CHEMBL619237,1.0,,8.0,,,,,702.0,4170.0,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells
,BAO_0000357,B,,,12166.0,H,,Autocuration,10089.0,,,CHEMBL619238,1.0,,8.0,,,,,,4171.0,Inhibitory concentration to inhibit 5-lipoxygenase in the rat
,BAO_0000357,B,,,12166.0,H,,Expert,10193.0,,,CHEMBL619239,1.0,,8.0,,,,,,4172.0,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase
,BAO_0000357,B,,,12166.0,H,,Autocuration,11966.0,,,CHEMBL619240,1.0,,8.0,,,,,,4173.0,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM
,BAO_0000019,B,,,12166.0,H,,Autocuration,12251.0,,,CHEMBL875417,1.0,,8.0,,,,,,4174.0,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,211.0,,,CHEMBL619241,1.0,,8.0,,,,,702.0,4175.0,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1)
,BAO_0000019,F,,,12166.0,H,,Expert,12251.0,,,CHEMBL619242,1.0,,8.0,,,,,,4176.0,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,12495.0,,,CHEMBL883796,1.0,,8.0,,,,,702.0,4177.0,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells
,BAO_0000357,B,,,12166.0,H,,Autocuration,414.0,,,CHEMBL619243,1.0,,8.0,,,,,,4178.0,Tested for its inhibitory activity against 5-lipoxygenase
,BAO_0000357,B,,,12166.0,H,,Autocuration,414.0,,,CHEMBL619244,1.0,,8.0,,,,,,4179.0,Tested for its inhibitory activity against 5-lipoxygenase; Not determined
,BAO_0000019,B,,,12166.0,H,,Expert,10325.0,,,CHEMBL619245,1.0,,8.0,,,,,,4180.0,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)"
,BAO_0000019,B,,,12166.0,H,,Expert,11966.0,,,CHEMBL619246,1.0,,8.0,,,,,,4181.0,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes
,BAO_0000219,B,,RBL-1,12166.0,H,,Expert,165.0,,,CHEMBL619984,1.0,,8.0,,,,,702.0,4182.0,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,165.0,,,CHEMBL619985,1.0,,8.0,,,,,702.0,4183.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,165.0,,,CHEMBL619986,1.0,,8.0,,,,,702.0,4184.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.
,BAO_0000219,B,,RBL-1,12166.0,H,,Expert,165.0,,,CHEMBL619987,1.0,,8.0,,,,,702.0,4185.0,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.
,BAO_0000218,B,,,12166.0,H,,Autocuration,11311.0,,,CHEMBL619988,1.0,,8.0,,,,,,4186.0,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,11311.0,,,CHEMBL619989,1.0,,8.0,,,,,702.0,4187.0,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,11311.0,,,CHEMBL619990,1.0,,8.0,,,,,702.0,4188.0,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells
,BAO_0000219,B,,,12166.0,H,,Autocuration,11311.0,,,CHEMBL619991,1.0,,8.0,,,,,,4189.0,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS]
,BAO_0000219,B,,,12166.0,H,,Autocuration,11311.0,,,CHEMBL619992,1.0,,8.0,,,,,,4190.0,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro)
,BAO_0000218,B,In vivo,,12166.0,H,,Autocuration,11311.0,,,CHEMBL619993,1.0,,8.0,,,,,,4191.0,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo)
,BAO_0000219,F,,RBL-2H3,12166.0,H,,Autocuration,11311.0,,,CHEMBL619994,1.0,,8.0,,,,,663.0,4192.0,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells
,BAO_0000219,F,,RBL-2H3,12166.0,H,,Autocuration,11311.0,,,CHEMBL619995,1.0,,8.0,,,,,663.0,4193.0,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells
,BAO_0000019,B,,,12166.0,H,,Autocuration,11311.0,,,CHEMBL619996,1.0,,8.0,,,,,,4194.0,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS]
,BAO_0000019,B,,,12166.0,H,,Autocuration,11732.0,,,CHEMBL619997,1.0,,8.0,,,,,,4195.0,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase
,BAO_0000019,B,,,12166.0,H,,Expert,11732.0,,,CHEMBL619998,1.0,,8.0,,,,,,4196.0,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.
,BAO_0000019,B,,,12166.0,H,,Expert,11087.0,,,CHEMBL619999,1.0,,8.0,,,,,,4197.0,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells
,BAO_0000019,B,,,12166.0,H,,Autocuration,11087.0,,,CHEMBL620000,1.0,,8.0,,,,,,4198.0,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,11087.0,,,CHEMBL620001,1.0,,8.0,,,,,702.0,4199.0,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells
,BAO_0000357,B,,,12166.0,D,Rattus norvegicus,Expert,11087.0,,10116.0,CHEMBL620002,1.0,,9.0,,,,,,4200.0,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,496.0,,,CHEMBL620003,1.0,,8.0,,,,,702.0,4201.0,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells
,BAO_0000219,F,,RBL-1,12166.0,H,,Expert,13986.0,,,CHEMBL620004,1.0,,8.0,,,,,702.0,4202.0,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production
,BAO_0000357,B,,,12166.0,H,,Autocuration,11520.0,,,CHEMBL874063,1.0,,8.0,,,,,,4203.0,Compound was evaluated for the inhibition of 5-lipoxygenase
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,10293.0,,,CHEMBL620005,1.0,,8.0,,,,,702.0,4204.0,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,303.0,,,CHEMBL620006,1.0,,8.0,,,,,702.0,4205.0,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,303.0,,,CHEMBL620007,1.0,,8.0,,,,,702.0,4206.0,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9247.0,,,CHEMBL620008,1.0,,8.0,,,,,702.0,4207.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM
,BAO_0000219,B,,RBL-1,12166.0,D,Rattus norvegicus,Expert,9247.0,,10116.0,CHEMBL620009,1.0,,9.0,,,,,702.0,4208.0,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9247.0,,,CHEMBL620010,1.0,,8.0,,,,,702.0,4209.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9247.0,,,CHEMBL620011,1.0,,8.0,,,,,702.0,4210.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9247.0,,,CHEMBL620677,1.0,,8.0,,,,,702.0,4211.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9247.0,,,CHEMBL620678,1.0,,8.0,,,,,702.0,4212.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9247.0,,,CHEMBL620679,1.0,,8.0,,,,,702.0,4213.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9247.0,,,CHEMBL620680,1.0,,8.0,,,,,702.0,4214.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM
,BAO_0000357,B,,,12166.0,D,Rattus norvegicus,Expert,11481.0,,10116.0,CHEMBL620838,1.0,,9.0,,,,,,4215.0,Inhibitory activity against 5-lipoxygenase at 10 uM
,BAO_0000357,B,,,12166.0,H,,Autocuration,105.0,,,CHEMBL620839,1.0,,8.0,,,,,,4216.0,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition
,BAO_0000357,B,,,12166.0,H,,Expert,9029.0,,,CHEMBL620840,1.0,,8.0,,,,,,4217.0,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Expert,1175.0,,,CHEMBL620841,1.0,,8.0,,,,,702.0,4218.0,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,12118.0,,,CHEMBL620842,1.0,,8.0,,,,,702.0,4219.0,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,12118.0,,,CHEMBL620843,1.0,,8.0,,,,,702.0,4220.0,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,12118.0,,,CHEMBL620844,1.0,,8.0,,,,,702.0,4221.0,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9225.0,,,CHEMBL620845,1.0,,8.0,,,,,702.0,4222.0,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM
,BAO_0000019,B,,,12166.0,H,,Autocuration,9401.0,,,CHEMBL620846,1.0,,8.0,,,,,,4223.0,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration
,BAO_0000357,B,,,12166.0,H,,Autocuration,137.0,,,CHEMBL873951,1.0,,8.0,,,,,,4224.0,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM
,BAO_0000357,B,,,12166.0,H,,Autocuration,137.0,,,CHEMBL620847,1.0,,8.0,,,,,,4225.0,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,4717.0,,,CHEMBL620848,1.0,,8.0,,,,,702.0,4226.0,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,3595.0,,,CHEMBL620849,1.0,,8.0,,,,,702.0,4227.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,10501.0,,,CHEMBL620850,1.0,,8.0,,,,,702.0,4228.0,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,10501.0,,,CHEMBL620851,1.0,,8.0,,,,,702.0,4229.0,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,10501.0,,,CHEMBL620852,1.0,,8.0,,,,,702.0,4230.0,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,12526.0,,,CHEMBL875098,1.0,,8.0,,,,,702.0,4231.0,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187
,BAO_0000219,B,,RBL-1,12166.0,D,Rattus norvegicus,Expert,14799.0,,10116.0,CHEMBL620853,1.0,,9.0,,,,,702.0,4232.0,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM
,BAO_0000019,B,,,12166.0,H,,Autocuration,14799.0,,,CHEMBL620854,1.0,,8.0,,,,,,4233.0,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,3595.0,,,CHEMBL620855,1.0,,8.0,,,,,702.0,4234.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Expert,3595.0,,,CHEMBL839884,1.0,,8.0,,,,,702.0,4235.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,12526.0,,,CHEMBL620856,1.0,,8.0,,,,,702.0,4236.0,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,12526.0,,,CHEMBL620857,1.0,,8.0,,,,,702.0,4237.0,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187
,BAO_0000019,B,,,12166.0,H,,Autocuration,10193.0,,,CHEMBL620858,1.0,,8.0,,,,,,4238.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM
,BAO_0000019,B,,,12166.0,H,,Autocuration,10193.0,,,CHEMBL620859,1.0,,8.0,,,,,,4239.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM
,BAO_0000019,B,,,12166.0,H,,Autocuration,10193.0,,,CHEMBL620860,1.0,,8.0,,,,,,4240.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM
,BAO_0000019,B,,,12166.0,H,,Autocuration,10193.0,,,CHEMBL620861,1.0,,8.0,,,,,,4241.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM
,BAO_0000357,B,,,12166.0,H,,Expert,9138.0,,,CHEMBL620862,1.0,,8.0,,,,,,4242.0,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO)
,BAO_0000357,B,,,12166.0,H,,Autocuration,9138.0,,,CHEMBL620863,1.0,,8.0,,,,,,4243.0,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM
,BAO_0000019,B,,,12166.0,H,,Autocuration,11966.0,,,CHEMBL620864,1.0,,8.0,,,,,,4244.0,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,165.0,,,CHEMBL620865,1.0,,8.0,,,,,702.0,4245.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,165.0,,,CHEMBL620866,1.0,,8.0,,,,,702.0,4246.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM
,BAO_0000219,B,,RBL-2H3,12166.0,H,,Autocuration,11311.0,,,CHEMBL620867,1.0,,8.0,,,,,663.0,4247.0,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells
,BAO_0000219,B,,RBL-2H3,12166.0,H,,Autocuration,11311.0,,,CHEMBL620868,1.0,,8.0,,,,,663.0,4248.0,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells
,BAO_0000219,F,,RBL-2H3,12166.0,H,,Autocuration,11311.0,,,CHEMBL620869,1.0,,8.0,,,,,663.0,4249.0,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells
,BAO_0000019,F,,,12166.0,H,,Autocuration,11311.0,,,CHEMBL873952,1.0,,8.0,,,,,,4250.0,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase
,BAO_0000357,B,,,12166.0,H,,Autocuration,11311.0,,,CHEMBL875099,1.0,,8.0,,,,,,4251.0,The compound was tested for inhibition of isolated 5-lipoxygenase
,BAO_0000219,F,,RBL-2H3,12166.0,H,,Autocuration,11311.0,,,CHEMBL620870,1.0,,8.0,,,,,663.0,4252.0,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells
,BAO_0000019,B,,,12166.0,H,,Autocuration,11087.0,,,CHEMBL618261,1.0,,8.0,,,,,,4253.0,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM
,BAO_0000019,B,,,12166.0,H,,Autocuration,11087.0,,,CHEMBL618262,1.0,,8.0,,,,,,4254.0,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM
,BAO_0000019,B,,,12166.0,H,,Autocuration,11087.0,,,CHEMBL619428,1.0,,8.0,,,,,,4255.0,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM
,BAO_0000019,B,,,12166.0,H,,Autocuration,11087.0,,,CHEMBL619429,1.0,,8.0,,,,,,4256.0,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration
,BAO_0000019,B,,,12166.0,H,,Autocuration,11087.0,,,CHEMBL619430,1.0,,8.0,,,,,,4257.0,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,496.0,,,CHEMBL620017,1.0,,8.0,,,,,702.0,4258.0,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,496.0,,,CHEMBL620018,1.0,,8.0,,,,,702.0,4259.0,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM
,BAO_0000219,F,,RBL-1,12166.0,H,,Autocuration,13986.0,,,CHEMBL620019,1.0,,8.0,,,,,702.0,4260.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM
,BAO_0000219,F,,RBL-1,12166.0,H,,Autocuration,13986.0,,,CHEMBL620020,1.0,,8.0,,,,,702.0,4261.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM
,BAO_0000219,F,,RBL-1,12166.0,H,,Autocuration,13986.0,,,CHEMBL620021,1.0,,8.0,,,,,702.0,4262.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM
,BAO_0000219,F,,RBL-1,12166.0,H,,Autocuration,13986.0,,,CHEMBL620022,1.0,,8.0,,,,,702.0,4263.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM
,BAO_0000219,F,,RBL-1,12166.0,H,,Autocuration,13986.0,,,CHEMBL620023,1.0,,8.0,,,,,702.0,4264.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39
,BAO_0000219,F,,RBL-1,12166.0,H,,Autocuration,13986.0,,,CHEMBL620024,1.0,,8.0,,,,,702.0,4265.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM
,BAO_0000219,F,,RBL-1,12166.0,H,,Autocuration,13986.0,,,CHEMBL620025,1.0,,8.0,,,,,702.0,4266.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM
,BAO_0000219,F,,RBL-1,12166.0,H,,Autocuration,13986.0,,,CHEMBL620026,1.0,,8.0,,,,,702.0,4267.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM
,BAO_0000219,F,,RBL-1,12166.0,H,,Autocuration,13986.0,,,CHEMBL620027,1.0,,8.0,,,,,702.0,4268.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM
,BAO_0000019,F,,,12166.0,D,Rattus norvegicus,Expert,13986.0,,10116.0,CHEMBL620028,1.0,,9.0,,,,,,4269.0,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM
,BAO_0000357,B,,,12166.0,H,,Autocuration,10193.0,,,CHEMBL620029,1.0,,8.0,,,,,,4270.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase
,BAO_0000357,B,,,12166.0,H,,Autocuration,9295.0,,,CHEMBL620030,1.0,,8.0,,,,,,4271.0,Compound was tested for the percent of inhibition against 5-LO at 10 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,4717.0,,,CHEMBL875415,1.0,,8.0,,,,,702.0,4272.0,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,4717.0,,,CHEMBL618256,1.0,,8.0,,,,,702.0,4273.0,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,11854.0,,,CHEMBL618257,1.0,,8.0,,,,,702.0,4274.0,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,11854.0,,,CHEMBL618258,1.0,,8.0,,,,,702.0,4275.0,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,11854.0,,,CHEMBL618259,1.0,,8.0,,,,,702.0,4276.0,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM
,BAO_0000019,B,,,12166.0,H,,Autocuration,10193.0,,,CHEMBL618260,1.0,,8.0,,,,,,4277.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9295.0,,,CHEMBL618215,1.0,,8.0,,,,,702.0,4278.0,Percent inhibition against RBL-1 5-LO in vitro at 10 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9295.0,,,CHEMBL618390,1.0,,8.0,,,,,702.0,4279.0,Percent inhibition against RBL-1 5-LO in vitro at 100 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9295.0,,,CHEMBL618391,1.0,,8.0,,,,,702.0,4280.0,Percent inhibition against RBL-1 5-LO in vitro at 30 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,9295.0,,,CHEMBL618392,1.0,,8.0,,,,,702.0,4281.0,Percent inhibition against RBL-1 5-LO in vitro at 300 uM
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,165.0,,,CHEMBL618393,1.0,,8.0,,,,,702.0,4282.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM
,BAO_0000219,B,,,12166.0,H,,Autocuration,11311.0,,,CHEMBL618394,1.0,,8.0,,,,,,4283.0,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration
,BAO_0000219,B,,RBL-1,12166.0,H,Homo sapiens,Expert,10489.0,,9606.0,CHEMBL618395,1.0,,8.0,,,,,702.0,4284.0,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1)
,BAO_0000219,B,,RBL-1,12166.0,D,Rattus norvegicus,Expert,10489.0,,10116.0,CHEMBL618396,1.0,,9.0,,,,,702.0,4285.0,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1)
,BAO_0000219,B,,RBL-1,12166.0,D,Rattus norvegicus,Expert,10489.0,,10116.0,CHEMBL858253,1.0,,9.0,,,,,702.0,4286.0,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1)
,BAO_0000019,B,,,12166.0,D,Rattus norvegicus,Autocuration,14799.0,,10116.0,CHEMBL618397,1.0,,9.0,,,,,,4287.0,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells
,BAO_0000357,B,,,12054.0,H,Glycine max,Autocuration,9295.0,,3847.0,CHEMBL618398,1.0,,8.0,,,,,,4288.0,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM)
,BAO_0000019,B,,,22226.0,U,,Autocuration,16811.0,,,CHEMBL618399,1.0,,0.0,,,,,,4289.0,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay"
,BAO_0000357,B,,,55.0,H,,Expert,168.0,,,CHEMBL618400,1.0,,8.0,,,,,,4290.0,In vitro inhibition of 5-Lipoxygenase; Inactive.
,BAO_0000357,B,,,55.0,H,,Autocuration,6309.0,,,CHEMBL618401,1.0,,8.0,,,,,,4291.0,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition
,BAO_0000357,B,,,55.0,H,,Autocuration,6309.0,,,CHEMBL618402,1.0,,8.0,,,,,,4292.0,Inhibitory concentration against 5-lipoxygenase; No inhibition
,BAO_0000219,B,,RBL-1,55.0,H,,Autocuration,3092.0,,,CHEMBL876400,1.0,,8.0,,,,,702.0,4293.0,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig
,BAO_0000357,B,,,55.0,H,,Expert,168.0,,,CHEMBL618403,1.0,,8.0,,,,,,4294.0,Inhibitory activity against 5-lipoxygenase.
,BAO_0000357,B,,,55.0,H,,Autocuration,168.0,,,CHEMBL618404,1.0,,8.0,,,,,,4295.0,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive
,BAO_0000357,B,,,55.0,H,,Autocuration,168.0,,,CHEMBL618405,1.0,,8.0,,,,,,4296.0,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM
,BAO_0000357,B,,,55.0,H,,Autocuration,168.0,,,CHEMBL618406,1.0,,8.0,,,,,,4297.0,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM
,BAO_0000019,F,,,55.0,H,,Expert,12338.0,,,CHEMBL618407,1.0,,8.0,,,,,,4298.0,Inhibitory concentration against arachidonic acid 5-lipoxygenation
,BAO_0000357,B,,,55.0,H,,Autocuration,4501.0,,,CHEMBL618408,1.0,,8.0,,,,,,4299.0,Tested for the inhibitory activity against 5-lipoxygenase
,BAO_0000357,B,,,55.0,H,,Autocuration,1132.0,,,CHEMBL618409,1.0,,8.0,,,,,,4300.0,Compound was tested for its inhibitory activity against 5-lipoxygenase
,BAO_0000357,B,,,55.0,H,,Autocuration,2117.0,,,CHEMBL618410,1.0,,8.0,,,,,,4301.0,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed
,BAO_0000357,B,,,55.0,H,,Autocuration,168.0,,,CHEMBL618411,1.0,,8.0,,,,,,4302.0,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active
,BAO_0000357,B,,,55.0,H,,Autocuration,168.0,,,CHEMBL618412,1.0,,8.0,,,,,,4303.0,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined
,BAO_0000219,B,,RBL-1,12166.0,H,,Autocuration,13575.0,,,CHEMBL618413,1.0,,8.0,,,,,702.0,4304.0,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase
,BAO_0000357,B,,,12166.0,H,,Autocuration,11089.0,,,CHEMBL618414,1.0,,8.0,,,,,,4305.0,
,BAO_0000357,B,,,10102.0,H,,Autocuration,216.0,,,CHEMBL618415,1.0,,8.0,,,,,,4306.0,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP)
,BAO_0000019,B,,,10102.0,H,,Autocuration,13165.0,,,CHEMBL618416,1.0,,8.0,,,,,,4307.0,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations
,BAO_0000357,B,,,10102.0,H,,Autocuration,3278.0,,,CHEMBL876401,1.0,,8.0,,,,,,4308.0,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.
,BAO_0000357,B,,,10102.0,H,,Expert,3278.0,,,CHEMBL618417,1.0,,8.0,,,,,,4309.0,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.
,BAO_0000357,B,,,10102.0,H,,Autocuration,11966.0,,,CHEMBL618418,1.0,,8.0,,,,,,4310.0,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein
,BAO_0000357,B,,,10102.0,H,,Autocuration,175.0,,,CHEMBL618419,1.0,,8.0,,,,,,4311.0,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein"
,BAO_0000357,B,,,10102.0,H,,Autocuration,175.0,,,CHEMBL618420,1.0,,8.0,,,,,,4312.0,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)"
,BAO_0000357,B,,,10102.0,H,,Autocuration,13449.0,,,CHEMBL618421,1.0,,8.0,,,,,,4313.0,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay
,BAO_0000019,B,,,11238.0,H,,Autocuration,12014.0,,,CHEMBL618422,1.0,,8.0,,,,,,4314.0,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane
,BAO_0000019,B,,,11238.0,H,,Autocuration,12014.0,,,CHEMBL618423,1.0,,8.0,,,,,,4315.0,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant)
,BAO_0000019,B,,,11238.0,H,,Autocuration,12014.0,,,CHEMBL618424,1.0,,8.0,,,,,,4316.0,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate)
,BAO_0000220,B,,,100284.0,S,,Intermediate,99.0,,,CHEMBL618425,1.0,,2.0,,,,,,4317.0,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit
,BAO_0000019,F,,,22226.0,U,Homo sapiens,Autocuration,4349.0,,9606.0,CHEMBL618426,1.0,,0.0,,,,,,4318.0,The dark toxicity against 543 human galactophore carcinoma cells
,BAO_0000219,F,,Panel (56 tumour cell lines),80623.0,N,Homo sapiens,Expert,4071.0,,9606.0,CHEMBL618427,1.0,,1.0,,,,,390.0,4319.0,Tested in vitro for cytotoxicity against 56 human tumor cell lines
,BAO_0000219,F,,5637,80008.0,N,Homo sapiens,Expert,17589.0,,9606.0,CHEMBL618428,1.0,,1.0,,,,,345.0,4320.0,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value
,BAO_0000219,F,,5637,80008.0,N,Homo sapiens,Intermediate,15002.0,,9606.0,CHEMBL618429,1.0,,1.0,,,,,345.0,4321.0,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.
,BAO_0000219,F,,5637,80008.0,N,Homo sapiens,Intermediate,13958.0,,9606.0,CHEMBL618430,1.0,,1.0,,,,,345.0,4322.0,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line"
,BAO_0000219,F,,5637,80008.0,N,Homo sapiens,Expert,17589.0,,9606.0,CHEMBL618431,1.0,,1.0,,,,,345.0,4323.0,Growth inhibition against human 5637 cell lines
,BAO_0000219,F,,5637,80008.0,N,Homo sapiens,Expert,16748.0,,9606.0,CHEMBL883799,1.0,,1.0,,,,,345.0,4324.0,Antitumor activity against human bladder carcinoma 5637 cells.
,BAO_0000219,F,,5637,80008.0,N,Homo sapiens,Intermediate,16747.0,,9606.0,CHEMBL618432,1.0,,1.0,,,,,345.0,4325.0,Antitumor activity against human bladder carcinoma 5637 cells
,BAO_0000219,F,,5637,80008.0,N,Homo sapiens,Intermediate,16747.0,,9606.0,CHEMBL618433,1.0,,1.0,,,,,345.0,4326.0,Antitumor activity against human bladder carcinoma 5637 cells
,BAO_0000357,B,,,10443.0,D,Bos taurus,Expert,15285.0,,9913.0,CHEMBL618434,1.0,,9.0,,,,,,4327.0,In vitro inhibition of bovine trypsin(Trp).
,BAO_0000219,B,,CV-1,240.0,H,Cercopithecidae,Expert,3726.0,,9527.0,CHEMBL618435,1.0,,8.0,,,,,407.0,4328.0,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor
,BAO_0000357,B,,,10577.0,H,,Autocuration,5033.0,,,CHEMBL876402,1.0,,8.0,,,,,,4329.0,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor
,BAO_0000019,F,,,104698.0,H,,Autocuration,11756.0,,,CHEMBL618436,1.0,,6.0,,,,,,4330.0,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.
,BAO_0000218,F,In vivo,,22226.0,U,,Autocuration,11953.0,,,CHEMBL618437,1.0,,0.0,,,,,,4331.0,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat
,BAO_0000357,B,,,20033.0,D,Cavia porcellus,Intermediate,5033.0,,10141.0,CHEMBL618438,1.0,,9.0,,,,,,4332.0,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor
,BAO_0000251,A,,,17045.0,H,Rattus norvegicus,Expert,11347.0,Microsomes,10116.0,CHEMBL883800,1.0,,8.0,,,,,,4333.0,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes
,BAO_0000251,A,,,17045.0,H,Rattus norvegicus,Expert,11347.0,Microsomes,10116.0,CHEMBL618439,1.0,,8.0,,,,,,4334.0,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes
,BAO_0000019,F,,,22226.0,U,,Intermediate,1229.0,,,CHEMBL618440,1.0,,0.0,,,,,,4335.0,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive
,BAO_0000019,F,,,22226.0,U,,Intermediate,1229.0,,,CHEMBL618441,1.0,,0.0,,,,,,4336.0,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive
,BAO_0000019,B,,,11938.0,H,Trypanosoma brucei,Expert,17588.0,,5691.0,CHEMBL618442,1.0,,8.0,,,,,,4337.0,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli
,BAO_0000019,B,,,11938.0,H,Trypanosoma brucei,Autocuration,17588.0,,5691.0,CHEMBL618443,1.0,,8.0,,,,,,4338.0,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition
,BAO_0000019,B,,,11938.0,H,Ovis aries,Expert,17588.0,,9940.0,CHEMBL619158,1.0,,8.0,,,,,,4339.0,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver
,BAO_0000019,B,,,11938.0,H,Ovis aries,Autocuration,17588.0,,9940.0,CHEMBL620974,1.0,,8.0,,,,,,4340.0,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition
,BAO_0000357,B,,,11938.0,H,,Autocuration,16485.0,,,CHEMBL620975,1.0,,8.0,,,,,,4341.0,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase
,BAO_0000019,F,,,22226.0,U,Homo sapiens,Intermediate,4337.0,,9606.0,CHEMBL620976,1.0,,0.0,,,,,,4342.0,Average inhibitory concentration against 60 human cell lines was reported
,BAO_0000019,F,,,22226.0,U,Homo sapiens,Expert,4112.0,,9606.0,CHEMBL620977,1.0,,0.0,,,,,,4343.0,Inhibition of proliferation in NCI panel of 60 human tumor cell lines
,BAO_0000219,F,,Panel NCI-60 (60 carcinoma cell lines),80315.0,N,Homo sapiens,Intermediate,16160.0,,9606.0,CHEMBL620978,1.0,,1.0,,,,,542.0,4344.0,Cancer specificity was measured from the +/- value under average log LC50 60-cell line
,BAO_0000219,F,,Panel NCI-60 (60 carcinoma cell lines),80315.0,N,Homo sapiens,Intermediate,16160.0,,9606.0,CHEMBL620979,1.0,,1.0,,,,,542.0,4345.0,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. 
,BAO_0000219,F,,Panel NCI-60 (60 carcinoma cell lines),80315.0,N,,Expert,17376.0,,,CHEMBL620980,1.0,,1.0,,,,,542.0,4346.0,In vitro mean growth inhibitory activity against 60-cell panel
,BAO_0000219,F,,Panel NCI-60 (60 carcinoma cell lines),80315.0,N,,Expert,17376.0,,,CHEMBL620981,1.0,,1.0,,,,,542.0,4347.0,In vitro mean growth lethal concentration against 60-cell panel
,BAO_0000219,F,,Panel NCI-60 (60 carcinoma cell lines),80315.0,N,,Expert,17376.0,,,CHEMBL620982,1.0,,1.0,,,,,542.0,4348.0,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel
,BAO_0000219,F,,Panel NCI-60 (60 carcinoma cell lines),80315.0,N,,Expert,17376.0,,,CHEMBL620983,1.0,,1.0,,,,,542.0,4349.0,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel
,BAO_0000019,F,,,104775.0,H,,Autocuration,3241.0,,,CHEMBL620984,1.0,,4.0,,,,,,4350.0,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM
,BAO_0000019,F,,,104775.0,H,,Autocuration,3241.0,,,CHEMBL620985,1.0,,4.0,,,,,,4351.0,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM
,BAO_0000357,B,,,275.0,H,,Expert,3725.0,,,CHEMBL620986,1.0,,8.0,,,,,,4352.0,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha
,BAO_0000218,F,,,50425.0,N,Plasmodium falciparum,Expert,10805.0,,5833.0,CHEMBL620987,1.0,,1.0,,,,,,4353.0,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase
,BAO_0000218,F,,,50425.0,N,Plasmodium falciparum,Expert,10805.0,,5833.0,CHEMBL620988,1.0,,1.0,,,,,,4354.0,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells
,BAO_0000218,F,,,50425.0,N,Plasmodium falciparum,Expert,10805.0,,5833.0,CHEMBL620989,1.0,,1.0,,,,,,4355.0,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.
,BAO_0000218,F,,,50425.0,N,Plasmodium falciparum,Expert,10805.0,,5833.0,CHEMBL620990,1.0,,1.0,,,,,,4356.0,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.
,BAO_0000218,F,,,50425.0,N,Plasmodium falciparum,Intermediate,10805.0,,5833.0,CHEMBL620991,1.0,,1.0,,,,,,4357.0,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.
,BAO_0000218,F,,6C3HED,80628.0,N,Mus musculus,Intermediate,10144.0,,10090.0,CHEMBL620992,1.0,,1.0,,,,,850.0,4358.0,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice
,BAO_0000218,F,,6C3HED,80628.0,N,Mus musculus,Intermediate,10144.0,,10090.0,CHEMBL620993,1.0,,1.0,,,,,850.0,4359.0,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice
,BAO_0000218,F,,6C3HED,80628.0,N,Mus musculus,Intermediate,10144.0,,10090.0,CHEMBL620994,1.0,,1.0,,,,,850.0,4360.0,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice
,BAO_0000218,F,,6C3HED,80628.0,N,Mus musculus,Intermediate,10144.0,,10090.0,CHEMBL620995,1.0,,1.0,,,,,850.0,4361.0,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice
,BAO_0000218,F,,6C3HED,80628.0,N,Mus musculus,Intermediate,10144.0,,10090.0,CHEMBL620996,1.0,,1.0,,,,,850.0,4362.0,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice
,BAO_0000218,F,,6C3HED,80628.0,N,Mus musculus,Intermediate,10144.0,,10090.0,CHEMBL875581,1.0,,1.0,,,,,850.0,4363.0,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice
,BAO_0000218,F,In vivo,,22224.0,U,Mus musculus,Autocuration,10685.0,,10090.0,CHEMBL620997,1.0,,0.0,,,,,,4364.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg
,BAO_0000218,F,In vivo,,22224.0,U,Mus musculus,Autocuration,10685.0,,10090.0,CHEMBL620998,1.0,,0.0,,,,,,4365.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg
,BAO_0000218,F,In vivo,,22224.0,U,Mus musculus,Autocuration,10685.0,,10090.0,CHEMBL620999,1.0,,0.0,,,,,,4366.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days)
,BAO_0000218,F,In vivo,,22224.0,U,Mus musculus,Autocuration,10685.0,,10090.0,CHEMBL621000,1.0,,0.0,,,,,,4367.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg
,BAO_0000218,F,In vivo,,22224.0,U,Mus musculus,Autocuration,10685.0,,10090.0,CHEMBL621001,1.0,,0.0,,,,,,4368.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg
,BAO_0000218,F,In vivo,,22224.0,U,Mus musculus,Autocuration,10685.0,,10090.0,CHEMBL621002,1.0,,0.0,,,,,,4369.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg
,BAO_0000218,F,In vivo,,22224.0,U,Mus musculus,Autocuration,10685.0,,10090.0,CHEMBL621003,1.0,,0.0,,,,,,4370.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg
,BAO_0000218,F,In vivo,,22224.0,U,Mus musculus,Autocuration,10685.0,,10090.0,CHEMBL621004,1.0,,0.0,,,,,,4371.0,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg"
,BAO_0000218,F,In vivo,,22224.0,U,Mus musculus,Autocuration,10685.0,,10090.0,CHEMBL621005,1.0,,0.0,,,,,,4372.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days)
,BAO_0000218,F,In vivo,,22224.0,U,Mus musculus,Autocuration,10685.0,,10090.0,CHEMBL621006,1.0,,0.0,,,,,,4373.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days)
,BAO_0000218,F,In vivo,,22224.0,U,Mus musculus,Autocuration,10685.0,,10090.0,CHEMBL621007,1.0,,0.0,,,,,,4374.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg
,BAO_0000218,F,,,22224.0,U,Mus musculus,Autocuration,10144.0,,10090.0,CHEMBL621008,1.0,,0.0,,,,,,4375.0,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice
,BAO_0000218,F,,,22224.0,U,Mus musculus,Autocuration,10144.0,,10090.0,CHEMBL621009,1.0,,0.0,,,,,,4376.0,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice
,BAO_0000218,F,,,22224.0,U,Mus musculus,Autocuration,10144.0,,10090.0,CHEMBL857705,1.0,,0.0,,,,,,4377.0,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice
,BAO_0000218,F,,,22224.0,U,Mus musculus,Autocuration,10144.0,,10090.0,CHEMBL619828,1.0,,0.0,,,,,,4378.0,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice
,BAO_0000218,F,,,22224.0,U,Mus musculus,Autocuration,10685.0,,10090.0,CHEMBL619829,1.0,,0.0,,,,,,4379.0,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally
,BAO_0000218,F,,,22224.0,U,Mus musculus,Autocuration,10685.0,,10090.0,CHEMBL619830,1.0,,0.0,,,,,,4380.0,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally
,BAO_0000218,F,,,22224.0,U,Mus musculus,Autocuration,10685.0,,10090.0,CHEMBL619831,1.0,,0.0,,,,,,4381.0,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally
,BAO_0000218,F,,,22224.0,U,Mus musculus,Autocuration,10685.0,,10090.0,CHEMBL619832,1.0,,0.0,,,,,,4382.0,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally
,BAO_0000218,A,,,22224.0,U,Mus musculus,Autocuration,10685.0,,10090.0,CHEMBL619833,1.0,,0.0,,,,,,4383.0,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10
,BAO_0000218,A,,,22224.0,U,Mus musculus,Autocuration,10685.0,,10090.0,CHEMBL619834,1.0,,0.0,,,,,,4384.0,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10
,BAO_0000218,A,,,22224.0,U,Mus musculus,Autocuration,10685.0,,10090.0,CHEMBL619835,1.0,,0.0,,,,,,4385.0,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10
,BAO_0000218,A,,,22224.0,U,Mus musculus,Autocuration,10685.0,,10090.0,CHEMBL619836,1.0,,0.0,,,,,,4386.0,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10
,BAO_0000218,F,,6C3HED,80628.0,N,Mus musculus,Intermediate,8831.0,,10090.0,CHEMBL619837,1.0,,1.0,,,,,850.0,4387.0,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg"
,BAO_0000218,F,In vivo,,22224.0,U,,Autocuration,11704.0,,,CHEMBL619838,1.0,,0.0,,,,,,4388.0,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,11704.0,,10090.0,CHEMBL619839,1.0,,1.0,,,,,,4389.0,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10
,BAO_0000218,F,In vivo,6C3HED,80628.0,N,Mus musculus,Intermediate,10685.0,,10090.0,CHEMBL619840,1.0,,1.0,,,,,850.0,4390.0,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line
,BAO_0000218,F,In vivo,6C3HED,80628.0,N,Mus musculus,Intermediate,10685.0,,10090.0,CHEMBL619841,1.0,,1.0,,,,,850.0,4391.0,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition
,BAO_0000218,F,,6C3HED,80628.0,N,Mus musculus,Expert,11368.0,,10090.0,CHEMBL857704,1.0,,1.0,,,,,850.0,4392.0,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8)
,BAO_0000218,F,,6C3HED,80628.0,N,Mus musculus,Intermediate,11368.0,,10090.0,CHEMBL619842,1.0,,1.0,,,,,850.0,4393.0,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8)
,BAO_0000218,F,,6C3HED,80628.0,N,Mus musculus,Expert,11368.0,,10090.0,CHEMBL619843,1.0,,1.0,,,,,850.0,4394.0,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8)
,BAO_0000019,B,,,22226.0,U,Staphylococcus aureus,Autocuration,17763.0,,1280.0,CHEMBL619844,1.0,,0.0,,,,,,4395.0,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase"
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL857855,1.0,,0.0,Liver,,,2107.0,,4396.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL619845,1.0,,0.0,Liver,,,2107.0,,4397.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL619846,1.0,,0.0,Liver,,,2107.0,,4398.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL619847,1.0,,0.0,Liver,,,2107.0,,4399.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL619848,1.0,,0.0,Liver,,,2107.0,,4400.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL620893,1.0,,0.0,Liver,,,2107.0,,4401.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL620894,1.0,,0.0,Liver,,,2107.0,,4402.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL620895,1.0,,0.0,Liver,,,2107.0,,4403.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL620896,1.0,,0.0,Liver,,,2107.0,,4404.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL620897,1.0,,0.0,Liver,,,2107.0,,4405.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL620898,1.0,,0.0,Liver,,,2107.0,,4406.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM
,BAO_0000251,B,,,22226.0,U,Rattus norvegicus,Autocuration,7411.0,Microsomes,10116.0,CHEMBL620899,1.0,,0.0,Liver,,,2107.0,,4407.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,347.0,,9527.0,CHEMBL620900,1.0,,0.0,Plasma,,,1969.0,,4408.0,The apparent total plasma clearance in monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,3341.0,,9527.0,CHEMBL620901,1.0,,0.0,,,,,,4409.0,Compound was evaluated for Hepatic clearance in monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,17853.0,,9527.0,CHEMBL620902,1.0,,0.0,,,,,,4410.0,Lower clearance in monkey (i.v.) at 0.5 mpk
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,4514.0,,9527.0,CHEMBL620903,1.0,,0.0,,,,,,4411.0,Plasma clearance in rhesus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,6062.0,,9527.0,CHEMBL620904,1.0,,0.0,,,,,,4412.0,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,6821.0,,9527.0,CHEMBL620905,1.0,,0.0,,,,,,4413.0,Plasma clearance of compound was determined in monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,6057.0,,9527.0,CHEMBL620906,1.0,,0.0,,,,,,4414.0,Plasma clearance was calculated in rhesus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5145.0,,9527.0,CHEMBL875420,1.0,,0.0,,,,,,4415.0,Plasma clearance in rhesus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,6641.0,,9527.0,CHEMBL620907,1.0,,0.0,,,,,,4416.0,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally)
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5472.0,,9527.0,CHEMBL620908,1.0,,0.0,,,,,,4417.0,Plasma clearance was evaluated in rhesus
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,4257.0,,9527.0,CHEMBL620909,1.0,,0.0,,,,,,4418.0,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5546.0,,9527.0,CHEMBL620910,1.0,,0.0,,,,,,4419.0,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5334.0,,9527.0,CHEMBL620911,1.0,,0.0,,,,,,4420.0,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male)
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5334.0,,9527.0,CHEMBL620912,1.0,,0.0,,,,,,4421.0,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male)
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,17509.0,,9527.0,CHEMBL620913,1.0,,0.0,,,,,,4422.0,Cmax 24 hr after 2 mg/kg oral administration in monkeys
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,6535.0,,9527.0,CHEMBL620914,1.0,,0.0,,,,,,4423.0,Cmax in monkey after administration of 1 mg/kg iv
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5668.0,,9527.0,CHEMBL620915,1.0,,0.0,,,,,,4424.0,Cmax was determine after peroral administration at 10 mpk in Rhesus
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5922.0,,9527.0,CHEMBL620916,1.0,,0.0,,,,,,4425.0,Cmax in cynomolgus monkey by iv administration
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5922.0,,9527.0,CHEMBL620917,1.0,,0.0,,,,,,4426.0,Cmax in cynomolgus monkey by po administration
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,6078.0,,9527.0,CHEMBL620918,1.0,,0.0,,,,,,4427.0,Cmax value evaluated in monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,2661.0,,9527.0,CHEMBL620919,1.0,,0.0,,,,,,4428.0,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,3249.0,,9527.0,CHEMBL620920,1.0,,0.0,Plasma,,,1969.0,,4429.0,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,3249.0,,9527.0,CHEMBL620921,1.0,,0.0,Plasma,,,1969.0,,4430.0,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5553.0,,9527.0,CHEMBL620922,1.0,,0.0,Plasma,,,1969.0,,4431.0,Maximal plasma concentration in squirrel monkeys
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,1916.0,,9527.0,CHEMBL620923,1.0,,0.0,,,,,,4432.0,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,6227.0,,9527.0,CHEMBL620924,1.0,,0.0,Plasma,,,1969.0,,4433.0,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,4809.0,,9527.0,CHEMBL620925,1.0,,0.0,,,,,,4434.0,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg)
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5355.0,,9527.0,CHEMBL620926,1.0,,0.0,,,,,,4435.0,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5355.0,,9527.0,CHEMBL620927,1.0,,0.0,,,,,,4436.0,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5355.0,,9527.0,CHEMBL620928,1.0,,0.0,,,,,,4437.0,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5355.0,,9527.0,CHEMBL620929,1.0,,0.0,,,,,,4438.0,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,6221.0,,9527.0,CHEMBL620930,1.0,,0.0,Plasma,,,1969.0,,4439.0,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,167.0,,9527.0,CHEMBL620931,1.0,,0.0,,,,,,4440.0,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,167.0,,9527.0,CHEMBL620932,1.0,,0.0,,,,,,4441.0,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours
,BAO_0000218,A,In vivo,,22224.0,U,monkey,Autocuration,4257.0,,9443.0,CHEMBL620933,1.0,,0.0,,,,,,4442.0,Absolute bioavailability was evaluated in monkey
,BAO_0000218,A,In vivo,,22224.0,U,monkey,Autocuration,6221.0,,9443.0,CHEMBL620934,1.0,,0.0,,,,,,4443.0,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined
,BAO_0000218,A,In vivo,,22224.0,U,monkey,Autocuration,17667.0,,9443.0,CHEMBL620935,1.0,,0.0,,,,,,4444.0,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration
,BAO_0000218,A,In vivo,,22224.0,U,Macaca mulatta,Autocuration,17267.0,,9544.0,CHEMBL620936,1.0,,0.0,,,,,,4445.0,Bioavailability of compound was determined in rhesus monkey
,BAO_0000218,A,In vivo,,22224.0,U,marmosets,Autocuration,4256.0,,38020.0,CHEMBL620937,1.0,,0.0,,,,,,4446.0,Bioavailability determined after oral administration in marmoset
,BAO_0000218,A,In vivo,,22224.0,U,Macaca fascicularis,Autocuration,4256.0,,9541.0,CHEMBL620938,1.0,,0.0,,,,,,4447.0,Oral bioavailability in cynomolgus monkey
,BAO_0000218,A,In vivo,,22224.0,U,monkey,Autocuration,17853.0,,9443.0,CHEMBL620939,1.0,,0.0,,,,,,4448.0,Bioavailability in monkey (p.o.) at 2.0 mpk
,BAO_0000218,A,In vivo,,22224.0,U,monkey,Autocuration,16365.0,,9443.0,CHEMBL620940,1.0,,0.0,,,,,,4449.0,Bioavailability was evaluated after oral administration in monkey
,BAO_0000218,A,In vivo,,22224.0,U,Macaca fascicularis,Autocuration,1916.0,,9541.0,CHEMBL620941,1.0,,0.0,,,,,,4450.0,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration
,BAO_0000218,A,In vivo,,22224.0,U,Macaca mulatta,Autocuration,5334.0,,9544.0,CHEMBL620942,1.0,,0.0,,,,,,4451.0,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male)
,BAO_0000218,A,In vivo,,22224.0,U,Macaca mulatta,Autocuration,5334.0,,9544.0,CHEMBL620943,1.0,,0.0,,,,,,4452.0,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male)
,BAO_0000218,A,In vivo,,22224.0,U,monkey,Autocuration,17592.0,,9443.0,CHEMBL620944,1.0,,0.0,,,,,,4453.0,Bioavailability of the compound was determined in monkey
,BAO_0000218,A,In vivo,,22224.0,U,Saimiri sciureus,Autocuration,1399.0,,9521.0,CHEMBL620945,1.0,,0.0,,,,,,4454.0,Bioavailability in squirrel monkey (dose 5 mg/kg)
,BAO_0000218,A,In vivo,,22224.0,U,monkey,Autocuration,4809.0,,9443.0,CHEMBL620946,1.0,,0.0,,,,,,4455.0,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg)
,BAO_0000218,A,In vivo,,22224.0,U,monkey,Autocuration,3341.0,,9443.0,CHEMBL620947,1.0,,0.0,,,,,,4456.0,Oral bioavailability in monkey
,BAO_0000218,A,In vivo,,22224.0,U,Saimiri sciureus,Autocuration,64.0,,9521.0,CHEMBL620948,1.0,,0.0,,,,,,4457.0,Compound was tested for bioavailability in squirrel monkey
,BAO_0000218,A,In vivo,,22224.0,U,Macaca mulatta,Autocuration,5005.0,,9544.0,CHEMBL620949,1.0,,0.0,,,,,,4458.0,Oral bioavailability in Rhesus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Macaca mulatta,Autocuration,5005.0,,9544.0,CHEMBL620950,1.0,,0.0,,,,,,4459.0,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.)
,BAO_0000218,A,In vivo,,22224.0,U,Macaca fascicularis,Autocuration,5237.0,,9541.0,CHEMBL620951,1.0,,0.0,,,,,,4460.0,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable
,BAO_0000218,A,In vivo,,22224.0,U,Macaca fascicularis,Autocuration,5237.0,,9541.0,CHEMBL620952,1.0,,0.0,,,,,,4461.0,Oral bioavailability in cynomolgus monkeys was determined; Acceptable
,BAO_0000218,A,In vivo,,22224.0,U,monkey,Autocuration,5302.0,,9443.0,CHEMBL875421,1.0,,0.0,,,,,,4462.0,Oral bioavailability in monkey (dose 5 mg/kg)
,BAO_0000218,A,In vivo,,22224.0,U,monkey,Autocuration,17667.0,,9443.0,CHEMBL620953,1.0,,0.0,,,,,,4463.0,Oral bioavailability of compound at 5 mg/kg in monkey
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6161.0,,9615.0,CHEMBL873491,1.0,,1.0,,,,,,4464.0,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6161.0,,9615.0,CHEMBL620954,1.0,,1.0,,,,,,4465.0,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3854.0,,9615.0,CHEMBL620955,1.0,,1.0,Plasma,,,1969.0,,4466.0,Plasma half life determined
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,993.0,,9615.0,CHEMBL618097,1.0,,1.0,Plasma,,,1969.0,,4467.0,Plasma half life in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4514.0,,9615.0,CHEMBL618268,1.0,,1.0,Plasma,,,1969.0,,4468.0,Plasma half-life in Beagle dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5334.0,,9615.0,CHEMBL618269,1.0,,1.0,Plasma,,,1969.0,,4469.0,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5334.0,,9615.0,CHEMBL618270,1.0,,1.0,Plasma,,,1969.0,,4470.0,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1466.0,,9615.0,CHEMBL618271,1.0,,1.0,,,,,,4471.0,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1466.0,,9615.0,CHEMBL873493,1.0,,1.0,,,,,,4472.0,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5313.0,,9615.0,CHEMBL621031,1.0,,1.0,,,,,,4473.0,Tested for the half life period in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5313.0,,9615.0,CHEMBL621032,1.0,,1.0,,,,,,4474.0,Tested for the half life period in dog at dosage of 10 mpk
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3880.0,,9615.0,CHEMBL621033,1.0,,1.0,,,,,,4475.0,The compound was tested for half life in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3639.0,,9615.0,CHEMBL621034,1.0,,1.0,Plasma,,,1969.0,,4476.0,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma."
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3880.0,,9615.0,CHEMBL621035,1.0,,1.0,,,,,,4477.0,The half life was determined
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3918.0,,9615.0,CHEMBL621036,1.0,,1.0,Plasma,,,1969.0,,4478.0,The plasma half-life in dogs
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,16452.0,,9615.0,CHEMBL621037,1.0,,1.0,Plasma,,,1969.0,,4479.0,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,17796.0,,9615.0,CHEMBL619812,1.0,,1.0,,,,,,4480.0,Half life in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5983.0,,9615.0,CHEMBL619813,1.0,,1.0,,,,,,4481.0,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1466.0,,9615.0,CHEMBL873335,1.0,,1.0,,,,,,4482.0,tmax upon peroral administration of 10.0 mg/Kg dose in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16456.0,,9615.0,CHEMBL619814,1.0,,1.0,,,,,,4483.0,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg
,BAO_0000218,A,In vivo,,50506.0,N,Mustela putorius furo,Expert,6113.0,,9669.0,CHEMBL619815,1.0,,1.0,,,,,,4484.0,Cmax in ferrets after 30 mg/kg oral dose
,BAO_0000218,F,In vivo,,50506.0,N,Mustela putorius furo,Expert,6113.0,,9669.0,CHEMBL619816,1.0,,1.0,,,,,,4485.0,Emesis in ferrets at 30 mg/kg oral dose
,BAO_0000218,A,In vivo,,22224.0,U,Macaca fascicularis,Autocuration,17796.0,,9541.0,CHEMBL619817,1.0,,0.0,,,,,,4486.0,Bioavailability in cynomolgus monkey
,BAO_0000218,A,In vivo,,100710.0,N,Macaca fascicularis,Intermediate,17796.0,,9541.0,CHEMBL619818,1.0,,1.0,,,,,,4487.0,Volume of distribution in cynomolgus
,BAO_0000218,A,,,22224.0,U,Cavia porcellus,Autocuration,5308.0,,10141.0,CHEMBL619819,1.0,,0.0,Plasma,,,1969.0,,4488.0,AUC tested in guinea pig when 3 mg/kg dose was given perorally
,BAO_0000218,A,,,22224.0,U,Cavia porcellus,Autocuration,4877.0,,10141.0,CHEMBL619820,1.0,,0.0,,,,,,4489.0,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg
,BAO_0000218,A,,,22224.0,U,Cavia porcellus,Autocuration,4876.0,,10141.0,CHEMBL875419,1.0,,0.0,,,,,,4490.0,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg"
,BAO_0000218,A,In vivo,,22224.0,U,Cavia porcellus,Autocuration,4878.0,,10141.0,CHEMBL619821,1.0,,0.0,Plasma,,,1969.0,,4491.0,AUC in guinea pig after 3mg/kg oral dose
,BAO_0000218,A,In vivo,,22224.0,U,Cavia porcellus,Autocuration,5308.0,,10141.0,CHEMBL619822,1.0,,0.0,,,,,,4492.0,Bioavailability in guinea pig was tested
,BAO_0000218,A,In vivo,,22224.0,U,Cavia porcellus,Autocuration,4877.0,,10141.0,CHEMBL619823,1.0,,0.0,,,,,,4493.0,Tested for oral bioavailability in guinea pig at 5 mg/kg
,BAO_0000218,A,In vivo,,22224.0,U,Cavia porcellus,Autocuration,4876.0,,10141.0,CHEMBL619824,1.0,,0.0,,,,,,4494.0,Tested for the oral bioavailability of the compound
,BAO_0000218,A,In vivo,,22224.0,U,Cavia porcellus,Autocuration,4876.0,,10141.0,CHEMBL619825,1.0,,0.0,,,,,,4495.0,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported
,BAO_0000218,A,In vivo,,22224.0,U,Cavia porcellus,Autocuration,5308.0,,10141.0,CHEMBL619826,1.0,,0.0,,,,,,4496.0,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally
,BAO_0000218,A,In vivo,,22224.0,U,Cavia porcellus,Autocuration,4877.0,,10141.0,CHEMBL619827,1.0,,0.0,Lung,,,2048.0,,4497.0,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg
,BAO_0000218,A,In vivo,,22224.0,U,Cavia porcellus,Autocuration,4878.0,,10141.0,CHEMBL618167,1.0,,0.0,,,,,,4498.0,Cmax in guinea pig after 3mg/kg oral dose
,BAO_0000019,A,,,22224.0,U,Cavia porcellus,Autocuration,5689.0,,10141.0,CHEMBL618168,1.0,,0.0,Blood,,,178.0,,4499.0,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram
,BAO_0000019,A,,,22224.0,U,Cavia porcellus,Autocuration,5689.0,,10141.0,CHEMBL618169,1.0,,0.0,Brain,,,955.0,,4500.0,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram
,BAO_0000019,A,,,22224.0,U,Cavia porcellus,Autocuration,5689.0,,10141.0,CHEMBL618170,1.0,,0.0,,,,,,4501.0,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram
,BAO_0000019,A,,,22224.0,U,Cavia porcellus,Autocuration,5689.0,,10141.0,CHEMBL618171,1.0,,0.0,Intestine,,,160.0,,4502.0,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram
,BAO_0000019,A,,,22224.0,U,Cavia porcellus,Autocuration,5689.0,,10141.0,CHEMBL618172,1.0,,0.0,Kidney,,,2113.0,,4503.0,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram
,BAO_0000019,A,,,22224.0,U,Cavia porcellus,Autocuration,5689.0,,10141.0,CHEMBL618173,1.0,,0.0,Liver,,,2107.0,,4504.0,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram
,BAO_0000019,A,,,22224.0,U,Cavia porcellus,Autocuration,5689.0,,10141.0,CHEMBL618174,1.0,,0.0,,,,,,4505.0,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram
,BAO_0000019,A,,,22224.0,U,Cavia porcellus,Autocuration,5689.0,,10141.0,CHEMBL875408,1.0,,0.0,Spleen,,,2106.0,,4506.0,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram
,BAO_0000218,A,In vivo,,22224.0,U,Cavia porcellus,Autocuration,14465.0,,10141.0,CHEMBL839827,1.0,,0.0,,,,,,4507.0,Elimination T1/2 in Guinea pig (PO dose)
,BAO_0000019,A,,,22224.0,U,Cavia porcellus,Autocuration,5689.0,,10141.0,CHEMBL618175,1.0,,0.0,,,,,,4508.0,Partition coefficient was measured as -log (counts per min )
,BAO_0000218,A,In vivo,,22224.0,U,Cavia porcellus,Autocuration,611.0,,10141.0,CHEMBL618176,1.0,,0.0,,,,,,4509.0,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism
,BAO_0000218,A,In vivo,,22224.0,U,Cavia porcellus,Autocuration,611.0,,10141.0,CHEMBL618177,1.0,,0.0,,,,,,4510.0,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism
,BAO_0000218,A,In vivo,,22224.0,U,Cavia porcellus,Autocuration,14465.0,,10141.0,CHEMBL618178,1.0,,0.0,,,,,,4511.0,Elimination T1/2 in Guinea pig (PO dose)
,BAO_0000218,A,In vivo,,22224.0,U,Cavia porcellus,Autocuration,4876.0,,10141.0,CHEMBL618179,1.0,,0.0,,,,,,4512.0,"Tested for the half life period of the compound, intravenously"
,BAO_0000019,A,,,22224.0,U,Cavia porcellus,Autocuration,5689.0,,10141.0,CHEMBL873489,1.0,,0.0,,,,,,4513.0,Half-life was measured
,BAO_0000019,A,,,22224.0,U,Cavia porcellus,Autocuration,7515.0,,10141.0,CHEMBL618180,1.0,,0.0,,,,,,4514.0,The time required for onset of inotropy after addition of a single dose of delta F75
,BAO_0000218,A,In vivo,,22224.0,U,Cavia porcellus,Autocuration,17667.0,,10141.0,CHEMBL618181,1.0,,0.0,,,,,,4515.0,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration
,BAO_0000218,A,In vivo,,22224.0,U,Cavia porcellus,Autocuration,17667.0,,10141.0,CHEMBL618182,1.0,,0.0,,,,,,4516.0,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration
,BAO_0000218,A,In vivo,,22224.0,U,Cricetulus griseus,Autocuration,4727.0,,10029.0,CHEMBL618183,1.0,,0.0,,,,,,4517.0,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL618184,1.0,,1.0,,,,,,4518.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL618185,1.0,,1.0,,,,,,4519.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL618186,1.0,,1.0,,,,,,4520.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL618187,1.0,,1.0,,,,,,4521.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL618188,1.0,,1.0,,,,,,4522.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL875409,1.0,,1.0,,,,,,4523.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL618189,1.0,,1.0,,,,,,4524.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618190,1.0,,1.0,Blood,,,178.0,,4525.0,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618191,1.0,,1.0,Blood,,,178.0,,4526.0,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618192,1.0,,1.0,Blood,,,178.0,,4527.0,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618193,1.0,,1.0,Bone,,,10000001.0,,4528.0,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618194,1.0,,1.0,Bone,,,10000001.0,,4529.0,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618195,1.0,,1.0,Bone,,,10000001.0,,4530.0,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618196,1.0,,1.0,Brain,,,955.0,,4531.0,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618197,1.0,,1.0,Brain,,,955.0,,4532.0,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618198,1.0,,1.0,Brain,,,955.0,,4533.0,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618199,1.0,,1.0,Heart,,,948.0,,4534.0,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618200,1.0,,1.0,Heart,,,948.0,,4535.0,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618201,1.0,,1.0,Heart,,,948.0,,4536.0,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618202,1.0,,1.0,Intestine,,,160.0,,4537.0,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618203,1.0,,1.0,Intestine,,,160.0,,4538.0,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618204,1.0,,1.0,Intestine,,,160.0,,4539.0,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618205,1.0,,1.0,Kidney,,,2113.0,,4540.0,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618206,1.0,,1.0,Kidney,,,2113.0,,4541.0,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618207,1.0,,1.0,Kidney,,,2113.0,,4542.0,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618208,1.0,,1.0,Liver,,,2107.0,,4543.0,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618932,1.0,,1.0,Liver,,,2107.0,,4544.0,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618933,1.0,,1.0,Liver,,,2107.0,,4545.0,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618934,1.0,,1.0,Lung,,,2048.0,,4546.0,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618935,1.0,,1.0,Lung,,,2048.0,,4547.0,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618936,1.0,,1.0,Lung,,,2048.0,,4548.0,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618937,1.0,,1.0,Muscle tissue,,,2385.0,,4549.0,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL618938,1.0,,1.0,Muscle tissue,,,2385.0,,4550.0,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL619104,1.0,,1.0,Muscle tissue,,,2385.0,,4551.0,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL619105,1.0,,1.0,Spleen,,,2106.0,,4552.0,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL619106,1.0,,1.0,Spleen,,,2106.0,,4553.0,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL619107,1.0,,1.0,Spleen,,,2106.0,,4554.0,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL875410,1.0,,1.0,Stomach,,,945.0,,4555.0,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL619108,1.0,,1.0,Stomach,,,945.0,,4556.0,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3655.0,,10090.0,CHEMBL619109,1.0,,1.0,Stomach,,,945.0,,4557.0,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16597.0,,10090.0,CHEMBL619110,1.0,,1.0,,,,,,4558.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT
,BAO_0000218,F,In vivo,,50594.0,N,Mus musculus,Intermediate,16597.0,,10090.0,CHEMBL619111,1.0,,1.0,,,,,,4559.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16597.0,,10090.0,CHEMBL619112,1.0,,1.0,,,,,,4560.0,MRT value at a dose of 10 mg/kg intravenous administration in mice.
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16597.0,,10090.0,CHEMBL619113,1.0,,1.0,,,,,,4561.0,MRT value at a dose of 10 mg/kg peroral administration in mice.
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL619114,1.0,,1.0,,,,,,4562.0,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg
,BAO_0000218,F,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL619115,1.0,,1.0,,,,,,4563.0,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,3830.0,,9606.0,CHEMBL619116,1.0,,1.0,,,,,478.0,4564.0,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,3829.0,,9606.0,CHEMBL619117,1.0,,1.0,,,,,478.0,4565.0,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,2040.0,,9606.0,CHEMBL619118,1.0,,1.0,,,,,478.0,4566.0,Compound was evaluated for cytotoxicity against A2780 cell lines.
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15684.0,,9606.0,CHEMBL619119,1.0,,1.0,,,,,478.0,4567.0,Potentiation of growth inhibition of A2780 by compound alone in experiment 1
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15684.0,,9606.0,CHEMBL619120,1.0,,1.0,,,,,478.0,4568.0,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15684.0,,9606.0,CHEMBL619121,1.0,,1.0,,,,,478.0,4569.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15684.0,,9606.0,CHEMBL619122,1.0,,1.0,,,,,478.0,4570.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15684.0,,9606.0,CHEMBL619123,1.0,,1.0,,,,,478.0,4571.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15684.0,,9606.0,CHEMBL619124,1.0,,1.0,,,,,478.0,4572.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,2859.0,,9606.0,CHEMBL619125,1.0,,1.0,,,,,478.0,4573.0,Compound was evaluated for cytotoxicity against A2780 cell line
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,5618.0,,9606.0,CHEMBL875411,1.0,,1.0,,,,,478.0,4574.0,In vitro inhibitory activity against human tumor cell line A2780
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15684.0,,9606.0,CHEMBL619126,1.0,,1.0,,,,,478.0,4575.0,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15684.0,,9606.0,CHEMBL619127,1.0,,1.0,,,,,478.0,4576.0,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15684.0,,9606.0,CHEMBL619128,1.0,,1.0,,,,,478.0,4577.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15684.0,,9606.0,CHEMBL619129,1.0,,1.0,,,,,478.0,4578.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,2113.0,,9606.0,CHEMBL619130,1.0,,1.0,,,,,478.0,4579.0,The compound was tested for cytotoxic potency against A2780 human tumor cell lines
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,2113.0,,9606.0,CHEMBL619131,1.0,,1.0,,,,,478.0,4580.0,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16745.0,,9606.0,CHEMBL619132,1.0,,1.0,,,,,478.0,4581.0,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.
,BAO_0000218,F,,A2780,81034.0,N,Homo sapiens,Expert,16597.0,,9606.0,CHEMBL619133,1.0,,1.0,,,,,478.0,4582.0,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15684.0,,9606.0,CHEMBL619134,1.0,,1.0,,,,,478.0,4583.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15684.0,,9606.0,CHEMBL619135,1.0,,1.0,,,,,478.0,4584.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,2040.0,,9606.0,CHEMBL619136,1.0,,1.0,,,,,478.0,4585.0,Compound was evaluated for cytotoxicity against A2780 cis cell lines.
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,2040.0,,9606.0,CHEMBL619137,1.0,,1.0,,,,,478.0,4586.0,Relative resistance factor in A2780 cisplatin-resistant line
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16165.0,,9606.0,CHEMBL883713,1.0,,1.0,,,,,478.0,4587.0,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16165.0,,9606.0,CHEMBL875412,1.0,,1.0,,,,,478.0,4588.0,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.
,BAO_0000218,F,,A2780,81034.0,N,Homo sapiens,Expert,16597.0,,9606.0,CHEMBL619138,1.0,,1.0,,,,,478.0,4589.0,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7
,BAO_0000218,F,,A2780,81034.0,N,Homo sapiens,Expert,16597.0,,9606.0,CHEMBL619262,1.0,,1.0,,,,,478.0,4590.0,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,3992.0,,9606.0,CHEMBL619139,1.0,,1.0,,,,,478.0,4591.0,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,10553.0,,9606.0,CHEMBL619140,1.0,,1.0,,,,,478.0,4592.0,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15608.0,,9606.0,CHEMBL619141,1.0,,1.0,,,,,478.0,4593.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15608.0,,9606.0,CHEMBL619142,1.0,,1.0,,,,,478.0,4594.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15608.0,,9606.0,CHEMBL619143,1.0,,1.0,,,,,478.0,4595.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15608.0,,9606.0,CHEMBL619144,1.0,,1.0,,,,,478.0,4596.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15608.0,,9606.0,CHEMBL619145,1.0,,1.0,,,,,478.0,4597.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15608.0,,9606.0,CHEMBL619146,1.0,,1.0,,,,,478.0,4598.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15569.0,,9606.0,CHEMBL619147,1.0,,1.0,,,,,478.0,4599.0,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,17420.0,,9606.0,CHEMBL619148,1.0,,1.0,,,,,478.0,4600.0,Antiproliferative effect of compound on A2780/DX cell line
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,17420.0,,9606.0,CHEMBL619149,1.0,,1.0,,,,,478.0,4601.0,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15099.0,,9606.0,CHEMBL619150,1.0,,1.0,,,,,478.0,4602.0,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI)
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15099.0,,9606.0,CHEMBL619151,1.0,,1.0,,,,,478.0,4603.0,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI)
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,17672.0,,9606.0,CHEMBL883794,1.0,,1.0,,,,,478.0,4604.0,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,17672.0,,9606.0,CHEMBL619152,1.0,,1.0,,,,,478.0,4605.0,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,17270.0,,9606.0,CHEMBL619153,1.0,,1.0,,,,,478.0,4606.0,In vitro cytotoxicity against A2780ADR cell line
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,17270.0,,9606.0,CHEMBL619154,1.0,,1.0,,,,,478.0,4607.0,In vitro cytotoxicity against A2780CIS cell line
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,5574.0,,9606.0,CHEMBL619155,1.0,,1.0,,,,,478.0,4608.0,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,2113.0,,9606.0,CHEMBL619156,1.0,,1.0,,,,,478.0,4609.0,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16913.0,,9606.0,CHEMBL619157,1.0,,1.0,,,,,478.0,4610.0,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines"
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16913.0,,9606.0,CHEMBL619797,1.0,,1.0,,,,,478.0,4611.0,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines"
,BAO_0000218,A,In vivo,,22224.0,U,Macaca mulatta,Autocuration,17839.0,,9544.0,CHEMBL619798,1.0,,0.0,,,,,,4612.0,Oral bioavailability of compound in rhesus macaques
,BAO_0000218,A,In vivo,,22224.0,U,monkey,Autocuration,6821.0,,9443.0,CHEMBL619799,1.0,,0.0,,,,,,4613.0,Oral bioavailability in monkey
,BAO_0000218,A,In vivo,,22224.0,U,monkey,Autocuration,6078.0,,9443.0,CHEMBL619800,1.0,,0.0,,,,,,4614.0,Oral bioavailability evaluated in monkey
,BAO_0000218,A,In vivo,,22224.0,U,monkey,Autocuration,6535.0,,9443.0,CHEMBL619801,1.0,,0.0,,,,,,4615.0,Oral bioavailability in monkey (dose 1 mg/kg p.o.)
,BAO_0000218,A,In vivo,,22224.0,U,Macaca mulatta,Autocuration,4449.0,,9544.0,CHEMBL619802,1.0,,0.0,,,,,,4616.0,Oral bioavailability in Rhesus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Macaca mulatta,Autocuration,6057.0,,9544.0,CHEMBL619803,1.0,,0.0,,,,,,4617.0,Oral bioavailability was calculated in rhesus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Macaca fascicularis,Autocuration,5922.0,,9541.0,CHEMBL619965,1.0,,0.0,,,,,,4618.0,Oral bioavailability in cynomolgus monkey
,BAO_0000218,A,In vivo,,22224.0,U,monkey,Autocuration,5940.0,,9443.0,CHEMBL619966,1.0,,0.0,,,,,,4619.0,Oral bioavailability in monkey
,BAO_0000218,A,In vivo,,22224.0,U,monkey,Autocuration,6265.0,,9443.0,CHEMBL619967,1.0,,0.0,,,,,,4620.0,Oral bioavailability in monkey
,BAO_0000218,A,In vivo,,22224.0,U,monkey,Autocuration,6265.0,,9443.0,CHEMBL620073,1.0,,0.0,,,,,,4621.0,Oral bioavailability in monkey (dose 1 mg/kg)
,BAO_0000218,A,In vivo,,22224.0,U,monkey,Autocuration,6265.0,,9443.0,CHEMBL620074,1.0,,0.0,,,,,,4622.0,Oral bioavailability in monkey (dose 5 mg/kg)
,BAO_0000218,A,In vivo,,22224.0,U,monkey,Autocuration,5940.0,,9443.0,CHEMBL620075,1.0,,0.0,,,,,,4623.0,Oral bioavailability in monkey
,BAO_0000218,A,In vivo,,22224.0,U,monkey,Autocuration,5940.0,,9443.0,CHEMBL620076,1.0,,0.0,,,,,,4624.0,Oral bioavailability in monkey
,BAO_0000218,A,In vivo,,22224.0,U,Macaca mulatta,Autocuration,4514.0,,9544.0,CHEMBL620077,1.0,,0.0,,,,,,4625.0,Oral bioavailability in rhesus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Macaca mulatta,Autocuration,5546.0,,9544.0,CHEMBL620078,1.0,,0.0,,,,,,4626.0,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration
,BAO_0000218,A,In vivo,,22224.0,U,Saimiri sciureus,Autocuration,5553.0,,9521.0,CHEMBL620079,1.0,,0.0,,,,,,4627.0,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg
,BAO_0000218,A,In vivo,,22224.0,U,monkey,Autocuration,6641.0,,9443.0,CHEMBL620080,1.0,,0.0,,,,,,4628.0,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally)
,BAO_0000218,A,In vivo,,22224.0,U,Macaca mulatta,Autocuration,5472.0,,9544.0,CHEMBL620081,1.0,,0.0,,,,,,4629.0,Oral bioavailability in Rhesus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Macaca mulatta,Autocuration,5668.0,,9544.0,CHEMBL620082,1.0,,0.0,,,,,,4630.0,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.)
,BAO_0000218,A,In vivo,,22224.0,U,monkey,Autocuration,5711.0,,9443.0,CHEMBL620083,1.0,,0.0,,,,,,4631.0,Oral bioavailability in monkey at 10 mg/kg of the compound
,BAO_0000218,A,In vivo,,22224.0,U,Macaca mulatta,Autocuration,5145.0,,9544.0,CHEMBL620084,1.0,,0.0,,,,,,4632.0,Bioavailability in Rhesus monkey
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,3443.0,,9527.0,CHEMBL620085,1.0,,0.0,,,,,,4633.0,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,3443.0,,9527.0,CHEMBL874595,1.0,,0.0,,,,,,4634.0,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,3249.0,,9527.0,CHEMBL873352,1.0,,0.0,,,,,,4635.0,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,3249.0,,9527.0,CHEMBL620086,1.0,,0.0,,,,,,4636.0,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5355.0,,9527.0,CHEMBL620087,1.0,,0.0,,,,,,4637.0,Mean residence time was determined after intravenous administration in cynomolgus monkeys
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5355.0,,9527.0,CHEMBL620088,1.0,,0.0,,,,,,4638.0,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5355.0,,9527.0,CHEMBL620089,1.0,,0.0,,,,,,4639.0,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,4809.0,,9527.0,CHEMBL620090,1.0,,0.0,,,,,,4640.0,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg)
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,4809.0,,9527.0,CHEMBL620091,1.0,,0.0,,,,,,4641.0,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg)
,BAO_0000251,A,,,22224.0,U,Cercopithecidae,Autocuration,14294.0,Microsomes,9527.0,CHEMBL620092,1.0,,0.0,,,,,,4642.0,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak)
,BAO_0000251,A,,,22224.0,U,Cercopithecidae,Autocuration,14294.0,Microsomes,9527.0,CHEMBL620093,1.0,,0.0,,,,,,4643.0,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak)
,BAO_0000251,A,,,22224.0,U,Cercopithecidae,Autocuration,14294.0,Microsomes,9527.0,CHEMBL620094,1.0,,0.0,,,,,,4644.0,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak)
,BAO_0000251,A,,,22224.0,U,Cercopithecidae,Autocuration,14294.0,Microsomes,9527.0,CHEMBL620095,1.0,,0.0,,,,,,4645.0,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak)
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,3443.0,,9527.0,CHEMBL620096,1.0,,0.0,,,,,,4646.0,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,3443.0,,9527.0,CHEMBL620097,1.0,,0.0,,,,,,4647.0,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,11271.0,,9527.0,CHEMBL620098,1.0,,0.0,,,,,,4648.0,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,3443.0,,9527.0,CHEMBL620099,1.0,,0.0,,,,,,4649.0,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,3443.0,,9527.0,CHEMBL620100,1.0,,0.0,,,,,,4650.0,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,6821.0,,9527.0,CHEMBL620101,1.0,,0.0,,,,,,4651.0,Elimination Half-life of compound was determined in monkey
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,17267.0,,9527.0,CHEMBL620102,1.0,,0.0,,,,,,4652.0,Half life of compound was determined in rhesus monkey
,BAO_0000366,A,,,22224.0,U,Cercopithecidae,Autocuration,5819.0,,9527.0,CHEMBL620103,1.0,,0.0,Plasma,,,1969.0,,4653.0,Half life in monkey plasma
,BAO_0000366,A,,,22224.0,U,Cercopithecidae,Autocuration,5819.0,,9527.0,CHEMBL620104,1.0,,0.0,Plasma,,,1969.0,,4654.0,Half life in monkey plasma; Not detected
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,1916.0,,9527.0,CHEMBL874596,1.0,,0.0,,,,,,4655.0,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,17509.0,,9527.0,CHEMBL873490,1.0,,0.0,,,,,,4656.0,Half-life 24 hr after 2 mg/kg iv administration in monkeys
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,1399.0,,9527.0,CHEMBL620105,1.0,,0.0,,,,,,4657.0,Terminal half life of the compound.
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,1916.0,,9527.0,CHEMBL620780,1.0,,0.0,,,,,,4658.0,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,4809.0,,9527.0,CHEMBL620781,1.0,,0.0,,,,,,4659.0,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg)
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,5546.0,,9527.0,CHEMBL620956,1.0,,0.0,,,,,,4660.0,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,3443.0,,9527.0,CHEMBL620957,1.0,,0.0,Urine,,,1088.0,,4661.0,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,3443.0,,9527.0,CHEMBL620958,1.0,,0.0,Urine,,,1088.0,,4662.0,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,4257.0,,9527.0,CHEMBL620959,1.0,,0.0,,,,,,4663.0,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,6221.0,,9527.0,CHEMBL620960,1.0,,0.0,,,,,,4664.0,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5472.0,,9527.0,CHEMBL620961,1.0,,0.0,,,,,,4665.0,Volume of distribution was evaluated in rhesus
,BAO_0000218,A,In vivo,,22224.0,U,Cricetulus griseus,Autocuration,4727.0,,10029.0,CHEMBL620962,1.0,,0.0,,,,,,4666.0,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration
,BAO_0000218,A,In vivo,,22224.0,U,Cricetulus griseus,Autocuration,4727.0,,10029.0,CHEMBL620963,1.0,,0.0,,,,,,4667.0,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration
,BAO_0000218,A,In vivo,,22224.0,U,Cricetulus griseus,Autocuration,4727.0,,10029.0,CHEMBL620964,1.0,,0.0,,,,,,4668.0,Bioavailability in hamster was determined
,BAO_0000218,A,In vivo,,22224.0,U,Cricetulus griseus,Autocuration,4727.0,,10029.0,CHEMBL620965,1.0,,0.0,,,,,,4669.0,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration
,BAO_0000218,A,In vivo,,22224.0,U,Cricetulus griseus,Autocuration,4727.0,,10029.0,CHEMBL620966,1.0,,0.0,,,,,,4670.0,Bioavailability in hamster at a dose of 3 mg/kg by oral administration
,BAO_0000221,A,,,22224.0,U,Cricetulus griseus,Autocuration,4727.0,,10029.0,CHEMBL620967,1.0,,0.0,Blood,,,178.0,,4671.0,Half life of compound was determined in hamster blood
,BAO_0000019,A,,,22224.0,U,Sus scrofa,Autocuration,1452.0,,9823.0,CHEMBL620968,1.0,,0.0,,,,,,4672.0,Michaelis-Menten constant of the compound.
,BAO_0000019,A,,,22224.0,U,Sus scrofa,Autocuration,1452.0,,9823.0,CHEMBL874597,1.0,,0.0,,,,,,4673.0,Vmax value was measured at 0 uM concentration of silyl ether.
,BAO_0000019,A,,,22224.0,U,Sus scrofa,Autocuration,1452.0,,9823.0,CHEMBL620969,1.0,,0.0,,,,,,4674.0,Vmax value was measured at 10 uM concentration of silyl ether.
,BAO_0000019,A,,,22224.0,U,Sus scrofa,Autocuration,1452.0,,9823.0,CHEMBL620970,1.0,,0.0,,,,,,4675.0,Vmax value was measured at 5 uM concentration of silyl ether.
,BAO_0000357,B,,,235.0,D,Homo sapiens,Expert,11706.0,,9606.0,CHEMBL620971,1.0,,9.0,,,,,,4676.0,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant
,BAO_0000218,A,,,22224.0,U,Homo sapiens,Autocuration,1916.0,,9606.0,CHEMBL620972,1.0,,0.0,,,,,,4677.0,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,17791.0,,9606.0,CHEMBL620973,1.0,,0.0,,,,,,4678.0,Compound was evaluated for area under the curve expressed as (h*ug/ml)
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,7766.0,,9606.0,CHEMBL618243,1.0,,0.0,,,,,,4679.0,Active metabolite of ifosfamide determined in humans; A-Active
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6567.0,,9606.0,CHEMBL618244,1.0,,0.0,,,,,,4680.0,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6567.0,,9606.0,CHEMBL618245,1.0,,0.0,,,,,,4681.0,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6567.0,,9606.0,CHEMBL618246,1.0,,0.0,,,,,,4682.0,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6567.0,,9606.0,CHEMBL618247,1.0,,0.0,,,,,,4683.0,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace
,BAO_0000218,A,,,22224.0,U,Homo sapiens,Autocuration,17791.0,,9606.0,CHEMBL618248,1.0,,0.0,,,,,,4684.0,Compound was evaluated for oral bioavailability in human
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,7766.0,,9606.0,CHEMBL618249,1.0,,0.0,Urine,,,1088.0,,4685.0,Metabolite of ifosfamide determined in urine; NF-Not found
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6852.0,,9606.0,CHEMBL618250,1.0,,0.0,,,,,,4686.0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B)
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6852.0,,9606.0,CHEMBL874598,1.0,,0.0,,,,,,4687.0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6852.0,,9606.0,CHEMBL618251,1.0,,0.0,,,,,,4688.0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6852.0,,9606.0,CHEMBL618252,1.0,,0.0,,,,,,4689.0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6852.0,,9606.0,CHEMBL618253,1.0,,0.0,,,,,,4690.0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6852.0,,9606.0,CHEMBL618254,1.0,,0.0,,,,,,4691.0,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C)
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6852.0,,9606.0,CHEMBL618255,1.0,,0.0,,,,,,4692.0,Percent of compound in healthy individuals (Group D)
,BAO_0000251,A,,,22224.0,U,Homo sapiens,Autocuration,4397.0,Microsomes,9606.0,CHEMBL618983,1.0,,0.0,Liver,,,2107.0,,4693.0,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,17409.0,,9606.0,CHEMBL618984,1.0,,0.0,,,,,,4694.0,Binding towards human plasma protein at 10 uM
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,17409.0,,9606.0,CHEMBL618985,1.0,,0.0,,,,,,4695.0,Binding towards human plasma protein at 100 uM
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,17176.0,,9606.0,CHEMBL618986,1.0,,0.0,,,,,,4696.0,Human plasma protein binding activity was determined
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,15444.0,,9606.0,CHEMBL618987,1.0,,0.0,,,,,,4697.0,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.)
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,17267.0,,9606.0,CHEMBL618988,1.0,,0.0,,,,,,4698.0,Percent binding of compound towards human plasma protein was determined
,BAO_0000251,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,5944.0,Microsomes,9606.0,CHEMBL618989,1.0,,0.0,Liver,,,2107.0,,4699.0,Plasma clearance in human liver microsomes
,BAO_0000251,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,5668.0,Microsomes,9606.0,CHEMBL618990,1.0,,0.0,Liver,,,2107.0,,4700.0,In vitro intrinsic clearance in human liver microsome
,BAO_0000251,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,5669.0,Microsomes,9606.0,CHEMBL618991,1.0,,0.0,Liver,,,2107.0,,4701.0,In vitro intrinsic clearance in human liver microsome
,BAO_0000251,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,5041.0,Microsomes,9606.0,CHEMBL876725,1.0,,0.0,,,,,,4702.0,In vitro microsome metabolism clearance in human was determined
,BAO_0000251,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,5041.0,Microsomes,9606.0,CHEMBL618992,1.0,,0.0,,,,,,4703.0,In vitro microsome metabolism clearance in human was determined; High
,BAO_0000251,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,5041.0,Microsomes,9606.0,CHEMBL618993,1.0,,0.0,,,,,,4704.0,In vitro microsome metabolism clearance in human was determined; ND denotes no data
,BAO_0000251,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,5676.0,Microsomes,9606.0,CHEMBL618994,1.0,,0.0,Liver,,,2107.0,,4705.0,Pharmacokinetic property (clearance) in human liver microsome
,BAO_0000251,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,5944.0,Microsomes,9606.0,CHEMBL618995,1.0,,0.0,Liver,,,2107.0,,4706.0,Plasma clearance in human liver microsomes
,BAO_0000251,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,17538.0,Microsomes,9606.0,CHEMBL618996,1.0,,0.0,Liver,,,2107.0,,4707.0,In vitro clearance in human liver microsomes
,BAO_0000251,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,6331.0,Microsomes,9606.0,CHEMBL618997,1.0,,0.0,Liver,,,2107.0,,4708.0,Intrinsic clearance in human liver microsomes was determined
,BAO_0000251,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,5948.0,Microsomes,9606.0,CHEMBL618998,1.0,,0.0,Liver,,,2107.0,,4709.0,Intrinsic clearance in human liver microsomes was determined
,BAO_0000218,A,In vivo,,22224.0,U,Homo sapiens,Autocuration,5965.0,,9606.0,CHEMBL618999,1.0,,0.0,,,,,,4710.0,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human
,BAO_0000218,A,In vivo,,22224.0,U,Homo sapiens,Autocuration,1916.0,,9606.0,CHEMBL620223,1.0,,0.0,,,,,,4711.0,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration
,BAO_0000218,A,,,22224.0,U,Homo sapiens,Autocuration,5965.0,,9606.0,CHEMBL620224,1.0,,0.0,,,,,,4712.0,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,1299.0,,9606.0,CHEMBL620225,1.0,,0.0,,,,,,4713.0,Stability in human plasma 2 hr after incubation expressed as percent concentration
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,1299.0,,9606.0,CHEMBL620226,1.0,,0.0,,,,,,4714.0,Stability in human plasma 4 hr after incubation expressed as percent concentration
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,7766.0,,9606.0,CHEMBL620227,1.0,,0.0,Urine,,,1088.0,,4715.0,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,7766.0,,9606.0,CHEMBL876726,1.0,,0.0,Urine,,,1088.0,,4716.0,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,7766.0,,9606.0,CHEMBL620228,1.0,,0.0,Urine,,,1088.0,,4717.0,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,7766.0,,9606.0,CHEMBL620229,1.0,,0.0,Urine,,,1088.0,,4718.0,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
,BAO_0000218,F,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL620230,1.0,,1.0,,,,,,4719.0,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg
,BAO_0000218,F,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL620231,1.0,,1.0,,,,,,4720.0,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg
,BAO_0000218,F,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL620232,1.0,,1.0,,,,,,4721.0,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg
,BAO_0000218,F,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL620233,1.0,,1.0,,,,,,4722.0,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,14294.0,,10090.0,CHEMBL620234,1.0,,1.0,,,,,,4723.0,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak)
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,14294.0,,10090.0,CHEMBL620235,1.0,,1.0,,,,,,4724.0,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak)
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,14294.0,,10090.0,CHEMBL620236,1.0,,1.0,,,,,,4725.0,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak)
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,6251.0,,10090.0,CHEMBL620237,1.0,,1.0,Liver,,,2107.0,,4726.0,In vitro metabolic potential in mouse liver microsomes
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17582.0,,10090.0,CHEMBL620238,1.0,,1.0,,,,,,4727.0,Ability of compound to bind to plasma protein was evaluated in HSA cells
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17811.0,,10090.0,CHEMBL620239,1.0,,1.0,Adrenal gland,,,2369.0,,4728.0,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled)
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17811.0,,10090.0,CHEMBL620240,1.0,,1.0,Brain,,,955.0,,4729.0,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17811.0,,10090.0,CHEMBL620241,1.0,,1.0,Brain,,,955.0,,4730.0,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17811.0,,10090.0,CHEMBL876727,1.0,,1.0,,,,,,4731.0,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled)
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17811.0,,10090.0,CHEMBL620242,1.0,,1.0,Kidney,,,2113.0,,4732.0,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled)
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17811.0,,10090.0,CHEMBL620243,1.0,,1.0,,,,,,4733.0,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled)
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,5288.0,,10090.0,CHEMBL620244,1.0,,1.0,,,,,,4734.0,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,2717.0,,10090.0,CHEMBL620245,1.0,,1.0,Serum,,,1977.0,,4735.0,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,2717.0,,10090.0,CHEMBL620246,1.0,,1.0,Serum,,,1977.0,,4736.0,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,2717.0,,10090.0,CHEMBL620247,1.0,,1.0,Serum,,,1977.0,,4737.0,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17753.0,,10090.0,CHEMBL620248,1.0,,1.0,Plasma,,,1969.0,,4738.0,Half life of compound was determined in plasma of mice at 24 mg/Kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17753.0,,10090.0,CHEMBL873497,1.0,,1.0,Plasma,,,1969.0,,4739.0,Half life of compound was determined in plasma of mice at 40 mg/Kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17753.0,,10090.0,CHEMBL620249,1.0,,1.0,Plasma,,,1969.0,,4740.0,Half life of compound was determined in plasma of mice at 5 mg/Kg
,BAO_0000218,F,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL620250,1.0,,1.0,,,,,,4741.0,Half life after intraperitoneal administration in mice at 18 uM/kg
,BAO_0000218,F,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL620251,1.0,,1.0,,,,,,4742.0,Half life after intraperitoneal administration in mice at 23 uM/kg
,BAO_0000218,F,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL620252,1.0,,1.0,,,,,,4743.0,Half life after intraperitoneal administration in mice at 25 uM/kg
,BAO_0000218,F,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL620253,1.0,,1.0,,,,,,4744.0,Half life after intraperitoneal administration in mice at 26 uM/kg
,BAO_0000218,F,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL620254,1.0,,1.0,,,,,,4745.0,Half life after intravenous administration in mice at 23 uM/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL620255,1.0,,1.0,,,,,,4746.0,Half life after intravenous administration in mice at 24 uM/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16597.0,,10090.0,CHEMBL620256,1.0,,1.0,,,,,,4747.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,2675.0,,10090.0,CHEMBL876728,1.0,,1.0,,,,,,4748.0,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,2675.0,,10090.0,CHEMBL620257,1.0,,1.0,,,,,,4749.0,Maximum time required to reach Cp max was evaluated in mice after oral administration
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16597.0,,10090.0,CHEMBL620258,1.0,,1.0,,,,,,4750.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2)
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,4890.0,,10090.0,CHEMBL620259,1.0,,1.0,,,,,,4751.0,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period"
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,429.0,,10090.0,CHEMBL620260,1.0,,1.0,,,,,,4752.0,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17837.0,,10090.0,CHEMBL620261,1.0,,1.0,Blood,,,178.0,,4753.0,Half life of compound in mouse blood following i.v. administration of 10 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16597.0,,10090.0,CHEMBL620262,1.0,,1.0,,,,,,4754.0,Half life at a dose of 10 mg/kg intravenous administration in mice.
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16597.0,,10090.0,CHEMBL620263,1.0,,1.0,,,,,,4755.0,Half life at a dose of 10 mg/kg peroral administration in mice.
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,6619.0,,10090.0,CHEMBL620264,1.0,,1.0,,,,,,4756.0,Half life in ob/ob mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,4066.0,,10090.0,CHEMBL620265,1.0,,1.0,,,,,,4757.0,Half-life at a single subcutaneous administration of 40 mg/kg in mice
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,4239.0,,10090.0,CHEMBL620266,1.0,,1.0,,,,,,4758.0,Half-life was measured in mouse
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5969.0,,10090.0,CHEMBL620267,1.0,,1.0,,,,,,4759.0,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,8999.0,,10090.0,CHEMBL619364,1.0,,1.0,,,,,,4760.0,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,8999.0,,10090.0,CHEMBL619365,1.0,,1.0,,,,,,4761.0,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17641.0,,10090.0,CHEMBL619366,1.0,,1.0,Brain,,,955.0,,4762.0,T2 in brain of mice at the oral dose of 50 mg/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17641.0,,10090.0,CHEMBL619367,1.0,,1.0,Kidney,,,2113.0,,4763.0,T2 in kidney of mice at the oral dose of 50 mg/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17641.0,,10090.0,CHEMBL619368,1.0,,1.0,Liver,,,2107.0,,4764.0,T2 in liver of mice at the oral dose of 50 mg/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17641.0,,10090.0,CHEMBL619369,1.0,,1.0,Lung,,,2048.0,,4765.0,T2 in lungs of mice at the oral dose of 50 mg/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17641.0,,10090.0,CHEMBL876729,1.0,,1.0,Spleen,,,2106.0,,4766.0,T2 in spleen of mice at the oral dose of 50 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16597.0,,10090.0,CHEMBL619370,1.0,,1.0,,,,,,4767.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,4890.0,,10090.0,CHEMBL619371,1.0,,1.0,,,,,,4768.0,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant"
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,429.0,,10090.0,CHEMBL619372,1.0,,1.0,,,,,,4769.0,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,429.0,,10090.0,CHEMBL620012,1.0,,1.0,,,,,,4770.0,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5969.0,,10090.0,CHEMBL620013,1.0,,1.0,,,,,,4771.0,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16913.0,,9606.0,CHEMBL620014,1.0,,1.0,,,,,478.0,4772.0,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines"
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16913.0,,9606.0,CHEMBL620015,1.0,,1.0,,,,,478.0,4773.0,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines"
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16913.0,,9606.0,CHEMBL621010,1.0,,1.0,,,,,478.0,4774.0,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines"
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16913.0,,9606.0,CHEMBL621011,1.0,,1.0,,,,,478.0,4775.0,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines"
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16913.0,,9606.0,CHEMBL621012,1.0,,1.0,,,,,478.0,4776.0,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines"
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16913.0,,9606.0,CHEMBL621013,1.0,,1.0,,,,,478.0,4777.0,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines"
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,17270.0,,9606.0,CHEMBL621014,1.0,,1.0,,,,,478.0,4778.0,In vitro cytotoxicity against A2780TAX cell line
,BAO_0000219,F,,A2780cisR,80017.0,N,Homo sapiens,Intermediate,5618.0,,9606.0,CHEMBL618154,1.0,,1.0,,,,,481.0,4779.0,In vitro inhibitory activity against human tumor cell line A2780cis
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,17777.0,,9606.0,CHEMBL618155,1.0,,1.0,,,,,478.0,4780.0,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines
,BAO_0000219,F,,A2780cisR,80017.0,N,Homo sapiens,Intermediate,16112.0,,9606.0,CHEMBL618156,1.0,,1.0,,,,,481.0,4781.0,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line
,BAO_0000219,F,,A2780cisR,80017.0,N,Homo sapiens,Intermediate,15748.0,,9606.0,CHEMBL618157,1.0,,1.0,,,,,481.0,4782.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma )
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,6633.0,,9606.0,CHEMBL618328,1.0,,1.0,,,,,478.0,4783.0,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16930.0,,9606.0,CHEMBL618329,1.0,,1.0,,,,,478.0,4784.0,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,17496.0,,9606.0,CHEMBL618330,1.0,,1.0,,,,,478.0,4785.0,Cytotoxicity against human ovarian carcinoma A2780cisR cell line
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,12989.0,,9606.0,CHEMBL618331,1.0,,1.0,,,,,478.0,4786.0,In vitro antitumor activity against A2780cisR cell line.
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,4840.0,,9606.0,CHEMBL618332,1.0,,1.0,,,,,478.0,4787.0,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin)
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,12989.0,,9606.0,CHEMBL618333,1.0,,1.0,,,,,478.0,4788.0,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line
,BAO_0000219,F,,A2780cisR,80017.0,N,Homo sapiens,Intermediate,16745.0,,9606.0,CHEMBL618334,1.0,,1.0,,,,,481.0,4789.0,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,16597.0,,9606.0,CHEMBL618335,1.0,,1.0,,,,,478.0,4790.0,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation
,BAO_0000019,B,,,11736.0,D,Rattus norvegicus,Expert,16547.0,,10116.0,CHEMBL618336,1.0,,9.0,,,,,,4791.0,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes
,BAO_0000019,F,,,11736.0,H,,Expert,16547.0,,,CHEMBL618337,1.0,,8.0,,,,,,4792.0,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity)
,BAO_0000019,F,,,11736.0,D,Rattus norvegicus,Expert,16547.0,,10116.0,CHEMBL618338,1.0,,9.0,,,,,,4793.0,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity)
,BAO_0000219,F,,HEK293,278.0,D,Homo sapiens,Expert,15856.0,,9606.0,CHEMBL618339,1.0,,9.0,,,,,722.0,4794.0,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX
,BAO_0000219,F,,HEK293,278.0,D,Homo sapiens,Expert,15856.0,,9606.0,CHEMBL618340,1.0,,9.0,,,,,722.0,4795.0,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M
,BAO_0000019,B,,,11831.0,D,Mus musculus,Expert,16547.0,,10090.0,CHEMBL618341,1.0,,9.0,,,,,,4796.0,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes
,BAO_0000019,F,,,11831.0,H,,Expert,16547.0,,,CHEMBL618342,1.0,,8.0,,,,,,4797.0,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity)
,BAO_0000019,F,,,11831.0,D,Mus musculus,Expert,16547.0,,10090.0,CHEMBL618343,1.0,,9.0,,,,,,4798.0,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity)
,BAO_0000357,B,,,280.0,H,,Expert,17402.0,,,CHEMBL621038,1.0,,8.0,,,,,,4799.0,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM
,BAO_0000219,F,,T-cells,22226.0,U,Homo sapiens,Autocuration,11746.0,,9606.0,CHEMBL621039,1.0,,0.0,,,,,574.0,4800.0,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01)
,BAO_0000219,F,,T-cells,22226.0,U,Homo sapiens,Autocuration,11746.0,,9606.0,CHEMBL621040,1.0,,0.0,,,,,574.0,4801.0,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active
,BAO_0000219,F,,A-375,80018.0,N,Homo sapiens,Intermediate,5455.0,,9606.0,CHEMBL621041,1.0,,1.0,,,,,455.0,4802.0,Compound was evaluated for cytotoxic activity against human melanoma cell line A375
,BAO_0000219,F,,A-375,80018.0,N,Homo sapiens,Intermediate,2068.0,,9606.0,CHEMBL621042,1.0,,1.0,,,,,455.0,4803.0,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.
,BAO_0000219,F,,A-375,80018.0,N,Homo sapiens,Intermediate,2683.0,,9606.0,CHEMBL621043,1.0,,1.0,,,,,455.0,4804.0,In vitro antitumor activity against A375cell line extracted form melanoma
,BAO_0000219,F,,A-375,80018.0,N,Homo sapiens,Expert,15313.0,,9606.0,CHEMBL621044,1.0,,1.0,,,,,455.0,4805.0,Inhibition of cell growth in (A375) melan cell line
,BAO_0000219,F,,A-375,80018.0,N,Homo sapiens,Intermediate,13739.0,,9606.0,CHEMBL621045,1.0,,1.0,,,,,455.0,4806.0,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375
,BAO_0000219,F,,A-375,80018.0,N,Homo sapiens,Intermediate,13739.0,,9606.0,CHEMBL621046,1.0,,1.0,,,,,455.0,4807.0,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375
,BAO_0000219,F,,A-375,80018.0,N,Homo sapiens,Intermediate,14750.0,,9606.0,CHEMBL621047,1.0,,1.0,,,,,455.0,4808.0,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.
,BAO_0000219,F,,A-427,80019.0,N,Homo sapiens,Intermediate,14777.0,,9606.0,CHEMBL621048,1.0,,1.0,,,,,797.0,4809.0,Antiproliferative activity measured against A427 human lung carcinoma
,BAO_0000219,F,,A-427,80019.0,N,Homo sapiens,Intermediate,14777.0,,9606.0,CHEMBL883798,1.0,,1.0,,,,,797.0,4810.0,Antiproliferative activity measured against A427 human lung carcinoma
,BAO_0000219,F,,A-427,80019.0,N,Homo sapiens,Intermediate,17672.0,,9606.0,CHEMBL621049,1.0,,1.0,,,,,797.0,4811.0,Cytotoxicity against lung carcinoma A427 tumor cell lines
,BAO_0000219,F,,A-427,80019.0,N,Homo sapiens,Intermediate,14368.0,,9606.0,CHEMBL621050,1.0,,1.0,,,,,797.0,4812.0,Inhibition of large cell lung carcinoma (A427)
,BAO_0000219,F,,A-427,80019.0,N,Homo sapiens,Intermediate,14368.0,,9606.0,CHEMBL621051,1.0,,1.0,,,,,797.0,4813.0,Inhibition of large cell lung carcinoma (A427) after 48-h treatment
,BAO_0000219,F,,A-427,80019.0,N,Homo sapiens,Intermediate,13866.0,,9606.0,CHEMBL621052,1.0,,1.0,,,,,797.0,4814.0,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr
,BAO_0000219,F,,A-427,80019.0,N,Homo sapiens,Intermediate,2545.0,,9606.0,CHEMBL621053,1.0,,1.0,,,,,797.0,4815.0,Inhibitory concentration in human lung carcinoma A427 cell line
,BAO_0000219,F,,A-427,80019.0,N,Homo sapiens,Intermediate,2545.0,,9606.0,CHEMBL621054,1.0,,1.0,,,,,797.0,4816.0,Inhibitory concentration in human lung carcinoma A427/VCR cell line
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,6062.0,,9527.0,CHEMBL621055,1.0,,0.0,,,,,,4817.0,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,4578.0,,9527.0,CHEMBL876398,1.0,,0.0,,,,,,4818.0,Tested for volume of distribution upon iv administration to african green monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,17592.0,,9527.0,CHEMBL621056,1.0,,0.0,,,,,,4819.0,Volume of distribution in monkey
,BAO_0000218,A,In vivo,,22224.0,U,Macaca mulatta,Autocuration,5005.0,,9544.0,CHEMBL621057,1.0,,0.0,,,,,,4820.0,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po
,BAO_0000218,A,In vivo,,22224.0,U,Macaca mulatta,Autocuration,5005.0,,9544.0,CHEMBL621058,1.0,,0.0,,,,,,4821.0,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5922.0,,9527.0,CHEMBL621059,1.0,,0.0,,,,,,4822.0,Pharmacokinetic property(Vdss) in cynomolgus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5355.0,,9527.0,CHEMBL621060,1.0,,0.0,,,,,,4823.0,The distribution volume after intravenous administration in cynomolgus monkeys
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5355.0,,9527.0,CHEMBL621061,1.0,,0.0,,,,,,4824.0,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5355.0,,9527.0,CHEMBL621062,1.0,,0.0,,,,,,4825.0,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,6057.0,,9527.0,CHEMBL621063,1.0,,0.0,,,,,,4826.0,Volume displacement was calculated in rhesus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5145.0,,9527.0,CHEMBL621064,1.0,,0.0,,,,,,4827.0,Volume of distribution in steady state was determined in rhesus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,6821.0,,9527.0,CHEMBL621065,1.0,,0.0,,,,,,4828.0,Volume of distribution of compound was determined in monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5334.0,,9527.0,CHEMBL621066,1.0,,0.0,,,,,,4829.0,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male)
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5334.0,,9527.0,CHEMBL621067,1.0,,0.0,,,,,,4830.0,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male)
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,6641.0,,9527.0,CHEMBL621068,1.0,,0.0,,,,,,4831.0,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally)
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,2661.0,,9527.0,CHEMBL876399,1.0,,0.0,,,,,,4832.0,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,6535.0,,9527.0,CHEMBL621069,1.0,,0.0,,,,,,4833.0,Volume distribution in monkey after administration of 1 mg/kg iv
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,4809.0,,9527.0,CHEMBL621070,1.0,,0.0,,,,,,4834.0,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg)
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,6062.0,,9527.0,CHEMBL621071,1.0,,0.0,,,,,,4835.0,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,3443.0,,9527.0,CHEMBL621072,1.0,,0.0,,,,,,4836.0,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,4578.0,,9527.0,CHEMBL618209,1.0,,0.0,,,,,,4837.0,Oral systemic bioavailability upon iv administration to african green monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,4809.0,,9527.0,CHEMBL618210,1.0,,0.0,,,,,,4838.0,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg)
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,11271.0,,9527.0,CHEMBL618211,1.0,,0.0,,,,,,4839.0,Baboon plasma free fraction. 
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,6057.0,,9527.0,CHEMBL618212,1.0,,0.0,,,,,,4840.0,Area under the curve was calculated in rhesus monkey after iv administration
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,6057.0,,9527.0,CHEMBL618213,1.0,,0.0,,,,,,4841.0,Area under the curve was calculated in rhesus monkey after peroral administration
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,17853.0,,9527.0,CHEMBL618214,1.0,,0.0,,,,,,4842.0,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5302.0,,9527.0,CHEMBL873492,1.0,,0.0,,,,,,4843.0,Half life period in monkey after 5 mg/kg dose
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,4257.0,,9527.0,CHEMBL618272,1.0,,0.0,,,,,,4844.0,Half-life was determined in monkey after 3 mg/kg of i.v. dose
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,4257.0,,9527.0,CHEMBL618273,1.0,,0.0,,,,,,4845.0,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,13501.0,,9527.0,CHEMBL618274,1.0,,0.0,Plasma,,,1969.0,,4846.0,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5394.0,,9527.0,CHEMBL618275,1.0,,0.0,,,,,,4847.0,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,2661.0,,9527.0,CHEMBL618276,1.0,,0.0,,,,,,4848.0,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,3341.0,,9527.0,CHEMBL618277,1.0,,0.0,,,,,,4849.0,Compound was evaluated for terminal half life in monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,3045.0,,9527.0,CHEMBL618278,1.0,,0.0,,,,,,4850.0,Compound was evaluated for the half life period after iv administration in cynomolgus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Macaca mulatta,Autocuration,5005.0,,9544.0,CHEMBL618279,1.0,,0.0,Plasma,,,1969.0,,4851.0,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,4847.0,,9527.0,CHEMBL618280,1.0,,0.0,,,,,,4852.0,Half life of compound was determined in squirrel monkey
,BAO_0000218,A,In vivo,,22224.0,U,Macaca fascicularis,Autocuration,4256.0,,9541.0,CHEMBL618281,1.0,,0.0,,,,,,4853.0,Half life after iv administration in cynomolgus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,6535.0,,9527.0,CHEMBL618282,1.0,,0.0,Plasma,,,1969.0,,4854.0,Half life in monkey plasma after administration of 1 mg/kg iv
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,6057.0,,9527.0,CHEMBL618283,1.0,,0.0,,,,,,4855.0,Half life was calculated in rhesus monkey
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,17592.0,,9527.0,CHEMBL618284,1.0,,0.0,,,,,,4856.0,Half life in monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,6641.0,,9527.0,CHEMBL618285,1.0,,0.0,,,,,,4857.0,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally)
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,5472.0,,9527.0,CHEMBL618286,1.0,,0.0,,,,,,4858.0,Half life was evaluated in rhesus
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,6221.0,,9527.0,CHEMBL618287,1.0,,0.0,,,,,,4859.0,Half life period after oral administration (2.5 mg/kg) in monkey was determined
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5668.0,,9527.0,CHEMBL618288,1.0,,0.0,,,,,,4860.0,Half life period was determine after peroral administration at 10 mpk in Rhesus
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,4809.0,,9527.0,CHEMBL876393,1.0,,0.0,,,,,,4861.0,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg)
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5546.0,,9527.0,CHEMBL618289,1.0,,0.0,,,,,,4862.0,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5553.0,,9527.0,CHEMBL618290,1.0,,0.0,,,,,,4863.0,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,6078.0,,9527.0,CHEMBL618291,1.0,,0.0,,,,,,4864.0,Half-life was calculated in monkey
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,5147.0,,9527.0,CHEMBL618292,1.0,,0.0,,,,,,4865.0,Half-life in Squirrel monkey
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,5145.0,,9527.0,CHEMBL618293,1.0,,0.0,,,,,,4866.0,Half-life in rhesus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,6062.0,,9527.0,CHEMBL618294,1.0,,0.0,,,,,,4867.0,Half-life was measured in monkey after an iv dose of 1 mg/kg
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5355.0,,9527.0,CHEMBL618295,1.0,,0.0,,,,,,4868.0,Half-life period after intravenous administration in cynomolgus monkeys
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5355.0,,9527.0,CHEMBL618296,1.0,,0.0,,,,,,4869.0,Half-life period after oral administration in cynomolgus monkeys
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5355.0,,9527.0,CHEMBL618297,1.0,,0.0,,,,,,4870.0,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,7766.0,,9606.0,CHEMBL618298,1.0,,0.0,Urine,,,1088.0,,4871.0,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,7766.0,,9606.0,CHEMBL618299,1.0,,0.0,Urine,,,1088.0,,4872.0,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,7766.0,,9606.0,CHEMBL618300,1.0,,0.0,Urine,,,1088.0,,4873.0,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,7766.0,,9606.0,CHEMBL618301,1.0,,0.0,Urine,,,1088.0,,4874.0,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,7766.0,,9606.0,CHEMBL618302,1.0,,0.0,Urine,,,1088.0,,4875.0,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,7766.0,,9606.0,CHEMBL876394,1.0,,0.0,Urine,,,1088.0,,4876.0,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,7766.0,,9606.0,CHEMBL618303,1.0,,0.0,Urine,,,1088.0,,4877.0,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,7766.0,,9606.0,CHEMBL618304,1.0,,0.0,Urine,,,1088.0,,4878.0,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined
,BAO_0000218,A,In vivo,,22224.0,U,Homo sapiens,Autocuration,1916.0,,9606.0,CHEMBL618305,1.0,,0.0,,,,,,4879.0,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined
,BAO_0000218,A,In vivo,,22224.0,U,Homo sapiens,Autocuration,16643.0,,9606.0,CHEMBL618306,1.0,,0.0,,,,,,4880.0,Oral bioavailability in human
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,17248.0,,9606.0,CHEMBL618307,1.0,,0.0,,,,,,4881.0,Compound was tested for human plasma protein binding
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,17248.0,,9606.0,CHEMBL618308,1.0,,0.0,,,,,,4882.0,Compound was tested for human plasma protein binding; Not determined
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6241.0,,9606.0,CHEMBL618309,1.0,,0.0,,,,,,4883.0,Protein binding activity of compound in human plasma; % Free
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,17716.0,,9606.0,CHEMBL618310,1.0,,0.0,,,,,,4884.0,Unbound fraction (plasma)
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,17605.0,,9606.0,CHEMBL873353,1.0,,0.0,Plasma,,,1969.0,,4885.0,Half life for the hydrolysis of compound in human blood serum
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,17625.0,,9606.0,CHEMBL618311,1.0,,0.0,Plasma,,,1969.0,,4886.0,Half life period in human plasma using phosphate buffer (0.08 M)
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,17625.0,,9606.0,CHEMBL618312,1.0,,0.0,Plasma,,,1969.0,,4887.0,Half life period in human plasma using phosphate buffer (0.1 M)
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,17747.0,,9606.0,CHEMBL618313,1.0,,0.0,Plasma,,,1969.0,,4888.0,Half-life in human plasma was determined
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,15613.0,,9606.0,CHEMBL618314,1.0,,0.0,,,,,,4889.0,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,354.0,,9606.0,CHEMBL618315,1.0,,0.0,,,,,,4890.0,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT)
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,3741.0,,9606.0,CHEMBL618316,1.0,,0.0,,,,,,4891.0,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma"
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,3741.0,,9606.0,CHEMBL618317,1.0,,0.0,,,,,,4892.0,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)"
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,3741.0,,9606.0,CHEMBL620138,1.0,,0.0,,,,,,4893.0,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)"
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,17599.0,,9606.0,CHEMBL858280,1.0,,0.0,,,,,,4894.0,Partition coefficient (logP)
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,5486.0,,9606.0,CHEMBL620139,1.0,,0.0,,,,,,4895.0,In vitro metabolic stability in human was measured as pmol/min/mg/protein
,BAO_0000251,A,,,22224.0,U,Homo sapiens,Autocuration,5600.0,Microsomes,9606.0,CHEMBL620140,1.0,,0.0,,,,,,4896.0,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,14294.0,,9606.0,CHEMBL620141,1.0,,0.0,,,,,,4897.0,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak)
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,14294.0,,9606.0,CHEMBL620142,1.0,,0.0,,,,,,4898.0,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak)
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,14294.0,,9606.0,CHEMBL620143,1.0,,0.0,,,,,,4899.0,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak)
,BAO_0000251,A,,,22224.0,U,Homo sapiens,Autocuration,14294.0,Microsomes,9606.0,CHEMBL620144,1.0,,0.0,,,,,,4900.0,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak)
,BAO_0000251,A,,,22224.0,U,Homo sapiens,Autocuration,14294.0,Microsomes,9606.0,CHEMBL620145,1.0,,0.0,,,,,,4901.0,Metabolism of compound in human microsomes ('++++' indicates largest observed peak)
,BAO_0000251,A,,,22224.0,U,Homo sapiens,Autocuration,14294.0,Microsomes,9606.0,CHEMBL620146,1.0,,0.0,,,,,,4902.0,Metabolism of compound in human microsomes; Trace
,BAO_0000251,A,,,22224.0,U,Homo sapiens,Autocuration,6260.0,Microsomes,9606.0,CHEMBL620147,1.0,,0.0,Liver,,,2107.0,,4903.0,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes
,BAO_0000251,A,,,22224.0,U,Homo sapiens,Autocuration,6187.0,Microsomes,9606.0,CHEMBL620148,1.0,,0.0,,,,,,4904.0,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min
,BAO_0000251,A,,,22224.0,U,Homo sapiens,Autocuration,6251.0,Microsomes,9606.0,CHEMBL620149,1.0,,0.0,Liver,,,2107.0,,4905.0,In vitro metabolic potential in human liver microsomes
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,3246.0,,9606.0,CHEMBL876412,1.0,,0.0,,,,,,4906.0,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,17313.0,,9606.0,CHEMBL619352,1.0,,0.0,,,,,,4907.0,Tested for human plasma protein binding of the compound; Not tested
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6227.0,,9606.0,CHEMBL619353,1.0,,0.0,,,,,,4908.0,Compound was tested for percent protein binding (PB) in human
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,5530.0,,9606.0,CHEMBL619354,1.0,,0.0,Plasma,,,1969.0,,4909.0,Protein binding in human plasma
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6108.0,,9606.0,CHEMBL619355,1.0,,0.0,,,,,,4910.0,Permeability coefficient (B to A) in Caco-2 cell
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6108.0,,9606.0,CHEMBL619356,1.0,,0.0,,,,,,4911.0,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,2774.0,,9606.0,CHEMBL619357,1.0,,0.0,,,,,,4912.0,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3)
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,16643.0,,9606.0,CHEMBL619358,1.0,,0.0,,,,,,4913.0,In vitro rate of absorption observed as Caco-2 permeability in humans
,BAO_0000219,A,,Caco-2,22224.0,U,Homo sapiens,Autocuration,17582.0,,9606.0,CHEMBL619359,1.0,,0.0,,,,,495.0,4914.0,Cellular permeability of compound was determined in Caco-2 cells; High
,BAO_0000219,A,,Caco-2,22224.0,U,Homo sapiens,Autocuration,6838.0,,9606.0,CHEMBL619360,1.0,,0.0,,,,,495.0,4915.0,Permeability in Caco-2 cells of compound
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6108.0,,9606.0,CHEMBL619361,1.0,,0.0,,,,,,4916.0,Permeability coefficient (A to B) in Caco-2 cell
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6108.0,,9606.0,CHEMBL619362,1.0,,0.0,,,,,,4917.0,Permeability coefficient (B to A) in Caco-2 cell
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6108.0,,9606.0,CHEMBL619363,1.0,,0.0,,,,,,4918.0,Permeability coefficient (Papp) (Caco-2 cell monolayer)
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,2146.0,,9606.0,CHEMBL618942,1.0,,0.0,,,,,,4919.0,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,4514.0,,9606.0,CHEMBL618943,1.0,,0.0,,,,,,4920.0,Compound was tested for protein binding in human plasma
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6108.0,,9606.0,CHEMBL618944,1.0,,0.0,,,,,,4921.0,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,7766.0,,9606.0,CHEMBL618945,1.0,,0.0,Urine,,,1088.0,,4922.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5969.0,,10090.0,CHEMBL618946,1.0,,1.0,,,,,,4923.0,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3277.0,,10090.0,CHEMBL876413,1.0,,1.0,,,,,,4924.0,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4)
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3802.0,,10090.0,CHEMBL618947,1.0,,1.0,,,,,,4925.0,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,2862.0,,10090.0,CHEMBL618948,1.0,,1.0,Plasma,,,1969.0,,4926.0,Time taken to reach maximum concentration in plasma upon oral administration in mouse
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,6348.0,,10090.0,CHEMBL618949,1.0,,1.0,Plasma,,,1969.0,,4927.0,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration
,BAO_0000218,F,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL618950,1.0,,1.0,,,,,,4928.0,Tmax after intraperitoneal administration in mice at 23 uM/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5781.0,,10090.0,CHEMBL618951,1.0,,1.0,,,,,,4929.0,Tmax after oral administration at 30 mg/kg in ICR mouse
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL618952,1.0,,1.0,,,,,,4930.0,Tmax after peroral administration in mice at 2.4 uM/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,4066.0,,10090.0,CHEMBL618953,1.0,,1.0,,,,,,4931.0,Tmax at a single subcutaneous administration of 40 mg/kg in mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17641.0,,10090.0,CHEMBL618954,1.0,,1.0,Brain,,,955.0,,4932.0,Tmax in brain of mice at the oral dose of 50 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17641.0,,10090.0,CHEMBL618955,1.0,,1.0,Kidney,,,2113.0,,4933.0,Tmax in kidney of mice at the oral dose of 50 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17641.0,,10090.0,CHEMBL618956,1.0,,1.0,Liver,,,2107.0,,4934.0,Tmax in liver of mice at the oral dose of 50 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17641.0,,10090.0,CHEMBL618957,1.0,,1.0,Lung,,,2048.0,,4935.0,Tmax in lungs of mice at the oral dose of 50 mg/kg
,BAO_0000218,F,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL618958,1.0,,1.0,,,,,,4936.0,Tmax in mice at 18 uM/kg i.p. administration
,BAO_0000218,F,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL618959,1.0,,1.0,,,,,,4937.0,Tmax in mice at 23 uM/kg i.v. administration
,BAO_0000218,F,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL618960,1.0,,1.0,,,,,,4938.0,Tmax in mice at 25 uM/kg i.p. administration
,BAO_0000218,F,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL876723,1.0,,1.0,,,,,,4939.0,Tmax in mice at 26 uM/kg i.p. administration
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17641.0,,10090.0,CHEMBL618961,1.0,,1.0,Spleen,,,2106.0,,4940.0,Tmax in spleen of mice at the oral dose of 50 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16597.0,,10090.0,CHEMBL618962,1.0,,1.0,,,,,,4941.0,Tmax value at a dose of 10 mg/kg intravenous administration in mice.
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16597.0,,10090.0,CHEMBL618963,1.0,,1.0,,,,,,4942.0,Tmax value at a dose of 10 mg/kg peroral administration in mice.
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,5951.0,,10090.0,CHEMBL618964,1.0,,1.0,,,,,,4943.0,Tmax value in IRC mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5506.0,,10090.0,CHEMBL618965,1.0,,1.0,,,,,,4944.0,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5506.0,,10090.0,CHEMBL618966,1.0,,1.0,,,,,,4945.0,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,429.0,,10090.0,CHEMBL618967,1.0,,1.0,Urine,,,1088.0,,4946.0,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr )
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,429.0,,10090.0,CHEMBL618968,1.0,,1.0,Urine,,,1088.0,,4947.0,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr)
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,4066.0,,10090.0,CHEMBL618969,1.0,,1.0,Urine,,,1088.0,,4948.0,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h)
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17734.0,,10090.0,CHEMBL618970,1.0,,1.0,,,,,,4949.0,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17734.0,,10090.0,CHEMBL618971,1.0,,1.0,,,,,,4950.0,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,6062.0,,10090.0,CHEMBL618972,1.0,,1.0,,,,,,4951.0,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5969.0,,10090.0,CHEMBL618973,1.0,,1.0,,,,,,4952.0,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5969.0,,10090.0,CHEMBL618974,1.0,,1.0,,,,,,4953.0,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5969.0,,10090.0,CHEMBL618975,1.0,,1.0,,,,,,4954.0,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5980.0,,10090.0,CHEMBL618976,1.0,,1.0,,,,,,4955.0,Vd in mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17592.0,,10090.0,CHEMBL618977,1.0,,1.0,,,,,,4956.0,Volume of distribution in mouse
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,6348.0,,10090.0,CHEMBL876724,1.0,,1.0,,,,,,4957.0,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17753.0,,10090.0,CHEMBL618978,1.0,,1.0,,,,,,4958.0,Volume of distribution of compound in plasma was determined at 24 mg/Kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17753.0,,10090.0,CHEMBL618979,1.0,,1.0,,,,,,4959.0,Volume of distribution of compound in plasma was determined at 40 mg/Kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17753.0,,10090.0,CHEMBL618980,1.0,,1.0,,,,,,4960.0,Volume of distribution of compound in plasma was determined at 5 mg/Kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,4239.0,,10090.0,CHEMBL618981,1.0,,1.0,,,,,,4961.0,Pharmacokinetic property (vdss) was measured in mouse
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,2862.0,,10090.0,CHEMBL618982,1.0,,1.0,,,,,,4962.0,Value distribution upon iv administration in mouse
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17734.0,,10090.0,CHEMBL620150,1.0,,1.0,,,,,,4963.0,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,2675.0,,10090.0,CHEMBL620151,1.0,,1.0,,,,,,4964.0,Volume of distribution was evaluated in mice after intravenous administration
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,2675.0,,10090.0,CHEMBL620152,1.0,,1.0,,,,,,4965.0,Volume of distribution was evaluated in mice after oral administration
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17837.0,,10090.0,CHEMBL620153,1.0,,1.0,,,,,,4966.0,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5727.0,,10090.0,CHEMBL876395,1.0,,1.0,,,,,,4967.0,Steady state volume of distribution was determined in mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17852.0,,10090.0,CHEMBL620154,1.0,,1.0,,,,,,4968.0,Volume distribution (steady state) of compound was determined in mouse
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL620155,1.0,,1.0,,,,,,4969.0,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16597.0,,10090.0,CHEMBL620156,1.0,,1.0,,,,,,4970.0,Vss value at a dose of 10 mg/kg intravenous administration in mice.
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,6062.0,,10090.0,CHEMBL620157,1.0,,1.0,,,,,,4971.0,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL620158,1.0,,1.0,Kidney,,,2113.0,,4972.0,Biodistribution of compound (oxidized form) in in kidney tissue
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL620159,1.0,,1.0,Blood,,,178.0,,4973.0,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL620160,1.0,,1.0,Blood,,,178.0,,4974.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution"
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL620161,1.0,,1.0,Blood,,,178.0,,4975.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
,BAO_0000219,F,,A-427,80019.0,N,Homo sapiens,Intermediate,10708.0,,9606.0,CHEMBL620162,1.0,,1.0,,,,,797.0,4976.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Expert,16597.0,,9606.0,CHEMBL620163,1.0,,1.0,,,,,500.0,4977.0,Inhibition of A431 human squamous cell carcinoma cell proliferation
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Expert,16062.0,,9606.0,CHEMBL620833,1.0,,1.0,,,,,500.0,4978.0,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Expert,16062.0,,9606.0,CHEMBL876396,1.0,,1.0,,,,,500.0,4979.0,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Expert,16958.0,,9606.0,CHEMBL620834,1.0,,1.0,,,,,500.0,4980.0,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Expert,6700.0,,9606.0,CHEMBL620835,1.0,,1.0,,,,,500.0,4981.0,Inhibition of A431 human carcinoma cell proliferation
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Expert,17226.0,,9606.0,CHEMBL620836,1.0,,1.0,,,,,500.0,4982.0,In vitro inhibition of A431 (human carcinoma) cell basal growth.
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,6828.0,,9606.0,CHEMBL620837,1.0,,1.0,,,,,500.0,4983.0,Inhibitory concentration of compound against growth of human A431 cell line; Resistant
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,12314.0,,9606.0,CHEMBL621017,1.0,,1.0,,,,,500.0,4984.0,In vitro cytotoxicity against epidermoid carcinoma cell line
,BAO_0000218,F,,A-431,9.0,D,Homo sapiens,Expert,13412.0,,9606.0,CHEMBL621018,1.0,,9.0,,,,,500.0,4985.0,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R"
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,13299.0,,9606.0,CHEMBL621019,1.0,,1.0,,,,,500.0,4986.0,Antiproliferative activity of compound was measured on human tumor cell line A431.
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,17420.0,,9606.0,CHEMBL621020,1.0,,1.0,,,,,500.0,4987.0,Antiproliferative effect of compound on A431 cell line expressing mutant p53
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,13678.0,,9606.0,CHEMBL621021,1.0,,1.0,,,,,500.0,4988.0,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound
,BAO_0000219,F,,A-431,9.0,H,,Expert,14171.0,,,CHEMBL621022,1.0,,8.0,,,,,500.0,4989.0,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Expert,6333.0,,9606.0,CHEMBL621023,1.0,,1.0,,,,,500.0,4990.0,Tested for antiproliferative activity against human A431 cells
,BAO_0000219,F,,A-431,9.0,D,Homo sapiens,Expert,2356.0,,9606.0,CHEMBL621024,1.0,,9.0,,,,,500.0,4991.0,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Expert,15578.0,,9606.0,CHEMBL621025,1.0,,1.0,,,,,500.0,4992.0,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Expert,5126.0,,9606.0,CHEMBL621026,1.0,,1.0,,,,,500.0,4993.0,Inhibition of A431 cell proliferation
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Expert,6844.0,,9606.0,CHEMBL621027,1.0,,1.0,,,,,500.0,4994.0,Cytotoxic effect on A431 human epidermoid carcinoma cells
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Expert,6844.0,,9606.0,CHEMBL876397,1.0,,1.0,,,,,500.0,4995.0,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM)
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,4925.0,,9606.0,CHEMBL883797,1.0,,1.0,,,,,500.0,4996.0,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,4925.0,,9606.0,CHEMBL621028,1.0,,1.0,,,,,500.0,4997.0,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,13978.0,,9606.0,CHEMBL621029,1.0,,1.0,,,,,500.0,4998.0,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,16786.0,,9606.0,CHEMBL621030,1.0,,1.0,,,,,500.0,4999.0,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure
,BAO_0000219,F,,A-431,9.0,H,,Expert,13412.0,,,CHEMBL621147,1.0,,8.0,,,,,500.0,5000.0,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R
,BAO_0000218,F,,A-431,80852.0,N,Homo sapiens,Intermediate,17824.0,,9606.0,CHEMBL621148,1.0,,1.0,,,,,500.0,5001.0,In vivo antiproliferative activity against A431 cell line
,BAO_0000219,F,,A-431,9.0,D,Homo sapiens,Expert,12751.0,,9606.0,CHEMBL621149,1.0,,9.0,,,,,500.0,5002.0,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Expert,12380.0,,9606.0,CHEMBL621150,1.0,,1.0,,,,,500.0,5003.0,Inhibition of A431 human epidermoid carcinoma cell proliferation
,BAO_0000219,F,,A-431,9.0,D,Homo sapiens,Expert,4959.0,,9606.0,CHEMBL621151,1.0,,9.0,,,,,500.0,5004.0,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,6333.0,,9606.0,CHEMBL621152,1.0,,1.0,,,,,500.0,5005.0,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178)
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,6333.0,,9606.0,CHEMBL621153,1.0,,1.0,,,,,500.0,5006.0,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38)
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,6333.0,,9606.0,CHEMBL884000,1.0,,1.0,,,,,500.0,5007.0,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21)
,BAO_0000019,F,,,9.0,D,Homo sapiens,Expert,5296.0,,9606.0,CHEMBL621154,1.0,,9.0,,,,,,5008.0,Inhibition of EGFR overexpressing A431 cell proliferation
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Expert,12624.0,,9606.0,CHEMBL621155,1.0,,1.0,,,,,500.0,5009.0,Inhibition of A431 cell proliferation
,BAO_0000219,F,,A-431,9.0,D,Homo sapiens,Expert,14926.0,,9606.0,CHEMBL621156,1.0,,9.0,,,,,500.0,5010.0,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor
,BAO_0000219,F,,A-431,9.0,D,Homo sapiens,Expert,14926.0,,9606.0,CHEMBL621157,1.0,,9.0,,,,,500.0,5011.0,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor"
,BAO_0000219,F,,A-431,9.0,H,,Expert,14926.0,,,CHEMBL621158,1.0,,8.0,,,,,500.0,5012.0,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor)
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,15144.0,,9606.0,CHEMBL621159,1.0,,1.0,,,,,500.0,5013.0,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,15144.0,,9606.0,CHEMBL621160,1.0,,1.0,,,,,500.0,5014.0,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,5245.0,,9606.0,CHEMBL621161,1.0,,1.0,,,,,500.0,5015.0,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,5245.0,,9606.0,CHEMBL621162,1.0,,1.0,,,,,500.0,5016.0,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,5245.0,,9606.0,CHEMBL621163,1.0,,1.0,,,,,500.0,5017.0,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,5245.0,,9606.0,CHEMBL621164,1.0,,1.0,,,,,500.0,5018.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,5245.0,,9606.0,CHEMBL621165,1.0,,1.0,,,,,500.0,5019.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,5922.0,,9527.0,CHEMBL619159,1.0,,0.0,,,,,,5020.0,Half-life period in cynomolgus monkey
,BAO_0000366,A,In vitro,,22224.0,U,Cercopithecidae,Autocuration,1116.0,,9527.0,CHEMBL619160,1.0,,0.0,Plasma,,,1969.0,,5021.0,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma"
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,17853.0,,9527.0,CHEMBL619161,1.0,,0.0,,,,,,5022.0,Longer half-life in monkey (i.v.) at 0.5 mpk
,BAO_0000366,A,,,22224.0,U,Cercopithecidae,Autocuration,993.0,,9527.0,CHEMBL619162,1.0,,0.0,Plasma,,,1969.0,,5023.0,Plasma half life in monkey
,BAO_0000366,A,,,22224.0,U,Cercopithecidae,Autocuration,4514.0,,9527.0,CHEMBL619163,1.0,,0.0,Plasma,,,1969.0,,5024.0,Plasma half-life in rhesus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5334.0,,9527.0,CHEMBL619164,1.0,,0.0,Plasma,,,1969.0,,5025.0,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male)
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5334.0,,9527.0,CHEMBL619320,1.0,,0.0,Plasma,,,1969.0,,5026.0,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male)
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,4578.0,,9527.0,CHEMBL619321,1.0,,0.0,,,,,,5027.0,Tested for half life upon iv administration to african green monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,2661.0,,9527.0,CHEMBL873336,1.0,,0.0,,,,,,5028.0,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5355.0,,9527.0,CHEMBL619322,1.0,,0.0,,,,,,5029.0,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5355.0,,9527.0,CHEMBL619323,1.0,,0.0,,,,,,5030.0,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5355.0,,9527.0,CHEMBL619324,1.0,,0.0,,,,,,5031.0,The time for peak concentration value after oral administration in cynomolgus monkeys
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,11271.0,,9527.0,CHEMBL619325,1.0,,0.0,,,,,,5032.0,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,11271.0,,9527.0,CHEMBL876411,1.0,,0.0,,,,,,5033.0,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,11271.0,,9527.0,CHEMBL619326,1.0,,0.0,,,,,,5034.0,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,11271.0,,9527.0,CHEMBL619327,1.0,,0.0,,,,,,5035.0,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,11271.0,,9527.0,CHEMBL619328,1.0,,0.0,,,,,,5036.0,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,11271.0,,9527.0,CHEMBL619329,1.0,,0.0,,,,,,5037.0,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,11271.0,,9527.0,CHEMBL619330,1.0,,0.0,,,,,,5038.0,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,11271.0,,9527.0,CHEMBL619331,1.0,,0.0,,,,,,5039.0,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,11271.0,,9527.0,CHEMBL619332,1.0,,0.0,,,,,,5040.0,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,11271.0,,9527.0,CHEMBL619333,1.0,,0.0,,,,,,5041.0,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,11271.0,,9527.0,CHEMBL619334,1.0,,0.0,,,,,,5042.0,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,11271.0,,9527.0,CHEMBL619335,1.0,,0.0,,,,,,5043.0,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,11271.0,,9527.0,CHEMBL619336,1.0,,0.0,,,,,,5044.0,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,11271.0,,9527.0,CHEMBL619337,1.0,,0.0,,,,,,5045.0,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,11271.0,,9527.0,CHEMBL619338,1.0,,0.0,,,,,,5046.0,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,11271.0,,9527.0,CHEMBL619339,1.0,,0.0,,,,,,5047.0,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,5809.0,,10116.0,CHEMBL619340,1.0,,1.0,,,,,,5048.0,Bioavailability in rat (cannulated) (dose 2 mg/kg)
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,17720.0,,10116.0,CHEMBL873496,1.0,,1.0,Plasma,,,1969.0,,5049.0,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration
,BAO_0000218,A,,,50597.0,N,Rattus norvegicus,Intermediate,3546.0,,10116.0,CHEMBL619341,1.0,,1.0,Plasma,,,1969.0,,5050.0,AUC value in rat after IV administration at a dose of 10 mg/kg
,BAO_0000218,A,,,50597.0,N,Rattus norvegicus,Intermediate,3546.0,,10116.0,CHEMBL619342,1.0,,1.0,Plasma,,,1969.0,,5051.0,AUC value in rat after oral administration at a dose of 10 mg/kg
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,3546.0,,10116.0,CHEMBL619343,1.0,,1.0,,,,,,5052.0,Cmax value in rat after oral administration at a dose of 10 mg/kg
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,3546.0,,10116.0,CHEMBL619344,1.0,,1.0,,,,,,5053.0,Bioavailability in rat after oral administration at a dose of 10 mg/kg
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,3546.0,,10116.0,CHEMBL619345,1.0,,1.0,,,,,,5054.0,Tmax value in rat after oral administration at a dose of 10 mg/kg
,BAO_0000218,A,,,50597.0,N,Rattus norvegicus,Intermediate,3546.0,,10116.0,CHEMBL619346,1.0,,1.0,,,,,,5055.0,Vc value in rat after IV administration at a dose of 10 mg/kg
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,3546.0,,10116.0,CHEMBL619347,1.0,,1.0,,,,,,5056.0,Half life period in rat after IV administration at a dose of 10 mg/kg
,BAO_0000019,A,,,22224.0,U,Papio hamadryas,Autocuration,10625.0,,9557.0,CHEMBL619348,1.0,,0.0,,,,,,5057.0,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon
,BAO_0000019,A,,,22224.0,U,Papio hamadryas,Autocuration,10625.0,,9557.0,CHEMBL619349,1.0,,0.0,,,,,,5058.0,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11)
,BAO_0000019,A,,,22224.0,U,Papio hamadryas,Autocuration,10625.0,,9557.0,CHEMBL619350,1.0,,0.0,,,,,,5059.0,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11)
,BAO_0000019,A,,,22224.0,U,Papio hamadryas,Autocuration,10625.0,,9557.0,CHEMBL619351,1.0,,0.0,,,,,,5060.0,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound
,BAO_0000019,A,,,22224.0,U,Papio hamadryas,Autocuration,10625.0,,9557.0,CHEMBL875953,1.0,,0.0,,,,,,5061.0,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound
,BAO_0000019,A,,,22224.0,U,Papio hamadryas,Autocuration,10625.0,,9557.0,CHEMBL621716,1.0,,0.0,,,,,,5062.0,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound
,BAO_0000019,A,,,22224.0,U,Papio hamadryas,Autocuration,10625.0,,9557.0,CHEMBL621717,1.0,,0.0,,,,,,5063.0,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound
,BAO_0000019,A,,,22224.0,U,Papio hamadryas,Autocuration,10625.0,,9557.0,CHEMBL621718,1.0,,0.0,,,,,,5064.0,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon
,BAO_0000019,A,,,22224.0,U,beagle,Autocuration,3510.0,,9615.0,CHEMBL621719,1.0,,0.0,,,,,,5065.0,Area under curve after 1 mpk peroral administration to beagles
,BAO_0000019,A,,,22224.0,U,beagle,Autocuration,3510.0,,9615.0,CHEMBL621720,1.0,,0.0,,,,,,5066.0,Area under curve after 2 mpk peroral administration to beagles
,BAO_0000218,A,In vivo,,22224.0,U,beagle,Autocuration,3510.0,,9615.0,CHEMBL621721,1.0,,0.0,,,,,,5067.0,Cmax value after 1 mpk peroral administration to beagles
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,7766.0,,9606.0,CHEMBL621722,1.0,,0.0,Urine,,,1088.0,,5068.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,7766.0,,9606.0,CHEMBL621723,1.0,,0.0,Urine,,,1088.0,,5069.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,7766.0,,9606.0,CHEMBL621724,1.0,,0.0,Urine,,,1088.0,,5070.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,7766.0,,9606.0,CHEMBL623443,1.0,,0.0,Urine,,,1088.0,,5071.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,7766.0,,9606.0,CHEMBL623444,1.0,,0.0,Urine,,,1088.0,,5072.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,7766.0,,9606.0,CHEMBL623445,1.0,,0.0,Urine,,,1088.0,,5073.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,7766.0,,9606.0,CHEMBL623446,1.0,,0.0,Urine,,,1088.0,,5074.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4
,BAO_0000251,A,,,22224.0,U,Homo sapiens,Autocuration,16643.0,Microsomes,9606.0,CHEMBL623447,1.0,,0.0,Liver,,,2107.0,,5075.0,Metabolic stability observed at 30 min after administration in human liver microsomes
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6852.0,,9606.0,CHEMBL623448,1.0,,0.0,,,,,,5076.0,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6852.0,,9606.0,CHEMBL623449,1.0,,0.0,,,,,,5077.0,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6852.0,,9606.0,CHEMBL623450,1.0,,0.0,,,,,,5078.0,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients
,BAO_0000251,A,,,22224.0,U,Homo sapiens,Autocuration,6567.0,Microsomes,9606.0,CHEMBL623451,1.0,,0.0,Liver,,,2107.0,,5079.0,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer"
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6570.0,,9606.0,CHEMBL623452,1.0,,0.0,,,,,,5080.0,Metabolic stability (% remaining at 30 mins) in human S9.
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6570.0,,9606.0,CHEMBL623453,1.0,,0.0,,,,,,5081.0,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined
,BAO_0000251,A,,,22224.0,U,Homo sapiens,Autocuration,5237.0,Microsomes,9606.0,CHEMBL623454,1.0,,0.0,Liver,,,2107.0,,5082.0,Percent parent compound remaining after 20 min incubation with human liver microsomes
,BAO_0000251,A,,,22224.0,U,Homo sapiens,Autocuration,5237.0,Microsomes,9606.0,CHEMBL623455,1.0,,0.0,Liver,,,2107.0,,5083.0,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data
,BAO_0000251,A,,,22224.0,U,Homo sapiens,Autocuration,5237.0,Microsomes,9606.0,CHEMBL624371,1.0,,0.0,Liver,,,2107.0,,5084.0,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data
,BAO_0000218,A,,,22224.0,U,Homo sapiens,Autocuration,5202.0,,9606.0,CHEMBL624372,1.0,,0.0,,,,,,5085.0,First pass metabolism and metabolic bioavailability using human hepatic microsomes
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,5481.0,,9606.0,CHEMBL624373,1.0,,0.0,,,,,,5086.0,Percent compound remaining in human plasma after incubation for 60 min at 37 C.
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,5481.0,,9606.0,CHEMBL624374,1.0,,0.0,,,,,,5087.0,Percent remaining in human plasma after incubation for 60 min at 37 C.
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,3956.0,,9606.0,CHEMBL624556,1.0,,0.0,,,,,,5088.0,The percent remaining in human plasma after 30 min was determined
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,5074.0,,9606.0,CHEMBL624557,1.0,,0.0,Plasma,,,1969.0,,5089.0,Conversion rate of the prodrug in human plasma
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,5074.0,,9606.0,CHEMBL624558,1.0,,0.0,Plasma,,,1969.0,,5090.0,Conversion rate of the prodrug in human plasma; ND means no data
,BAO_0000221,A,,,22224.0,U,Homo sapiens,Autocuration,4727.0,,9606.0,CHEMBL624559,1.0,,0.0,Blood,,,178.0,,5091.0,Half life of compound was determined in human blood
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,5965.0,,9606.0,CHEMBL624560,1.0,,0.0,,,,,,5092.0,Half life of compound was determined in man with once daily dosing
,BAO_0000251,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,5732.0,Microsomes,9606.0,CHEMBL624561,1.0,,0.0,,,,,,5093.0,Half life in human microsomes
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,5819.0,,9606.0,CHEMBL624562,1.0,,0.0,Plasma,,,1969.0,,5094.0,Half life in human plasma
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,5819.0,,9606.0,CHEMBL624563,1.0,,0.0,Plasma,,,1969.0,,5095.0,Half life in human plasma; Not detected
,BAO_0000218,A,In vivo,,22224.0,U,Homo sapiens,Autocuration,1916.0,,9606.0,CHEMBL624564,1.0,,0.0,,,,,,5096.0,Half life period was evaluated against man at a dose of 10 mg/kg after po administration
,BAO_0000251,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,6597.0,Microsomes,9606.0,CHEMBL624565,1.0,,0.0,Liver,,,2107.0,,5097.0,Half-life for oxidative metabolic stability was determined using rat liver microsomes
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,5229.0,,9606.0,CHEMBL875152,1.0,,0.0,Plasma,,,1969.0,,5098.0,Half-life in human plasma
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,5229.0,,9606.0,CHEMBL624566,1.0,,0.0,Plasma,,,1969.0,,5099.0,Half-life of the parent prodrug in plasma
,BAO_0000366,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,2192.0,,9606.0,CHEMBL873805,1.0,,0.0,Plasma,,,1969.0,,5100.0,In vitro half life in human plasma was determined
,BAO_0000251,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,3032.0,Microsomes,9606.0,CHEMBL624567,1.0,,0.0,Liver,,,2107.0,,5101.0,The compound was tested In Vitro for half life in human liver microsomes.
,BAO_0000218,A,In vivo,,22224.0,U,Homo sapiens,Autocuration,1916.0,,9606.0,CHEMBL624568,1.0,,0.0,,,,,,5102.0,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration
,BAO_0000218,A,In vivo,,22224.0,U,Homo sapiens,Autocuration,17716.0,,9606.0,CHEMBL624569,1.0,,0.0,,,,,,5103.0,Observed volume of distribution
,BAO_0000218,A,In vivo,,22224.0,U,Homo sapiens,Autocuration,15778.0,,9606.0,CHEMBL624570,1.0,,0.0,,,,,,5104.0,Oral bioavailability in human
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,17313.0,,9606.0,CHEMBL624571,1.0,,0.0,,,,,,5105.0,Tested for human plasma protein binding of the compound
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,4231.0,,9606.0,CHEMBL624572,1.0,,0.0,,,,,,5106.0,"First order rate constant, k was determined in human plasma"
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,4755.0,,9606.0,CHEMBL624573,1.0,,0.0,,,,,,5107.0,Observed rate constant in 80% human plasma at 37 degree Centigrade
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,4755.0,,9606.0,CHEMBL875153,1.0,,0.0,,,,,,5108.0,Observed rate constant in 80% human plasma at 37 degree Centigrade
,BAO_0000251,A,,,22224.0,U,Homo sapiens,Autocuration,16907.0,Microsomes,9606.0,CHEMBL624574,1.0,,0.0,Liver,,,2107.0,,5109.0,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,10839.0,,9606.0,CHEMBL624575,1.0,,0.0,,,,,,5110.0,The compound was tested for the plasma binding in human
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,10839.0,,9606.0,CHEMBL624576,1.0,,0.0,,,,,,5111.0,Plasma protein binding (human)
,BAO_0000251,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,3199.0,Microsomes,9606.0,CHEMBL624577,1.0,,0.0,Liver,,,2107.0,,5112.0,Compound was evaluated for half-life in human liver microsomes
,BAO_0000221,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,1345.0,,9606.0,CHEMBL624578,1.0,,0.0,Blood,,,178.0,,5113.0,Half life measured in vitro for its stability in human blood
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,4297.0,,9606.0,CHEMBL622796,1.0,,0.0,Serum,,,1977.0,,5114.0,Half life in human serum
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,4297.0,,9606.0,CHEMBL622797,1.0,,0.0,Serum,,,1977.0,,5115.0,Half life in human serum; ND=not determined
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,4297.0,,9606.0,CHEMBL622798,1.0,,0.0,,,,,,5116.0,Half life were determined in CEM-SS cell extract in decomposition step 1
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,4297.0,,9606.0,CHEMBL622799,1.0,,0.0,,,,,,5117.0,Half life were determined in CEM-SS cell extract in decomposition step 2
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,4231.0,,9606.0,CHEMBL622800,1.0,,0.0,Plasma,,,1969.0,,5118.0,Half life of the in human plasma
,BAO_0000220,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,5633.0,S9,9606.0,CHEMBL622801,1.0,,0.0,,,,,,5119.0,Half life period in human hepatic S9 fraction was determined
,BAO_0000251,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,5633.0,Microsomes,9606.0,CHEMBL622802,1.0,,0.0,Liver,,,2107.0,,5120.0,Half life period in human liver microsome was determined
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,17791.0,,9606.0,CHEMBL622803,1.0,,0.0,,,,,,5121.0,Half life period was determined; 6-7
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,17791.0,,9606.0,CHEMBL875154,1.0,,0.0,,,,,,5122.0,Half life period was evaluated in human
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,3160.0,,9606.0,CHEMBL622804,1.0,,0.0,Plasma,,,1969.0,,5123.0,Half life time in human plasma
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622805,1.0,,1.0,Brain,,,955.0,,5124.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622611,1.0,,1.0,Heart,,,948.0,,5125.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol."
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622612,1.0,,1.0,Heart,,,948.0,,5126.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL875160,1.0,,1.0,Kidney,,,2113.0,,5127.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol."
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622613,1.0,,1.0,Kidney,,,2113.0,,5128.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution"
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622614,1.0,,1.0,Kidney,,,2113.0,,5129.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622615,1.0,,1.0,Liver,,,2107.0,,5130.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol."
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622616,1.0,,1.0,Liver,,,2107.0,,5131.0,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622617,1.0,,1.0,Liver,,,2107.0,,5132.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622618,1.0,,1.0,Spleen,,,2106.0,,5133.0,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622619,1.0,,1.0,Spleen,,,2106.0,,5134.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution"
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622620,1.0,,1.0,Spleen,,,2106.0,,5135.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622621,1.0,,1.0,Brain,,,955.0,,5136.0,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622622,1.0,,1.0,Blood,,,178.0,,5137.0,Biodistribution of compound (oxidized form) in blood tissue
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622623,1.0,,1.0,Blood,,,178.0,,5138.0,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622624,1.0,,1.0,Blood,,,178.0,,5139.0,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution"
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622625,1.0,,1.0,Blood,,,178.0,,5140.0,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622626,1.0,,1.0,Blood,,,178.0,,5141.0,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622627,1.0,,1.0,Blood,,,178.0,,5142.0,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution"
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622628,1.0,,1.0,Brain,,,955.0,,5143.0,Biodistribution of compound (oxidized form) in brain tissue of mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622629,1.0,,1.0,Brain,,,955.0,,5144.0,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622630,1.0,,1.0,Brain,,,955.0,,5145.0,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO"
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622631,1.0,,1.0,Brain,,,955.0,,5146.0,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol."
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622632,1.0,,1.0,Brain,,,955.0,,5147.0,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution"
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622633,1.0,,1.0,Brain,,,955.0,,5148.0,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution"
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622634,1.0,,1.0,Heart,,,948.0,,5149.0,Biodistribution of compound (oxidized form) in heart tissue of mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622635,1.0,,1.0,Heart,,,948.0,,5150.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL875161,1.0,,1.0,Heart,,,948.0,,5151.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL622636,1.0,,1.0,Heart,,,948.0,,5152.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO"
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL623335,1.0,,1.0,Heart,,,948.0,,5153.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol."
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL623336,1.0,,1.0,Heart,,,948.0,,5154.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution"
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL623337,1.0,,1.0,Kidney,,,2113.0,,5155.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL623338,1.0,,1.0,Kidney,,,2113.0,,5156.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution"
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL623339,1.0,,1.0,Kidney,,,2113.0,,5157.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO"
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL623524,1.0,,1.0,Kidney,,,2113.0,,5158.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol."
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL623525,1.0,,1.0,Kidney,,,2113.0,,5159.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution"
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL623526,1.0,,1.0,Liver,,,2107.0,,5160.0,Biodistribution of compound (oxidized form) in liver tissue
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL623527,1.0,,1.0,Liver,,,2107.0,,5161.0,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16438.0,,10090.0,CHEMBL623528,1.0,,1.0,Liver,,,2107.0,,5162.0,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,5245.0,,9606.0,CHEMBL624615,1.0,,1.0,,,,,500.0,5163.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,5245.0,,9606.0,CHEMBL621672,1.0,,1.0,,,,,500.0,5164.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability
,BAO_0000218,F,,A-431,80852.0,N,,Expert,16289.0,,,CHEMBL621673,1.0,,1.0,,,,,500.0,5165.0,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)"
,BAO_0000218,F,,A-431,80852.0,N,,Expert,16289.0,,,CHEMBL621674,1.0,,1.0,,,,,500.0,5166.0,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)"
,BAO_0000219,F,,A-431,9.0,D,Homo sapiens,Expert,16093.0,,9606.0,CHEMBL884002,1.0,,9.0,,,,,500.0,5167.0,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,16825.0,,9606.0,CHEMBL621850,1.0,,1.0,,,,,500.0,5168.0,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. "
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,4848.0,,9606.0,CHEMBL621851,1.0,,1.0,,,,,500.0,5169.0,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells
,BAO_0000219,F,,A-431,9.0,D,Homo sapiens,Expert,14827.0,,9606.0,CHEMBL621852,1.0,,9.0,,,,,500.0,5170.0,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells
,BAO_0000219,F,,A-431,9.0,D,Homo sapiens,Expert,14827.0,,9606.0,CHEMBL621853,1.0,,9.0,,,,,500.0,5171.0,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture
,BAO_0000218,F,,A-431,80852.0,N,,Expert,16289.0,,,CHEMBL621854,1.0,,1.0,,,,,500.0,5172.0,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)"
,BAO_0000218,F,,A-431,80852.0,N,,Expert,16289.0,,,CHEMBL621855,1.0,,1.0,,,,,500.0,5173.0,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)"
,BAO_0000218,F,,A-431,80852.0,N,,Expert,16289.0,,,CHEMBL623724,1.0,,1.0,,,,,500.0,5174.0,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)"
,BAO_0000218,F,,A-431,80852.0,N,,Expert,16289.0,,,CHEMBL623725,1.0,,1.0,,,,,500.0,5175.0,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24"
,BAO_0000218,F,,A-431,80852.0,N,,Expert,16289.0,,,CHEMBL623726,1.0,,1.0,,,,,500.0,5176.0,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26"
,BAO_0000219,F,,A-431,9.0,D,Homo sapiens,Expert,16289.0,,9606.0,CHEMBL623727,1.0,,9.0,,,,,500.0,5177.0,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound"
,BAO_0000219,F,,A-431,9.0,H,,Expert,16289.0,,,CHEMBL623728,1.0,,8.0,,,,,500.0,5178.0,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound
,BAO_0000218,F,,A-431,80852.0,N,,Expert,16289.0,,,CHEMBL623729,1.0,,1.0,,,,,500.0,5179.0,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24"
,BAO_0000218,F,,A-431,80852.0,N,,Expert,16289.0,,,CHEMBL623730,1.0,,1.0,,,,,500.0,5180.0,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26"
,BAO_0000218,F,,A-431,80852.0,N,,Expert,16289.0,,,CHEMBL623731,1.0,,1.0,,,,,500.0,5181.0,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26"
,BAO_0000218,F,,A-431,80852.0,N,Mus musculus,Expert,14555.0,,10090.0,CHEMBL623732,1.0,,1.0,,,,,500.0,5182.0,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration"
,BAO_0000218,F,,A-431,80852.0,N,Mus musculus,Expert,14555.0,,10090.0,CHEMBL623733,1.0,,1.0,,,,,500.0,5183.0,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration"
,BAO_0000218,F,,A-431,80852.0,N,Mus musculus,Expert,14555.0,,10090.0,CHEMBL623734,1.0,,1.0,,,,,500.0,5184.0,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration"
,BAO_0000218,F,,A-431,80852.0,N,Mus musculus,Expert,14555.0,,10090.0,CHEMBL623735,1.0,,1.0,,,,,500.0,5185.0,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration"
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Expert,1937.0,,9606.0,CHEMBL623736,1.0,,1.0,,,,,500.0,5186.0,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,13739.0,,9606.0,CHEMBL623737,1.0,,1.0,,,,,500.0,5187.0,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,3558.0,,9606.0,CHEMBL623738,1.0,,1.0,,,,,500.0,5188.0,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Intermediate,3558.0,,9606.0,CHEMBL875168,1.0,,1.0,,,,,500.0,5189.0,Dose giving a 50% decrease in the living cell number (A437 cells)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,17686.0,,9606.0,CHEMBL623739,1.0,,1.0,,,,,646.0,5190.0,In vitro inhibitory concentration against proliferation of A459 cell line.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5305.0,,9606.0,CHEMBL623740,1.0,,1.0,,,,,646.0,5191.0,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,3614.0,,9606.0,CHEMBL624424,1.0,,1.0,,,,,646.0,5192.0,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,17229.0,,9606.0,CHEMBL624425,1.0,,1.0,,,,,624.0,5193.0,In vitro antitumor activity against renal A498 tumor cell lines
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,15935.0,,9606.0,CHEMBL624426,1.0,,1.0,,,,,624.0,5194.0,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors"
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,15935.0,,9606.0,CHEMBL624427,1.0,,1.0,,,,,624.0,5195.0,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium"
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,15560.0,,9606.0,CHEMBL624428,1.0,,1.0,,,,,624.0,5196.0,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,13891.0,,9606.0,CHEMBL624429,1.0,,1.0,,,,,624.0,5197.0,Cytotoxicity concentration against human kidney carcinoma A-498 cell line
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,13891.0,,9606.0,CHEMBL624620,1.0,,1.0,,,,,624.0,5198.0,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,13788.0,,9606.0,CHEMBL624621,1.0,,1.0,,,,,624.0,5199.0,Cytotoxicity on kidney carcinoma (A-498) cell line
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,15403.0,,9606.0,CHEMBL624622,1.0,,1.0,,,,,624.0,5200.0,Compound was evaluated against Human cell line renal A498
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,1009.0,,9606.0,CHEMBL624623,1.0,,1.0,,,,,624.0,5201.0,Compound was tested for inhibition of A498 human renal cancer cell line
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,1043.0,,9606.0,CHEMBL874365,1.0,,1.0,,,,,624.0,5202.0,Growth inhibitory activity against A498 human cancer cell line
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,5858.0,,9606.0,CHEMBL624624,1.0,,1.0,,,,,624.0,5203.0,In vitro antitumor activity against human renal A498 cell line
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,5958.0,,9606.0,CHEMBL624625,1.0,,1.0,,,,,624.0,5204.0,In vitro cytotoxic activity against renal (A498) cell line
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,5506.0,,9606.0,CHEMBL624626,1.0,,1.0,,,,,624.0,5205.0,In vitro cytotoxic activity against human renal cancer (A498) cell line
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,12781.0,,9606.0,CHEMBL624627,1.0,,1.0,,,,,624.0,5206.0,Tested for cytostatic activity against renal A498 cell line
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,14399.0,,9606.0,CHEMBL883157,1.0,,1.0,,,,,624.0,5207.0,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Expert,5958.0,,9606.0,CHEMBL624628,1.0,,1.0,,,,,624.0,5208.0,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M
,BAO_0000218,A,In vivo,,22224.0,U,beagle,Autocuration,3510.0,,9615.0,CHEMBL624629,1.0,,0.0,,,,,,5209.0,Cmax value after 2 mpk peroral administration to beagles
beagle,BAO_0000218,A,In vivo,,22224.0,U,Canis lupus familiaris,Autocuration,3510.0,,9615.0,CHEMBL623551,1.0,,0.0,,,,,,5210.0,Bioavailability
beagle,BAO_0000218,A,In vivo,,22224.0,U,Canis lupus familiaris,Autocuration,3510.0,,9615.0,CHEMBL623552,1.0,,0.0,,,,,,5211.0,Bioavailability after 1 mpk peroral administration to beagles
beagle,BAO_0000218,A,In vivo,,22224.0,U,Canis lupus familiaris,Autocuration,3510.0,,9615.0,CHEMBL623553,1.0,,0.0,,,,,,5212.0,Bioavailability after 2 mpk peroral administration to beagles
,BAO_0000019,A,,,22224.0,U,Bos taurus,Autocuration,3085.0,,9913.0,CHEMBL623554,1.0,,0.0,,,,,,5213.0,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9
,BAO_0000019,A,,,22224.0,U,Bos taurus,Autocuration,3085.0,,9913.0,CHEMBL623555,1.0,,0.0,,,,,,5214.0,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat
,BAO_0000019,A,,,22224.0,U,Bos taurus,Autocuration,3085.0,,9913.0,CHEMBL623556,1.0,,0.0,,,,,,5215.0,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound
,BAO_0000019,A,,,22224.0,U,Bos taurus,Autocuration,9372.0,,9913.0,CHEMBL623557,1.0,,0.0,,,,,,5216.0,Solubility against bovine alpha-chymotrypsin
,BAO_0000019,A,,,22224.0,U,Bos taurus,Autocuration,3085.0,,9913.0,CHEMBL623558,1.0,,0.0,,,,,,5217.0,Rate constant of the bovine serum albumin catalyzed reaction of the compound
,BAO_0000019,A,,,22224.0,U,Bos taurus,Autocuration,3085.0,,9913.0,CHEMBL623559,1.0,,0.0,,,,,,5218.0,Rate constant of the bovine serum albumin catalyzed reaction of the compound
,BAO_0000221,A,,,22224.0,U,Bos taurus,Autocuration,1469.0,,9913.0,CHEMBL623560,1.0,,0.0,Spleen,,,2106.0,,5219.0,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg
,BAO_0000019,A,,,22224.0,U,Bos taurus,Autocuration,4297.0,,9913.0,CHEMBL623561,1.0,,0.0,,,,,,5220.0,Half life in culture medium containing 10% of heat inactivated foetal calf serum
,BAO_0000019,A,,,22224.0,U,Bos taurus,Autocuration,4297.0,,9913.0,CHEMBL623562,1.0,,0.0,,,,,,5221.0,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined
,BAO_0000019,A,,,22224.0,U,Bos taurus,Autocuration,17585.0,,9913.0,CHEMBL623563,1.0,,0.0,,,,,,5222.0,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2
,BAO_0000221,A,,,22224.0,U,Bos taurus,Autocuration,1336.0,,9913.0,CHEMBL623564,1.0,,0.0,Spleen,,,2106.0,,5223.0,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase
,BAO_0000019,A,,,22224.0,U,Bos taurus,Autocuration,3085.0,,9913.0,CHEMBL873806,1.0,,0.0,,,,,,5224.0,Half life in presence of 2 mg/mL BSA at pH 8.8
,BAO_0000019,A,,,22224.0,U,Bos taurus,Autocuration,2857.0,,9913.0,CHEMBL623565,1.0,,0.0,,,,,,5225.0,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1
,BAO_0000019,A,,,22224.0,U,Bos taurus,Autocuration,2857.0,,9913.0,CHEMBL623566,1.0,,0.0,,,,,,5226.0,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2
,BAO_0000019,A,,,22224.0,U,Bos taurus,Autocuration,2857.0,,9913.0,CHEMBL623567,1.0,,0.0,,,,,,5227.0,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined
,BAO_0000019,A,,,22224.0,U,Bos taurus,Autocuration,1540.0,,9913.0,CHEMBL623568,1.0,,0.0,,,,,,5228.0,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6316.0,,9615.0,CHEMBL623569,1.0,,1.0,Plasma,,,1969.0,,5229.0,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,17594.0,,9615.0,CHEMBL623570,1.0,,1.0,Plasma,,,1969.0,,5230.0,AUC after administration at 100 mg/kg/day in dogs
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4953.0,,9615.0,CHEMBL624254,1.0,,1.0,Plasma,,,1969.0,,5231.0,AUC in dog at 0-24 hr by peroral administration at 3 mpk
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,16907.0,,9615.0,CHEMBL624255,1.0,,1.0,Plasma,,,1969.0,,5232.0,AUC value after 15 mg/kg iv dose in Dogs
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,16907.0,,9615.0,CHEMBL624256,1.0,,1.0,Plasma,,,1969.0,,5233.0,AUC value after 30 mg/kg po dose in Dogs
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,2959.0,,9615.0,CHEMBL624257,1.0,,1.0,Plasma,,,1969.0,,5234.0,AUC value after administration of 4 mg/Kg oral dose in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,17594.0,,9615.0,CHEMBL624258,1.0,,1.0,Plasma,,,1969.0,,5235.0,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5356.0,,9615.0,CHEMBL875277,1.0,,1.0,,,,,,5236.0,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,16807.0,,9615.0,CHEMBL622667,1.0,,1.0,,,,,,5237.0,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4527.0,,9615.0,CHEMBL622668,1.0,,1.0,,,,,,5238.0,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4527.0,,9615.0,CHEMBL622669,1.0,,1.0,,,,,,5239.0,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,15660.0,,9615.0,CHEMBL622670,1.0,,1.0,,,,,,5240.0,Area under curve determined in dogs after intravenous administration of 3 mg/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,15660.0,,9615.0,CHEMBL622671,1.0,,1.0,,,,,,5241.0,Area under curve determined in dogs after oral administration of 10 mg/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5802.0,,9615.0,CHEMBL622672,1.0,,1.0,,,,,,5242.0,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Expert,3598.0,,9615.0,CHEMBL622673,1.0,,1.0,,,,,,5243.0,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Expert,3598.0,,9615.0,CHEMBL622674,1.0,,1.0,,,,,,5244.0,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5944.0,,9615.0,CHEMBL622675,1.0,,1.0,,,,,,5245.0,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5944.0,,9615.0,CHEMBL622676,1.0,,1.0,,,,,,5246.0,Area under curve determined in dog at a dose of 10 mg/kg by oral administration
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5944.0,,9615.0,CHEMBL622677,1.0,,1.0,,,,,,5247.0,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5944.0,,9615.0,CHEMBL622678,1.0,,1.0,,,,,,5248.0,Area under curve determined in dog at a dose of 5 mg/kg by oral administration
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4186.0,,9615.0,CHEMBL622679,1.0,,1.0,,,,,,5249.0,Area under curve in dog after administration of 20 mg/kg dose through peroral route
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5007.0,,9615.0,CHEMBL622680,1.0,,1.0,,,,,,5250.0,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5668.0,,9615.0,CHEMBL622681,1.0,,1.0,,,,,,5251.0,Area under curve was determine after peroral administration at 10 mpk in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5668.0,,9615.0,CHEMBL875278,1.0,,1.0,,,,,,5252.0,Area under curve was determine after peroral administration at 5 mpk in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5006.0,,9615.0,CHEMBL622682,1.0,,1.0,,,,,,5253.0,Area under curve was determined
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5006.0,,9615.0,CHEMBL622683,1.0,,1.0,,,,,,5254.0,Area under curve in dogs
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3771.0,,9615.0,CHEMBL622684,1.0,,1.0,,,,,,5255.0,Area under curve in dogs at 10 mg/kg dose fo oral administration
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3771.0,,9615.0,CHEMBL622685,1.0,,1.0,,,,,,5256.0,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3771.0,,9615.0,CHEMBL622686,1.0,,1.0,,,,,,5257.0,Area under curve in dogs at 3 mg/kg dose fo intravenous administration
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,1916.0,,9615.0,CHEMBL618344,1.0,,1.0,,,,,,5258.0,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5302.0,,9615.0,CHEMBL875582,1.0,,1.0,,,,,,5259.0,Area under curve value in dog at a dose of 5 mg/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5600.0,,9615.0,CHEMBL618345,1.0,,1.0,,,,,,5260.0,Area under curve was determined after 0.1 mg/kg iv administration in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5600.0,,9615.0,CHEMBL618346,1.0,,1.0,,,,,,5261.0,Area under curve was determined after 0.3 mg/kg po administration in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,17764.0,,9615.0,CHEMBL618347,1.0,,1.0,,,,,,5262.0,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4368.0,,9615.0,CHEMBL618348,1.0,,1.0,,,,,,5263.0,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,5318.0,,9606.0,CHEMBL618349,1.0,,0.0,,,,,,5264.0,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,5318.0,,9606.0,CHEMBL618350,1.0,,0.0,,,,,,5265.0,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,5318.0,,9606.0,CHEMBL618351,1.0,,0.0,,,,,,5266.0,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,5318.0,,9606.0,CHEMBL618352,1.0,,0.0,,,,,,5267.0,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase
,BAO_0000221,A,,,22224.0,U,Homo sapiens,Autocuration,14518.0,,9606.0,CHEMBL873494,1.0,,0.0,Blood,,,178.0,,5268.0,Time taken to reduce 50% of the concentration of compound in blood plasma
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,2209.0,,9606.0,CHEMBL618353,1.0,,0.0,Plasma,,,1969.0,,5269.0,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I)."
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,6787.0,,9606.0,CHEMBL618354,1.0,,0.0,Plasma,,,1969.0,,5270.0,Half life in human plasma
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,4898.0,,9606.0,CHEMBL875583,1.0,,0.0,Plasma,,,1969.0,,5271.0,Half life in human plasma was reported
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6072.0,,9606.0,CHEMBL618355,1.0,,0.0,Serum,,,1977.0,,5272.0,Half life in human serum
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,16907.0,,9606.0,CHEMBL618356,1.0,,0.0,Plasma,,,1969.0,,5273.0,Half life upon exposure to human plasma
,BAO_0000251,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,5656.0,Microsomes,9606.0,CHEMBL618357,1.0,,0.0,,,,,,5274.0,t1/2 in human microsomes
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,4755.0,,9606.0,CHEMBL618358,1.0,,0.0,Plasma,,,1969.0,,5275.0,Half life period in 80% human plasma at 37 degree Centigrade
,BAO_0000221,A,,,22224.0,U,Homo sapiens,Autocuration,17503.0,,9606.0,CHEMBL618359,1.0,,0.0,Zone of skin,,,14.0,,5276.0,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4)
,BAO_0000366,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,12357.0,,9606.0,CHEMBL618360,1.0,,0.0,Plasma,,,1969.0,,5277.0,Half-life measured in in vitro Cathepsin B assay in human plasma
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,3076.0,,9606.0,CHEMBL618361,1.0,,0.0,,,,,,5278.0,Half-life at initial concentration of 5*10e-5 M in CEM cell extract
,BAO_0000251,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,6410.0,Microsomes,9606.0,CHEMBL618362,1.0,,0.0,Liver,,,2107.0,,5279.0,Half-life determined by human liver microsome stability assay at a concentration of 5 uM
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,3741.0,,9606.0,CHEMBL618363,1.0,,0.0,Plasma,,,1969.0,,5280.0,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma"
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,3741.0,,9606.0,CHEMBL618364,1.0,,0.0,Plasma,,,1969.0,,5281.0,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)"
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,3741.0,,9606.0,CHEMBL875584,1.0,,0.0,Plasma,,,1969.0,,5282.0,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)"
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,1540.0,,9606.0,CHEMBL618365,1.0,,0.0,,,,,,5283.0,Half-life in the CEM cell extracts
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,2905.0,,9606.0,CHEMBL873495,1.0,,0.0,Plasma,,,1969.0,,5284.0,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,2905.0,,9606.0,CHEMBL618366,1.0,,0.0,Plasma,,,1969.0,,5285.0,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,5523.0,,9606.0,CHEMBL618367,1.0,,0.0,,,,,,5286.0,Half-life was determined
,BAO_0000221,A,,,22224.0,U,Homo sapiens,Autocuration,1499.0,,9606.0,CHEMBL618368,1.0,,0.0,Blood,,,178.0,,5287.0,Half-life (human blood stability)
,BAO_0000221,A,,,22224.0,U,Homo sapiens,Autocuration,1499.0,,9606.0,CHEMBL618369,1.0,,0.0,Blood,,,178.0,,5288.0,Half-life (human blood stability); no data
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,17065.0,,9606.0,CHEMBL618370,1.0,,0.0,Plasma,,,1969.0,,5289.0,Half-life in human plasma
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,6861.0,,9606.0,CHEMBL618371,1.0,,0.0,,,,,,5290.0,CYP3A4 metabolism half-life (t1/2)
,BAO_0000221,A,,,22224.0,U,Homo sapiens,Autocuration,1499.0,,9606.0,CHEMBL618372,1.0,,0.0,Blood,,,178.0,,5291.0,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability)
,BAO_0000366,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,530.0,,9606.0,CHEMBL618373,1.0,,0.0,Plasma,,,1969.0,,5292.0,In vitro half life in human plasma
,BAO_0000366,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,1116.0,,9606.0,CHEMBL618374,1.0,,0.0,Plasma,,,1969.0,,5293.0,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma"
,BAO_0000366,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,6695.0,,9606.0,CHEMBL618375,1.0,,0.0,Plasma,,,1969.0,,5294.0,In vitro hydrolysis in human plasma
,BAO_0000366,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,6695.0,,9606.0,CHEMBL618376,1.0,,0.0,Plasma,,,1969.0,,5295.0,In vitro hydrolysis in human plasma; no data
,BAO_0000251,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,10.0,Microsomes,9606.0,CHEMBL618377,1.0,,0.0,Liver,,,2107.0,,5296.0,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,993.0,,9606.0,CHEMBL618378,1.0,,0.0,Plasma,,,1969.0,,5297.0,Plasma half life in human
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,15429.0,,9606.0,CHEMBL618379,1.0,,0.0,Plasma,,,1969.0,,5298.0,Stability after incubation with human plasma (at 37 degree C)
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,1675.0,,9606.0,CHEMBL618380,1.0,,0.0,Plasma,,,1969.0,,5299.0,T1/2 was evaluated in human plasma
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,2209.0,,9606.0,CHEMBL618381,1.0,,0.0,Plasma,,,1969.0,,5300.0,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I)."
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,2209.0,,9606.0,CHEMBL618382,1.0,,0.0,Plasma,,,1969.0,,5301.0,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined"
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,5318.0,,9606.0,CHEMBL618383,1.0,,0.0,,,,,,5302.0,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase
,BAO_0000019,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,2412.0,,9606.0,CHEMBL618384,1.0,,0.0,,,,,,5303.0,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase
,BAO_0000019,A,In vitro,,22224.0,U,Homo sapiens,Autocuration,2412.0,,9606.0,CHEMBL618385,1.0,,0.0,,,,,,5304.0,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,2906.0,,9606.0,CHEMBL619099,1.0,,0.0,Plasma,,,1969.0,,5305.0,The release rate of the free drug from the substrate in human plasma by human plasma stability assay
,BAO_0000366,A,,,22224.0,U,Homo sapiens,Autocuration,2906.0,,9606.0,CHEMBL619100,1.0,,0.0,Plasma,,,1969.0,,5306.0,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,5495.0,,9606.0,CHEMBL619101,1.0,,0.0,,,,,,5307.0,Time taken for 50% to be consumed by serum PON1 was determined
,BAO_0000019,A,,,22224.0,U,Homo sapiens,Autocuration,5495.0,,9606.0,CHEMBL619102,1.0,,0.0,,,,,,5308.0,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed
,BAO_0000251,A,,,22224.0,U,Homo sapiens,Autocuration,4397.0,Microsomes,9606.0,CHEMBL619103,1.0,,0.0,Liver,,,2107.0,,5309.0,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes
,BAO_0000218,A,,,22224.0,U,Mus sp.,Autocuration,2413.0,,10095.0,CHEMBL619268,1.0,,0.0,,,,,,5310.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour
,BAO_0000218,A,,,22224.0,U,Mus sp.,Autocuration,2413.0,,10095.0,CHEMBL619269,1.0,,0.0,,,,,,5311.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour
,BAO_0000218,A,,,22224.0,U,Mus sp.,Autocuration,2413.0,,10095.0,CHEMBL619270,1.0,,0.0,,,,,,5312.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour
,BAO_0000218,A,,,22224.0,U,Mus sp.,Autocuration,2413.0,,10095.0,CHEMBL619271,1.0,,0.0,,,,,,5313.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour
,BAO_0000218,A,,,22224.0,U,Mus sp.,Autocuration,2413.0,,10095.0,CHEMBL875585,1.0,,0.0,,,,,,5314.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour
,BAO_0000218,A,,,22224.0,U,Mus sp.,Autocuration,2413.0,,10095.0,CHEMBL619272,1.0,,0.0,,,,,,5315.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,6058.0,,9606.0,CHEMBL619273,1.0,,1.0,,,,,391.0,5316.0,Compound tested for growth inhibition of renal cancer cell line 786-0
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,17708.0,,9606.0,CHEMBL619274,1.0,,1.0,,,,,391.0,5317.0,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Expert,14017.0,,9606.0,CHEMBL619275,1.0,,1.0,,,,,391.0,5318.0,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,16818.0,,9606.0,CHEMBL619276,1.0,,1.0,,,,,391.0,5319.0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration"
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,16818.0,,9606.0,CHEMBL619277,1.0,,1.0,,,,,391.0,5320.0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration"
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,16818.0,,9606.0,CHEMBL619278,1.0,,1.0,,,,,391.0,5321.0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration"
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,11970.0,,9606.0,CHEMBL619279,1.0,,1.0,,,,,391.0,5322.0,Tested for cytotoxicity against 786-0 cell lines in renal cancer
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,12400.0,,9606.0,CHEMBL858458,1.0,,1.0,,,,,391.0,5323.0,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Expert,12888.0,,9606.0,CHEMBL619280,1.0,,1.0,,,,,391.0,5324.0,Cytotoxic effect on renal cancer line 786-0
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,15300.0,,9606.0,CHEMBL619281,1.0,,1.0,,,,,391.0,5325.0,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,14769.0,,9606.0,CHEMBL619282,1.0,,1.0,,,,,391.0,5326.0,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells )
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,15895.0,,9606.0,CHEMBL619283,1.0,,1.0,,,,,391.0,5327.0,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line"
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,17376.0,,9606.0,CHEMBL619284,1.0,,1.0,,,,,391.0,5328.0,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,14882.0,,9606.0,CHEMBL619285,1.0,,1.0,,,,,391.0,5329.0,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,14882.0,,9606.0,CHEMBL619286,1.0,,1.0,,,,,391.0,5330.0,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death)
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,15176.0,,9606.0,CHEMBL619287,1.0,,1.0,,,,,391.0,5331.0,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,12696.0,,9606.0,CHEMBL857455,1.0,,1.0,,,,,391.0,5332.0,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,2496.0,,9606.0,CHEMBL883801,1.0,,1.0,,,,,391.0,5333.0,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma)
,BAO_0000219,F,,791T cell line,80641.0,N,Homo sapiens,Intermediate,11831.0,,9606.0,CHEMBL619288,1.0,,1.0,,,,,972.0,5334.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression
,BAO_0000219,F,,791T cell line,80641.0,N,Homo sapiens,Intermediate,11831.0,,9606.0,CHEMBL619289,1.0,,1.0,,,,,972.0,5335.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL)
,BAO_0000219,F,,791T cell line,80641.0,N,Homo sapiens,Intermediate,11831.0,,9606.0,CHEMBL619290,1.0,,1.0,,,,,972.0,5336.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved
,BAO_0000219,F,,791T cell line,80641.0,N,Homo sapiens,Intermediate,11831.0,,9606.0,CHEMBL619291,1.0,,1.0,,,,,972.0,5337.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33)
,BAO_0000219,F,,791T cell line,80641.0,N,Homo sapiens,Intermediate,11831.0,,9606.0,CHEMBL619292,1.0,,1.0,,,,,972.0,5338.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26)
,BAO_0000219,F,,791T cell line,80641.0,N,Homo sapiens,Intermediate,11831.0,,9606.0,CHEMBL619293,1.0,,1.0,,,,,972.0,5339.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved
,BAO_0000219,F,,791T cell line,80641.0,N,Homo sapiens,Intermediate,11831.0,,9606.0,CHEMBL619294,1.0,,1.0,,,,,972.0,5340.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33)
,BAO_0000219,F,,791T cell line,80641.0,N,Homo sapiens,Intermediate,11831.0,,9606.0,CHEMBL619295,1.0,,1.0,,,,,972.0,5341.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26)
,BAO_0000219,F,,791T cell line,80641.0,N,Homo sapiens,Intermediate,11831.0,,9606.0,CHEMBL619296,1.0,,1.0,,,,,972.0,5342.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved)
,BAO_0000219,F,,791T cell line,80641.0,N,Homo sapiens,Intermediate,11831.0,,9606.0,CHEMBL619297,1.0,,1.0,,,,,972.0,5343.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved
,BAO_0000219,F,,786-0,80640.0,N,Homo sapiens,Intermediate,12782.0,,9606.0,CHEMBL619298,1.0,,1.0,,,,,391.0,5344.0,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line
,BAO_0000019,F,,,22226.0,U,,Intermediate,1229.0,,,CHEMBL619299,1.0,,0.0,,,,,,5345.0,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Expert,15313.0,,9606.0,CHEMBL619300,1.0,,1.0,,,,,741.0,5346.0,Inhibition of cell growth in drug resistant 8226 myeloma cell line
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Expert,15313.0,,9606.0,CHEMBL619301,1.0,,1.0,,,,,741.0,5347.0,Inhibition of cell growth in drug sensitive 8226 myeloma cell line
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,11544.0,,9606.0,CHEMBL619302,1.0,,1.0,,,,,741.0,5348.0,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL619303,1.0,,1.0,,,,,741.0,5349.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL619304,1.0,,1.0,,,,,741.0,5350.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL857706,1.0,,1.0,,,,,741.0,5351.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill)
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL619305,1.0,,1.0,,,,,741.0,5352.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill)
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL619306,1.0,,1.0,,,,,741.0,5353.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill)
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL619307,1.0,,1.0,,,,,741.0,5354.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill)
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL619308,1.0,,1.0,,,,,741.0,5355.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill)
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL619309,1.0,,1.0,,,,,741.0,5356.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill)
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL619310,1.0,,1.0,,,,,741.0,5357.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill)
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,14769.0,,9606.0,CHEMBL619311,1.0,,1.0,,,,,624.0,5358.0,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells )
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,15354.0,,9606.0,CHEMBL619312,1.0,,1.0,,,,,624.0,5359.0,Compound was tested for the growth inhibition of A498 renal tumor cell line
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,17445.0,,9606.0,CHEMBL619313,1.0,,1.0,,,,,624.0,5360.0,In vitro cytotoxicity against human tumor A498 cell line (renal cancer)
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,4337.0,,9606.0,CHEMBL619314,1.0,,1.0,,,,,624.0,5361.0,In vitro inhibitory concentration against renal cancer cell line A498
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,15277.0,,9606.0,CHEMBL619959,1.0,,1.0,,,,,624.0,5362.0,Cytotoxicity against A 498 tumor cell line
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,4812.0,,9606.0,CHEMBL619960,1.0,,1.0,,,,,624.0,5363.0,In vitro antitumor activity against A498 human cancer cell line
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,4812.0,,9606.0,CHEMBL619961,1.0,,1.0,,,,,624.0,5364.0,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening)
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,4995.0,,9606.0,CHEMBL619962,1.0,,1.0,,,,,624.0,5365.0,Inhibitory dose required against A498 human tumor cell lines
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,5847.0,,9606.0,CHEMBL875586,1.0,,1.0,,,,,624.0,5366.0,Anticancer activity against one renal cancer (A498 cell line)
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,6557.0,,9606.0,CHEMBL619963,1.0,,1.0,,,,,624.0,5367.0,In vitro cytotoxicity against melanoma A498 cell line
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,2597.0,,9606.0,CHEMBL619964,1.0,,1.0,,,,,624.0,5368.0,Compound was tested for growth inhibitory activity against A498 cell line
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,6058.0,,9606.0,CHEMBL620108,1.0,,1.0,,,,,624.0,5369.0,Compound tested for growth inhibition of renal cancer cell line A498
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,17708.0,,9606.0,CHEMBL620109,1.0,,1.0,,,,,624.0,5370.0,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,15176.0,,9606.0,CHEMBL620110,1.0,,1.0,,,,,624.0,5371.0,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,15300.0,,9606.0,CHEMBL620111,1.0,,1.0,,,,,624.0,5372.0,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,11970.0,,9606.0,CHEMBL620112,1.0,,1.0,,,,,624.0,5373.0,Tested for cytotoxicity against A498 cell lines in renal cancer
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,12400.0,,9606.0,CHEMBL620113,1.0,,1.0,,,,,624.0,5374.0,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Expert,12888.0,,9606.0,CHEMBL620114,1.0,,1.0,,,,,624.0,5375.0,Cytotoxic effect on renal cancer lines A498
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,3030.0,,9606.0,CHEMBL620115,1.0,,1.0,,,,,624.0,5376.0,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,14769.0,,9606.0,CHEMBL620116,1.0,,1.0,,,,,624.0,5377.0,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells )
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,17376.0,,9606.0,CHEMBL620117,1.0,,1.0,,,,,624.0,5378.0,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,16558.0,,9606.0,CHEMBL620118,1.0,,1.0,,,,,624.0,5379.0,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,5194.0,,9606.0,CHEMBL620119,1.0,,1.0,,,,,624.0,5380.0,Cytotoxicity against human kidney carcinoma cell lines A4982LM
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,10708.0,,9606.0,CHEMBL620120,1.0,,1.0,,,,,624.0,5381.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,16880.0,,9606.0,CHEMBL620121,1.0,,1.0,,,,,646.0,5382.0,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,10196.0,,9606.0,CHEMBL620122,1.0,,1.0,,,,,646.0,5383.0,Antitumor activity against A549 human lung carcinoma cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,10196.0,,9606.0,CHEMBL620123,1.0,,1.0,,,,,646.0,5384.0,Antitumor activity against A549 human lung carcinoma cell line in experiment 1
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,10196.0,,9606.0,CHEMBL620124,1.0,,1.0,,,,,646.0,5385.0,Antitumor activity against A549 human lung carcinoma cell line in experiment 2
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,12083.0,,9606.0,CHEMBL620125,1.0,,1.0,,,,,646.0,5386.0,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line"
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,16464.0,,9606.0,CHEMBL620126,1.0,,1.0,,,,,646.0,5387.0,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16464.0,,9606.0,CHEMBL883027,1.0,,1.0,,,,,646.0,5388.0,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,16470.0,,9606.0,CHEMBL620127,1.0,,1.0,,,,,646.0,5389.0,In vitro cytotoxic activity against human lung A549 cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16470.0,,9606.0,CHEMBL620128,1.0,,1.0,,,,,646.0,5390.0,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16470.0,,9606.0,CHEMBL620129,1.0,,1.0,,,,,646.0,5391.0,In vitro cytotoxic activity against human lung A549 cell line)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16470.0,,9606.0,CHEMBL620130,1.0,,1.0,,,,,646.0,5392.0,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,16582.0,,9606.0,CHEMBL620131,1.0,,1.0,,,,,646.0,5393.0,In vitro cytotoxicity against human non small-cell-lung cell line A549.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,15935.0,,9606.0,CHEMBL620132,1.0,,1.0,,,,,646.0,5394.0,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors"
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,15935.0,,9606.0,CHEMBL620133,1.0,,1.0,,,,,646.0,5395.0,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium"
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,16597.0,,9606.0,CHEMBL620134,1.0,,1.0,,,,,646.0,5396.0,Inhibition of A549 human lung carcinoma cell proliferation
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17376.0,,9606.0,CHEMBL620135,1.0,,1.0,,,,,646.0,5397.0,Inhibitory activity against A549 lung adenocarcinoma cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16496.0,,9606.0,CHEMBL620136,1.0,,1.0,,,,,646.0,5398.0,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16152.0,,9606.0,CHEMBL620137,1.0,,1.0,,,,,646.0,5399.0,in vitro anticancer activity against cultured A549 human tumor(lung) cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16152.0,,9606.0,CHEMBL620268,1.0,,1.0,,,,,646.0,5400.0,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16464.0,,9606.0,CHEMBL620269,1.0,,1.0,,,,,646.0,5401.0,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,2288.0,,9606.0,CHEMBL620270,1.0,,1.0,,,,,646.0,5402.0,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17350.0,,9606.0,CHEMBL620271,1.0,,1.0,,,,,646.0,5403.0,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,4090.0,,9606.0,CHEMBL620272,1.0,,1.0,,,,,646.0,5404.0,Inhibition of A549 cancer cell proliferation
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,4090.0,,9606.0,CHEMBL620273,1.0,,1.0,,,,,646.0,5405.0,Inhibition of A549 cancer cell proliferation (Not tested)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17350.0,,9606.0,CHEMBL620274,1.0,,1.0,,,,,646.0,5406.0,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4197.0,,9606.0,CHEMBL620275,1.0,,1.0,,,,,646.0,5407.0,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17072.0,,9606.0,CHEMBL620276,1.0,,1.0,,,,,646.0,5408.0,Antiproliferative potency determined as inhibitory concentration against A549 cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17072.0,,9606.0,CHEMBL620277,1.0,,1.0,,,,,646.0,5409.0,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5194.0,,9606.0,CHEMBL620278,1.0,,1.0,,,,,646.0,5410.0,Cytotoxicity against Renal cell lines A549 was determined
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4257.0,,9615.0,CHEMBL620279,1.0,,1.0,,,,,,5411.0,Area under curve was determined in dog after a 3 mg/kg of oral dose
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6123.0,,9615.0,CHEMBL620280,1.0,,1.0,,,,,,5412.0,Area under curve was determined in dog after oral administration at 1 mg/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,1337.0,,9615.0,CHEMBL620281,1.0,,1.0,,,,,,5413.0,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,1337.0,,9615.0,CHEMBL620282,1.0,,1.0,,,,,,5414.0,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,8833.0,,9615.0,CHEMBL621134,1.0,,1.0,,,,,,5415.0,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,8833.0,,9615.0,CHEMBL621135,1.0,,1.0,,,,,,5416.0,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,8833.0,,9615.0,CHEMBL621136,1.0,,1.0,,,,,,5417.0,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,8833.0,,9615.0,CHEMBL621137,1.0,,1.0,,,,,,5418.0,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,17657.0,,9615.0,CHEMBL621138,1.0,,1.0,Plasma,,,1969.0,,5419.0,Area under plasma concentration time curve in dog upon oral administration
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,17650.0,,9615.0,CHEMBL875587,1.0,,1.0,Plasma,,,1969.0,,5420.0,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,1977.0,,9615.0,CHEMBL621139,1.0,,1.0,,,,,,5421.0,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,1977.0,,9615.0,CHEMBL621140,1.0,,1.0,,,,,,5422.0,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3132.0,,9615.0,CHEMBL621141,1.0,,1.0,,,,,,5423.0,Area under the curve for the compound was obtained when tested in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5473.0,,9615.0,CHEMBL621142,1.0,,1.0,,,,,,5424.0,Area under the curve at a dose of 1 mg/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5474.0,,9615.0,CHEMBL621143,1.0,,1.0,,,,,,5425.0,Area under the curve at a dose of 1 mg/kg (oral)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5474.0,,9615.0,CHEMBL621144,1.0,,1.0,,,,,,5426.0,Area under the curve at i.v. dose of 0.2 mg/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6062.0,,9615.0,CHEMBL621145,1.0,,1.0,,,,,,5427.0,Area under the curve was measured in dog after an iv dose of 1 mg/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4709.0,,9615.0,CHEMBL621146,1.0,,1.0,,,,,,5428.0,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,2652.0,,9615.0,CHEMBL622567,1.0,,1.0,,,,,,5429.0,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,2652.0,,9615.0,CHEMBL622568,1.0,,1.0,,,,,,5430.0,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,2877.0,,9615.0,CHEMBL622569,1.0,,1.0,,,,,,5431.0,Compound was evaluated for area under the curve in dog blood.
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5444.0,,9615.0,CHEMBL622570,1.0,,1.0,,,,,,5432.0,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5130.0,,9615.0,CHEMBL622571,1.0,,1.0,Plasma,,,1969.0,,5433.0,AUC in dog after oral dose (1 mg/kg)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6265.0,,9615.0,CHEMBL622572,1.0,,1.0,,,,,,5434.0,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4657.0,,9615.0,CHEMBL622573,1.0,,1.0,,,,,,5435.0,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported."
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,16367.0,,9615.0,CHEMBL622574,1.0,,1.0,,,,,,5436.0,Pharmacokinetic parameter AUC after intravenous administration to dogs
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,16367.0,,9615.0,CHEMBL622575,1.0,,1.0,,,,,,5437.0,Pharmacokinetic parameter AUC after oral administration to dogs
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,9579.0,,9615.0,CHEMBL622576,1.0,,1.0,,,,,,5438.0,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,9579.0,,9615.0,CHEMBL622577,1.0,,1.0,,,,,,5439.0,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5983.0,,9615.0,CHEMBL622578,1.0,,1.0,,,,,,5440.0,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6241.0,,9615.0,CHEMBL622579,1.0,,1.0,,,,,,5441.0,Pharmacokinetic property in dogs after oral administration at 1 mg/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5313.0,,9615.0,CHEMBL622580,1.0,,1.0,,,,,,5442.0,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog"
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5313.0,,9615.0,CHEMBL622581,1.0,,1.0,,,,,,5443.0,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk"
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6642.0,,9615.0,CHEMBL622582,1.0,,1.0,,,,,,5444.0,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6642.0,,9615.0,CHEMBL622583,1.0,,1.0,,,,,,5445.0,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6641.0,,9615.0,CHEMBL622584,1.0,,1.0,,,,,,5446.0,Oral AUCN in dog (dosed at 0.5 mpk iv )
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6642.0,,9615.0,CHEMBL622585,1.0,,1.0,,,,,,5447.0,Oral AUCN in dog (dosed at 0.5 mpk iv )
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,17791.0,,9615.0,CHEMBL622586,1.0,,1.0,,,,,,5448.0,Compound was evaluated for oral bioavailability in dog; 90-100
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,17655.0,,9615.0,CHEMBL623281,1.0,,1.0,,,,,,5449.0,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,17655.0,,9615.0,CHEMBL623282,1.0,,1.0,,,,,,5450.0,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6596.0,,9615.0,CHEMBL623283,1.0,,1.0,,,,,,5451.0,PAPP (membrane permeability) in dog kidney cell monolayer assay
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3880.0,,9615.0,CHEMBL623284,1.0,,1.0,,,,,,5452.0,Oral bioavailability in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,16367.0,,9615.0,CHEMBL623285,1.0,,1.0,,,,,,5453.0,Bioavailability administered orally at a dose of 10 mg/kg to dogs
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,17409.0,,9615.0,CHEMBL623463,1.0,,1.0,Plasma,,,1969.0,,5454.0,Plasma protein binding towards dog plasma at 10 uM
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,17409.0,,9615.0,CHEMBL875952,1.0,,1.0,Plasma,,,1969.0,,5455.0,Plasma protein binding towards dog plasma at 100 uM
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,2959.0,,9615.0,CHEMBL621705,1.0,,1.0,,,,,,5456.0,Bioavailability in dog (dose 4 mg/kg p.o.)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,13501.0,,9615.0,CHEMBL621706,1.0,,1.0,,,,,,5457.0,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4527.0,,9615.0,CHEMBL621707,1.0,,1.0,,,,,,5458.0,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,15145.0,,9615.0,CHEMBL621708,1.0,,1.0,,,,,,5459.0,Bioavailability in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4219.0,,9615.0,CHEMBL621709,1.0,,1.0,,,,,,5460.0,Bioavailability
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17538.0,,9615.0,CHEMBL621710,1.0,,1.0,,,,,,5461.0,Oral bioavailability in dog (dose 10 mg/kg)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17538.0,,9615.0,CHEMBL621711,1.0,,1.0,,,,,,5462.0,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1466.0,,9615.0,CHEMBL621712,1.0,,1.0,,,,,,5463.0,Bioavailability in dog (dose 10.0 mg/kg p.o.)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17650.0,,9615.0,CHEMBL621713,1.0,,1.0,,,,,,5464.0,Bioavailability was measured in dogs after an oral dose of 10 uM/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3132.0,,9615.0,CHEMBL621714,1.0,,1.0,,,,,,5465.0,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog
,BAO_0000218,A,,,22224.0,U,Mus sp.,Autocuration,2413.0,,10095.0,CHEMBL621715,1.0,,0.0,,,,,,5466.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour
,BAO_0000218,A,,,22224.0,U,Mus sp.,Autocuration,2413.0,,10095.0,CHEMBL623717,1.0,,0.0,Liver,,,2107.0,,5467.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour
,BAO_0000218,A,,,22224.0,U,Mus sp.,Autocuration,2413.0,,10095.0,CHEMBL623718,1.0,,0.0,Liver,,,2107.0,,5468.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour
,BAO_0000218,A,,,22224.0,U,Mus sp.,Autocuration,2413.0,,10095.0,CHEMBL623719,1.0,,0.0,Liver,,,2107.0,,5469.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour
,BAO_0000218,A,,,22224.0,U,Mus sp.,Autocuration,2413.0,,10095.0,CHEMBL623720,1.0,,0.0,,,,,,5470.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour
,BAO_0000218,A,,,22224.0,U,Mus sp.,Autocuration,2413.0,,10095.0,CHEMBL623721,1.0,,0.0,,,,,,5471.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour
,BAO_0000218,A,,,22224.0,U,Mus sp.,Autocuration,2413.0,,10095.0,CHEMBL623722,1.0,,0.0,Muscle tissue,,,2385.0,,5472.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour
,BAO_0000218,A,,,22224.0,U,Mus sp.,Autocuration,2413.0,,10095.0,CHEMBL623723,1.0,,0.0,Muscle tissue,,,2385.0,,5473.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour
,BAO_0000218,A,,,22224.0,U,Mus sp.,Autocuration,2413.0,,10095.0,CHEMBL618543,1.0,,0.0,Muscle tissue,,,2385.0,,5474.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour
,BAO_0000218,A,,,22224.0,U,Mus sp.,Autocuration,2413.0,,10095.0,CHEMBL618544,1.0,,0.0,Spleen,,,2106.0,,5475.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour
,BAO_0000218,A,,,22224.0,U,Mus sp.,Autocuration,2413.0,,10095.0,CHEMBL875155,1.0,,0.0,Spleen,,,2106.0,,5476.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour
,BAO_0000218,A,,,22224.0,U,Mus sp.,Autocuration,2413.0,,10095.0,CHEMBL618545,1.0,,0.0,,,,,,5477.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour
,BAO_0000218,A,,,22224.0,U,Mus sp.,Autocuration,2413.0,,10095.0,CHEMBL618546,1.0,,0.0,,,,,,5478.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour
,BAO_0000218,A,,,22224.0,U,Mus sp.,Autocuration,2413.0,,10095.0,CHEMBL623529,1.0,,0.0,,,,,,5479.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour
,BAO_0000218,A,,,22224.0,U,Mus sp.,Autocuration,2413.0,,10095.0,CHEMBL623530,1.0,,0.0,,,,,,5480.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour
,BAO_0000218,A,,,22224.0,U,Mus sp.,Autocuration,2413.0,,10095.0,CHEMBL621764,1.0,,0.0,,,,,,5481.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,17827.0,,9527.0,CHEMBL621765,1.0,,0.0,,,,,,5482.0,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound)
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,17827.0,,9527.0,CHEMBL621766,1.0,,0.0,Cerebellum,,,2037.0,,5483.0,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound)
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,17827.0,,9527.0,CHEMBL621767,1.0,,0.0,Frontal cortex,,,1870.0,,5484.0,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound)
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,17827.0,,9527.0,CHEMBL621768,1.0,,0.0,,,,,,5485.0,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound)
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,17827.0,,9527.0,CHEMBL621769,1.0,,0.0,Striatum,,,2435.0,,5486.0,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound)
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,17827.0,,9527.0,CHEMBL621770,1.0,,0.0,,,,,,5487.0,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound)
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,17827.0,,9527.0,CHEMBL621771,1.0,,0.0,Cerebellum,,,2037.0,,5488.0,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound)
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,17827.0,,9527.0,CHEMBL621772,1.0,,0.0,Frontal cortex,,,1870.0,,5489.0,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound)
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,17827.0,,9527.0,CHEMBL621773,1.0,,0.0,,,,,,5490.0,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound)
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,17827.0,,9527.0,CHEMBL621774,1.0,,0.0,Striatum,,,2435.0,,5491.0,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound)
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,17791.0,,9527.0,CHEMBL621775,1.0,,0.0,,,,,,5492.0,Compound was evaluated for oral bioavailability in rats
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,17667.0,,9527.0,CHEMBL621776,1.0,,0.0,Plasma,,,1969.0,,5493.0,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,17791.0,,9527.0,CHEMBL621777,1.0,,0.0,,,,,,5494.0,Half life period was evaluated in monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,110.0,,9527.0,CHEMBL875162,1.0,,0.0,,,,,,5495.0,Half-life in rhesus monkeys by intravenous administration of dose
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,5781.0,,10090.0,CHEMBL621778,1.0,,1.0,Plasma,,,1969.0,,5496.0,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17734.0,,10090.0,CHEMBL621779,1.0,,1.0,Plasma,,,1969.0,,5497.0,AUC after intraperitoneal administration of 100 mg/kg in mice
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17718.0,,10090.0,CHEMBL622479,1.0,,1.0,Plasma,,,1969.0,,5498.0,AUC value was determined after oral administration
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,4573.0,,10090.0,CHEMBL622480,1.0,,1.0,,,,,,5499.0,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,3277.0,,10090.0,CHEMBL622481,1.0,,1.0,,,,,,5500.0,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4)
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,2862.0,,10090.0,CHEMBL622482,1.0,,1.0,,,,,,5501.0,Area under curve by ioral administration in mouse
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,2862.0,,10090.0,CHEMBL622483,1.0,,1.0,,,,,,5502.0,Area under curve by iv administration in mouse
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,5951.0,,10090.0,CHEMBL622484,1.0,,1.0,,,,,,5503.0,Area under curve at 0-8 hr in IRC mice after peroral administration
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17729.0,,10090.0,CHEMBL622641,1.0,,1.0,,,,,,5504.0,Area under curve when injected i.p. in mice at a dose of 50 mg/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17728.0,,10090.0,CHEMBL622642,1.0,,1.0,,,,,,5505.0,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17728.0,,10090.0,CHEMBL622643,1.0,,1.0,,,,,,5506.0,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17729.0,,10090.0,CHEMBL622644,1.0,,1.0,,,,,,5507.0,Area under curve when injected intravenously in mice at a dose of 20 mg/kg
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL622645,1.0,,1.0,,,,,741.0,5508.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL622646,1.0,,1.0,,,,,741.0,5509.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL621238,1.0,,1.0,,,,,741.0,5510.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill)
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL621239,1.0,,1.0,,,,,741.0,5511.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill)
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL621240,1.0,,1.0,,,,,741.0,5512.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill)
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL621241,1.0,,1.0,,,,,741.0,5513.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill)
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL621242,1.0,,1.0,,,,,741.0,5514.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill)
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL620350,1.0,,1.0,,,,,741.0,5515.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill)
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL620351,1.0,,1.0,,,,,741.0,5516.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL620352,1.0,,1.0,,,,,741.0,5517.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL620353,1.0,,1.0,,,,,741.0,5518.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill)
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL620354,1.0,,1.0,,,,,741.0,5519.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill)
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL620355,1.0,,1.0,,,,,741.0,5520.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill)
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL620356,1.0,,1.0,,,,,741.0,5521.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill)
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL620357,1.0,,1.0,,,,,741.0,5522.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill)
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,9424.0,,9606.0,CHEMBL620358,1.0,,1.0,,,,,741.0,5523.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill)
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Expert,9424.0,,9606.0,CHEMBL620359,1.0,,1.0,,,,,741.0,5524.0,In vitro inhibition of human 8226 myeloma tumor cell line growth.
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,11544.0,,9606.0,CHEMBL620360,1.0,,1.0,,,,,741.0,5525.0,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,17378.0,,9606.0,CHEMBL620361,1.0,,1.0,,,,,741.0,5526.0,Cytotoxicity of compound against 8226/DOX1V cells
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,17378.0,,9606.0,CHEMBL620362,1.0,,1.0,,,,,741.0,5527.0,Cytotoxicity of compound against 8226/S cells
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,17079.0,,9606.0,CHEMBL620363,1.0,,1.0,,,,,741.0,5528.0,Inhibitory concentration against 8226 myeloma cancer cell line
,BAO_0000219,F,,RPMI-8226,80433.0,N,Homo sapiens,Intermediate,17079.0,,9606.0,CHEMBL620364,1.0,,1.0,,,,,741.0,5529.0,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line
,BAO_0000219,F,,833K,80647.0,N,Homo sapiens,Intermediate,13466.0,,9606.0,CHEMBL620365,1.0,,1.0,,,,,854.0,5530.0,Inhibition of cell growth was studied in human teratocarcinoma (833K).
,BAO_0000219,F,,833K,80647.0,N,Homo sapiens,Intermediate,13466.0,,9606.0,CHEMBL620366,1.0,,1.0,,,,,854.0,5531.0,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined'
,BAO_0000219,F,,833K,80647.0,N,Homo sapiens,Expert,2392.0,,9606.0,CHEMBL620367,1.0,,1.0,,,,,854.0,5532.0,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells
,BAO_0000219,F,,833K,80647.0,N,Homo sapiens,Intermediate,2392.0,,9606.0,CHEMBL620368,1.0,,1.0,,,,,854.0,5533.0,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data
,BAO_0000019,B,,,22226.0,U,,Autocuration,6608.0,,,CHEMBL620369,1.0,,0.0,,,,,,5534.0,Inhibitory activity against caspase-1
,BAO_0000357,B,,,45.0,H,Enterococcus faecalis,Autocuration,10199.0,,1351.0,CHEMBL620370,1.0,,8.0,,,,,,5535.0,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound
,BAO_0000219,F,,8701-BC,80648.0,N,Homo sapiens,Intermediate,17749.0,,9606.0,CHEMBL620371,1.0,,1.0,,,,,705.0,5536.0,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay
,BAO_0000219,F,,8701-BC,80648.0,N,Homo sapiens,Intermediate,17749.0,,9606.0,CHEMBL620372,1.0,,1.0,,,,,705.0,5537.0,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM
,BAO_0000019,F,,,22226.0,U,,Intermediate,1229.0,,,CHEMBL876492,1.0,,0.0,,,,,,5538.0,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive
,BAO_0000019,F,,,22226.0,U,,Intermediate,1229.0,,,CHEMBL620373,1.0,,0.0,,,,,,5539.0,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive
,BAO_0000019,F,,,22226.0,U,,Intermediate,1229.0,,,CHEMBL620374,1.0,,0.0,,,,,,5540.0,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive
,BAO_0000019,B,,,22226.0,U,,Autocuration,6390.0,,,CHEMBL620375,1.0,,0.0,,,,,,5541.0,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin
,BAO_0000019,F,,,22226.0,U,Streptococcus pyogenes,Autocuration,16219.0,,1314.0,CHEMBL857902,1.0,,0.0,,,,,,5542.0,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB
,BAO_0000019,F,,,22226.0,U,Streptococcus pyogenes,Autocuration,16219.0,,1314.0,CHEMBL620376,1.0,,0.0,,,,,,5543.0,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB
,BAO_0000357,B,,,11922.0,H,,Autocuration,17043.0,,,CHEMBL620377,1.0,,8.0,,,,,,5544.0,Percent inhibition against Cdc25C phosphatase at 50 uM of compound
,BAO_0000219,F,,KB ,81115.0,N,Homo sapiens,Intermediate,6929.0,,9606.0,CHEMBL620378,1.0,,1.0,,,,,324.0,5545.0,Tested for in vitro cytotoxic potency of compound in 9KB assay
,BAO_0000219,A,,KB ,81115.0,N,Homo sapiens,Intermediate,6929.0,,9606.0,CHEMBL620379,1.0,,1.0,,,,,324.0,5546.0,Tested for in vitro cytotoxic potency of compound in 9KB assay
,BAO_0000219,F,,,22226.0,U,Homo sapiens,Autocuration,7083.0,,9606.0,CHEMBL620380,1.0,,0.0,,,,,,5547.0,In vitro cytotoxicity of compound was tested against 9KB cells.
,BAO_0000219,F,,9L,80653.0,N,Rattus norvegicus,Intermediate,12446.0,,10116.0,CHEMBL884006,1.0,,1.0,,,,,392.0,5548.0,Cytotoxic concentration against 9L cells was determined on day 3
,BAO_0000219,F,,9L,80653.0,N,Rattus norvegicus,Expert,15345.0,,10116.0,CHEMBL620381,1.0,,1.0,,,,,392.0,5549.0,Tested in vitro for anticancer activity against 9L cells
,BAO_0000219,F,,9L,80653.0,N,Rattus norvegicus,Expert,15345.0,,10116.0,CHEMBL620382,1.0,,1.0,,,,,392.0,5550.0,Tested in vitro for anticancer activity against 9L cells; Not determined
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,6301.0,,9606.0,CHEMBL620383,1.0,,1.0,,,,,646.0,5551.0,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4833.0,,9606.0,CHEMBL876493,1.0,,1.0,,,,,646.0,5552.0,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4833.0,,9606.0,CHEMBL620384,1.0,,1.0,,,,,646.0,5553.0,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4833.0,,9606.0,CHEMBL620385,1.0,,1.0,,,,,646.0,5554.0,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,13330.0,,9606.0,CHEMBL620386,1.0,,1.0,,,,,646.0,5555.0,Cytotoxicity against human lung carcinoma A549 cell line
,BAO_0000219,F,,A549,25.0,D,Homo sapiens,Expert,17517.0,,9606.0,CHEMBL620387,1.0,,9.0,,,,,646.0,5556.0,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.
,BAO_0000219,F,,A549,25.0,D,Homo sapiens,Expert,17517.0,,9606.0,CHEMBL621404,1.0,,9.0,,,,,646.0,5557.0,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%."
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,14425.0,,9606.0,CHEMBL621405,1.0,,1.0,,,,,646.0,5558.0,"In vitro growth inhibition of A549, lung carcinoma"
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,14425.0,,9606.0,CHEMBL621406,1.0,,1.0,,,,,646.0,5559.0,"In vitro growth inhibition of A549, lung carcinoma."
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,5228.0,,9606.0,CHEMBL621407,1.0,,1.0,,,,,646.0,5560.0,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5351.0,,9606.0,CHEMBL621408,1.0,,1.0,,,,,646.0,5561.0,Cytotoxic activity against human lung cancer A549 cell line was determined
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,12198.0,,9606.0,CHEMBL885345,1.0,,1.0,,,,,646.0,5562.0,Cytotoxicity against human solid tumor lung carcinoma A549 cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,13891.0,,9606.0,CHEMBL621409,1.0,,1.0,,,,,646.0,5563.0,Cytotoxicity concentration against human lung carcinoma A-549 cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,5677.0,,9606.0,CHEMBL876034,1.0,,1.0,,,,,646.0,5564.0,Cytotoxicity in A549 (human carcinoma) cell line.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,13788.0,,9606.0,CHEMBL621410,1.0,,1.0,,,,,646.0,5565.0,Cytotoxicity on lung carcinoma (A-549) cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,13384.0,,9606.0,CHEMBL621411,1.0,,1.0,,,,,646.0,5566.0,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,6726.0,,9606.0,CHEMBL621412,1.0,,1.0,,,,,646.0,5567.0,Effective dose of compound against replication of A549 cell line was evaluated
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,3455.0,,9606.0,CHEMBL621413,1.0,,1.0,,,,,646.0,5568.0,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5726.0,,9606.0,CHEMBL621414,1.0,,1.0,,,,,646.0,5569.0,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5726.0,,9606.0,CHEMBL621415,1.0,,1.0,,,,,646.0,5570.0,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,3936.0,,9606.0,CHEMBL621416,1.0,,1.0,,,,,646.0,5571.0,The compound was evaluated for antiproliferative activity against A549 cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,14991.0,,9606.0,CHEMBL621417,1.0,,1.0,,,,,646.0,5572.0,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5243.0,,9606.0,CHEMBL621418,1.0,,1.0,,,,,646.0,5573.0,Concentration required for growth inhibition of human lung carcinoma cell line A549
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,12858.0,,9606.0,CHEMBL621419,1.0,,1.0,,,,,646.0,5574.0,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,6776.0,,9606.0,CHEMBL621420,1.0,,1.0,,,,,646.0,5575.0,Growth inhibition against A549 cell line was evaluated
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16558.0,,9606.0,CHEMBL875823,1.0,,1.0,,,,,646.0,5576.0,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,4583.0,,9606.0,CHEMBL621421,1.0,,1.0,,,,,646.0,5577.0,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,13514.0,,9606.0,CHEMBL621422,1.0,,1.0,,,,,646.0,5578.0,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,15166.0,,9606.0,CHEMBL884014,1.0,,1.0,,,,,646.0,5579.0,Chemosensitivity against DT-diaphorase rich A549 cell lines
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,13873.0,,9606.0,CHEMBL621423,1.0,,1.0,,,,,646.0,5580.0,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,6447.0,,9606.0,CHEMBL621424,1.0,,1.0,,,,,646.0,5581.0,In vitro cytotoxicity against human A549 (lung cancer) cell line.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,2068.0,,9606.0,CHEMBL621425,1.0,,1.0,,,,,646.0,5582.0,In vitro antitumor activity against A549 (lung) human tumor cell lines.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,1863.0,,9606.0,CHEMBL621426,1.0,,1.0,,,,,646.0,5583.0,In vitro cytotoxic activity against human lung carcinoma A549 cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,13873.0,,9606.0,CHEMBL621427,1.0,,1.0,,,,,646.0,5584.0,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,13873.0,,9606.0,CHEMBL621428,1.0,,1.0,,,,,646.0,5585.0,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,13873.0,,9606.0,CHEMBL621429,1.0,,1.0,,,,,646.0,5586.0,Tested against A549 lung carcinoma in the sulforhodamine B assay.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,579.0,,9606.0,CHEMBL621430,1.0,,1.0,,,,,646.0,5587.0,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,579.0,,9606.0,CHEMBL621431,1.0,,1.0,,,,,646.0,5588.0,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4584.0,,9606.0,CHEMBL621432,1.0,,1.0,,,,,646.0,5589.0,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,5421.0,,9606.0,CHEMBL621433,1.0,,1.0,,,,,646.0,5590.0,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5421.0,,9606.0,CHEMBL875824,1.0,,1.0,,,,,646.0,5591.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5421.0,,9606.0,CHEMBL621434,1.0,,1.0,,,,,646.0,5592.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5421.0,,9606.0,CHEMBL621435,1.0,,1.0,,,,,646.0,5593.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,14188.0,,9606.0,CHEMBL621436,1.0,,1.0,,,,,646.0,5594.0,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,14188.0,,9606.0,CHEMBL621437,1.0,,1.0,,,,,646.0,5595.0,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,15354.0,,9606.0,CHEMBL621438,1.0,,1.0,,,,,646.0,5596.0,Compound was tested for the growth inhibition of A549 lung tumor cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,14253.0,,9606.0,CHEMBL621439,1.0,,1.0,,,,,646.0,5597.0,Growth inhibition of human non-small-lung carcinoma (A549) cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,13873.0,,9606.0,CHEMBL621440,1.0,,1.0,,,,,646.0,5598.0,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3043.0,,9615.0,CHEMBL621441,1.0,,1.0,,,,,,5599.0,Oral bioavailability in dog (conscious)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3045.0,,9615.0,CHEMBL621442,1.0,,1.0,,,,,,5600.0,Compound was evaluated for the oral bioavailability after oral administration in dog.
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3022.0,,9615.0,CHEMBL621443,1.0,,1.0,,,,,,5601.0,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4453.0,,9615.0,CHEMBL621444,1.0,,1.0,,,,,,5602.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1696.0,,9615.0,CHEMBL625133,1.0,,1.0,,,,,,5603.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5045.0,,9615.0,CHEMBL625134,1.0,,1.0,,,,,,5604.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5356.0,,9615.0,CHEMBL625135,1.0,,1.0,,,,,,5605.0,Oral bioavailability in dog (fasted)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17764.0,,9615.0,CHEMBL625136,1.0,,1.0,,,,,,5606.0,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6448.0,,9615.0,CHEMBL625137,1.0,,1.0,,,,,,5607.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1475.0,,9615.0,CHEMBL625138,1.0,,1.0,,,,,,5608.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3788.0,,9615.0,CHEMBL625139,1.0,,1.0,,,,,,5609.0,Percent bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3639.0,,9615.0,CHEMBL872264,1.0,,1.0,,,,,,5610.0,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,13397.0,,9615.0,CHEMBL625140,1.0,,1.0,,,,,,5611.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,2137.0,,9615.0,CHEMBL624436,1.0,,1.0,,,,,,5612.0,The compound was evaluated for bioavailability in dogs; 34-44
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,2959.0,,9615.0,CHEMBL624437,1.0,,1.0,,,,,,5613.0,Bioavailability in dog (dose 4 mg/kg p.o.)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6448.0,,9615.0,CHEMBL872261,1.0,,1.0,,,,,,5614.0,Oral bioavailability in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6084.0,,9615.0,CHEMBL624438,1.0,,1.0,,,,,,5615.0,8 hour trough Blood level in dog was measured after administration of compound
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3639.0,,9615.0,CHEMBL624439,1.0,,1.0,Plasma,,,1969.0,,5616.0,The compound was tested for maximum concentration ( Cmax ) in dog plasma.
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6316.0,,9615.0,CHEMBL624440,1.0,,1.0,,,,,,5617.0,C24 after oral administration at 5 mg/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5238.0,,9615.0,CHEMBL624441,1.0,,1.0,,,,,,5618.0,Clearance after oral and iv dosing in dogs
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,17796.0,,9615.0,CHEMBL624442,1.0,,1.0,Plasma,,,1969.0,,5619.0,Clearance of the drug was measured in the plasma of dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,2652.0,,9615.0,CHEMBL624443,1.0,,1.0,,,,,,5620.0,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5654.0,,9615.0,CHEMBL624444,1.0,,1.0,,,,,,5621.0,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6621.0,,9615.0,CHEMBL624445,1.0,,1.0,,,,,,5622.0,Clearance of compound was determined in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6505.0,,9615.0,CHEMBL624446,1.0,,1.0,,,,,,5623.0,Clearance on i.v. administration of 2 mg/kg was measured in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5802.0,,9615.0,CHEMBL624447,1.0,,1.0,,,,,,5624.0,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17267.0,,9615.0,CHEMBL624448,1.0,,1.0,,,,,,5625.0,Plasma clearance in dog was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4521.0,,9615.0,CHEMBL624449,1.0,,1.0,,,,,,5626.0,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6535.0,,9615.0,CHEMBL624450,1.0,,1.0,,,,,,5627.0,Plasma clearance in dog after administration of 0.25 mg/kg iv
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6535.0,,9615.0,CHEMBL875942,1.0,,1.0,,,,,,5628.0,Plasma clearance in dog after administration of 1 mg/kg iv
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6535.0,,9615.0,CHEMBL624451,1.0,,1.0,,,,,,5629.0,Plasma clearance in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5542.0,,9615.0,CHEMBL624452,1.0,,1.0,,,,,,5630.0,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5199.0,,9615.0,CHEMBL624453,1.0,,1.0,,,,,,5631.0,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16907.0,,9615.0,CHEMBL624454,1.0,,1.0,,,,,,5632.0,Plasma clearance after 15 mg/kg iv dose in Dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16907.0,,9615.0,CHEMBL624455,1.0,,1.0,,,,,,5633.0,Plasma clearance after 30 mg/kg po dose in Dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16367.0,,9615.0,CHEMBL624456,1.0,,1.0,,,,,,5634.0,Plasma administration to dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5505.0,,9615.0,CHEMBL624457,1.0,,1.0,,,,,,5635.0,Plasma clearance was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6215.0,,9615.0,CHEMBL624458,1.0,,1.0,,,,,,5636.0,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1466.0,,9615.0,CHEMBL624459,1.0,,1.0,,,,,,5637.0,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog
,BAO_0000251,A,In vitro,,102164.0,S,Homo sapiens,Intermediate,5007.0,Microsomes,9606.0,CHEMBL624460,1.0,,2.0,Liver,,,2107.0,,5638.0,Intrinsic clearance in human liver microsomes
,BAO_0000251,A,In vitro,,102164.0,S,Homo sapiens,Intermediate,5007.0,Microsomes,9606.0,CHEMBL624461,1.0,,2.0,Liver,,,2107.0,,5639.0,Intrinsic clearance in human liver microsomes
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16452.0,,9615.0,CHEMBL875943,1.0,,1.0,,,,,,5640.0,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16452.0,,9615.0,CHEMBL624462,1.0,,1.0,,,,,,5641.0,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16452.0,,9615.0,CHEMBL624463,1.0,,1.0,,,,,,5642.0,Clearance in dog (dose 1 mg/kg i.v.)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6221.0,,9615.0,CHEMBL624464,1.0,,1.0,,,,,,5643.0,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5007.0,,9615.0,CHEMBL624465,1.0,,1.0,,,,,,5644.0,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5668.0,,9615.0,CHEMBL624466,1.0,,1.0,,,,,,5645.0,Plasma clearance after peroral administration at 10 mpk in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5668.0,,9615.0,CHEMBL624467,1.0,,1.0,,,,,,5646.0,Plasma clearance after peroral administration at 5 mpk in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5668.0,,9615.0,CHEMBL624468,1.0,,1.0,,,,,,5647.0,Plasma clearance after peroral administration at 5 mg/kg in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,15660.0,,9615.0,CHEMBL624469,1.0,,1.0,,,,,,5648.0,Plasma clearance was measured in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,15660.0,,9615.0,CHEMBL624470,1.0,,1.0,,,,,,5649.0,Plasma clearance was measured in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5983.0,,9615.0,CHEMBL624471,1.0,,1.0,,,,,,5650.0,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5600.0,,9615.0,CHEMBL624472,1.0,,1.0,,,,,,5651.0,Total clearance was determined after 0.1 mg/kg iv administration in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17764.0,,9615.0,CHEMBL622775,1.0,,1.0,,,,,,5652.0,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6039.0,,9615.0,CHEMBL622776,1.0,,1.0,,,,,,5653.0,Clearance after intravenous administration of 0.5 mg/kg in dog was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6039.0,,9615.0,CHEMBL622777,1.0,,1.0,,,,,,5654.0,Clearance after intravenous administration of 1.0 mg/kg in dog was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6039.0,,9615.0,CHEMBL622778,1.0,,1.0,,,,,,5655.0,Clearance after peroral administration of 0.2 mg/kg in dog was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4368.0,,9615.0,CHEMBL622779,1.0,,1.0,,,,,,5656.0,Clearance by intravenous administration of 1.2 mg/kg in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4305.0,,9615.0,CHEMBL622780,1.0,,1.0,,,,,,5657.0,Clearance by iv administration in dogs at a dose of 1 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1918.0,,9615.0,CHEMBL622781,1.0,,1.0,Plasma,,,1969.0,,5658.0,Clearance value was evaluated in dog plasma
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6005.0,,9615.0,CHEMBL622782,1.0,,1.0,,,,,,5659.0,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4839.0,,9615.0,CHEMBL622783,1.0,,1.0,Plasma,,,1969.0,,5660.0,Compound was tested for plasma clearance in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4239.0,,9615.0,CHEMBL622784,1.0,,1.0,,,,,,5661.0,Pharmacokinetic property (Plasma clearance) was measured in dog
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17729.0,,10090.0,CHEMBL622785,1.0,,1.0,,,,,,5662.0,Area under curve when injected perorally in mice at a dose of 50 mg/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17728.0,,10090.0,CHEMBL622786,1.0,,1.0,,,,,,5663.0,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,5302.0,,10090.0,CHEMBL622787,1.0,,1.0,,,,,,5664.0,Area under curve value in mouse at a dose of 10 mg/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,5506.0,,10090.0,CHEMBL875949,1.0,,1.0,,,,,,5665.0,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,5506.0,,10090.0,CHEMBL622788,1.0,,1.0,,,,,,5666.0,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice
,BAO_0000218,F,,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL622789,1.0,,1.0,,,,,,5667.0,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg
,BAO_0000218,F,,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL622790,1.0,,1.0,,,,,,5668.0,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg
,BAO_0000218,F,,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL622791,1.0,,1.0,,,,,,5669.0,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg
,BAO_0000218,F,,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL622792,1.0,,1.0,,,,,,5670.0,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL622793,1.0,,1.0,,,,,,5671.0,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17753.0,,10090.0,CHEMBL622794,1.0,,1.0,,,,,,5672.0,Area under curve was determined for the compound at 24 mg/Kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17753.0,,10090.0,CHEMBL622795,1.0,,1.0,,,,,,5673.0,Area under curve was determined for the compound at 40 mg/Kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17753.0,,10090.0,CHEMBL621803,1.0,,1.0,,,,,,5674.0,Area under curve was determined for the compound at 5 mg/Kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,3132.0,,10090.0,CHEMBL621804,1.0,,1.0,,,,,,5675.0,Area under the curve for the compound is obtained at dose 25 mg/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,3132.0,,10090.0,CHEMBL621805,1.0,,1.0,,,,,,5676.0,Area under the curve for the compound was obtained when tested in mouse
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17837.0,,10090.0,CHEMBL621806,1.0,,1.0,,,,,,5677.0,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17837.0,,10090.0,CHEMBL621807,1.0,,1.0,,,,,,5678.0,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,6062.0,,10090.0,CHEMBL621808,1.0,,1.0,,,,,,5679.0,Area under the curve was measured in mouse after an iv dose of 1 mg/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,4066.0,,10090.0,CHEMBL621809,1.0,,1.0,,,,,,5680.0,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,16597.0,,10090.0,CHEMBL621810,1.0,,1.0,,,,,,5681.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot)
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,14239.0,,10090.0,CHEMBL875164,1.0,,1.0,,,,,,5682.0,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,14239.0,,10090.0,CHEMBL621811,1.0,,1.0,,,,,,5683.0,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,4890.0,,10090.0,CHEMBL621812,1.0,,1.0,,,,,,5684.0,"Compound was evaluated for the pharmacokinetic parameter, area under curve"
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,429.0,,10090.0,CHEMBL621813,1.0,,1.0,,,,,,5685.0,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr )
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,429.0,,10090.0,CHEMBL621814,1.0,,1.0,,,,,,5686.0,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr)
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,5969.0,,10090.0,CHEMBL621815,1.0,,1.0,,,,,,5687.0,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,5969.0,,10090.0,CHEMBL621816,1.0,,1.0,,,,,,5688.0,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,5969.0,,10090.0,CHEMBL621817,1.0,,1.0,,,,,,5689.0,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,6091.0,,10090.0,CHEMBL621818,1.0,,1.0,,,,,,5690.0,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,6091.0,,10090.0,CHEMBL621819,1.0,,1.0,,,,,,5691.0,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,6091.0,,10090.0,CHEMBL621820,1.0,,1.0,,,,,,5692.0,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,6091.0,,10090.0,CHEMBL621821,1.0,,1.0,,,,,,5693.0,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,6178.0,,10090.0,CHEMBL621822,1.0,,1.0,,,,,,5694.0,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,6178.0,,10090.0,CHEMBL619474,1.0,,1.0,,,,,,5695.0,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,6619.0,,10090.0,CHEMBL619475,1.0,,1.0,,,,,,5696.0,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)"
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,6619.0,,10090.0,CHEMBL619476,1.0,,1.0,,,,,,5697.0,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)"
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,3760.0,,10090.0,CHEMBL619477,1.0,,1.0,,,,,,5698.0,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice"
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,3760.0,,10090.0,CHEMBL619478,1.0,,1.0,,,,,,5699.0,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice"
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,3760.0,,10090.0,CHEMBL619479,1.0,,1.0,,,,,,5700.0,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice"
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,3760.0,,10090.0,CHEMBL619480,1.0,,1.0,,,,,,5701.0,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice"
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,3192.0,,10090.0,CHEMBL619481,1.0,,1.0,,,,,,5702.0,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,3192.0,,10090.0,CHEMBL619482,1.0,,1.0,,,,,,5703.0,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,2675.0,,10090.0,CHEMBL619483,1.0,,1.0,,,,,,5704.0,Area under the curve was evaluated in mice after intravenous administration
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,2675.0,,10090.0,CHEMBL619484,1.0,,1.0,,,,,,5705.0,Area under the curve was evaluated in mice after oral administration
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,16597.0,,10090.0,CHEMBL619485,1.0,,1.0,Plasma,,,1969.0,,5706.0,AUC total value at a dose of 10 mg/kg intravenous administration in mice.
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,16597.0,,10090.0,CHEMBL619486,1.0,,1.0,Plasma,,,1969.0,,5707.0,AUC total value at a dose of 10 mg/kg peroral administration in mice.
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,16597.0,,10090.0,CHEMBL619487,1.0,,1.0,,,,,,5708.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot)
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17734.0,,10090.0,CHEMBL619488,1.0,,1.0,,,,,,5709.0,AUMC after intraperitoneal administration of 100 mg/kg in mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL620106,1.0,,1.0,Blood,,,178.0,,5710.0,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram
,BAO_0000219,F,,9L,80653.0,N,,Intermediate,15345.0,,,CHEMBL620107,1.0,,1.0,,,,,392.0,5711.0,The compound was tested in vitro for anticancer activity against 9L cells
,BAO_0000019,F,,,22226.0,U,Rattus norvegicus,Autocuration,2181.0,,10116.0,CHEMBL620283,1.0,,0.0,,,,,,5712.0,Anti proliferation activity determined; Weak effect
,BAO_0000219,F,,,22226.0,U,Rattus norvegicus,Autocuration,2181.0,,10116.0,CHEMBL875176,1.0,,0.0,,,,,,5713.0,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process
,BAO_0000219,F,,,22226.0,U,Rattus norvegicus,Autocuration,2181.0,,10116.0,CHEMBL620284,1.0,,0.0,,,,,,5714.0,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells
,BAO_0000219,F,,,22226.0,U,Rattus norvegicus,Autocuration,2181.0,,10116.0,CHEMBL623515,1.0,,0.0,,,,,,5715.0,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process
,BAO_0000019,F,,,22226.0,U,Mus musculus,Autocuration,10486.0,,10090.0,CHEMBL623516,1.0,,0.0,,,,,,5716.0,The cytotoxic activity was in vitro tested by 9PS assay method
,BAO_0000019,F,,,22226.0,U,Mus musculus,Autocuration,10486.0,,10090.0,CHEMBL623517,1.0,,0.0,,,,,,5717.0,The cytotoxic activity was in vitro tested by 9PS assay method.
,BAO_0000019,A,,,22224.0,U,,Autocuration,15508.0,,,CHEMBL857878,1.0,,0.0,,,,,,5718.0,Partition coefficient (logD6.5)
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,5242.0,,9606.0,CHEMBL623518,1.0,,1.0,,,,,478.0,5719.0,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells
,BAO_0000219,F,,A-375,80018.0,N,Homo sapiens,Intermediate,16167.0,,9606.0,CHEMBL624195,1.0,,1.0,,,,,455.0,5720.0,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM)
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Expert,4782.0,,9606.0,CHEMBL624196,1.0,,1.0,,,,,500.0,5721.0,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line
,BAO_0000219,F,,A-431,9.0,D,Homo sapiens,Expert,16093.0,,9606.0,CHEMBL624197,1.0,,9.0,,,,,500.0,5722.0,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,2596.0,,9606.0,CHEMBL624198,1.0,,1.0,,,,,624.0,5723.0,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,2596.0,,9606.0,CHEMBL621287,1.0,,1.0,,,,,624.0,5724.0,in vitro cytotoxicity against A 498 cancer cell line
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,3239.0,,9606.0,CHEMBL621288,1.0,,1.0,,,,,624.0,5725.0,In vitro cytotoxic activity against renal (A 498) cancer cell line.
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,1847.0,,9606.0,CHEMBL876496,1.0,,1.0,,,,,624.0,5726.0,Cytotoxic activity against A 498 renal cancer cell lines.
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,10553.0,,9606.0,CHEMBL621289,1.0,,1.0,,,,,624.0,5727.0,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen
,BAO_0000019,F,,,22226.0,U,Staphylococcus aureus,Autocuration,16219.0,,1280.0,CHEMBL621290,1.0,,0.0,,,,,,5728.0,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i
,BAO_0000019,F,,,22226.0,U,Staphylococcus aureus,Autocuration,16219.0,,1280.0,CHEMBL621291,1.0,,0.0,,,,,,5729.0,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i
,BAO_0000019,F,,,22226.0,U,Staphylococcus aureus,Autocuration,16219.0,,1280.0,CHEMBL621292,1.0,,0.0,,,,,,5730.0,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c
,BAO_0000019,F,,,22226.0,U,Staphylococcus aureus,Autocuration,16219.0,,1280.0,CHEMBL621293,1.0,,0.0,,,,,,5731.0,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4782.0,,9606.0,CHEMBL621294,1.0,,1.0,,,,,646.0,5732.0,Inhibitory concentration required against A 549 lung cancer cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,11805.0,,9606.0,CHEMBL621295,1.0,,1.0,,,,,646.0,5733.0,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,11805.0,,9606.0,CHEMBL884007,1.0,,1.0,,,,,646.0,5734.0,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,2007.0,,9606.0,CHEMBL621296,1.0,,1.0,,,,,646.0,5735.0,In vitro cytotoxicity against lung cancer A 549 cell lines
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4594.0,,9606.0,CHEMBL621297,1.0,,1.0,,,,,646.0,5736.0,Compound was tested for its cytotoxicity against A 549 cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,6018.0,,9606.0,CHEMBL839828,1.0,,1.0,,,,,646.0,5737.0,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay."
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,6018.0,,9606.0,CHEMBL620397,1.0,,1.0,,,,,646.0,5738.0,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data"
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,3599.0,,9606.0,CHEMBL620398,1.0,,1.0,,,,,646.0,5739.0,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,2551.0,,9606.0,CHEMBL620399,1.0,,1.0,,,,,646.0,5740.0,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,16132.0,,9606.0,CHEMBL620400,1.0,,1.0,,,,,646.0,5741.0,In vitro inhibition of A549 (human lung cancer) cell growth.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16132.0,,9606.0,CHEMBL620401,1.0,,1.0,,,,,646.0,5742.0,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,2551.0,,9606.0,CHEMBL620402,1.0,,1.0,,,,,646.0,5743.0,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,2551.0,,9606.0,CHEMBL620403,1.0,,1.0,,,,,646.0,5744.0,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM)
,BAO_0000218,F,,,22226.0,U,,Autocuration,11913.0,,,CHEMBL620404,1.0,,0.0,,,,,,5745.0,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h
,BAO_0000218,F,In vivo,,104694.0,H,,Autocuration,12621.0,,,CHEMBL620405,1.0,,4.0,,,,,,5746.0,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.
,BAO_0000218,F,In vivo,,104694.0,H,,Autocuration,12621.0,,,CHEMBL620406,1.0,,4.0,,,,,,5747.0,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.
,BAO_0000218,F,In vivo,,104694.0,H,,Autocuration,12621.0,,,CHEMBL620407,1.0,,4.0,,,,,,5748.0,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.
,BAO_0000218,F,In vivo,,104694.0,H,,Autocuration,12621.0,,,CHEMBL620408,1.0,,4.0,,,,,,5749.0,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.
,BAO_0000218,F,In vivo,,104694.0,H,,Autocuration,12621.0,,,CHEMBL620409,1.0,,4.0,,,,,,5750.0,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Expert,3600.0,,9606.0,CHEMBL620410,1.0,,1.0,,,,,624.0,5751.0,Inhibition of A-498 human Renal cell proliferation
,BAO_0000019,F,,,22226.0,U,Rattus norvegicus,Autocuration,1796.0,,10116.0,CHEMBL620411,1.0,,0.0,,,,,,5752.0,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM"
,BAO_0000019,F,,,22226.0,U,Rattus norvegicus,Autocuration,1796.0,,10116.0,CHEMBL620412,1.0,,0.0,,,,,,5753.0,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM"
,BAO_0000019,F,,,22226.0,U,Rattus norvegicus,Autocuration,1796.0,,10116.0,CHEMBL876596,1.0,,0.0,,,,,,5754.0,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM"
,BAO_0000219,F,,A 172,80012.0,N,Homo sapiens,Expert,16464.0,,9606.0,CHEMBL620413,1.0,,1.0,,,,,622.0,5755.0,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay
,BAO_0000219,F,,A 172,80012.0,N,Homo sapiens,Intermediate,16464.0,,9606.0,CHEMBL620414,1.0,,1.0,,,,,622.0,5756.0,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5
,BAO_0000219,F,,A 172,80012.0,N,Homo sapiens,Intermediate,16464.0,,9606.0,CHEMBL620415,1.0,,1.0,,,,,622.0,5757.0,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,13617.0,,9606.0,CHEMBL620416,1.0,,1.0,,,,,646.0,5758.0,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4584.0,,9606.0,CHEMBL620417,1.0,,1.0,,,,,646.0,5759.0,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,13799.0,,9606.0,CHEMBL620418,1.0,,1.0,,,,,646.0,5760.0,Cytotoxic activity evaluated against A549 tumor cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16726.0,,9606.0,CHEMBL620419,1.0,,1.0,,,,,646.0,5761.0,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16109.0,,9606.0,CHEMBL620420,1.0,,1.0,,,,,646.0,5762.0,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16109.0,,9606.0,CHEMBL620421,1.0,,1.0,,,,,646.0,5763.0,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,15474.0,,9606.0,CHEMBL620422,1.0,,1.0,,,,,646.0,5764.0,Cytotoxicity against A549 tumor cell line determined by WST-1 assay
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,6851.0,,9606.0,CHEMBL620423,1.0,,1.0,,,,,646.0,5765.0,Cytotoxicity of compound against A549 cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,17534.0,,9606.0,CHEMBL620424,1.0,,1.0,,,,,646.0,5766.0,Cytotoxicity against human lung cell carcinoma A549 cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,2621.0,,9606.0,CHEMBL620425,1.0,,1.0,,,,,646.0,5767.0,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,830.0,,9606.0,CHEMBL620426,1.0,,1.0,,,,,646.0,5768.0,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,14255.0,,9606.0,CHEMBL620427,1.0,,1.0,,,,,646.0,5769.0,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,14255.0,,9606.0,CHEMBL620428,1.0,,1.0,,,,,646.0,5770.0,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,1590.0,,9606.0,CHEMBL620429,1.0,,1.0,,,,,646.0,5771.0,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,6146.0,,9606.0,CHEMBL620430,1.0,,1.0,,,,,646.0,5772.0,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,17427.0,,9606.0,CHEMBL839887,1.0,,1.0,,,,,646.0,5773.0,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5280.0,,9606.0,CHEMBL620431,1.0,,1.0,,,,,646.0,5774.0,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16786.0,,9606.0,CHEMBL884010,1.0,,1.0,,,,,646.0,5775.0,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5895.0,,9606.0,CHEMBL620538,1.0,,1.0,,,,,646.0,5776.0,In vitro cytotoxicity against A549 (human lung cancer)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,14297.0,,9606.0,CHEMBL620539,1.0,,1.0,,,,,646.0,5777.0,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.
,BAO_0000218,F,,A549,80682.0,N,Homo sapiens,Intermediate,17824.0,,9606.0,CHEMBL623373,1.0,,1.0,,,,,646.0,5778.0,In vivo antiproliferative activity against A549 cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,14368.0,,9606.0,CHEMBL623374,1.0,,1.0,,,,,646.0,5779.0,Inhibition of non-small-cell lung adenocarcinoma (A549)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,14368.0,,9606.0,CHEMBL623375,1.0,,1.0,,,,,646.0,5780.0,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,14254.0,,9606.0,CHEMBL623376,1.0,,1.0,,,,,646.0,5781.0,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,15897.0,,9606.0,CHEMBL623377,1.0,,1.0,,,,,646.0,5782.0,Inhibitory activity against A549 cell line using MTT assay(Wild type p53)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,13866.0,,9606.0,CHEMBL623378,1.0,,1.0,,,,,646.0,5783.0,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,13370.0,,9606.0,CHEMBL623379,1.0,,1.0,,,,,646.0,5784.0,Inhibitory activity of compound against human A549 lung carcinoma cell line.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4862.0,,9606.0,CHEMBL623380,1.0,,1.0,,,,,646.0,5785.0,Inhibitory activity against A549 lung cancer cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4862.0,,9606.0,CHEMBL623381,1.0,,1.0,,,,,646.0,5786.0,Inhibitory activity against Taxol-resistant A549 lung cancer cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4862.0,,9606.0,CHEMBL623382,1.0,,1.0,,,,,646.0,5787.0,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,15970.0,,9606.0,CHEMBL623383,1.0,,1.0,,,,,646.0,5788.0,Inhibitory concentration against A549 (lung cancer) cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,17713.0,,9606.0,CHEMBL623384,1.0,,1.0,,,,,646.0,5789.0,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4833.0,,9606.0,CHEMBL623385,1.0,,1.0,,,,,646.0,5790.0,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,13736.0,,9606.0,CHEMBL623386,1.0,,1.0,,,,,646.0,5791.0,Activity against A549 cancer cell line.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4312.0,,9606.0,CHEMBL884105,1.0,,1.0,,,,,646.0,5792.0,The compound was evaluated for cytotoxicity against A549 cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5421.0,,9606.0,CHEMBL623387,1.0,,1.0,,,,,646.0,5793.0,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5421.0,,9606.0,CHEMBL621568,1.0,,1.0,,,,,646.0,5794.0,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,14717.0,,9606.0,CHEMBL621569,1.0,,1.0,,,,,646.0,5795.0,Growth inhibitory activity was measured for human A549 tumor cell line.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4634.0,,9606.0,CHEMBL621570,1.0,,1.0,,,,,646.0,5796.0,Inhibitory activity against A549 lung cancer cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,1149.0,,9606.0,CHEMBL621571,1.0,,1.0,,,,,646.0,5797.0,Inhibitory activity against A549 cell line; inactive
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,5421.0,,9606.0,CHEMBL621572,1.0,,1.0,,,,,646.0,5798.0,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,5421.0,,9606.0,CHEMBL621573,1.0,,1.0,,,,,646.0,5799.0,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5421.0,,9606.0,CHEMBL621574,1.0,,1.0,,,,,646.0,5800.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,3320.0,,9606.0,CHEMBL621575,1.0,,1.0,,,,,646.0,5801.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,3320.0,,9606.0,CHEMBL621576,1.0,,1.0,,,,,646.0,5802.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,3320.0,,9606.0,CHEMBL621577,1.0,,1.0,,,,,646.0,5803.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,3320.0,,9606.0,CHEMBL621578,1.0,,1.0,,,,,646.0,5804.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,3320.0,,9606.0,CHEMBL621579,1.0,,1.0,,,,,646.0,5805.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5726.0,,9606.0,CHEMBL621580,1.0,,1.0,,,,,646.0,5806.0,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17800.0,,9615.0,CHEMBL621581,1.0,,1.0,,,,,,5807.0,Plasma clearance (in vivo) in mongrel dogs was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5985.0,,9615.0,CHEMBL621582,1.0,,1.0,,,,,,5808.0,Plasma clearance was measured in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5530.0,,9615.0,CHEMBL621583,1.0,,1.0,,,,,,5809.0,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5530.0,,9615.0,CHEMBL621584,1.0,,1.0,,,,,,5810.0,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4839.0,,9615.0,CHEMBL621585,1.0,,1.0,Plasma,,,1969.0,,5811.0,Tested for plasma clearance in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3639.0,,9615.0,CHEMBL621586,1.0,,1.0,,,,,,5812.0,The compound was tested for clearance in dog plasma.
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4838.0,,9615.0,CHEMBL875835,1.0,,1.0,,,,,,5813.0,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration"
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4137.0,,9615.0,CHEMBL621587,1.0,,1.0,,,,,,5814.0,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5017.0,,9615.0,CHEMBL621588,1.0,,1.0,Plasma,,,1969.0,,5815.0,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg)
,BAO_0000218,A,In vitro,,50588.0,N,Canis lupus familiaris,Intermediate,17538.0,Microsomes,9615.0,CHEMBL621589,1.0,,1.0,Liver,,,2107.0,,5816.0,In vitro clearance in dog liver microsomes
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6161.0,,9615.0,CHEMBL621590,1.0,,1.0,,,,,,5817.0,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6161.0,,9615.0,CHEMBL621591,1.0,,1.0,,,,,,5818.0,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1696.0,,9615.0,CHEMBL621592,1.0,,1.0,,,,,,5819.0,Plasma clearance in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6762.0,,9615.0,CHEMBL621593,1.0,,1.0,,,,,,5820.0,Clearance rate in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5932.0,,9615.0,CHEMBL621594,1.0,,1.0,Plasma,,,1969.0,,5821.0,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6305.0,,9615.0,CHEMBL621595,1.0,,1.0,,,,,,5822.0,Clearance in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4942.0,,9615.0,CHEMBL621596,1.0,,1.0,,,,,,5823.0,Plasma clearance in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4219.0,,9615.0,CHEMBL621597,1.0,,1.0,,,,,,5824.0,Plasma clearance was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17853.0,,9615.0,CHEMBL621598,1.0,,1.0,,,,,,5825.0,Lower clearance in dog (i.v.) at 0.5 mpk
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4514.0,,9615.0,CHEMBL621599,1.0,,1.0,,,,,,5826.0,Plasma clearance in Beagle dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6448.0,,9615.0,CHEMBL875836,1.0,,1.0,,,,,,5827.0,Plasma clearance (Clp) in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6227.0,,9615.0,CHEMBL621600,1.0,,1.0,,,,,,5828.0,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6227.0,,9615.0,CHEMBL621601,1.0,,1.0,,,,,,5829.0,Plasma clearance (pharmacokinetic parameter) in dog was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6062.0,,9615.0,CHEMBL618474,1.0,,1.0,,,,,,5830.0,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6821.0,,9615.0,CHEMBL618475,1.0,,1.0,,,,,,5831.0,Plasma clearance of compound was determined in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4709.0,,9615.0,CHEMBL624524,1.0,,1.0,,,,,,5832.0,Plasma clearance after intravenous administration of 1 mg/kg in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4521.0,,9615.0,CHEMBL624525,1.0,,1.0,,,,,,5833.0,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5374.0,,9615.0,CHEMBL624526,1.0,,1.0,,,,,,5834.0,Plasma clearance in dog was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6057.0,,9615.0,CHEMBL624527,1.0,,1.0,,,,,,5835.0,Plasma clearance was calculated in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4727.0,,9615.0,CHEMBL624528,1.0,,1.0,,,,,,5836.0,Plasma clearance at the dose of 2 mg/kg in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5145.0,,9615.0,CHEMBL624529,1.0,,1.0,,,,,,5837.0,Plasma clearance in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17657.0,,9615.0,CHEMBL624530,1.0,,1.0,,,,,,5838.0,Plasma clearance in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17657.0,,9615.0,CHEMBL624531,1.0,,1.0,,,,,,5839.0,Plasma clearance in dog; Unable to calculate
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5145.0,,9615.0,CHEMBL624532,1.0,,1.0,,,,,,5840.0,Plasma clearance in rhesus monkey
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6642.0,,9615.0,CHEMBL624533,1.0,,1.0,,,,,,5841.0,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6641.0,,9615.0,CHEMBL624534,1.0,,1.0,,,,,,5842.0,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6642.0,,9615.0,CHEMBL624535,1.0,,1.0,,,,,,5843.0,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5472.0,,9615.0,CHEMBL624536,1.0,,1.0,,,,,,5844.0,Plasma clearance was evaluated in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5472.0,,9615.0,CHEMBL624537,1.0,,1.0,,,,,,5845.0,Plasma clearance was evaluated in dog; Not tested
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5472.0,,9615.0,CHEMBL624538,1.0,,1.0,,,,,,5846.0,Plasma clearance was evaluated in rhesus
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5472.0,,9615.0,CHEMBL624539,1.0,,1.0,,,,,,5847.0,Plasma clearance was evaluated in rhesus; Not tested
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4257.0,,9615.0,CHEMBL624540,1.0,,1.0,,,,,,5848.0,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6679.0,,9615.0,CHEMBL624541,1.0,,1.0,,,,,,5849.0,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5546.0,,9615.0,CHEMBL624542,1.0,,1.0,,,,,,5850.0,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6348.0,,9615.0,CHEMBL624543,1.0,,1.0,,,,,,5851.0,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5474.0,,9615.0,CHEMBL624544,1.0,,1.0,,,,,,5852.0,Clearance value at a dose of 0.2 mg/kg i.v.
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6316.0,,9615.0,CHEMBL624545,1.0,,1.0,Plasma,,,1969.0,,5853.0,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17594.0,,9615.0,CHEMBL624546,1.0,,1.0,,,,,,5854.0,Cmax after oral dose of compound at 3 mg/kg in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17594.0,,9615.0,CHEMBL875957,1.0,,1.0,,,,,,5855.0,Cmax after single intravenous bolus of 1 mg/kg in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5802.0,,9615.0,CHEMBL624547,1.0,,1.0,,,,,,5856.0,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6535.0,,9615.0,CHEMBL624548,1.0,,1.0,,,,,,5857.0,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6535.0,,9615.0,CHEMBL624549,1.0,,1.0,,,,,,5858.0,Cmax in dog after administration of 1 mg/kg iv
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1466.0,,9615.0,CHEMBL624550,1.0,,1.0,Plasma,,,1969.0,,5859.0,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6505.0,,9615.0,CHEMBL621613,1.0,,1.0,,,,,,5860.0,Cmax on p.o. administration of 10 mg/kg was measured in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5668.0,,9615.0,CHEMBL621614,1.0,,1.0,,,,,,5861.0,Cmax was determine after peroral administration at 10 mpk in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5668.0,,9615.0,CHEMBL623431,1.0,,1.0,,,,,,5862.0,Cmax was determine after peroral administration at 5 mpk in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5668.0,,9615.0,CHEMBL623432,1.0,,1.0,,,,,,5863.0,Cmax was determine after peroral administration at 5 mg/kg in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5600.0,,9615.0,CHEMBL623433,1.0,,1.0,,,,,,5864.0,Cmax after 0.3 mg/kg po administration in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17764.0,,9615.0,CHEMBL623434,1.0,,1.0,,,,,,5865.0,Cmax after peroral administration in dogs at 2.4 uM/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6123.0,,9615.0,CHEMBL623435,1.0,,1.0,,,,,,5866.0,Cmax in dog after oral administration at 1 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6123.0,,9615.0,CHEMBL623436,1.0,,1.0,,,,,,5867.0,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6757.0,,9615.0,CHEMBL875958,1.0,,1.0,,,,,,5868.0,Cmax upon oral administration in male Beagle dog at 10 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16907.0,,9615.0,CHEMBL623437,1.0,,1.0,,,,,,5869.0,Cmax value after 15 mg/kg iv dose in Dogs
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL623438,1.0,,1.0,Blood,,,178.0,,5870.0,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL623439,1.0,,1.0,Blood,,,178.0,,5871.0,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL623440,1.0,,1.0,Bone,,,10000001.0,,5872.0,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL623441,1.0,,1.0,Bone,,,10000001.0,,5873.0,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL623442,1.0,,1.0,Bone,,,10000001.0,,5874.0,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL623469,1.0,,1.0,,,,,,5875.0,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL623470,1.0,,1.0,,,,,,5876.0,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL623471,1.0,,1.0,,,,,,5877.0,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL623472,1.0,,1.0,Heart,,,948.0,,5878.0,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL623473,1.0,,1.0,Heart,,,948.0,,5879.0,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL623474,1.0,,1.0,Heart,,,948.0,,5880.0,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL623475,1.0,,1.0,Kidney,,,2113.0,,5881.0,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL623476,1.0,,1.0,Kidney,,,2113.0,,5882.0,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL623477,1.0,,1.0,Kidney,,,2113.0,,5883.0,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL621896,1.0,,1.0,Intestine,,,160.0,,5884.0,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL621897,1.0,,1.0,Intestine,,,160.0,,5885.0,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL621898,1.0,,1.0,Intestine,,,160.0,,5886.0,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL621899,1.0,,1.0,Liver,,,2107.0,,5887.0,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL621900,1.0,,1.0,Liver,,,2107.0,,5888.0,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL621901,1.0,,1.0,Liver,,,2107.0,,5889.0,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL621902,1.0,,1.0,Lung,,,2048.0,,5890.0,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL621903,1.0,,1.0,Lung,,,2048.0,,5891.0,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL622587,1.0,,1.0,Lung,,,2048.0,,5892.0,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL620285,1.0,,1.0,Muscle tissue,,,2385.0,,5893.0,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL875285,1.0,,1.0,Muscle tissue,,,2385.0,,5894.0,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL620286,1.0,,1.0,Muscle tissue,,,2385.0,,5895.0,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL620287,1.0,,1.0,,,,,,5896.0,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL620288,1.0,,1.0,,,,,,5897.0,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL620289,1.0,,1.0,,,,,,5898.0,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL620290,1.0,,1.0,Intestine,,,160.0,,5899.0,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL620291,1.0,,1.0,Intestine,,,160.0,,5900.0,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL620292,1.0,,1.0,Intestine,,,160.0,,5901.0,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL620293,1.0,,1.0,Spleen,,,2106.0,,5902.0,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL620294,1.0,,1.0,Spleen,,,2106.0,,5903.0,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL618614,1.0,,1.0,Spleen,,,2106.0,,5904.0,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL618615,1.0,,1.0,Stomach,,,945.0,,5905.0,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL618616,1.0,,1.0,Stomach,,,945.0,,5906.0,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
,BAO_0000219,F,,A 172,80012.0,N,Homo sapiens,Expert,2036.0,,9606.0,CHEMBL618617,1.0,,1.0,,,,,622.0,5907.0,Cytotoxicity against A-172 human tumor cell lines
,BAO_0000219,F,,A 172,80012.0,N,Homo sapiens,Intermediate,2357.0,,9606.0,CHEMBL618618,1.0,,1.0,,,,,622.0,5908.0,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line
,BAO_0000219,F,,A204,80014.0,N,Homo sapiens,Intermediate,1457.0,,9606.0,CHEMBL618619,1.0,,1.0,,,,,623.0,5909.0,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,4379.0,,9606.0,CHEMBL618620,1.0,,1.0,,,,,478.0,5910.0,Tested for antiproliferative activity against A-2780 tumoral cell line
,BAO_0000219,F,,A-375,80018.0,N,Homo sapiens,Intermediate,1093.0,,9606.0,CHEMBL618621,1.0,,1.0,,,,,455.0,5911.0,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined
,BAO_0000219,F,,A-375,80018.0,N,Homo sapiens,Intermediate,12152.0,,9606.0,CHEMBL618622,1.0,,1.0,,,,,455.0,5912.0,Tested in vitro against A-375 cell line human melanoma
,BAO_0000219,F,,A-427,80019.0,N,Homo sapiens,Expert,16464.0,,9606.0,CHEMBL618623,1.0,,1.0,,,,,797.0,5913.0,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay
,BAO_0000219,F,,A-427,80019.0,N,Homo sapiens,Intermediate,16464.0,,9606.0,CHEMBL618624,1.0,,1.0,,,,,797.0,5914.0,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5
,BAO_0000219,F,,A-427,80019.0,N,Homo sapiens,Expert,16582.0,,9606.0,CHEMBL618625,1.0,,1.0,,,,,797.0,5915.0,In vitro cytotoxicity against human non small-cell-lung cell line A-427.
,BAO_0000219,F,,A-427,80019.0,N,Homo sapiens,Intermediate,16464.0,,9606.0,CHEMBL618626,1.0,,1.0,,,,,797.0,5916.0,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5
,BAO_0000219,F,,A-427,80019.0,N,Homo sapiens,Intermediate,10413.0,,9606.0,CHEMBL618627,1.0,,1.0,,,,,797.0,5917.0,Antitumor activity on A-427 lung carcinoma cell lines
,BAO_0000219,F,,A-427,80019.0,N,Homo sapiens,Intermediate,6418.0,,9606.0,CHEMBL618628,1.0,,1.0,,,,,797.0,5918.0,Cytotoxic activity against human A-427 lung tumor cell line
,BAO_0000219,F,,A-427,80019.0,N,Homo sapiens,Expert,17134.0,,9606.0,CHEMBL618629,1.0,,1.0,,,,,797.0,5919.0,In vitro antitumor effects against human A-427 cell lines.
,BAO_0000219,F,,A-427,80019.0,N,Homo sapiens,Expert,16132.0,,9606.0,CHEMBL618630,1.0,,1.0,,,,,797.0,5920.0,In vitro inhibition of A-427 (human lung cancer) cell growth.
,BAO_0000219,F,,A-427,80019.0,N,Homo sapiens,Intermediate,16132.0,,9606.0,CHEMBL618631,1.0,,1.0,,,,,797.0,5921.0,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available
,BAO_0000219,F,,A-427,80019.0,N,Homo sapiens,Intermediate,16780.0,,9606.0,CHEMBL618632,1.0,,1.0,,,,,797.0,5922.0,Cytotoxic activity of compound against A-427 lung human tumor cell line
,BAO_0000219,F,,A-431,80852.0,N,Homo sapiens,Expert,4085.0,,9606.0,CHEMBL618633,1.0,,1.0,,,,,500.0,5923.0,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,1276.0,,9606.0,CHEMBL619315,1.0,,1.0,,,,,624.0,5924.0,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Expert,3498.0,,9606.0,CHEMBL619316,1.0,,1.0,,,,,624.0,5925.0,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,1169.0,,9606.0,CHEMBL619317,1.0,,1.0,,,,,624.0,5926.0,Cytotoxicity against human kidney carcinoma A-498cell lines
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,4450.0,,9606.0,CHEMBL619318,1.0,,1.0,,,,,624.0,5927.0,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,3311.0,,9606.0,CHEMBL619319,1.0,,1.0,,,,,624.0,5928.0,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,4461.0,,9606.0,CHEMBL619739,1.0,,1.0,,,,,624.0,5929.0,Antitumor cytotoxic activity against A-498 cell line was determined
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,3311.0,,9606.0,CHEMBL619740,1.0,,1.0,,,,,624.0,5930.0,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,3311.0,,9606.0,CHEMBL883158,1.0,,1.0,,,,,624.0,5931.0,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,1457.0,,9606.0,CHEMBL884012,1.0,,1.0,,,,,624.0,5932.0,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,3664.0,,9606.0,CHEMBL619741,1.0,,1.0,,,,,624.0,5933.0,In vitro inhibitory activity against A-498 ovarian cancer cell lines
,BAO_0000219,F,,A498,80021.0,N,Homo sapiens,Intermediate,15895.0,,9606.0,CHEMBL619742,1.0,,1.0,,,,,624.0,5934.0,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line"
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,11843.0,,9606.0,CHEMBL876610,1.0,,1.0,,,,,646.0,5935.0,Inhibition of growth lung non-small cell carcinoma A-549 cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,11843.0,,9606.0,CHEMBL619743,1.0,,1.0,,,,,646.0,5936.0,Inhibition of growth of lung non-small cell carcinoma A-549 cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17705.0,,9606.0,CHEMBL619744,1.0,,1.0,,,,,646.0,5937.0,In vitro antiproliferative activity against human A-549 NSCL cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17705.0,,9606.0,CHEMBL619745,1.0,,1.0,,,,,646.0,5938.0,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4369.0,,9606.0,CHEMBL619746,1.0,,1.0,,,,,646.0,5939.0,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4369.0,,9606.0,CHEMBL619747,1.0,,1.0,,,,,646.0,5940.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4369.0,,9606.0,CHEMBL619748,1.0,,1.0,,,,,646.0,5941.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4369.0,,9606.0,CHEMBL619749,1.0,,1.0,,,,,646.0,5942.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4369.0,,9606.0,CHEMBL619750,1.0,,1.0,,,,,646.0,5943.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4369.0,,9606.0,CHEMBL624014,1.0,,1.0,,,,,646.0,5944.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4369.0,,9606.0,CHEMBL624015,1.0,,1.0,,,,,646.0,5945.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,4787.0,,9606.0,CHEMBL885344,1.0,,1.0,,,,,646.0,5946.0,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4787.0,,9606.0,CHEMBL623224,1.0,,1.0,,,,,646.0,5947.0,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,6513.0,,9606.0,CHEMBL623225,1.0,,1.0,,,,,646.0,5948.0,Cytotoxic activity against A-549 cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,6690.0,,9606.0,CHEMBL622698,1.0,,1.0,,,,,646.0,5949.0,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,6690.0,,9606.0,CHEMBL622699,1.0,,1.0,,,,,646.0,5950.0,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,12263.0,,9606.0,CHEMBL622700,1.0,,1.0,,,,,646.0,5951.0,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line"
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,1054.0,,9606.0,CHEMBL622701,1.0,,1.0,,,,,646.0,5952.0,Compound was tested for cytotoxic activity against human lung carcinoma (A-549)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,1359.0,,9606.0,CHEMBL622702,1.0,,1.0,,,,,646.0,5953.0,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,3547.0,,9606.0,CHEMBL622703,1.0,,1.0,,,,,646.0,5954.0,Cytotoxic activity against human lung carcinoma (A-549) cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,5771.0,,9606.0,CHEMBL622704,1.0,,1.0,,,,,646.0,5955.0,Cytotoxic activity towards A-549 cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,14425.0,,9606.0,CHEMBL622705,1.0,,1.0,,,,,646.0,5956.0,"In vitro percent inhibition of A549, lung carcinoma."
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,14425.0,,9606.0,CHEMBL622706,1.0,,1.0,,,,,646.0,5957.0,"In vitro percent inhibition of A549, lung carcinoma"
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,14425.0,,9606.0,CHEMBL622707,1.0,,1.0,,,,,646.0,5958.0,"In vitro percent inhibition of A549, lung carcinoma."
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,14425.0,,9606.0,CHEMBL622708,1.0,,1.0,,,,,646.0,5959.0,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23"
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5280.0,,9606.0,CHEMBL622709,1.0,,1.0,,,,,646.0,5960.0,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,15176.0,,9606.0,CHEMBL622710,1.0,,1.0,,,,,646.0,5961.0,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,15300.0,,9606.0,CHEMBL622711,1.0,,1.0,,,,,646.0,5962.0,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay
,BAO_0000218,F,,A549,80682.0,N,Homo sapiens,Intermediate,17824.0,,9606.0,CHEMBL622712,1.0,,1.0,,,,,646.0,5963.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose"
,BAO_0000218,F,,A549,80682.0,N,Homo sapiens,Intermediate,17824.0,,9606.0,CHEMBL622713,1.0,,1.0,,,,,646.0,5964.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose"
,BAO_0000218,F,,A549,80682.0,N,Homo sapiens,Intermediate,17824.0,,9606.0,CHEMBL622714,1.0,,1.0,,,,,646.0,5965.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose"
,BAO_0000218,F,,A549,80682.0,N,Homo sapiens,Intermediate,17824.0,,9606.0,CHEMBL622715,1.0,,1.0,,,,,646.0,5966.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose"
,BAO_0000218,F,,A549,80682.0,N,Homo sapiens,Intermediate,17824.0,,9606.0,CHEMBL622716,1.0,,1.0,,,,,646.0,5967.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose"
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17824.0,,9606.0,CHEMBL622717,1.0,,1.0,,,,,646.0,5968.0,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested"
,BAO_0000218,F,,A549,80682.0,N,Homo sapiens,Intermediate,17528.0,,9606.0,CHEMBL622718,1.0,,1.0,,,,,646.0,5969.0,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,6870.0,,9606.0,CHEMBL622719,1.0,,1.0,,,,,646.0,5970.0,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,6870.0,,9606.0,CHEMBL622720,1.0,,1.0,,,,,646.0,5971.0,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,6870.0,,9606.0,CHEMBL622721,1.0,,1.0,,,,,646.0,5972.0,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,6870.0,,9606.0,CHEMBL622722,1.0,,1.0,,,,,646.0,5973.0,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16726.0,,9606.0,CHEMBL876030,1.0,,1.0,,,,,646.0,5974.0,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,6170.0,,9606.0,CHEMBL620206,1.0,,1.0,,,,,646.0,5975.0,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation"
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,6583.0,,9606.0,CHEMBL620207,1.0,,1.0,,,,,646.0,5976.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,6583.0,,9606.0,CHEMBL620208,1.0,,1.0,,,,,646.0,5977.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,6583.0,,9606.0,CHEMBL620209,1.0,,1.0,,,,,646.0,5978.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,6583.0,,9606.0,CHEMBL620210,1.0,,1.0,,,,,646.0,5979.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,6583.0,,9606.0,CHEMBL621639,1.0,,1.0,,,,,646.0,5980.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17321.0,,9606.0,CHEMBL621640,1.0,,1.0,,,,,646.0,5981.0,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,17528.0,,9606.0,CHEMBL621641,1.0,,1.0,,,,,646.0,5982.0,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,12888.0,,9606.0,CHEMBL621642,1.0,,1.0,,,,,646.0,5983.0,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4312.0,,9606.0,CHEMBL621643,1.0,,1.0,,,,,646.0,5984.0,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4312.0,,9606.0,CHEMBL621644,1.0,,1.0,,,,,646.0,5985.0,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4312.0,,9606.0,CHEMBL621645,1.0,,1.0,,,,,646.0,5986.0,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data
,BAO_0000219,F,,A549,80682.0,N,Mus musculus,Intermediate,17737.0,,10090.0,CHEMBL621646,1.0,,1.0,,,,,646.0,5987.0,In vitro antiproliferative activity against A549 cell line
,BAO_0000219,F,,A549,80682.0,N,,Intermediate,6630.0,,,CHEMBL621647,1.0,,1.0,,,,,646.0,5988.0,Synergism with indomethacin in A549 cells
,BAO_0000219,F,,A549,80682.0,N,,Intermediate,6630.0,,,CHEMBL621648,1.0,,1.0,,,,,646.0,5989.0,Synergism with tolmetin in A549 cells
,BAO_0000219,F,,A549,80682.0,N,,Intermediate,6630.0,,,CHEMBL621649,1.0,,1.0,,,,,646.0,5990.0,Synergism with sulindac in A549 cells
,BAO_0000219,F,,A549,80682.0,N,,Intermediate,6630.0,,,CHEMBL621650,1.0,,1.0,,,,,646.0,5991.0,Antagonism of indomethacin in A549 cells
,BAO_0000219,F,,A549,80682.0,N,,Intermediate,6630.0,,,CHEMBL621651,1.0,,1.0,,,,,646.0,5992.0,Antagonism of sulindac in A549 cells
,BAO_0000219,F,,A549,80682.0,N,,Intermediate,6630.0,,,CHEMBL621652,1.0,,1.0,,,,,646.0,5993.0,Antagonism of tolmetin in A549 cells
,BAO_0000219,F,,A549,80682.0,N,,Intermediate,6630.0,,,CHEMBL621653,1.0,,1.0,,,,,646.0,5994.0,Synergism with indomethacin in A549 cells
,BAO_0000219,F,,A549,80682.0,N,,Intermediate,6630.0,,,CHEMBL621654,1.0,,1.0,,,,,646.0,5995.0,Synergism with sulindac in A549 cells
,BAO_0000219,F,,A549,80682.0,N,,Intermediate,6630.0,,,CHEMBL621655,1.0,,1.0,,,,,646.0,5996.0,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16907.0,,9615.0,CHEMBL621656,1.0,,1.0,,,,,,5997.0,Cmax value after 30 mg/kg po dose in Dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5944.0,,9615.0,CHEMBL621657,1.0,,1.0,,,,,,5998.0,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5944.0,,9615.0,CHEMBL621658,1.0,,1.0,,,,,,5999.0,Cmax value determined in dog at a dose of 10 mg/kg by oral administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5944.0,,9615.0,CHEMBL621659,1.0,,1.0,,,,,,6000.0,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5944.0,,9615.0,CHEMBL621660,1.0,,1.0,,,,,,6001.0,Cmax value determined in dog at a dose of 5 mg/kg by oral administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,2959.0,,9615.0,CHEMBL621661,1.0,,1.0,,,,,,6002.0,Cmax value after administration of 4 mg/Kg oral dose in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6241.0,,9615.0,CHEMBL621662,1.0,,1.0,,,,,,6003.0,Cmax value in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6241.0,,9615.0,CHEMBL621663,1.0,,1.0,,,,,,6004.0,Cmax value in dogs after oral administration at 1 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,2652.0,,9615.0,CHEMBL621664,1.0,,1.0,,,,,,6005.0,Bioavailability as Cmax in dogs at 5 mg/kg oral dose
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1806.0,,9615.0,CHEMBL621665,1.0,,1.0,Plasma,,,1969.0,,6006.0,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1806.0,,9615.0,CHEMBL621666,1.0,,1.0,Plasma,,,1969.0,,6007.0,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1021.0,,9615.0,CHEMBL621667,1.0,,1.0,,,,,,6008.0,Concentration maxima after oral dosing in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1021.0,,9615.0,CHEMBL876738,1.0,,1.0,,,,,,6009.0,Concentration maxima after oral dosing in dogs; not available
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1021.0,,9615.0,CHEMBL621668,1.0,,1.0,,,,,,6010.0,Concentration maxima after oral dosing in dogs; not available
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5444.0,,9615.0,CHEMBL621669,1.0,,1.0,,,,,,6011.0,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5444.0,,9615.0,CHEMBL621670,1.0,,1.0,,,,,,6012.0,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5444.0,,9615.0,CHEMBL621671,1.0,,1.0,,,,,,6013.0,In vivo maximal concentration was calculated at 1 mg/kg in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5444.0,,9615.0,CHEMBL622360,1.0,,1.0,,,,,,6014.0,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5444.0,,9615.0,CHEMBL622361,1.0,,1.0,,,,,,6015.0,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5130.0,,9615.0,CHEMBL622362,1.0,,1.0,Plasma,,,1969.0,,6016.0,Cmax in dog plasma after oral dose (1 mg/kg)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3249.0,,9615.0,CHEMBL622363,1.0,,1.0,Plasma,,,1969.0,,6017.0,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5473.0,,9615.0,CHEMBL622364,1.0,,1.0,Plasma,,,1969.0,,6018.0,Maximal plasma concentration at a dose of 1 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5474.0,,9615.0,CHEMBL622365,1.0,,1.0,Plasma,,,1969.0,,6019.0,Maximal plasma concentration at a dose of 1 mg/kg (oral)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4657.0,,9615.0,CHEMBL622533,1.0,,1.0,Plasma,,,1969.0,,6020.0,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3031.0,,9615.0,CHEMBL622534,1.0,,1.0,,,,,,6021.0,Maximum concentration of compound in dog was evaluated.
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4527.0,,9615.0,CHEMBL622535,1.0,,1.0,,,,,,6022.0,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4186.0,,9615.0,CHEMBL876739,1.0,,1.0,,,,,,6023.0,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5007.0,,9615.0,CHEMBL622536,1.0,,1.0,,,,,,6024.0,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3132.0,,9615.0,CHEMBL622537,1.0,,1.0,Plasma,,,1969.0,,6025.0,Maximum concentration obtained in dog plasma was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5006.0,,9615.0,CHEMBL622538,1.0,,1.0,,,,,,6026.0,Maximum concentration was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4727.0,,9615.0,CHEMBL627867,1.0,,1.0,,,,,,6027.0,Maximum concentration at the dose of 2 mg/kg in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1916.0,,9615.0,CHEMBL627868,1.0,,1.0,,,,,,6028.0,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1918.0,,9615.0,CHEMBL627869,1.0,,1.0,Plasma,,,1969.0,,6029.0,Maximum concentration was evaluated in dog plasma
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3045.0,,9615.0,CHEMBL627870,1.0,,1.0,,,,,,6030.0,Maximum concentration was evaluated after 75 min after administration in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,9579.0,,9615.0,CHEMBL627871,1.0,,1.0,Plasma,,,1969.0,,6031.0,Maximum plasma concentration determined in dog after oral administration of 17b
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,9579.0,,9615.0,CHEMBL627872,1.0,,1.0,Plasma,,,1969.0,,6032.0,Maximum plasma concentration determined in dog after oral administration of 2b
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,933.0,,9615.0,CHEMBL627873,1.0,,1.0,Plasma,,,1969.0,,6033.0,Maximum plasma concentration in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17839.0,,9615.0,CHEMBL627874,1.0,,1.0,Plasma,,,1969.0,,6034.0,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17839.0,,9615.0,CHEMBL627875,1.0,,1.0,Plasma,,,1969.0,,6035.0,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17839.0,,9615.0,CHEMBL627876,1.0,,1.0,Plasma,,,1969.0,,6036.0,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17839.0,,9615.0,CHEMBL627877,1.0,,1.0,Plasma,,,1969.0,,6037.0,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6348.0,,9615.0,CHEMBL627878,1.0,,1.0,Plasma,,,1969.0,,6038.0,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16367.0,,9615.0,CHEMBL627879,1.0,,1.0,Plasma,,,1969.0,,6039.0,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1337.0,,9615.0,CHEMBL875355,1.0,,1.0,Plasma,,,1969.0,,6040.0,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1337.0,,9615.0,CHEMBL627880,1.0,,1.0,Plasma,,,1969.0,,6041.0,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5199.0,,9615.0,CHEMBL627881,1.0,,1.0,Plasma,,,1969.0,,6042.0,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17650.0,,9615.0,CHEMBL627882,1.0,,1.0,Plasma,,,1969.0,,6043.0,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6679.0,,9615.0,CHEMBL627883,1.0,,1.0,Plasma,,,1969.0,,6044.0,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5356.0,,9615.0,CHEMBL628526,1.0,,1.0,Plasma,,,1969.0,,6045.0,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5356.0,,9615.0,CHEMBL628527,1.0,,1.0,Plasma,,,1969.0,,6046.0,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6227.0,,9615.0,CHEMBL628528,1.0,,1.0,Plasma,,,1969.0,,6047.0,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6227.0,,9615.0,CHEMBL628529,1.0,,1.0,Plasma,,,1969.0,,6048.0,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6227.0,,9615.0,CHEMBL628530,1.0,,1.0,Plasma,,,1969.0,,6049.0,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6227.0,,9615.0,CHEMBL625243,1.0,,1.0,Plasma,,,1969.0,,6050.0,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Expert,3598.0,,9615.0,CHEMBL625244,1.0,,1.0,Plasma,,,1969.0,,6051.0,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4368.0,,9615.0,CHEMBL625245,1.0,,1.0,,,,,,6052.0,Maximum concentration by intravenous administration of 1.2 mg/kg in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6265.0,,9615.0,CHEMBL625246,1.0,,1.0,,,,,,6053.0,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL625247,1.0,,1.0,Stomach,,,945.0,,6054.0,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL625248,1.0,,1.0,Urine,,,1088.0,,6055.0,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL625249,1.0,,1.0,Urine,,,1088.0,,6056.0,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,7767.0,,10090.0,CHEMBL625250,1.0,,1.0,Urine,,,1088.0,,6057.0,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17811.0,,10090.0,CHEMBL625251,1.0,,1.0,,,,,,6058.0,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17811.0,,10090.0,CHEMBL875356,1.0,,1.0,,,,,,6059.0,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17827.0,,10090.0,CHEMBL625252,1.0,,1.0,,,,,,6060.0,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound)
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17827.0,,10090.0,CHEMBL625253,1.0,,1.0,Blood,,,178.0,,6061.0,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound)
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17827.0,,10090.0,CHEMBL625254,1.0,,1.0,,,,,,6062.0,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound)
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17827.0,,10090.0,CHEMBL625255,1.0,,1.0,,,,,,6063.0,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound)
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17827.0,,10090.0,CHEMBL625256,1.0,,1.0,,,,,,6064.0,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound)
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17827.0,,10090.0,CHEMBL625257,1.0,,1.0,Blood,,,178.0,,6065.0,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound)
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17827.0,,10090.0,CHEMBL625258,1.0,,1.0,Blood,,,178.0,,6066.0,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound)
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17827.0,,10090.0,CHEMBL625259,1.0,,1.0,,,,,,6067.0,Compound was evaluated for washout rate in mice (Radiolabeled compound)
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17827.0,,10090.0,CHEMBL625260,1.0,,1.0,,,,,,6068.0,Compound was evaluated for washout rate in mice after radiolabeled ligand injected
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17827.0,,10090.0,CHEMBL625261,1.0,,1.0,,,,,,6069.0,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)"
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17827.0,,10090.0,CHEMBL625262,1.0,,1.0,,,,,,6070.0,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)"
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17827.0,,10090.0,CHEMBL622639,1.0,,1.0,,,,,,6071.0,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)"
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17257.0,,10090.0,CHEMBL622640,1.0,,1.0,,,,,,6072.0,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17257.0,,10090.0,CHEMBL622812,1.0,,1.0,,,,,,6073.0,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17257.0,,10090.0,CHEMBL622813,1.0,,1.0,,,,,,6074.0,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17257.0,,10090.0,CHEMBL622814,1.0,,1.0,,,,,,6075.0,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17827.0,,10090.0,CHEMBL622815,1.0,,1.0,,,,,,6076.0,Time at maximum activity in mice (Radiolabeled compound)
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,3760.0,,10090.0,CHEMBL625342,1.0,,1.0,,,,,,6077.0,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,3760.0,,10090.0,CHEMBL625343,1.0,,1.0,,,,,,6078.0,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17409.0,,10090.0,CHEMBL877591,1.0,,1.0,,,,,,6079.0,Binding towards mouse plasma protein at 10 uM
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17409.0,,10090.0,CHEMBL625344,1.0,,1.0,,,,,,6080.0,Binding towards mouse plasma protein at 100 uM
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,2675.0,,10090.0,CHEMBL625345,1.0,,1.0,,,,,,6081.0,Bioavailability was evaluated in mice after intravenous administration
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,2675.0,,10090.0,CHEMBL625346,1.0,,1.0,,,,,,6082.0,Bioavailability was evaluated in mice after oral administration
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3132.0,,10090.0,CHEMBL625347,1.0,,1.0,,,,,,6083.0,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3132.0,,10090.0,CHEMBL625348,1.0,,1.0,,,,,,6084.0,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16597.0,,10090.0,CHEMBL625349,1.0,,1.0,,,,,,6085.0,Bioavailability at a dose of 10 mg/kg peroral administration in mice.
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,2862.0,,10090.0,CHEMBL625350,1.0,,1.0,,,,,,6086.0,Oral bioavailability in mouse
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL882952,1.0,,1.0,,,,,,6087.0,Oral bioavailability after intravenous administration in mice at 24 uM/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL625351,1.0,,1.0,Brain,,,955.0,,6088.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL625352,1.0,,1.0,Brain,,,955.0,,6089.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL877592,1.0,,1.0,Brain,,,955.0,,6090.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL625353,1.0,,1.0,Brain,,,955.0,,6091.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL625354,1.0,,1.0,Brain,,,955.0,,6092.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL626019,1.0,,1.0,Brain,,,955.0,,6093.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL626020,1.0,,1.0,Heart,,,948.0,,6094.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL626021,1.0,,1.0,Heart,,,948.0,,6095.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL626022,1.0,,1.0,Heart,,,948.0,,6096.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL626192,1.0,,1.0,Heart,,,948.0,,6097.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,1276.0,,9606.0,CHEMBL626193,1.0,,1.0,,,,,646.0,6098.0,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,3498.0,,9606.0,CHEMBL626194,1.0,,1.0,,,,,646.0,6099.0,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,1169.0,,9606.0,CHEMBL626195,1.0,,1.0,,,,,646.0,6100.0,Cytotoxicity against human lung carcinoma A-549 cell lines
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4450.0,,9606.0,CHEMBL626196,1.0,,1.0,,,,,646.0,6101.0,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,358.0,,9606.0,CHEMBL626197,1.0,,1.0,,,,,646.0,6102.0,In vitro cytotoxicity against human lung carcinoma cell line A-549
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,358.0,,9606.0,CHEMBL626198,1.0,,1.0,,,,,646.0,6103.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,358.0,,9606.0,CHEMBL626199,1.0,,1.0,,,,,646.0,6104.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,358.0,,9606.0,CHEMBL626200,1.0,,1.0,,,,,646.0,6105.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,358.0,,9606.0,CHEMBL626201,1.0,,1.0,,,,,646.0,6106.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,358.0,,9606.0,CHEMBL626202,1.0,,1.0,,,,,646.0,6107.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,358.0,,9606.0,CHEMBL626203,1.0,,1.0,,,,,646.0,6108.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,15167.0,,9606.0,CHEMBL626204,1.0,,1.0,,,,,646.0,6109.0,In vitro cytotoxicity against A-549 human lung cancer cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4139.0,,9606.0,CHEMBL624701,1.0,,1.0,,,,,646.0,6110.0,In vitro cytotoxicity against human lung carcinoma (A-549) cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,833.0,,9606.0,CHEMBL624702,1.0,,1.0,,,,,646.0,6111.0,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,15718.0,,9606.0,CHEMBL624703,1.0,,1.0,,,,,646.0,6112.0,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,12373.0,,9606.0,CHEMBL624704,1.0,,1.0,,,,,646.0,6113.0,Tested in vitro for cytotoxicity against A-549 lung cancer cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,637.0,,9606.0,CHEMBL624705,1.0,,1.0,,,,,646.0,6114.0,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,14867.0,,9606.0,CHEMBL624706,1.0,,1.0,,,,,646.0,6115.0,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4461.0,,9606.0,CHEMBL624707,1.0,,1.0,,,,,646.0,6116.0,Antitumor cytotoxic activity against A-549 cell line was determined
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5406.0,,9606.0,CHEMBL624708,1.0,,1.0,,,,,646.0,6117.0,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported"
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4457.0,,9606.0,CHEMBL624709,1.0,,1.0,,,,,646.0,6118.0,Compound was tested for cytotoxicity against A-549 human solid tumor cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,1386.0,,9606.0,CHEMBL884107,1.0,,1.0,,,,,646.0,6119.0,Antineoplastic activity against A-549 (human lung carcinoma) cell line.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,3265.0,,9606.0,CHEMBL624710,1.0,,1.0,,,,,646.0,6120.0,Antitumoral activity was assayed against A-549 cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,2359.0,,9606.0,CHEMBL624711,1.0,,1.0,,,,,646.0,6121.0,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4457.0,,9606.0,CHEMBL624712,1.0,,1.0,,,,,646.0,6122.0,Compound was tested for cytotoxicity against A-549 human solid tumor cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,12454.0,,9606.0,CHEMBL624713,1.0,,1.0,,,,,646.0,6123.0,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,1481.0,,9606.0,CHEMBL624714,1.0,,1.0,,,,,646.0,6124.0,Compound was tested for inhibition of cell growth of A-549 cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,1750.0,,9606.0,CHEMBL624715,1.0,,1.0,,,,,646.0,6125.0,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5065.0,,9606.0,CHEMBL624716,1.0,,1.0,,,,,646.0,6126.0,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,808.0,,9606.0,CHEMBL619505,1.0,,1.0,,,,,646.0,6127.0,In vitro cytotoxicity against A549-human lung carcinoma cells.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,16364.0,,9606.0,CHEMBL619506,1.0,,1.0,,,,,646.0,6128.0,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,1847.0,,9606.0,CHEMBL619507,1.0,,1.0,,,,,646.0,6129.0,Cytotoxic activity against A-549 cell lines.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,1747.0,,9606.0,CHEMBL619508,1.0,,1.0,,,,,646.0,6130.0,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,1003.0,,9606.0,CHEMBL619509,1.0,,1.0,,,,,646.0,6131.0,Cytotoxicity against human A549 non small cell lung cell lines
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,15313.0,,9606.0,CHEMBL619510,1.0,,1.0,,,,,646.0,6132.0,Inhibition of cell growth in (A-549) lung cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,3122.0,,9606.0,CHEMBL619511,1.0,,1.0,,,,,646.0,6133.0,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16049.0,,9606.0,CHEMBL619512,1.0,,1.0,,,,,646.0,6134.0,In vitro antitumor activity against A-549 tumor cells.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,17134.0,,9606.0,CHEMBL619513,1.0,,1.0,,,,,646.0,6135.0,In vitro antitumor effects against human A-549 cell lines.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,6406.0,,9606.0,CHEMBL619514,1.0,,1.0,,,,,646.0,6136.0,In vitro cytotoxic activity of compound against A-549 cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,627.0,,9606.0,CHEMBL619515,1.0,,1.0,,,,,646.0,6137.0,In vitro cytotoxicity against human lung carcinoma A-549 cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,12307.0,,9606.0,CHEMBL619516,1.0,,1.0,,,,,646.0,6138.0,In vitro cytotoxicity against human non-small cell lung carcinoma A549
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17861.0,,9606.0,CHEMBL884005,1.0,,1.0,,,,,646.0,6139.0,In vitro cytotoxicity against human A-549 cancer cell line was evaluated
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,6682.0,,9606.0,CHEMBL619517,1.0,,1.0,,,,,646.0,6140.0,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,6663.0,,9606.0,CHEMBL619518,1.0,,1.0,,,,,646.0,6141.0,Inhibitory concentration of compound against A-549 cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,2454.0,,9606.0,CHEMBL619519,1.0,,1.0,,,,,646.0,6142.0,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,14709.0,,9606.0,CHEMBL876489,1.0,,1.0,,,,,646.0,6143.0,cytotoxic activity against leukemia (A-549) cancer cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,15718.0,,9606.0,CHEMBL619520,1.0,,1.0,,,,,646.0,6144.0,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,15718.0,,9606.0,CHEMBL619521,1.0,,1.0,,,,,646.0,6145.0,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17130.0,,9606.0,CHEMBL619522,1.0,,1.0,,,,,646.0,6146.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17130.0,,9606.0,CHEMBL619523,1.0,,1.0,,,,,646.0,6147.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17130.0,,9606.0,CHEMBL619524,1.0,,1.0,,,,,646.0,6148.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17130.0,,9606.0,CHEMBL619525,1.0,,1.0,,,,,646.0,6149.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)
,BAO_0000219,F,,A549,80682.0,N,,Intermediate,6630.0,,,CHEMBL619526,1.0,,1.0,,,,,646.0,6150.0,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16726.0,,9606.0,CHEMBL619527,1.0,,1.0,,,,,646.0,6151.0,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17846.0,,9606.0,CHEMBL619528,1.0,,1.0,,,,,646.0,6152.0,Cytotoxicity against A549 cells; No cytotoxicity
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,3415.0,,9606.0,CHEMBL619529,1.0,,1.0,,,,,646.0,6153.0,Cytotoxicity against human lung carcinoma (A549) cell lines
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,3415.0,,9606.0,CHEMBL619530,1.0,,1.0,,,,,646.0,6154.0,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5609.0,,9606.0,CHEMBL876490,1.0,,1.0,,,,,646.0,6155.0,In vitro anticancer activity against human lung (A549) cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17206.0,,9606.0,CHEMBL619531,1.0,,1.0,,,,,646.0,6156.0,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17206.0,,9606.0,CHEMBL619532,1.0,,1.0,,,,,646.0,6157.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17206.0,,9606.0,CHEMBL619533,1.0,,1.0,,,,,646.0,6158.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17206.0,,9606.0,CHEMBL619534,1.0,,1.0,,,,,646.0,6159.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17206.0,,9606.0,CHEMBL620164,1.0,,1.0,,,,,646.0,6160.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17206.0,,9606.0,CHEMBL620165,1.0,,1.0,,,,,646.0,6161.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,16295.0,,9606.0,CHEMBL620166,1.0,,1.0,,,,,646.0,6162.0,Inhibition of A549 human lung tumor cell proliferation
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16825.0,,9606.0,CHEMBL620167,1.0,,1.0,,,,,646.0,6163.0,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. "
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,3439.0,,9606.0,CHEMBL620168,1.0,,1.0,,,,,646.0,6164.0,In vitro cytotoxicity against human tumor cell line A549
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,10870.0,,9606.0,CHEMBL620338,1.0,,1.0,,,,,646.0,6165.0,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. 
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4845.0,,9606.0,CHEMBL620339,1.0,,1.0,,,,,646.0,6166.0,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5822.0,,9606.0,CHEMBL620340,1.0,,1.0,,,,,646.0,6167.0,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5822.0,,9606.0,CHEMBL620341,1.0,,1.0,,,,,646.0,6168.0,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5822.0,,9606.0,CHEMBL876491,1.0,,1.0,,,,,646.0,6169.0,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16381.0,,9606.0,CHEMBL620342,1.0,,1.0,,,,,646.0,6170.0,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16381.0,,9606.0,CHEMBL620343,1.0,,1.0,,,,,646.0,6171.0,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16381.0,,9606.0,CHEMBL620344,1.0,,1.0,,,,,646.0,6172.0,% inhibition against A549 cells (lung cancer) at 4 ug/mL
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5609.0,,9606.0,CHEMBL620345,1.0,,1.0,,,,,646.0,6173.0,In vitro anticancer activity against human lung (A549) cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4644.0,,9606.0,CHEMBL620346,1.0,,1.0,,,,,646.0,6174.0,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4644.0,,9606.0,CHEMBL620347,1.0,,1.0,,,,,646.0,6175.0,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4644.0,,9606.0,CHEMBL620348,1.0,,1.0,,,,,646.0,6176.0,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4644.0,,9606.0,CHEMBL620349,1.0,,1.0,,,,,646.0,6177.0,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5822.0,,9606.0,CHEMBL618667,1.0,,1.0,,,,,646.0,6178.0,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,3415.0,,9606.0,CHEMBL618668,1.0,,1.0,,,,,646.0,6179.0,Percentage inhibition of human lung carcinoma (A549) cell lines
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16726.0,,9606.0,CHEMBL876031,1.0,,1.0,,,,,646.0,6180.0,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17206.0,,9606.0,CHEMBL618759,1.0,,1.0,,,,,646.0,6181.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined"
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17206.0,,9606.0,CHEMBL618760,1.0,,1.0,,,,,646.0,6182.0,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17206.0,,9606.0,CHEMBL619000,1.0,,1.0,,,,,646.0,6183.0,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17206.0,,9606.0,CHEMBL619001,1.0,,1.0,,,,,646.0,6184.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)"
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17206.0,,9606.0,CHEMBL619002,1.0,,1.0,,,,,646.0,6185.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM"
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17206.0,,9606.0,CHEMBL619003,1.0,,1.0,,,,,646.0,6186.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM"
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17206.0,,9606.0,CHEMBL619597,1.0,,1.0,,,,,646.0,6187.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM"
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17206.0,,9606.0,CHEMBL619598,1.0,,1.0,,,,,646.0,6188.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM"
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17206.0,,9606.0,CHEMBL619599,1.0,,1.0,,,,,646.0,6189.0,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17206.0,,9606.0,CHEMBL619600,1.0,,1.0,,,,,646.0,6190.0,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16726.0,,9606.0,CHEMBL619601,1.0,,1.0,,,,,646.0,6191.0,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17206.0,,9606.0,CHEMBL619602,1.0,,1.0,,,,,646.0,6192.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17206.0,,9606.0,CHEMBL619603,1.0,,1.0,,,,,646.0,6193.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17206.0,,9606.0,CHEMBL619604,1.0,,1.0,,,,,646.0,6194.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17206.0,,9606.0,CHEMBL619605,1.0,,1.0,,,,,646.0,6195.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6084.0,,9615.0,CHEMBL619606,1.0,,1.0,,,,,,6196.0,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6084.0,,9615.0,CHEMBL876032,1.0,,1.0,,,,,,6197.0,Pharmacokinetic activity (Cmax) in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4809.0,,9615.0,CHEMBL619607,1.0,,1.0,,,,,,6198.0,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5983.0,,9615.0,CHEMBL619608,1.0,,1.0,,,,,,6199.0,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6251.0,,9615.0,CHEMBL619609,1.0,,1.0,,,,,,6200.0,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5932.0,,9615.0,CHEMBL619610,1.0,,1.0,Plasma,,,1969.0,,6201.0,Cmax in dog plasma after 30mg/kg oral dose
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4273.0,,9615.0,CHEMBL619611,1.0,,1.0,Blood,,,178.0,,6202.0,Tested for the peak blood level in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5313.0,,9615.0,CHEMBL619612,1.0,,1.0,,,,,,6203.0,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog"
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5313.0,,9615.0,CHEMBL619613,1.0,,1.0,,,,,,6204.0,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk"
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6221.0,,9615.0,CHEMBL619614,1.0,,1.0,Blood,,,178.0,,6205.0,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4709.0,,9615.0,CHEMBL619615,1.0,,1.0,,,,,,6206.0,Concentration in the plasma after intravenous administration of 1 mg/kg in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,167.0,,9615.0,CHEMBL619616,1.0,,1.0,,,,,,6207.0,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6241.0,,9615.0,CHEMBL619617,1.0,,1.0,Plasma,,,1969.0,,6208.0,Final plasma concentration in dogs after oral administration at 1 mg/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,344.0,,9615.0,CHEMBL619618,1.0,,1.0,,,,,,6209.0,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,344.0,,9615.0,CHEMBL876033,1.0,,1.0,,,,,,6210.0,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,344.0,,9615.0,CHEMBL619619,1.0,,1.0,,,,,,6211.0,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,2189.0,,9615.0,CHEMBL619620,1.0,,1.0,,,,,,6212.0,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,2189.0,,9615.0,CHEMBL619621,1.0,,1.0,Urine,,,1088.0,,6213.0,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,2189.0,,9615.0,CHEMBL619622,1.0,,1.0,Urine,,,1088.0,,6214.0,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,2189.0,,9615.0,CHEMBL618874,1.0,,1.0,Urine,,,1088.0,,6215.0,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4257.0,,9615.0,CHEMBL618875,1.0,,1.0,,,,,,6216.0,Absolute bioavailability was evaluated in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6221.0,,9615.0,CHEMBL618876,1.0,,1.0,,,,,,6217.0,Bioavailability after oral administration (2.5 mg/kg) in dog was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6215.0,,9615.0,CHEMBL618877,1.0,,1.0,,,,,,6218.0,Bioavailability after peroral administration (1 mg/kg) was determined in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17267.0,,9615.0,CHEMBL618878,1.0,,1.0,,,,,,6219.0,Bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6621.0,,9615.0,CHEMBL618879,1.0,,1.0,,,,,,6220.0,Bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3854.0,,9615.0,CHEMBL618880,1.0,,1.0,,,,,,6221.0,Bioavailability after intravenous administration in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3854.0,,9615.0,CHEMBL618881,1.0,,1.0,,,,,,6222.0,Bioavailability after peroral administration in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5007.0,,9615.0,CHEMBL618882,1.0,,1.0,,,,,,6223.0,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4333.0,,9615.0,CHEMBL624226,1.0,,1.0,,,,,,6224.0,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4333.0,,9615.0,CHEMBL624227,1.0,,1.0,Plasma,,,1969.0,,6225.0,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5006.0,,9615.0,CHEMBL624228,1.0,,1.0,,,,,,6226.0,Bioavailability
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5199.0,,9615.0,CHEMBL624229,1.0,,1.0,,,,,,6227.0,Bioavailability
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4368.0,,9615.0,CHEMBL624230,1.0,,1.0,,,,,,6228.0,Bioavailability by intravenous administration of 1.2 mg/kg in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3771.0,,9615.0,CHEMBL624231,1.0,,1.0,,,,,,6229.0,Bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4953.0,,9615.0,CHEMBL624232,1.0,,1.0,,,,,,6230.0,Bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5064.0,,9615.0,CHEMBL625127,1.0,,1.0,,,,,,6231.0,Bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17657.0,,9615.0,CHEMBL625128,1.0,,1.0,,,,,,6232.0,Bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17796.0,,9615.0,CHEMBL621675,1.0,,1.0,,,,,,6233.0,Bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17853.0,,9615.0,CHEMBL621676,1.0,,1.0,,,,,,6234.0,Bioavailability in dog (p.o.) at 2.0 mpk
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4521.0,,9615.0,CHEMBL621677,1.0,,1.0,,,,,,6235.0,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4521.0,,9615.0,CHEMBL621678,1.0,,1.0,,,,,,6236.0,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5006.0,,9615.0,CHEMBL621679,1.0,,1.0,,,,,,6237.0,Bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16365.0,,9615.0,CHEMBL621680,1.0,,1.0,,,,,,6238.0,Bioavailability was evaluated after oral administration in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1916.0,,9615.0,CHEMBL621681,1.0,,1.0,,,,,,6239.0,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1918.0,,9615.0,CHEMBL876740,1.0,,1.0,,,,,,6240.0,Bioavailability was evaluated in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4239.0,,9615.0,CHEMBL621682,1.0,,1.0,,,,,,6241.0,Bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6505.0,,9615.0,CHEMBL621683,1.0,,1.0,,,,,,6242.0,Bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5334.0,,9615.0,CHEMBL621684,1.0,,1.0,,,,,,6243.0,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5334.0,,9615.0,CHEMBL621685,1.0,,1.0,,,,,,6244.0,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4809.0,,9615.0,CHEMBL621686,1.0,,1.0,,,,,,6245.0,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6348.0,,9615.0,CHEMBL621687,1.0,,1.0,,,,,,6246.0,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6005.0,,9615.0,CHEMBL621688,1.0,,1.0,,,,,,6247.0,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17804.0,,9615.0,CHEMBL621689,1.0,,1.0,,,,,,6248.0,Bioavailability of compound in dog was determined after peroral administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3184.0,,9615.0,CHEMBL621690,1.0,,1.0,,,,,,6249.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1806.0,,9615.0,CHEMBL621691,1.0,,1.0,,,,,,6250.0,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1806.0,,9615.0,CHEMBL875941,1.0,,1.0,,,,,,6251.0,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1806.0,,9615.0,CHEMBL621692,1.0,,1.0,,,,,,6252.0,Compound was evaluated for oral bioavailability in dogs; 37-38 %
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4839.0,,9615.0,CHEMBL621693,1.0,,1.0,,,,,,6253.0,Bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5017.0,,9615.0,CHEMBL621694,1.0,,1.0,,,,,,6254.0,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.)
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL621695,1.0,,1.0,Heart,,,948.0,,6255.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL621696,1.0,,1.0,Heart,,,948.0,,6256.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL621697,1.0,,1.0,Kidney,,,2113.0,,6257.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL621698,1.0,,1.0,Kidney,,,2113.0,,6258.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL623420,1.0,,1.0,Kidney,,,2113.0,,6259.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL623421,1.0,,1.0,Kidney,,,2113.0,,6260.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL623422,1.0,,1.0,Kidney,,,2113.0,,6261.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL623423,1.0,,1.0,Kidney,,,2113.0,,6262.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL623424,1.0,,1.0,Liver,,,2107.0,,6263.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL623425,1.0,,1.0,Liver,,,2107.0,,6264.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL623426,1.0,,1.0,Liver,,,2107.0,,6265.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL623427,1.0,,1.0,Liver,,,2107.0,,6266.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL623428,1.0,,1.0,Liver,,,2107.0,,6267.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL875947,1.0,,1.0,Liver,,,2107.0,,6268.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL623429,1.0,,1.0,Lung,,,2048.0,,6269.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL623430,1.0,,1.0,Lung,,,2048.0,,6270.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL622588,1.0,,1.0,Lung,,,2048.0,,6271.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL622589,1.0,,1.0,Lung,,,2048.0,,6272.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL622751,1.0,,1.0,Lung,,,2048.0,,6273.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,846.0,,10090.0,CHEMBL622752,1.0,,1.0,Lung,,,2048.0,,6274.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL622753,1.0,,1.0,,,,,42.0,6275.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL622647,1.0,,1.0,,,,,42.0,6276.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL875163,1.0,,1.0,,,,,42.0,6277.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL622648,1.0,,1.0,,,,,42.0,6278.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL622649,1.0,,1.0,,,,,42.0,6279.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL622650,1.0,,1.0,Brain,,,955.0,42.0,6280.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL622651,1.0,,1.0,Brain,,,955.0,42.0,6281.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL622652,1.0,,1.0,Brain,,,955.0,42.0,6282.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL622653,1.0,,1.0,Brain,,,955.0,42.0,6283.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL622654,1.0,,1.0,Brain,,,955.0,42.0,6284.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL622655,1.0,,1.0,Heart,,,948.0,42.0,6285.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL622656,1.0,,1.0,Heart,,,948.0,42.0,6286.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL622657,1.0,,1.0,Heart,,,948.0,42.0,6287.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL622658,1.0,,1.0,Heart,,,948.0,42.0,6288.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL622659,1.0,,1.0,Heart,,,948.0,42.0,6289.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL624630,1.0,,1.0,Kidney,,,2113.0,42.0,6290.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL624631,1.0,,1.0,Kidney,,,2113.0,42.0,6291.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL624632,1.0,,1.0,Kidney,,,2113.0,42.0,6292.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17130.0,,9606.0,CHEMBL624633,1.0,,1.0,,,,,646.0,6293.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17130.0,,9606.0,CHEMBL624634,1.0,,1.0,,,,,646.0,6294.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17130.0,,9606.0,CHEMBL624635,1.0,,1.0,,,,,646.0,6295.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17130.0,,9606.0,CHEMBL624636,1.0,,1.0,,,,,646.0,6296.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml))
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,3263.0,,9606.0,CHEMBL857055,1.0,,1.0,,,,,646.0,6297.0,Antineoplastic activity against A-549 (human lung carcinoma) cell line.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,6663.0,,9606.0,CHEMBL624637,1.0,,1.0,,,,,646.0,6298.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,6663.0,,9606.0,CHEMBL624638,1.0,,1.0,,,,,646.0,6299.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,6663.0,,9606.0,CHEMBL874366,1.0,,1.0,,,,,646.0,6300.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,6663.0,,9606.0,CHEMBL624639,1.0,,1.0,,,,,646.0,6301.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,6663.0,,9606.0,CHEMBL624640,1.0,,1.0,,,,,646.0,6302.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,6663.0,,9606.0,CHEMBL624641,1.0,,1.0,,,,,646.0,6303.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,6663.0,,9606.0,CHEMBL624642,1.0,,1.0,,,,,646.0,6304.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,6663.0,,9606.0,CHEMBL624643,1.0,,1.0,,,,,646.0,6305.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,6663.0,,9606.0,CHEMBL624644,1.0,,1.0,,,,,646.0,6306.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,6663.0,,9606.0,CHEMBL624645,1.0,,1.0,,,,,646.0,6307.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,3983.0,,9606.0,CHEMBL619445,1.0,,1.0,,,,,646.0,6308.0,The compound was evaluated for its cytotoxic potency against A-549 cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,11141.0,,9606.0,CHEMBL839886,1.0,,1.0,,,,,646.0,6309.0,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5076.0,,9606.0,CHEMBL619446,1.0,,1.0,,,,,646.0,6310.0,Cytotoxic activity of compound against A-549 tumor cell line.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,3311.0,,9606.0,CHEMBL619447,1.0,,1.0,,,,,646.0,6311.0,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,3311.0,,9606.0,CHEMBL619448,1.0,,1.0,,,,,646.0,6312.0,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,3311.0,,9606.0,CHEMBL619449,1.0,,1.0,,,,,646.0,6313.0,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5076.0,,9606.0,CHEMBL619450,1.0,,1.0,,,,,646.0,6314.0,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4150.0,,9606.0,CHEMBL619451,1.0,,1.0,,,,,646.0,6315.0,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,2150.0,,9606.0,CHEMBL619452,1.0,,1.0,,,,,646.0,6316.0,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4644.0,,9606.0,CHEMBL619453,1.0,,1.0,,,,,646.0,6317.0,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,263.0,,9606.0,CHEMBL874367,1.0,,1.0,,,,,646.0,6318.0,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,11333.0,,9606.0,CHEMBL619454,1.0,,1.0,,,,,646.0,6319.0,Cytotoxic concentration against A-549 tumor cells.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,11333.0,,9606.0,CHEMBL619455,1.0,,1.0,,,,,646.0,6320.0,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,15895.0,,9606.0,CHEMBL619456,1.0,,1.0,,,,,646.0,6321.0,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line"
,BAO_0000218,F,,,50191.0,N,Acinetobacter baumannii,Expert,16677.0,,470.0,CHEMBL619457,1.0,,1.0,,,,,,6322.0,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A
,BAO_0000218,F,,,50192.0,N,Acinetobacter calcoaceticus,Intermediate,10624.0,,471.0,CHEMBL619458,1.0,,1.0,,,,,,6323.0,Activity against Acinetobacter calcoaceticus (AC54)
,BAO_0000218,F,,,50274.0,N,Aspergillus flavus,Expert,16717.0,,5059.0,CHEMBL619459,1.0,,1.0,,,,,,6324.0,In vitro antifungal activity against Aspergillus flavus CM74
,BAO_0000218,F,,,50274.0,N,Aspergillus flavus,Expert,16717.0,,5059.0,CHEMBL619460,1.0,,1.0,,,,,,6325.0,In vitro antifungal activity against Aspergillus flavus CM74
,BAO_0000218,F,,,50416.0,N,Aspergillus fumigatus,Intermediate,5513.0,,746128.0,CHEMBL619461,1.0,,1.0,,,,,,6326.0,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration
,BAO_0000218,F,,,50416.0,N,Aspergillus fumigatus,Intermediate,15962.0,,746128.0,CHEMBL619462,1.0,,1.0,,,,,,6327.0,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC)
,BAO_0000218,F,,,50416.0,N,Aspergillus fumigatus,Intermediate,15962.0,,746128.0,CHEMBL620388,1.0,,1.0,,,,,,6328.0,Antimicrobial activity against Aspergillus fumigatus (MIC)
,BAO_0000218,F,,,50416.0,N,Aspergillus fumigatus,Intermediate,15962.0,,746128.0,CHEMBL620389,1.0,,1.0,,,,,,6329.0,Antimicrobial activity against Aspergillus fumigatus (MIC)
,BAO_0000218,F,,,50416.0,N,Aspergillus fumigatus,Intermediate,15962.0,,746128.0,CHEMBL620390,1.0,,1.0,,,,,,6330.0,In vitro antimicrobial activity against Aspergillus fumigatus (MIC)
,BAO_0000218,F,,,50416.0,N,Aspergillus fumigatus,Expert,16717.0,,746128.0,CHEMBL620391,1.0,,1.0,,,,,,6331.0,In vitro antifungal activity against Aspergillus fumigatus 48238E
,BAO_0000218,F,,,50416.0,N,Aspergillus fumigatus,Expert,16717.0,,746128.0,CHEMBL621073,1.0,,1.0,,,,,,6332.0,In vitro antifungal activity against Aspergillus fumigatus 48238E
,BAO_0000218,F,,,50296.0,N,Actinomyces naeslundii,Intermediate,8117.0,,1655.0,CHEMBL621074,1.0,,1.0,,,,,,6333.0,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631
,BAO_0000218,F,,,50366.0,N,Actinomyces viscosus,Intermediate,8117.0,,1656.0,CHEMBL621075,1.0,,1.0,,,,,,6334.0,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100
,BAO_0000218,F,,,50535.0,N,Acanthocheilonema viteae,Intermediate,15472.0,,6277.0,CHEMBL619554,1.0,,1.0,,,,,,6335.0,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally)
,BAO_0000218,F,,,50535.0,N,Acanthocheilonema viteae,Intermediate,15472.0,,6277.0,CHEMBL619555,1.0,,1.0,,,,,,6336.0,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally)
,BAO_0000218,F,,,50169.0,N,Aggregatibacter actinomycetemcomitans,Intermediate,16443.0,,714.0,CHEMBL619556,1.0,,1.0,,,,,,6337.0,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527
,BAO_0000218,F,,,50169.0,N,Aggregatibacter actinomycetemcomitans,Intermediate,16443.0,,714.0,CHEMBL619557,1.0,,1.0,,,,,,6338.0,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2
,BAO_0000218,F,,,50169.0,N,Aggregatibacter actinomycetemcomitans,Intermediate,16443.0,,714.0,CHEMBL619558,1.0,,1.0,,,,,,6339.0,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17206.0,,9606.0,CHEMBL619559,1.0,,1.0,,,,,646.0,6340.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17206.0,,9606.0,CHEMBL619560,1.0,,1.0,,,,,646.0,6341.0,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16381.0,,9606.0,CHEMBL619561,1.0,,1.0,,,,,646.0,6342.0,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16381.0,,9606.0,CHEMBL619562,1.0,,1.0,,,,,646.0,6343.0,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16381.0,,9606.0,CHEMBL619563,1.0,,1.0,,,,,646.0,6344.0,% inhibition against A549 cells (lung cancer) at 4 ug/mL
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16381.0,,9606.0,CHEMBL857457,1.0,,1.0,,,,,646.0,6345.0,GI values against A549 cells (lung cancer)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17206.0,,9606.0,CHEMBL619564,1.0,,1.0,,,,,646.0,6346.0,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16325.0,,9606.0,CHEMBL619565,1.0,,1.0,,,,,646.0,6347.0,Inhibitory activity against A549 human adenocarcinoma
,BAO_0000218,F,,A549,80682.0,N,Homo sapiens,Intermediate,10708.0,,9606.0,CHEMBL619566,1.0,,1.0,,,,,646.0,6348.0,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg
,BAO_0000218,F,,A549,80682.0,N,Homo sapiens,Intermediate,10708.0,,9606.0,CHEMBL619567,1.0,,1.0,,,,,646.0,6349.0,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17376.0,,9606.0,CHEMBL619568,1.0,,1.0,,,,,646.0,6350.0,Inhibitory activity against A549 lung adenocarcinoma cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17376.0,,9606.0,CHEMBL619569,1.0,,1.0,,,,,646.0,6351.0,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17488.0,,9606.0,CHEMBL619570,1.0,,1.0,,,,,646.0,6352.0,Cytotoxicity against human A549 lung cells
,BAO_0000218,F,,A549,80682.0,N,Homo sapiens,Intermediate,17404.0,,9606.0,CHEMBL619571,1.0,,1.0,,,,,646.0,6353.0,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,10958.0,,9606.0,CHEMBL619572,1.0,,1.0,,,,,646.0,6354.0,Growth inhibition of A549 (human lung carcinoma) cell line.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,17099.0,,9606.0,CHEMBL619573,1.0,,1.0,,,,,646.0,6355.0,Effective dose required for inhibitory activity against A549 human tumor cell line.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17099.0,,9606.0,CHEMBL619574,1.0,,1.0,,,,,646.0,6356.0,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4096.0,,9606.0,CHEMBL619575,1.0,,1.0,,,,,646.0,6357.0,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,4096.0,,9606.0,CHEMBL619576,1.0,,1.0,,,,,646.0,6358.0,Cytotoxicity evaluated against A549 tumor cell lines; significant activity
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,4096.0,,9606.0,CHEMBL619577,1.0,,1.0,,,,,646.0,6359.0,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,2525.0,,9606.0,CHEMBL619578,1.0,,1.0,,,,,646.0,6360.0,In vitro inhibitory activity against A549 tumor cell culture
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,2525.0,,9606.0,CHEMBL884009,1.0,,1.0,,,,,646.0,6361.0,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,5302.0,,9606.0,CHEMBL619579,1.0,,1.0,,,,,646.0,6362.0,Activity against human lung cancer with mutated beta-tubulin (A549-T2415)
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16325.0,,9606.0,CHEMBL619580,1.0,,1.0,,,,,646.0,6363.0,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,16939.0,,9606.0,CHEMBL619581,1.0,,1.0,,,,,646.0,6364.0,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17229.0,,9606.0,CHEMBL619582,1.0,,1.0,,,,,646.0,6365.0,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17380.0,,9606.0,CHEMBL619583,1.0,,1.0,,,,,646.0,6366.0,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17380.0,,9606.0,CHEMBL876502,1.0,,1.0,,,,,646.0,6367.0,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,1903.0,,9606.0,CHEMBL619584,1.0,,1.0,,,,,646.0,6368.0,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,3838.0,,9606.0,CHEMBL619585,1.0,,1.0,,,,,646.0,6369.0,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,14696.0,,9606.0,CHEMBL619586,1.0,,1.0,,,,,646.0,6370.0,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,3838.0,,9606.0,CHEMBL619587,1.0,,1.0,,,,,646.0,6371.0,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,1522.0,,9606.0,CHEMBL619588,1.0,,1.0,,,,,646.0,6372.0,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,12400.0,,9606.0,CHEMBL619589,1.0,,1.0,,,,,646.0,6373.0,Tested in vitro for cytotoxicity in A549/ATCC cell lines
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,14696.0,,9606.0,CHEMBL619590,1.0,,1.0,,,,,646.0,6374.0,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,14769.0,,9606.0,CHEMBL619591,1.0,,1.0,,,,,646.0,6375.0,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells )
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,14696.0,,9606.0,CHEMBL619592,1.0,,1.0,,,,,646.0,6376.0,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,1888.0,,9606.0,CHEMBL619593,1.0,,1.0,,,,,646.0,6377.0,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,12016.0,,9606.0,CHEMBL620217,1.0,,1.0,,,,,646.0,6378.0,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,6058.0,,9606.0,CHEMBL620218,1.0,,1.0,,,,,646.0,6379.0,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17708.0,,9606.0,CHEMBL620219,1.0,,1.0,,,,,646.0,6380.0,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,12301.0,,9606.0,CHEMBL620220,1.0,,1.0,,,,,646.0,6381.0,Antitumor activity against A549/ATCC cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,11970.0,,9606.0,CHEMBL625141,1.0,,1.0,,,,,646.0,6382.0,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Expert,11818.0,,9606.0,CHEMBL625142,1.0,,1.0,,,,,646.0,6383.0,In vitro cytotoxicity against A549/ATCC cell line.
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,12400.0,,9606.0,CHEMBL625143,1.0,,1.0,,,,,646.0,6384.0,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,3381.0,,9606.0,CHEMBL625144,1.0,,1.0,,,,,646.0,6385.0,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,17376.0,,9606.0,CHEMBL622474,1.0,,1.0,,,,,646.0,6386.0,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line
,BAO_0000219,F,,A549,80682.0,N,Homo sapiens,Intermediate,10708.0,,9606.0,CHEMBL884104,1.0,,1.0,,,,,646.0,6387.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay
,BAO_0000219,F,,,22226.0,U,Homo sapiens,Autocuration,2964.0,,9606.0,CHEMBL622475,1.0,,0.0,,,,,,6388.0,Cytotoxicity was evaluated against A649 human mammary carcinoma cells
,BAO_0000218,A,In vivo,,22224.0,U,Canis lupus familiaris,Intermediate,5005.0,,9615.0,CHEMBL622476,1.0,,0.0,,,,,,6389.0,Compound was tested for oral bioavailability in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6229.0,,9615.0,CHEMBL875831,1.0,,1.0,,,,,,6390.0,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6229.0,,9615.0,CHEMBL622477,1.0,,1.0,,,,,,6391.0,Compound was tested for orally bioavailable in dogs with a half life of 1.2h
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5374.0,,9615.0,CHEMBL622478,1.0,,1.0,,,,,,6392.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5374.0,,9615.0,CHEMBL623172,1.0,,1.0,,,,,,6393.0,Compound was tested for the oral bioavailability in dog; No availability
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6265.0,,9615.0,CHEMBL623173,1.0,,1.0,,,,,,6394.0,Oral bioavailability in dog (dose 5 mg/kg)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5654.0,,9615.0,CHEMBL623174,1.0,,1.0,,,,,,6395.0,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5654.0,,9615.0,CHEMBL623175,1.0,,1.0,,,,,,6396.0,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16456.0,,9615.0,CHEMBL623340,1.0,,1.0,,,,,,6397.0,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5302.0,,9615.0,CHEMBL623341,1.0,,1.0,,,,,,6398.0,Oral bioavailability in dog (dose 5 mg/kg)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3624.0,,9615.0,CHEMBL623342,1.0,,1.0,,,,,,6399.0,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16452.0,,9615.0,CHEMBL623343,1.0,,1.0,,,,,,6400.0,Oral bioavailability of active FTIs in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5802.0,,9615.0,CHEMBL623344,1.0,,1.0,,,,,,6401.0,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Expert,3598.0,,9615.0,CHEMBL623345,1.0,,1.0,,,,,,6402.0,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17839.0,,9615.0,CHEMBL875832,1.0,,1.0,,,,,,6403.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6762.0,,9615.0,CHEMBL623346,1.0,,1.0,,,,,,6404.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6821.0,,9615.0,CHEMBL623347,1.0,,1.0,,,,,,6405.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6821.0,,9615.0,CHEMBL623348,1.0,,1.0,,,,,,6406.0,Oral bioavailability of compound was determined in dog; Not tested
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5210.0,,9615.0,CHEMBL623349,1.0,,1.0,,,,,,6407.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6227.0,,9615.0,CHEMBL623350,1.0,,1.0,,,,,,6408.0,Oral bioavailability (10 mg/kg) was determined in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,761.0,,9615.0,CHEMBL623351,1.0,,1.0,,,,,,6409.0,Oral bioavailability
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,761.0,,9615.0,CHEMBL623352,1.0,,1.0,,,,,,6410.0,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,761.0,,9615.0,CHEMBL623353,1.0,,1.0,,,,,,6411.0,Oral bioavailability administered in solution in rats
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16907.0,,9615.0,CHEMBL875833,1.0,,1.0,,,,,,6412.0,Oral bioavailability after 30 mg/kg po dose in Dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5474.0,,9615.0,CHEMBL623354,1.0,,1.0,,,,,,6413.0,Oral bioavailability at a dose of 1 mg/kg in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6535.0,,9615.0,CHEMBL623355,1.0,,1.0,,,,,,6414.0,Oral bioavailability in dog (dose 1 mg/kg p.o.)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6535.0,,9615.0,CHEMBL623356,1.0,,1.0,,,,,,6415.0,Oral bioavailability in Dog; ND = not determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3352.0,,9615.0,CHEMBL623357,1.0,,1.0,,,,,,6416.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6168.0,,9615.0,CHEMBL623358,1.0,,1.0,,,,,,6417.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5988.0,,9615.0,CHEMBL623359,1.0,,1.0,,,,,,6418.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4942.0,,9615.0,CHEMBL623360,1.0,,1.0,,,,,,6419.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4942.0,,9615.0,CHEMBL623361,1.0,,1.0,,,,,,6420.0,Oral bioavailability in dogs; No data
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,14541.0,,9615.0,CHEMBL623362,1.0,,1.0,,,,,,6421.0,Oral bioavailability measured in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4449.0,,9615.0,CHEMBL623363,1.0,,1.0,,,,,,6422.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6057.0,,9615.0,CHEMBL623364,1.0,,1.0,,,,,,6423.0,Oral bioavailability was calculated in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5600.0,,9615.0,CHEMBL875834,1.0,,1.0,,,,,,6424.0,Oral bioavailability after 0.3 mg/kg po administration in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5542.0,,9615.0,CHEMBL623365,1.0,,1.0,,,,,,6425.0,Oral bioavailability in dog (i.v. dosing)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5542.0,,9615.0,CHEMBL623366,1.0,,1.0,,,,,,6426.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5546.0,,9615.0,CHEMBL623367,1.0,,1.0,,,,,,6427.0,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4514.0,,9615.0,CHEMBL623368,1.0,,1.0,,,,,,6428.0,Oral bioavailability in Beagle dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3624.0,,9615.0,CHEMBL623369,1.0,,1.0,,,,,,6429.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3854.0,,9615.0,CHEMBL623370,1.0,,1.0,,,,,,6430.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5836.0,,9615.0,CHEMBL623371,1.0,,1.0,,,,,,6431.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5940.0,,9615.0,CHEMBL623372,1.0,,1.0,,,,,,6432.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6168.0,,9615.0,CHEMBL621351,1.0,,1.0,,,,,,6433.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6227.0,,9615.0,CHEMBL621352,1.0,,1.0,,,,,,6434.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6251.0,,9615.0,CHEMBL621353,1.0,,1.0,,,,,,6435.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6448.0,,9615.0,CHEMBL621354,1.0,,1.0,,,,,,6436.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6647.0,,9615.0,CHEMBL621355,1.0,,1.0,,,,,,6437.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5940.0,,9615.0,CHEMBL621356,1.0,,1.0,,,,,,6438.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,933.0,,9615.0,CHEMBL621357,1.0,,1.0,,,,,,6439.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5210.0,,9615.0,CHEMBL621358,1.0,,1.0,,,,,,6440.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6642.0,,9615.0,CHEMBL621359,1.0,,1.0,,,,,,6441.0,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6641.0,,9615.0,CHEMBL621360,1.0,,1.0,,,,,,6442.0,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6642.0,,9615.0,CHEMBL621361,1.0,,1.0,,,,,,6443.0,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5472.0,,9615.0,CHEMBL621362,1.0,,1.0,,,,,,6444.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5985.0,,9615.0,CHEMBL621363,1.0,,1.0,,,,,,6445.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,15660.0,,9615.0,CHEMBL621364,1.0,,1.0,,,,,,6446.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5530.0,,9615.0,CHEMBL621166,1.0,,1.0,,,,,,6447.0,Oral bioavailability in dog (dose 0.2 mg/kg i.v.)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5530.0,,9615.0,CHEMBL621167,1.0,,1.0,,,,,,6448.0,Oral bioavailability in dog (dose 1 mg/kg i.v.)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6305.0,,9615.0,CHEMBL621168,1.0,,1.0,,,,,,6449.0,Oral bioavailability (F) in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5210.0,,9615.0,CHEMBL621169,1.0,,1.0,,,,,,6450.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5238.0,,9615.0,CHEMBL875950,1.0,,1.0,,,,,,6451.0,Bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5668.0,,9615.0,CHEMBL621170,1.0,,1.0,,,,,,6452.0,Oral bioavailability in dog (dose 10 mg/kg)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5668.0,,9615.0,CHEMBL621171,1.0,,1.0,,,,,,6453.0,Oral bioavailability after peroral administration at 5 mpk in Dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5668.0,,9615.0,CHEMBL621172,1.0,,1.0,,,,,,6454.0,Oral bioavailability in dog (dose 5 mg/kg)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6084.0,,9615.0,CHEMBL621173,1.0,,1.0,,,,,,6455.0,Oral bioavailability in dog (dose 10 mg/kg)
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621174,1.0,,1.0,Kidney,,,2113.0,42.0,6456.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621175,1.0,,1.0,Kidney,,,2113.0,42.0,6457.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621176,1.0,,1.0,Liver,,,2107.0,42.0,6458.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621177,1.0,,1.0,Liver,,,2107.0,42.0,6459.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621178,1.0,,1.0,Liver,,,2107.0,42.0,6460.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621179,1.0,,1.0,Liver,,,2107.0,42.0,6461.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621180,1.0,,1.0,Liver,,,2107.0,42.0,6462.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL875951,1.0,,1.0,Lung,,,2048.0,42.0,6463.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621181,1.0,,1.0,Lung,,,2048.0,42.0,6464.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621182,1.0,,1.0,Lung,,,2048.0,42.0,6465.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621183,1.0,,1.0,Lung,,,2048.0,42.0,6466.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621184,1.0,,1.0,Lung,,,2048.0,42.0,6467.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621185,1.0,,1.0,,,,,42.0,6468.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621186,1.0,,1.0,,,,,42.0,6469.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621187,1.0,,1.0,,,,,42.0,6470.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621188,1.0,,1.0,,,,,42.0,6471.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621189,1.0,,1.0,,,,,42.0,6472.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621190,1.0,,1.0,Spleen,,,2106.0,42.0,6473.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL618520,1.0,,1.0,Spleen,,,2106.0,42.0,6474.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621739,1.0,,1.0,Spleen,,,2106.0,42.0,6475.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621740,1.0,,1.0,Spleen,,,2106.0,42.0,6476.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621741,1.0,,1.0,Spleen,,,2106.0,42.0,6477.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621742,1.0,,1.0,,,,,42.0,6478.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621743,1.0,,1.0,,,,,42.0,6479.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621744,1.0,,1.0,,,,,42.0,6480.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621745,1.0,,1.0,,,,,42.0,6481.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621746,1.0,,1.0,,,,,42.0,6482.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621747,1.0,,1.0,,,,,42.0,6483.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621748,1.0,,1.0,,,,,42.0,6484.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621749,1.0,,1.0,,,,,42.0,6485.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621750,1.0,,1.0,,,,,42.0,6486.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621751,1.0,,1.0,,,,,42.0,6487.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621752,1.0,,1.0,Heart,,,948.0,42.0,6488.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621753,1.0,,1.0,Heart,,,948.0,42.0,6489.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL875955,1.0,,1.0,Heart,,,948.0,42.0,6490.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621754,1.0,,1.0,Heart,,,948.0,42.0,6491.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621755,1.0,,1.0,Heart,,,948.0,42.0,6492.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL621756,1.0,,1.0,Liver,,,2107.0,42.0,6493.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL624199,1.0,,1.0,Liver,,,2107.0,42.0,6494.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL624200,1.0,,1.0,Liver,,,2107.0,42.0,6495.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL624375,1.0,,1.0,Liver,,,2107.0,42.0,6496.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL624376,1.0,,1.0,Liver,,,2107.0,42.0,6497.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL624377,1.0,,1.0,Lung,,,2048.0,42.0,6498.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL624378,1.0,,1.0,Lung,,,2048.0,42.0,6499.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours
,BAO_0000218,F,,,50067.0,N,aeinetobacter anitrotap,Intermediate,12269.0,,107673.0,CHEMBL857901,1.0,,1.0,,,,,,6500.0,Compound tested for the antimicrobial activity against Acinetobacter anitratus
,BAO_0000218,F,,,50067.0,N,Acinetobacter calcoaceticus subsp. anitratus,Intermediate,12269.0,,107673.0,CHEMBL875274,1.0,,1.0,,,,,,6501.0,Compound tested for the antimicrobial activity against Acinetobacter anitratus
,BAO_0000218,F,,,50067.0,N,Acinetobacter calcoaceticus subsp. anitratus,Intermediate,12269.0,,107673.0,CHEMBL624379,1.0,,1.0,,,,,,6502.0,Compound tested for the antimicrobial activity against Acinetobacter anitratus
,BAO_0000218,F,,,50067.0,N,aeinetobacter anitrotap,Intermediate,12269.0,,107673.0,CHEMBL624380,1.0,,1.0,,,,,,6503.0,Compound tested for the antimicrobial activity against Acinetobacter anitratus
,BAO_0000218,F,,,50192.0,N,Acinetobacter calcoaceticus,Intermediate,10624.0,,471.0,CHEMBL624381,1.0,,1.0,,,,,,6504.0,Activity against Acinetobacter calcoaceticus (AC54)
,BAO_0000218,F,,,50714.0,N,Anolis carolinensis,Intermediate,17216.0,,28377.0,CHEMBL624382,1.0,,1.0,,,,,,6505.0,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity
,BAO_0000218,F,,,50714.0,N,Anolis carolinensis,Intermediate,17216.0,,28377.0,CHEMBL624383,1.0,,1.0,,,,,,6506.0,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity
,BAO_0000218,F,,,50296.0,N,Actinomyces naeslundii,Intermediate,9560.0,,1655.0,CHEMBL624384,1.0,,1.0,,,,,,6507.0,Chlorohexidine coefficient for Actinomyces naeslundii 631
,BAO_0000218,F,,,50296.0,N,Actinomyces naeslundii,Intermediate,9560.0,,1655.0,CHEMBL624385,1.0,,1.0,,,,,,6508.0,Chlorohexidine coefficient for Actinomyces naeslundii B74
,BAO_0000218,F,,,50296.0,N,Actinomyces naeslundii,Intermediate,9560.0,,1655.0,CHEMBL624386,1.0,,1.0,,,,,,6509.0,Chlorohexidine coefficient for Actinomyces naeslundii N/3
,BAO_0000218,F,,,50296.0,N,Actinomyces naeslundii,Intermediate,9560.0,,1655.0,CHEMBL624387,1.0,,1.0,,,,,,6510.0,Chlorohexidine coefficient for Actinomyces naeslundii N/9
,BAO_0000218,F,,,50296.0,N,Actinomyces naeslundii,Intermediate,9560.0,,1655.0,CHEMBL624388,1.0,,1.0,,,,,,6511.0,Plaque bactericidal index against Actinomyces naeslundii 631
,BAO_0000218,F,,,50296.0,N,Actinomyces naeslundii,Intermediate,9560.0,,1655.0,CHEMBL624389,1.0,,1.0,,,,,,6512.0,Plaque bactericidal index against Actinomyces naeslundii N/9
,BAO_0000218,F,,,50296.0,N,Actinomyces naeslundii,Intermediate,9560.0,,1655.0,CHEMBL624390,1.0,,1.0,,,,,,6513.0,Plaque bactericidal index against Actinomyces naeslundii B74
,BAO_0000218,F,,,50296.0,N,Actinomyces naeslundii,Intermediate,9560.0,,1655.0,CHEMBL875275,1.0,,1.0,,,,,,6514.0,Plaque bactericidal index against Actinomyces naeslundii N/3
,BAO_0000218,F,,,50056.0,N,Artemia salina,Intermediate,114.0,,85549.0,CHEMBL624391,1.0,,1.0,,,,,,6515.0,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay
,BAO_0000218,F,,,50056.0,N,Artemia salina,Intermediate,114.0,,85549.0,CHEMBL623636,1.0,,1.0,,,,,,6516.0,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity"
,BAO_0000218,F,,,50532.0,N,Ascaris suum,Intermediate,10841.0,,6253.0,CHEMBL623637,1.0,,1.0,,,,,,6517.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM
,BAO_0000218,F,,,50532.0,N,Ascaris suum,Intermediate,10841.0,,6253.0,CHEMBL623638,1.0,,1.0,,,,,,6518.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM
,BAO_0000218,F,,,50532.0,N,Ascaris suum,Intermediate,10841.0,,6253.0,CHEMBL623639,1.0,,1.0,,,,,,6519.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM
,BAO_0000218,F,,,50532.0,N,Ascaris suum,Intermediate,10841.0,,6253.0,CHEMBL623640,1.0,,1.0,,,,,,6520.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM
,BAO_0000218,F,,,50532.0,N,Ascaris suum,Intermediate,10841.0,,6253.0,CHEMBL623641,1.0,,1.0,,,,,,6521.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM
,BAO_0000218,F,,,50532.0,N,Ascaris suum,Intermediate,10841.0,,6253.0,CHEMBL623642,1.0,,1.0,,,,,,6522.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.
,BAO_0000218,F,,,50532.0,N,Ascaris suum,Intermediate,10841.0,,6253.0,CHEMBL623643,1.0,,1.0,,,,,,6523.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM
,BAO_0000218,F,,,50532.0,N,Ascaris suum,Intermediate,10841.0,,6253.0,CHEMBL623644,1.0,,1.0,,,,,,6524.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM
,BAO_0000218,F,,,50532.0,N,Ascaris suum,Intermediate,10841.0,,6253.0,CHEMBL623645,1.0,,1.0,,,,,,6525.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM
,BAO_0000218,F,,,50532.0,N,Ascaris suum,Intermediate,10841.0,,6253.0,CHEMBL623646,1.0,,1.0,,,,,,6526.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM
,BAO_0000218,F,,,50532.0,N,Ascaris suum,Intermediate,10841.0,,6253.0,CHEMBL623647,1.0,,1.0,,,,,,6527.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM
,BAO_0000218,F,,,50532.0,N,Ascaris suum,Intermediate,10841.0,,6253.0,CHEMBL623648,1.0,,1.0,,,,,,6528.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM
,BAO_0000218,F,,,50366.0,N,Actinomyces viscosus,Intermediate,8117.0,,1656.0,CHEMBL623649,1.0,,1.0,,,,,,6529.0,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus
,BAO_0000218,F,,,50366.0,N,Actinomyces viscosus,Intermediate,8117.0,,1656.0,CHEMBL623650,1.0,,1.0,,,,,,6530.0,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus
,BAO_0000218,F,,,50366.0,N,Actinomyces viscosus,Intermediate,9560.0,,1656.0,CHEMBL623651,1.0,,1.0,,,,,,6531.0,Chlorohexidine coefficient for Actinomyces viscosus 8A06
,BAO_0000218,F,,,50366.0,N,Actinomyces viscosus,Expert,9560.0,,1656.0,CHEMBL623652,1.0,,1.0,,,,,,6532.0,Chlorohexidine coefficient for Actinomyces viscosus M-100
,BAO_0000218,F,,,50366.0,N,Actinomyces viscosus,Intermediate,9560.0,,1656.0,CHEMBL623653,1.0,,1.0,,,,,,6533.0,Chlorohexidine coefficient for Actinomyces viscosus M-626
,BAO_0000218,F,,,50366.0,N,Actinomyces viscosus,Intermediate,9560.0,,1656.0,CHEMBL623654,1.0,,1.0,,,,,,6534.0,Chlorohexidine coefficient for Actinomyces viscosus T14V
,BAO_0000218,F,,,50366.0,N,Actinomyces viscosus,Intermediate,9560.0,,1656.0,CHEMBL623655,1.0,,1.0,,,,,,6535.0,Plaque bactericidal index against Actinomyces viscosus 8A06
,BAO_0000218,F,,,50366.0,N,Actinomyces viscosus,Intermediate,9560.0,,1656.0,CHEMBL623656,1.0,,1.0,,,,,,6536.0,Plaque bactericidal index against Actinomyces viscosus M-100
,BAO_0000218,F,,,50366.0,N,Actinomyces viscosus,Expert,9560.0,,1656.0,CHEMBL623657,1.0,,1.0,,,,,,6537.0,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient
,BAO_0000218,F,,,50366.0,N,Actinomyces viscosus,Intermediate,9560.0,,1656.0,CHEMBL623658,1.0,,1.0,,,,,,6538.0,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)"
,BAO_0000218,F,,,50366.0,N,Actinomyces viscosus,Intermediate,9560.0,,1656.0,CHEMBL623659,1.0,,1.0,,,,,,6539.0,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)"
,BAO_0000218,F,,,50366.0,N,Actinomyces viscosus,Intermediate,9560.0,,1656.0,CHEMBL623660,1.0,,1.0,,,,,,6540.0,Plaque bactericidal index against Actinomyces viscosus 626
,BAO_0000218,F,,,50366.0,N,Actinomyces viscosus,Intermediate,9560.0,,1656.0,CHEMBL623661,1.0,,1.0,,,,,,6541.0,Plaque bactericidal index against Actinomyces viscosus T14V
,BAO_0000218,F,,,50535.0,N,Acanthocheilonema viteae,Intermediate,10986.0,,6277.0,CHEMBL875281,1.0,,1.0,,,,,,6542.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose
,BAO_0000218,F,,,50535.0,N,Acanthocheilonema viteae,Intermediate,10986.0,,6277.0,CHEMBL623662,1.0,,1.0,,,,,,6543.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose
,BAO_0000218,F,,,50535.0,N,Acanthocheilonema viteae,Intermediate,10986.0,,6277.0,CHEMBL623663,1.0,,1.0,,,,,,6544.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose
,BAO_0000218,F,,,50535.0,N,Acanthocheilonema viteae,Intermediate,10986.0,,6277.0,CHEMBL623664,1.0,,1.0,,,,,,6545.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose
,BAO_0000218,F,,,50535.0,N,Acanthocheilonema viteae,Intermediate,10986.0,,6277.0,CHEMBL623665,1.0,,1.0,,,,,,6546.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose
,BAO_0000219,F,,A673,80023.0,N,Homo sapiens,Intermediate,10708.0,,9606.0,CHEMBL621856,1.0,,1.0,,,,,165.0,6547.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay
,BAO_0000219,F,,A704,80661.0,N,Homo sapiens,Intermediate,10708.0,,9606.0,CHEMBL620432,1.0,,1.0,,,,,645.0,6548.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay
,BAO_0000219,F,,,22226.0,U,Rattus norvegicus,Autocuration,416.0,,10116.0,CHEMBL620433,1.0,,0.0,,,,,,6549.0,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells
,BAO_0000219,F,,A9,80024.0,N,Mus musculus,Intermediate,14354.0,,10090.0,CHEMBL620434,1.0,,1.0,,,,,625.0,6550.0,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors
,BAO_0000219,F,,A9,80024.0,N,Mus musculus,Intermediate,14354.0,,10090.0,CHEMBL620435,1.0,,1.0,,,,,625.0,6551.0,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors
,BAO_0000219,F,,A9,80024.0,N,Homo sapiens,Intermediate,5116.0,,9606.0,CHEMBL620436,1.0,,1.0,,,,,625.0,6552.0,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested
,BAO_0000219,F,,A9,80024.0,N,Homo sapiens,Intermediate,5116.0,,9606.0,CHEMBL876597,1.0,,1.0,,,,,625.0,6553.0,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line
,BAO_0000219,F,,Human ovarian carcinoma cell line,81037.0,N,Homo sapiens,Expert,15694.0,,9606.0,CHEMBL620437,1.0,,1.0,,,,,874.0,6554.0,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation
,BAO_0000219,F,,A9,80024.0,N,Mus musculus,Expert,13038.0,,10090.0,CHEMBL620438,1.0,,1.0,,,,,625.0,6555.0,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM."
,BAO_0000219,F,,A9,80024.0,N,Mus musculus,Expert,13038.0,,10090.0,CHEMBL620439,1.0,,1.0,,,,,625.0,6556.0,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.
,BAO_0000219,F,,A9,80024.0,N,Mus musculus,Expert,10923.0,,10090.0,CHEMBL619657,1.0,,1.0,,,,,625.0,6557.0,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.
,BAO_0000219,F,,A9,80024.0,N,Mus musculus,Intermediate,10923.0,,10090.0,CHEMBL619658,1.0,,1.0,,,,,625.0,6558.0,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined
,BAO_0000219,F,,A9,80024.0,N,Mus musculus,Intermediate,10923.0,,10090.0,CHEMBL619659,1.0,,1.0,,,,,625.0,6559.0,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive
,BAO_0000019,F,,,10649.0,H,,Expert,10923.0,,,CHEMBL619660,1.0,,8.0,,,,,,6560.0,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar"
,BAO_0000219,F,,A9,80024.0,N,Mus musculus,Intermediate,10923.0,,10090.0,CHEMBL619661,1.0,,1.0,,,,,625.0,6561.0,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined
,BAO_0000219,F,,A9,80024.0,N,Mus musculus,Intermediate,10923.0,,10090.0,CHEMBL619662,1.0,,1.0,,,,,625.0,6562.0,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive
,BAO_0000219,F,,AA6,80663.0,N,Cricetulus griseus,Intermediate,8158.0,,10029.0,CHEMBL619663,1.0,,1.0,,,,,975.0,6563.0,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined
,BAO_0000219,F,,,22226.0,U,Homo sapiens,Autocuration,15494.0,,9606.0,CHEMBL619664,1.0,,0.0,,,,,,6564.0,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.
,BAO_0000219,F,,,22226.0,U,Homo sapiens,Autocuration,15494.0,,9606.0,CHEMBL619665,1.0,,0.0,,,,,,6565.0,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation."
,BAO_0000219,F,,AA5,80662.0,N,Homo sapiens,Intermediate,12348.0,,9606.0,CHEMBL883244,1.0,,1.0,,,,,974.0,6566.0,Anti -HIV activity was measured against AA5/HIV-1(IIIB)
,BAO_0000219,F,,AA5,80662.0,N,Homo sapiens,Intermediate,12348.0,,9606.0,CHEMBL884011,1.0,,1.0,,,,,974.0,6567.0,Cytotoxicity was measured against AA5/HIV-1(IIIB)
,BAO_0000219,F,,AA5,80662.0,N,Homo sapiens,Intermediate,2726.0,,9606.0,CHEMBL619666,1.0,,1.0,,,,,974.0,6568.0,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell
,BAO_0000219,F,,U-937,80566.0,N,Homo sapiens,Intermediate,2726.0,,9606.0,CHEMBL619667,1.0,,1.0,,,,,379.0,6569.0,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell
,BAO_0000219,F,,UV4,80578.0,N,Cricetulus griseus,Intermediate,10747.0,,10029.0,CHEMBL619668,1.0,,1.0,,,,,274.0,6570.0,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Expert,11005.0,,10029.0,CHEMBL619669,1.0,,1.0,,,,,185.0,6571.0,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8"
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,12687.0,,10029.0,CHEMBL876608,1.0,,1.0,,,,,185.0,6572.0,Average intracellular compound concentration when the hypoxic SER=1.6
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,12687.0,,10029.0,CHEMBL619670,1.0,,1.0,,,,,185.0,6573.0,Average intracellular compound concentration when the hypoxic SER=1.6.
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,12687.0,,10029.0,CHEMBL619671,1.0,,1.0,,,,,185.0,6574.0,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,12687.0,,10029.0,CHEMBL619672,1.0,,1.0,,,,,185.0,6575.0,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,12687.0,,10029.0,CHEMBL619673,1.0,,1.0,,,,,185.0,6576.0,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,13436.0,,10029.0,CHEMBL619674,1.0,,1.0,,,,,185.0,6577.0,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay."
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,13435.0,,10029.0,CHEMBL619675,1.0,,1.0,,,,,185.0,6578.0,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml"
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,13302.0,,10029.0,CHEMBL619676,1.0,,1.0,,,,,185.0,6579.0,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,12687.0,,10029.0,CHEMBL619677,1.0,,1.0,,,,,185.0,6580.0,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition
,BAO_0000219,A,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,12687.0,,10029.0,CHEMBL619678,1.0,,1.0,,,,,185.0,6581.0,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition
,BAO_0000219,A,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,12687.0,,10029.0,CHEMBL619679,1.0,,1.0,,,,,185.0,6582.0,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.
,BAO_0000219,A,,CHO-AA8,80089.0,N,Cricetulus griseus,Expert,12878.0,,10029.0,CHEMBL619680,1.0,,1.0,,,,,185.0,6583.0,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay
,BAO_0000219,A,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,12878.0,,10029.0,CHEMBL621457,1.0,,1.0,,,,,185.0,6584.0,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Expert,14367.0,,10029.0,CHEMBL876609,1.0,,1.0,,,,,185.0,6585.0,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,14367.0,,10029.0,CHEMBL621458,1.0,,1.0,,,,,185.0,6586.0,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay
,BAO_0000219,F,,CHO-AA8,80089.0,N,hampster,Expert,12398.0,,36483.0,CHEMBL621459,1.0,,1.0,,,,,185.0,6587.0,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Expert,12878.0,,10029.0,CHEMBL621460,1.0,,1.0,,,,,185.0,6588.0,Aerobic growth inhibition in Chinese hamster cell line AA8
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Expert,13820.0,,10029.0,CHEMBL621461,1.0,,1.0,,,,,185.0,6589.0,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Expert,13436.0,,10029.0,CHEMBL621462,1.0,,1.0,,,,,185.0,6590.0,Inhibition of growth under aerobic conditions in AA8 cells
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6084.0,,9615.0,CHEMBL621463,1.0,,1.0,,,,,,6591.0,Oral bioavailability in dog (dose 10 mg/kg)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5711.0,,9615.0,CHEMBL621464,1.0,,1.0,,,,,,6592.0,Oral bioavailability in dog at 10 mg/kg of the compound
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4353.0,,9615.0,CHEMBL621465,1.0,,1.0,,,,,,6593.0,Oral bioavailability in dog (dose 5 uM/kg)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4353.0,,9615.0,CHEMBL621466,1.0,,1.0,,,,,,6594.0,Oral bioavailability in dog (dose 5 uM/kg)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17800.0,,9615.0,CHEMBL621467,1.0,,1.0,,,,,,6595.0,Oral bioavailability in dog (mongrel)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3994.0,,9615.0,CHEMBL621468,1.0,,1.0,,,,,,6596.0,Oral bioavailability in dog (dose 10 mg/kg)
,BAO_0000218,F,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3994.0,,9615.0,CHEMBL876734,1.0,,1.0,,,,,,6597.0,Oral bioavailability in dog (dose 10 mg/kg)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5145.0,,9615.0,CHEMBL618476,1.0,,1.0,,,,,,6598.0,Bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16452.0,,9615.0,CHEMBL618477,1.0,,1.0,,,,,,6599.0,Bioavailability in dog (dose 1 mg/kg i.v.)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16452.0,,9615.0,CHEMBL618478,1.0,,1.0,,,,,,6600.0,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5983.0,,9615.0,CHEMBL618479,1.0,,1.0,,,,,,6601.0,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4273.0,,9615.0,CHEMBL618480,1.0,,1.0,,,,,,6602.0,Bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,12500.0,,9615.0,CHEMBL618481,1.0,,1.0,,,,,,6603.0,Bioavailability in dog (dose 3-10 mg/kg)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,12500.0,,9615.0,CHEMBL618482,1.0,,1.0,Plasma,,,1969.0,,6604.0,The compound was tested for bioavailability of compound in plasma of dog; Complete
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3639.0,,9615.0,CHEMBL618483,1.0,,1.0,,,,,,6605.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3880.0,,9615.0,CHEMBL618484,1.0,,1.0,,,,,,6606.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4838.0,,9615.0,CHEMBL618485,1.0,,1.0,,,,,,6607.0,Bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,15600.0,,9615.0,CHEMBL618486,1.0,,1.0,,,,,,6608.0,oral bioavailability was measured in dogs
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,17248.0,,9615.0,CHEMBL618487,1.0,,1.0,,,,,,6609.0,Compound was tested for plasma protein binding in dog; Not determined
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,17248.0,,9615.0,CHEMBL618488,1.0,,1.0,,,,,,6610.0,Compound was tested for plasma protein binding of dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,17248.0,,9615.0,CHEMBL876735,1.0,,1.0,,,,,,6611.0,Compound was tested for plasma protein binding of dog; Not determined
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,17443.0,,9615.0,CHEMBL618489,1.0,,1.0,,,,,,6612.0,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4186.0,,9615.0,CHEMBL618490,1.0,,1.0,,,,,,6613.0,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3749.0,,9615.0,CHEMBL618491,1.0,,1.0,,,,,,6614.0,Half life was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3249.0,,9615.0,CHEMBL618492,1.0,,1.0,,,,,,6615.0,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3022.0,,9615.0,CHEMBL873354,1.0,,1.0,,,,,,6616.0,Half life was evaluated in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3749.0,,9615.0,CHEMBL618493,1.0,,1.0,,,,,,6617.0,Half life was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,2517.0,,9615.0,CHEMBL618494,1.0,,1.0,,,,,,6618.0,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,2517.0,,9615.0,CHEMBL618495,1.0,,1.0,Heart,,,948.0,,6619.0,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,2517.0,,9615.0,CHEMBL618496,1.0,,1.0,Kidney,,,2113.0,,6620.0,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,2517.0,,9615.0,CHEMBL618497,1.0,,1.0,Liver,,,2107.0,,6621.0,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,2517.0,,9615.0,CHEMBL618498,1.0,,1.0,Lung,,,2048.0,,6622.0,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,2517.0,,9615.0,CHEMBL618499,1.0,,1.0,Spleen,,,2106.0,,6623.0,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3639.0,,9615.0,CHEMBL876736,1.0,,1.0,,,,,,6624.0,LogP in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6227.0,,9615.0,CHEMBL618500,1.0,,1.0,,,,,,6625.0,Partition coefficient (logP)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6227.0,,9615.0,CHEMBL857831,1.0,,1.0,,,,,,6626.0,Partition coefficient in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17764.0,,9615.0,CHEMBL618501,1.0,,1.0,,,,,,6627.0,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4809.0,,9615.0,CHEMBL618502,1.0,,1.0,,,,,,6628.0,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5600.0,,9615.0,CHEMBL618503,1.0,,1.0,,,,,,6629.0,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,14294.0,,9615.0,CHEMBL618504,1.0,,1.0,,,,,,6630.0,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,14294.0,,9615.0,CHEMBL618505,1.0,,1.0,,,,,,6631.0,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,14294.0,,9615.0,CHEMBL618506,1.0,,1.0,,,,,,6632.0,Metabolism of compound in dog S9 microsomes; Trace
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6251.0,,9615.0,CHEMBL618507,1.0,,1.0,Liver,,,2107.0,,6633.0,In vitro metabolic potential in dog liver microsomes
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3748.0,,9615.0,CHEMBL876737,1.0,,1.0,,,,,,6634.0,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,2713.0,,9615.0,CHEMBL618508,1.0,,1.0,,,,,,6635.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6512.0,,9615.0,CHEMBL618509,1.0,,1.0,,,,,,6636.0,Oral bioavailability in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6679.0,,9615.0,CHEMBL618510,1.0,,1.0,,,,,,6637.0,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3749.0,,9615.0,CHEMBL618511,1.0,,1.0,,,,,,6638.0,The compound was tested for bioavailability in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3749.0,,9615.0,CHEMBL618512,1.0,,1.0,,,,,,6639.0,The compound was tested for oral bioavailability in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6742.0,,9615.0,CHEMBL618513,1.0,,1.0,,,,,,6640.0,Oral bioavailability in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6227.0,,9615.0,CHEMBL618514,1.0,,1.0,,,,,,6641.0,Compound was tested for percent protein binding (PB) in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6874.0,,9615.0,CHEMBL620052,1.0,,1.0,,,,,,6642.0,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,2877.0,,9615.0,CHEMBL620053,1.0,,1.0,Plasma,,,1969.0,,6643.0,Compound was evaluated for plasma clearance.
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,12500.0,,9615.0,CHEMBL620054,1.0,,1.0,Plasma,,,1969.0,,6644.0,The compound was tested for plasma clearance in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,12500.0,,9615.0,CHEMBL620055,1.0,,1.0,Plasma,,,1969.0,,6645.0,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4709.0,,9615.0,CHEMBL620056,1.0,,1.0,,,,,,6646.0,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5542.0,,9615.0,CHEMBL620057,1.0,,1.0,Liver,,,2107.0,,6647.0,In vitro relative rate of metabolism was determined in dog liver microsomes
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17594.0,,9615.0,CHEMBL618939,1.0,,1.0,,,,,,6648.0,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,2652.0,,9615.0,CHEMBL618940,1.0,,1.0,,,,,,6649.0,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17764.0,,9615.0,CHEMBL618941,1.0,,1.0,,,,,,6650.0,Half life after intravenous administration in dogs at 1.2 uM/kg
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL624473,1.0,,1.0,Lung,,,2048.0,42.0,6651.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL624474,1.0,,1.0,Lung,,,2048.0,42.0,6652.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL624475,1.0,,1.0,Lung,,,2048.0,42.0,6653.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL624476,1.0,,1.0,,,,,42.0,6654.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL623478,1.0,,1.0,,,,,42.0,6655.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL623479,1.0,,1.0,,,,,42.0,6656.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL623480,1.0,,1.0,,,,,42.0,6657.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours
,BAO_0000218,A,,CCRF S-180,50594.0,N,Mus musculus,Intermediate,6599.0,,10090.0,CHEMBL623481,1.0,,1.0,,,,,42.0,6658.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17641.0,,10090.0,CHEMBL623482,1.0,,1.0,Brain,,,955.0,,6659.0,C2 in brain of mice at the oral dose of 50 mg/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17641.0,,10090.0,CHEMBL623483,1.0,,1.0,Kidney,,,2113.0,,6660.0,C2 in kidney of mice at the oral dose of 50 mg/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17641.0,,10090.0,CHEMBL623484,1.0,,1.0,Liver,,,2107.0,,6661.0,C2 in liver of mice at the oral dose of 50 mg/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17641.0,,10090.0,CHEMBL623485,1.0,,1.0,Lung,,,2048.0,,6662.0,C2 in lungs of mice at the oral dose of 50 mg/kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17641.0,,10090.0,CHEMBL623486,1.0,,1.0,Spleen,,,2106.0,,6663.0,C2 in spleen of mice at the oral dose of 50 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17852.0,,10090.0,CHEMBL623487,1.0,,1.0,,,,,,6664.0,Plasma clearance in mouse
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL623488,1.0,,1.0,,,,,,6665.0,Clearance of compound after intravenous administration in mice at 24 uM/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17837.0,,10090.0,CHEMBL623489,1.0,,1.0,,,,,,6666.0,Clearance from mouse blood following i.v. administration of 10 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,2675.0,,10090.0,CHEMBL875157,1.0,,1.0,,,,,,6667.0,Clearance was evaluated in mice after intravenous administration
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,2675.0,,10090.0,CHEMBL623490,1.0,,1.0,,,,,,6668.0,Clearance was evaluated in mice after oral administration
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,4239.0,,10090.0,CHEMBL623491,1.0,,1.0,,,,,,6669.0,Pharmacokinetic property (Plasma clearance) was measured in mouse
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17753.0,,10090.0,CHEMBL623492,1.0,,1.0,,,,,,6670.0,Plasma clearance of compound was determined at 40 mg/Kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17753.0,,10090.0,CHEMBL623493,1.0,,1.0,,,,,,6671.0,Plasma clearance of at 24 mg/Kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17753.0,,10090.0,CHEMBL623494,1.0,,1.0,,,,,,6672.0,Plasma clearance at 24 mg/Kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17753.0,,10090.0,CHEMBL623495,1.0,,1.0,,,,,,6673.0,Plasma clearance at 5 mg/Kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5727.0,,10090.0,CHEMBL623496,1.0,,1.0,,,,,,6674.0,Plasma clearance in mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,2862.0,,10090.0,CHEMBL623497,1.0,,1.0,,,,,,6675.0,Plasma clearance value upon iv administration in mouse
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5980.0,,10090.0,CHEMBL623498,1.0,,1.0,Plasma,,,1969.0,,6676.0,Total plasma clearance in mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17592.0,,10090.0,CHEMBL623499,1.0,,1.0,,,,,,6677.0,Clearance in mouse
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17718.0,,10090.0,CHEMBL623500,1.0,,1.0,,,,,,6678.0,Clearance value was determined
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16597.0,,10090.0,CHEMBL623501,1.0,,1.0,,,,,,6679.0,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.
,BAO_0000100,P,,,22229.0,U,,Intermediate,17384.0,,,CHEMBL875158,1.0,,0.0,,,,,,6680.0,Calculated partition coefficient (clogP)
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,6062.0,,10090.0,CHEMBL623502,1.0,,1.0,,,,,,6681.0,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17734.0,,10090.0,CHEMBL623503,1.0,,1.0,,,,,,6682.0,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,6348.0,,10090.0,CHEMBL623504,1.0,,1.0,,,,,,6683.0,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5969.0,,10090.0,CHEMBL623505,1.0,,1.0,,,,,,6684.0,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5969.0,,10090.0,CHEMBL623506,1.0,,1.0,,,,,,6685.0,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5969.0,,10090.0,CHEMBL623507,1.0,,1.0,,,,,,6686.0,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16597.0,,10090.0,CHEMBL623508,1.0,,1.0,,,,,,6687.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5781.0,,10090.0,CHEMBL623509,1.0,,1.0,,,,,,6688.0,Cmax after oral administration at 30 mg/kg in ICR mouse
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL875159,1.0,,1.0,,,,,,6689.0,Cmax after peroral administration in mice at 2.4 uM/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17641.0,,10090.0,CHEMBL623510,1.0,,1.0,Brain,,,955.0,,6690.0,Cmax in brain of mice at the oral dose of 50 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17641.0,,10090.0,CHEMBL623511,1.0,,1.0,Kidney,,,2113.0,,6691.0,Cmax in kidney of mice at the oral dose of 50 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17641.0,,10090.0,CHEMBL623512,1.0,,1.0,Liver,,,2107.0,,6692.0,Cmax in liver of mice at the oral dose of 50 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17641.0,,10090.0,CHEMBL623513,1.0,,1.0,Lung,,,2048.0,,6693.0,Cmax in lungs of mice at the oral dose of 50 mg/kg
,BAO_0000218,F,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL623514,1.0,,1.0,,,,,,6694.0,Cmax in mice at 18 uM/kg i.p. administration
,BAO_0000218,F,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL622609,1.0,,1.0,,,,,,6695.0,Cmax in mice at 23 uM/kg i.v. administration
,BAO_0000218,F,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL622610,1.0,,1.0,,,,,,6696.0,Cmax in mice at 24 uM/kg i.p. administration
,BAO_0000218,F,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL621823,1.0,,1.0,,,,,,6697.0,Cmax in mice at 25 uM/kg i.p. administration
,BAO_0000218,F,In vivo,,50594.0,N,Mus musculus,Intermediate,17764.0,,10090.0,CHEMBL621824,1.0,,1.0,,,,,,6698.0,Cmax in mice at 26 uM/kg i.p. administration
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17641.0,,10090.0,CHEMBL621825,1.0,,1.0,Spleen,,,2106.0,,6699.0,Cmax in spleen of mice at the oral dose of 50 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16597.0,,10090.0,CHEMBL621826,1.0,,1.0,,,,,,6700.0,Cmax value at a dose of 10 mg/kg intravenous administration in mice.
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,16597.0,,10090.0,CHEMBL621827,1.0,,1.0,,,,,,6701.0,Cmax value at a dose of 10 mg/kg peroral administration in mice.
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5727.0,,10090.0,CHEMBL621828,1.0,,1.0,,,,,,6702.0,Cmax value was determined
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5951.0,,10090.0,CHEMBL621829,1.0,,1.0,,,,,,6703.0,Cmax value in IRC mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5506.0,,10090.0,CHEMBL621830,1.0,,1.0,,,,,,6704.0,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5506.0,,10090.0,CHEMBL621831,1.0,,1.0,,,,,,6705.0,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,14239.0,,10090.0,CHEMBL621832,1.0,,1.0,Plasma,,,1969.0,,6706.0,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,4890.0,,10090.0,CHEMBL624579,1.0,,1.0,Plasma,,,1969.0,,6707.0,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration"
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,429.0,,10090.0,CHEMBL624580,1.0,,1.0,,,,,,6708.0,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg
,BAO_0000218,F,,,50535.0,N,Acanthocheilonema viteae,Intermediate,10986.0,,6277.0,CHEMBL624581,1.0,,1.0,,,,,,6709.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose
,BAO_0000218,F,,,50535.0,N,Acanthocheilonema viteae,Intermediate,10986.0,,6277.0,CHEMBL624582,1.0,,1.0,,,,,,6710.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose
,BAO_0000218,F,,,50535.0,N,Acanthocheilonema viteae,Intermediate,10986.0,,6277.0,CHEMBL624583,1.0,,1.0,,,,,,6711.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose
,BAO_0000219,F,,A-375,80018.0,N,Homo sapiens,Intermediate,13227.0,,9606.0,CHEMBL624584,1.0,,1.0,,,,,455.0,6712.0,Inhibitory activity against human tumor cell line A0375 melanoma.
,BAO_0000249,B,,,12512.0,D,Rattus norvegicus,Expert,4481.0,Brain membranes,10116.0,CHEMBL624585,1.0,,9.0,,,,,,6713.0,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes
,BAO_0000019,F,,,114.0,D,Homo sapiens,Expert,16931.0,,9606.0,CHEMBL875165,1.0,,9.0,,,,,,6714.0,Forskolin-induced cAMP production at human A1 adenosine receptor
,BAO_0000219,F,,CHO,114.0,H,,Autocuration,3850.0,,,CHEMBL619490,1.0,,8.0,,,,,449.0,6715.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.
,BAO_0000219,F,,CHO,114.0,H,,Autocuration,3850.0,,,CHEMBL619491,1.0,,8.0,,,,,449.0,6716.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells
,BAO_0000219,F,,CHO,114.0,H,,Expert,3850.0,,,CHEMBL619492,1.0,,8.0,,,,,449.0,6717.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM
,BAO_0000219,F,,CHO,114.0,H,,Expert,3850.0,,,CHEMBL619493,1.0,,8.0,,,,,449.0,6718.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration
,BAO_0000219,F,,CHO,114.0,H,,Autocuration,3850.0,,,CHEMBL619494,1.0,,8.0,,,,,449.0,6719.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells
,BAO_0000219,F,,CHO,114.0,H,,Autocuration,3850.0,,,CHEMBL619495,1.0,,8.0,,,,,449.0,6720.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement
,BAO_0000219,F,,CHO,114.0,H,,Autocuration,3850.0,,,CHEMBL619496,1.0,,8.0,,,,,449.0,6721.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.
,BAO_0000219,F,,CHO,114.0,D,Homo sapiens,Expert,3850.0,,9606.0,CHEMBL619497,1.0,,9.0,,,,,449.0,6722.0,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells
,BAO_0000219,F,,CHO,114.0,H,,Autocuration,3850.0,,,CHEMBL619498,1.0,,8.0,,,,,449.0,6723.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM
,BAO_0000219,F,,CHO,114.0,H,,Autocuration,3850.0,,,CHEMBL619499,1.0,,8.0,,,,,449.0,6724.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.
,BAO_0000219,F,,CHO,114.0,H,,Expert,3850.0,,,CHEMBL619500,1.0,,8.0,,,,,449.0,6725.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration
,BAO_0000219,F,,CHO,114.0,H,,Autocuration,3850.0,,,CHEMBL619501,1.0,,8.0,,,,,449.0,6726.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.
,BAO_0000219,F,,CHO,114.0,H,,Expert,3850.0,,,CHEMBL619502,1.0,,8.0,,,,,449.0,6727.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells
,BAO_0000219,F,,CHO,114.0,H,,Autocuration,3850.0,,,CHEMBL619503,1.0,,8.0,,,,,449.0,6728.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM
,BAO_0000219,F,,CHO,114.0,H,,Autocuration,3850.0,,,CHEMBL619504,1.0,,8.0,,,,,449.0,6729.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells
,BAO_0000219,F,,CHO,114.0,H,,Autocuration,3850.0,,,CHEMBL621298,1.0,,8.0,,,,,449.0,6730.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.
,BAO_0000219,F,,CHO,114.0,H,,Expert,3850.0,,,CHEMBL621299,1.0,,8.0,,,,,449.0,6731.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration
,BAO_0000219,F,,CHO,114.0,H,,Autocuration,3850.0,,,CHEMBL621300,1.0,,8.0,,,,,449.0,6732.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells
,BAO_0000219,F,,CHO,114.0,H,,Autocuration,3850.0,,,CHEMBL621301,1.0,,8.0,,,,,449.0,6733.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.
,BAO_0000219,F,,CHO,114.0,H,,Expert,3850.0,,,CHEMBL621302,1.0,,8.0,,,,,449.0,6734.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells
,BAO_0000219,F,,A10,80013.0,N,Oryctolagus cuniculus,Intermediate,12680.0,,9986.0,CHEMBL621303,1.0,,1.0,,,,,164.0,6735.0,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells
,BAO_0000219,F,,A10,22226.0,U,Rattus norvegicus,Autocuration,1313.0,,10116.0,CHEMBL621304,1.0,,0.0,,,,,164.0,6736.0,In vitro potassium channel opening activity in A10 (smooth muscle) cells
,BAO_0000219,F,,A10,22226.0,U,Rattus norvegicus,Autocuration,1313.0,,10116.0,CHEMBL621305,1.0,,0.0,,,,,164.0,6737.0,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive
,BAO_0000219,F,,A10,80013.0,N,Rattus norvegicus,Intermediate,17567.0,,10116.0,CHEMBL621306,1.0,,1.0,,,,,164.0,6738.0,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats
,BAO_0000219,F,,A10,80013.0,N,Rattus norvegicus,Intermediate,17567.0,,10116.0,CHEMBL618444,1.0,,1.0,,,,,164.0,6739.0,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats
,BAO_0000219,F,,A10,80013.0,N,Rattus norvegicus,Intermediate,11819.0,,10116.0,CHEMBL618445,1.0,,1.0,,,,,164.0,6740.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,13436.0,,10029.0,CHEMBL618446,1.0,,1.0,,,,,185.0,6741.0,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,12687.0,,10029.0,CHEMBL618447,1.0,,1.0,,,,,185.0,6742.0,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,12651.0,,10029.0,CHEMBL618448,1.0,,1.0,,,,,185.0,6743.0,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,13300.0,,10029.0,CHEMBL618449,1.0,,1.0,,,,,185.0,6744.0,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,15296.0,,10029.0,CHEMBL618637,1.0,,1.0,,,,,185.0,6745.0,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,15328.0,,10029.0,CHEMBL618638,1.0,,1.0,,,,,185.0,6746.0,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay."
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,13302.0,,10029.0,CHEMBL618639,1.0,,1.0,,,,,185.0,6747.0,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure)
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Expert,14367.0,,10029.0,CHEMBL618640,1.0,,1.0,,,,,185.0,6748.0,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure"
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Expert,17002.0,,10029.0,CHEMBL618641,1.0,,1.0,,,,,185.0,6749.0,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,13436.0,,10029.0,CHEMBL618642,1.0,,1.0,,,,,185.0,6750.0,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,13435.0,,10029.0,CHEMBL618643,1.0,,1.0,,,,,185.0,6751.0,Inhibitory activity against aerobic growth of AA8 cells.
,BAO_0000219,A,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,10503.0,,10029.0,CHEMBL884013,1.0,,1.0,,,,,185.0,6752.0,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Expert,10503.0,,10029.0,CHEMBL622723,1.0,,1.0,,,,,185.0,6753.0,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,10503.0,,10029.0,CHEMBL622724,1.0,,1.0,,,,,185.0,6754.0,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Expert,15090.0,,10029.0,CHEMBL622725,1.0,,1.0,,,,,185.0,6755.0,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Expert,10368.0,,10029.0,CHEMBL622726,1.0,,1.0,,,,,185.0,6756.0,Cytotoxicity against AA8 cell line
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,12651.0,,10029.0,CHEMBL622727,1.0,,1.0,,,,,185.0,6757.0,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4)
,BAO_0000219,A,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,12687.0,,10029.0,CHEMBL622728,1.0,,1.0,,,,,185.0,6758.0,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6)
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,12687.0,,10029.0,CHEMBL622729,1.0,,1.0,,,,,185.0,6759.0,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6)
,BAO_0000219,A,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,12687.0,,10029.0,CHEMBL622730,1.0,,1.0,,,,,185.0,6760.0,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6)
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,1890.0,,10029.0,CHEMBL622731,1.0,,1.0,,,,,185.0,6761.0,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,10747.0,,10029.0,CHEMBL622732,1.0,,1.0,,,,,185.0,6762.0,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Intermediate,10747.0,,10029.0,CHEMBL622733,1.0,,1.0,,,,,185.0,6763.0,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.
,BAO_0000218,F,,,22224.0,U,Cricetulus griseus,Autocuration,11616.0,,10029.0,CHEMBL622734,1.0,,0.0,,,,,,6764.0,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose)
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Expert,11616.0,,10029.0,CHEMBL622735,1.0,,1.0,,,,,185.0,6765.0,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.
,BAO_0000219,F,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,3471.0,,10029.0,CHEMBL618746,1.0,,0.0,,,,,185.0,6766.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions
,BAO_0000219,F,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,3471.0,,10029.0,CHEMBL618747,1.0,,0.0,,,,,185.0,6767.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions
,BAO_0000219,F,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,3471.0,,10029.0,CHEMBL620540,1.0,,0.0,,,,,185.0,6768.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions
,BAO_0000219,F,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,3471.0,,10029.0,CHEMBL620541,1.0,,0.0,,,,,185.0,6769.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions
,BAO_0000219,F,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,3471.0,,10029.0,CHEMBL620542,1.0,,0.0,,,,,185.0,6770.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions
,BAO_0000219,F,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,3471.0,,10029.0,CHEMBL620543,1.0,,0.0,,,,,185.0,6771.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions
,BAO_0000219,F,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,3471.0,,10029.0,CHEMBL618832,1.0,,0.0,,,,,185.0,6772.0,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Expert,11616.0,,10029.0,CHEMBL618833,1.0,,1.0,,,,,185.0,6773.0,Concentration required to reduce AA8 cell survival by 10%
,BAO_0000219,F,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,2656.0,,10029.0,CHEMBL618834,1.0,,0.0,,,,,185.0,6774.0,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells"
,BAO_0000219,F,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,10518.0,,10029.0,CHEMBL618835,1.0,,0.0,,,,,185.0,6775.0,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay
,BAO_0000219,F,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,10518.0,,10029.0,CHEMBL618836,1.0,,0.0,,,,,185.0,6776.0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay
,BAO_0000219,F,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,10518.0,,10029.0,CHEMBL618837,1.0,,0.0,,,,,185.0,6777.0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5
,BAO_0000219,F,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,10518.0,,10029.0,CHEMBL618838,1.0,,0.0,,,,,185.0,6778.0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2
,BAO_0000219,F,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,16156.0,,10029.0,CHEMBL618839,1.0,,0.0,,,,,185.0,6779.0,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air
,BAO_0000219,F,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,2656.0,,10029.0,CHEMBL618840,1.0,,0.0,,,,,185.0,6780.0,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells
,BAO_0000019,F,,,22224.0,U,Cricetulus griseus,Autocuration,11005.0,,10029.0,CHEMBL618841,1.0,,0.0,,,,,,6781.0,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8"
,BAO_0000219,F,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,11942.0,,10029.0,CHEMBL618842,1.0,,0.0,,,,,185.0,6782.0,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure
,BAO_0000219,F,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,2128.0,,10029.0,CHEMBL618843,1.0,,0.0,,,,,185.0,6783.0,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16907.0,,9615.0,CHEMBL618844,1.0,,1.0,,,,,,6784.0,Half life period after 15 mg/kg iv dose in Dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16907.0,,9615.0,CHEMBL618845,1.0,,1.0,,,,,,6785.0,Half life period after 30 mg/kg po dose in Dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,9579.0,,9615.0,CHEMBL618846,1.0,,1.0,,,,,,6786.0,Half life was measured after oral 2b administration (tested in 6 dogs)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,9579.0,,9615.0,CHEMBL618847,1.0,,1.0,,,,,,6787.0,Half life was measured in dog after oral 17b administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,9579.0,,9615.0,CHEMBL618848,1.0,,1.0,,,,,,6788.0,Pharmacokinetic parameter T max determined in dog after oral administration of 17b
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,9579.0,,9615.0,CHEMBL618849,1.0,,1.0,,,,,,6789.0,Pharmacokinetic parameter T max determined in dog after oral administration of 2b
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16907.0,,9615.0,CHEMBL618850,1.0,,1.0,,,,,,6790.0,Tmax value after 15 mg/kg iv dose in Dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16907.0,,9615.0,CHEMBL618851,1.0,,1.0,,,,,,6791.0,Tmax value after 30 mg/kg po dose in Dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3184.0,,9615.0,CHEMBL873815,1.0,,1.0,,,,,,6792.0,Compound was evaluated for its half life when administered intravenously in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5017.0,,9615.0,CHEMBL618852,1.0,,1.0,Plasma,,,1969.0,,6793.0,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6821.0,,9615.0,CHEMBL618853,1.0,,1.0,,,,,,6794.0,Elimination Half-life of compound was determined in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17839.0,,9615.0,CHEMBL618854,1.0,,1.0,,,,,,6795.0,Half life of compound in dog following oral administration
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,17267.0,,9615.0,CHEMBL618855,1.0,,1.0,,,,,,6796.0,Half life of compound was determined in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4727.0,,9615.0,CHEMBL618856,1.0,,1.0,Blood,,,178.0,,6797.0,Half life of compound was determined in dog blood
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5238.0,,9615.0,CHEMBL875827,1.0,,1.0,,,,,,6798.0,Half life after oral and iv dosing in dogs
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4942.0,,9615.0,CHEMBL618857,1.0,,1.0,,,,,,6799.0,Half life in dogs in hours
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6505.0,,9615.0,CHEMBL618858,1.0,,1.0,,,,,,6800.0,Half life on i.v. administration of 2 mg/kg was measured in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5130.0,,9615.0,CHEMBL618859,1.0,,1.0,,,,,,6801.0,t1/2 in dog after oral dose (1 mg/kg)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,1475.0,,9615.0,CHEMBL618860,1.0,,1.0,,,,,,6802.0,Half life was evaluated in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17804.0,,9615.0,CHEMBL618861,1.0,,1.0,,,,,,6803.0,Half life period of compound was determined after intravenous administration at 2 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17804.0,,9615.0,CHEMBL622539,1.0,,1.0,,,,,,6804.0,Half life period of compound was determined after peroral administration at 2 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6084.0,,9615.0,CHEMBL622540,1.0,,1.0,,,,,,6805.0,Half life period (10 mg/kg) was determined in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6084.0,,9615.0,CHEMBL873803,1.0,,1.0,,,,,,6806.0,Half life period (10 mg/kg) was determined in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5542.0,,9615.0,CHEMBL873804,1.0,,1.0,,,,,,6807.0,Half life period by iv administration in dog at a dose of 0.3 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5542.0,,9615.0,CHEMBL624311,1.0,,1.0,,,,,,6808.0,Half life period by po administration in dog at a dose of 0.3 mg/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6084.0,,9615.0,CHEMBL624312,1.0,,1.0,,,,,,6809.0,Half life period in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6241.0,,9615.0,CHEMBL624313,1.0,,1.0,,,,,,6810.0,Half life period in dogs after oral administration at 1 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1916.0,,9615.0,CHEMBL624314,1.0,,1.0,,,,,,6811.0,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6621.0,,9615.0,CHEMBL624315,1.0,,1.0,,,,,,6812.0,Half-life of compound was determined in dogs
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,1696.0,,9615.0,CHEMBL624316,1.0,,1.0,Plasma,,,1969.0,,6813.0,Half-life in dog plasma
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,17800.0,,9615.0,CHEMBL624317,1.0,,1.0,,,,,,6814.0,Half-life in mongrel dogs was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17657.0,,9615.0,CHEMBL624318,1.0,,1.0,,,,,,6815.0,Half-life in dog upon oral administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17657.0,,9615.0,CHEMBL624319,1.0,,1.0,,,,,,6816.0,Half-life in dog upon oral administration; Unable to calculate
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4239.0,,9615.0,CHEMBL624496,1.0,,1.0,,,,,,6817.0,Half-life was measured in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5985.0,,9615.0,CHEMBL624497,1.0,,1.0,,,,,,6818.0,Half-life was measured in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,9932.0,,9615.0,CHEMBL624498,1.0,,1.0,,,,,,6819.0,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5199.0,,9615.0,CHEMBL624499,1.0,,1.0,,,,,,6820.0,Oral half life was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5199.0,,9615.0,CHEMBL624500,1.0,,1.0,Plasma,,,1969.0,,6821.0,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,1475.0,,9615.0,CHEMBL624501,1.0,,1.0,Plasma,,,1969.0,,6822.0,Plasma half life was evaluated
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,1475.0,,9615.0,CHEMBL623666,1.0,,1.0,Plasma,,,1969.0,,6823.0,Plasma half life was evaluated in Dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,1475.0,,9615.0,CHEMBL623667,1.0,,1.0,Plasma,,,1969.0,,6824.0,Plasma half life was evaluated in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6316.0,,9615.0,CHEMBL623668,1.0,,1.0,,,,,,6825.0,T1/2 (Half-life) was after oral administration at 5 mg/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4883.0,,9615.0,CHEMBL623669,1.0,,1.0,,,,,,6826.0,Tested for the half life value in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4727.0,,9615.0,CHEMBL623670,1.0,,1.0,,,,,,6827.0,Maximum time at the dose of 2 mg/kg in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1916.0,,9615.0,CHEMBL623671,1.0,,1.0,,,,,,6828.0,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1337.0,,9615.0,CHEMBL875945,1.0,,1.0,Blood,,,178.0,,6829.0,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1337.0,,9615.0,CHEMBL623672,1.0,,1.0,Blood,,,178.0,,6830.0,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6265.0,,9615.0,CHEMBL623673,1.0,,1.0,,,,,,6831.0,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4809.0,,9615.0,CHEMBL623674,1.0,,1.0,,,,,,6832.0,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5983.0,,9615.0,CHEMBL623675,1.0,,1.0,,,,,,6833.0,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5313.0,,9615.0,CHEMBL872526,1.0,,1.0,,,,,,6834.0,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog"
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5313.0,,9615.0,CHEMBL623676,1.0,,1.0,,,,,,6835.0,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk"
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17650.0,,9615.0,CHEMBL623677,1.0,,1.0,Plasma,,,1969.0,,6836.0,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5199.0,,9615.0,CHEMBL623678,1.0,,1.0,Plasma,,,1969.0,,6837.0,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,933.0,,9615.0,CHEMBL623679,1.0,,1.0,Plasma,,,1969.0,,6838.0,Time taken for maximum plasma concentration in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16367.0,,9615.0,CHEMBL623680,1.0,,1.0,,,,,,6839.0,Time to reach Cmax after oral administration to dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6348.0,,9615.0,CHEMBL623681,1.0,,1.0,Plasma,,,1969.0,,6840.0,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6316.0,,9615.0,CHEMBL623682,1.0,,1.0,,,,,,6841.0,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6215.0,,9615.0,CHEMBL623683,1.0,,1.0,,,,,,6842.0,Tmax after peroral administration (1 mg/kg) was determined in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Expert,3598.0,,9615.0,CHEMBL623684,1.0,,1.0,,,,,,6843.0,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4527.0,,9615.0,CHEMBL622745,1.0,,1.0,,,,,,6844.0,Tmax by oral administration at a dose of 10 uM/kg in dog was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17764.0,,9615.0,CHEMBL622746,1.0,,1.0,,,,,,6845.0,Tmax after peroral administration in dogs at 2.4 uM/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5969.0,,10090.0,CHEMBL622747,1.0,,1.0,,,,,,6846.0,In vivo Cmax in mice at dose of 100 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5969.0,,10090.0,CHEMBL622748,1.0,,1.0,,,,,,6847.0,In vivo Cmax in mice at dose of 50 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,4573.0,,10090.0,CHEMBL622749,1.0,,1.0,,,,,,6848.0,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3277.0,,10090.0,CHEMBL622750,1.0,,1.0,Plasma,,,1969.0,,6849.0,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4)
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17734.0,,10090.0,CHEMBL623411,1.0,,1.0,Plasma,,,1969.0,,6850.0,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3132.0,,10090.0,CHEMBL875946,1.0,,1.0,Plasma,,,1969.0,,6851.0,Maximum concentration obtained in mouse plasma was determined
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3132.0,,10090.0,CHEMBL623412,1.0,,1.0,Plasma,,,1969.0,,6852.0,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,6348.0,,10090.0,CHEMBL623413,1.0,,1.0,Plasma,,,1969.0,,6853.0,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17729.0,,10090.0,CHEMBL623414,1.0,,1.0,Plasma,,,1969.0,,6854.0,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17729.0,,10090.0,CHEMBL623415,1.0,,1.0,Plasma,,,1969.0,,6855.0,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17729.0,,10090.0,CHEMBL623416,1.0,,1.0,Plasma,,,1969.0,,6856.0,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17728.0,,10090.0,CHEMBL623417,1.0,,1.0,Plasma,,,1969.0,,6857.0,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17728.0,,10090.0,CHEMBL623418,1.0,,1.0,Plasma,,,1969.0,,6858.0,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17728.0,,10090.0,CHEMBL623419,1.0,,1.0,Plasma,,,1969.0,,6859.0,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,4066.0,,10090.0,CHEMBL622816,1.0,,1.0,,,,,,6860.0,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,6178.0,,10090.0,CHEMBL623313,1.0,,1.0,,,,,,6861.0,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,6178.0,,10090.0,CHEMBL623314,1.0,,1.0,,,,,,6862.0,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3760.0,,10090.0,CHEMBL876788,1.0,,1.0,,,,,,6863.0,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3760.0,,10090.0,CHEMBL623315,1.0,,1.0,,,,,,6864.0,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3760.0,,10090.0,CHEMBL623316,1.0,,1.0,,,,,,6865.0,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3760.0,,10090.0,CHEMBL623317,1.0,,1.0,,,,,,6866.0,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5961.0,,10090.0,CHEMBL623319,1.0,,1.0,,,,,,6868.0,Cmax in male mice after 2 mg/kg oral dose
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,6137.0,,10090.0,CHEMBL623320,1.0,,1.0,,,,,,6869.0,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3802.0,,10090.0,CHEMBL623321,1.0,,1.0,,,,,,6870.0,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,3535.0,,10090.0,CHEMBL623322,1.0,,1.0,,,,,,6871.0,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,3535.0,,10090.0,CHEMBL623323,1.0,,1.0,,,,,,6872.0,Concentration in plasma (systemic) following oral dose in mouse at 1 hr
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,3535.0,,10090.0,CHEMBL623324,1.0,,1.0,,,,,,6873.0,Concentration in plasma (systemic) following oral dose in mouse at 24 hr
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,3535.0,,10090.0,CHEMBL623325,1.0,,1.0,,,,,,6874.0,Concentration in plasma (systemic) following oral dose in mouse at 2 hr
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,3535.0,,10090.0,CHEMBL623326,1.0,,1.0,,,,,,6875.0,Concentration in plasma (systemic) following oral dose in mouse at 4 hr
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,3535.0,,10090.0,CHEMBL623327,1.0,,1.0,,,,,,6876.0,Concentration in plasma (systemic) following oral dose in mouse at 6 hr
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,2862.0,,10090.0,CHEMBL623328,1.0,,1.0,Plasma,,,1969.0,,6877.0,Maximum concentration in plasma upon oral administration in mouse
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,2675.0,,10090.0,CHEMBL623329,1.0,,1.0,Plasma,,,1969.0,,6878.0,Maximum plasma concentration was evaluated in mice after oral administration
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,2675.0,,10090.0,CHEMBL623330,1.0,,1.0,Plasma,,,1969.0,,6879.0,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,5399.0,,10090.0,CHEMBL876789,1.0,,1.0,,,,,,6880.0,Dose at which the compound induced fecal excretion in mice
,BAO_0000219,F,,A10,80013.0,N,Rattus norvegicus,Expert,11819.0,,10116.0,CHEMBL623333,1.0,,1.0,,,,,164.0,6893.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM
,BAO_0000219,F,,A10,80013.0,N,Rattus norvegicus,Expert,11819.0,,10116.0,CHEMBL623334,1.0,,1.0,,,,,164.0,6894.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM
,BAO_0000219,F,,A10,80013.0,N,Rattus norvegicus,Expert,11819.0,,10116.0,CHEMBL627536,1.0,,1.0,,,,,164.0,6895.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM
,BAO_0000219,F,,A10,80013.0,N,Rattus norvegicus,Expert,11819.0,,10116.0,CHEMBL627537,1.0,,1.0,,,,,164.0,6896.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM
,BAO_0000219,F,,A10,80013.0,N,Rattus norvegicus,Intermediate,16361.0,,10116.0,CHEMBL627538,1.0,,1.0,,,,,164.0,6897.0,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM)
,BAO_0000219,F,,A121,80655.0,N,Homo sapiens,Intermediate,2288.0,,9606.0,CHEMBL884106,1.0,,1.0,,,,,393.0,6898.0,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line
,BAO_0000219,F,,A121,80655.0,N,Homo sapiens,Intermediate,10404.0,,9606.0,CHEMBL625294,1.0,,1.0,,,,,393.0,6899.0,Anticancer activity against human ovarian carcinoma A121 cells
,BAO_0000219,F,,A121,80655.0,N,Homo sapiens,Intermediate,14790.0,,9606.0,CHEMBL625295,1.0,,1.0,,,,,393.0,6900.0,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM
,BAO_0000219,F,,A121,80655.0,N,Homo sapiens,Intermediate,14790.0,,9606.0,CHEMBL625296,1.0,,1.0,,,,,393.0,6901.0,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM
,BAO_0000219,F,,A121,80655.0,N,Homo sapiens,Expert,14253.0,,9606.0,CHEMBL625297,1.0,,1.0,,,,,393.0,6902.0,Growth inhibition of human ovarian carcinoma (A121) cell line
,BAO_0000219,F,,A121,80655.0,N,Homo sapiens,Expert,13617.0,,9606.0,CHEMBL625298,1.0,,1.0,,,,,393.0,6903.0,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.
,BAO_0000219,F,,A121,80655.0,N,Homo sapiens,Intermediate,1003.0,,9606.0,CHEMBL625960,1.0,,1.0,,,,,393.0,6904.0,Cytotoxicity against human A121 ovarian cells
,BAO_0000219,F,,A121,80655.0,N,Homo sapiens,Intermediate,830.0,,9606.0,CHEMBL625961,1.0,,1.0,,,,,393.0,6905.0,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines
,BAO_0000219,F,,A121,80655.0,N,Homo sapiens,Intermediate,12307.0,,9606.0,CHEMBL625962,1.0,,1.0,,,,,393.0,6906.0,In vitro cytotoxicity against human ovarian carcinoma A21
,BAO_0000219,F,,A121,80655.0,N,Homo sapiens,Intermediate,14254.0,,9606.0,CHEMBL624717,1.0,,1.0,,,,,393.0,6907.0,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure
,BAO_0000219,F,,A121,80655.0,N,Homo sapiens,Intermediate,13370.0,,9606.0,CHEMBL624718,1.0,,1.0,,,,,393.0,6908.0,Inhibitory activity of compound against human A121 ovarian cell line.
,BAO_0000219,F,,A121,80655.0,N,Homo sapiens,Intermediate,14790.0,,9606.0,CHEMBL624719,1.0,,1.0,,,,,393.0,6909.0,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.
,BAO_0000219,F,,A121,80655.0,N,Homo sapiens,Intermediate,3614.0,,9606.0,CHEMBL624720,1.0,,1.0,,,,,393.0,6910.0,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure
,BAO_0000219,F,,A 172,80012.0,N,Homo sapiens,Intermediate,2664.0,,9606.0,CHEMBL624721,1.0,,1.0,,,,,622.0,6911.0,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line
,BAO_0000219,F,,A 172,80012.0,N,Homo sapiens,Expert,2037.0,,9606.0,CHEMBL624722,1.0,,1.0,,,,,622.0,6912.0,In vitro cytotoxicity against A172 human tumor cell lines.
,BAO_0000219,F,,A 172,80012.0,N,Homo sapiens,Intermediate,14539.0,,9606.0,CHEMBL877597,1.0,,1.0,,,,,622.0,6913.0,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM
,BAO_0000219,F,,A 172,80012.0,N,Homo sapiens,Intermediate,2836.0,,9606.0,CHEMBL624723,1.0,,1.0,,,,,622.0,6914.0,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line
,BAO_0000219,F,,A 172,80012.0,N,Homo sapiens,Intermediate,10708.0,,9606.0,CHEMBL624724,1.0,,1.0,,,,,622.0,6915.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay
,BAO_0000224,B,,,104729.0,H,Canis lupus familiaris,Autocuration,8975.0,,9615.0,CHEMBL624725,1.0,,4.0,,,,,,6916.0,Association constant against A2 adenosine receptor
,BAO_0000219,F,,A2,80656.0,N,fish,Intermediate,7645.0,,,CHEMBL624726,1.0,,1.0,,,,,1085.0,6917.0,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma
,BAO_0000224,B,,,104713.0,D,Rattus norvegicus,Autocuration,11377.0,,10116.0,CHEMBL857535,1.0,,5.0,,,,,,6918.0,Ratio of Ki for adenosine A2 and A1 receptor binding
,BAO_0000219,F,,A204,80014.0,N,Homo sapiens,Expert,13528.0,,9606.0,CHEMBL624727,1.0,,1.0,,,,,623.0,6919.0,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line
,BAO_0000219,F,,A204,80014.0,N,Homo sapiens,Expert,10160.0,,9606.0,CHEMBL624728,1.0,,1.0,,,,,623.0,6920.0,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined
,BAO_0000219,F,,A2058,80015.0,N,Homo sapiens,Intermediate,15144.0,,9606.0,CHEMBL624729,1.0,,1.0,,,,,404.0,6921.0,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines
,BAO_0000219,F,,A253 cell line,80657.0,N,Homo sapiens,Intermediate,13160.0,,9606.0,CHEMBL624730,1.0,,1.0,,,,,973.0,6922.0,Growth inhibition against Human squamous cell line(A 253)
,BAO_0000219,F,,A253 cell line,80657.0,N,Homo sapiens,Intermediate,12898.0,,9606.0,CHEMBL624731,1.0,,1.0,,,,,973.0,6923.0,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line
,BAO_0000219,F,,A253 cell line,80657.0,N,Homo sapiens,Intermediate,13069.0,,9606.0,CHEMBL624732,1.0,,1.0,,,,,973.0,6924.0,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells
,BAO_0000219,F,,A253 cell line,80657.0,N,Homo sapiens,Intermediate,15984.0,,9606.0,CHEMBL883245,1.0,,1.0,,,,,973.0,6925.0,Growth inhibition of A253 cell lines.
,BAO_0000219,F,,A253 cell line,80657.0,N,Homo sapiens,Intermediate,15564.0,,9606.0,CHEMBL624733,1.0,,1.0,,,,,973.0,6926.0,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h)
,BAO_0000219,F,,A253 cell line,80657.0,N,Homo sapiens,Intermediate,15564.0,,9606.0,CHEMBL624734,1.0,,1.0,,,,,973.0,6927.0,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined
,BAO_0000219,F,,A253 cell line,80657.0,N,Homo sapiens,Intermediate,15564.0,,9606.0,CHEMBL624735,1.0,,1.0,,,,,973.0,6928.0,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,4720.0,,9606.0,CHEMBL621780,1.0,,1.0,,,,,478.0,6929.0,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16112.0,,9606.0,CHEMBL877598,1.0,,1.0,,,,,478.0,6930.0,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,16597.0,,9606.0,CHEMBL621781,1.0,,1.0,,,,,478.0,6931.0,Cytotoxic activity against A2780 human ovarian carcinoma cell line
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16378.0,,9606.0,CHEMBL621782,1.0,,1.0,,,,,478.0,6932.0,Cytotoxicity against human cancer cell lines A2780 (ovarian)
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,16085.0,,9606.0,CHEMBL621783,1.0,,1.0,,,,,478.0,6933.0,Growth and colony formation inhibition of A2780 ovarian cancer cell lines
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16317.0,,9606.0,CHEMBL621784,1.0,,1.0,,,,,478.0,6934.0,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15748.0,,9606.0,CHEMBL621785,1.0,,1.0,,,,,478.0,6935.0,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma )
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,16597.0,,9606.0,CHEMBL621968,1.0,,1.0,,,,,478.0,6936.0,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,16597.0,,9606.0,CHEMBL621969,1.0,,1.0,,,,,478.0,6937.0,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,16597.0,,9606.0,CHEMBL621970,1.0,,1.0,,,,,478.0,6938.0,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15608.0,,9606.0,CHEMBL621971,1.0,,1.0,,,,,478.0,6939.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15608.0,,9606.0,CHEMBL621972,1.0,,1.0,,,,,478.0,6940.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15608.0,,9606.0,CHEMBL884108,1.0,,1.0,,,,,478.0,6941.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5
,BAO_0000019,F,,,22224.0,U,Cricetulus griseus,Autocuration,15296.0,,10029.0,CHEMBL623826,1.0,,0.0,,,,,,6942.0,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).
,BAO_0000219,A,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,10251.0,,10029.0,CHEMBL623827,1.0,,0.0,,,,,185.0,6943.0,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay
,BAO_0000219,F,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,10251.0,,10029.0,CHEMBL623828,1.0,,0.0,,,,,185.0,6944.0,Evaluated for growth inhibition of AA8 cells under aerobic conditions
,BAO_0000219,F,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,10251.0,,10029.0,CHEMBL623829,1.0,,0.0,,,,,185.0,6945.0,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions
,BAO_0000219,F,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,10251.0,,10029.0,CHEMBL623830,1.0,,0.0,,,,,185.0,6946.0,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2)
,BAO_0000019,F,,,22224.0,U,Cricetulus griseus,Autocuration,11858.0,,10029.0,CHEMBL623831,1.0,,0.0,,,,,,6947.0,Growth inhibition against CHO-derived cell line AA8
,BAO_0000219,F,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,11858.0,,10029.0,CHEMBL623832,1.0,,0.0,,,,,185.0,6948.0,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control]
,BAO_0000219,F,,CHO-AA8,80089.0,N,hampster,Expert,11616.0,,36483.0,CHEMBL623833,1.0,,1.0,,,,,185.0,6949.0,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Expert,11616.0,,10029.0,CHEMBL623834,1.0,,1.0,,,,,185.0,6950.0,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions
,BAO_0000219,F,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,10518.0,,10029.0,CHEMBL623835,1.0,,0.0,,,,,185.0,6951.0,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay
,BAO_0000219,F,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,11396.0,,10029.0,CHEMBL623836,1.0,,0.0,,,,,185.0,6952.0,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours
,BAO_0000219,F,,CHO-AA8,22224.0,U,Cricetulus griseus,Autocuration,10518.0,,10029.0,CHEMBL623837,1.0,,0.0,,,,,185.0,6953.0,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay
,BAO_0000219,F,,CHO-AA8,80089.0,N,Cricetulus griseus,Expert,11616.0,,10029.0,CHEMBL623838,1.0,,1.0,,,,,185.0,6954.0,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.
,BAO_0000019,F,,,12675.0,H,,Autocuration,14837.0,,,CHEMBL623839,1.0,,8.0,,,,,,6955.0,compound was evaluated for association constant (Ka) of isolated serum protein AAG
,BAO_0000019,F,,,12675.0,H,,Autocuration,14837.0,,,CHEMBL623840,1.0,,8.0,,,,,,6956.0,Number of binding sites (n) of isolated serum protein AAG
,BAO_0000225,B,,,22222.0,M,,Intermediate,16037.0,,,CHEMBL623841,1.0,,3.0,,,,,,6957.0,Association constant for binding to AATT duplex
,BAO_0000219,F,,ABAE,100090.0,N,Homo sapiens,Expert,16597.0,,9606.0,CHEMBL623842,1.0,,1.0,,,,,416.0,6958.0,Inhibition of ABAE human fibroblast cell proliferation
,BAO_0000218,F,,AC755,80668.0,N,Mus musculus,Intermediate,8831.0,,10090.0,CHEMBL623843,1.0,,1.0,,,,,1064.0,6959.0,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg"
,BAO_0000218,F,,,102444.0,D,Oryctolagus cuniculus,Expert,13419.0,,9986.0,CHEMBL618669,1.0,,9.0,,,,,,6960.0,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model
,BAO_0000218,F,In vivo,,102444.0,D,Oryctolagus cuniculus,Expert,13419.0,,9986.0,CHEMBL618670,1.0,,9.0,,,,,,6961.0,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay
,BAO_0000357,B,,,69.0,H,,Autocuration,15778.0,,,CHEMBL618671,1.0,,8.0,,,,,,6962.0,Inhibitory activity against angiotensin-converting enzyme (ACE).
,BAO_0000357,B,,,69.0,H,,Autocuration,15778.0,,,CHEMBL618672,1.0,,8.0,,,,,,6963.0,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.
,BAO_0000219,F,,ACH-2 cell line,80669.0,N,Homo sapiens,Intermediate,12988.0,,9606.0,CHEMBL618673,1.0,,1.0,,,,,978.0,6964.0,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells
,BAO_0000219,F,,ACH-2 cell line,80669.0,N,Homo sapiens,Intermediate,12988.0,,9606.0,CHEMBL618674,1.0,,1.0,,,,,978.0,6965.0,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate)
,BAO_0000219,F,,T cell line,22224.0,U,Human immunodeficiency virus 1,Autocuration,12988.0,,11676.0,CHEMBL618675,1.0,,0.0,,,,,998.0,6966.0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2
,BAO_0000219,F,,T cell line,22224.0,U,Human immunodeficiency virus 1,Autocuration,12988.0,,11676.0,CHEMBL618676,1.0,,0.0,,,,,998.0,6967.0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate)
,BAO_0000219,F,,T cell line,22224.0,U,Human immunodeficiency virus 1,Autocuration,12988.0,,11676.0,CHEMBL618677,1.0,,0.0,,,,,998.0,6968.0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate)
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,11843.0,,9606.0,CHEMBL618678,1.0,,1.0,,,,,626.0,6969.0,Inhibition of growth of renal cancer ACHN cell line
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,16939.0,,9606.0,CHEMBL618679,1.0,,1.0,,,,,626.0,6970.0,Inhibition of growth of ACHN renal cancer cell line
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,4782.0,,9606.0,CHEMBL618680,1.0,,1.0,,,,,626.0,6971.0,Inhibitory concentration required against ACHN renal cancer cell line
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Expert,6310.0,,9606.0,CHEMBL618681,1.0,,1.0,,,,,626.0,6972.0,Concentration required to inhibit growth of human renal (ACHN) cell line
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,6310.0,,9606.0,CHEMBL618682,1.0,,1.0,,,,,626.0,6973.0,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,12858.0,,9606.0,CHEMBL618683,1.0,,1.0,,,,,626.0,6974.0,Cytotoxic activity against ACHN Renal cancer cell line
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,17380.0,,9606.0,CHEMBL618684,1.0,,1.0,,,,,626.0,6975.0,Cytotoxicity evaluation against ACHN renal cancer cells
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,5858.0,,9606.0,CHEMBL618685,1.0,,1.0,,,,,626.0,6976.0,In vitro antitumor activity against human renal ACHN cell line
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,3838.0,,9606.0,CHEMBL876499,1.0,,1.0,,,,,626.0,6977.0,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,3838.0,,9606.0,CHEMBL618686,1.0,,1.0,,,,,626.0,6978.0,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,5406.0,,9606.0,CHEMBL618687,1.0,,1.0,,,,,626.0,6979.0,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported"
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,4071.0,,9606.0,CHEMBL618688,1.0,,1.0,,,,,626.0,6980.0,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Expert,4071.0,,9606.0,CHEMBL618689,1.0,,1.0,,,,,626.0,6981.0,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,4071.0,,9606.0,CHEMBL618690,1.0,,1.0,,,,,626.0,6982.0,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,15002.0,,9606.0,CHEMBL618691,1.0,,1.0,,,,,626.0,6983.0,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,14769.0,,9606.0,CHEMBL619373,1.0,,1.0,,,,,626.0,6984.0,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells )
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,13958.0,,9606.0,CHEMBL884008,1.0,,1.0,,,,,626.0,6985.0,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma"
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,1665.0,,9606.0,CHEMBL619374,1.0,,1.0,,,,,626.0,6986.0,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,15354.0,,9606.0,CHEMBL619375,1.0,,1.0,,,,,626.0,6987.0,Compound was tested for the growth inhibition of ACHN renal tumor cell line
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,15354.0,,9606.0,CHEMBL619376,1.0,,1.0,,,,,626.0,6988.0,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,13978.0,,9606.0,CHEMBL619377,1.0,,1.0,,,,,626.0,6989.0,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,6798.0,,9606.0,CHEMBL619378,1.0,,1.0,,,,,626.0,6990.0,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,2959.0,,9615.0,CHEMBL872527,1.0,,1.0,,,,,,6991.0,Tmax value after administration of 4 mg/Kg oral dose in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,9932.0,,9615.0,CHEMBL876500,1.0,,1.0,,,,,,6992.0,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously"
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5546.0,,9615.0,CHEMBL619379,1.0,,1.0,,,,,,6993.0,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16907.0,,9615.0,CHEMBL619538,1.0,,1.0,,,,,,6994.0,Volume distribution after 15 mg/kg iv dose in Dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16907.0,,9615.0,CHEMBL619539,1.0,,1.0,,,,,,6995.0,Volume distribution after 30 mg/kg po dose in Dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4257.0,,9615.0,CHEMBL619540,1.0,,1.0,,,,,,6996.0,Volume of distribution was determined in dog after a 3 mg/kg of iv dose
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4305.0,,9615.0,CHEMBL619541,1.0,,1.0,,,,,,6997.0,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5472.0,,9615.0,CHEMBL619542,1.0,,1.0,,,,,,6998.0,Volume of distribution was evaluated in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6062.0,,9615.0,CHEMBL619543,1.0,,1.0,,,,,,6999.0,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Expert,3598.0,,9615.0,CHEMBL619544,1.0,,1.0,,,,,,7000.0,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,12500.0,,9615.0,CHEMBL619545,1.0,,1.0,,,,,,7001.0,The compound was tested for volume of distribution in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,12500.0,,9615.0,CHEMBL619546,1.0,,1.0,,,,,,7002.0,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6227.0,,9615.0,CHEMBL619547,1.0,,1.0,,,,,,7003.0,Vd (1 mg/kg) was determined in dog (in vivo)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6227.0,,9615.0,CHEMBL619548,1.0,,1.0,,,,,,7004.0,Vd in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4219.0,,9615.0,CHEMBL619549,1.0,,1.0,,,,,,7005.0,Volume distribution was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1696.0,,9615.0,CHEMBL619550,1.0,,1.0,,,,,,7006.0,Volume of distribution in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5542.0,,9615.0,CHEMBL876501,1.0,,1.0,,,,,,7007.0,Volume of distribution by as 4 fold increase by iv administration in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5199.0,,9615.0,CHEMBL619551,1.0,,1.0,,,,,,7008.0,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6348.0,,9615.0,CHEMBL619552,1.0,,1.0,,,,,,7009.0,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4727.0,,9615.0,CHEMBL619553,1.0,,1.0,,,,,,7010.0,Volume distribution at the dose of 2 mg/kg in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16367.0,,9615.0,CHEMBL618722,1.0,,1.0,,,,,,7011.0,Steady state volume of distribution was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,2652.0,,9615.0,CHEMBL618723,1.0,,1.0,,,,,,7012.0,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16452.0,,9615.0,CHEMBL618724,1.0,,1.0,,,,,,7013.0,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16452.0,,9615.0,CHEMBL618725,1.0,,1.0,,,,,,7014.0,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16452.0,,9615.0,CHEMBL618726,1.0,,1.0,,,,,,7015.0,Bioavailability in dog (dose 1 mg/kg i.v.)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5334.0,,9615.0,CHEMBL618727,1.0,,1.0,,,,,,7016.0,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4239.0,,9615.0,CHEMBL624233,1.0,,1.0,,,,,,7017.0,Pharmacokinetic property (vdss) was measured in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4709.0,,9615.0,CHEMBL624234,1.0,,1.0,,,,,,7018.0,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5600.0,,9615.0,CHEMBL624235,1.0,,1.0,,,,,,7019.0,Vdss was determined after iv 0.1 mg/kg administration in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6057.0,,9615.0,CHEMBL624236,1.0,,1.0,,,,,,7020.0,Volume displacement was calculated in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5654.0,,9615.0,CHEMBL624237,1.0,,1.0,,,,,,7021.0,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5505.0,,9615.0,CHEMBL624238,1.0,,1.0,,,,,,7022.0,Volume distribution constant was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4527.0,,9615.0,CHEMBL624239,1.0,,1.0,,,,,,7023.0,Volume distribution at a dose of 1 uM/kg in dog was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4521.0,,9615.0,CHEMBL875829,1.0,,1.0,,,,,,7024.0,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4521.0,,9615.0,CHEMBL624240,1.0,,1.0,,,,,,7025.0,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,15660.0,,9615.0,CHEMBL624241,1.0,,1.0,,,,,,7026.0,Volume distribution (Vdss) was measured in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,15660.0,,9615.0,CHEMBL624242,1.0,,1.0,,,,,,7027.0,Volume distribution (Vdss) was measured in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6679.0,,9615.0,CHEMBL624243,1.0,,1.0,,,,,,7028.0,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5145.0,,9615.0,CHEMBL624244,1.0,,1.0,,,,,,7029.0,Volume of distribution in steady state was determined in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6821.0,,9615.0,CHEMBL624245,1.0,,1.0,,,,,,7030.0,Volume of distribution of compound was determined in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4137.0,,9615.0,CHEMBL624246,1.0,,1.0,,,,,,7031.0,Volume of distribution after intravenous administration of 1 mg/kg/h in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5334.0,,9615.0,CHEMBL624247,1.0,,1.0,,,,,,7032.0,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,15660.0,,9615.0,CHEMBL624248,1.0,,1.0,,,,,,7033.0,Volume of distribution (Vdss) was measured in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6642.0,,9615.0,CHEMBL624249,1.0,,1.0,,,,,,7034.0,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6641.0,,9615.0,CHEMBL624250,1.0,,1.0,,,,,,7035.0,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6642.0,,9615.0,CHEMBL624251,1.0,,1.0,,,,,,7036.0,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,11659.0,,9615.0,CHEMBL624252,1.0,,1.0,,,,,,7037.0,Maximum rate of depolarization of the upstroke of the action potential
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6448.0,,9615.0,CHEMBL624253,1.0,,1.0,,,,,,7038.0,Steady state volume distribution in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5474.0,,9615.0,CHEMBL624950,1.0,,1.0,,,,,,7039.0,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1466.0,,9615.0,CHEMBL624951,1.0,,1.0,,,,,,7040.0,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6535.0,,9615.0,CHEMBL875830,1.0,,1.0,,,,,,7041.0,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6535.0,,9615.0,CHEMBL624952,1.0,,1.0,,,,,,7042.0,Volume distribution in dog after administration of 1 mg/kg iv
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17764.0,,9615.0,CHEMBL624953,1.0,,1.0,,,,,,7043.0,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6215.0,,9615.0,CHEMBL624954,1.0,,1.0,,,,,,7044.0,Vss after intravenous administration (0.5 mg/kg) was determined in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6505.0,,9615.0,CHEMBL624955,1.0,,1.0,,,,,,7045.0,Vss on i.v. administration of 2 mg/kg was measured in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3639.0,,9615.0,CHEMBL624956,1.0,,1.0,,,,,,7046.0,Vss was determined
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3639.0,,9615.0,CHEMBL625129,1.0,,1.0,,,,,,7047.0,Vss in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6062.0,,9615.0,CHEMBL625130,1.0,,1.0,,,,,,7048.0,Volume of distribution was measured in dog after an iv dose of 1 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4942.0,,9615.0,CHEMBL625131,1.0,,1.0,,,,,,7049.0,Volume distribution in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17796.0,,9615.0,CHEMBL625132,1.0,,1.0,,,,,,7050.0,Volume of distribution in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4883.0,,9615.0,CHEMBL872263,1.0,,1.0,,,,,,7051.0,Tested for the oral bioavailability in dog
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17837.0,,10090.0,CHEMBL624336,1.0,,1.0,,,,,,7060.0,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17729.0,,10090.0,CHEMBL624337,1.0,,1.0,,,,,,7061.0,Bioavailability after i.p. administration of 50 mg/kg of dose in mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17729.0,,10090.0,CHEMBL624338,1.0,,1.0,,,,,,7062.0,Bioavailability after peroral administration of 50 mg/kg of dose in mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,4239.0,,10090.0,CHEMBL624339,1.0,,1.0,,,,,,7063.0,Bioavailability was measured in mouse
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17592.0,,10090.0,CHEMBL624340,1.0,,1.0,,,,,,7064.0,Bioavailability in mouse
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,6348.0,,10090.0,CHEMBL624341,1.0,,1.0,,,,,,7065.0,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,2801.0,,10090.0,CHEMBL624342,1.0,,1.0,,,,,,7066.0,Bioavailability in mouse
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,2801.0,,10090.0,CHEMBL624343,1.0,,1.0,,,,,,7067.0,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17718.0,,10090.0,CHEMBL624344,1.0,,1.0,,,,,,7068.0,Oral bioavailability in mouse
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5727.0,,10090.0,CHEMBL624345,1.0,,1.0,,,,,,7069.0,Oral availability at 50 mg/kg po in male mice
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5302.0,,10090.0,CHEMBL624346,1.0,,1.0,,,,,,7070.0,Oral bioavailability in mouse (dose 10 mg/kg)
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Expert,3598.0,,10090.0,CHEMBL624347,1.0,,1.0,,,,,,7071.0,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5961.0,,10090.0,CHEMBL624348,1.0,,1.0,,,,,,7072.0,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose"
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,6091.0,,10090.0,CHEMBL622754,1.0,,1.0,,,,,,7074.0,Oral bioavailability in mouse
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,6091.0,,10090.0,CHEMBL622755,1.0,,1.0,,,,,,7075.0,Oral bioavailability in vivo in mice;ND=Not determined
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,5711.0,,10090.0,CHEMBL622756,1.0,,1.0,,,,,,7076.0,Oral bioavailability in mouse at 10 mg/kg of the compound
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17728.0,,10090.0,CHEMBL622757,1.0,,1.0,,,,,,7077.0,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.)
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,17728.0,,10090.0,CHEMBL622758,1.0,,1.0,,,,,,7078.0,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.)
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3802.0,,10090.0,CHEMBL622759,1.0,,1.0,,,,,,7079.0,Tested for bioavailability of the compound
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,3802.0,,10090.0,CHEMBL622760,1.0,,1.0,,,,,,7080.0,Tested for half life at the dose of 10 mg/kg when administered intravenously
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,14029.0,,10090.0,CHEMBL622761,1.0,,1.0,Plasma,,,1969.0,,7081.0,The plasma half life of compound was determined on EDTA prepared by mouse plasma. 
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,14029.0,,10090.0,CHEMBL622762,1.0,,1.0,Plasma,,,1969.0,,7082.0,The plasma half life of compound was determined on heparin prepared by human plasma. 
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,14029.0,,10090.0,CHEMBL622763,1.0,,1.0,Plasma,,,1969.0,,7083.0,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,14029.0,,10090.0,CHEMBL622764,1.0,,1.0,Plasma,,,1969.0,,7084.0,The plasma half life of compound was determined on heparin prepared by mouse plasma. 
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,14029.0,,10090.0,CHEMBL622765,1.0,,1.0,Plasma,,,1969.0,,7085.0,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded
,BAO_0000218,F,,,50594.0,N,Mus musculus,Intermediate,17753.0,,10090.0,CHEMBL622766,1.0,,1.0,,,,,,7086.0,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17753.0,,10090.0,CHEMBL622767,1.0,,1.0,,,,,,7087.0,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg
,BAO_0000218,A,,,50594.0,N,Mus musculus,Intermediate,17753.0,,10090.0,CHEMBL622768,1.0,,1.0,,,,,,7088.0,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL875948,1.0,,1.0,Blood,,,178.0,,7089.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL622769,1.0,,1.0,Blood,,,178.0,,7090.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL622770,1.0,,1.0,Blood,,,178.0,,7091.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL622771,1.0,,1.0,Blood,,,178.0,,7092.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL622772,1.0,,1.0,Blood,,,178.0,,7093.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL622773,1.0,,1.0,Blood,,,178.0,,7094.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL622774,1.0,,1.0,Blood,,,178.0,,7095.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL621725,1.0,,1.0,Bone,,,10000001.0,,7096.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL621726,1.0,,1.0,Bone,,,10000001.0,,7097.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15608.0,,9606.0,CHEMBL621727,1.0,,1.0,,,,,478.0,7098.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,3290.0,,9606.0,CHEMBL622413,1.0,,1.0,,,,,478.0,7099.0,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,2859.0,,9606.0,CHEMBL622414,1.0,,1.0,,,,,478.0,7100.0,Compound was evaluated for cytotoxicity against A2780 cell line
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,15688.0,,9606.0,CHEMBL622415,1.0,,1.0,,,,,478.0,7101.0,Inhibition of A2780 cell clonogenic assay
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,5642.0,,9606.0,CHEMBL884001,1.0,,1.0,,,,,478.0,7102.0,Cytotoxic effect on ovarian cancer cell line (A2780)
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,6633.0,,9606.0,CHEMBL622416,1.0,,1.0,,,,,478.0,7103.0,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,3906.0,,9606.0,CHEMBL622417,1.0,,1.0,,,,,478.0,7104.0,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL"
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,6788.0,,9606.0,CHEMBL622590,1.0,,1.0,,,,,478.0,7105.0,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,17582.0,,9606.0,CHEMBL622591,1.0,,1.0,,,,,478.0,7106.0,Antiproliferative activity against human A2780 cells
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,17764.0,,9606.0,CHEMBL622592,1.0,,1.0,,,,,478.0,7107.0,Inhibition of human A2780 cell proliferation
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,17764.0,,9606.0,CHEMBL622593,1.0,,1.0,,,,,478.0,7108.0,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,17764.0,,9606.0,CHEMBL622594,1.0,,1.0,,,,,478.0,7109.0,Inhibition of human A2780 cell proliferation (No data)
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,2815.0,,9606.0,CHEMBL622595,1.0,,1.0,,,,,478.0,7110.0,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16930.0,,9606.0,CHEMBL622596,1.0,,1.0,,,,,478.0,7111.0,Compound was evaluated against human Ovarian carcinoma cell line A2780
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,17777.0,,9606.0,CHEMBL622597,1.0,,1.0,,,,,478.0,7112.0,Growth inhibition against A2780 wild-type ovarian cell lines
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,17777.0,,9606.0,CHEMBL622598,1.0,,1.0,,,,,478.0,7113.0,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data
,BAO_0000019,F,,,104766.0,D,Homo sapiens,Autocuration,16936.0,,9606.0,CHEMBL622599,1.0,,5.0,,,,,,7114.0,Inhibition of tubulin polymerization in human ovarian cancer cell lines
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,13759.0,,9606.0,CHEMBL622600,1.0,,1.0,,,,,478.0,7115.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,13759.0,,9606.0,CHEMBL622601,1.0,,1.0,,,,,478.0,7116.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,13759.0,,9606.0,CHEMBL622602,1.0,,1.0,,,,,478.0,7117.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,13759.0,,9606.0,CHEMBL622603,1.0,,1.0,,,,,478.0,7118.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15292.0,,9606.0,CHEMBL622604,1.0,,1.0,,,,,478.0,7119.0,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15292.0,,9606.0,CHEMBL622605,1.0,,1.0,,,,,478.0,7120.0,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,15069.0,,9606.0,CHEMBL622606,1.0,,1.0,,,,,478.0,7121.0,In vitro inhibition of human ovarian cell line A2780
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,15069.0,,9606.0,CHEMBL619463,1.0,,1.0,,,,,478.0,7122.0,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR)."
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,14073.0,,9606.0,CHEMBL619464,1.0,,1.0,,,,,478.0,7123.0,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro)
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,14553.0,,9606.0,CHEMBL619465,1.0,,1.0,,,,,478.0,7124.0,Concentration required to inhibit A2780-cell growth by 50%
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,13040.0,,9606.0,CHEMBL619466,1.0,,1.0,,,,,478.0,7125.0,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,6891.0,,9606.0,CHEMBL619467,1.0,,1.0,,,,,478.0,7126.0,Cytotoxic effect on human ovarian (A2780) cancer cell line
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15569.0,,9606.0,CHEMBL619468,1.0,,1.0,,,,,478.0,7127.0,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,14190.0,,9606.0,CHEMBL619469,1.0,,1.0,,,,,478.0,7128.0,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,15014.0,,9606.0,CHEMBL619470,1.0,,1.0,,,,,478.0,7129.0,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15014.0,,9606.0,CHEMBL619471,1.0,,1.0,,,,,478.0,7130.0,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,17496.0,,9606.0,CHEMBL619472,1.0,,1.0,,,,,478.0,7131.0,Cytotoxicity against human ovarian carcinoma A2780 cell line
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,13617.0,,9606.0,CHEMBL619473,1.0,,1.0,,,,,478.0,7132.0,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line"
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,13617.0,,9606.0,CHEMBL874368,1.0,,1.0,,,,,478.0,7133.0,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line"
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,13617.0,,9606.0,CHEMBL884003,1.0,,1.0,,,,,478.0,7134.0,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line"
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,13617.0,,9606.0,CHEMBL622690,1.0,,1.0,,,,,478.0,7135.0,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line"
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,17672.0,,9606.0,CHEMBL622691,1.0,,1.0,,,,,478.0,7136.0,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,4544.0,,9606.0,CHEMBL622692,1.0,,1.0,,,,,478.0,7137.0,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,4544.0,,9606.0,CHEMBL623406,1.0,,1.0,,,,,478.0,7138.0,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16317.0,,9606.0,CHEMBL884004,1.0,,1.0,,,,,478.0,7139.0,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay"
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15099.0,,9606.0,CHEMBL623407,1.0,,1.0,,,,,478.0,7140.0,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,13978.0,,9606.0,CHEMBL623408,1.0,,1.0,,,,,478.0,7141.0,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,12989.0,,9606.0,CHEMBL623409,1.0,,1.0,,,,,478.0,7142.0,In vitro antitumor activity against A2780 cell line.
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,5574.0,,9606.0,CHEMBL623410,1.0,,1.0,,,,,478.0,7143.0,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,13528.0,,9606.0,CHEMBL623576,1.0,,1.0,,,,,478.0,7144.0,In vitro cytotoxicity against A2780 human ovarian cancer cell line
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,12782.0,,9606.0,CHEMBL623577,1.0,,1.0,,,,,626.0,7145.0,Inhibitory activity against kidney A-CHN tumor cell growth in culture
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,14255.0,,9606.0,CHEMBL623578,1.0,,1.0,,,,,626.0,7146.0,The IC50 value was measured on ACHN cell line in renal tumor type.
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,16364.0,,9606.0,CHEMBL623579,1.0,,1.0,,,,,626.0,7147.0,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Expert,17376.0,,9606.0,CHEMBL623580,1.0,,1.0,,,,,626.0,7148.0,In vitro lethal concentration against most sensitive ACHN cell line
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,12016.0,,9606.0,CHEMBL623581,1.0,,1.0,,,,,626.0,7149.0,Tested for cytotoxic activity against renal cancer ACHN cell line
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,6058.0,,9606.0,CHEMBL857456,1.0,,1.0,,,,,626.0,7150.0,Compound tested for growth inhibition of renal cancer cell line ACHN
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,17708.0,,9606.0,CHEMBL623582,1.0,,1.0,,,,,626.0,7151.0,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,15176.0,,9606.0,CHEMBL623583,1.0,,1.0,,,,,626.0,7152.0,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,2806.0,,9606.0,CHEMBL623584,1.0,,1.0,,,,,626.0,7153.0,In vitro anticancer activity against ACHN renal cancer cell line
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,15300.0,,9606.0,CHEMBL623585,1.0,,1.0,,,,,626.0,7154.0,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,16364.0,,9606.0,CHEMBL623586,1.0,,1.0,,,,,626.0,7155.0,Percent selectivity was evaluated in renal ACHN cell lines
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,13859.0,,9606.0,CHEMBL623587,1.0,,1.0,,,,,626.0,7156.0,In vitro inhibitory activity against renal ACHN cancer cell line
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,11970.0,,9606.0,CHEMBL875279,1.0,,1.0,,,,,626.0,7157.0,Tested for cytotoxicity against ACHN cell lines in renal cancer
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,2450.0,,9606.0,CHEMBL623588,1.0,,1.0,,,,,626.0,7158.0,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,12696.0,,9606.0,CHEMBL623589,1.0,,1.0,,,,,626.0,7159.0,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,12400.0,,9606.0,CHEMBL623590,1.0,,1.0,,,,,626.0,7160.0,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Expert,12888.0,,9606.0,CHEMBL623591,1.0,,1.0,,,,,626.0,7161.0,Cytotoxic effect on renal cancer line ACHN
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,3156.0,,9606.0,CHEMBL623592,1.0,,1.0,,,,,626.0,7162.0,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,3381.0,,9606.0,CHEMBL623593,1.0,,1.0,,,,,626.0,7163.0,In vitro inhibition of Renal Cancer ACHN cell lines
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,16747.0,,9606.0,CHEMBL623594,1.0,,1.0,,,,,626.0,7164.0,Antitumor activity against human renal adenocarcinoma ACHN cells
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Expert,16748.0,,9606.0,CHEMBL621833,1.0,,1.0,,,,,626.0,7165.0,Antitumor activity against human renal adenocarcinoma ACHN cells.
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,12062.0,,9606.0,CHEMBL621834,1.0,,1.0,,,,,626.0,7166.0,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,14769.0,,9606.0,CHEMBL621835,1.0,,1.0,,,,,626.0,7167.0,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells )
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,15895.0,,9606.0,CHEMBL621836,1.0,,1.0,,,,,626.0,7168.0,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line"
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,17376.0,,9606.0,CHEMBL621837,1.0,,1.0,,,,,626.0,7169.0,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,14882.0,,9606.0,CHEMBL875280,1.0,,1.0,,,,,626.0,7170.0,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,14882.0,,9606.0,CHEMBL621838,1.0,,1.0,,,,,626.0,7171.0,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).
,BAO_0000219,F,,ACHN,80025.0,N,Homo sapiens,Intermediate,15661.0,,9606.0,CHEMBL621839,1.0,,1.0,,,,,626.0,7172.0,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.
,BAO_0000019,A,,,22224.0,U,,Autocuration,9680.0,,,CHEMBL621840,1.0,,0.0,,,,,,7173.0,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade
,BAO_0000019,F,,,10647.0,H,,Autocuration,14579.0,,,CHEMBL621841,1.0,,8.0,,,,,,7174.0,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.
,BAO_0000218,F,,HEL,50529.0,N,Cytomegalovirus,Expert,17290.0,,10358.0,CHEMBL622979,1.0,,1.0,,,,,468.0,7175.0,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.
,BAO_0000218,F,,,50529.0,N,Cytomegalovirus,Intermediate,17290.0,,10358.0,CHEMBL876595,1.0,,1.0,,,,,,7176.0,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data
,BAO_0000357,B,,,12159.0,H,,Autocuration,15891.0,,,CHEMBL620221,1.0,,8.0,,,,,,7177.0,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA)
,BAO_0000357,B,,,12159.0,H,,Autocuration,15890.0,,,CHEMBL620222,1.0,,8.0,,,,,,7178.0,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA)
,BAO_0000219,F,,ADDP cell line,80670.0,N,Bos taurus,Intermediate,3801.0,,9913.0,CHEMBL620506,1.0,,1.0,,,,,979.0,7179.0,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound
,BAO_0000219,F,,ADJ/PC6,80671.0,N,Mus musculus,Intermediate,9222.0,,10090.0,CHEMBL620507,1.0,,1.0,,,,,980.0,7180.0,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells
,BAO_0000219,F,,ADJ/PC6,80671.0,N,Mus musculus,Intermediate,9222.0,,10090.0,CHEMBL620508,1.0,,1.0,,,,,980.0,7181.0,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells
,BAO_0000219,F,,ADJ/PC6,80671.0,N,Mus musculus,Intermediate,7257.0,,10090.0,CHEMBL620509,1.0,,1.0,,,,,980.0,7182.0,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor"
,BAO_0000219,F,,ADJ/PC6,80671.0,N,Mus musculus,Intermediate,7257.0,,10090.0,CHEMBL620510,1.0,,1.0,,,,,980.0,7183.0,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg
,BAO_0000219,A,,ADJ/PC6,80671.0,N,Mus musculus,Intermediate,7257.0,,10090.0,CHEMBL620511,1.0,,1.0,,,,,980.0,7184.0,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group
,BAO_0000219,F,,ADJ/PC6,80671.0,N,Mus musculus,Intermediate,8084.0,,10090.0,CHEMBL620512,1.0,,1.0,,,,,980.0,7185.0,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells
,BAO_0000019,F,,,22224.0,U,Mus musculus,Autocuration,14943.0,,10090.0,CHEMBL620513,1.0,,0.0,,,,,,7186.0,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma
,BAO_0000019,F,,,22224.0,U,Mus musculus,Autocuration,14943.0,,10090.0,CHEMBL620514,1.0,,0.0,,,,,,7187.0,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined
,BAO_0000019,F,,,22224.0,U,Mus musculus,Autocuration,14943.0,,10090.0,CHEMBL620515,1.0,,0.0,,,,,,7188.0,Tested for cytotoxicity against ADJ/PC6 plasmacytoma
,BAO_0000218,A,In vivo,,22224.0,U,Bacillus subtilis,Autocuration,10524.0,,1423.0,CHEMBL620516,1.0,,0.0,,,,,,7189.0,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3546.0,,9615.0,CHEMBL620517,1.0,,1.0,Plasma,,,1969.0,,7190.0,AUC value in dog after IV administration at a dose of 5 mg/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3546.0,,9615.0,CHEMBL620518,1.0,,1.0,Plasma,,,1969.0,,7191.0,AUC value in dog after oral administration at a dose of 5 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3546.0,,9615.0,CHEMBL620519,1.0,,1.0,,,,,,7192.0,Cmax value in dog after oral administration at a dose of 5 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3546.0,,9615.0,CHEMBL621386,1.0,,1.0,,,,,,7193.0,Bioavailability in dog after oral administration at a dose of 5 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3546.0,,9615.0,CHEMBL621387,1.0,,1.0,,,,,,7194.0,Tmax value in dog after oral administration at a dose of 5 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3184.0,,9615.0,CHEMBL621388,1.0,,1.0,,,,,,7195.0,Compound was evaluated for its clearance when administered intravenously in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16456.0,,9615.0,CHEMBL621389,1.0,,1.0,,,,,,7196.0,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4809.0,,9615.0,CHEMBL621390,1.0,,1.0,,,,,,7197.0,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg)
,BAO_0000100,P,,,22229.0,U,,Intermediate,4219.0,,,CHEMBL621391,1.0,,0.0,,,,,,7198.0,Calculated partition coefficient (clogP)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3748.0,,9615.0,CHEMBL621392,1.0,,1.0,,,,,,7199.0,Half life in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3132.0,,9615.0,CHEMBL621393,1.0,,1.0,,,,,,7200.0,Time taken for EC90 was determined when tested in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4219.0,,9615.0,CHEMBL621394,1.0,,1.0,,,,,,7201.0,Half life (iv) was determined
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,16907.0,,9615.0,CHEMBL621395,1.0,,1.0,Liver,,,2107.0,,7202.0,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6057.0,,9615.0,CHEMBL621396,1.0,,1.0,,,,,,7203.0,Area under the curve was calculated in dog after iv administration
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6057.0,,9615.0,CHEMBL621397,1.0,,1.0,,,,,,7204.0,Area under the curve was calculated in dog after peroral administration
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,17853.0,,9615.0,CHEMBL621398,1.0,,1.0,,,,,,7205.0,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3639.0,,9615.0,CHEMBL618818,1.0,,1.0,,,,,,7206.0,pKa was evaluated in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,14541.0,,9615.0,CHEMBL618819,1.0,,1.0,,,,,,7207.0,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16456.0,,9615.0,CHEMBL618820,1.0,,1.0,,,,,,7208.0,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16456.0,,9615.0,CHEMBL873810,1.0,,1.0,,,,,,7209.0,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,2652.0,,9615.0,CHEMBL876606,1.0,,1.0,,,,,,7210.0,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3624.0,,9615.0,CHEMBL618821,1.0,,1.0,,,,,,7211.0,Compound was evaluated for the half-life (t 1/2) in hours
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1337.0,,9615.0,CHEMBL618822,1.0,,1.0,Blood,,,178.0,,7212.0,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,1337.0,,9615.0,CHEMBL618823,1.0,,1.0,Blood,,,178.0,,7213.0,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4709.0,,9615.0,CHEMBL618824,1.0,,1.0,,,,,,7214.0,Half life after intravenous administration of 1 mg/kg in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,15660.0,,9615.0,CHEMBL618825,1.0,,1.0,,,,,,7215.0,Half life was measured in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5302.0,,9615.0,CHEMBL618826,1.0,,1.0,,,,,,7216.0,Half life period in dog after 5 mg/kg dose
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,17791.0,,9615.0,CHEMBL618827,1.0,,1.0,,,,,,7217.0,Half life period was evaluated in dog; 4-4.8
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6348.0,,9615.0,CHEMBL618828,1.0,,1.0,,,,,,7218.0,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4257.0,,9615.0,CHEMBL618829,1.0,,1.0,,,,,,7219.0,Half-life was determined in dog after a3 mg/kg of iv dose
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3771.0,,9615.0,CHEMBL618830,1.0,,1.0,,,,,,7220.0,Half-life was determined
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6305.0,,9615.0,CHEMBL618831,1.0,,1.0,,,,,,7221.0,Half life in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,13501.0,,9615.0,CHEMBL619489,1.0,,1.0,Plasma,,,1969.0,,7222.0,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17594.0,,9615.0,CHEMBL619649,1.0,,1.0,,,,,,7223.0,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3045.0,,9615.0,CHEMBL876607,1.0,,1.0,,,,,,7224.0,Compound was evaluated for the half life period after iv administration in Beagle dog.
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3043.0,,9615.0,CHEMBL619650,1.0,,1.0,,,,,,7225.0,Compound was evaluated for the half life period after oral administration in conscious dog.
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4839.0,,9615.0,CHEMBL619651,1.0,,1.0,,,,,,7226.0,Compound was tested for half life in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4839.0,,9615.0,CHEMBL619652,1.0,,1.0,,,,,,7227.0,Compound was tested for its half life in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5802.0,,9615.0,CHEMBL619653,1.0,,1.0,,,,,,7228.0,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,17839.0,,9615.0,CHEMBL619654,1.0,,1.0,,,,,,7229.0,Half life of compound in dog was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4219.0,,9615.0,CHEMBL619655,1.0,,1.0,,,,,,7230.0,Half life (iv) was determined
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,13966.0,,9615.0,CHEMBL619656,1.0,,1.0,Blood,,,178.0,,7231.0,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3994.0,,9615.0,CHEMBL873812,1.0,,1.0,Plasma,,,1969.0,,7232.0,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration
,BAO_0000218,F,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3994.0,,9615.0,CHEMBL621365,1.0,,1.0,Plasma,,,1969.0,,7233.0,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4453.0,,9615.0,CHEMBL621366,1.0,,1.0,,,,,,7234.0,Half life in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6535.0,,9615.0,CHEMBL621367,1.0,,1.0,Plasma,,,1969.0,,7235.0,Half life in dog plasma
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6535.0,,9615.0,CHEMBL621368,1.0,,1.0,Plasma,,,1969.0,,7236.0,Half life in dog plasma after administration of 0.25 mg/kg iv
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6535.0,,9615.0,CHEMBL621369,1.0,,1.0,Plasma,,,1969.0,,7237.0,Half life in dog plasma after administration of 1 mg/kg iv
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3132.0,,9615.0,CHEMBL621370,1.0,,1.0,Plasma,,,1969.0,,7238.0,Half life in dog plasma was determined at dose 10 mg/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5374.0,,9615.0,CHEMBL621371,1.0,,1.0,,,,,,7239.0,Half life in dog was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5007.0,,9615.0,CHEMBL621372,1.0,,1.0,,,,,,7240.0,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg)
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,16907.0,,9615.0,CHEMBL621373,1.0,,1.0,Plasma,,,1969.0,,7241.0,Half life upon exposure to human plasma
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6057.0,,9615.0,CHEMBL621374,1.0,,1.0,,,,,,7242.0,Half life was calculated in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5006.0,,9615.0,CHEMBL621375,1.0,,1.0,,,,,,7243.0,Half life was determined
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5473.0,,9615.0,CHEMBL621376,1.0,,1.0,,,,,,7244.0,Half life was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4368.0,,9615.0,CHEMBL619624,1.0,,1.0,,,,,,7245.0,Half life by intravenous administration of 1.2 mg/kg in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6448.0,,9615.0,CHEMBL875840,1.0,,1.0,,,,,,7246.0,Half life in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4353.0,,9615.0,CHEMBL619625,1.0,,1.0,,,,,,7247.0,Half life in dog after intra venous administration of the compound
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4353.0,,9615.0,CHEMBL619626,1.0,,1.0,,,,,,7248.0,Half life in dog after intra venous administration of the compound; ND means Not determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4353.0,,9615.0,CHEMBL619627,1.0,,1.0,,,,,,7249.0,Half life in dog after po administration of the compound
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4353.0,,9615.0,CHEMBL873817,1.0,,1.0,,,,,,7250.0,Half life in dog after po administration of the compound; ND means Not determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6265.0,,9615.0,CHEMBL619628,1.0,,1.0,,,,,,7251.0,Half life in dog at the single oral dose of 1 mg/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5006.0,,9615.0,CHEMBL619629,1.0,,1.0,,,,,,7252.0,Half life in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5356.0,,9615.0,CHEMBL619630,1.0,,1.0,,,,,,7253.0,Half life in dogs at 1 mg/kg oral dosing; 35-100 min
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,405.0,,9615.0,CHEMBL619631,1.0,,1.0,,,,,,7254.0,Half life in rat
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6642.0,,9615.0,CHEMBL619632,1.0,,1.0,,,,,,7255.0,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only)
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL619633,1.0,,1.0,Bone,,,10000001.0,,7256.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL875841,1.0,,1.0,Bone,,,10000001.0,,7257.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL619634,1.0,,1.0,Bone,,,10000001.0,,7258.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL619635,1.0,,1.0,Bone,,,10000001.0,,7259.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL619636,1.0,,1.0,Bone,,,10000001.0,,7260.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL619637,1.0,,1.0,Gut,,,10000004.0,,7261.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL619638,1.0,,1.0,Gut,,,10000004.0,,7262.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL619639,1.0,,1.0,Gut,,,10000004.0,,7263.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL619640,1.0,,1.0,Gut,,,10000004.0,,7264.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL619641,1.0,,1.0,Gut,,,10000004.0,,7265.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL619642,1.0,,1.0,Gut,,,10000004.0,,7266.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL619643,1.0,,1.0,Gut,,,10000004.0,,7267.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL619644,1.0,,1.0,Heart,,,948.0,,7268.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL621112,1.0,,1.0,Heart,,,948.0,,7269.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL621113,1.0,,1.0,Heart,,,948.0,,7270.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL621114,1.0,,1.0,Heart,,,948.0,,7271.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL621115,1.0,,1.0,Heart,,,948.0,,7272.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL621116,1.0,,1.0,Heart,,,948.0,,7273.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL621117,1.0,,1.0,Heart,,,948.0,,7274.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL621118,1.0,,1.0,Kidney,,,2113.0,,7275.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL621119,1.0,,1.0,Kidney,,,2113.0,,7276.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL621120,1.0,,1.0,Kidney,,,2113.0,,7277.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL621757,1.0,,1.0,Kidney,,,2113.0,,7278.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL621758,1.0,,1.0,Kidney,,,2113.0,,7279.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL621759,1.0,,1.0,Kidney,,,2113.0,,7280.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL621760,1.0,,1.0,Kidney,,,2113.0,,7281.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL621761,1.0,,1.0,Liver,,,2107.0,,7282.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL621762,1.0,,1.0,Liver,,,2107.0,,7283.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL621763,1.0,,1.0,Liver,,,2107.0,,7284.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL624502,1.0,,1.0,Liver,,,2107.0,,7285.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL624503,1.0,,1.0,Liver,,,2107.0,,7286.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL624504,1.0,,1.0,Liver,,,2107.0,,7287.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL624505,1.0,,1.0,Liver,,,2107.0,,7288.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL624506,1.0,,1.0,Lung,,,2048.0,,7289.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,5895.0,,9606.0,CHEMBL624507,1.0,,1.0,,,,,478.0,7290.0,In vitro cytotoxicity against A2780 (human ovarian cancer)
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,6338.0,,9606.0,CHEMBL624508,1.0,,1.0,,,,,478.0,7291.0,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15163.0,,9606.0,CHEMBL624509,1.0,,1.0,,,,,478.0,7292.0,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15163.0,,9606.0,CHEMBL624510,1.0,,1.0,,,,,478.0,7293.0,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,15000.0,,9606.0,CHEMBL875956,1.0,,1.0,,,,,478.0,7294.0,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,15000.0,,9606.0,CHEMBL839885,1.0,,1.0,,,,,478.0,7295.0,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,14729.0,,9606.0,CHEMBL624511,1.0,,1.0,,,,,478.0,7296.0,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,17270.0,,9606.0,CHEMBL624512,1.0,,1.0,,,,,478.0,7297.0,In vitro cytotoxicity against A2780 cell line
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,5685.0,,9606.0,CHEMBL624513,1.0,,1.0,,,,,478.0,7298.0,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,3563.0,,9606.0,CHEMBL624514,1.0,,1.0,,,,,478.0,7299.0,In vitro inhibitory activity against human ovarian cancer A2780 cell line
,BAO_0000218,F,,A2780,81034.0,N,Homo sapiens,Intermediate,17753.0,,9606.0,CHEMBL618547,1.0,,1.0,,,,,478.0,7300.0,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16317.0,,9606.0,CHEMBL618548,1.0,,1.0,,,,,478.0,7301.0,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay"
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16936.0,,9606.0,CHEMBL618549,1.0,,1.0,,,,,478.0,7302.0,Inhibition of tubulin polymerization in analogy of ca.
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,3801.0,,9606.0,CHEMBL618550,1.0,,1.0,,,,,478.0,7303.0,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,6181.0,,9606.0,CHEMBL618551,1.0,,1.0,,,,,478.0,7304.0,Cytotoxic effect in ovarian cancer cell line (A2780)
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,5318.0,,9606.0,CHEMBL618552,1.0,,1.0,,,,,478.0,7305.0,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,4840.0,,9606.0,CHEMBL618553,1.0,,1.0,,,,,478.0,7306.0,Tested for the cytotoxicity in A2780 ovarian cell line
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15748.0,,9606.0,CHEMBL618554,1.0,,1.0,,,,,478.0,7307.0,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma )
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,15748.0,,9606.0,CHEMBL618555,1.0,,1.0,,,,,478.0,7308.0,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma
,BAO_0000219,F,,A2780cisR,80017.0,N,,Intermediate,15748.0,,,CHEMBL618556,1.0,,1.0,,,,,481.0,7309.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma
,BAO_0000219,F,,A2780cisR,80017.0,N,,Intermediate,15748.0,,,CHEMBL618557,1.0,,1.0,,,,,481.0,7310.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma )
,BAO_0000219,F,,A2780cisR,80017.0,N,,Intermediate,15748.0,,,CHEMBL618558,1.0,,1.0,,,,,481.0,7311.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data
,BAO_0000219,F,,A2780cisR,80017.0,N,,Intermediate,15748.0,,,CHEMBL618559,1.0,,1.0,,,,,481.0,7312.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma)
,BAO_0000218,F,,A2780,81034.0,N,Homo sapiens,Intermediate,17753.0,,9606.0,CHEMBL618560,1.0,,1.0,,,,,478.0,7313.0,In vivo log of cells killed after administration of compound in A2780 cell line
,BAO_0000218,F,In vivo,A2780,81034.0,N,Homo sapiens,Intermediate,17753.0,,9606.0,CHEMBL618561,1.0,,1.0,,,,,478.0,7314.0,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16936.0,,9606.0,CHEMBL618562,1.0,,1.0,,,,,478.0,7315.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16936.0,,9606.0,CHEMBL618563,1.0,,1.0,,,,,478.0,7316.0,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16936.0,,9606.0,CHEMBL618564,1.0,,1.0,,,,,478.0,7317.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16936.0,,9606.0,CHEMBL618565,1.0,,1.0,,,,,478.0,7318.0,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data
,BAO_0000218,F,,A2780,81034.0,N,Homo sapiens,Intermediate,17528.0,,9606.0,CHEMBL618566,1.0,,1.0,,,,,478.0,7319.0,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2)
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,6633.0,,9606.0,CHEMBL618567,1.0,,1.0,,,,,478.0,7320.0,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,15000.0,,9606.0,CHEMBL618568,1.0,,1.0,,,,,478.0,7321.0,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,17528.0,,9606.0,CHEMBL618569,1.0,,1.0,,,,,478.0,7322.0,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16936.0,,9606.0,CHEMBL621857,1.0,,1.0,,,,,478.0,7323.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16936.0,,9606.0,CHEMBL621858,1.0,,1.0,,,,,478.0,7324.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16936.0,,9606.0,CHEMBL621859,1.0,,1.0,,,,,478.0,7325.0,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16936.0,,9606.0,CHEMBL621860,1.0,,1.0,,,,,478.0,7326.0,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)"
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16936.0,,9606.0,CHEMBL621861,1.0,,1.0,,,,,478.0,7327.0,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM )
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Expert,16936.0,,9606.0,CHEMBL621862,1.0,,1.0,,,,,478.0,7328.0,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )"
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16936.0,,9606.0,CHEMBL621863,1.0,,1.0,,,,,478.0,7329.0,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM )
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16936.0,,9606.0,CHEMBL621864,1.0,,1.0,,,,,478.0,7330.0,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM )
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,16936.0,,9606.0,CHEMBL621865,1.0,,1.0,,,,,478.0,7331.0,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM )
,BAO_0000219,F,,A2780,81034.0,N,Mus musculus,Intermediate,17737.0,,10090.0,CHEMBL621866,1.0,,1.0,,,,,478.0,7332.0,In vitro antiproliferative activity against A2780 cell line
,BAO_0000219,F,,A2780,81034.0,N,Mus musculus,Expert,17764.0,,10090.0,CHEMBL621867,1.0,,1.0,,,,,478.0,7333.0,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,3830.0,,9606.0,CHEMBL621868,1.0,,1.0,,,,,478.0,7334.0,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr
,BAO_0000219,F,,A2780,81034.0,N,Homo sapiens,Intermediate,3829.0,,9606.0,CHEMBL875282,1.0,,1.0,,,,,478.0,7335.0,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3546.0,,9615.0,CHEMBL621869,1.0,,1.0,,,,,,7336.0,Vc value in dog after IV administration at a dose of 5 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,3546.0,,9615.0,CHEMBL621870,1.0,,1.0,,,,,,7337.0,Half life period in dog after IV administration at a dose of 5 mg/kg
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,5668.0,,9527.0,CHEMBL621871,1.0,,0.0,,,,,,7338.0,Area under curve was determine after peroral administration at 10 mpk in Rhesus
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,3443.0,,9527.0,CHEMBL621243,1.0,,0.0,Plasma,,,1969.0,,7339.0,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,3443.0,,9527.0,CHEMBL621244,1.0,,0.0,Plasma,,,1969.0,,7340.0,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
,BAO_0000218,A,In vivo,,22224.0,U,Macaca fascicularis,Autocuration,4256.0,,9541.0,CHEMBL621245,1.0,,0.0,,,,,,7341.0,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Macaca fascicularis,Autocuration,4256.0,,9541.0,CHEMBL621246,1.0,,0.0,,,,,,7342.0,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Macaca fascicularis,Autocuration,4256.0,,9541.0,CHEMBL621247,1.0,,0.0,,,,,,7343.0,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Rattus norvegicus,Autocuration,4256.0,,10116.0,CHEMBL618386,1.0,,0.0,,,,,,7344.0,Oral Bioavailability in rat
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,1916.0,,9527.0,CHEMBL618387,1.0,,0.0,,,,,,7345.0,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,5302.0,,9527.0,CHEMBL618388,1.0,,0.0,,,,,,7346.0,Area under curve value in monkey at a dose of 5 mg/kg
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,4257.0,,9527.0,CHEMBL618389,1.0,,0.0,,,,,,7347.0,Area under curve was determined in monkey after a 3 mg/kg of oral dose
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,5355.0,,9527.0,CHEMBL618574,1.0,,0.0,,,,,,7348.0,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,5355.0,,9527.0,CHEMBL618575,1.0,,0.0,,,,,,7349.0,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,5355.0,,9527.0,CHEMBL618576,1.0,,0.0,,,,,,7350.0,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,6078.0,,9527.0,CHEMBL618577,1.0,,0.0,,,,,,7351.0,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,6078.0,,9527.0,CHEMBL876487,1.0,,0.0,,,,,,7352.0,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,6062.0,,9527.0,CHEMBL618578,1.0,,0.0,,,,,,7353.0,Area under the curve was measured in monkey after an iv dose of 1 mg/kg
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,2661.0,,9527.0,CHEMBL618579,1.0,,0.0,,,,,,7354.0,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,2661.0,,9527.0,CHEMBL618580,1.0,,0.0,,,,,,7355.0,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,5394.0,,9527.0,CHEMBL618581,1.0,,0.0,,,,,,7356.0,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,4397.0,,9527.0,CHEMBL618582,1.0,,0.0,,,,,,7357.0,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,17509.0,,9527.0,CHEMBL618583,1.0,,0.0,,,,,,7358.0,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,17509.0,,9527.0,CHEMBL618584,1.0,,0.0,,,,,,7359.0,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,6641.0,,9527.0,CHEMBL618585,1.0,,0.0,,,,,,7360.0,Oral AUCN in monkey (dosed at 0.5 mpk iv )
,BAO_0000218,A,,,22224.0,U,Cercopithecidae,Autocuration,5355.0,,9527.0,CHEMBL618586,1.0,,0.0,,,,,,7361.0,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration)
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,3443.0,,9527.0,CHEMBL618587,1.0,,0.0,,,,,,7362.0,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,3443.0,,9527.0,CHEMBL618588,1.0,,0.0,,,,,,7363.0,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,17409.0,,9527.0,CHEMBL618589,1.0,,0.0,,,,,,7364.0,Binding towards monkey plasma protein at 10 uM
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,17409.0,,9527.0,CHEMBL618590,1.0,,0.0,,,,,,7365.0,Binding towards monkey plasma protein at 100 uM
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,1052.0,,9527.0,CHEMBL872262,1.0,,0.0,,,,,,7366.0,Apparent bioavailability in squirrel monkey was determined
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,13501.0,,9527.0,CHEMBL618591,1.0,,0.0,,,,,,7367.0,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey
,BAO_0000218,A,In vivo,,22224.0,U,monkey,Autocuration,17509.0,,9443.0,CHEMBL618592,1.0,,0.0,,,,,,7368.0,Bioavailability in monkey (dose 2 mg/kg)
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5394.0,,9527.0,CHEMBL876488,1.0,,0.0,,,,,,7369.0,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,2661.0,,9527.0,CHEMBL618593,1.0,,0.0,,,,,,7370.0,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey
,BAO_0000218,A,In vivo,,22224.0,U,monkey,Autocuration,11219.0,,9443.0,CHEMBL618594,1.0,,0.0,,,,,,7371.0,Bioavailability in monkey (i.d. dosing)
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,3045.0,,9527.0,CHEMBL618595,1.0,,0.0,,,,,,7372.0,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined
,BAO_0000019,A,,,22224.0,U,Cercopithecidae,Autocuration,17796.0,,9527.0,CHEMBL621469,1.0,,0.0,,,,,,7373.0,Clearance of the drug was measured in cynomolgus
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,1399.0,,9527.0,CHEMBL621470,1.0,,0.0,,,,,,7374.0,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,2661.0,,9527.0,CHEMBL621471,1.0,,0.0,,,,,,7375.0,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Macaca mulatta,Autocuration,5005.0,,9544.0,CHEMBL621472,1.0,,0.0,Plasma,,,1969.0,,7376.0,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,17267.0,,9527.0,CHEMBL621473,1.0,,0.0,,,,,,7377.0,Plasma clearance in rhesus monkey was determined
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,6535.0,,9527.0,CHEMBL621474,1.0,,0.0,,,,,,7378.0,Plasma clearance in monkey after administration of 1 mg/kg iv
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5922.0,,9527.0,CHEMBL621475,1.0,,0.0,,,,,,7379.0,Plasma clearance in cynomolgus monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,6221.0,,9527.0,CHEMBL621476,1.0,,0.0,,,,,,7380.0,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5668.0,,9527.0,CHEMBL624290,1.0,,0.0,,,,,,7381.0,Plasma clearance after peroral administration at 10 mpk in Rhesus
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5355.0,,9527.0,CHEMBL624291,1.0,,0.0,,,,,,7382.0,The total clearance was determined after intravenous administration in cynomolgus monkeys
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5355.0,,9527.0,CHEMBL624292,1.0,,0.0,,,,,,7383.0,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,5355.0,,9527.0,CHEMBL624293,1.0,,0.0,,,,,,7384.0,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,4578.0,,9527.0,CHEMBL624294,1.0,,0.0,,,,,,7385.0,Tested for Clearance upon iv administration to african green monkey
,BAO_0000218,A,In vivo,,22224.0,U,Cercopithecidae,Autocuration,17592.0,,9527.0,CHEMBL624295,1.0,,0.0,,,,,,7386.0,Clearance in monkey
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6641.0,,9615.0,CHEMBL624296,1.0,,1.0,,,,,,7387.0,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6642.0,,9615.0,CHEMBL624297,1.0,,1.0,,,,,,7388.0,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16367.0,,9615.0,CHEMBL624298,1.0,,1.0,,,,,,7389.0,Half life was evaluated after intravenous administration to dogs
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5472.0,,9615.0,CHEMBL624299,1.0,,1.0,,,,,,7390.0,Half life was evaluated in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5474.0,,9615.0,CHEMBL624300,1.0,,1.0,,,,,,7391.0,Half life was evaluated in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5654.0,,9615.0,CHEMBL624301,1.0,,1.0,,,,,,7392.0,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6227.0,,9615.0,CHEMBL624302,1.0,,1.0,,,,,,7393.0,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6227.0,,9615.0,CHEMBL876026,1.0,,1.0,,,,,,7394.0,Half life period after intravenous administration in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6221.0,,9615.0,CHEMBL624303,1.0,,1.0,,,,,,7395.0,Half life period after oral administration (2.5 mg/kg) in dog was determined
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4527.0,,9615.0,CHEMBL624304,1.0,,1.0,,,,,,7396.0,Half life period at a dose of 1 uM/kg in dog was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5668.0,,9615.0,CHEMBL624305,1.0,,1.0,,,,,,7397.0,Half life period was determine after peroral administration at 10 mpk in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5668.0,,9615.0,CHEMBL624306,1.0,,1.0,,,,,,7398.0,Half life period was determine after peroral administration at 5 mpk in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,3854.0,,9615.0,CHEMBL624307,1.0,,1.0,,,,,,7399.0,Half life period was determined
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5505.0,,9615.0,CHEMBL624308,1.0,,1.0,,,,,,7400.0,Half life period was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6251.0,,9615.0,CHEMBL624309,1.0,,1.0,,,,,,7401.0,Half life period by iv administration in dog at a dose of 6 mg/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,1918.0,,9615.0,CHEMBL624310,1.0,,1.0,,,,,,7402.0,Half life period was evaluated in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5546.0,,9615.0,CHEMBL625003,1.0,,1.0,,,,,,7403.0,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4809.0,,9615.0,CHEMBL625004,1.0,,1.0,,,,,,7404.0,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6215.0,,9615.0,CHEMBL625005,1.0,,1.0,,,,,,7405.0,Half life time after intravenous administration (0.5 mg/kg) was determined in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4527.0,,9615.0,CHEMBL873813,1.0,,1.0,,,,,,7406.0,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17594.0,,9615.0,CHEMBL625006,1.0,,1.0,,,,,,7407.0,Half-life after oral dose of compound at 3 mg/kg in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17839.0,,9615.0,CHEMBL625007,1.0,,1.0,,,,,,7408.0,Half-life of compound in dog following p.o. administration of 0.5 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17839.0,,9615.0,CHEMBL876027,1.0,,1.0,,,,,,7409.0,Half-life of compound in dog following p.o. administration of 0.9 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17839.0,,9615.0,CHEMBL625008,1.0,,1.0,,,,,,7410.0,Half-life of compound in dog following p.o. administration of 0.95 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17839.0,,9615.0,CHEMBL625009,1.0,,1.0,,,,,,7411.0,Half-life of compound in dog following p.o. administration of 1 mg/kg
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5210.0,,9615.0,CHEMBL625010,1.0,,1.0,Plasma,,,1969.0,,7412.0,Half-life of compound in plasma of dog was determined
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5210.0,,9615.0,CHEMBL625011,1.0,,1.0,,,,,,7413.0,Half-life of compound was determined in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,2959.0,,9615.0,CHEMBL621553,1.0,,1.0,,,,,,7414.0,Half-life after administration of 4 mg/Kg oral dose in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4137.0,,9615.0,CHEMBL621554,1.0,,1.0,,,,,,7415.0,Half-life after intravenous administration of 1 mg/kg/h in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5064.0,,9615.0,CHEMBL621555,1.0,,1.0,,,,,,7416.0,Half-life in Dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5147.0,,9615.0,CHEMBL621556,1.0,,1.0,,,,,,7417.0,Half-life in Dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,5145.0,,9615.0,CHEMBL621557,1.0,,1.0,,,,,,7418.0,Half-life in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6123.0,,9615.0,CHEMBL621558,1.0,,1.0,,,,,,7419.0,Half-life in dog after oral administration at 1 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6123.0,,9615.0,CHEMBL621559,1.0,,1.0,,,,,,7420.0,Half-life in dog after oral administration at 1 mg/kg; nd is not determined
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4333.0,,9615.0,CHEMBL621560,1.0,,1.0,,,,,,7421.0,Half-life in dogs
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,4333.0,,9615.0,CHEMBL876028,1.0,,1.0,,,,,,7422.0,Half-life in dogs; ND indicates not determined
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,12500.0,,9615.0,CHEMBL621561,1.0,,1.0,Plasma,,,1969.0,,7423.0,Half-life in plasma of dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,12500.0,,9615.0,CHEMBL621562,1.0,,1.0,Plasma,,,1969.0,,7424.0,Half-life in plasma of dog at dose of 3-10 mgkg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6005.0,,9615.0,CHEMBL621563,1.0,,1.0,,,,,,7425.0,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6062.0,,9615.0,CHEMBL621564,1.0,,1.0,,,,,,7426.0,Half-life was measured in dog after an iv dose of 1 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17650.0,,9615.0,CHEMBL621565,1.0,,1.0,,,,,,7427.0,Half-life was measured in dogs after an oral dose of 10 uM/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5530.0,,9615.0,CHEMBL621566,1.0,,1.0,,,,,,7428.0,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5530.0,,9615.0,CHEMBL621567,1.0,,1.0,,,,,,7429.0,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5600.0,,9615.0,CHEMBL622978,1.0,,1.0,,,,,,7430.0,Half-life of the compound after 0.3 mg/kg po administration in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6039.0,,9615.0,CHEMBL873814,1.0,,1.0,,,,,,7431.0,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6039.0,,9615.0,CHEMBL623219,1.0,,1.0,,,,,,7432.0,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6039.0,,9615.0,CHEMBL624477,1.0,,1.0,,,,,,7433.0,Half-life period after peroral administration of 0.2 mg/kg in dog was determined
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,6227.0,,9615.0,CHEMBL624478,1.0,,1.0,,,,,,7434.0,t1/2 in dog
,BAO_0000218,A,,,50588.0,N,Canis lupus familiaris,Intermediate,14541.0,,9615.0,CHEMBL624479,1.0,,1.0,,,,,,7435.0,Half-life period measured in dogs
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4521.0,,9615.0,CHEMBL624480,1.0,,1.0,,,,,,7436.0,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4521.0,,9615.0,CHEMBL623595,1.0,,1.0,,,,,,7437.0,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,6679.0,,9615.0,CHEMBL623596,1.0,,1.0,,,,,,7438.0,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration
,BAO_0000218,A,In vitro,,50588.0,N,Canis lupus familiaris,Intermediate,1116.0,,9615.0,CHEMBL623597,1.0,,1.0,Plasma,,,1969.0,,7439.0,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma"
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5444.0,,9615.0,CHEMBL623598,1.0,,1.0,,,,,,7440.0,In vivo half life period was calculated at 1 mg/kg in dog
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,5444.0,,9615.0,CHEMBL623599,1.0,,1.0,,,,,,7441.0,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,17853.0,,9615.0,CHEMBL623600,1.0,,1.0,,,,,,7442.0,Longer half-life in dog (i.v.) at 0.5 mpk
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,4353.0,,9615.0,CHEMBL623601,1.0,,1.0,,,,,,7443.0,Oral bioavailability in dog (dose 5 uM/kg)
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16452.0,,9615.0,CHEMBL623602,1.0,,1.0,,,,,,7444.0,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16452.0,,9615.0,CHEMBL623603,1.0,,1.0,,,,,,7445.0,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously
,BAO_0000218,A,In vivo,,50588.0,N,Canis lupus familiaris,Intermediate,16452.0,,9615.0,CHEMBL623604,1.0,,1.0,,,,,,7446.0,Bioavailability in dog (dose 1 mg/kg i.v.)
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL623605,1.0,,1.0,Lung,,,2048.0,,7447.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL623606,1.0,,1.0,Lung,,,2048.0,,7448.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL623607,1.0,,1.0,Lung,,,2048.0,,7449.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL623608,1.0,,1.0,Lung,,,2048.0,,7450.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL623609,1.0,,1.0,Lung,,,2048.0,,7451.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL623610,1.0,,1.0,Lung,,,2048.0,,7452.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL623611,1.0,,1.0,Muscle tissue,,,2385.0,,7453.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL623612,1.0,,1.0,Muscle tissue,,,2385.0,,7454.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL623613,1.0,,1.0,Muscle tissue,,,2385.0,,7455.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL623614,1.0,,1.0,Muscle tissue,,,2385.0,,7456.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL623615,1.0,,1.0,Muscle tissue,,,2385.0,,7457.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL623616,1.0,,1.0,Muscle tissue,,,2385.0,,7458.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL623617,1.0,,1.0,Muscle tissue,,,2385.0,,7459.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL875944,1.0,,1.0,Zone of skin,,,14.0,,7460.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL623618,1.0,,1.0,Zone of skin,,,14.0,,7461.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL623619,1.0,,1.0,Zone of skin,,,14.0,,7462.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL623620,1.0,,1.0,Zone of skin,,,14.0,,7463.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL623621,1.0,,1.0,Zone of skin,,,14.0,,7464.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL623622,1.0,,1.0,Zone of skin,,,14.0,,7465.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL623623,1.0,,1.0,Zone of skin,,,14.0,,7466.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL623624,1.0,,1.0,Spleen,,,2106.0,,7467.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL618521,1.0,,1.0,Spleen,,,2106.0,,7468.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL618522,1.0,,1.0,Spleen,,,2106.0,,7469.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL618523,1.0,,1.0,Spleen,,,2106.0,,7470.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL618524,1.0,,1.0,Spleen,,,2106.0,,7471.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL618525,1.0,,1.0,Spleen,,,2106.0,,7472.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL624586,1.0,,1.0,Spleen,,,2106.0,,7473.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL624587,1.0,,1.0,Stomach,,,945.0,,7474.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL624588,1.0,,1.0,Stomach,,,945.0,,7475.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL624589,1.0,,1.0,Stomach,,,945.0,,7476.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL624590,1.0,,1.0,Stomach,,,945.0,,7477.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL624591,1.0,,1.0,Stomach,,,945.0,,7478.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL624592,1.0,,1.0,Stomach,,,945.0,,7479.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
,BAO_0000218,A,In vivo,,50594.0,N,Mus musculus,Intermediate,10107.0,,10090.0,CHEMBL624593,1.0,,1.0,Stomach,,,945.0,,7480.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,4689.0,,10116.0,CHEMBL624594,1.0,,1.0,,,,,,7481.0,Oral bioavailability in rat
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,4950.0,,10116.0,CHEMBL624595,1.0,,1.0,,,,,,7482.0,Tested for the bioavailability in rat
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,5328.0,,10116.0,CHEMBL624596,1.0,,1.0,,,,,,7483.0,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.)
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,406.0,,10116.0,CHEMBL624597,1.0,,1.0,,,,,,7484.0,Bioavailability in rat
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,12500.0,,10116.0,CHEMBL624598,1.0,,1.0,,,,,,7485.0,Bioavailability in rat
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,12500.0,,10116.0,CHEMBL624599,1.0,,1.0,,,,,,7486.0,Bioavailability in rat (dose 3-10 mg/kg)
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,5247.0,,10116.0,CHEMBL875166,1.0,,1.0,,,,,,7487.0,Bioavailability in rat
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,4186.0,,10116.0,CHEMBL624600,1.0,,1.0,Plasma,,,1969.0,,7488.0,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,4186.0,,10116.0,CHEMBL624601,1.0,,1.0,Plasma,,,1969.0,,7489.0,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,6647.0,,10116.0,CHEMBL624602,1.0,,1.0,,,,,,7490.0,Half life after oral administration was determined in rats at 6 mg/kg
,BAO_0000218,A,,,50597.0,N,Rattus norvegicus,Intermediate,6484.0,,10116.0,CHEMBL624603,1.0,,1.0,,,,,,7491.0,Half life was determined
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,3249.0,,10116.0,CHEMBL624604,1.0,,1.0,,,,,,7492.0,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,6281.0,,10116.0,CHEMBL624605,1.0,,1.0,Plasma,,,1969.0,,7493.0,Plasma half life in rat at oral dose 2.8 mg/mk body weight
,BAO_0000218,A,,,50597.0,N,Rattus norvegicus,Intermediate,3307.0,,10116.0,CHEMBL624606,1.0,,1.0,,,,,,7494.0,Half life in rats
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,12058.0,,10116.0,CHEMBL624607,1.0,,1.0,Blood,,,178.0,,7495.0,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration
,BAO_0000218,A,,,50597.0,N,Rattus norvegicus,Intermediate,8833.0,,10116.0,CHEMBL624608,1.0,,1.0,,,,,,7496.0,Hill coefficient of the compound
,BAO_0000218,A,,,50597.0,N,Rattus norvegicus,Intermediate,3193.0,,10116.0,CHEMBL624609,1.0,,1.0,Blood,,,178.0,,7497.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min
,BAO_0000218,A,,,50597.0,N,Rattus norvegicus,Intermediate,3193.0,,10116.0,CHEMBL624610,1.0,,1.0,Blood,,,178.0,,7498.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min
,BAO_0000218,A,,,50597.0,N,Rattus norvegicus,Intermediate,3193.0,,10116.0,CHEMBL624611,1.0,,1.0,Blood,,,178.0,,7499.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min
,BAO_0000218,A,,,50597.0,N,Rattus norvegicus,Intermediate,3193.0,,10116.0,CHEMBL624612,1.0,,1.0,Blood,,,178.0,,7500.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min
,BAO_0000218,A,,,50597.0,N,Rattus norvegicus,Intermediate,3193.0,,10116.0,CHEMBL875167,1.0,,1.0,Blood,,,178.0,,7501.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min
,BAO_0000218,A,,,50597.0,N,Rattus norvegicus,Intermediate,3193.0,,10116.0,CHEMBL624613,1.0,,1.0,Blood,,,178.0,,7502.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min
,BAO_0000218,A,,,50597.0,N,Rattus norvegicus,Intermediate,3193.0,,10116.0,CHEMBL624614,1.0,,1.0,Blood,,,178.0,,7503.0,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min"
,BAO_0000218,A,,,50597.0,N,Rattus norvegicus,Intermediate,5960.0,,10116.0,CHEMBL624392,1.0,,1.0,,,,,,7504.0,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,13950.0,,10116.0,CHEMBL624393,1.0,,1.0,Brain,,,955.0,,7505.0,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,13950.0,,10116.0,CHEMBL624394,1.0,,1.0,Brain,,,955.0,,7506.0,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,13950.0,,10116.0,CHEMBL624395,1.0,,1.0,Brain,,,955.0,,7507.0,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,13950.0,,10116.0,CHEMBL624396,1.0,,1.0,Brain,,,955.0,,7508.0,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,13950.0,,10116.0,CHEMBL624397,1.0,,1.0,Brain,,,955.0,,7509.0,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,13950.0,,10116.0,CHEMBL624398,1.0,,1.0,Thyroid gland,,,2046.0,,7510.0,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,13950.0,,10116.0,CHEMBL624399,1.0,,1.0,Thyroid gland,,,2046.0,,7511.0,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,13950.0,,10116.0,CHEMBL624400,1.0,,1.0,Thyroid gland,,,2046.0,,7512.0,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,13950.0,,10116.0,CHEMBL624401,1.0,,1.0,Thyroid gland,,,2046.0,,7513.0,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,13950.0,,10116.0,CHEMBL624402,1.0,,1.0,Thyroid gland,,,2046.0,,7514.0,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,9866.0,,10116.0,CHEMBL624403,1.0,,1.0,Blood,,,178.0,,7515.0,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,9866.0,,10116.0,CHEMBL624404,1.0,,1.0,Blood,,,178.0,,7516.0,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,9866.0,,10116.0,CHEMBL624405,1.0,,1.0,Blood,,,178.0,,7517.0,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,9866.0,,10116.0,CHEMBL624406,1.0,,1.0,Bone,,,10000001.0,,7518.0,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,9866.0,,10116.0,CHEMBL624407,1.0,,1.0,Bone,,,10000001.0,,7519.0,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,9866.0,,10116.0,CHEMBL624408,1.0,,1.0,Bone,,,10000001.0,,7520.0,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,9866.0,,10116.0,CHEMBL618644,1.0,,1.0,Heart,,,948.0,,7521.0,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,9866.0,,10116.0,CHEMBL618645,1.0,,1.0,Heart,,,948.0,,7522.0,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig
,BAO_0000218,A,In vivo,,50597.0,N,Rattus norvegicus,Intermediate,9866.0,,10116.0,CHEMBL618646,1.0,,1.0,Heart,,,948.0,,7523.0,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr
